<SEC-DOCUMENT>0001193125-15-343845.txt : 20151014
<SEC-HEADER>0001193125-15-343845.hdr.sgml : 20151014
<ACCEPTANCE-DATETIME>20151014171644
ACCESSION NUMBER:		0001193125-15-343845
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20151014
DATE AS OF CHANGE:		20151014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205414
		FILM NUMBER:		151158655

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d63294dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<HTML><HEAD>
<TITLE>POS AM</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 14, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-205414</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>POST-EFFECTIVE AMENDMENT NO. 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AYTU BIOSCIENCE, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>47-0883144</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>373 Inverness Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 206 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Englewood,
Colorado 80112 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 437-6580 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Joshua R. Disbrow </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>373 Inverness Parkway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 206 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Englewood,
Colorado 80112 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (720)&nbsp;437-6580 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alexander M. Donaldson, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wyrick Robbins Yates &amp; Ponton LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4101 Lake Boone Trail, Suite 300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Raleigh, North Carolina 27607 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(919) 781-4000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;), check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the Securities Act of 1933, as amended, or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No.&nbsp;2 to our registration statement on Form S-1 (File No.&nbsp;333-205414) (the &#147;Registration Statement&#148;) is
being filed to update the Registration Statement to include information from our Annual Report on Form 10-K for the year ended June&nbsp;30, 2015, filed on September&nbsp;28, 2015. This amended Registration Statement relates to the continued
registration of 2,462,259 outstanding shares of common stock and 102,613 shares of common stock issuable upon the exercise of outstanding warrants, all of which have been registered for resale by the selling stockholders identified in the prospectus
included in the Registration Statement.&nbsp;As of October 2, 2015, no shares had been resold by the selling stockholders. We are not registering any additional securities under this Post-Effective Amendment. All filing fees payable in connection
with the registration of these securities were previously paid by us in connection with the filing of the Registration Statement on July&nbsp;1, 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this prospectus is not complete and may be changed. The selling
stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject to Completion, Dated October 14, 2015 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63294cov1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>2,564,872 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the
sale or other disposition from time to time of up to 2,564,872 shares of our common stock by the selling stockholders named in this prospectus. We are not selling any shares of common stock under this prospectus and will not receive any of the
proceeds from the sale of shares of common stock by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell or otherwise dispose of the shares of
common stock covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the selling stockholders may sell or otherwise dispose of their shares of common stock in the section entitled
&#147;Plan of Distribution&#148; on page&nbsp;109.&nbsp;The&nbsp;selling shareholders will pay all brokerage fees and commissions and similar expenses. We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to
the registration of the shares with the Securities and Exchange Commission. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the OTCQB Market operated by OTC Markets
Group, Inc. (or OTCQB) under the ticker symbol &#147;AYTU.&#148; On October 12, 2015, the last reported bid price of our common stock on the OTCQB was $4.35. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common
stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#toc63294_3">Risk Factors</A>&#148; beginning&nbsp;on&nbsp;page&nbsp;11&nbsp;of this prospectus, and under
similar headings in any amendments or supplements to this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_6">Market for Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_9">Change in Certifying Accountant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_12">Transactions with Related Persons</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_13">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_14">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_15">Security Ownership of Certain Beneficial Owners and Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_17">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_18">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_19">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc63294_20">Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus, as supplemented and amended. We have not, and the
selling stockholders have not, authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus may only be accurate on the date of
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We urge you to read carefully this prospectus, as supplemented and amended, before deciding whether to invest in any of the common stock
being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Aytu,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our,&#148; &#147;our company&#148; and &#147;our business&#148; refer to Aytu BioScience, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various U.S. federal trademark registrations
and applications, and unregistered trademarks and servicemarks, including Zertane, Vyrix, RedoxSYS, MiOXSYS, ProstaScint and Luoxis. All other trade names, trademarks and service marks appearing in this prospectus are the property of their
respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this prospectus, appear with the trade name, trademark or service mark notice and then
throughout the remainder of this prospectus without trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not
contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this
prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including &#147;Risk Factors&#148; beginning on page 11, and the financial statements and related notes included in this prospectus.
</I></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty
healthcare company concentrating on developing and commercializing products with an initial focus on urological conditions. We are focused primarily on the urological disorders market and initially sexual dysfunction, urological cancers and male
infertility. We are currently focused on commercializing our ProstaScint&reg; product, which we plan to launch through a focused commercial infrastructure in the U.S. while developing corporate relationships outside the U.S. to launch ProstaScint in
major healthcare markets around the world. We acquired ProstaScint in May 2015 from Jazz Pharmaceuticals. ProstaScint, which is approved by the U.S. Food and Drug Administration, or FDA, is a marketed biologic imaging agent specifically indicated
for the diagnostic staging of prostate cancer patients. We plan to launch the RedoxSYS&reg; oxidation-reduction potential system, or the RedoxSYS System, into the global research market while developing numerous clinical applications for this
potential first-in-class diagnostic device, including an application for the detection of infertility in semen. We have developed a RedoxSYS product line extension called MiOXSYS&#153; intended for use in male infertility assessment, for which this
product is undergoing clinical studies. Further, we are entering late-stage development of our lead therapeutic candidate, Zertane, which is being studied in premature ejaculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidate Zertane is in clinical development for the treatment of premature ejaculation. The premature ejaculation market in the U.S. and Europe
is expected to reach over $1.3 billion in annual sales by 2017, representing a projected increase of 10.3% from 2010. According to recent published analyses, premature ejaculation, or PE, is a highly prevalent male sexual dysfunction affecting
20-30% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription products in the United States
to treat PE, and to our knowledge, only two other prescription products have been approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing
medications, and cognitive behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of our recent acquisition of ProstaScint, we are now commercial stage and generating sales for this FDA-approved prostate cancer imaging agent. As
prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused product pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 218,000 annual
cases (as of 2010). Further, more than 2,200,000 men were alive with some history of prostate cancer in 2006, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes
the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion by 2017, compound annual growth rate, or CAGR of 7.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are actively developing the global market for the RedoxSYS System across a range of applications. Specifically, we have begun commercializing RedoxSYS
System for research use through direct selling, distribution partners, and academic collaborators. Over the past 18 months, we have engaged in over 60 trials around the world whereby prominent researchers are implementing oxidation-reduction
potential as a marker in both chronic and acute illnesses and disorders in both clinical research as well as basic science research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our
extensive network of researchers, the RedoxSYS System has demonstrated the potential to have broad clinical applications. Studies are now underway at a major U.S. university in the area of male infertility. Thus, we have developed the MiOXSYS System
to uniquely detect oxidation-reduction potential in semen specimens. Male infertility is prevalent, underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300
million by 2020 with a CAGR of nearly 5% from 2013 to 2020. Oxidative stress is broadly implicated in the pathophysiology of oxidative stress, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However,
antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress, sperm motility
and morphology, and potentially enabling the monitor of patients&#146; responses to antioxidant therapy as a treatment regimen for infertility. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The technology underpinning the RedoxSYS and MiOXSYS systems was developed by Luoxis Diagnostics, Inc. in
the two years immediately preceding the merger between Luoxis, Vyrix Pharmaceuticals, Inc., and us (under our former name of Rosewind Corporation) in April 2015. Upon the consummation of the merger, the RedoxSYS System and MiOXSYS System became our
assets. Prior to the incorporation of Luoxis, the predecessor technologies that are now incorporated into these products were developed by the research team of Dr.&nbsp;David Bar-Or when he was at DMI BioSciences, Inc. and subsequently at Ampio
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Products </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zertane for
Premature Ejaculation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our premature ejaculation product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of
tramadol hydrochloride patented for the on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA, as the active ingredient is
already well characterized for the treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we
believe it will be the first commercial product approved by the FDA for PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective August&nbsp;18, 2014 the Drug Enforcement Administration, or DEA,
began classifying tramadol as a Schedule IV substance, including its salts, isomers, and salts of isomers. Tramadol has a low potential for abuse relative to the drugs or substances in Schedule III and has a currently accepted medical use in
treatment in the U.S. for moderate to moderately severe pain. We expect the same classification for Zertane regardless of the indication, including premature ejaculation. As a result of this classification, manufacturers are required to print
&#147;C-IV&#148; on the labeling of commercial containers of tramadol. It is unclear as to what extent the FDA and/or the DEA would expect manufacturers of tramadol-containing products to further control its distribution or monitor its use. However,
we do not expect this classification to adversely affect the commercial potential for Zertane considering that tramadol has a long history of use and a low potential for abuse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The method of use patents covering the use of tramadol for premature ejaculation were originally developed and held by Ampio (our parent predecessor company).
However, these patents and all related intellectual property were assigned to Vyrix when it was established as an Ampio subsidiary. Following the Merger of Vyrix, Luoxis and us, the patents were transferred and are now solely owned by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint for Prostate Cancer Imaging </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key
part of our strategy is to identify, acquire, license, or otherwise promote marketed, complementary urology assets in order to establish a commercial footprint and generate revenues for already-approved or near-term medical products. To that end we
acquired ProstaScint from Jazz Pharmaceuticals shortly after the Merger. ProstaScint received FDA approval on October&nbsp;28, 1996 and was initially marketed by Cytogen Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint (capromab pendetide) is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint targets
Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. Indium (In 111) is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody is infused into the patient and is taken up by prostate
cancer cells which can be detected and visualized with single-photon emission tomography (SPECT). ProstaScint has been shown to be clinically effective in determining the course of treatment for a patient who has had a prostatectomy and/or has
suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in newly diagnosed patients classified as high-risk or with recurrent prostate cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple clinical studies have been conducted in the United States and published in peer-reviewed publications. These studies consistently demonstrate
substantial clinical efficacy of ProstaScint in staging prostate cancer patients and specifically identifying whether the cancer is confined to the prostate or has metastasized to other parts of the body. Through more accurate clinical staging and
identification of metastatic prostate cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RedoxSYS System for Research Use </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed the development of the RedoxSYS System during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our
compliance with global quality standards in medical device manufacturing. This enables the launch of the RedoxSYS System into the research market around the world. We also received a CE marking in Europe and Health Canada clearance to begin the
market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched sales efforts into the research market in late 2014 and since that time have already
placed the RedoxSYS System at a number of prominent research centers in the United States, Europe, Israel, Japan, Taiwan, Singapore and Korea. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MiOXSYS System for Male Infertility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of
our strategy to develop future clinical applications of the RedoxSYS System, we have conducted initial studies in male reproductive health. Male infertility is a significant medical condition in which oxidative stress is well known to play a
substantial role. As such, we believe developing a clinical application to assess oxidative stress levels with the uniquely designed and programmed MiOXSYS System for semen analysis represents a significant commercial opportunity. Oxidative stress
is well established as a leading contributing factor to male infertility. Further, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess
oxidative stress in semen and seminal plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. Further, currently available tests are cumbersome, time consuming to perform, and costly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have conducted initial proof-of-concept clinical studies in male infertility with a leading research center in the United States, which demonstrates
that oxidation-reduction potential effectively measures oxidative stress levels in semen and seminal plasma &#150; and that these levels strongly correlate with established markers of infertility. Semen analysis studies are routinely conducted to
assess causes of infertility, so we expect clinicians and oxidative stress researchers to readily integrate the MiOXSYS System into routine use upon the completion of more extensive studies and regulatory clearance for this use. Additional studies
are now in the late planning stages that will evaluate the MiOXSYS System&#146;s performance in the detection of oxidative stress levels and correlations with key semen parameters in both healthy and infertile males. The MiOXSYS System must receive
510(k) de novo clearance from the FDA before we can market it for clinical use in the United States. Of the $300 million male infertility market projected for 2020, the North American, Middle Eastern, and Asia Pacific markets dominate due to
prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already established distribution relationships and direct access to major oxidative stress researchers in many of these important
markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An attractive aspect of the reproductive health market relates to reimbursement, as infertility treatments and the associated diagnostic tests
are generally paid directly by patients. The current infertility treatments and associated diagnostics typically cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced oxidative stress test would consume nominal
relative costs while providing specific, actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications that lower oxidative stress
(e.g., smoking cessation, exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS System could effectively guide treatment in the infertile patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an extensive range of intellectual property across our primary assets, Zertane, MiOXSYS, and RedoxSYS. We have patent protection in the United States
and several other large markets worldwide. Specifically, we have numerous patents issued and pending for the RedoxSYS/MiOXSYS systems and their use in the U.S., Europe, Israel, and major markets in Asia inclusive of Japan, Korea, China, and the
Middle East. Further, we have patent protection in the United States and several other large markets worldwide for the use of tramadol hydrochloride to treat PE. We also have intellectual property specifically covering Zertane-ED, our product
candidate to treat comorbid premature ejaculation and erectile dysfunction, or ED, that has issued patents in several large markets worldwide and is pending in the United States. However, we are not actively developing Zertane-ED at this time. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </I></B>(trimethoprim solution)<B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 5, 2015, we purchased from FSC Laboratories, Inc. the assets related to its product known as
Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trimethoprim solution), including certain intellectual property and contracts, inventory, work in process and all marketing and sales assets and materials related solely to Primsol.
Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections (UTIs). This differentiated product is appropriate for UTI patients
that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (&#147;sulfa&#148;). This acquisition adds a second established brand to our product portfolio. We
expect to benefit from and continue to grow Primsol&#146;s established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. This allows us
to utilize the same sales channel as ProstaScint, leading to potential commercial synergies. For a description of the Primsol acquisition, see &#147;Recent Developments.&#148; </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Develop a pipeline of therapeutics and diagnostics focused on urological conditions, with a focus on the initiation and completion of two Phase 3 clinical trials for Zertane in the United States and the development of
worldwide commercialization and marketing partnerships. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Commercialize FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We plan to commercialize ProstaScint in the U.S. and in key markets around the world.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Establish the RedoxSYS System initially as a research tool and establish MiOXSYS as a clinical diagnostic device with application in male infertility. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Acquire established marketed products and late-stage development assets within our core urology focus. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Therapeutic Product
Candidate &#150; Zertane </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of
tramadol hydrochloride patented for the on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA, as the active ingredient is
already well characterized for the treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we
believe it will be the first commercial product approved by the FDA for PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are three main types of NDAs, which are covered by Section&nbsp;505 of
the FDCA: (1)&nbsp;an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1)); (2)&nbsp;an application that contains full reports of investigations of safety and effectiveness but where at least some of
the information required for approval comes from studies not conducted by or for the applicant and for which the application has not obtained a right of reference (Section 505(b)(2)); and (3)&nbsp;an application that contains information to show
that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (Section 505(j)).
Section&nbsp;505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the preIND briefing meeting with Ampio and in June 2012, the FDA agreed that our NDA may be submitted under
Section&nbsp;505(b)(2). As such, we intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and 21-692) to support the safety and efficacy demonstrated in
our clinical program. Relying on Section&nbsp;505(b)(2) is advantageous because we or our collaborators may not be required (i)&nbsp;to perform the full range of safety and efficacy trials that is otherwise required to secure approval of a new drug,
and (ii)&nbsp;obtain a &#147;right of reference&#148; from the applicant that obtained approval of the previously approved drug. However, a Section&nbsp;505(b)(2) application must support the proposed change of the previously approved drug by
including necessary and adequate information, as determined by the FDA, and the FDA may still require us to perform a portion or the full range of safety and efficacy trials. There can be no assurance that we would be successful under any
Section&nbsp;505(b)(2) application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to recent published analyses, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men
worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to
our knowledge, only one oral prescription product has been approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive
behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of significant development work performed by a previous corporate partner, Zertane has already been evaluated outside the United States in two Phase
1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. This development work has demonstrated a favorable safety and efficacy profile of Zertane in men with PE and helped inform the design and endpoints of the Phase 3
clinical trials we will need to obtain FDA approval. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized, which we believe will eliminate the need for us to conduct additional
pre-clinical studies and safety </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials. We believe we are well positioned to initiate Phase 3 clinical trials with Zertane in the United States. Upon completion of the trials, if successful, we plan to submit a New Drug
Application, or NDA, and subsequently market Zertane in the United States, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for Zertane is focused on the initiation and
completion of the Phase 3 clinical program in the United States and the development of worldwide commercialization and marketing partnerships. We expect to finalize clinical development of Zertane, seek FDA marketing approval and &#150; if
approved&#151;commercialize the product candidate in the United States either directly or via partnerships. While we have not yet submitted an IND for Zertane to the FDA that would allow us to initiate the planned Phase 3 trial, we expect to submit
the IND in the second half of 2015. We will seek partnerships to commercialize Zertane in rest of world, or ROW, 6 markets. We already have partnerships in place to market Zertane in South Korea (Daewoong Pharmaceutical Co., Ltd.) and Brazil (FBM
Farma Industria Farmaceutica), which could provide near-term revenue for us if, working with our partners, we are able to successfully obtain regulatory approval in those countries. In addition, we recently entered into an agreement with Endo
Ventures Limited, which recently acquired Paladin Labs Inc., or Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain
countries in Sub-Saharan Africa, Colombia and Latin America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PE Market </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE is a significant unmet medical need
in the United States and worldwide as it causes significant emotional distress for affected men and their partners. According to an article published in <I>European Urology</I> in 2010 and a survey published in the <I>Journal of the American Medical
Association (JAMA)</I> in 1999, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. However, most prevalence data on PE is based on patient surveys, which are inherently subjective, and therefore some of the men
surveyed may not have PE as it is defined by major medical societies. In a 2007 study published in <I>European Urology</I>, the incidence of PE was assessed via a web-based survey of 12,133 men ages 18-70 in the United States, Germany and Italy. In
this survey, 2,754 or 22.7% of the men reported that they suffer from PE. The vast majority (87.9%)&nbsp;of men with PE wished that they had more control over time to climax. Additionally, a majority (57.6%)&nbsp;of the men surveyed reported that
they would seek medical treatment if they knew that a pill to control ejaculation were available. We believe men would also ask their doctor about treatment options if their partner suggested it. Additional primary company market research indicated
that over 66% of patients that see a urologist for PE were self-referred, which we believe further demonstrates that PE is a condition for which patients are actively seeking treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, there are no approved prescription pharmaceuticals in the United States to treat PE and only two pharmaceuticals known to be approved elsewhere in
the world. Current &#147;off label&#148; or unapproved therapies used to treat PE carry with them unwanted side effects and inconsistent or limited effectiveness. Topical over-the-counter, or OTC, options are not preferred due to route of
administration and may also have an impact on partner satisfaction. Oral therapeutics, specifically selective serotonin reuptake inhibitors, or SSRIs, carry potentially significant side effects; the most notable of which is diminished libido. PDE-5
inhibitors have been prescribed &#147;off label&#148; for PE but have not demonstrated efficacy. Outside of oral or topical therapeutics, non-medical options include behavioral therapy and relationship counseling, both of which can be time consuming
and stressful and frequently ineffective for men and their partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe patients and their partners are generally dissatisfied with existing
pharmacologic and non-pharmacologic treatments for PE. Based on primary market research commissioned by us, which included discussions with a cross section of clinicians that treat patients with PE, we believe that there are significant issues with
existing PE treatments demonstrating a real need for a safe and effective, FDA-approved product to treat PE that does not have a ramp-up period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead
product candidate, Zertane for premature ejaculation, contains 89 mg tramadol hydrochloride in an orally dissolving tablet, or ODT. Tramadol hydrochloride is a well-established, centrally acting synthetic analgesic and has been used for more than
30&nbsp;years as a treatment for moderate to severe pain. The drug and its active metabolite (M1, <I>O</I>-desmethyltramadol) act as an opiate agonist, apparently by selective activity at the &micro;-receptor. Although the mechanism by which
tramadol hydrochloride delays ejaculation has not been identified, numerous laboratory studies have shown that tramadol hydrochloride also acts as an <I>N</I>-methyl-D-aspartate receptor antagonist, 5-hydroxytryptamine type 2C receptor antagonist, 5
nicotinic acetylcholine receptor antagonist, M1 and M3 </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
muscarinic acetylcholine receptor antagonist, and a serotonin and norepinephrine modulator. It is possible that one or a combination of these effects leads to a delay in ejaculation. The relative
contribution of tramadol hydrochloride versus its M1 metabolite to delay ejaculation is unknown. However, the metabolite is six times more potent than the parent drug in producing analgesia in animal models and 200 times more potent in
&micro;-receptor binding. As a pain medication, tramadol hydrochloride has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. However, we intend that our labeling for
Zertane, if regulatory approval is obtained, will suggest &#147;as required&#148; dosing before sexual intercourse and not to exceed one tablet per day. Based on previous clinical studies, we believe that limiting the dosing to no more than once per
day will minimize any side effects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Marketed, FDA-Approved Prostate Imaging Product &#150; ProstaScint </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;20, 2015, we acquired ProstaScint from Jazz Pharmaceuticals. ProstaScint is already approved by the FDA and is generating revenues. As such, we
expect to launch a commercial infrastructure in order to support increased sales and distribution of ProstaScint in the U.S. ProstaScint, or capromab pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a
specific antigen. ProstaScint targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. A radioactive substance called Indium In 111 is attached to the proprietary, mouse-derived antibody. The radiolabeled
antibody is infused into the patient and is taken up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography, or SPECT). ProstaScint has been shown to be clinically
effective in determining the course of treatment for a patient who has had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in newly diagnosed patients
classified as High Risk or with recurrent prostate cancer. In addition to U.S. approval ProstaScint has also been approved by Health Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint
fills an important medical need in the detection of a common illness facing a significant number of men in the U.S. and around the world. Prostate cancer is the most common cancer among men in the United States, with an estimated 218,000 annual
cases (as of 2010). Further, more than 1,800,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need
for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint has several unique selling features that we believe will enable significant sales growth and regular use by healthcare providers diagnosing and
treating prostate cancer. ProstaScint is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. In multiple clinical studies researchers have shown that when SPECT/CT
scans were used in patients pre-treated with ProstaScint, ProstaScint imaging was highly sensitive in detecting prostate cancer and significantly predictive of 10-year biochemical disease free survival in prostate cancer patients (86.6% vs. 65.5%;
p=0.0014). Importantly, ProstaScint is already approved by the FDA with a history of sales in the U.S. Additionally, the American Cancer Society specifically recognizes ProstaScint by name in current prostate cancer diagnosis guidelines. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Select ProstaScint Clinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple clinical studies have been conducted in the United States and published in peer-reviewed publications. These studies consistently demonstrate
substantial clinical efficacy of ProstaScint in staging prostate cancer patients and specifically identifying whether the cancer is confined to the prostate or has metastasized to other parts of the body. Through more accurate clinical staging and
identification of metastatic prostate cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings for ProstaScint from select studies are summarized below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Principal Investigator(s)/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:85.35pt; font-size:8pt; font-family:Times New Roman"><B>Primary Authors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman"><B>Publication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:63.70pt; font-size:8pt; font-family:Times New Roman"><B>Patient Population</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:65.25pt; font-size:8pt; font-family:Times New Roman"><B>Conclusion/Results</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ellis RJ et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Int. J. Radiation Oncology Biol. Phy. (2010)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patients presenting for primary radiotherapy having a clinical diagnosis of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and SPECT/CT (N=239)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Haseman MK et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Urology (2007)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Men with prostate cancer who underwent imaging with ProstaScint pretreatment; Patients were divided according to the presence or absence of central abdominal uptake(CAU) (N=341)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were 10 times higher in patients
identified with ProstaScint as having central abdominal uptake (p=0.005).</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ellis RJ et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brachytherapy (2005)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Men with prostate cancer of all risk categories who underwent imaging with ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical disease recurrence regardless of the patient&#146;s risk category; 7-year outcomes data from brachytherapy patients with treatment based on the
ProstaScint scan showed a significant difference in biochemical disease-free survival.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Radiation oncology experts have published numerous papers expressing the potential for expanded use of ProstaScint in prostate
cancer imaging due to advances in imaging technologies since its FDA approval in 1996. Since the early 2000s significantly greater image resolution has been enabled due to the advent of dual head cameras (and improved imaging in general) along with
the use of co-registered images where radiologists now combine the images of SPECT and computerized tomography (CT) or magnetic resonance imaging (MRI). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Marketed Research Instrument &#150; The RedoxSYS System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our leading diagnostic product candidate, the RedoxSYS System, is now fully developed for research use. RedoxSYS is a novel, portable device that measures
oxidation-reduction potential, or ORP, a global measure of oxidative stress. This system is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide
range of both acute and chronic conditions. To date, Canadian and European regulators have characterized RedoxSYS System as Class II medical device and regulated them accordingly. Classification of a medical device as Class II in Europe and Canada
indicates that the device is generally regarded as posing medium risk, and non-invasive medical devices that come into contact with injured skin are generally classified as Class II. As we have conducted initial validation studies with the RedoxSYS
System across a range of conditions and obtained a CE marking in Europe and Health Canada clearance to begin the market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is
recognized, we are now initiating commercialization for use of the RedoxSYS System as a research tool. By employing a focused commercial infrastructure and a focused network of distributors around the world, we believe we can efficiently penetrate
the academic and industry-based research centers who study oxidative stress. With this growth in the research market, we intend to develop clinical applications for the RedoxSYS System. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for the RedoxSYS System is to continue deployment of this system at leading academic centers
around the world, develop research collaborations with key opinion leaders in oxidative stress research, identify clinical applications for the platform, and aggressively pursue infertility studies to establish efficacy of the system in this setting
of care. In 2013 and 2014, we deployed the RedoxSYS System around the world in the development of numerous future clinical applications. While many areas of study have been undertaken, we have focused research resources on high-value areas where
significant medical needs remain unmet. Given our initial orientation around trauma, the studies completed thus far have focused on large conditions related to critical care. These initial studies demonstrated the initial clinical validation for the
RedoxSYS System and represent substantial opportunities as growth applications and markets following initial entry into the research and infertility markets. As our direct commercial efforts will focus on male infertility, we expect that other areas
of clinical use would be pursued through partnerships with corporate partners established in these non-urological clinical channels. A significant potential opportunity that has presented promise through our research is the application of ORP in the
study of male infertility. ORP represents a unique approach to assessing oxidative stress in male infertility as it relates to semen analysis, and early clinical studies have been conducted. We are now beginning larger-scale clinical studies with a
globally recognized U.S. university in male infertility. As such we have developed a RedoxSYS System line extension called MiOXSYS specifically designed and programmed to detect oxidative stress in semen specimens. Oxidative stress is widely
assessed in semen analysis laboratories as part of male infertility assessment, and we believe the MiOXSYS System, if proven effective, will provide a simple, comprehensive solution to oxidative stress detection and management of antioxidant and
lifestyle intervention in this underserved market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to augment our core development and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related
to urological disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through asset purchases, licensing, co-development, or collaborative commercial
arrangements (co-promotions, co-marketing, etc.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team has extensive experience across a wide range of business development activities and
have in-licensed or acquired products from large, mid-sized, and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect that we will rapidly advance our internal products as well
as externally sourced assets. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 5, 2015, we entered into and closed on an asset purchase agreement with FSC Laboratories, Inc. (the
&#147;Seller&#148;). Pursuant to the agreement, we purchased assets related to the Seller&#146;s product known as Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trimethoprim solution), including certain intellectual property and
contracts, inventory, work in process and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to the sale
and marketing of Primsol arising after the closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We paid $500,000 at closing for the Primsol Business and we agreed to pay an additional $141,694
payable within five&nbsp;days&nbsp;after transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 payable no&nbsp;later than&nbsp;March 31, 2016, (b) $500,000 payable no later than June 30, 2016, and (c)
$250,000 payable no later than September&nbsp;30, 2016 (together, the &#147;Installment Payments&#148;), for a total purchase price of $1,891,694. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
agreement contains customary representations and warranties and covenants by each party. The agreement contains customary indemnification provisions by each party, including, subject to certain limitations, the indemnification by each party for any
losses arising out of any breach of the other party&#146;s representations or warranties or any breach or failure to perform any of its covenants under the agreement, as well as any liabilities related to the Primsol Business prior to the closing
(as to us) and after the closing (as to the Seller). Our sole right to and source of indemnification under the agreement is an offset against the Installment Payments and payment of such offset amount into an escrow account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also provides that for a period of one year after the closing the Seller will not directly or indirectly sell, market, promote, advertise or
distribute anywhere in the world any urinary tract anti-infective pharmaceutical or treatment product containing trimethoprim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 8, 2015, we and
Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us. The agreement provides that we may engage Biovest from time to time to provide services in
accordance with mutually agreed upon project addendums and purchase orders. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or
storage of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with
project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of
four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30&nbsp;days written notice of a material breach under the agreement. In addition, we may terminate the agreement or any project
addendum under the agreement upon 180 days written notice for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with entering into the agreement, we submitted a work order to
Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as Rosewind
Corporation on August&nbsp;9, 2002 in the State of Colorado. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix Pharmaceuticals, Inc., or Vyrix, was incorporated under the laws of the State of
Delaware on November&nbsp;18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out of the sexual dysfunction
therapeutics business, including the late-stage men&#146;s health product candidates, Zertane and Zertane-ED, from Ampio, which carve out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws of the
State of Delaware on January&nbsp;24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger. Luoxis was focused on initially developing and advancing the RedoxSYS System. The MiOXSYS System was developed following
the completed development of the RedoxSYS System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2015, Rosewind formed Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc.,
each a wholly-owned subsidiary formed for the purpose of the Merger, and on April&nbsp;16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis, and Vyrix and Luoxis became
subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with Rosewind as the surviving corporation (herein referred to as the Merger). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the closing of the Merger, Rosewind abandoned its pre-merger business plans to develop a sailing school, and we now solely pursue the
specialty healthcare market, focusing on urological related conditions, including the business of Vyrix and Luoxis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2015, we
(i)&nbsp;reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and (ii)&nbsp;effected a reverse stock split in
</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which each common stock holder received one share of common stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split). All share and per share amounts in this
prospectus have been adjusted to reflect the effect of the Reverse Stock Split. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_2"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to 2,564,872 shares of our common stock, as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,037,147 shares of common stock issued in the Merger to the stockholders of Luoxis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,425,112 shares held by certain Rosewind shareholders issued prior to the merger; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">102,613 shares of common stock issuable at a price of $4.53 per share upon the exercise of warrants issued to the placement agent for a private placement conducted by Luoxis. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by the selling stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,564,872&nbsp;shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock outstanding before the offering <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,259,681&nbsp;shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after the offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,259,681 shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock OTCCQB Symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">AYTU</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on the number of shares outstanding as of September&nbsp;30, 2015. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of shares in this offering. The selling stockholders will receive all net proceeds from the sale of
shares of our common stock in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never paid dividends on our capital stock and do not anticipate paying any dividends for the foreseeable future. See &#147;Dividend Policy.&#148; </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock includes a high degree of risk. Prior to making a decision about investing in our common stock, you should consider carefully
the specific factors discussed below, together with all of the other information contained in this prospectus. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely
be materially and adversely affected. This could cause the market price of our common stock to decline and could cause you to lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited operating history, have incurred losses, and can give no assurance of profitability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage healthcare company with a limited operating history. We have not generated material revenue to date and are not profitable, and have
incurred losses in each year since our inception. Our net loss for the years ended June&nbsp;30, 2015 and 2014 was $7.7 million and $5.6 million, respectively. We have not demonstrated the ability to be a profit-generating enterprise, and without
significant financing, there is substantial doubt about our ability to continue as a going concern. We expect to incur substantial losses for the foreseeable future. Our ability to generate revenue is uncertain, and we may never achieve
profitability. We have a very limited operating history on which investors can evaluate our potential for future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered
by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. regulatory approval of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign regulatory approval of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of sufficient capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertain market acceptance of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated problems, delays, and expense relating to product development and implementation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">technological changes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of our limited operating history, and the increasingly competitive nature
of the markets in which we compete, our historical financial data, which, prior to April&nbsp;16, 2015, consists of allocations of expenses from Ampio, is of limited value in anticipating future operating expenses. Our planned expense levels will be
based in part on our expectations concerning future operations, which is difficult to forecast accurately based on our stage of development. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not received any material revenues from the commercialization of our products or product candidates and might not receive significant revenues
from the commercialization of products and our product candidates in the near term. Even though ProstaScint is an approved drug that we are marketing, we only acquired it in May 2015 and have limited experience on which to base the revenue we could
expect to receive. To obtain revenues from our products and product candidates, we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products and completing clinical trials
of our product candidates, obtaining positive results from the clinical trials, achieving marketing approval for these product candidates, manufacturing, marketing and selling our existing products and those products for which we, or our
collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, if any, may never succeed in these
activities and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure
to obtain necessary capital when needed may force us to delay, limit or terminate our product expansion and development efforts or other operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through clinical development. Developing product candidates is expensive, lengthy and risky, and we expect
our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance Zertane into two planned Phase 3 clinical trials in the United States and develop the RedoxSYS System for
additional applications. In addition, we are expending resources to expand the market for ProstaScint, which might not be successful or might take longer and be more expensive than anticipated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, our cash and cash equivalents were $7.4 million. Our operating plan may change as a result of many factors currently unknown to us,
and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and
licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, our product candidates. Raising funds in the current economic environment, as well
our lack of operating history, may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific
strategic considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our
ability to expand any existing product or develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms
of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline.
The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such
as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could
also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are
unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain the capital necessary to fund our operations, we will be unable to successfully expand, develop, obtain regulatory approval of, and
commercialize, our products and product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development of pharmaceutical products, medical diagnostics and medical devices is
capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in, and the costs of, our pre-clinical studies and clinical trials and other research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, prioritization and number of our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of securing manufacturing arrangements for commercial production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of establishing or contracting for sales and marketing capabilities for any existing products and if we obtain regulatory clearances to market our product candidates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual property rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through collaboration arrangements, sales of our securities,
debt financings, or by out-licensing one or more of our product candidates. Dislocations in the financial markets have generally made equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet
our fundraising needs. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our technologies,
research or development programs or our commercialization efforts. Additional funding, if obtained, may significantly dilute existing shareholders if that financing is obtained through issuing equity or instruments convertible into equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance with public company
reporting and other requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that Vyrix and Luoxis did
not incur as private companies. In addition, the rules and regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our
corporate governance practices, with which we will need to comply. Further, we will be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results. Based on currently available
information and assumptions, we estimate that we will incur approximately $500,000 in expenses on an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel will need to devote
substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Product Development, Regulatory Approval and Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to develop our current or any future product candidates. Our product candidates will require substantial additional clinical development,
testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous
review and regulation by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product
candidate, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and may include post-marketing studies and
surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process and is commercialized.
Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market a product in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any
foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many
reasons, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to demonstrate that a product candidate is safe and effective to the satisfaction of the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may require that we conduct additional clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may not approve the formulation, labeling or specifications of any product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse
by patients or the public in general; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may not accept data generated at our clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval
of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may change its approval policies or adopt new regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These same risks apply to applicable
foreign regulatory agencies from whom we may seek approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these factors, many of which are beyond our control,
could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate. Moreover, because a substantial portion of our business is dependent upon our existing product candidates, any such setback in our pursuit
of regulatory approval would have a material adverse effect on our business and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Favorable results in the prior clinical trials of
Zertane outside of the United States may not be predictive of the results in our planned Phase 3 clinical trials of Zertane in the United States or the designs of our Phase 3 clinical trials may be inadequate for FDA approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving
promising results in earlier-stage development. The prior clinical trials of Zertane showed favorable safety and efficacy data; however, we will have different enrollment criteria in our planned Phase 3 clinical trials. In the Phase 2 clinical
trials, we were able to enroll patients utilizing a broader definition of PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ejaculation latency, most commonly quantified using intravaginal
ejaculation latency time, or IELT, is a dominant component of PE assessment in clinical trials. IELT is defined as the time between vaginal intromission and intravaginal ejaculation. Although a standard cut-off for ejaculatory latency does not
exist, it has been suggested that an IELT of two minutes or less may serve as an adequately sensitive criterion for defining PE and some studies have used IELT values from one to two minutes for defining PE. In a pre-IND meeting with FDA, we agreed
to use an IELT of less than or equal to 1 minute as one of the enrollment criteria for our planned Phase 3 clinical trials. The previous European Phase 3 trials allowed for an IELT of less than two minutes however a significant proportion of
enrollees had an IELT of one minute or less. In our planned Phase 3 clinical trials, we will be utilizing the definition of lifelong PE adopted by the International Society for Sexual Medicine, or the ISSM: &#147;premature ejaculation is a male
sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal
consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.&#148; As a result, we may encounter difficulty enrolling a sufficient number of patients in a timely fashion and we may not observe a similarly favorable
safety and efficacy profile as our prior clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ampio obtained guidance from the FDA on our planned Phase 3 trials at a pre-IND meeting held in June
2012, including information to help us define the target patient population, select co-primary endpoints and design an acceptable patient-reported outcome measure. As a result of direction provided at the meeting, along with the existing data from
six clinical trials of Zertane conducted outside the U.S. to date, we believe we are positioned to advance Zertane into Phase 3 clinical trials in the United States. However, we can provide no assurance that the FDA will not change its guidance
about our planned Phase 3 clinical trials and require us to significantly modify the design of, or endpoints for, our planned clinical trials. Any change in the guidance we have received could delay and/or render more expensive our planned Phase 3
trial for Zertane. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were not involved in any of the prior clinical studies for Zertane and are relying on the data collected from those prior clinical
trials by various third parties, including a previous partner of our majority stockholder, Ampio Pharmaceuticals. Dr.&nbsp;David Bar-Or (now the Chief Scientific Officer of Ampio Pharmaceuticals) discovered the utility of tramadol hydrochloride for
the treatment of PE in June 1999, and this discovery and accompanying intellectual property were at that time the property of DMI BioSciences, Inc., or DMI BioSciences. DMI BioSciences conducted various clinical trials, prior to licensing the
worldwide rights to tramadol hydrochloride for PE to Biovail Laboratories International, or Biovail. Biovail also conducted several clinical trials and began two Phase 3 clinical trials, which trials were completed by Ampio upon its acquisition of
DMI Biosciences, to whom the rights had reverted. This lack of prior involvement may have a negative impact on our understanding of these prior clinical trials and the design of our planned Phase 3 trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to successfully acquire new products, we may lose market position. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquiring new products will be an important factor in our sales growth, including products that already have been developed and found market acceptance. If we
fail to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue source to help pay for our development activities as well as possible acquisitions. This would delay our business
plan, which could have a negative adverse effect on our business and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not secure collaborations with strategic partners to test,
commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key
aspect of our current strategy is to selectively enter into collaborations with third parties to conduct clinical testing, as well as to commercialize and manufacture product candidates. If we are able to identify and reach an agreement with one or
more collaborators, our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements typically call for
milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety are demonstrated. The current
economic environment may result in potential collaborators electing to reduce their external spending, which may prevent us from developing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize products using our product candidates.
Collaborations involving our product candidates pose a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing their own or another party&#146;s product candidate; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may decide to terminate or not to renew the collaboration for these or other reasons. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
result, collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example, our former collaborator that licensed Zertane conducted clinical trials which we believe
demonstrated efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated the collaboration agreement. The Merger also created a potential conflict with a principal customer
of the acquired company, which sells a product to treat premature ejaculation in certain European markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration agreements are generally
terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that
achieve the collaborator&#146;s objectives and meet our expectations, we may be unable to advance our product candidates and may not generate meaningful revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or our strategic partners may choose not to continue an existing product or choose not to develop a product candidate at any time during development,
which would reduce or eliminate our potential return on investment for that product. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time and for any reason, we or our strategic partners
may decide to discontinue the development or commercialization of a product or product candidate. If we terminate a program in which we have invested significant resources, we will reduce the return, or not receive any return, on our investment and
we will have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic partners terminates a program, we will not receive any future milestone payments or royalties relating to that program
under our agreement with that party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are expected to undergo clinical trials that are time-consuming and expensive, the
outcomes of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we or our collaborators may
incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pre-clinical testing and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any
clinical studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical testing and clinical development necessary to commercialize a drug or biologic, and delays or failure can occur
at any stage. Interim results of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be certain that we will not face similar setbacks. The design of a clinical trial
can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in one or more trials would be a major
set-back for that product candidate and for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development programs, which could
have a material adverse effect on our business, prospects and financial condition and on the value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with clinical
testing and trials, we face a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic, or has unacceptable side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients may die or suffer other adverse effects for reasons that may or may not be related to the product candidate being tested; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not confirm the positive results of earlier testing or trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to establish the safety and efficacy of the product candidate. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of pre-clinical studies do not necessarily predict clinical success, and larger and later-stage
clinical trials may not produce the same results as earlier-stage clinical trials. Frequently, product candidates developed by pharmaceutical companies have shown promising results in early pre-clinical studies or clinical trials, but have
subsequently suffered significant setbacks or failed in later clinical trials. In addition, clinical trials of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not successfully complete pre-clinical and clinical development, we will be unable to market and sell products derived from our product candidates
and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before an NDA may be submitted to the FDA. Although there are a large number
of drugs and biologics in development in the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization, and only a small number achieve widespread
physician and consumer acceptance following regulatory approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive regulatory approval of any
of these product candidates and our business, prospects and financial condition will be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays, suspensions and terminations in
our clinical trials could result in increased costs to us and delay or prevent our ability to generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are very
expensive, time-consuming, and difficult to design, implement and complete. We currently expect clinical trials of our therapeutic product candidates could take up to 24 months to complete, but the completion of trials for these candidates may be
delayed for a variety of reasons, including delays in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable terms with prospective contract research organizations and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">validating test methods to support quality testing of the drug substance and drug product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining sufficient quantities of the drug substance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing sufficient quantities of a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining approval of an Investigational New Drug application, or IND, from the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining dosing and clinical design and making related adjustments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective
treatments for the relevant disease and the eligibility criteria for the clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commencement and completion of clinical trials
for our product candidates may be delayed, suspended or terminated due to a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of effectiveness of product candidates during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse events, safety issues or side effects relating to the product candidates or their formulation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to raise additional capital in sufficient amounts to continue clinical trials or development programs, which are very expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to enter into collaborations relating to the development and commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability or the inability of our collaborators to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect
to clinical trial results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our collaborators to advance our product candidates through clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in patient monitoring and data collection due to failure of patients to maintain contact after treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of our data, and regulatory commitments and requirements by the FDA and similar foreign regulatory agencies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors may also ultimately lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical
trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, we may encounter delays or product candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in FDA policy or interpretation during the period of product development. If we obtain
required regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminishment of any competitive advantages that such product candidates may have or attain. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, if
we fail to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminishment of any competitive advantages that such product candidates may have or attain; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays or termination in clinical trials or commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or seizures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of manufacturing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawals of previously approved marketing applications; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, civil penalties, and criminal prosecutions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or our collaborators intend to seek FDA approval
for some of our product candidates using an expedited process established by the FDA. If we, or our collaborators, are unable to secure clearances to use expedited development pathways from the FDA for certain of our drug product candidates, we, or
they, may be required to conduct additional pre-clinical studies or clinical trials beyond those that we, or they, contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals and of any product
revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of clinical trials, we expect to submit NDAs to the FDA at various times in the future under
Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA. NDAs submitted under this section are eligible to receive FDA approval by relying in part on the FDA&#146;s findings of safety and efficacy for a previously approved
drug. We specifically intend to do this for Zertane. The FDA&#146;s 1999 guidance on Section&nbsp;505(b)(2) applications states that new indications for a previously approved drug, a new combination </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product, a modified active ingredient, or changes in dosage form, strength, formulation, and route of administration of a previously approved product are encompassed within the
Section&nbsp;505(b)(2) NDA process. Relying on Section&nbsp;505(b)(2) is advantageous because we or our collaborators may not be required (i)&nbsp;to perform the full range of safety and efficacy trials that is otherwise required to secure approval
of a new drug, and (ii)&nbsp;obtain a &#147;right of reference&#148; from the applicant that obtained approval of the previously approved drug. However, a Section&nbsp;505(b)(2) application must support the proposed change of the previously approved
drug by including necessary and adequate information, as determined by the FDA, and the FDA may still require us to perform a portion or the full range of safety and efficacy trials. There can be no assurance that we would be successful under any
Section&nbsp;505(b)(2) application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The approval process outside the United States varies among countries and may limit our ability to develop,
manufacture and sell our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market and sell our products in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing. We may conduct clinical trials for, and seek regulatory approval to market, our product
candidates in countries other than the United States. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may decide to first seek regulatory approvals of a product candidate in
countries other than the United States, or we may simultaneously seek regulatory approvals in the United States and other countries. If we or our collaborators seek marketing approval for a product candidate outside the United States, we will be
subject to the regulatory requirements of health authorities in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit a European Marketing Authorization Application, or MAA, to the
European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the
time required to obtain approval may differ from that required to obtain FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining regulatory approvals from health authorities in
countries outside the United States is likely to subject us to all of the risks associated with obtaining FDA approval described above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other
country, and approval by foreign health authorities does not ensure marketing approval by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or our collaborators, obtain
marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or they market our products, which could materially impair our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product at
a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or the patient population that may utilize the product, or may be required to carry a
warning in its labeling and on its packaging. Products with boxed warnings are subject to more restrictive advertising regulations than products without such warnings. These restrictions could make it more difficult to market any product candidate
effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any of our products and product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to
post-marketing restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with
our products following approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of our approved products and product candidates for which we, or our collaborators, obtain marketing
approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such products, among other things, are or will be subject to continual requirements of and review by the FDA
and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance
and corresponding maintenance of records and documents, requirements regarding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for
which the product may be marketed or to the conditions of approval, including the FDA requirement to implement a REMS to ensure that the benefits of a drug or biological product outweigh its risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The
FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in
accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we, or our collaborators, do not market any of our product candidates for which we,
or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our
product candidates may be delayed, and our business will be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We sometimes estimate for planning purposes the timing of the accomplishment
of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory
filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs,
receipt of marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement of
the milestones to vary considerably from our estimates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our available capital resources or capital constraints we experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to
identify and enroll patients who meet clinical trial eligibility criteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our receipt of approvals from the FDA and other regulatory agencies and the timing thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other actions, decisions or rules issued by regulators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efforts of our collaborators with respect to the commercialization of our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our
business, prospects and results of operations may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials and perform data collection
and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely, and will rely
in the future, on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development activities
or clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the third parties do not successfully carry out their contractual duties or fail to meet regulatory obligations or expected deadlines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we replace a third party; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the quality or accuracy of the data obtained by third parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third party performance failures may increase our development costs, delay our ability to obtain regulatory
approval, and delay or prevent the commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter
into replacement arrangements without incurring delays or additional costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, for Zertane, we are currently using, and relying on, single
suppliers and single manufacturers for drug supply for our planned Phase 3 clinical trials and our commercial products. Although there are potential alternative suppliers and manufacturers for Zertane if need be, we have not qualified these vendors
to date. If we were required to change vendors, it could result in a failure to meet regulatory requirements or projected timelines and necessary quality standards for successful manufacturing of the various required lots of material for our
development and commercialization efforts, any of which could have an adverse effect on our business, prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if
collaborators with which we contract in the future successfully complete clinical trials of our product candidates, those product candidates may not be commercialized successfully for other reasons. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we contract with collaborators that successfully complete clinical trials for one or more of our product candidates, those candidates may not be
commercialized for other reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to receive regulatory clearances required to market them as drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being subject to proprietary rights held by others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being difficult or expensive to manufacture on a commercial scale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">having adverse side effects that make their use less desirable; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failing to compete effectively with products or treatments commercialized by competitors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Relying on
third-party manufacturers may result in delays in our clinical trials, product introductions and product supply. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing and commercializing
new medicines and devices entails significant risks and expenses. Our clinical trials may be delayed if third-party manufacturers are unable to assure a sufficient quantity of the drug product to meet our study needs. If our clinical trials are
delayed, our commercialization efforts may be impeded, or our costs may increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once regulatory approval is obtained, a marketed product and its
manufacturer are subject to continual review. The discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer or manufacturing facility, including withdrawal of the product from the
market. Any manufacturers with which we contract are required to operate in accordance with FDA-mandated current good manufacturing practices, or cGMPs. A failure of any of our contract manufacturers to establish and follow cGMPs and to document
their adherence to such practices could lead to significant delays in the launch of our products candidates into the market or in the continued supply of any product after approval. Failure by third-party manufacturers to comply with applicable
regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, revocation or suspension of marketing approval for any products granted pre-market approvals, seizures or recalls of products, operating
restrictions, and criminal prosecutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if any manufacture needs to be replaced or new or increased product supplies obtained, we might not be
able to locate and engage a new manufacturer on a timely basis or at all. Any of these events could have a material adverse effect on sales of an approved product, which could negatively impact our financial condition and our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from companies with considerably more resources and experience than we
have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our potential competitors have substantially greater financial, technical, personnel and marketing resources than we do. In addition, many of these
competitors have significantly greater resources devoted to product development and pre-clinical research. Our ability to compete successfully will depend largely on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand the market for any approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully commercialize our product candidates alone or with commercial partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discover and develop product candidates that are superior to other products in the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain required regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain qualified personnel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain patent and/or other proprietary protection for our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical
companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and
commercialize medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While no oral medication has been approved by the FDA for PE, Priligy (dapoxetine) has been approved in some countries. Many commonly prescribed oral
medications may delay orgasm and be prescribed alone or in combination with other treatments. These medications include antidepressants, treatments for erectile dysfunction and tramadol for the treatment of pain. We also are aware of topical
products which are over-the-counter, or OTC, monograph products for premature ejaculation which include brands such as Promescent (Absorption Pharmaceuticals), a topical spray approved by the FDA in 2013, EjectDelay (Innovus Pharma) and PreBoost
(Aspen Park Pharmaceuticals), all of which would compete with Zertane. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the RedoxSYS System and ProstaScint, we also compete with companies that
design, manufacture and market already existing and new in-vitro diagnostics systems and tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that we will face increased competition in
the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of
our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more
substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not
generate sufficient revenue to become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any new product that competes with a currently-approved product must demonstrate compelling advantages
in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If we are not able to compete effectively against our current and future competitors, our business will not grow and our
financial condition and operations will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of our product candidates are commercialized, they may not be accepted by physicians,
patients, or the medical community in general. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the medical community accepts a product as safe and efficacious for its indicated use,
physicians may choose to restrict the use of the product if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any existing medicines or
treatments. We cannot predict the degree of market acceptance of any product candidate that receives marketing approval, which will depend on a number of factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demonstration of the clinical efficacy and safety of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approved labeling for the product and any required warnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the advantages and disadvantages of the product compared to alternative treatments; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our and any collaborator&#146;s ability to educate the medical community about the safety and effectiveness of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reimbursement policies of government and third-party payors pertaining to the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market price of our product relative to competing treatments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of Zertane, tramadol
hydrochloride is a well-established centrally acting synthetic analgesic that has been used for more than 30 years as a treatment for moderate to severe pain. As an opioid, tramadol hydrochloride has been associated with certain adverse effects
including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. As a result, physicians may be reluctant to prescribe Zertane to treat premature ejaculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zertane will, and our other product candidates may, contain controlled substances, the manufacture, use, sale, importation, exportation, prescribing and
distribution of which are subject to regulation by the DEA. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can commercialize Zertane, and potentially our other product candidates,
the DEA will need to determine the controlled substance schedule, taking into account the recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially diminish any regulatory
exclusivity periods for which we may be eligible. Zertane will, and our other product candidates may, if approved, be regulated as &#147;controlled substances&#148; as defined in the Controlled Substances Act of 1970, or CSA, and the implementing
regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to
our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw
materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and
may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of
abuse among such substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that Zertane will, and our other product candidates may, be listed by the DEA as Schedule IV controlled substances
under the CSA. Consequently, the manufacturing, shipping, storing, selling and using of the products will be subject to a high degree of regulation. Also, distribution, prescribing and dispensing of these drugs are highly regulated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is
specific to the particular location, activity and controlled substance schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of their restrictive nature, these laws and regulations could
limit commercialization of our product candidates containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities,
consent decrees, criminal and civil penalties and state actions, among other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generic tramadol hydrochloride is available in the
United States and abroad for treatment of pain. Although the generic drug is not available in the same dosage or formulation as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off
label&#148; for the treatment of PE instead of Zertane, which would adversely affect our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zertane is a specifically formulated,
unique dosage of tramadol hydrochloride, generic tramadol hydrochloride is commercially available in the United States and abroad for treatment of pain. Although the generic drug is not available in the same dosage or form as Zertane for treatment
of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of PE instead of Zertane, which would adversely affect our business. Patients could use generic tramadol hydrochloride
dosages that are either higher or lower than what may be approved for Zertane or they could attempt to split dosages to arrive at reasonably similar dosages approved for Zertane. While any such &#147;off label&#148; use of generic tramadol
hydrochloride for treatment of PE may constitute infringement of our patent portfolio, liability in that circumstance would be at the level of the physician or the patient making enforcement difficult or impractical. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment
initiatives, may negatively impact our ability to generate revenues if we obtain regulatory approval to market a product. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The continuing efforts
of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our or our collaborators&#146; ability to set a price we believe is fair for our products, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to generate revenues and achieve profitability; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of capital. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2010 enactments of the Patient Protection and Affordable Care Act, or PPACA,
and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act, are expected to significantly impact the provision of, and payment for, health care in the United States. Various provisions of these laws have only
recently taken effect or have yet to take effect, and are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing
conditions, establish health insurance exchanges, and provide additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government
insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and medical devices and reduce demand and prices for our products and product candidates, if approved. This could harm
our or our collaborators&#146; ability to market any products and generate revenues. Although we do not expect to receive significant revenues from reimbursement of our products by commercial third-party payors and government payors, cost
containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products and product candidates approved in the future,
and could cause an increase in our compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be
unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or any of our
future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a drug or medical c device must be approved before it may be
lawfully marketed. The requirements governing pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the medicinal product on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that any country that has price
controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the European Union do not
follow price structures of the United States and generally tend to have significantly lower prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products and product candidates may cause
undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. For example, adverse events associated with tramadol use in general and observed in the PE clinical trials included:
gastrointestinal, or GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, headache) and decreased blood pressure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if a product candidate receives marketing approval and we or others identify undesirable side effects
caused by the product after the approval, or if drug abuse is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw or limit their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide to remove the product from the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for injury caused to individuals exposed to or taking the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market
acceptance of the affected product candidate and could substantially increase the costs of commercializing an affected product or product candidates and significantly impact our ability to successfully commercialize or maintain sales of our product
or product candidates and generate revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint may prove to be difficult to effectively commercialize following our acquisition of the
product from Jazz Pharmaceuticals. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues
following our acquisition of ProstaScint in May 2015. Specifically, we may encounter difficulty by virtue of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to secure continuing prescribing of ProstaScint by current or previous users of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to effectively transfer and scale manufacturing as needed to maintain an adequate commercial supply; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to gain regulatory clearance required as the new distributor of the product in the U.S. and elsewhere where we seek to commercialize ProstaScint; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to adequately resource a manufacturing site transfer, which, we expect, will be required in order to guarantee ongoing commercial supply; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of ProstaScint; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to effectively identify and align with commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed
to enable commercial success of ProstaScint. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may use hazardous chemicals and biological materials in our business. Any claims
relating to improper handling, storage or disposal of these materials could be time consuming and costly. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development processes
may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury
or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage,
handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and
may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or
operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are
interpreted and enforced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to
obtain and maintain required clearances or approvals could prevent us from broadly commercializing the MiOXSYS System for clinical use. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
MiOXSYS System is subject to 510(k) clearance by the FDA prior to its marketing for commercial use in the United States, and to regulatory approvals required by foreign governmental entities prior to its marketing outside the United States. In
addition, any changes or modifications to a device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, may require the submission of
a new application for 510(k) clearance, pre-market approval, or foreign regulatory approvals. The 510(k) clearance and pre-market approval processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and
uncertain. It generally takes from four to twelve months from submission to obtain 510(k) clearance, and from one to three years from submission to obtain pre-market approval; however, it may take longer, and 510(k) clearance or pre-market approval
may never be obtained. We have limited experience in filing FDA applications for 510(k) clearance and pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory requirements even after obtaining
clearance or approval. There can be no assurance that we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain
compliance with FDA regulatory requirements could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial results will
depend on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success
depends on the acceptance by our target customers, third-party payors and the medical community that our products and product candidates are reliable, safe and cost-effective. Many factors may affect the market acceptance and commercial success of
our products and product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to convince our potential customers of the advantages and economic value our products and product candidates over existing technologies and products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative convenience and ease of our products and product candidates over existing technologies and products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the introduction of new technologies and competing products that may make our products and product candidates a less attractive for our target customers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in training medical personnel on the proper use of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of third-party payors to reimburse our target customers that adopt our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acceptance in the medical community of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent and success of our marketing and sales efforts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third-party payors do not reimburse our customers for the products we
may sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While ProstaScint is already FDA-approved and generating revenues in the U.S., the product may not continue to receive physician, hospital, or laboratory
acceptance, or it may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product candidates is approved and reaches the market, the product may not achieve physician, hospital, or laboratory acceptance, or
it may not obtain adequate reimbursement from third party payors. We expect to sell our products and product candidates to target customers substantially all of whom receive reimbursement for the health care services they provide to their patients
from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors,
including each third-party payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate and medically necessary for the specific indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors may deny reimbursement for covered products if
they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures
and devices deemed to be experimental. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement approval for a product from each government or third- party payor is a time
consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to
gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a
profit or even cover their costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of
reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available
for any product or product candidate, which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which would result in a significant
shortfall in achieving revenue expectations and negatively impact our business, prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing risks and
inefficiencies may adversely affect our ability to produce our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the acquisition of ProstaScint from Jazz Pharmaceuticals, we
expect to resume the relationship with the third-party manufacturer of ProstaScint. We expect to transition the site of manufacture within the current manufacturer&#146;s qualified sites. During this transition we may not be able to supply
sufficient quantities and on a timely basis, while maintaining product quality, acceptable manufacturing costs and complying with regulatory requirements, such as quality system regulations. In addition, we expect to engage third parties to
manufacture components of the RedoxSYS and MiOXSYS systems. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing capabilities. In determining the required quantities of any product and the
manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing any products,
there could be significant differences between our estimates and the actual amounts of product we require. If we do not effectively transition sites with our manufacturing and development partners to enable to production scale of ProstaScint, or if
we do not secure collaborations with manufacturing and development partners to enable production to scale of the RedoxSYS and MiOXSYS systems, we may not be successful in selling ProstaScint or in commercializing the RedoxSYS and MiOXSYS systems in
the event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reliance on third parties for regulatory compliance and quality assurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible breaches of manufacturing agreements by the third parties because of factors beyond our control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible regulatory violations or manufacturing problems experienced by our suppliers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to effectively and
rapidly transition our site of ProstaScint manufacture. We may not be able to meet the demand for the RedoxSYS System if one or more of any third-party manufacturers is not able to supply us with the necessary components that meet our
specifications. It may be difficult to find alternate suppliers for any of our products or product candidates in a timely manner and on terms acceptable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur
significant expenses to comply with, and experience delays in our product commercialization as a result of these regulations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing
processes and facilities of third-party manufacturers we engage are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance,
labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could
cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including
the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administrative or judicially imposed sanctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall or seizure of the product in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production or distribution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s refusal to grant pending future clearance or pre-market approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal or suspension of marketing clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the export of the product in question; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">criminal prosecution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these actions, in combination or alone, could prevent us from marketing,
distributing or selling the RedoxSYS System or ProstaScint or any other approved product, and would likely harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a product
defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception.
Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial
resources, expose us to product liability or other claims, and harm our reputation with customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in sales and
marketing and may be unable to successfully commercialize our products and product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a company, we have limited marketing, sales and
distribution experience and capabilities. Our ability to achieve profitability depends on attracting and retaining customers for our products and product candidates, and building brand loyalty. To successfully perform sales, marketing, distribution
and customer support functions, we will face a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain skilled support team, marketing staff and sales force necessary to increase the market for our approved products and to commercialize and gain market acceptance for our product
candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our sales and marketing team to identify and penetrate the potential customer base; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the difficulty of establishing brand recognition and loyalty for our diagnostic products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may
seek to enlist one or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world. If we do seek to enter into these arrangements, we may not be successful
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in attracting desirable sales and distribution partners, or we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those of any
third-party sales and distribution partners, are not successful, our currently approved products may not achieve increased market acceptance and our product candidates may not gain market acceptance, which would materially impact our business and
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face intense competition from established and new companies in the in-vitro diagnostics field. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete with companies that design, manufacture and market already-existing and new in-vitro diagnostics systems and tests. We anticipate that we will face
increased competition in the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete
or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest
in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete
successfully, we may not generate sufficient revenue to become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth depends, in part, on our ability to penetrate foreign
markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future profitability will depend, in
part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to primarily rely on collaboration with third parties. If we commercialize our products or product candidates in foreign markets, we
would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to directly control commercial activities because we are relying on third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">import or export licensing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer accounts receivable collection times; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer lead times for shipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">language barriers for technical training; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency exchange rate fluctuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our customers&#146; ability to obtain reimbursement for our products in foreign markets; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign sales of our products or product candidates could also be adversely affected by the imposition of governmental controls, political and economic
instability, trade restrictions and changes in tariffs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to various regulations pertaining to the marketing of our products.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or
acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential patients to request our products and services. Additionally, any product promotion educational activities, support of continuing
medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly
and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under
a federal healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payer, not only the Medicare and Medicaid programs, and do
not contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction of our product candidates,
which may have a material adverse effect on our business, operating results and financial condition. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellectual Property Risks
Related to Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may decline if we do not adequately protect our proprietary rights. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends on obtaining and maintaining proprietary rights to our products and product candidates as well as successfully defending these
rights against third-party challenges. We will only be able to protect our products and product candidates from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them.
Our ability to obtain patent protection for our products and product candidates is uncertain due to a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to make the inventions covered by pending patent applications or issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to file patent applications for our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop identical, similar or alternative products, compositions or devices and uses thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any or all of our pending patent applications may not result in issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our compositions, devices and methods may not be patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may identify prior art or other bases which could invalidate our patents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we have or obtain
patents covering our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products that
are similar or identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices, and some of these relate to our products and product candidates. These could materially affect
our ability to sell our products and develop our product candidates. Because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our products and
product candidates may infringe. These patent applications may have priority over patent applications filed by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining a patent
portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of
patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition,
there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant
management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those
that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our
competitive position could suffer, which could harm our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical and
medical device patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual questions. The
interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions
and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty.
Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter
partes review in the USPTO. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction
in the scope of one or more of the claims of the patent or patent application. In addition, such interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued
patents may not provide us with sufficient protection against competitive products or processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, changes in or different interpretations of
patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and commercialize our technology and products and product candidates without providing any compensation to us, or may limit the number of
patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to obtain and maintain patent protection and trade secret protection of our products and product candidates, we could lose our competitive
advantage and competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developments in patent law could have a negative impact on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the United States Supreme Court, other federal courts, the United States Congress or the USPTO may change the standards of patentability
and any such changes could have a negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which
was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system, changes the way issued patents are
challenged, and changes the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The
USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions,
became effective on March&nbsp;16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any,
impact the America Invents Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent
applications, all of which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection, because we operate in the highly technical field of discovery and development of therapies and
medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment
agreements with our employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all
confidential information developed by the party or made known to the party by us during the course of the party&#146;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering
services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security
measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent
an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Trade secrets may be
independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was
independently developed by a competitor, our competitive position could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to enforce our intellectual property rights
throughout the world. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United
States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the
enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the
misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of
patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive
and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of
our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability
to obtain adequate protection for our technology and the enforcement of intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert ownership or commercial
rights to inventions we develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual
property. We have or expect to have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with
collaborators with respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of
intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#146;s materials where
required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&#146;s samples, we may be limited in our ability to capitalize on the market potential of these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective,
or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value
of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either
outcome could have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that our employees or consultants have wrongfully used or disclosed
confidential information or misappropriated trade secrets. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We might employ individuals who were previously employed at universities or other
biopharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may
be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other
third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A dispute
concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant litigation in the pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not
currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products or product candidates infringe the
intellectual property rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the
patented drugs, compositions or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire
scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other
similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of
litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could lead to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#146;s patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and
business, prospects and financial condition. As a result, we could be prevented from commercializing our products and product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Organization, Structure and Operation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio controls us, including having the ability to control the election of our directors, and its interests may conflict with or differ from your
interests as stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, Ampio owned 81.5% of our outstanding common stock. If Ampio were to choose so, as a result
of its stock ownership, Ampio may be able to influence our management and affairs and control all matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation, or sale of all or
substantially all of our assets or other major corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market price of our common stock. This control may delay, deter or prevent acts that would be favored by our other stockholders, as the interests of Ampio may not always coincide with our
interests or the interests of our other stockholders. For example, Ampio may seek to cause us to take courses of action that, in its judgment, could enhance its investment in us, but which might involve risks to our other stockholders or adversely
affect us or our other stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to achieve some or all of the benefits that we expect to achieve from our separation from
Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a stand-alone, independent public company, we believe that our business will benefit from, among other things, allowing our management
to design and implement corporate policies and strategies that are based primarily on the characteristics of our business, allowing us to focus our financial resources wholly on our own operations and implement and maintain a capital structure
designed to meet our own specific needs. However, as a result of our separation from Ampio in April 2015 there is a risk that we may be more susceptible to market fluctuations and other adverse events than we would have been if we were still a part
of Ampio. We may not be able to achieve some or all of the benefits that we expect to achieve as a stand-alone healthcare company or such benefits may be delayed or may not occur at all. For example, there can be no assurance that analysts and
investors will place a greater value on our company as a stand-alone healthcare company than on our business as a part of Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our historical
financial information as a business conducted by Ampio may not be representative of our results as an independent public company. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical
financial information included or incorporated herein does not necessarily reflect what our financial position, operating results or cash flows would have been had we been an independent entity during the historical periods presented. The historical
costs and expenses reflected in our financial statements include amounts for certain corporate functions historically provided by Ampio, including costs of finance and other administrative services, and income taxes. These expense allocations were
developed on the basis of what we and Ampio considered to be reasonable prices for the utilization of services provided or the benefits received by us. The historical financial information in our audited financial statements may not be indicative of
what our results of operations, financial position, changes in equity and cash flows would have been had we been a separate stand-alone entity during the periods presented or will be in the future. We have not made adjustments to reflect many
significant changes that will occur in our cost structure, funding and operations as a result of our separation from Ampio, including changes in our employee base, changes in our tax structure, potential increased costs associated with reduced
economies of scale and increased costs associated with being a publicly traded, stand-alone company, such as audit fees, directors and officers insurance costs and compliance costs, nor have we made offsetting adjustments to reflect the benefits of
this offering, as these factors are presently difficult to quantify. These same risks will apply to the financial information of the ProstaScint business when it is included in our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have received better terms from unaffiliated third parties than the terms we received in our agreements with Ampio. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements related to our separation from Ampio, including the assignment and assumption agreement, services agreement and the other agreements, were
negotiated in the context of our separation from Ampio while we were still part of Ampio and, accordingly, may not reflect terms that would have resulted from arm&#146;s-length negotiations among unaffiliated third parties. The terms of the
agreements we negotiated in the context of our separation related to, among other things, allocation of assets, liabilities, rights, indemnifications and other obligations among Ampio and us. We may have received better terms from third parties
because third parties may have competed with each other to win our business. Our sole director is also a member of the Ampio board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to
operate our business effectively may suffer if we or Ampio terminate our services agreement, or if we are unable to establish on a cost-effective basis our own administrative and other support functions in order to operate as a stand-alone company
after the expiration or termination of our services agreement with Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Merger, we relied on administrative and other resources of
Ampio to operate our business. We have entered into a services agreement to retain the ability for specified periods to use certain Ampio resources. We may elect to continue this agreement for an indefinite period of time. Any decision by us to
terminate this agreement would be approved by disinterested members of our management and board of directors under our procedures regarding related party transactions. After the termination of this agreement, we would need to create our own
administrative and other support systems or contract with third parties to replace Ampio&#146;s services. These services </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be provided at the same level, and we may not be able to obtain the same benefits that we received prior to the separation. These services may not be sufficient to meet our needs, and if
our agreement with Ampio is terminated, we may not be able to replace these services at all or obtain these services at prices and on terms as favorable as we currently have with Ampio. Any failure or significant downtime in our own administrative
systems or in Ampio&#146;s administrative systems during the transitional period could result in unexpected costs, impact our results or prevent us from paying our suppliers or employees and performing other administrative services on a timely
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse developments at Ampio could negatively impact our company. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acquired the businesses of Vyrix (Zertane) and Luoxis (the RedoxSYS and MiOXSYS systems) from Ampio in the Merger. In addition, Joshua Disbrow and Jarrett
Disbrow held executive positions at Ampio and/or its subsidiaries prior to the Merger. Further, at June&nbsp;30, 2015, Ampio owned approximately 81.5% of our outstanding common stock. As a result, negative developments, including negative publicity,
at Ampio could be imputed to our company and have an adverse impact on our business and prospects, including our ability to raise capital or enter into collaborations, and on the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may seek to hold us responsible for liabilities of Ampio that we did not assume in our agreements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our separation from Ampio, Ampio has generally agreed to retain all liabilities that did not historically arise from our business. Third
parties may seek to hold us responsible for Ampio&#146;s retained liabilities. Under our agreements with Ampio, Ampio has agreed to indemnify us for claims and losses relating to these retained liabilities. However, if those liabilities are
significant and we are ultimately liable for them, we cannot assure you that we will be able to recover the full amount of our losses from Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any disputes that arise between us and Ampio with respect to our past and ongoing relationships could harm our business operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise between Ampio and us in a number of areas relating to our past and ongoing relationships, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with non-compete provisions applicable to Ampio and us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">labor, tax, employee benefit, indemnification and other matters arising from our separation from Ampio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distribution and supply obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee retention and recruiting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business combinations involving us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales or distributions by Ampio of all or any portion of its ownership interest in us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the nature, quality and pricing of transitional services Ampio has agreed to provide us; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business opportunities that may be attractive to both Ampio and us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to resolve any
potential conflicts, and even if we do, the resolution may be less favorable than if we were dealing with an unaffiliated party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements we have
entered into with Ampio may be amended upon agreement between the parties. While we are controlled by Ampio, Ampio may be able to require us to agree to amendments to these agreements that may be less favorable to us than the original terms of the
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of our management may have conflicts of interest because of their ownership of Ampio common stock, options to acquire Ampio common
stock and positions with Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our sole director and three of our executive officers own Ampio common stock and options to purchase Ampio common
stock. In addition, our sole director is also the Chief Executive Officer and a director of Ampio and our Chief Financial Officer is also the Chief Financial Officer of Ampio. Ownership of Ampio common stock and options to purchase Ampio common
stock by our director and officers and the presence of a director of Ampio on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our board of directors could create, or appear to create, conflicts of interest with respect to matters involving both us and Ampio. For example, corporate opportunities may arise that are
applicable or complementary to both of our businesses and that each business would be free to pursue, such as the potential acquisition of a particular business or technology. However, we do not believe that Ampio intends to acquire businesses that
are focused on urological disorders. We have not established at this time any procedural mechanisms to address actual or perceived conflicts of interest of these individuals and expect that our board of directors, in the exercise of its fiduciary
duties, will determine how to address any actual or perceived conflicts of interest on a case-by-case basis. If any corporate opportunity arises and if our sole director or officers do not pursue it on our behalf, we may not become aware of, and may
potentially lose, a significant business opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to develop and expand our company, and we may encounter difficulties in managing
this development and expansion, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we had nine full-time employees, and in connection
with being a public company, we expect to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial
systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount
of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our
infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial
resources from other projects, such as the planned expanded commercialization of our approved products and the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our
expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to expand the market for our
approved products and develop our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new
personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends to a significant degree upon the technical and management skills of our officers and key personnel, including in
particular those of Joshua Disbrow, our Chief Executive Officer, and Jarrett Disbrow, our Chief Operating Officer. The loss of the services of any of these individuals would likely have a material adverse effect on us. Our success also will depend
upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key personnel. The loss of any of our key
executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
compete for such personnel against numerous companies, including larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting or retaining such
personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product
candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical and
medical device products. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration of a patient&#146;s condition, injury or even death. Once a product is approved for sale and
commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. These lawsuits may divert our management from
pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits
which may be costly to defend and could materially harm our business, financial condition and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we expect to maintain general
liability, clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect
against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products and product candidates that receive regulatory approval, which could adversely affect our
business. Product liability claims could also harm our reputation, which may adversely affect our collaborators&#146; ability to commercialize our products successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In order to satisfy our obligations as a public company, we may need to hire additional qualified accounting and financial personnel with appropriate
public company experience in the event that we no longer utilize the finance and administrative functions of Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we must
establish and maintain effective disclosure and financial controls. We may need to hire additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit
and maintain such personnel. Even if we are able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion of
management resources from product development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our third-party contractors or consultants, may
fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of
security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for
our product candidates which could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our
data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product
candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits
of such acquisitions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with
our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected
benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. These risks apply to our acquisition of ProstaScint in May 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we had federal net operating loss carryforwards of approximately $17.1 million. The available net operating losses, if not utilized
to offset taxable income in future periods, will begin to expire in 2031 and will completely expire in 2034. Under the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and the regulations promulgated thereunder, including, without
limitation, the consolidated income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards and other tax attributes (such as research tax credits) to offset our income. Were Ampio&#146;s
equity ownership interest in our Company to fall below 80% and we were to be deconsolidated from Ampio&#146;s consolidated federal income tax group, certain of our net operating loss carryforwards may not be available to us and we would not be able
to use them to offset our U.S. federal taxable income. In the event of such a deconsolidation, it is possible that certain other tax attributes and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our Company and Ampio do not have a tax sharing agreement that could mitigate the loss of net
operating losses and other tax attributes resulting from a deconsolidation or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint and several liability of group members. In addition to the
deconsolidation risk, an &#147;ownership change&#148; (generally a 50% change (by value) in equity ownership over a three-year period) under Section&nbsp;382 of the Code could limit our ability to offset, post-change, our U.S. federal taxable
income. Section&nbsp;382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses.
Either the deconsolidation or the ownership change scenario could result in increased future tax liability to us. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to
Securities Markets and Investment in our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is not now, and there may never be, an active, liquid and orderly trading market
for our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is not now, nor has there been since our inception, any substantial trading activity in our common stock or a market
for shares of our common stock, and an active trading market for our shares may never develop or be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite period of time. Although
our common stock is quoted on the OTCQB, an over-the-counter quotation system, trading of our common stock is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing standards of any
national securities exchange, and we presently anticipate that our common stock will continue to be quoted on the OTCQB or another over-the-counter quotation system in the foreseeable future. In those venues, our stockholders may find it difficult
to obtain accurate quotations as to the market value of their shares of our common stock, and may find few buyers to purchase their stock and few market makers to support its price. As a result of these and other factors, you may be unable to resell
your shares of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair our ability to raise capital by selling additional equity in the future, and may impair our ability to enter
into strategic partnerships or acquire companies or products by using shares of our common stock as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our share price is volatile and
may be influenced by numerous factors, some of which are beyond our control. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common stock is likely to be highly
volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this report, these factors
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the products or product candidates we acquire for commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated adverse results or delays in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to commercialize our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated serious safety concerns related to the use of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our dependence on third parties, including CROs and scientific and medical advisors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in quarterly operating results; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the estimates and projections of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar
companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions or trends in the healthcare, biotechnology and pharmaceutical industries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products offered by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain an adequate rate of growth and manage such growth; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuances of debt or equity securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general political and economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effects of natural or man-made catastrophic events; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other events or factors, many of which are beyond our control. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and
the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described
in these &#147;Risk Factors,&#148; could have a dramatic and material adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FINRA sales practice
requirements may limit a stockholder&#146;s ability to buy and sell our stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Industry Regulatory Authority, or FINRA, has adopted
rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their
non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#146;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has
indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our common stock, they may make it more difficult
for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and any trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any trading market for our common stock that may develop will depend in part on the research and reports
that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities or industry analysts commence coverage of our company,
the trading price for our stock would be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock
price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have material liabilities that have not been discovered as a result of the Merger. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Merger, the former business plan and management of Rosewind have been abandoned and replaced with the business and management team of Vyrix
and Luoxis. Prior to the Merger, there were no relationships or other connections among the businesses or individuals associated with Rosewind and Vyrix and Luoxis. As a result, we may have material liabilities that have not been discovered as a
result of the Merger. We could experience losses as a result of any such undisclosed liabilities that are discovered, which could materially harm our business, prospects and financial condition. Although the Merger Agreement contains customary
representations and warranties from Rosewind concerning its assets, liabilities, financial condition and affairs, there may be limited or no recourse against Rosewind&#146;s pre-Merger stockholders or principals in the event those representations
prove to be untrue. As a result, our stockholders will bear some, or all, of the risks relating to any such unknown or undisclosed liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may be exposed to additional risks as a result of &#147;going public&#148; by means of a merger transaction. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be exposed to additional
risks because the business of Vyrix and Luoxis has become a public company through a &#147;reverse merger&#148; transaction. There has been increased focus by government agencies on transactions such as the Merger in recent years, and we may be
subject to increased scrutiny by the SEC and other government agencies and holders of our securities as a result of the completion of that transaction. Additionally, our &#147;going public&#148; by means of a reverse merger transaction may make it
more difficult for us to obtain coverage from securities analysts of major brokerage firms following the Merger because there may be little incentive to those brokerage firms to recommend the purchase of our common stock. The occurrence of any such
event could cause our business or stock price to suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we became public by means of a &#147;reverse merger,&#148; it may be more
difficult to list on a national exchange such as the NASDAQ, NYSE or NYSE MKT. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be more difficult to list on a major exchange because we
have conducted a reverse merger. In 2011, the SEC approved new rules of the three major U.S. listing markets that toughen the standards that companies going public through a reverse merger must meet to become listed on those exchanges. Under the
rules, NASDAQ, NYSE and NYSE MKT impose more stringent listing requirements for companies that become public through a reverse merger. Specifically, the rules prohibit a reverse merger company from applying to list on either the NASDAQ, NYSE or NYSE
MKT until: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the company has completed a one-year &#147;seasoning period&#148; by trading in the U.S. over the counter market or on another regulated U.S. or foreign exchange following the reverse merger, and filed all required
reports with the SEC, including audited financial statements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the company maintains the requisite minimum share price for a sustained period, and for at least 30 of the 60 trading days, immediately prior to its listing application and the exchange&#146;s decision to list.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible for a reverse merger company to be exempt from these special requirements, but only if a listing is in connection with a
substantial, firm commitment underwritten public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a substantial number of shares of authorized but unissued capital stock, and if
we issue additional shares of our capital stock in the future, our existing stockholders will be diluted. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation
authorize the issuance of up to 300,000,000 shares of our common stock and up to 50,000,000 shares of preferred stock with the rights, preferences and privileges that our Board of Directors may determine from time to time. As of June&nbsp;30, 2015,
we had 14,259,681 shares of our common stock issued and outstanding, which represents 4.75% of our total authorized shares. In addition to capital raising activities, which we expect to continue to pursue in order to raise the funding we will need
in order to continue our operations, other possible business and financial uses for our authorized capital stock include, without limitation, future stock splits, acquiring other companies, businesses or products in exchange for shares of our
capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting and retaining employees by the issuance of additional securities under our equity compensation plans, or other
transactions and corporate purposes that our Board of Directors deems are in the best interest of our company. Additionally, shares of our capital stock could be used for anti-takeover purposes or to delay or prevent changes in control or our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management. Any future issuances of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value, they may have rights, preferences and
privileges that are superior to those of our common stock, and they may have an adverse effect on our business or the trading price of our common stock. The issuance of any additional shares of our common stock will reduce the book value per share
and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could cause our stock
price to fall. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public
market after the legal restrictions on resale discussed in this prospectus lapse or after those shares become registered for resale pursuant to an effective registration statement, the trading price of our common stock could decline. As of
September&nbsp;30, 2015, a total of 14,259,681 shares of our common stock were outstanding. Of those shares, only approximately 3.5% are currently freely tradable, without restriction, in the public market. We have registered for resale under the
Securities Act an aggregate of 2,463,080&nbsp;shares of our common stock held by persons who are not affiliates of Ampio and those shares are freely tradable, except for shares held by our affiliates, provided the holders comply with applicable
prospectus delivery requirements, and any sales of those shares or any perception in the market that such sales may occur could cause the trading price of our common stock to decline. Additionally, as of September 30, 2015, an aggregate of
12,629,624 shares subject to lock-up agreements entered into in connection with the Merger became or will become freely tradable upon the phased expiration of the lock-up agreements on April&nbsp;16, 2017 (3,910,133 shares), October&nbsp;16, 2017
(2,906,517 shares), April&nbsp;16, 2018 (2,906,517 shares) and October&nbsp;16, 2018 (2,906,517 shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have outstanding convertible notes that
we issued in July and August 2015, in the aggregate principal amount of approximately $5.2 million. The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of our common stock equal in an amount equal to
120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of our next public offering of our stock resulting in
proceeds to us of at least $5,000,000 in gross proceeds (excluding indebtedness converted in such financing) prior to the maturity date of the notes, referred to as a Qualified Financing. The principal and accrued interest under the notes will
automatically convert into a number of shares of such equity securities of our company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the lesser of (i)&nbsp;the lowest price paid by an investor
in such financing or (ii)&nbsp;$4.63. In the event that we sell equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to
convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of our capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal
and accrued interest by the lesser of (a)&nbsp;the lowest cash price per share paid by purchasers of shares in such financing, or (b)&nbsp;$4.63. If these notes are converted, the shares of common stock issuable upon conversion could be sold. We are
registering for resale under the Securities Act an aggregate of 1,484,282&nbsp;shares of our common stock into which these convertible notes may convert, and upon the effectiveness of that registration those shares will be freely tradable without
restriction. The perception of such issuance and sale could negatively impact the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also are registering for resale under the
Securities Act all of the 11,626,068&nbsp;shares of our common stock owned by Ampio, and upon the effectiveness of that registration those shares will be freely tradable without restriction. The perception of such sale could negatively impact the
price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, shares of common stock that are reserved for future issuance under our future equity incentive plans will
become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, Rule 144 and Rule 701 under the Securities Act, and any future registration of such shares under the Securities Act. If these
additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could
result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that significant additional
capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to
time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material
dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future sales of our common stock by us or resales of our common stock by our existing
stockholders could cause the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market price of our common stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such
shares, and any sales of such shares in the market, could have an adverse effect on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some provisions of our
charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult
for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its
discretion from time to time and without stockholder approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting the removal of directors by the stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allowing for the creation of a staggered board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminating the ability of stockholders to call a special meeting of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for
stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a
Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are
approved by the board of directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or beneficial to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change
in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are
willing to pay for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The elimination of personal liability against our directors and officers under Delaware law and the existence
of indemnification rights held by our directors, officers and employees may result in substantial expenses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and
our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of
Incorporation and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive officers provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized
by the Delaware law and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to
substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing a
lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay cash dividends on our capital stock in the foreseeable future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of
cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion
of the our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our common stock is subject to the &#147;penny stock&#148; rules of the SEC and the trading market in the
securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has
adopted Rule 15g-9 which establishes the definition of a &#147;penny stock,&#148; for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share,
subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that a broker or dealer approve a person&#146;s account for transactions in penny stocks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to approve a person&#146;s account for transactions in penny stocks, the broker or dealer must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain financial information and investment experience objectives of the person; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of
transactions in penny stocks. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule
prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the basis on which the broker or dealer made the suitability determination; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that the broker or dealer received a signed, written agreement from the investor prior to the transaction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, brokers may be less willing to execute transactions in securities subject to the &#147;penny stock&#148; rules. This may make it more difficult for
investors to dispose of common stock and cause a decline in the market value of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disclosure also has to be made about the risks of investing in
penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor
in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; and &#147;Business,&#148; contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this
prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need for, and ability to raise, additional capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number, designs, results and timing of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the regulatory review process and any regulatory approvals that may be issued or denied by the U.S. Food and Drug Administration or other regulatory agencies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to secure collaborators to license, manufacture, market and sell any products for which we receive regulatory approval in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the medical benefits, effectiveness and safety of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture sufficient amounts of our product candidates for clinical trials and our products for commercialization activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercial success and market acceptance of any of our products and product candidates that are approved for marketing in the United States or other countries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety and efficacy of medicines or treatments introduced by competitors that are targeted to indications which our products and product candidates have been developed to treat; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current or prospective collaborators&#146; compliance or non-compliance with their obligations under our agreements with them; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors discussed elsewhere in this prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking
statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148;
&#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things,
those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those
implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and
Exchange Commission as exhibits to this prospectus completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not
rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds from the resale of the shares of common stock under this prospectus are solely for the accounts of the selling stockholders identified in this
prospectus. We will not receive any proceeds from the sale of shares under this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_6"></A>MARKET FOR COMMON
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is quoted on the OTCQB under the symbol &#147;AYTU.&#148; The following table sets forth the range of bid and asked closing
quotations for our common stock on the OTCQB for the periods shown. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent actual transactions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 12, 2015, the bid and asked price as reported on the OTCQB of our common stock were each $4.35. As of October
12, 2015, there were 126 holders of record of our common stock. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid any cash dividends on our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for
use in our operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined by the Board of Directors in light of conditions then existing, including earnings, financial condition, capital
requirements and other factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the dividend: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we would not be able to pay our debts as they become due in the usual course of business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set forth above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably
believe are likely to limit materially the future payment of dividends on common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has the right to authorize the issuance of
preferred stock, without further stockholder approval, the holders of which may have preferences over the holders of our common stock as to payment of dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_8"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty healthcare company
concentrating on developing and commercializing products with an initial focus on urological indications and related conditions. We are focused primarily on the urological disorders market and specifically sexual dysfunction, urological cancers and
male infertility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through a multi-step reverse triangular merger, on April&nbsp;16, 2015, Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) and Luoxis
Diagnostics, Inc. (&#147;Luoxis&#148;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis.
On June&nbsp;8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and&nbsp;effected a reverse stock split in which each common
stock holder received one share of common stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split). All share and per share amounts in this prospectus have been adjusted to reflect the effect of the Reverse
Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2015, we entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc., pursuant to which we purchased
assets related to Jazz Pharmaceuticals&#146; product known as ProstaScint<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and
work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of Jazz Pharmaceuticals&#146; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of
the upfront payment of $1.0 million. We also agreed to pay an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory and $227,000 payable on September&nbsp;30, 2015 (which represents a portion of
certain FDA fees). We also will pay 8% on its net sales made after October&nbsp;31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2015, we entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we
purchased assets related to FSC&#146;s product known as Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing
and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of FSC&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We paid
$500,000 at closing for the Primsol Business and we agreed to pay an additional $141,694 payable within five days after transfer of the Primsol-related product inventory. We also agreed to pay an additional (a)&nbsp;$500,000 payable no later than
March&nbsp;31, 2016, (b)&nbsp;$500,000 payable no later than June&nbsp;30, 2016, and (c)&nbsp;$250,000 payable no later than September&nbsp;30, 2016 (together, the &#147;Installment Payments&#148;), for a total purchase price of $1,891,694. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have financed operations through a combination of private and public debt and equity financings including the net proceeds from the private
placement of stocks as well as a convertible note. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at
least the next 12 months. See &#147;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not received any significant revenues from the commercialization of
our product candidates and do not expect to receive significant revenues from the commercialization of our product candidates in the near term. However, we have recognized limited revenue from ProstaScint sales. We have incurred accumulated net
losses since our inception, and as of June&nbsp;30, 2015, we had a deficit accumulated of $18.4 million. Our net loss $7.7 million for the year ended June&nbsp;30, 2015 and $5.6 million for the year ended June&nbsp;30, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Significant Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These historical financial
statements prior to April&nbsp;16, 2015 include the financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to the Vyrix Acquired Assets from March&nbsp;23, 2011, the date Ampio
originally acquired the Vyrix assets (the &#147;Vyrix Acquired Assets&#148;) through its merger with DMI BioSciences, Inc. (&#147;BioSciences&#148;) and the financial statements of Luoxis from its inception in January 2013, combined with the
carve-out financial statements related to Luoxis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and
the Vyrix Acquired Assets and the statement of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, <I>General Instructions to Financial Statements,
and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements</I>. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and
Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio&#146;s books. In addition, we allocated corporate overhead costs based on a
review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$253,000 in 2014. We also prepared a calculation of income tax expense and deferred income tax assets and liabilities on a &#147;separate return&#148; basis (see Note 4 &#150; Income Taxes).
These financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#148;, &#147;us&#148; and &#147;our&#148; as referred to herein include Vyrix and Luoxis, collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our activities, being primarily research and development, have not generated significant revenue to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider all highly
liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Our investment policy is to preserve principal and maintain liquidity. We
periodically monitor our positions with, and the credit quality of the financial institutions with which we invest. Periodically, throughout the year, we have maintained balances in excess of federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreements and
Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of
the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones recognized at the time the milestones are achieved. Royalties will be
recognized as revenue when earned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product&nbsp;&amp; Service Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or
determinable and collectability is reasonably assured. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fixed Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fixed assets are recorded at cost and after being placed in service, are depreciated using the straight-line method over estimated useful lives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In-Process Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In-process
research and development (&#147;IPRD&#148;) relates to the Zertane product and clinical trial data acquired in connection with the 2011 acquisition of BioSciences. The $7,500,000 recorded was based on an independent, third party appraisal of the
fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. Once the Zertane product obtains regulatory approval and commercial production
begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If we decided to abandon the Zertane product, the IPRD would be expensed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs of establishing patents, consisting
of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, is $500,000. The Zertane patents were acquired in connection with the 2011
acquisition of BioSciences and the cost is being amortized over the remaining U.S. patent lives of approximately 11 years. The cost of the RedoxSYS/MiOXSYS patents was $380,000 and is being amortized over the remaining U.S. patent lives of
approximately 15 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions
include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of
definite and indefinite lived assets. Actual results could differ from these estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are included in the consolidated tax returns of Ampio. Our taxes are computed and reported on a &#147;separate return&#148; basis for these financial
statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for
taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is
more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of income taxes and related income tax positions taken would be subject to audits by federal and state tax authorities if we filed these taxes on a
separate basis. We have adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the
benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. We believe that we have no material uncertain tax positions. Our policy is to record a liability for the difference
between the benefits that are both recognized and measured pursuant to the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 740-10, Accounting for Uncertainty in Income Taxes&#151;an
interpretation of FASB Statement No.&nbsp;109 (&#147;ASC 740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the
period in which the determination is made. We report tax-related interest and penalties as a component of income tax expense. During the periods reported, our management has concluded that no significant tax position requires recognition under ASC
740-10. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account
for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation
costs ratably over the period of service using the graded method. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred with expenses recorded in the respective periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying
amounts of financial instruments, including cash and cash equivalents, accounts payable and other current assets and other liabilities are carried at cost which approximates fair value due to the short maturity of these instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu routinely
performs an annual evaluation of the recoverability of the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is
warranted. Based on its evaluation as of June&nbsp;30, 2015 and 2014, respectively, no impairment existed for long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Newly Issued
Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2015, the FASB issued Accounting Standards Update (&#147;ASU&#148;) 2015-10, &#147;Technical Corrections and
Improvements&#148;. The amendments represent changes to clarify the codification, correct unintended application of guidance, or make minor improvements to the codification that are not expected to have a significant effect on current accounting
practice or create a significant administrative cost. In addition, some of the amendments will make the codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the
presentation of guidance in the codification. The amendments that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. Early adoption is
permitted, including adoption in an interim period. All other amendments will be effective upon issuance. We are evaluating the impact of ASU 2015-10 on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued&nbsp;ASU 2015-03,&nbsp;&#147;Interest - Imputation of Interest (Subtopic 835-30):
Simplifying the Presentation of Debt Issuance Costs.&#148;&nbsp;The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt
liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting principle. The
update is effective for fiscal years beginning after December&nbsp;15, 2015. Early adoption is permitted for financial statements that have not been previously issued. We are evaluating the impact of ASU 2015-03 on its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the FASB issued ASU 2015-01, &#147;Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by
Eliminating the Concept of Extraordinary Items.&#148; The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary
events and transactions. The amendment is effective for annual reporting periods beginning after December&nbsp;15, 2015 and subsequent interim periods with early application permitted. We are evaluating the impact the adoption of ASU 2015-01 will
have on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU No.&nbsp;2014-15, &#147;Presentation of Financial Statements-Going Concern
(Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial
doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December&nbsp;15, 2016, with early adoption
permitted. We are evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU 2014-09
regarding ASC Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be
entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted but not prior to the original public organization effective date of
December&nbsp;15, 2016. We are evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations&#151;June 30, 2015 Compared to June&nbsp;30, 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of operations for the year ended June&nbsp;30, 2015 (&#147;2015&#148;) and the year ended June&nbsp;30, 2014 (&#147;2014&#148;) reflected losses of
approximately $7,723,000 and $5,579,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated significant revenue in our operating history. The total revenue recognized during 2015 and 2014 was $262,000 and $59,000, respectively.
Revenue is earned from the amortization of advanced payments received on our license agreements. In 2012, we received a payment of $500,000 for our license agreement of Zertane with a Korean pharmaceutical company. This payment was deferred and is
being recognized over 10 years. In 2014, we received a payment of $250,000 for our license agreement of Zertane with a Canadian-based supplier. This payment was deferred and is being recognized over seven years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $176,000 product and service revenue recognized in 2015 represents sales of our ProstaScint product and the RedoxSYS System. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs consist of clinical trials and sponsored research, labor, stock-based compensation, sponsored research &#150;
related party and consultants and other. These costs relate solely to research and development without an allocation of general and administrative expenses and are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trials and sponsored research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,244,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,411,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Labor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consultants and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,423,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,059,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of Years Ended June&nbsp;30, 2015 and 2014 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased $636,000, or 15.7%, in 2015 over 2014. This was due primarily to decreased costs in clinical trial and sponsored
research related to the Zertane trials. We expect research and development expenses to increase in 2016 as compared to the 2015 level due to ramping up the Zertane trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist of personnel costs for employees in executive, business development and operational functions and director fees; stock-based compensation; patents and intellectual property; professional fees including legal, auditing
and accounting; occupancy, travel and other including rent, governmental and regulatory compliance, insurance, investor/public relations and professional subscriptions. These costs are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Labor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">979,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">557,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Occupancy, travel and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,227,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,383,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of Years Ended June&nbsp;30, 2015 and 2014 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative costs increased $2,036,000, or 86.7%, in 2015 over 2014. The increase in professional fees, labor costs and stock-based compensation
primarily relates to increased costs related to the Merger and associated SEC filings and legal expenses, professional staffing, bonuses earned and stock options granted as well as the continuing vesting of stock option awards granted in previous
years. Occupancy, travel and other increased due to the additional travel to commercialize the RedoxSYS System. We expect general and administrative expenses to increase in 2016 due to the expected overall growth of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Operating Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
2015, our operating activities used $6.6 million in cash. The use of cash was approximately $1,089,000 lower than the net loss due primarily to non-cash charges for stock-based compensation, depreciation and amortization, amortization of prepaid
research and development related party, an increase in accounts payable and an increase in contingent consideration related to the ProstaScint asset purchase. Cash used in operating activities also included a $24,000 deferred tax benefit and
$561,000 decrease in payable to Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2014, our operating activities used $5.5 million in cash. The use of cash was approximately $77,000 lower
than the net loss due primarily to non-cash charges for stock-based compensation, depreciation and amortization and an increase in related party payable. Cash used in operating activities also included a $814,000 deferred tax benefit, a $497,000
increase in prepaid expenses and a $465,000 increase in research and development - related party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2015, cash was used to acquire ProstaScint as well as deposits for office space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2014, cash was used to purchase fixed assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net
Cash from Financing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2015 was $12.4 million which reflects a $7.4 million loan from Ampio
which was later converted to stock, $5 million stock subscription payment from Ampio, $27,000 paid out to Luoxis option holders pursuant to the Merger and $20,000 paid out for liabilities pursuant to the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2014 was $5.2 million which reflects a $4.6 million loan from Ampio and $637,000 in contributions from Ampio.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commitments
and contingencies are described below and summarized by the following table as of June&nbsp;30, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ProstaScint Inventory Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research agreement with related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical research and trial obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office Lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,222,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,427,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">433,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Office Lease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
June 2015, we entered into a 37 month operating lease. This lease has initial base rent is $2,900 a month, with total base rent over the term of the lease of approximately $112,000. We recognize rental expense of the facility on a straight-line
basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aytu Manufacturing and Commercial Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
entered into agreements with manufacturing companies to build its RedoxSYS and MiOXSYS systems. The current remaining commitment is $133,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Research and Trial Obligations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the Zertane clinical trials and RedoxSYS/MiOXSYS research studies, the remaining commitment is $329,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research
Agreement with Related Party </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June
2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without
cause by either party on 30 days&#146; notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint Inventory Transfer Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to pay $500,000 for the ProstaScint-related product inventory upon the inventory transfer in July 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2015, we entered into agreements with Ampio whereby we agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the
shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated
significant revenue as our primary activities are focused on research and development, advancing our primary product candidates, and raising capital. As of June&nbsp;30, 2015, we had cash and cash equivalents totaling $7.4 million available to fund
our operations and $1.2 million in accounts payable. Based upon the Ampio commitment to fund our operations with another $5.0 million and the sale of convertible notes in July and August 2015, we believe we have adequate capital to continue
operations through calendar year 2016 and into calendar year 2017. This projection is based on a number of assumptions that may prove to be wrong, and we could exhaust our available cash and cash equivalents earlier than presently anticipated. We
intend to seek additional capital within the next 12 months to expand our clinical development activities for Zertane and RedoxSYS/MiOXSYS as well as building out a sales force for our ProstaScint product. In addition, we intend to evaluate the
capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional
capital during the next 12 months at such time as we conclude that such capital is available on terms that we consider to be in the best interests of our company and our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared a budget for 2015 which reflects cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead
at an average cash burn rate of approximately $400,000 to $500,000 per month. Additional funds are planned for regulatory approvals, clinical trials, outsourced research and development and commercialization consulting. Accordingly, it will be
necessary to raise additional capital and/or enter into licensing or collaboration agreements. At this time, we expect to satisfy our future cash needs through Ampio&#146;s contributions to us and private or public sales of our securities or debt
financings. We cannot be certain that financing will be available to us on acceptable terms, or at all. Over the last three years, volatility in the financial markets has adversely affected the market capitalizations of many bioscience companies and
generally made equity and debt financing more difficult to obtain. This volatility, coupled with other factors, may limit our access to additional financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October of 2015 we acquired the Primsol business for $1.9 million which will be paid out over a one year period and entered into a manufacturing agreement
with Biovest to provide the active pharmaceutical ingredient for ProstaScint over a four year period at a total cost of $5.0 million of which $2.5 million is expected to be paid in fiscal 2016. We have updated our forecast for fiscal 2016 and 2017
as of October 12, 2015 and we still believe that we have adequate capital as of this date along with the $5.0 million that will be contributed by Ampio to continue our operations through calendar 2016 and into 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our plan to raise capital, during July and August 2015, we sold in a private placement convertible promissory notes with an aggregate principal
amount of $5.2 million. The notes are our unsecured obligation. Unless earlier converted, the notes will mature 18&nbsp;months from their respective dates of issuance which will be on January&nbsp;22, February&nbsp;11 and February&nbsp;28, 2017,
with an option to extend up to six months at our discretion (provided that in the event we exercise such extension option, the then applicable interest rate shall increase by 2% for such extension period). We do not have the right to prepay the
notes prior to the maturity date. Interest will accrue on the notes in the following amounts: (i)&nbsp;8% simple interest per annum for the first six months and (ii)&nbsp;12% simple interest per annum thereafter if not converted during the first six
months. If there has not been a registration statement on Form&nbsp;S-1 filed with the SEC for the registration of the shares of common stock underlying the notes by the expiration of the first six-month period then (a)&nbsp;the interest rate will
increase to 14% for the remainder of the period in which the notes remain outstanding and (b)&nbsp;any notes held by officers and directors of our Company will be subordinated to the remaining notes. Interest will accrue, is payable with the
principal upon maturity, conversion or acceleration of the notes and may be paid in kind or in cash, in our sole discretion. The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of our common stock equal
in an amount equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of our next public offering of our
stock resulting in proceeds to us of at least $5,000,000 in gross proceeds (excluding indebtedness converted in such financing) prior to the maturity date of the notes (a &#147;Qualified Financing&#148;). The principal and accrued interest under the
notes will automatically convert into a number of shares of such equity securities of our Company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the lesser of (i)&nbsp;the lowest price paid by
an investor in such financing or (ii)&nbsp;$4.63. In the event that we sell equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the
option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of our capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding
principal and accrued interest by the lesser of (i)&nbsp;the lowest cash price per share paid by purchasers of shares in such financing, or (ii)&nbsp;$4.63. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot raise adequate additional capital in the future when we require it, we will be required to delay,
reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts. We also may be required to relinquish greater or all rights to product candidates at an earlier stage of development or on less
favorable terms than we would otherwise choose. This may lead to impairment or other charges, which could materially affect our balance sheet and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have
off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &#147;variable interest entities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of Inflation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, we believe that our
operating expenses can be negatively impacted by increases in the cost of clinical trials due to inflation and rising health care costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_9"></A>CHANGE IN CERTIFYING ACCOUNTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective on April&nbsp;16, 2015 and with the approval of our Board of Directors, we dismissed HJ&nbsp;&amp; Associates, LLC, or HJ, as our independent
registered public accounting firm engaged to audit our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The report issued by HJ dated November&nbsp;26, 2014 relating to its audits
of our balance sheets as of August&nbsp;31, 2014 and 2013, and the related statements of operations, changes in stockholders&#146; equity (deficit) and cash flows for each of the fiscal years then ended, contained an explanatory paragraph stating
that there was substantial doubt about our ability to continue as a going concern. Other than as disclosed above, such reports did not contain an adverse opinion or disclaimer of opinion and were not qualified as to uncertainty, audit scope or
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our decision to dismiss HJ is not the result of any disagreement between us and HJ on matters of accounting principles or
practices, financial statement disclosure or auditing scope or procedures. During our two most recent fiscal years, there were no disagreements with HJ on any matter of accounting principles or practices, financial statement disclosure or auditing
scope or procedures, which disagreements, if not resolved to the satisfaction of HJ, would have caused HJ to make a reference to the subject matter of the disagreement in connection with its reports. Pursuant to the rules of the SEC applicable to
smaller reporting companies, HJ was not required to provide an attestation as to the effectiveness of our internal control over financial reporting for any period since our inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as disclosed above, there were no reportable events (as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K) during our two most
recent fiscal years. Our Board of Directors discussed the subject matter referred to above with HJ. We authorized HJ to respond fully and without limitation to all requests of our successor accountant concerning all matters related to the annual and
interim periods audited and reviewed by HJ, including with respect to the subject matter of any reportable event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provided HJ with a copy of the above
disclosures and requested that HJ furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of the letter dated April&nbsp;22, 2015, is
filed as Exhibit 16.1 to our Current Report on Form 8-K filed on April&nbsp;22, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective on April&nbsp;16, 2015 and with the approval of our Board
of Directors, we have engaged EKS&amp;H LLLP, or EKS&amp;H, as our new independent registered public accounting firm. EKS&amp;H was engaged by Vyrix and Luoxis prior to the Merger to audit their financial statements for the years ended June&nbsp;30,
2014 and 2013 and the related statements of operations, changes in stockholders&#146; equity and cash flows for each of the years then ended June&nbsp;30, 2014 and 2013 which are included in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During our two most recent fiscal years and through the date of our engagement of EKS&amp;H, neither we nor anyone on our behalf consulted with EKS&amp;H
regarding either (i)&nbsp;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to our financial statements, and no written report or oral
advice was provided to us by EKS&amp;H that was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii)&nbsp;any matter that was the subject of a disagreement (as that term is
defined in Item&nbsp;304(a)(1)(iv) of Regulation S-K promulgated under the Securities Act and the related instructions) or a reportable event (as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K) relating to our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty healthcare company
concentrating on developing and commercializing products with an initial focus on urological related conditions. We are focused primarily on the urological disorders market and specifically sexual dysfunction, urological cancers and male
infertility. We are currently focused on commercializing our ProstaScint&reg; product, which we plan to launch through a focused commercial infrastructure in the U.S. while developing corporate relationships outside the U.S. to launch ProstaScint in
major healthcare markets around the world. We acquired ProstaScint in May 2015 from Jazz Pharmaceuticals. ProstaScint, which is approved by the U.S. Food and Drug Administration, or FDA, is a marketed biologic imaging agent specifically indicated
for the diagnostic staging of prostate cancer patients. We have launched the RedoxSYS&reg; oxidation-reduction potential system, or the RedoxSYS System, into the global research market and are developing numerous clinical applications for this
potential first-in-class diagnostic device. Additionally, we have developed the MiOXSYS System as a diagnostic device for the detection of infertility in semen analysis. Further, we plan to enter Phase 3 clinical development for our lead therapeutic
candidate, Zertane, which is being studied in premature ejaculation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The premature ejaculation market in the U.S. and Europe is expected to reach over
$1.3 billion in annual sales in 2015, representing an increase of 10.3% since 2010. According to recent published analyses, premature ejaculation, or PE, is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. Based on
internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge,
only two other prescription products have been approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive behavior therapy
or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. In addition, approximately 32% of the more than 12,000 men with PE surveyed in a 2007 study
published in <I>European Urology</I> also suffered from ED. Accordingly, we believe that a combination product candidate to treat both PE and ED represents another significant worldwide market opportunity for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of our recent acquisition of ProstaScint, we are now commercial stage and generating sales for this FDA-approved prostate cancer imaging agent. As
prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused product pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 218,000 annual
cases (as of 2010). Further, more than 1,800,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need
for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are actively developing the global market for the RedoxSYS System across a range of applications. Specifically, we have begun commercializing the RedoxSYS
System for research use through direct selling, distribution partners, and academic collaborators. Over the past 18 months, we have engaged in over 60 trials around the world whereby prominent researchers are implementing oxidation-reduction
potential, or ORP, as a marker in both chronic and acute illnesses and disorders in both clinical research as well as basic science research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our
extensive network of researchers, the RedoxSYS System has demonstrated the potential to have broad clinical applications. Studies are now underway at a major U.S. university in the area of male infertility. As such, we developed the MiOXSYS System
as a line extension to RedoxSYS to specifically assess oxidative stress in semen as a tool to assess male infertility. Male infertility is prevalent, underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we expect
to bolster our research focus in this area with the MiOXSYS System to complement our focus on urologic conditions. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2013 to 2020.
Oxidative stress is broadly implicated in the pathophysiology of male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile
men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress and monitor patients&#146; responses to antioxidant therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 5, 2015, we purchased from FSC Laboratories, Inc. the assets related to its product known as
Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trimethoprim solution), including certain intellectual property and contracts, inventory, work in process and all marketing and sales assets and materials related solely to Primsol.
Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections (UTIs). This differentiated product is appropriate for UTI patients
that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (&#147;sulfa&#148;). This acquisition adds a second established brand to our product portfolio. We
expect to benefit from and continue to grow Primsol&#146;s established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. This allows us
to utilize the same sales channel as ProstaScint, leading to potential commercial synergies. For a description of the Primsol acquisition, see &#147;Prospectus Summary - Recent Developments.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Development Program </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63294tx056a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Diagnostic Development Program </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63294tx056b.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">505(b)(2) regulatory pathway </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">510(k) de novo regulatory pathway </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zertane </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our premature ejaculation product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for
the on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of pain, and we are relying on the
FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial product approved by the FDA for PE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of significant development work performed by a previous partner of Ampio, Zertane has already been evaluated outside the United States in two Phase
1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. The two Phase 1 safety trials were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89
mg) in healthy volunteers. Two randomized, placebo-controlled, blinded Phase 2 clinical trials were conducted in a total of 102 patients. These trials evaluated doses of tramadol hydrochloride between 25 and 120 mg in male subjects with PE. Two
placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight hours before a sexual
event. This development work has demonstrated a favorable safety and efficacy profile of Zertane in men with PE. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized, which should
eliminate the need for us to conduct additional pre-clinical studies and safety trials. Based on guidance received at a recent consultation meeting with the FDA, we believe we are well positioned to initiate a Phase 3 clinical program with Zertane
in the United States. Specifically, we believe the meeting clarified specific aspects of the trial, including the primary efficacy endpoints and patient inclusion and exclusion criteria. The FDA agreed to review a draft study protocol in advance of
us submitting our Investigational New Drug application, or IND. Upon completion of the program, if successful, we plan to submit a New Drug Application, or NDA, and subsequently market Zertane in the United States, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;20, 2015, we acquired
ProstaScint&reg; from Jazz Pharmaceuticals. ProstaScint Kit, or capromab pendetide (ProstaScint), is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint targets Prostate Specific Membrane
Antigen (PSMA), a protein uniquely expressed by prostate tissue. A radioactive substance called Indium In 111 is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody infused into the patient and is taken up by prostate
cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography, or SPECT). ProstaScint has been shown to be clinically effective in determining the course of treatment for a patient who has
had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in patients classified as High Risk or with recurrent prostate cancer. ProstaScint has been approved
by the FDA and Health Canada, and significant clinical data exist demonstrating the significant predictive value in prostate cancer staging. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the American Cancer Society prostate cancer is the most common cancer among men in the United
States, with an estimated 218,000 annual cases (as of 2010). Further, more than 1,800,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare
economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of
7.5%. Importantly, ProstaScint is the only FDA-approved radiopharmaceutical (for use in radioimmunoscintigraphy) specifically indicated for prostate cancer screening and is specifically highlighted in the American Cancer Society practice guidelines
for prostate cancer screening and staging. A radiopharmaceutical is a radioactive chemical or pharmaceutic preparation, labeled with a radionuclide in varying concentrations, which is used as a diagnostic or therapeutic agent. ProstaScint is labeled
with the radionuclide indium in 111 and is used as an imaging agent utilizing SPECT (single-photon emission computed tomography) imaging. Radioimmunoscintography is an imaging procedure involving the administration of radioactively-labeled
monoclonal antibodies to detect specific affected cells in a diagnostic procedure. Monoclonal antibodies are proteins specifically genetically engineered from a clone of a particular type of cell (a B cell) and programmed to enable a specific effect
on a cellular target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RedoxSYS System for Research Use </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed the development of the RedoxSYS System during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our
compliance with global quality standards in medical device manufacturing. This enabled the launch of the RedoxSYS System into the research market around the world. We also received a CE marking in Europe and Health Canada clearance to begin the
market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched sales efforts into the research market in late 2014 and since that time have already
placed the RedoxSYS System at a number of prominent research centers in the United States, Europe, and Israel. These research placements are depicted below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prominent U.S. Research Centers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63294tx057.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prominent Centers in Europe and Israel </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g63294tx058.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Johannes
Gutenberg-Universit&auml;t Mainz</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Mainz, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Uniklinik RWTH Aachen</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Aachen, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Universit&auml;tsklinikum Frankfurt</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Frankfurt, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Universit&auml;tsklinikum Rostock</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Rostock, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Charit&eacute; &#150; Universit&auml;tsmedizin Berlin</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Berlin, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Universit&auml;tsklinikum Schleswig-Holstein</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Kiel, Germany)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Cardiff University</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Cardiff, Wales, UK)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;University College London</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(London, England)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Imperial College London</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(London, England)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Southampton University</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Southampton, England)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;University of Li&egrave;ge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Wallonia, Belgium)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Universitatea de Medicin&#259; &#351;i Farmacie din Craiova</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Craiova, Romania)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;University of Thessaly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Larissa, Greece)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Western Galilee Hospital</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Nahariya, Israel)</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;Eliachar Research Laboratory</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(Nahariya, Israel)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to leverage these research relationships and build numerous applications in areas where researchers are studying
oxidative stress. Currently, there are no available research platforms that measure oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue, and cells). While oxidative stress
is commonly studied in research settings around the world (both academia and industry), the current assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To position the RedoxSYS System
effectively in the research market, we have placed key personnel in the United States, Europe, and Asia to develop direct research business relationships as well as distribution networks. From these networks, we expect to realize initial product
revenues for the RedoxSYS System for research applications in 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MiOXSYS System for Male Infertility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy to develop future clinical applications of the RedoxSYS System, we have conducted initial studies in reproductive health. Male
infertility is a significant medical condition in which oxidative stress is well known to play a substantial role. As such, we believe developing a specific instrument platform (called the MiOXSYS System) to assess oxidative stress levels in semen
and seminal fluid represents a significant commercial opportunity. Oxidative stress is well established as a leading contributing factor to male infertility. Further, a significant proportion of male infertility remains unexplained in part because
of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen and plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have conducted proof-of-concept studies in male infertility with the MiOXSYS System with a leading research center in the United States, which demonstrate
that oxidation-reduction potential effectively measures oxidative stress levels in semen and seminal plasma. Semen analysis studies are routinely conducted to assess causes of infertility, so we expect clinicians and oxidative stress researchers to
readily integrate the MiOXSYS System into routine clinical use. Additional studies are now underway to evaluate the MiOXSYS System&#146;s performance in the detection of oxidative stress levels in semen in healthy and infertile males. Of the
approximately $300 million male infertility market, the North American market and Asia Pacific market dominate due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already begun to
establish distribution relationships and direct access to major oxidative stress researchers and clinicians. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An attractive aspect of the reproductive health market relates to reimbursement as infertility treatments and the
associated diagnostic tests are generally paid directly by patients. The current infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced oxidative stress test would consume nominal relative
costs while providing specific, actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications that lower oxidative stress (e.g.,
smoking cessation, exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS System could effectively guide treatment in the infertile patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an extensive range of intellectual property across our two primary, near-term assets. We have patent protection in the United States and several other
large markets worldwide for the oxidation-reduction potential products and product candidates. Further, we have patent protection in the United States and several other large markets worldwide for the use of tramadol hydrochloride to treat PE. We
also have intellectual property specifically covering Zertane-ED, and methods of using Zertane-ED to treat comorbid PE and ED that has issued patents in several large markets worldwide and is pending in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key elements of our strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Develop a pipeline of therapeutics and diagnostics focused on urological conditions, with a focus on the initiation and completion of two Phase 3 clinical trials for Zertane in the United States and the development
of worldwide commercialization and marketing partnerships.</I>&nbsp;<I> </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate is Zertane, a Phase
3-ready oral product for the treatment of PE. Zertane is in advanced clinical studies, and we have already completed pivotal study-enabling studies in Europe that demonstrate favorable efficacy and safety in more than 600 patients with PE. We intend
to initiate and complete Phase 3 clinical trials in order to submit an NDA to obtain FDA approval for Zertane. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to maximize the value of Zertane
in the United States via either securing a licensing arrangement or commercializing it ourselves. We also expect to seek collaboration agreements to commercialize Zertane in the rest of world, or ROW, markets. We already have such agreements in
place to commercialize Zertane in South Korea and Brazil, Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America which will &#150; if approved &#150; provide royalty and milestone-based revenue for
us. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We plan to commercialize ProstaScint in the U.S. and in key markets around the world.
</I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because ProstaScint is already approved by the FDA, we expect to launch a commercial infrastructure in order to support increased sales
and distribution of ProstaScint in the U.S. In addition to U.S. approval, ProstaScint has also been approved by Health Canada. ProstaScint fills an important medical need in the detection of a common illness facing a significant number of men in the
U.S. and around the world. Prostate cancer is the most common cancer among men in the United States, with an estimated 218,000 annual cases (as of 2010). Further, more than 1,800,000 men are alive with some history of prostate cancer, and over
30,000 U.S. men die each year from the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint has several unique selling features that we believe will enable significant sales growth and
regular use by healthcare providers diagnosing and treating prostate cancer. ProstaScint is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. In multiple clinical
studies researchers have shown that when SPECT/CT scans were used in patients pre-treated with ProstaScint, ProstaScint imaging was highly sensitive in detecting prostate cancer and significantly predictive of 10-year biochemical disease free
survival in prostate cancer patients (86.6% vs. 65.5%; p=0.0014). Additionally, the American Cancer Society specifically recognizes ProstaScint by name in current prostate cancer diagnosis guidelines. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish the RedoxSYS System as a research tool and expand its application to other indications with a focus on male infertility and adjacent applications. </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead diagnostic product candidate is the MiOXSYS System, which is currently being studied in clinical trials at a major U.S. academic center to evaluate
its utility in measuring oxidative stress in infertile males. If successful, these clinical trials are expected to pave the way for our MiOXSYS System to enter the male infertility market around the world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS System is expected to be commercialized initially as a research tool, and pending the outcome of our
clinical studies &#150; oxidative stress as a key indicator of male infertility &#150; be commercialized for additional indications, if approved. Internationally, we intend to commercialize the RedoxSYS System for multiple potential indications
where oxidative stress is implicated, if approved. The United States will be our primary focus in terms of commercialization opportunities. However, we intend to leverage ROW opportunities to drive incremental revenue and adoption of our RedoxSYS
System as well as to facilitate research to develop further redox-modulated application for our RedoxSYS System. We intend to utilize distribution partners in Europe, Asia, and elsewhere to launch and grow sales in both research and diagnostic
applications. We have established research collaborations with over 20 leading academic centers around the world. Further, the RedoxSYS System has been used in numerous clinical studies supported by pharmaceutical companies. As oxidative stress is
widely studied in both academic and industry settings, the research application of the RedoxSYS System spans a wide range of applications in clinical research, basic science research, and health and wellness research. We seek, either directly or
through distributors, to commercialize the RedoxSYS System across a broad range of potential customers. To date, we have signed distribution agreements for the research market with four companies, including EuroBio in France, Una Health in the
United Kingdom, THP Medical in Austria, and KYS Technologies in Taiwan. We expect to significantly expand our distribution network throughout 2015 to enable entry into major markets in Europe and Asia. We plan to commercialize directly in the United
States. We expect these research collaborations will generate new findings and potential clinical applications for the RedoxSYS System. In turn, we believe this development of new data and publications will enable us to pursue adjunct conditions
where oxidative stress is implicated. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Acquire established marketed products and late-stage development assets within our focus.</I>&nbsp;<I> </I></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to diversify our product portfolio and create more value, we intend to seek to acquire complementary products or product candidates to develop and/or
commercialize including marketed assets. Initially, the focus will be on acquiring products or product candidates for urological conditions but we will opportunistically consider other products or product candidates based on their ability to create
value and complement our focus. We plan to pursue product acquisitions, inclusive of therapeutics, diagnostics, and devices, which will be evaluated for their strategic fit and potential for near-term and/or accretive value to us. In May 2015, we
acquired ProstaScint as part of this strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Therapeutic Product Candidate - Zertane </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for the
on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of pain, and we are relying on the
FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial prescription product approved by the FDA for
PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to recent published analyses, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. Based on internal market
research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge, only one oral
prescription product has been approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive behavior therapy or counseling, all
of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of significant
development work performed by a previous partner of Ampio, Zertane has already been evaluated outside the United States in two Phase 1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. This development work has
demonstrated a favorable safety and efficacy profile of Zertane in men with PE and helped inform the design and endpoints of the Phase 3 clinical trials we will need to obtain FDA approval. Furthermore, the safety and pharmacology of the drug
substance in Zertane, tramadol hydrochloride, is well characterized, which we believe will eliminate the need for us to conduct additional pre-clinical studies and safety trials. We believe we are well positioned to initiate Phase 3 clinical trials
with Zertane in the United States. Upon completion of the trials, if successful, we plan to submit an NDA to the FDA and subsequently market Zertane in the United States, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for Zertane is focused on the initiation and completion of the Phase 3 clinical program in the
United States and the development of worldwide commercialization and marketing partnerships. We expect to finalize clinical development of Zertane, seek FDA marketing approval and &#150; if approved&#151;commercialize the product candidate in the
United States either directly or via partnerships. We will seek partnerships to commercialize Zertane in rest of world, or ROW, markets. We already have partnerships in place to market Zertane in South Korea and Brazil, which could provide near-term
revenue for us if, working with our partners, we are able to successfully obtain regulatory approval in those countries. In addition, we recently entered into an agreement with Endo Ventures Limited, which recently acquired Paladin Labs Inc., or
Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. We also
intend to build awareness of PE in the United States with the intention of paving the way for successful product introduction and initiate pre-clinical work on Zertane-ED as a potential combination treatment for PE and ED. We expect to use a similar
clinical and commercial approach for Zertane-ED and we have a clinical development collaboration in place with our South Korean partner for the combination product candidate when we elect to actively pursue its development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PE Market Opportunity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is PE?
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medical literature contains several one-dimensional and multi-dimensional operational definitions of PE. The Diagnostic and Statistical Manual of
Mental Disorders defines PE as persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it, with the disturbance causing marked distress or interpersonal difficulty.
Alternately, the International Society for Sexual Medicine, or the ISSM, has adopted a new and evidence-based definition for lifelong PE: &#147;premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly
always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual
intimacy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE may be classified as lifelong (primary) or acquired (secondary). Lifelong PE is characterized by onset from the first sexual
experience and remains a problem throughout life. Acquired PE is characterized by either a gradual or subtle onset, with ejaculation being considered normal before onset of PE. Time to ejaculation is short but not usually as fast as in lifelong
(less than 1 minute in almost all encounters). We believe acquired PE and/or situational PE suggests a psychological cause and behavioral therapy and/or relationship counseling may be the most appropriate initial therapy. In contrast, we believe
lifelong PE suggests a biogenic cause and pharmacologic treatment is the most appropriate initial therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ejaculation latency, most commonly quantified
using intravaginal ejaculation latency time, or IELT, is a dominant component of PE assessment in clinical trials. IELT is defined as the time between vaginal intromission and intravaginal ejaculation. Although a standard cut-off for ejaculatory
latency does not exist, it has been suggested that an IELT of 2 minutes or less may serve as an adequately sensitive criterion for defining PE and some studies have used IELT values from 1 to 2&nbsp;minutes for defining PE. In a pre-IND meeting with
FDA, we agreed to use an IELT of less than or equal to 1 minute as one of the enrollment criteria for our planned Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, IELT
is not the sole criteria used to diagnose PE. We believe diagnosis of PE should also include a subject&#146;s perceived control over ejaculation, as well as distress and interpersonal difficulty due to the condition. The need to objectively assess
and diagnose PE beyond IELT has led to the development of several questionnaires within the male sexual dysfunction medical community including the Premature Ejaculation Diagnostic Tool (PEDT), Premature Ejaculation Profile, or PEP, the Index of
Premature Ejaculation (IPE), and the Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD). In collaboration with the FDA, Ampio has also developed a modified version of PEP known as the Patient Outcome for Premature Ejaculation,
referred to as the POPE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevalence of PE </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE
is a significant medical need in the United States and worldwide as it causes significant emotional distress for affected men and their partners. According to an article published in <I>European Urology</I> in 2010 and a survey published in the
<I>Journal of the American Medical Association (JAMA)</I> in 1999, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. However, most prevalence data on PE is based on patient surveys,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which are inherently subjective, and therefore some of the men surveyed may not have PE as it is defined by the medical societies noted above. In a 2007 study published in <I>European
Urology</I>, the incidence of PE was assessed via a web-based survey of 12,133 men ages 18-70 in the United States, Germany and Italy. In this survey, 2,754 or 22.7%, of the men reported that they suffer from PE. The vast majority (87.9%)&nbsp;of
men with PE wished that they had more control over time to climax. Additionally, a majority (57.6%)&nbsp;of the men surveyed reported that they would seek medical treatment if they knew that a pill to control ejaculation were available. We believe
men would also ask their doctor about treatment options if their partner suggested it. Additional primary company market research by a prominent pharmaceutical market research consulting firm commissioned by Ampio indicated that over 66% of patients
that see a urologist for PE were self-referred, which we believe further demonstrates that PE is a condition for which patients are actively seeking treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing therapies do not satisfy the significant PE market need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, there are no approved prescription pharmaceuticals in the United States to treat PE and only two pharmaceuticals known to be approved elsewhere in
the world. Current &#147;off label&#148; or unapproved therapies used to treat PE carry with them unwanted side effects and inconsistent or limited effectiveness. Topical over-the-counter, or OTC, options are not preferred due to route of
administration and may also have an impact on partner satisfaction. Oral therapeutics, specifically selective serotonin reuptake inhibitors, or SSRIs, carry potentially significant side effects most notably of which is diminished libido. PDE-5
inhibitors have been prescribed &#147;off label&#148; for PE but have not demonstrated efficacy. Outside of oral or topical therapeutics, non-medical options include behavioral therapy and relationship counseling, both of which can be time consuming
and stressful and frequently ineffective for men and their partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates the current methods used to treat patients with PE
and the associated issues based upon our sponsored market research: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:89.45pt; font-size:8pt; font-family:Times New Roman"><B>Pharmacologic Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Issues</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tricyclic antidepressants <B>*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fatigue, nausea, dizziness, dry mouth, hypotension</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Short-acting SSRIs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nausea, diarrhea, headache, dizziness, risk of suicidal ideation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Long-acting SSRIs <B>*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ED, decreased libido, fatigue, nausea, increased perspiration</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Topical desensitizing agents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Messy, numbing of vagina, skin irritation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PDE-5 inhibitors <B>*</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ineffectiveness, headache, flushing, nausea</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:106.35pt; font-size:8pt; font-family:Times New Roman"><B>Non-Pharmacologic Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Issues</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#147;Stop-Start&#148; strategy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Requires an understanding partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#147;Squeeze&#148; method</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Requires an understanding partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Psychological therapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Time consuming for patients; costly, long-term benefits unknown</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:89.45pt; font-size:8pt; font-family:Times New Roman"><B>Pharmacologic Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Issues</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Relationship counseling</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Time consuming, costly, requires an understanding partner</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>NOT approved for treatment of PE. </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe patients and their partners are generally dissatisfied
with existing pharmacologic and non-pharmacologic treatments for PE. Based on primary market research by a prominent pharmaceutical market research consulting firm commissioned by Ampio, which previously owned the rights to Zertane and is our
largest stockholder, which included discussions with a cross section of clinicians that treat patients with PE, we believe that there are significant issues with existing PE treatments demonstrating a real need for a safe and effective, FDA-approved
product to treat PE that does not have a ramp-up period. This primary market research supports that ideal product characteristics include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fewer side effects than anti-depressants, such as SSRIs, that are used &#147;off-label&#148; for PE; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quick onset/on-demand usage. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zertane </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
lead therapeutic product candidate, Zertane for premature ejaculation, contains 89 mg tramadol hydrochloride in an orally dissolving tablet, or ODT. Tramadol hydrochloride is a well-established, centrally acting synthetic analgesic and has been used
for more than 30&nbsp;years as a treatment for moderate to severe pain. The drug and its active metabolite (M1, <I>O</I>-desmethyltramadol) act as an opiate agonist, apparently by selective activity at the &micro;-receptor. Although the mechanism by
which tramadol hydrochloride delays ejaculation has not been identified, numerous laboratory studies have shown that tramadol hydrochloride also acts as an <I>N</I>-methyl-D-aspartate receptor antagonist, 5-hydroxytryptamine type 2C receptor
antagonist, 5 nicotinic acetylcholine receptor antagonist, M1 and M3 muscarinic acetylcholine receptor antagonist, and a serotonin and norepinephrine modulator. It is possible that one or a combination of these effects leads to a delay in
ejaculation. The relative contribution of tramadol hydrochloride versus its M1 metabolite to delay ejaculation is unknown. However, the metabolite is six times more potent than the parent drug in producing analgesia in animal models and 200 times
more potent in &micro;-receptor binding. As a pain medication, tramadol hydrochloride has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. However, we intend that our
labeling for Zertane, if regulatory approval is obtained, will suggest &#147;as required&#148; dosing before sexual intercourse and not to exceed one tablet per day. Based on previous clinical studies, we believe that limiting the dosing to no more
than once per day will minimize any side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an alternative to antidepressant and anxiolytic medication, tramadol hydrochloride has been
recognized as a potential therapy for treatment of PE, after an association was observed between its use and improvements in ejaculation latency time. The combination of completed clinical trials, primarily performed in Europe, planned clinical
trials in the United States, and literature are intended to establish the safety and efficacy of Zertane in the treatment of the condition and standardize the dose and dosing regimen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>History of Zertane </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;David Bar-Or
discovered the utility of tramadol hydrochloride for the treatment of PE in June 1999, and this discovery and accompanying intellectual property were the property of&nbsp;DMI BioSciences, Inc., or DMI BioSciences.&nbsp;DMI BioSciences conducted two
Phase 2 clinical studies in male subjects with PE using a pharmacy-compounded gelatin capsule preparation.&nbsp;A proof-of-concept Phase 2 study was initiated in March 2003, and final patient assessments were on July&nbsp;7, 2003.&nbsp;A
dose-ranging study Phase 2 study was initiated in September 2004 and final patient assessments were in October 2005. In 2007, DMI BioSciences licensed the worldwide rights to tramadol hydrochloride for PE to Biovail Laboratories International, or
Biovail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail had previously entered into a product development and licensing agreement with Ethypharm S.A., or Ethypharm, in 2002, which had
developed an ODT formulation of tramadol hydrochloride using its proprietary FLASHTAB technology.&nbsp;In this agreement, Biovail acquired the rights to develop and market Ethypharm&#146;s tramadol hydrochloride ODT product for use in the management
of pain. In March of 2004, Biovail submitted a Section&nbsp;505(b)(2) NDA (US NDA 21,639) to FDA for market registration of tramadol hydrochloride ODT 50&nbsp;mg (RYBIX) for the management of moderate to moderately severe pain, and this NDA was
granted approval in May 2005. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail decided not to launch the RYBIX 50&nbsp;mg ODT product in the United States, and in 2009, signed an NDA agreement
with Ethypharm pursuant to which Ethypharm acquired all the rights to RYBIX 50&nbsp;mg ODT and Biovail acquired the rights to develop, manufacture and market a FLASHTAB ODT product containing tramadol hydrochloride for the symptomatic treatment of
PE.&nbsp;In this agreement, Biovail assigned to Ethypharm all of Biovail&#146;s rights, title and interest in and to the approved NDA for RYBIX, the regulatory documentation and product rights to enable Ethypharm to develop and market RYBIX in the
United States for the management of pain.&nbsp;In addition, the agreement granted Biovail the right to reference and use all data, regulatory filings and regulatory communication, including the approved NDA for RYBIX, the product rights (including
any information, data, know-how, formulas, assays, or intellectual property contained in the approved NDA) and any and all related regulatory documentation that would be relevant for the purposes of developing, manufacturing or marketing the
tramadol hydrochloride ODT product for PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using the newly acquired FLASHTAB technology and manufacturing processes obtained in the NDA agreement with
Ethypharm, Biovail developed two strengths of tramadol hydrochloride ODT (62 and 89&nbsp;mg) for use in four NDA-enabling clinical trials: two Phase 1 pharmacokinetic/bioavailability and two Phase 3 placebo-controlled pivotal trials.&nbsp;These
trials were initiated in the latter half of 2009.&nbsp;In&nbsp;July 2010, Biovail terminated the clinical trials </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Europe as a direct result of a merger with Valeant Pharmaceuticals International, or Valeant, which was announced in June 2010 but was finalized in September 2010. Following the merger,
Valeant adopted a new research and development model and began identifying product development programs that did not align with this new R&amp;D model. In connection with this new R&amp;D model, Valeant decided to terminate Biovail&#146;s licensing
agreement for tramadol hydrochloride for PE and also to terminate the ongoing Phase 3 studies. The Valeant model did not include compounds that had any regulatory or clinical risk (i.e., were still in development) and instead was focused solely on
&#147;commercially ready&#148; products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail withdrew from its licensing agreement with DMI BioSciences and the worldwide rights to tramadol
hydrochloride for PE reverted back to DMI BioSciences, which was acquired in March 2011 by Ampio. In December of 2011, the Ethypharm-Biovail NDA Agreement was transferred to Ampio in an asset purchase from Valeant, providing Ampio access to all
data, regulatory filings and rights to develop, manufacture and market tramadol hydrochloride ODT for PE. Ampio completed clinical study reports for the European Phase&nbsp;3 studies and submitted tramadol hydrochloride 89&nbsp;mg ODT for marketing
authorization in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2013, Ampio spun out the assets and agreements associated with its sexual dysfunction treatment portfolio,
including Zertane, to its then wholly-owned subsidiary Vyrix. We acquired Vyrix in April 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six European clinical trials have been completed with Zertane: two Phase 1 trials in healthy volunteers and two Phase 2 and two Phase&nbsp;3 trials in men with
lifelong PE. The two Phase&nbsp;1 safety trials were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89&nbsp;mg)&nbsp;in healthy volunteers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two randomized, placebo-controlled, blinded Phase 2 clinical trials were conducted in a total of 102&nbsp;patients. The first of these showed that a single
25-mg dose of conventionally formulated immediate release tramadol hydrochloride (i.e., immediate-release gelatin capsules) was safe, well-tolerated and prolonged time to ejaculation in some, but not all, patients. The second trial evaluated three
higher doses of tramadol hydrochloride: 65 mg, 85 mg and 120 mg. In this trial, a clear dose response was seen for both efficacy and safety, leading DMI Biosciences to conclude that the optimal tramadol hydrochloride dose to treat PE was likely to
be in the range 60-90 mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol
hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight&nbsp;hours before a sexual event. A total of 677 patients were randomized in the trials and received either the 62 or 89 mg ODT or a matching
placebo ODT. Our claim that Zertane was efficacious in the Phase 3 trials is based on at least one of the two doses resulting in statistically significant improvements in both IELT and PEP measures (i.e., co-primary endpoints) from baseline to the
end of the trial. Using IELT in combination with a self-report questionnaire (e.g., PEP or POPE) has gained acceptance as meaningful measures of pharmacoactivity and efficacy in the scientific and regulatory communities. The results of the Phase 3
trials suggest that tramadol hydrochloride 89&nbsp;mg ODT is consistently more effective as a treatment for PE than tramadol hydrochloride 62&nbsp;mg ODT. In accordance with the definitions from the clinical trial protocols, only the tramadol
hydrochloride 89 mg ODT dose satisfied the claim for effective treatment of PE in both Phase 3 trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the six prior clinical trials of Zertane. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial&nbsp;Name</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:54.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Dates/Sponsor)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Age)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Enrollment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Design</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Duration&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Double-blind</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:44.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zertane</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:34.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dose&nbsp;(mg)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:72.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Noteworthy Findings</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-101</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(June&nbsp;26,&nbsp;2009 to
July&nbsp;5, 2009/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Healthy males and females <FONT STYLE="white-space:nowrap">(18-55</FONT> yr)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Comparative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall systemic exposure of tramadol hydrochloride and 2 metabolites were similar following 89&nbsp;mg ODT and the reference 89&nbsp;mg
tramadol hydrochloride solution.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">13 subjects experienced a total of 37 adverse events
(AEs) during the study. Most common AEs were GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, headache).</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-102</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(July 14, 2009 to July&nbsp;30,
2009/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Healthy males</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">(19-55</FONT> yr)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">424</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Alcohol interaction study</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no significant difference in the peak and total systemic exposures of tramadol hydrochloride compared to when tramadol
hydrochloride 89&nbsp;mg ODT was taken with water, or with either strength of alcohol.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tramadol hydrochloride was well tolerated with alcohol. 7&nbsp;subjects experienced 11&nbsp;AEs, most frequently decreased blood pressure and
dizziness.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNL 40237</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(March&nbsp;13, 2003</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">to July&nbsp;7, 2003/ DMI**)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Men with PE <FONT STYLE="white-space:nowrap">(18-70</FONT> yr)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Double-blind, randomized placebo-controlled</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3 weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with tramadol hydrochloride 25 mg had no statistically different effect than placebo in subjects with a baseline IELT of 2 minutes
or less (n=30; <I>P</I>=0.4560) or in a subpopulation of subjects with a baseline IELT of 1 minute or less (n=19; <I>P</I>=0.1796).</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">46 AEs emerged during treatment (28 with tramadol hydrochloride and 18 with placebo). There were no deaths, serious or other significant AEs. All AEs were of
mild intensity. Most common AEs were GI disorders (nausea) and central nervous system disorders (headache).</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial&nbsp;Name</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:54.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Dates/Sponsor)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Age)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Enrollment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Design</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Duration&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Double-blind</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:44.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zertane</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:34.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dose&nbsp;(mg)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:72.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Noteworthy Findings</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNL 40491</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(September&nbsp;28, 2004 to
October&nbsp;18, 2005/ DMI**)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Men with PE <FONT STYLE="white-space:nowrap">(18-70</FONT> yr)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Double-blind, randomized placebo-controlled</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12 weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">65, 85, 120</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tramadol hydrochloride significantly increased the median IELT compared to both Baseline and placebo. Statistically significant increases in
IELT compared to Baseline were observed to be 3.0-fold (<I>P</I>=0.0013), 4.2-fold (<I>P</I>&lt;0.0001), and 5.1-fold (<I>P</I> &lt;0.0001) for the 65-, 85-, and 120-mg dose levels, respectively.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Doses of 65 and 85 mg were generally well tolerated. 120&nbsp;mg was less well tolerated
with adverse events known to be associated with tramadol hydrochloride (headache, dizziness, somnolence, insomnia) and related to sexual function (penile hypoaesthesia, anorgasmia, and ED).</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-301</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(August 17, 2009 to
September&nbsp;9, 2010/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Men with PE <FONT STYLE="white-space:nowrap">(18-65</FONT> yr)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">221</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Double-blind, randomized placebo-controlled</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12 weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">62, 89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 89&nbsp;mg compared
to placebo (p&nbsp;=&nbsp;0.002). The significant difference was apparent at the first visit during the double-blind treatment period and each visit thereafter (p <U>&lt;</U> 0.05 for all Visits). Tramadol hydrochloride 62 mg and 89&nbsp;mg ODT
demonstrated statistically significant improvements in PEP measures compared with placebo.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">During the double-blind treatment or open-label extension periods, 21&nbsp;subjects experienced at least 1 treatment-emergent AE. There were no deaths or
serious AEs during the study.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trial&nbsp;Name</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:54.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Dates/Sponsor)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Age)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Enrollment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Design</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Duration&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Double-blind</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:44.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Zertane</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:34.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dose&nbsp;(mg)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:72.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Noteworthy Findings</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-302</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(September&nbsp;30, 2009 to
August&nbsp;23, 2010/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Men with PE <FONT STYLE="white-space:nowrap">(18-65</FONT> yr)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">456</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Double-blind, randomized placebo-controlled</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12 weeks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">62, 89</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 62 and 89&nbsp;mg
compared to placebo (p&nbsp;= 0.01 and p&nbsp;=&nbsp;0.02). Tramadol hydrochloride 62&nbsp;mg and 89 mg ODT demonstrated statistically significant improvements in both IELT and PEP measures compared with placebo.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A total of 28 out of 399&nbsp;subjects (7.5%) experienced at least 1 treatment-emergent AE
during the double-blind or open-label treatment period. No subject died or experienced a severe AE.</P></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>896</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Biovail Laboratories International, SRL </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"><I>DMI BioSciences, Inc. </I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Planned Phase 3 Clinical Program in United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the estimated size of the U.S. market opportunity for Zertane, FDA approval is a critical value driver for us in the near term. We believe we are
well positioned to quickly move into NDA-enabling Phase 3 clinical development in order to complete and submit our Section&nbsp;505(b)(2) NDA for Zertane. Ampio met with the FDA in a pre-IND meeting on June&nbsp;20, 2012 and we subsequently met with
the FDA on October&nbsp;23, 2014. As a result of these meetings, we have been able to define the number and key aspects of necessary trials to progress Zertane to an NDA that may be accepted for filing by the FDA; furthermore, the results from the
European trials will inform the design, endpoints and inclusion criteria for the U.S. Phase 3 program as well as recommendations by FDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients will be those with a subset of disease symptoms described by the ISSM Ad Hoc Committee for the Definition of PE; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Two tramadol hydrochloride doses (62 and 89&nbsp;mg)&nbsp;will be evaluated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The patient reported outcome questionnaire, or PEP, from the European Phase 3 trials, was modified to capture the most clinically significant aspects of PE from the ISSM definition &#150; now termed Patient Outcomes in
Premature Ejaculation, or POPE &#150; and this 4-question questionnaire will be validated during the first trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Key efficacy assessments will include intravaginal ejaculation latency time, or IELT, and the subject&#146;s frustration or bother due to PE; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total enrollment for each trial will be approximately 350 &#150; 400 subjects. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the Phase 3 trials
conducted in Europe, co-primary endpoints will be used for determination of efficacy. Both improvement in IELT, which will be captured by the partner in a blinded diary, and PE-related frustration or bother, which will be assessed after each sexual
intercourse attempt as well as at the final study visit by a single question in the POPE, will be evaluated as co-primary endpoints to determine efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to file the IND for Zertane in the second half of 2015. We are prepared to commence our Phase 3 clinical program soon after the IND
becomes effective because our supplies are already manufactured and packaged and only require appropriate clinical labeling of the product candidate. Importantly, our manufacturing process has already been validated at the site of commercial
manufacture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ROW Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond seeking U.S. NDA approval, we plan to leverage partnerships to gain approval and eventual marketing authorization for Zertane in several key markets
around the world. We already have partnerships in place with Daewoong Pharmaceuticals Co., Ltd. in South Korea and FBM Industria Farmaceutica Ltda. in Brazil, thereby providing potential royalty and milestone-based revenue if, working with our
partners, we are successfully able to obtain regulatory approval in those countries. In addition, our recent agreement with Paladin provides Paladin with exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South
Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. Before marketing any products in Brazil and South Korea, approval must be received from the Brazilian Health Surveillance Agency (Anvisa) and the Ministry of Food and Drug
Safety (MFDS, previously the Korean Food and Drug Administration), respectively. We intend to leverage the expertise of our local collaborators in these jurisdictions to navigate the regulatory requirements and help determine an efficient and
effective pathway to bringing Zertane to market. If required regulatory approvals are obtained, partnerships in ROW markets will potentially provide additional revenue to us and help to establish the Zertane brand and the role of tramadol
hydrochloride in PE around the world. Such clinical experience will be useful as we seek to impact treatment guidelines for PE and gather post-marketing data to better inform our U.S. NDA submission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Commercial Strategy
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the population and the anticipated pricing, the United States represents the largest PE opportunity and we will seek to maximize the market
potential for Zertane in one or more of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>License U.S. promotional rights to Zertane to an established pharmaceutical company &#150; </I>We will seek to secure a milestone and royalty-based agreement with a company to market Zertane to high-value U.S.
prescribers. Potential partners may already have a commercial presence in urology (the single largest prescriber population for PE drugs) as well as primary care physicians (the single largest category of physicians in the United States).
Alternatively, we may attempt to secure agreements with multiple partners to promote Zertane to different specialties: e.g., one for urology and one for primary care physicians. We may also consider divesting Zertane as an alternative to a licensing
agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize Zertane via our own commercial infrastructure &#150;</I> Our management has experience with all aspects of commercialization and we may deploy a specialized sales force to initiate promotion of Zertane
specifically to urologists. We may expand our commercial presence into primary care and other relevant physician specialties. Alternatively we may deploy a sales force of our own focused on urologists, while also seeking a partner for the larger
primary care segment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ROW Commercial Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated previously, we intend to leverage partnerships to market Zertane around the world. We will seek to collaborate in the largest viable markets with
companies that are well positioned to maximize sales of Zertane. Considerations for collaborations will include the prospective collaborator&#146;s presence in the therapeutic category of men&#146;s health, its ability to invest in the regulatory
and commercialization activities necessary, and its commitment to Zertane, our management team and economic terms. Countries will be prioritized for partnering based on viability of Zertane in the market, including but not limited to regulatory
pathway (i.e., the amount of regulatory work required for the partner to submit for approval); market conditions (markets that accept sexual health products); economic factors (pricing); and market size, as well as deal teams, including but not
limited to royalty and/or milestone based economic terms; upfront payments based on market; and commitment to marketing and/or regulatory investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
already have entered into collaboration agreements in South Korea and Brazil, which represent two of the larger ROW market opportunities. In addition, our recent agreement with Paladin provides Paladin with exclusive rights to market, sell and
distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. We will seek to enter into similar arrangements in additional countries with additional companies in order to capitalize
on the sizable opportunity for Zertane, and later, Zertane-ED. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ProstaScint Acquisition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;20, 2015, we acquired
ProstaScint<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from Jazz Pharmaceuticals. ProstaScint Kit, or capromab pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint
targets Prostate Specific Membrane Antigen, or PSMA, a protein uniquely expressed by prostate tissue. A radioactive substance called Indium In 111 is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody infused into the
patient and is taken up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography, or SPECT). ProstaScint has been shown to be clinically effective in determining the course
of treatment for a patient who has had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in patients classified as High Risk or with recurrent prostate
cancer. ProstaScint has been approved by the FDA and Health Canada, and significant clinical data exist demonstrating the significant predictive value in prostate cancer staging. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prostate Cancer Market </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the American
Cancer Society prostate cancer is the most common cancer among men in the United States, with an estimated 218,000 annual cases (as of 2010). Further, more than 1,800,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men
die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening
of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5%. Importantly, ProstaScint is the only FDA-approved radiopharmaceutical (for use in radioimmunoscintigraphy) specifically indicated for prostate cancer screening and is
specifically highlighted in the American Cancer Society practice guidelines for prostate cancer screening and staging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prostate cancer is classified into
four stages based on severity: Stage 1 &#150; 4. Stage 3 is considered &#147;High Risk&#148; and Stage 4 is when cancer has become metastatic. Radioimmunoscintigraphy has been established as diagnostic to stage cancer malignancy and one of the most
widespread clinical uses has been for the detection of prostate cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint Clinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple clinical studies have been conducted in the United States and published in peer-reviewed publications that consistently demonstrate substantial
clinical efficacy of ProstaScint in staging prostate cancer patients and specifically identify whether the cancer is confined to the prostate or has metastasized to other parts of the body. Through more accurate clinical staging and identification
of metastatic prostate cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings for ProstaScint from select studies are summarized below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:85.35pt; font-size:8pt; font-family:Times New Roman"><B>Principal Investigator(s)/<BR>Primary Authors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman"><B>Publication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:63.70pt; font-size:8pt; font-family:Times New Roman"><B>Patient Population</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:65.25pt; font-size:8pt; font-family:Times New Roman"><B>Conclusion/Results</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ellis RJ et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Int. J. Radiation Oncology Biol. Phy. (2010)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patients presenting for primary radiotherapy having a clinical diagnosis of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and SPECT/CT (N=239)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Haseman MK et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Urology (2007)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Men with prostate cancer who underwent imaging with ProstaScint pretreatment; Patients were divided according to the presence or absence of central abdominal uptake(CAU) (N=341)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were 10 times higher in patients
identified with ProstaScint as having central abdominal uptake (p=0.005).</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ellis RJ et al.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brachytherapy (2005)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Men with prostate cancer of all risk categories who underwent imaging with ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical disease recurrence regardless of the patient&#146;s risk category; 7-year outcomes data from brachytherapy patients with treatment based on the
ProstaScint scan showed a significant difference in biochemical disease-free survival.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Radiation oncology experts have published numerous papers expressing the potential for expanded use of ProstaScint in prostate
cancer imaging due to advances in imaging technologies since the product&#146;s initial approval. Since the early 2000s significantly greater image resolution has been enabled due to the advent of dual head cameras (and improved imaging in general)
along with the use of co-registered images where radiologists now combine the images of SPECT and computerized tomography, or CT, or magnetic resonance imaging, or MRI. Because of these factors we believe there is significant commercial opportunity
for ProstaScint. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint Product Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint is provided as a two-vial kit which contains all of the non-radioactive ingredients necessary to produce a single unit dose for administration by
intravenous injection. The ProstaScint vial contains 0.5&nbsp;mg of capromab pendetide in 1&nbsp;mL of sodium phosphate buffered saline solution adjusted to pH&nbsp;6; a sterile, pyrogen-free, clear, colorless solution that may contain some
translucent particles. The vial of sodium acetate buffer contains 82&nbsp;mg of sodium acetate in 2&nbsp;mL of Water for Injection adjusted to pH&nbsp;5-7 with glacial acetic acid; it is a sterile, pyrogen-free, clear, and colorless solution.
Neither solution contains a preservative. Each kit also includes one sterile 0.22&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>m Millex&reg; GV filter, prescribing information, and two identification labels. It may also be helpful in
conjunction with other scans (CT or MRI) for higher risk patients, by detecting lymph nodes in the abdomen that are involved with prostate cancer cells, but may still appear falsely normal on CT or MRI scans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The procedure to administer ProstaScint is as follows: the patient is given an intravenous, or IV, infusion of the monoclonal antibody, and 30 minutes later,
a scan is performed. A second scan is done between 96 and 120 hours (4-5 days) after the infusion. The first scan (on the day of the infusion) takes approximately 1 hour, while the second scan takes approximately 2.5 hours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint Uses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after
standard diagnostic evaluation (e.g.&nbsp;chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated in patients who are not at high risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic
evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium In&nbsp;111 ProstaScint following radiation therapy has not been studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided by Indium In&nbsp;111 ProstaScint imaging should be considered in conjunction with other diagnostic information. Scans that are
positive for metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu
of histological confirmation. ProstaScint is not indicated as a screening tool for carcinoma of the prostate nor for re-administration for the purpose of assessment of response to treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Novel Research Instrument &#150; The RedoxSYS System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our leading diagnostic product candidate, the RedoxSYS System, is now fully developed for research use. The RedoxSYS System was developed by Luoxis Diagnostics
in the two years immediately preceding the Merger between Luoxis, Vyrix, and us in April 2015. Upon the consummation of the Merger, the RedoxSYS System became our asset. Prior to the incorporation of Luoxis, the predecessor technologies that are now
incorporated into the RedoxSYS System were developed by the research team of Dr.&nbsp;David Bar-Or through a predecessor company, DMI BioSciences, Inc. that was acquired by Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS System is a novel, portable device that measures oxidation-reduction potential, or ORP, a global measure of oxidative stress. The RedoxSYS System
is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide range of both acute and chronic conditions. To date, Canadian and European regulators have
characterized the RedoxSYS System as Class II medical device and regulated them accordingly. Classification of a medical device as Class II in Europe and Canada indicates that the device is generally regarded as posing medium risk, and non-invasive
medical devices that come into contact with injured skin are generally classified as Class II. As we have conducted initial validation studies with the RedoxSYS System across a range of conditions and obtained a CE marking in Europe and Health
Canada clearance to begin the market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized, we are now initiating commercialization for use of the RedoxSYS System
as a research tool. By employing a focused commercial infrastructure and a growing network of distributors around the world, we believe we can efficiently penetrate the academic and industry-based research centers who study oxidative stress. With
this growth in the research market, we intend to develop clinical applications for the RedoxSYS System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for the RedoxSYS System is to
continue deployment of this system at leading academic centers around the world, develop research collaborations with key opinion leaders in oxidative stress research, identify clinical applications for the platform, and aggressively pursue
infertility studies to establish efficacy of the system in this setting of care. Our plans include introduction of the RedoxSYS System to researchers in the United States through a direct commercial effort while engaging with distributors in major
markets around the world, including Canada, Europe, and Asia (with a focus on Japan, Korea, Taiwan, Singapore and Malaysia). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oxidative Stress and
the Male Infertility Market Opportunity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An early potential opportunity that has presented promise through our research is the application of ORP
in the study of male infertility. ORP represents a unique approach to assessing oxidative stress in male infertility, and early proof-of-concept studies have been conducted. We are now beginning clinical studies with a globally recognized U.S.-based
university in male infertility. Oxidative stress is widely assessed in male infertility laboratories, and we believe the RedoxSYS System, if proven effective, will provide a simple, comprehensive solution to oxidative stress </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">detection and management of antioxidant and lifestyle intervention in this underserved market. Given the
preliminary results obtained from clinical trials conducted in semen analysis, we believe significant opportunity exists to launch a derivative product of RedoxSYS to specifically assess oxidative stress in the context of male infertility.
Accordingly, we developed the MiOXSYS System as a uniquely designed and programmed device specific to the detection of oxidation-reduction potential in semen and seminal fluid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oxidative stress plays a pivotal role in the pathogenesis of male infertility. The presence of excess levels of reactive oxygen species, or ROS, is associated
with both the structural and functional integrity of sperm. Moreover, these increased levels of ROS &#150; the increase of oxidative stress &#150; directly interfere with capacitation and fertilization. It is widely estimated that total infertility
is driven by male infertility in half of the cases, and the major factors influencing the rise in infertility among men are the change in lifestyle, increasing age, and environmental effects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevalence of Male Infertility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of all sexually
active adults, 12-15% are infertile and male infertility is the sole cause or contributing factor 50% of the time. The global male infertility market is large and growing. The market is expected to grow to more than $300 million globally by 2020,
with a CAGR of nearly 5% from 2013 to 2020. Despite the prevalence of male infertility, difficulties remain in effectively diagnosis root causes. Oxidative stress assessment is considered a standard practice but due to various factors is not
effectively used routinely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Role of ORP in Male Infertility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oxidation-reduction potential is defined in the published literature as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ORP in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents contribute to the
ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include thiols,
vitamin C, tocopherol, &szlig;-carotene, lycopene, uric acid, bilirubin, and flavinoids. Enzymes such as superoxide dismutase, or SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less reactive species. ORP
monitoring of plasma represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of the system.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that ORP represents a single, global measure of oxidative stress in a biological system, we believe the potential for ORP to serve as a standardized
marker in semen analysis and other aspects of infertility assessment is significant. A major limitation of oxidative stress assays relates to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress
(e.g., free radical proliferation, antioxidant depletion, DNA damage, etc.), it is important to have an integrated measure that combines all known and unknown oxidants and reductants in the respective system into one measurement. We believe ORP is
an integrated measure of oxidative stress that can be easily and quickly measured with the RedoxSYS System. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Current assays are incomplete and only </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>approximate global redox balance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Measures of oxidative stress: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63294tx073.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the context of infertility, having an integrated value representing all relevant biologic constituents contributing to
oxidative stress will enable simple, robust analysis in a four-minute test. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Existing infertility assessment tools do not satisfy the clinical need
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are various techniques in use to assess semen in cases of male infertility. The most commonly implemented techniques involve DNA
fragmentation, oxidative stress analysis, microscopic examination, sperm penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available oxidative stress analysis tools are widely considered expensive
and cumbersome to use in routine clinical practice. In both developed countries as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly impossible to implement with regularity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Opportunity for the RedoxSYS System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
believe the market opportunity for the RedoxSYS System is significant as scientists implicate oxidative stress in numerous diseases and acute conditions. Our initial focus of commercializing the RedoxSYS System for use in research enables us to
rapidly build a base of clinical validation and utility data across a range of illnesses. As such, we expect to generate early revenues from oxidative stress researchers implementing the RedoxSYS System into their routine oxidative stress research
programs while generating published clinical data demonstrating ORP&#146;s usefulness in disease monitoring and prognostic assessment. From a clinical perspective, we plan to continue our research efforts in male infertility while expanding future
applications in acute and chronic illnesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global male infertility market is in excess of $300 million, while the broader <I>in vitro</I>
diagnostics, or IVD, market is expected to grow to more than $80 billion by 2017. With a substantial base of conditions for which the MiOXSYS System may present utility, we expect to realize significant revenue potential from this first-in-class
system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our collaborative research efforts our scientific team has identified several diagnoses in which we believe the ORP technology derives
distinct values that may be useful in better identifying a patient&#146;s risk for the development of more severe illness &#150; beyond reproductive health and infertility. Further, we believe the ORP technology has the potential to better stratify
patients according to clinical characteristics detected uniquely by ORP measurements. Specific diseases where the RedoxSYS System has been initially studied include trauma, critical illness, stroke, heart failure, diabetes, and pregnancy. Multiple
other clinical areas exist where the system could be studied and potentially applied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diagnostics serve a key role in the health value chain by influencing the quality of patient care, health
outcomes and downstream resource requirements across a wide range of clinical conditions. From consumer-friendly at-home pregnancy and glucose monitoring tests to more complex automated laboratory-based systems, these tests are often first-line
health decision tools. While diagnostics comprise less than 5% of hospital costs and about 1.6% of all Medicare costs, their findings are commonly believed to influence as much as 60-70% of health care decision-making. The value of diagnostics
accrues not only to clinicians and patients, but to health care managers, third-party payors and quality assurance organizations that use diagnostic performance to measure and improve health care quality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORP is a tightly controlled measurement, much like the vital signs routinely measured in medical practice&#151;temperature, heart rate, respiratory rate,
blood pressure and oxygen saturation of blood. Abnormal changes in oxidation-reduction potential are closely associated with poor outcomes in critically ill patients, including traumatic brain injury, multi-trauma injury, stroke, sepsis, and
pneumonia. Rapid results are essential for optimal treatment adjustments in critical care areas such as emergency and intensive care departments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORP
results may also help determine which patients are at high risk of early readmission at hospital discharge, especially patients with heart attack, heart failure, stroke, and pneumonia, and this represents an incremental assessment not afforded by
currently available diagnostic tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous scientific studies confirm the clinical value of measuring oxidative stress. Recently, a large assortment
of blood and cell tests have been used in research studies to measure separate biomarkers of oxidative stress, such as lipid peroxidation, protein oxidation and total antioxidants, but currently many of these separate biomarker test results are
needed to start to assess total oxidative stress. Despite the importance of assessing oxidative stress, we are not aware of any practical or efficient method for measuring these oxidative stress biomarkers in a point-of-care setting. Oxidative
stress is often a marker for inflammation, which in turn indicates the presence of disease-related processes or developing conditions across a wide array of diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The worldwide IVD market was $44 billion in 2010 and is projected to grow to $82 billion by 2017. The IVD market includes all laboratory and hospital-based
sales and home-use, or over-the counter, product sales covering immunoassays, clinical chemistry, microbiology, hematology, histology/cytology, point-of-care testing, and over-the-counter diagnostics. The professional point-of-care testing worldwide
market is a significant opportunity and was in excess of $5 billion in 2009 and is expected to grow to almost $7 billion by 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, critical
care (an application for which the RedoxSYS System is targeted) constituted 14% ($700 million) of sales in 2009 with expected CAGR of 5%, and cardiac markers constituted 9% ($435 million) of sales in 2009 with expected CAGR of 8%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background on the RedoxSYS System </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the
RedoxSYS System is the first and only research and clinical diagnostic platform that provides an accurate, easy, and complete real-time assessment of redox status. Through the development and commercialization of the RedoxSYS System, we are
pioneering the true measurement of redox potential, also called oxidation-reduction potential, a novel measure of oxidative stress, which has been implicated in numerous critical injuries, illnesses, and chronic conditions with significant
appreciation of the role of oxidative stress in infertility. We believe the RedoxSYS platform has a broad range of potential in both research and clinical settings where no other methods exist to measure oxidation-reduction potential in biologic
specimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through research directed by Dr.&nbsp;David Bar-Or and Raphael Bar-Or at Ampio, we believe we have developed the first and only clinical
diagnostic device that measures ORP in biologic specimens (i.e., plasma, serum, semen, seminal plasma, cells, tissues, cell cultures, and others). This device, called the RedoxSYS System, rapidly measures ORP and antioxidant capacity, a global
marker of antioxidant reserve and concentration to provide a global picture of oxidative status. The system uses a small, bench top analyzer in conjunction with small, disposable sensors that work electrochemically without any liquid reagents or
difficult sample preparation. The RedoxSYS System has been CE marked and approved for use in Europe and Canada, and we are now collaborating with major medical centers around the world for its use in research. The RedoxSYS System is an easy-to-use
diagnostic device that can be used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in various research settings. Further, this portable device can be decentralized to multiple research sites and enable real-time reporting of oxidative stress values at the patient&#146;s point
of care or in a clinical laboratory setting. We received ISO 13485:2003 medical device certification in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS System has been developed over
an 18-year period by Dr.&nbsp;David Bar-Or, Raphael Bar-Or, and their colleagues, and the research and development work has focused on both the technical and clinical development of various applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The RedoxSYS System Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS System
is comprised of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant capacity of a biological fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a working
electrode and a reference electrode at equilibrium. The RedoxSYS System has been specifically studied in human whole blood, serum, plasma, semen, and other biological fluids. The RedoxSYS System measures two distinct elements to determine a
patient&#146;s oxidation reduction potential: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Static ORP &#150; the standard potential between a working electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance of redox agents and is what is
classically defined as ORP. Low ORP values mean that the biological sample is in the normal range of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Capacity &#150; the measure of antioxidant reserve available in the body&#146;s system. High capacity values mean that the biological sample has levels of antioxidant reserves. Lower than normal capacity values means
that the biological sample has below normal antioxidant reserves. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The RedoxSYS Analyzer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer is a portable, lightweight desktop platform that may be used in a clinical or research laboratory or near a patient care area. The
analyzer is a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional specimen collection procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader
consists of a Galvanostat analog circuit with greater than 1012 MHz input impedance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The analyzer contains a 10 MHz external crystal (internal 4X PLL for
40 MHz operation), and a programming/serial header is externally accessible. The device has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte)&nbsp;SPI Flash (3.3V)&nbsp;(Bulk data storage), and secondary storage of 2Mbit
(256Kbyte)&nbsp;SPI FRAM (3.3V)&nbsp;(Hi-Speed Storage). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer contains a user-friendly interface that is flexibly designed to
accommodate multiple endpoints depending upon the specific clinical condition being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators are visible through front panel mounted
lenses. Further, the reader contains three DPDT push-button switches (Left, Center, Right), power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection, and test completion signals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the RedoxSYS analyzer enables data transfer, has USB serial communication, and is configured for data download to a connected PC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer&#146;s power management consists of an external 5VDC power jack with input capacitance and filtering, a boost converter supplied by
external 5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader functions with or without the battery connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged use
outside of a laboratory setting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Image of the RedoxSYS Analyzer </B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63294tx076a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The RedoxSYS Sensor Strips </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ORP sensor strips, via standard biological specimen collection techniques, receive 20-40 microliters of a specimen from which the ORP clinical analysis is
performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated
with the sensors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Image of the RedoxSYS Sensor Strips </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g63294tx076b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Studies for Male Infertility &#150; The MiOXSYS System Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have begun clinical studies in male infertility with a prominent, U.S.-based university medical center utilizing the newly developed MiOXSYS System. If
successful, we anticipate we will demonstrate the MiOXSYS System&#146;s ability to measure oxidative stress in semen samples as an adjunctive measure of infertility. These studies are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:14.65pt; font-size:8pt; font-family:Times New Roman"><B>Aim</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.70pt; font-size:8pt; font-family:Times New Roman"><B>Hypothesis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:85.30pt; font-size:8pt; font-family:Times New Roman"><B>Methods and Procedures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:64.60pt; font-size:8pt; font-family:Times New Roman"><B>Expected Outcome</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The MiOXSYS System will be able to detect oxidation-reduction potential (ORP) in fresh seminal ejaculates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;Standardize the instrument for inter/intra observer and assay
variability</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.
&nbsp;&nbsp;&nbsp;&nbsp;Standardize the system for fresh ejaculate and seminal plasma measurements</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;Test the ability of the system to measure the effect of exogenous ROS in semen</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;Establish the effect
of time on ORP measurements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The assumption that MiOXSYS System can measure ORP in semen shall be confirmed</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:14.65pt; font-size:8pt; font-family:Times New Roman"><B>Aim</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.70pt; font-size:8pt; font-family:Times New Roman"><B>Hypothesis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:85.30pt; font-size:8pt; font-family:Times New Roman"><B>Methods and Procedures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:64.60pt; font-size:8pt; font-family:Times New Roman"><B>Expected Outcome</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ORP values can be detected in fresh and frozen semen samples</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;Compare the effect of rapid freezing on the ORP of the seminal ejaculate
and seminal plasma</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.
&nbsp;&nbsp;&nbsp;&nbsp;The effect of exogenous ROS addition to the ORP and capacitance of both ejaculate and seminal plasma after rapid freezing</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;Establish the effect of different subzero storage temperatures and storage time on ORP
measurement in frozen seminal ejaculate and seminal plasma samples</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;Comparing the effect of storage time after rapid freezing on the ORP of both the seminal
ejaculate and seminal plasma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It shall be confirmed that ORP can be measured in both fresh and frozen semen samples and that n differences will exist</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Establish ORP values in ejaculates of healthy men.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;Establish ORP values in seminal ejaculates of healthy men with normal
semen parameters i.e normal concentration, motility and morphology according to WHO, 2010</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;Establish the effect of varying sperm concentration 0, 10, 20, 40 and 100 X 10<SUP
STYLE="font-size:85%; vertical-align:top">6</SUP>/ mL on ORP levels (concentration response).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ORP values in ejaculates of healthy men will be established</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Establish ORP values in ejaculates of with different clinical characteristics.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;Establish the ORP values in seminal ejaculates in infertile men in the
absence or presence of leukocytes (Endtz negative and Endtz positive) samples.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;Establishing ORP in healthy normozoospermic donors and infertile men with an abnormal
spermiogram</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.
&nbsp;&nbsp;&nbsp;&nbsp;Examine effect of abstinence on ORP in semen samples from normozoospermic donors</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;ORP levels in infertile men with varicocele</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specific and different ORP values will be established in the ejaculates from men with different pathologies</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The ORP values correlate with ROS-TAC scores in ejaculates of healthy men.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;Comparative study between ORP and. ROS&#150;TAC scores as measured by chemiluminescence and total
antioxidant capacity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A positive correlation will be found between ORP values and ROS-TAC scores</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results from these clinical studies could validate that the MiOXSYS System can be used for detection of ORP in human
ejaculates and seminal plasma without requiring large sample volumes. Furthermore, it can show that the results obtained are comparable to the current parameters measured. This could validate the use of the MiOXSYS System in the clinical andrology
setting as a tool to provide real time information on oxidative status. If successful, these studies will provide substantial clinical validation for use of the MiOXSYS System in male infertility and enable a specific clinical application in the
field of andrology and male infertility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Study for Other Indications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond male infertility, we have generated robust clinical data with ORP. As much of our initial research efforts focused on trauma, research beginning in 2014
has expanded into research and clinical applications in the areas of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stroke; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sepsis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ventilator-Associated Pneumonia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Athletic exertion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hemodialysis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Post cardiac surgery; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Congestive heart failure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hip fracture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frailty; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Diabetic Kidney Disease. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have conducted numerous pre-clinical studies looking at various
neurodegenerative conditions including Parkinson&#146;s disease and multiple sclerosis. We have active research in place with over 20 key opinion leaders around the world with over 80 studies in various stages or planning or execution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2013 and 2014, we deployed the RedoxSYS System around the world in the development of numerous future clinical applications. While many areas of study have
been undertaken, we have focused research resources on high-value areas where significant medical needs remain unmet. Given our initial orientation around trauma, the studies completed thus far have focused on large conditions related to critical
care. These initial studies demonstrated the initial clinical validation for the RedoxSYS and MiOXSYS systems and represent substantial opportunities as growth applications and markets following initial entry into the research and infertility
markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initiated over 80 studies across a range of study types, ranging from studies in trauma, liver disease, diabetes, cardiac conditions,
wellness/exercise, and fertility. From this research has presented unique opportunities to deploy the RedoxSYS System to users in multiple markets around the world in various conditions. With a CE marking now in place and research instruments now
manufactured and ready for use, we are positioned to begin commercializing the RedoxSYS System. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Select Published Clinical Trials with
Oxidation-Reduction Potential </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant research has been performed on the ORP diagnostic platform, and numerous peer-reviewed publications
demonstrate the various considerations made in the development of this application in a clinical setting. Further, the research conducted to date demonstrates the clinical relevance of ORP as a diagnostic marker in trauma, the development of
transfusion-related acute lung injury, or TRALI, via blood transfusions, and other conditions. Over the past 20 years, Ampio/DMI Bioscience employees, Dr.&nbsp;Bar-Or, Raphael Bar-Or, Leonard Rael, and their colleagues, have employed the resources
of two Level 1 trauma centers in the state of Colorado. Specific, select studies reporting on the clinical role of ORP as it relates to trauma, acute lung injury related to blood transfusions, and traumatic brain injury include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Study Summary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:5.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:63.00pt; font-size:8pt; font-family:Times New Roman"><B>Outcome/Findings</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Oxidation-Reduction Potential in Trauma Patients</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy&nbsp;= 39</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Trauma&nbsp;= 10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Trauma patients admitted to a Level 1 trauma center</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Plasma ORP in multi-trauma patients increased during the first few days of hospitalization and approached normal ORP levels upon discharge</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Study Summary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:5.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:63.00pt; font-size:8pt; font-family:Times New Roman"><B>Outcome/Findings</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effect of Storage on Oxidative Biomarkers on Packed Red Blood Cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10 patient specimens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Critically ill patients with a risk of&nbsp;developing transfusion-related acute lung injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Oxidation-reduction potential significantly increased (p &lt; 0.05) in the day 42 sample versus the day 1 sample. The oxidation of human serum albumin increased by 63.6% during the storage time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plasma Oxidation-Reduction Potential and Protein Oxidation in Traumatic Brain Injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-head injury trauma patients = 26</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderate ITBI patients = 18</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy patients =</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Isolated traumatic brain injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Admission plasma ORP was significantly elevated in all traumatized patients compared to controls. Maximum ORP was detected on day 6 for severe ITBI and non-head injury traumatized patients. Maximum ORP values were significantly
higher p&lt;0.05) in the severe ITBI group compared to the non-head injury group</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Oxidation-reduction potential in trauma patients</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trauma patients = 39</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Healthy patients = 10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Critically injured patients</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The presence of an oxidative environment in the plasma of the critically injured as measured by ORP. ORP can differentiate the degree of oxidative stress based on the severity of the trauma and degree of inflammation</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Pathway </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We achieved ISO 13485: 2003 in early 2014 following the successful development of a compliant medical device quality system. Following the issuance of our ISO
certification, we were awarded a CE marking for the RedoxSYS System, which has enabled initial market development in Europe and markets that accept a CE marking. We also received Health Canada clearance, and we are now working with multiple centers
in Canada in research projects. In the United States, we intend to pursue 510k <I>de novo</I> clearance with the FDA for the MiOXSYS System. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Commercial Strategy
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the clinical studies to measure oxidative stress in male infertility are successful, we expect to pursue that intended use for the MiOXSYS
System via the FDA 510k de novo pathway. If cleared for the intended use, we intend to seek to commercialize MiOXSYS System as a new tool for the assessment of oxidative stress in infertility in men. We envision pursuing a direct sales effort to
high priority urology/andrology laboratories, infertility clinics and reference centers across the United States. We have identified the primary, influential centers in the United States and believe our commercial deployment will be efficient
through a focused sales and marketing effort. We intend to seek to sell </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the repeat ordering of the disposable, single use MiOXSYS sensor strips. We expect to realize a
substantial gross margin and profit margin on the basis of low cost of goods sold on both components of the system. We envision an average selling price for the disposable sensors of approximately $25-$40. We envision selling the MiOXSYS analyzers
for $5,500 but will also pursue an instrument rental agreement model with minimum disposable sensor purchase requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also intend to leverage our
urology commercialization efforts with other products with a focus on urology centers, infertility clinics, and reproductive health laboratories around the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe a focused sales force at the onset of commercialization will enable effective representation of our products and penetration of the reproductive
health market. Our sales efforts into the research markets will be enabled initially through a full-time business development professional who will focus on collaborative research and research sales to major oxidative stress centers in the United
States. We expect identical pricing in the research market as we intend to pursue in the clinical diagnostics markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ROW Commercial Strategy
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to undertake a similar strategy outside the United States for the RedoxSYS and MiOXSYS systems while complementing our efforts in
infertility and research with adjunct applications in critical care conditions. To efficiently execute across our strategy, we intend to utilize a network of established distributors in the target markets in Europe and Asia. We have already engaged
with distributors in three European countries and one Asian country, while many other potential distributors are in advanced stages of discussions with us. We anticipate slightly reduced pricing outside the United States for the disposable sensors
given the anticipated lower pricing observed ex-U.S. for diagnostic and research products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approval Process for Pharmaceutical Products </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA
Approval Process for Pharmaceutical Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The
Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and
marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial
sanctions, such as FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical product development in the United States typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical,
laboratory and animal studies under the FDA&#146;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated current good manufacturing requirements, or cGMP, including
a quality system regulating manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may begin in the United States, obtaining the approval of Institutional Review Boards, or IRBs,
at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for
which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and
novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pre-clinical tests generally include laboratory evaluation of a product candidate, its chemistry, formulation,
stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data and the clinical trial protocol, which
details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before
human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well
as international scientific standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time
period, raises concerns or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no guarantee that an IND based on those
studies will become effective, allowing clinical testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an independent IRB or
Ethics Committee, or EC. The IRB considers, among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&#146;s GCP requirements. The FDA and/or IRB may order the
temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical
trials, a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used. The main purpose of the trial is to assess a product candidate&#146;s safety
and the ability of the human body to tolerate the product candidate. Phase 1 clinical trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited
number of patients with the disease or medical condition for which it is intended to be used in order to: (i)&nbsp;further identify any possible adverse side effects and safety risks, (ii)&nbsp;assess the preliminary or potential efficacy of the
product candidate for specific target diseases or medical conditions, and (iii)&nbsp;assess dosage tolerance and determine the optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and to further
test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which is
intended to demonstrate the candidate product&#146;s clinical efficacy and adequate information for labeling of the approved drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are three main
types of NDAs, which are covered by Section&nbsp;505 of the FDC Act: (1)&nbsp;an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1)); (2)&nbsp;an application that contains full reports of
investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the application has not obtained a right of reference (Section
505(b)(2)); and (3)&nbsp;an application that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use,
among other things, to a previously approved product (Section 505(j)). Section&nbsp;505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the pre-IND briefing meeting with Ampio and in June
2012, the FDA agreed that our NDA may be submitted under Section&nbsp;505(b)(2). As such, we intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and
21-692) to support the safety and efficacy demonstrated in our clinical program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, an NDA is prepared
and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the
product&#146;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, currently
exceeding $2.3 million and the manufacturer and/or sponsor under an approved NDA are also subject to annual product and establishment user fees, currently approximately $0.1 million per product and $0.6 million per establishment. These fees are
typically increased annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on
the FDA&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of
NDAs. Most such applications for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed in six months. Priority review can be applied to drugs that the FDA determines offer major
advances in treatment, or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or
information intended to clarify information already </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory
committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but
it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is
manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response
letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial
marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the
potential risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU
can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially
affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or problems are identified following initial marketing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Hatch-Waxman Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon
approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book
can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as
the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of,
pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#147;generic equivalents&#148; to the listed drug, and can often be substituted by pharmacists under
prescriptions written for the original listed drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved
product in the FDA&#146;s Orange Book that: 1) the required patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent
expiration; or 4) the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a
Paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA
and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement
lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case
that is favorable to the ANDA applicant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ANDA application also will not be approved until any non-patent exclusivity listed in the Orange Book for the
referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients during which ANDAs for generic versions of those drugs cannot be submitted, unless the
submission contains a Paragraph IV challenge to a listed patent&#151;in which case the submission may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity during which FDA cannot
grant effective approval of an ANDA based on the approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use; the approval of which was
required to be supported by new clinical trials conducted by, or for, the applicant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory
approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by us
are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required to register their establishments with the FDA
and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. We cannot be certain that we
or our present or future contract manufacturers or suppliers will be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension
of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the
FDA approves one or more of our product candidates, we and the contract manufacturers we use for manufacture of clinical supplies and commercial supplies must provide certain updated safety and efficacy information. Product changes, as well as
certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug
or biologic product or medical devices, also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry
sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a
warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval Process for Medical Devices </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
United States, the FDCA, FDA regulations and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and
listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA regulates the design, manufacturing, servicing, sale and distribution of medical devices,
including molecular diagnostic test kits and instrumentation systems. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending
applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each medical device we wish to distribute commercially in the United States will require marketing authorization from the FDA
prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval, also called PMA approval. The type of marketing authorization is
generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control
deemed necessary to ensure the device&#146;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to
general controls applicable to all devices, such as requirements for device labeling, premarket notification and adherence to the FDA&#146;s current Good Manufacturing Practices, or cGMP, known as the Quality System Regulations, or QSR. Class II
devices are intermediate risk devices that are subject to general controls and may also be subject to special </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which
insufficient information exists to assure safety and effectiveness solely through general or special controls and include life sustaining, life-supporting or implantable devices, devices of substantial importance in preventing impairment of human
health, or which present a potential, unreasonable risk of illness or injury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most Class I devices and some Class II devices are exempted by regulation
from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible for marketing through the 510(k) clearance pathway. By
contrast, devices placed in Class III generally require PMA approval or 510(k) de novo clearance prior to commercial marketing. The PMA approval process is more stringent, time-consuming and expensive than the 510(k) clearance process, however, the
510(k) clearance process has also become increasingly stringent and expensive. The FDA has provided initial guidance to us that the RedoxSYS System is appropriate for the 510(k) clearance process, likely through the de novo pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">510(k) Clearance. To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the device
is &#147;substantially equivalent&#148; to a device legally marketed in the United States that is not subject to PMA approval, commonly known as the &#147;predicate device.&#148; A device is substantially equivalent if, with respect to the predicate
device, it has the same intended use and has either (i)&nbsp;the same technological characteristics or (ii)&nbsp;different technological characteristics and the information submitted demonstrates that the device is as safe and effective as a legally
marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may extend to a
year or more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application fees must accompany medical device submissions. Such fees under the Medical Device User Fees Act, or MDUFA, for 2015 are
approximately $258,000 for a full fee application and approximately $5,000 for a 510(k). Fees are adjusted annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are also establishment
registration and reporting fees of approximately $4,000 and $9,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device has received 510(k) clearance for a specific intended
use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of
an FDA user fee. The determination as to whether or not a modification could significantly affect the device&#146;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this
determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be
subject to significant regulatory fines or penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can submit a medical device for 510(k) clearance, we may have to perform a series of
generally short studies over a period of months, including method comparison, reproducibility, interference and stability studies to ensure that users can perform the test successfully. Some of these studies may take place in clinical environments,
but are not usually considered clinical trials. For PMA submissions, we would generally be required to conduct a longer clinical trial over a period of years that supports the clinical utility of the device and how the device will be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although clinical investigations of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations of
diagnostic tests, including our products and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations by intended users for intended uses of our products generally do not require the FDA&#146;s prior
approval but may require approval of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing is non-invasive, does not require an invasive sampling procedure that presents a
significant risk, does not intentionally introduce energy into the subject and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition, our products must be labeled per FDA
regulations &#147;for research use only-RUO&#148; or &#147;for investigational use only-IUO,&#148; and distribution controls must be established to assure that our products distributed for research, method comparisons or clinical evaluation studies
are used only for those purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation after FDA Clearance or Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any devices we manufacture or distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain
state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which include, among other things, testing, control and documentation requirements. Noncompliance with these
standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the government to grant 510(k) clearance or PMA approval of devices, withdrawal
of marketing approvals and criminal prosecutions, fines and imprisonment. Our contract manufacturers&#146; facilities operate under the FDA&#146;s cGMP requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulatory Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of the United
States, our ability to market our product candidates will be contingent also upon our receiving marketing authorizations from the appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory
approval process in most industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required
to obtain requisite approvals, may vary widely from country to country and differ from those required for FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, we are
required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE mark to certain of our products in order to sell the products in member countries of the European Union. The CE mark is an international symbol that
represents adherence to certain essential principles of safety and effectiveness mandated in the European Medical Device Directive, which are referred to as the &#147;essential requirements&#148;. Once affixed, the CE mark enables a product to be
sold within the European Economic Area, or EEA, which is composed of the 28 member states of the EU plus Norway, Iceland and Liechtenstein as well as other countries that accept the CE mark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To demonstrate compliance with the essential requirements, we must undergo a conformity assessment procedure which varies according to the type of medical
device and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile) where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its
products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a notified body.
Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The notified body issues a CE
certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the
manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we modify our
devices we may need to apply for permission to affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for any new products that we may develop in the future. Certain products regulated as medical devices
according to EC-Directives are subject to vigilance requirements for reporting of adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be subject to additional regulations in other
countries in which we market, sell and import our products, including Canada. We or our distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The International Standards Organization, or ISO, promulgates internationally recognized standards, including those for the requirements of quality systems.
To support ISO certifications, surveillance audits are conducted by a notified body yearly and recertification audits every three years that assess continued compliance with the relevant ISO standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Regulatory Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion
and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the
Department of Health and Human Services, the Drug Enforcement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and
local governments. In the United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S.
Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the
Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act.
Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and
unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive
recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply
with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties,
injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm
complies with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed
by us could materially affect our business in an adverse way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact
our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional
record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term
Restoration and Marketing Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and other specific aspects of the FDA approval of our drug candidates,
some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent
restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from
the product&#146;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that
application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the
FDA, reviews and approves the application for any patent term extension or restoration. In the future, if any of our NDA&#146;s are approved, we intend to apply for restoration of patent term for one of our currently owned or licensed patents to add
patent life beyond the current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently, the FDA stated that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each drug substance
in a fixed-combination drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5 year NCE
exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a
Section&nbsp;505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a
certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug.
This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original
indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain
circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs
from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate that the sales
of two of our product candidates (Zertane and the RedoxSYS System), once approved for sale, will be heavily dependent upon reimbursement by third-party payors. Traditionally, sales of pharmaceutical products that are not &#147;life style&#148;
indications depend, in part, on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing
reimbursements for medical products and services. ProstaScint is dependent upon reimbursement for continued use in the U.S. market, and ProstaScint does have a reimbursement code as assigned by the American Medical Association. ProstaScint is
currently reimbursed by Medicare, Medicaid, and various private health plans. However, reimbursement is not universally available throughout the United States for ProstaScint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lack of third-party reimbursement for our product candidate or a decision by a third-party payor to not cover our product candidates could reduce physician
usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in some
foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member
states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal
product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be
significantly lower. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DEA Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zertane,
because it contains tramadol, will be regulated as a &#147;controlled substance&#148; as defined in the Controlled Substances Act of 1970, or CSA, and the U.S. Drug Enforcement Agency&#146;s, or DEA, implementing regulations, which establish
registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are directly applicable to us and also applicable to our
manufacturers and to distributors, prescribers and dispensers of Zertane. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their
manufacture and packaging in order to prevent loss and diversion into illicit channels of commerce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DEA regulates controlled substances as Schedule
I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule&nbsp;II, III, IV or V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that Zertane will be listed by the DEA as Schedule IV controlled substances under the CSA.
Consequently, any importation of API for Zertane, as well as the manufacture, shipping, storage, sales and use of Zertane, will be subject to a high degree of regulation. Also, distribution and dispensing of these drugs are highly regulated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is
specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.
Similarly, separate registrations are also required for separate facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DEA typically inspects a facility to review its security measures prior
to issuing a registration and on a periodic basis. Reports must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special permits and notification
requirements apply to imports and exports of narcotic drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DEA establishes annually an aggregate quota for how much of a controlled substance may
be produced in total in the United States based on the DEA&#146;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement quotas from
time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. Our or our manufacturers&#146; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical
trials. Any delay, limitation or refusal by the DEA in establishing our or our manufacturers&#146; quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our
business, financial position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To enforce these requirements, the DEA conducts periodic inspections of registered establishments
that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material adverse
effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations
could result in criminal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states also independently regulate controlled substances. We and our manufacturers will be subject to
state regulation on distribution of these products, including, for example, state requirements for licensures or registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current Vyrix patent portfolio consists of 79 issued patents and nine pending applications worldwide. The portfolio primarily consists of three
families filed in the United States and throughout the world. The first family includes 30 issued patents for the use of tramadol to treat premature ejaculation. The standard 20-year expiration for patents in this family is in 2022. The other two
families are for the use of a combination of tramadol and a phosphodiesterase inhibitor to treat comorbid premature ejaculation and erectile dysfunction and to treat sexual dysfunction side effects associated with administration of tramadol. These
two families include issued patents in Europe, Australia, Canada, China, Mexico, New Zealand, Japan, the Philippines and South Africa and pending applications in the United States, Brazil, China, India, Japan, Korea, and the Philippines. The
standard 20-year expiration for patents in these families is in 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current RedoxSYS/MiOXSYS patent portfolio consists of 14 issued patents and 56
pending applications worldwide. The portfolio primarily consists of four families filed in the United States and throughout the world. The first family includes four issued patents and five pending applications with claims directed to the
measurement of the ORP of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family is in 2028. The second family includes two pending United States applications, and nine pending applications
worldwide with claims directed to the measurement of the ORP capacity of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family is in 2033. The third family includes eight issued patents and 18
pending applications with claims directed to devices and methods for the measurement of ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2032. The fourth family includes one pending United States application and
16 pending applications worldwide with claims directed to multiple layer gel test strip measurement devices and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2033. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProstaScint is protected by significant trade secrets, manufacturing know how related to the production of the
product&#146;s base monoclonal antibody, and a highly protected proprietary cell line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain trade secrets and proprietary know-how that we
seek to protect through confidentiality and nondisclosure agreements. These agreements may not provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. If we do
not adequately protect our trade secrets and proprietary know-how, our competitive position and business prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect
to seek United States and foreign patent protection for drug and diagnostic products we discover, as well as therapeutic and diagnostic products and processes. We expect also to seek patent protection or rely upon trade secret rights to protect
certain other technologies which may be used to discover and characterize drugs and diagnostic products and processes, and which may be used to develop novel therapeutic and diagnostic products and processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of companies such as ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any
certainty. Our issued and licensed patents, and those that may be issued to us in the future, may be challenged, invalidated or circumvented, and the rights granted under the patents or licenses may not provide us with meaningful protection or
competitive advantages. Our competitors may independently develop similar technologies or duplicate any technology developed by us, which could offset any advantages we might otherwise realize from our intellectual property. Furthermore, even if our
product candidates receive regulatory approval, the time required for development, testing, and regulatory review could mean that protection afforded us by our patents may only remain in effect for a short period after commercialization. The
expiration of patents or license rights we hold could adversely affect our ability to successfully commercialize our pharmaceutical drugs or diagnostics, thus harming our operating results and financial position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be able to protect our proprietary intellectual property rights from unauthorized use by third parties primarily to the extent that such rights are
covered by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate to protect our intellectual property from infringement, we may incur substantial costs and our officers may be forced to devote significant
time to litigation-related matters. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pending patent applications, or those we may file or license from third parties in the future, may not result in patents being issued. Until a patent is
issued, the claims covered by an application for patent may be narrowed or removed entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition, or conclude that without patent rights the risk of bringing
product candidates to market exceeds the returns we are likely to obtain. We are generally aware of the scientific research being conducted in the areas in which we focus our research and development efforts, but patent applications filed by others
are maintained in secrecy for at least 18 months and, in some cases in the United States, until the patent is issued. The publication of discoveries in scientific literature often occurs substantially later than the date on which the underlying
discoveries were made. As a result, it is possible that patent applications for products similar to our drug or diagnostic products and product candidates may have already been filed by others without our knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights, and it is
possible that our development of products and product candidates could be challenged by other pharmaceutical or biotechnology companies. If we become involved in litigation concerning the enforceability, scope and validity of the proprietary rights
of others, we may incur significant litigation or licensing expenses, be prevented from further developing or commercializing a product or product candidate, be required to seek licenses that may not be available from third parties on commercially
acceptable terms, if at all, or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The healthcare industry is highly
competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality
and breadth of an organization&#146;s technology; skill of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organization&#146;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average selling price of,
products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual property and patent rights and their protection; and sales and marketing capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of our products that we successfully develop will be clinically superior or scientifically preferable to products developed or
introduced by our competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE has traditionally been treated by behavioral or psychosexual therapy, antidepressant drugs, such as SSRIs, or topical
desensitizing agents, all of which have significant drawbacks. Behavioral and psychosexual therapy as a treatment for PE requires an understanding partner and can be frustrating, embarrassing, time consuming and expensive, among other things.
Antidepressant drugs are sometimes prescribed &#147;off-label&#148; and have numerous shortcomings, including side effects such as nausea, headaches, drop of libido, and ED, need for chronic dosing, ramp up periods, variable responses and unwanted
drug-drug interactions. Topical agents, including lidocaine-based products affect spontaneity, can numb a partner and be messy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dapoxetine (brand name
Priligy, owned by Furiex Pharmaceuticals, Inc, which is owned by Actavis plc, is currently the only approved oral prescription drug to treat PE, with approval in several European countries. Priligy is not approved in the United States. In addition,
we are aware of a topical product in late-stage development for PE by Plethora Solutions referred to as PSD502 and studies of Botox for the treatment of PE are being conducted in the United States. These products &#150; if approved in the United
States &#150; would represent competition and alternative choices for physicians and potential patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, generic tramadol hydrochloride is
available in the United States and abroad for treatment of pain. Although the generic drug is not available in the same dosage as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off
label&#148; for the treatment of PE instead of Zertane, if Zertane is approved for commercialization. Patients could use generic tramadol hydrochloride dosages that are either higher or lower than what will be approved for Zertane or they could
attempt to split dosages to arrive at the dosages approved for Zertane. While any such &#147;off label&#148; use of generic tramadol hydrochloride for treatment of PE may constitute infringement of the Vyrix patent portfolio, liability in that
circumstance would be at the level of the physician or the patient making enforcement difficult or impractical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, there are several FDA approved
imaging techniques for cancer in general, however there is only one specifically targeting prostate cancer - ProstaScint. The other imaging methods are F18-fluorodeoxyglucose (F18-FDG), C11-Acetate, and C11-Choline. The primary advantage of these
methods is that they all use PET imaging, a technique with better resolution than SPECT. The use of PET is also a disadvantage, however, since it uses radiolabels with short half-lives necessitating the need for a local or on-site cyclotron to
generate the labels. The half-life of fluorine-18 (F18) and of carbon-11 (C11) are approximately 110 and 20 minutes, respectively. The radiolabel used by ProstaScint is Indium-11, with a half-life of about 2-3 days. This longer time period allows
the radiolabel to be made remotely and shipped to the imaging facility; however it does use SPECT as the imaging modality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated, ProstaScint is
the only radio-imaging marker that is specific for prostate cancer. ProstaScint is based on radiolabeling the antibody against prostate specific membrane antigen, or PSMA, a protein express by prostate cells. This specificity for prostate cells is
what allows ProstaScint to detect the metastases of prostate cancer regardless of location. The mechanism of labeling for F18-FDG, C11-Acetate, and C11-Choline is the intracellular accumulation of these markers in cancer cells, due to the fact that
cancer cells typically have a higher cellular metabolism than non-cancerous cells. Thus, these markers can accumulate in any type of cancer cell with a high metabolism, unfortunately prostate cancer cells tend to have a lower cellular metabolism
resulting in higher false positives attributed to hyperplasia and prostatitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a meta-analysis of 21 studies evaluating accuracy, sensitivity,
specificity, positive/negative predictive values, ProstaScint using combined SPECT/CT imaging was comparable to PET/CT imaging based on F18-FDG and C11-Choline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are other oxidative stress diagnostic tests available throughout the world, although none are approved in the United States for clinical use. Diagnostic
systems that are marketed for clinical use outside the United States include the FRAS 4 system (H&amp;D srl), FREE Carpe Diem (Diacron International), and the FORM and FORMPlus systems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Callegari srl). These systems are used in both research and clinical settings but do not generate significant sales in the clinical setting. If approved in the United States for clinical use,
these systems could present competition to the RedoxSYS System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors may also succeed in obtaining FDA or other regulatory approvals for their
product candidates more rapidly than we are able to do, which could place us at a significant competitive disadvantage or deny us marketing exclusivity rights. Market acceptance of our product candidates will depend on a number of factors,
including: (i)&nbsp;potential advantages over existing or alternative therapies or tests, (ii)&nbsp;the actual or perceived safety of similar classes of products, (iii)&nbsp;the effectiveness of sales, marketing, and distribution capabilities, and
(iv)&nbsp;the scope of any approval provided by the FDA or foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe our product candidates possess attractive
attributes, we cannot assure you that our product candidates will achieve regulatory or market acceptance, or that we will be able to compete effectively in the pharmaceutical drug markets. If our product candidates fail to gain regulatory approvals
and acceptance in their intended markets, we may not generate meaningful revenues or achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy is to minimize fixed overhead by outsourcing much of our research and development activities. We believe we will benefit from Ampio&#146;s
research and development experience as well as regulatory expertise. Additionally, we intend to utilize consultants with domain experience for research, development and regulatory guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have consulting agreements in place with two such companies who are actively participating with us on the impending clinical trials for Zertane. When we
focus on Zertane-ED in the future, as planned, we intend to collaborate on pre-clinical studies and clinical trials with our partner in Korea, Daewoong Pharmaceuticals Co. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our RedoxSYS System has been developed in conjunction with numerous medical device and diagnostic development consultants. Further, we have relationships with
regulatory consultants who are actively assisting in the development of our regulatory strategy with the FDA. To complement our internal clinical research efforts with the RedoxSYS System, we have engaged with numerous universities around the world
to identify and develop research and clinical applications for the RedoxSYS System. Through these engagements we have access to data and analyses that enable us to develop new uses for the RedoxSYS and MiOXSYS systems. Additionally, we have formal
research agreements in place with two prominent U.S.-based universities and one prominent European university for which we are paying a research fee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business strategy is to use cGMP
compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial supplies if required by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners when possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a 10-year supply agreement with an established manufacturer of tramadol hydrochloride for Zertane. Importantly, product supply has been
produced for our planned clinical trials for Zertane. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acquired a two-year supply of ProstaScint through our asset purchase agreement with Jazz
Pharmaceuticals. Further, we intend to intend to transfer the manufacturing of ProstaScint to a new contract manufacturer, and have initiated discussions with the contract manufacturer and expect to sign an agreement whereby we will transfer the
production to a similar facility operated by the new contract manufacturer. Accordingly, we also expect to put a supply agreement in place for an extended duration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed the technical development of the RedoxSYS System by engaging contract development and manufacturing companies in the United States. We
secured supply and quality agreements with manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS and MiOXSYS sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical
device manufacturers. Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers have been audited by our quality engineers and are fully compliant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 8, 2015, we and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide
manufacturing services to us. The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. We expect to use the agreement from time to time for
manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of our products. The agreement provides customary terms and conditions, including those for performance of services by
Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement.
The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, we may terminate the
agreement or any project addendum under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for
ProstaScint over a four-year period at a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, we had 12 full-time employees and utilized the services of a number of consultants on a temporary basis. Overall, we have not
experienced any work stoppage and do not anticipate any work stoppage in the foreseeable future. None of our employees is subject to a collective bargaining agreement. Management believes that relations with our employees are good. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our services agreements with
Ampio, we use a portion of Ampio&#146;s office space as our office space, which is located in Englewood, Colorado. We have also opened a 1,333 square foot office in Raleigh, North Carolina for which the lease runs until July&nbsp;31, 2018.
Ampio&#146;s lease expires in 2024, and our cost for the office space is included in our quarterly payment under the services agreements. We expect to establish a new office in the Englewood, Colorado area in the near future. We believe our current
office space is sufficient to meet our current needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;19, 2015, Aytu entered into a 37 month non-cancellable operating lease for new
office space effective September&nbsp;1, 2015. The new lease has initial base rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements. We
recognize rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred
rent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently not party
to any material legal or administrative proceedings and are not aware of any material pending or threatened legal or administrative proceedings in which we will become involved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names and ages of all of our directors and executive officers as of June&nbsp;30, 2015. Our Board of Directors is currently
comprised of one member, who is elected annually to serve for one year or until his successor is duly elected and qualified, or until his earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors and are
appointed by the Board of Directors. Each of the director and executive officers listed below joined us upon the closing of the Merger on April&nbsp;16, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua R. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer, Secretary, and Treasurer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Macaluso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a biographical summary of the experience of our executive officers and directors during the past five years,
and an indication of directorships held by the director in other companies subject to the reporting requirements under the federal securities law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joshua R. Disbrow&#151;Chief
Executive Officer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joshua R. Disbrow has been employed by us since April&nbsp;16, 2015. Prior to the closing of the Merger, Mr.&nbsp;Disbrow was the
Chief Executive Officer of Luoxis since January 2013. Mr.&nbsp;Disbrow was also the Chief Operating Officer of Ampio since December 2012. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a
specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company&#146;s second full-time employee. Mr.&nbsp;Disbrow led the company&#146;s commercial efforts from inception to the company&#146;s acquisition in
2010 and growth to over $127 million in net sales in 2011. By the time Mr.&nbsp;Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care,
national accounts, and other commercial functions. Mr.&nbsp;Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management,
commercial operations and commercial strategy. Prior to joining Arbor, Mr.&nbsp;Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to
joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company. Mr.&nbsp;Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jarrett T. Disbrow, Ph.D.&#151;Chief Operating Officer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jarrett Disbrow has been employed by us since April&nbsp;16, 2015. Prior to the closing of the Merger, Mr.&nbsp;Disbrow was the Chief Executive Officer of
Vyrix since November 2013. Mr.&nbsp;Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr.&nbsp;Disbrow was the founder, president and chief
executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals&#146; acquisition in 2010, Mr.&nbsp;Disbrow remained with the company as vice president of commercial development. Prior to
founding Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr.&nbsp;Disbrow began his career with GlaxoWellcom, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions
of increasing responsibility in sales and later marketing. Mr.&nbsp;Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gregory A. Gould </I>&#151;<I>Chief Financial Officer, Secretary, and Treasurer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory A. Gould has been our Chief Financial Officer since April&nbsp;16, 2015. Mr.&nbsp;Gould is also the Chief Financial Officer of Ampio where he has been
employed since June 2014. Prior to joining Ampio, he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC from April 2012 until June 2014.&nbsp;Mr.&nbsp;Gould was Chief Financial
Officer, Treasurer and Secretary of SeraCare from November 2006 until the company was sold to Linden Capital Partners in April 2012.&nbsp;During the period from July 2011 until April 2012 Mr.&nbsp;Gould also served as the Interim President and Chief
Executive Officer of SeraCare Life </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sciences.&nbsp;Mr.&nbsp;Gould has held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an
emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr.&nbsp;Gould&#146;s tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855 million. He also played a critical
role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products. Mr.&nbsp;Gould was the Chief Financial Officer
at Colorado MedTech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company to KRG Capital Partners.&nbsp;Mr.&nbsp;Gould began his career as an auditor with Arthur Andersen,
LLP.&nbsp;He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company pursuing anti-viral agents for the treatment of HIV.&nbsp;Mr.&nbsp;Gould graduated from the University of Colorado with a BS in
Business Administration and is a Certified Public Accountant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael Macaluso</I>&#151;Director <I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Macaluso
has been a member of our Board of Directors since April&nbsp;16, 2015. Mr.&nbsp;Macaluso is also the Chief Executive Officer of Ampio where he founded Life Sciences and has been a member of the board of directors of Life Sciences, Ampio&#146;s
predecessor, since its inception. Mr.&nbsp;Macaluso has also been a member of our Board of Directors since the merger with Chay Enterprises in March 2010 and our Chief Executive Officer since January&nbsp;9, 2012. Mr.&nbsp;Macaluso was appointed
president of Isolagen, Inc. (AMEX: ILE) and served in that position from June 2001 to August 2001, when he was appointed chief executive officer. In June 2003, Mr.&nbsp;Macaluso was re-appointed as president of Isolagen and served as both chief
executive officer and president until September 2004. Mr.&nbsp;Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005. From October 1998 until June 2001, Mr.&nbsp;Macaluso was the owner of Page International
Communications, a manufacturing business. Mr.&nbsp;Macaluso was a founder and principal of International Printing and Publishing, a position Mr.&nbsp;Macaluso held from 1989 until 1997, when he sold that business to a private equity firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Macaluso&#146;s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate
finance led to the conclusion of our Board of Directors that he should serve as a director of our company in light of our business and structure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow, our Chief
Operating Officer, is the brother of Joshua R. Disbrow, our Chief Executive Officer. There are no other family relationships among or between any of our current or former executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Item&nbsp;402
of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation for our company&#146;s directors, former directors and named executive officers, in certain cases for each of the last
three completed fiscal years. On April&nbsp;16, 2015, we acquired Luoxis and Vyrix in the Merger. Because our sole director was a director on the boards of directors of Luoxis and Vyrix, and our named executive officers were, prior to the
April&nbsp;16, 2015, employed by Luoxis and Vyrix, we are providing past compensation information concerning such director and executive officers with respect to Luoxis and Vyrix. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In establishing
director compensation, our Board is guided by the following goals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the directors for work required for a company of our size and scope; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should align the directors&#146; interests with the long-term interests of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should assist with attracting and retaining qualified directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow, who served as a member of Vyrix&#146;s board of directors during 2014, did not receive any
compensation, equity awards or non-equity awards for his service as a director, although Mr.&nbsp;Disbrow did receive compensation in 2014 from and with respect to his employment with Vyrix. James B. Wiegand, who served as the sole director of
Rosewind in 2014, did not receive any compensation, equity awards or non-equity awards for his service as a director. Mr.&nbsp;Wiegand was appointed President, Chief Executive Officer and Secretary and a director of Rosewind on August&nbsp;9, 2002.
He resigned from all of his positions with us on April&nbsp;16, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet established a compensation package for our director, Michael
Macaluso, our non-employee and sole director, and future non-employee directors other than reimbursement of expenses incurred in connection with their service as director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding all compensation paid to non-employee directors of Vyrix and Luoxis during the fiscal year ended
June&nbsp;30, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Stock&nbsp;Option<BR>Awards&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>All&nbsp;Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Micael Macaluso (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary V. Cantrell (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John A. Donofrio Jr (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas J. Leb (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value computed in accordance with Financial Accounting Standards Board, or &#147;FASB&#148;, issued Accounting Standards Update, or &#147;ASC&#148;, Topic 718. These
pre-merger awards were cancelled in April 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Michael Macaluso was appointed a director of Luoxis in January 2013 and a director of Vyrix in November 2013. In connection with the Merger, he resigned from the boards of Luoxis and Vyrix and was appointed a director
of Aytu upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gary V. Cantrell was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">John A. Donofrio Jr. was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nicholas J. Leb was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From fiscal year 2012 to the completion of the Merger on April&nbsp;16, 2015, no compensation was earned by or paid to James B. Wiegand, the former President,
Chief Financial Officer and Secretary of Rosewind. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth all cash compensation earned, as well as certain other compensation paid or
accrued for the years ended June 30, 2015 and 2014 to each of the following named executive officers. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation of Named
Executive Officers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Award<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Award<BR>($) <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;in<BR>Pension&nbsp;Value<BR>and<BR>Nonqualified<BR>Deferred</B><br><B>Compensation<BR>Earnings</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Joshua R. Disbrow </B><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>since December 2012</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Jarrett T. Disbrow </B><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer,</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Secretary and Treasurer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gregory A. Gould </B><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer,</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>since June 2014</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vaughan Clift, M.D. </B><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Medical</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Option awards are reported at fair value at the date of grant. See Item&nbsp;15 of Part IV, &#147;Notes to the Financial Statements &#150; Note 7 &#150; Equity Instruments.&#148; These pre-merger awards were cancelled
in April 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Joshua R. Disbrow received a salary increase to $250,000 effective April&nbsp;16, 2015 when he was appointed Chief Executive Officer of Aytu. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Jarrett T. Disbrow received a salary increase to $250,000 effective April&nbsp;16, 2015 when he was appointed Chief Operating Officer of Aytu. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Gould was appointed to Chief Financial Officer, Secretary and Treasurer effective April&nbsp;16, 2015. His compensation expense is part of the shared service agreement with Ampio. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Clift resigned from his position as Chief Medical Officer of Vyrix on March&nbsp;31, 2015, prior to the Merger. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015,
there were no outstanding equity awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants of Plan-Based Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based awards to the Named Executive Officers as of June&nbsp;30, 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>All&nbsp;Other&nbsp;Option<BR>Awards:&nbsp;Number&nbsp;of<BR>Securities<BR>Underlying&nbsp;Options<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Exercise&nbsp;Price&nbsp;of<BR>Option&nbsp;Awards<BR>($/Share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;Date&nbsp;Fair<BR>Value&nbsp;of&nbsp;Option<BR>Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Named Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua R Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/11/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">198,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/11/2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value computed in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and may not correspond to the actual value
that will be realized by the named executive officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">These Luoxis options were accelerated and cancelled in connection with the Merger. Because the consideration paid to these holders of common stock of Luoxis was less than the exercise price of such options, no amount
was paid to the option holder in connection with the cancellation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The agreement is for a term of 24
months beginning on April&nbsp;16, 2015, subject to termination by us with or without Cause or as a result of officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr.&nbsp;Disbrow is entitled to receive
$250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries of the grant date.
Mr.&nbsp;Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his employment with us. The agreement is for a
term of 24 months beginning on April&nbsp;16, 2015, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr.&nbsp;Disbrow is entitled
to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries of the grant
date. Mr.&nbsp;Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments Provided Upon Termination for Good Reason or Without Cause </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreements, in the event Mr.&nbsp;Joshua Disbrow&#146;s or Mr.&nbsp;Jarrett Disbrow&#146;s employment is terminated without Cause by
us or either officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base salary in effect at the date of termination, as well as continued
participation in the health and welfare plans for up to two years. All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long as a Change in Control is not in effect,
then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24th the number of option shares multiplied by the
number of full months of such officer&#146;s employment shall be deemed vested and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be
exercisable by such officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; means, without the officer&#146;s written consent, there is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a
reduction in the officer&#146;s responsibilities or authority); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may
the base salary be reduced below certain specified amounts); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material change in the principal geographic location at which the officer must perform his services. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic violation which is a misdemeanor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful malfeasance or willful misconduct by the officer in connection with his employment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gross negligence in performing any of his duties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful and deliberate violation of any of our policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unintended but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction of the board; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful and deliberate breach of his obligations under the employment agreement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The severance benefits described above are contingent on each officer executing a general release of claims. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments Provided Upon a Change in Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreements, in the event of a Change in Control of us, all stock options, restricted stock and other stock-based grants granted or
may be granted in the future by us to the officers will immediately vest and become exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; means: the occurrence of
any of the following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acquisition by any individual, entity, or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act) (the &#147;Acquiring Person&#148;), other than us, or any of our Subsidiaries, of
beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding voting securities of us entitled to vote generally in the election
of directors (excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acquisition of us by another entity by means of any transaction or series of related transactions to which we are party (including, without limitation, any stock acquisition, reorganization, merger or consolidation
but excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes ) other than a transaction or series of related transactions in which the holders of the voting
securities of us outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of shares in us held by such holders prior to such
transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such other surviving or resulting entity is
a wholly-owned subsidiary immediately following such acquisition, its parent); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments Provided Upon Termination for Cause or Without Good Reason, Death or Disability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreements, in the event we end the officer&#146;s employment for Cause, if such officer resigns as an employee for reasons other
than an event of Good Reason, such officer dies or disability occurs, then we shall pay to the officer the accrued compensation but shall have no obligation to pay the officer any amount, whether for salary, benefits, bonuses, or other compensation
or expense reimbursements of any kind, accruing after the end of the employment, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be forfeited immediately upon the end of the
employment. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date we end the employment for Cause, or the date of the
officer&#146;s death or disability, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the officer or his personal representative or executor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:73.70pt; font-size:8pt; font-family:Times New Roman"><B>Recipient and Benefit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cause;<BR>Without&nbsp;good<BR>reason</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Cause:&nbsp;Good<BR>reason</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Death;<BR>Disability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;in<BR>Control</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Joshua Disbrow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of health benefits provided after termination <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>556,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Jarrett Disbrow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of health benefits provided after termination <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>556,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The value of such benefits is determined based on the estimated cost of providing health benefits to the Named Executive Officer for a period of two years. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_12"></A>TRANSACTIONS WITH RELATED PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We describe below all
transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal years, to which we were a party or will be a party, in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015,
pursuant to the Merger Agreement entered into among Rosewind, Luoxis, Vyrix and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first stage, each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding
shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive shares of our common stock. The Vyrix stock and the Luoxis stock were each converted at an exchange factor. The exchange factor for each
of them was determined upon the basis of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Vyrix were converted into shares of Vyrix as
the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation. After completion of the first stage, Vyrix and Luoxis became
subsidiaries of Rosewind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second stage, which occurred on the same day as the first stage, each of Vyrix and Luoxis merged with Rosewind with
Rosewind surviving. The first and second stage mergers are referred to collectively as the &#147;Merger.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Merger: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from
the board immediately thereafter. The board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer, Jarrett Disbrow as Chief Operating Officer and Gregory A. Gould as our Chief
Financial Officer, Secretary and Treasurer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ampio purchased 4,761,787 shares of our common stock for (i)&nbsp;issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger;
(ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Wiegand entered into a consulting agreement with us with a one year duration, providing for compensation of $50,000 to him. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of James Wiegand and Michael Wiegand executed a release in our favor. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of Ampio, James Wiegand, Michael Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated with Jarrett Disbrow entered into a lock-up agreement with us agreeing not to sell its shares of our company
for two years (except for the one with Ampio, more than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on or prior to June&nbsp;30, 2015. The Ampio lock-up agreement terminates upon a
change-in-control event of either our company or Ampio. Each other lock-up agreement terminates upon a change-of-control event of our company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Joshua Disbrow entered into an employment agreement with us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Jarrett Disbrow entered into an employment agreement with us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The sailing boat owned by Rosewind was transferred to James Wiegand upon the closing of the Merger in exchange for cancellation of indebtedness owing to James Wiegand in the amount of approximately $30,000 (being the
approximate value of the sailing boat). We paid James Wiegand $19,963 in May 2015 for accrued interest on this indebtedness and other expense that he had incurred prior to the Merger being completed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rosewind </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2014, Rosewind has a
secured promissory note to the sole officer and director for $30,985 for working capital. The loan carries a 6% interest rate, matures on demand and is secured by the sailing vessel. Accrued interest payable on the loan totaled $17,607 as of
August&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended August&nbsp;31, 2014, the sole officer of Rosewind contributed services valued at $3,690. This amount has been
booked to additional paid in capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which
Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts.
None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Luoxis and Vyrix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio Loan Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate
amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of
the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the
Ampio board of directors, as of such conversion date. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its
share purchase, and the loan agreement was terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to
lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as
amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without
penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such
conversion date. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement
was terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, Ampio received 4,761,787 shares of common stock of Aytu for (i)&nbsp;issuance to Aytu of a promissory note from
Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in
the amount of $4,000,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2013, Luoxis entered into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in
exchange for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio
provides corporate overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. Both agreements were assigned to us
upon the closing of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared
overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, Luoxis
entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month
to TRLLC in consideration for services related to research and development of Luoxis&#146; RedoxSYS System. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided
between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or Ratification of Transactions with Related Persons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the small size of our company, we do not at this time have a formal written policy regarding the review of related party transactions, and rely on our
Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviews any such transaction in light of the particular affiliation and interest of any involved director,
officer or other employee or stockholder and, if applicable, any such person&#146;s affiliates or immediate family members. Management aims to present transactions to our Board of Directors for approval before they are entered into or, if that is
not possible, for ratification after the transaction has occurred. If our Board of Directors finds that a conflict of interest exists, then it will determine the appropriate action or remedial action, if any. Our Board of Directors approves or
ratifies a transaction if it determines that the transaction is consistent with our best interests and the best interest of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director
Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is not listed on any exchange. Consequently no exchange rules regarding director independence are applicable to us.
Audit Committee members must satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered to be independent for purposes of Rule 10A-3, a member of
an audit committee of a listed company may not, other than in his or her </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from
the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our sole director,
Michael Macaluso, is not independent under the definition of either the NYSE or Nasdaq due to the payments we make to Ampio under the services agreements with Luoxis and Vyrix. However, even if our common stock was listed on either NYSE or Nasdaq,
we would be exempt from the director independence rules (other than those applicable to audit committees) due to exemptions for listed companies that are &#147;controlled companies,&#148; which are companies of which more than 50% of the voting
securities are held by one individual or entity. Because of Ampio beneficially owns 81.5% of our common stock, we would be a &#147;controlled company.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_13"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table set forth certain information regarding the selling stockholders and the shares of common stock beneficially owned by them, which
information is available to us as of September&nbsp;30, 2015. The selling stockholders may offer the shares under this prospectus from time to time and may elect to sell some, all or none of the shares set forth under this prospectus. However, for
the purposes of the table below, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. In addition, a selling stockholder may have sold, transferred or
otherwise disposed of all or a portion of that holder&#146;s shares of common stock since the date on which the selling stockholder provided information for this table. We have not made independent inquiries about such transfers or dispositions. See
the section entitled &#147;Plan of Distribution&#148; beginning on page 109. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule 13d-3(d)
promulgated by the SEC under the Securities Exchange Act of 1934, or the Exchange Act. The percentage of shares beneficially owned prior to the offering is based on 14,259,681 shares of our common stock outstanding as of September&nbsp;30, 2015.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;Before<BR>Any&nbsp;Sale</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>of</B><br><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock&nbsp;Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;After<BR>Sale&nbsp;of&nbsp;All&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;
Pursuant<BR>to&nbsp;this&nbsp;Prospectus&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Ackerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Alter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anderson Council Trust (A Wyoming Trust) <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premchand Beharry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mike Bello</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Belinda Biddle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julia Bounanno</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Brennan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beau Brooks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beau Brooks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June Brooks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Buck&nbsp;&amp; Barbara Buck JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buechel Patient Care Research&nbsp;&amp; EDU Fund Buechel Family LLP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gordon Burns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Byrne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Callaham and Callaham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Carmichael</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John M Casson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Chaussey&nbsp;&amp; Anna Chaussey JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Clanton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Collins&nbsp;&amp; Jamie Collins JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Don Collins&nbsp;&amp; Odessa Collins JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary J. Connell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip A. Convertini</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josh Ryan Cooks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chad Cordova</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;Before<BR>Any&nbsp;Sale</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>of</B><br><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock&nbsp;Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;After<BR>Sale&nbsp;of&nbsp;All&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;
Pursuant<BR>to&nbsp;this&nbsp;Prospectus&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Cordova</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Costello</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Crouch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sean Crouch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Cuttler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Linda R. Davidson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sven Dreher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nevenka Evtimova</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debya Fajardo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald Furrow&nbsp;&amp; Anna Furrow JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sam Gaby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genesis Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avjit Ghosh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexis Giannotti</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Giannotti Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Giordano Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kirsten Glen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sonja Gouak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Katherine Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Katherine Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carolyn Grobe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carolyn Grobe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald .L Grooms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shirley E. Hale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shirley E. Hale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Melissa R. Halliday</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Halliday</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bob Handshumaker&nbsp;&amp; Daisy Handshumaker JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ulfar Haraldson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ruth Harrison</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ruth Harrison TTEE Ruth Harrison Revocable Trust Dated 3/22/96</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Hicks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David E. Hicks&nbsp;&amp; Mark E. Lavesque JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard T. Higgins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory C. Howard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce Ingles&nbsp;&amp; Nancy Ingles JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Institute for Molecular Medicine Inc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mojdeh Javadi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;Before<BR>Any&nbsp;Sale</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>of</B><br><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock&nbsp;Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;After<BR>Sale&nbsp;of&nbsp;All&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;
Pursuant<BR>to&nbsp;this&nbsp;Prospectus&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Larry Johnston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Johnston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Jones&nbsp;&amp; Kelly Gonzales-Jones JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JSL Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Kuenn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Kuenn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lirtzman Holdings LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Charles Lombardi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">London Family Trust Robert S. London Trustee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edwin R Ludvik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Ludvik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brad Matousek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth Meritt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Miller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Miller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivan Mollov</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Montagino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Thomas Murdoch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diane D. Murphy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Nazzaro&nbsp;&amp; Mary Nazzaro JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred Neal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stanley E. Norfleet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel A. Noven</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Odell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig K. Olson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig K. Olson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vace Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Paterson&nbsp;&amp; Eileen Carey JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Payne&nbsp;&amp; Virginia Payne JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Piper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ghong P. Rector</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redstone Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delbert R. Reedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brett Richie&nbsp;&amp; Irene Richie JT TEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cynthia L. Roberts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephanie Ruyssers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dustin Sandoval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Sandoval</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schaack Family, LLP C/O Michael Schaack</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;Before<BR>Any&nbsp;Sale</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>of</B><br><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock&nbsp;Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;After<BR>Sale&nbsp;of&nbsp;All&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;
Pursuant<BR>to&nbsp;this&nbsp;Prospectus&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Schuster &amp; Mary Schuster JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Smith C/O Latcom LC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kenneth J. Stinnett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C UPPS Industrial Supply</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Talbert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Tilliss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald E Fernandez TOD Justin Fernandez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tree Farm Investment Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,567<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maxene Turrill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bradley C. Underwood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deanie J. Underwood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwood Family Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Underwood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Michael Underwood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert B. Vallender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Don Vestal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Waitkus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Whitton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan Widman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Susan Widman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James B. Wiegand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,266<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Wiegand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Wiegand</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calvin Wilbanks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Will</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence Willis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerry Winn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kendall J Wood&nbsp;&amp; Margaret A Wood JTTEN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kendell Wood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margaret Wood</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isadore Zaneski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jangiz Dermarkan <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Mazzone <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vace Partners <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen Farrell <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederick Meyers <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Bongiorno <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Boss <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;Before<BR>Any&nbsp;Sale</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>of</B><br><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock&nbsp;Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially&nbsp;Owned&nbsp;After<BR>Sale&nbsp;of&nbsp;All&nbsp;Shares&nbsp;of<BR>Common&nbsp;Stock&nbsp;
Pursuant<BR>to&nbsp;this&nbsp;Prospectus&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Cherry <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premchand Beharry <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Banquet <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce Inglis <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Sagarino <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Ingarra <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Gust <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Huckerby <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lane <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Spiller <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redsone Group Investors <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Belding <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Gaby <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Giordano <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jose Martinez <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Conroy <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Haddad <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kieran Mullarkey <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Adams <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phyllis Henderson <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kolinda Tomasic <SUP STYLE="font-size:85%; vertical-align:top">(5) (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-0-</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,564,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17.9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,564,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>-0-</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent of the outstanding shares of our common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Assumes that each selling stockholder will sell all of its shares of common stock subject to sale pursuant to this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares are held by an irrevocable trust for estate planning in which Joshua R. Disbrow is a beneficiary. Mr.&nbsp;Disbrow has been our Chief Executive Officer since April&nbsp;16, 2015. Mr.&nbsp;Disbrow does not
have or share investment control over the shares held by the trust, Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the
trust. As such, under Rule 16a-8(b) and related rules, Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares are held by an irrevocable trust for estate planning in which Jarrett T. Disbrow is a beneficiary. Mr.&nbsp;Disbrow has been our Chief Operating Officer since April&nbsp;16, 2015. Mr.&nbsp;Disbrow does not
have or share investment control over the shares held by the trust, Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the
trust. As such, under Rule 16a-8(b) and related rules, Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James B. Wiegand was our President and Chief Financial Officer from August 2002 until April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares issuable upon the exercise of warrants with an exercise price of $4.53 that expire on May&nbsp;30, 2018, all of which shares are being offered by this prospectus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on available information, we believe that this selling stockholder is an employee of a FINRA-registered broker-dealer. We believe that the selling stockholder has no agreement or understanding, directly or
indirectly, with any person to distribute the shares of common stock issuable upon exercise of the warrants held by the selling stockholder. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about any other selling stockholders will be included in prospectus supplements or post-effective
amendments, if required. Information about the selling stockholders may change from time to time. Any changed information with respect to which we are given notice will be included in prospectus supplements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_14"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the shares of common stock offered in this prospectus on behalf of the selling stockholders.&nbsp;The term selling stockholders, which as
used herein includes pledgees, donees, transferees or other successors-in-interest selling shares received from the selling stockholders as a gift, pledge, partnership distribution or other transfer after the date of this prospectus, may, from time
to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.&nbsp;The selling
stockholders will pay any brokerage commissions and similar selling expenses attributable to the sale of the shares.&nbsp;We will not receive any of the proceeds from the sale of the shares by the selling stockholders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices. To the extent a selling stockholder gifts, pledges or otherwise transfers the shares offered hereby, such transferees may offer and sell the shares from time to time under this
prospectus, provided that this prospectus has been amended under Rule&nbsp;424(b)(3)&nbsp;or other applicable provision of the Securities Act to include the name of such transferee in the list of selling stockholders under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on any national securities exchange or quotation service on which the common stock may be listed or quoted at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the over-the-counter market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in transactions otherwise than on these exchanges or systems or in the over-the-counter market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">privately negotiated transactions;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">short sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales pursuant to Rule 144;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broker-dealers may agree with a selling stockholder to sell a specified number of such shares at a stipulated price per share;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a combination of any such methods of sale; and</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other method permitted pursuant to applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time,
pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from
time to time, under this prospectus, or under an amendment to this prospectus under Rule&nbsp;424(b)(3)&nbsp;or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling
stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also
sell shares of common stock short and deliver these securities to close out its short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or
other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which
shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the shares of common stock offered by it will
be the purchase price of the common stock less discounts or commissions, if any. The selling stockholders reserves the right to accept and, together with its agents from time to time, to reject, in whole or in part, any proposed purchase of common
stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of common
stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be
set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules&nbsp;of Regulation&nbsp;M under the Exchange Act may apply to sales of shares in the
market and to the activities of the selling stockholders and its affiliates. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of
satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities
arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker dealers that act in connection with the sale of the shares might be deemed to
be &#147;underwriters&#148; as the term is defined in Section&nbsp;2(11) of the Securities Act. Consequently, any commissions received by these broker dealers and any profit on the resale of the shares sold by them while acting as principals might
be deemed to be underwriting discounts or commissions under the Securities Act. Because a selling stockholder may be deemed to be an &#147;underwriter&#148; as defined in Section&nbsp;2(11) of the Securities Act, the selling stockholders may be
subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open
market transactions in reliance upon Rule&nbsp;144 under the Securities Act of 1933, provided that such sale meets the criteria and conform to the requirements of that Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or
discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is
customary in the types of transactions involved. No such broker-dealer will receive compensation in excess of that permitted by NASD Rule 2440 and IM-2440. Any profits on the resale of shares of common stock by a broker-dealer acting as principal
might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by the selling stockholders. The selling
stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that agent, dealer or broker-dealer under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_15"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of August&nbsp;31, 2015 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each beneficial owner of more than 5% of our outstanding common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our director and named executive officers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our directors and executive officers as a group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with
the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60
days of August&nbsp;31, 2015. The percentage ownership information shown in the table is based upon 14,259,681 shares of common stock outstanding as of August&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole
voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed
outstanding shares of common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of August&nbsp;31, 2015. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained by us from public filings
made by the stockholders. Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio Pharmaceuticals, Inc. <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,626,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua R. Disbrow <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Macaluso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (four persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The address of Ampio Pharmaceuticals, Inc. is 373 Inverness Parkway, Suite 206, Englewood, CO 80112. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">558,567 shares are held by an irrevocable trust for estate planning in which Mr.&nbsp;Disbrow is a beneficiary. Mr.&nbsp;Disbrow does not have or share investment control over the shares held by the trust,
Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the trust. As such, under Rule&nbsp;16a-8(b) and related rules,
Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">558,567 shares are held by an irrevocable trust for estate planning in which Mr.&nbsp;Disbrow is a beneficiary. Mr.&nbsp;Disbrow does not have or share investment control over the shares held by the trust,
Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the trust. As such, under Rule&nbsp;16a-8(b) and related rules,
Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 300,000,000
shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred stock, $0.0001 par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30,
2015, a total of 14,259,681 shares of our common stock were issued and outstanding and no shares of our preferred stock were issued and outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to
one vote per share. Our Certificate of Incorporation does not expressly prohibit cumulative voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally
available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription,
redemption or conversion rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by,
the rights of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation
provides our Board of Directors with the authority to divide the preferred stock into series and to fix and determine the rights and preferences of the shares of any series of preferred stock established to the full extent permitted by the laws of
the State of Delaware and the Certificate of Incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, we had outstanding warrants to purchase an aggregate of 160,653 shares of our common stock. Of these warrants, 102,613 were
originally issued by Luoxis in 2013 and, in connection with the Merger, were converted into warrants to purchase shares of our common stock at a purchase price of $4.53 per share. These warrants expire on May 30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remaining 58,040 warrants to purchase shares of our common stock were issued to the placement agent in our private placement of convertible notes that we
conducted in July and August 2015. These placement agent warrants have a term of five years, will have an exercise price equal to 100% of the price per share at which equity securities are sold in our next equity financing, and provide for cashless
exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the
Merger, each of Vyrix and Luoxis had an option plan and had made equity grants thereunder. On April&nbsp;16, 2015, upon the closing of the Merger, an aggregate of $27,476 was paid to holders of in-the-money options and all equity compensation plans
of Vyrix and Luoxis were terminated and all the awards granted thereunder were cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2015, our stockholders approved the 2015 Stock
Option and Incentive Plan, which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any
awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock
available for issuance under the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2015 Plan is administered by our Board or a committee designated by the Board (as applicable, the
Administrator). The Administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and
conditions of each award, subject to the provisions of the 2015 Plan. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options and other awards to employees who are not subject to the reporting and other
provisions of Section&nbsp;16 of the Exchange Act and not subject to Section&nbsp;162(m) of the Code, subject to certain limitations and guidelines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons eligible to participate in the 2015 Plan are full or part-time officers, employees, non-employee
directors, directors and other key persons (including consultants and prospective officers) of our company and its subsidiaries as selected from time to time by the Administrator in its discretion. Approximately 25&nbsp;individuals are currently
eligible to participate in the 2015 Plan, which includes three officers, seven employees who are not officers, one non-employee director, and 12&nbsp;other individuals who are primarily consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2015 Plan provides that upon the effectiveness of a &#147;sale event&#148; as defined in the 2015 Plan, except as otherwise provided by the Administrator
in the award agreement, all stock options, stock appreciation rights and other awards will be assumed or continued by the successor entity and adjusted accordingly to take into account the impact of the transaction. To the extent, however, that the
parties to such sale event do not agree that all stock options, stock appreciation rights or any other awards shall be assumed or continued, then such stock options and stock appreciation rights shall become fully exercisable and the restrictions
and conditions on all such other awards with time-based conditions will automatically be deemed waived. Awards with conditions and restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with
a sale event in the Administrator&#146;s discretion. In addition, in the case of a sale event in which our stockholders will receive cash consideration, we may make or provide for a cash payment to participants holding options and stock appreciation
rights equal to the difference between the per share cash consideration and the exercise price of the options or stock appreciation rights in exchange for the cancellation thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the OTCQB Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the OTCQB Market under the symbol &#147;AYTU&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent of our common stock is Corporate Stock Transfer, Inc. Their address is 3200 Cherry Creek Drive South, Suite 430, Denver, CO 80209. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Anti-Takeover Law and Provisions of Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Law.</I> We are subject to Section&nbsp;203 of the Delaware General Corporation Law. Section&nbsp;203 generally prohibits a public
Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding specified shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the
affirmative vote of at least 66&nbsp;2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested
stockholder; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as any person that is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the owner of 15% or more of the outstanding voting stock of the corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an affiliate or associate of the corporation who was the owner of 15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant date; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the affiliates and associates of the above. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under specific circumstances, Section&nbsp;203 makes it more
difficult for an &#147;interested stockholder&#148; to effect various business combinations with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation&#146;s certificate of incorporation or
bylaws, elect not to be governed by this section, effective 12 months after adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws do not exclude us from
the restrictions of Section&nbsp;203. We anticipate that the provisions of Section&nbsp;203 might encourage companies interested in acquiring us to negotiate in advance with our board of directors since the stockholder approval requirement would be
avoided if a majority of the directors then in office approve either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and Bylaw. </I>Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an
actual or potential change of control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best
interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its
discretion from time to time and without stockholder approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting the removal of directors by the stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allowing for the creation of a staggered board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminating the ability of stockholders to call a special meeting of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_17"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Wyrick Robbins Yates&nbsp;&amp; Ponton, LLP,
Raleigh, North Carolina. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Aytu BioScience, Inc. at June&nbsp;30, 2015 and 2014, and for each of the two years in the period ended June&nbsp;30, 2015,
included in this prospectus and Registration Statement have been audited by EKS&amp;H LLLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc63294_19"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, which constitutes a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities Act, does not contain
all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, you should refer to the registration statement and the exhibits filed as part of that
document. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit
to the registration statement. Each of these statements is qualified in all respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of
the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the
SEC&#146;s website at <I>http://www.sec.gov</I>. We also maintain a website at <I>http://www.aytubio.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also read and
copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the
SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning
us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, (720)&nbsp;437-6500. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc63294_20"></A>I<SMALL>NDEX</SMALL> <SMALL>TO</SMALL>
<SMALL>THE</SMALL> F<SMALL>INANCIAL</SMALL> S<SMALL>TATEMENTS</SMALL> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_4">Statement of Stockholders&#146; Equity (Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin63294_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu Bioscience,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Englewood, Colorado </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying
balance sheets of Aytu Bioscience, Inc. (the &#147;Company&#148;) as of June&nbsp;30, 2015 and 2014, and the related statements of operations, stockholders&#146; equity, and cash flows for each of the periods then ended. The Company&#146;s
management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Aytu Bioscience, Inc. as of
June&nbsp;30, 2015 and 2014, and the results of its operations and its cash flows for each of the periods then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ EKS&amp;H LLLP </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;28, 2015,
except for Note 11 as to which the date is October&nbsp;14, 2015 </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, Colorado </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_2"></A>AYTU BIOSCIENCE, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,353,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,639,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">370,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">521,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,083,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,301,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed technology, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Customer contracts, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">711,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade names, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">628,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">699,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,142,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,714,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,226,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,016,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Liabilities and Stockholders&#146; Equity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,196,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payable to Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest payable to Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,092,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">664,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">425,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">511,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,610,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,646,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 in 2015 and 7,901,426 in
2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,996,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,026,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,381,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,657,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,616,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,369,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,226,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,016,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_3"></A>AYTU BIOSCIENCE, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Years Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product and service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,219,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,933,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,382,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,632,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,346,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss, before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,747,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,392,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,723,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,578,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of Aytu common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,207,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,949,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted Aytu net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_4"></A>AYTU BIOSCIENCE, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Stockholders&#146; Equity </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Parent&#146;s<br>Equity</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<BR>paid-in<br>capital</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ampio<br>Stock&nbsp;Subscription</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<br>Deficit</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>Stockholders&#146;<br>Equity</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - June&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,437,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,471,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,418,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,079,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,811,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment from Ampio in Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in exchange for Vyrix Acquired Assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,108,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,108,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,578,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,578,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - June&nbsp;30, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,901,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,026,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,657,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,369,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,164,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock to Ampio in exchange for Aytu debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities paid pursuant to the merger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis options paid-out pursuant to the merger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reverse merger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,596,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,723,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,723,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,259,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,996,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,381,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,616,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_5"></A>AYTU BIOSCIENCE, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B><B> </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,723,404</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,578,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(813,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in prepaid expenses, other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(465,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) increase in interest payable to Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) increase in payable to Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(561,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) increase in deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,634,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,501,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of ProstaScint Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,004,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible note from Ampio converted to stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis option payout pursuant to the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities paid out pursuant to the merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution from Ampio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,352,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,237,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,713,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,639,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,913,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,353,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,639,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash transactions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio unpaid debt converted to stock, received prior to 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration related to the ProstaScint purchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in exchange for Vyrix acquired assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,803,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party research and development liability included in prepaid research and development - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin63294_6"></A>AYTU BIOSCIENCE, INC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#150; Business, Acquisition of Assets and Basis of Presentation </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business/Acquisition of Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu BioScience, Inc. (&#147;Aytu&#148; or the &#147;Company&#148;) was incorporated as Rosewind Corporation on August&nbsp;9, 2002 in the State of Colorado.
Aytu was re-incorporated in the state of Delaware on June&nbsp;8, 2015. Aytu is a specialty healthcare company concentrating on developing and commercializing products focused primarily on the urological disorders market, specifically sexual
dysfunction, urological cancer and male infertility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu&#146;s current business was formed through a reverse triangular merger (the &#147;Merger&#148;) in which Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) and
Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) merged into Rosewind Corporation in a multi-step merger on April&nbsp;16, 2015. These historical financial statements prior to April&nbsp;16, 2015 include the combined financial statements of Vyrix
from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the &#147;Vyrix Acquired Assets&#148;) from March&nbsp;23, 2011, the date, its parent company Ampio
Pharmaceuticals, Inc. (&#147;Ampio&#148;) originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (&#147;BioSciences&#148;) and the financial statements of Luoxis from its inception in January 2013, combined with
the carve-out financial statements related to Luoxis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carve-out financial statements present the statements of financial position of Vyrix and Luoxis
and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial
Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entities. Although
Vyrix and Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio&#146;s books. In addition, the Company allocated corporate overhead
costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. The Company also prepared a
calculation of income tax expense and deferred income tax assets and liabilities on a &#147;separate return&#148; basis (see Note 4 &#150; Income Taxes). These financial statements do not include a carve-out for cash as the operations have
historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Company&#148; as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities, being primarily research and development, have not generated significant revenue to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, Ampio is the majority shareholder of 81.5% of Aytu&#146;s outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2015, in connection with the reincorporation as a Delaware corporation, we effected a reverse stock split in which each common stock holder
received one share of common stock for each every 12.174 shares then outstanding (the &#147;Reverse Stock Split&#148;). All share and per share amounts in this Annual Report have been adjusted to reflect the effect of the Reverse Stock Split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination&#151;ProstaScint </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2015, Aytu
entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the &#147;Seller&#148;). Pursuant to the agreement, Aytu purchased assets related to the Seller&#146;s product known as ProstaScint<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and
assumed certain of the Seller&#146;s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price consists of the upfront payment of $1.0 million. Aytu also agreed to pay an additional
$500,000 payable within five days after transfer for the ProstaScint-related product inventory and $227,000 payable on September&nbsp;30, 2015 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its
net sales made after October&nbsp;31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow. The total fair value consideration for the
purchase was $2.4 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s allocation on consideration transferred for ProstaScint as of the purchase date May&nbsp;20, 2015 is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Estimated&nbsp;Fair<BR>Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">727,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,391,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intangible assets will be amortized over a ten year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future amortization from the year ended June&nbsp;30, 2015 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pro Forma Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro-forma results presented below include the effects of the ProstaScint acquisition as if it has been consummated as of July&nbsp;1, 2013, with
adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets. The unaudited pro forma results do not reflect any operating
efficiency or potential cost savings which may result from the consolidation of ProstaScint. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results
of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of
operations or results that might have been achieved had the acquisition been consummated as of July&nbsp;1, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Years ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,736,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales - ProstaScint</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,818,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,054,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,065,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,933,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,417,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,388,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization and impairment of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,220,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,866,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss, before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,335,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,912,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,311,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,098,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#150; Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu
considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu&#146;s investment policy is to preserve principal
and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured
limits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License
Agreements and Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over
the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved.
Royalties will be recognized as revenue when earned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>P<I>roduct&nbsp;&amp; Service Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu recognizes revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been
rendered, the price is fixed or determinable and collectability is reasonably assured. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Estimated Sales Returns and Allowances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future
product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management
were to make different judgments or utilize different estimates, material differences in the amount of the Company&#146;s reported revenue could result.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are
recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June&nbsp;30, 2015 and 2014, no allowance for doubtful accounts has been recorded.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its
inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the
impairment is first recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on
management&#146;s judgment, Aytu capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory approval process, potential impediments to the
approval process, such as safety or efficacy, anticipated research and development initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. For product candidates that
have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is
expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and
development expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fixed Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fixed
assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Estimated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Useful&nbsp;Lives&nbsp;in&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3&nbsp;-&nbsp;5</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu recorded the following depreciation expense in the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In-Process Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In-process research and development (&#147;IPRD&#148;) relates to the Company&#146;s Zertane product and clinical trial data acquired in connection with the
2011 acquisition of BioSciences. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed
annually and written down if impaired. Once the Zertane product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the Company decided to
abandon the Zertane product, the IPRD would be expensed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents,
determined by an independent third party appraisal, is $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of BioSciences and are being amortized over the remaining U.S. patent lives of approximately 11 years which
expires in March 2022. The cost of the Luoxis patents was $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent lives of approximately 15 years which expires in March
2028. Patents consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">629,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu recorded the following amortization expense in the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future amortization from the year ended June&nbsp;30, 2015 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">629,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#146;s
(&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 805, &#147;Business Combinations&#148;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and
any non-controlling interest in the acquire; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets
and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the
fair value of the consideration paid over the fair value of the identified net assets acquired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ProstaScint&nbsp;purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Jazz Pharmaceuticals.
The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon
currently available data, as noted below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to
goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things,
deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required
to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding
estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances.
The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&nbsp;20, 2015. There was no impairment of goodwill for the year ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances,
stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of definite and indefinite lived
assets. Actual results could differ from these estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu is included in the consolidated tax returns of Ampio. Aytu&#146;s taxes are computed and reported on a &#147;separate return&#148; basis for these
financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are
recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of income taxes and related income tax positions taken would be subject to audits by federal and state tax authorities if Aytu filed these taxes on
a separate basis. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement
of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&#146;s policy is to record a
liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, &#147;Accounting for Uncertainty in Income Taxes&#151;an interpretation of FASB Statement No.&nbsp;109&#148; (&#147;ASC
740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company
reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company
determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development
costs are expensed as incurred with expenses recorded in the respective period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments, including cash and cash equivalents, accounts payable and other current assets and other liabilities are carried
at cost which approximates fair value due to the short maturity of these instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu routinely performs an annual evaluation of the recoverability of the carrying value of its long-lived assets to determine if facts and circumstances
indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is warranted. Based on its evaluation as of June&nbsp;30, 2015 and 2014, respectively, no impairment existed for long-lived assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Newly Issued Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June
2015, the FASB issued Accounting Standards Update (&#147;ASU&#148;) 2015-10, &#147;Technical Corrections and Improvements&#148;. The amendments represent changes to clarify the codification, correct unintended application of guidance, or make minor
improvements to the codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost. In addition, some of the amendments will make the codification easier to understand and
easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the codification. The amendments that require transition guidance are effective for all entities for fiscal years, and
interim periods within those fiscal years, beginning after December&nbsp;15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon issuance. The Company is evaluating the impact of
ASU 2015-10 on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued&nbsp;ASU 2015-03,&nbsp;&#147;Interest - Imputation of Interest (Subtopic 835-30):
Simplifying the Presentation of Debt Issuance Costs.&#148;&nbsp;The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt
liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting principle. The
update is effective for fiscal years beginning after December&nbsp;15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-03 on its financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the FASB issued ASU 2015-01, &#147;Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by
Eliminating the Concept of Extraordinary Items.&#148; The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary
events and transactions. The amendment is effective for annual reporting periods beginning after December&nbsp;15, 2015 and subsequent interim periods with early application permitted. The Company is evaluating the impact the adoption of ASU 2015-01
will have on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU No.&nbsp;2014-15, &#147;Presentation of Financial Statements-Going Concern
(Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial
doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December&nbsp;15, 2016, with early adoption
permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, &#147;Revenue from Contracts with
Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The
guidance will be effective for annual reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted but not prior to the original public organization effective date of December&nbsp;15, 2016. The Company is evaluating the
accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#150; License Agreement/Revenue Recognition </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was
assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&#147;PE&#148;) and for a combination drug to be developed,
utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront payment has been deferred and is being
recognized as license revenue over a ten year period. Milestone payments of $3,200,000 may be earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several years. In addition, Aytu
may earn a royalty based on 25% of net sales, as defined, if the royalty exceeds the transfer price of the Zertane product. No royalties have been earned to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, Vyrix entered into a Distribution and License Agreement (the &#147;Paladin Agreement&#148;) with Endo Ventures Limited, which recently acquired
Paladin Labs Inc. (&#147;Paladin&#148;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement
expires on a country by country basis upon the later of fifteen years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $250,000 to Vyrix upon signing the
Paladin Agreement and is obligated to make milestone payments aggregating up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment has been deferred and is
being recognized as license revenue over a seven year period. In addition, the Paladin Agreement provides that Paladin pay royalties based on sales volume. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#150; Income Taxes </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously discussed in Note 2 &#150; Summary of Significant Accounting Policies, the Company is included in Ampio&#146;s consolidated
tax returns. For purposes of these financial statements, the Company&#146;s taxes are computed and reported on a &#147;separate return&#148; basis. Ampio and Aytu do not have a tax sharing agreement. Accordingly, certain tax attributes, e.g., net
operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In the event that Ampio&#146;s ownership interest in Aytu falls below 80% and Aytu is deconsolidated from Ampio&#146;s consolidated income
tax return, the net operating loss carryforwards originated prior to the incorporation of Vyrix and Luoxis would no longer be available to Aytu and the related deferred income tax asset would be removed and recorded as a deemed dividend to the
parent, Ampio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and
State of Colorado) differs from the income tax provision (benefit) in the Aytu&#146;s financial statements. The following table reflects the reconciliation for the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years&nbsp;Ended&nbsp;June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.00</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.00</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State, net of federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.79</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.89</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.30</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.73</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial
reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current deferred income tax asset:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue short-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current deferred income tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deferred income tax assets (liabilities):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,337,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,847,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;197 intangible</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired in-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,779,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,779,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,210,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,863,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term deferred income tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred income tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu has recorded income tax benefits in its statements of operations since inception, stemming from its operating losses, and
is expected to incur operating losses for the foreseeable future. During the year ended June&nbsp;30, 2015, the net deferred tax liability was reduced to zero based upon the operating losses, thus Aytu established a valuation allowance offsetting
any future net deferred tax asset. As such, Aytu would no longer record income tax benefits in its results of operations after the year ended June&nbsp;30, 2015 because management is currently unable to conclude that it is more likely than not that
a benefit will be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible.
Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize
the benefits of these deductible differences, net of the valuation allowance provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has federal net operating loss carryforwards of approximately $17.1 million and $10.4 million as of
June&nbsp;30, 2015 and June&nbsp;30, 2014, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available net operating losses, if not utilized to offset taxable income in future periods, will
begin to expire in 2031 through 2034. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to
disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015 and 2014, the Company has no liability for gross unrecognized tax benefits or related interest and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company&#146;s accounting policies and
estimates, however, involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the
estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the
general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for years prior to 2011 and 2010, respectively. However, given the net operating losses generated since inception, all tax years since
inception are subject to examination. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#150; Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commitments and contingencies are described below and summarized by the following table as of June&nbsp;30, 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ProstaScint Inventory Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research agreement with related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical research and trial obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office Lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,222,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,427,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">433,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Fee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These
agreements will be in effect until they are terminated in writing by both parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ProstaScint Inventory Transfer Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu is obligated to pay $500,000 for the ProstaScint-related product inventory upon the inventory transfer in July 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement with Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June 2013. Under the terms of the Sponsored
Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146;
notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Research and Trial Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Zertane clinical trials and RedoxSYS research studies, the remaining commitment is $329,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aytu Manufacturing and Commercial Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu entered into agreements with manufacturing companies to build its RedoxSYS system. The current remaining commitment is $133,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Office Lease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2015, Aytu entered into a 37
month operating lease. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. The Company recognizes rental expense of the facility on a straight-line basis over the term of the
lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Years Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#150; Common Stock </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At June&nbsp;30,
2015 and 2014, Aytu had 300&nbsp;million shares of common stock authorized with a par value of $0.0001&nbsp;per share and 50&nbsp;million shares of preferred stock authorized with a par value of $0.0001 per share. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#150; Equity Instruments </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Merger,
Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828&nbsp;million shares of common stock, both of which were terminated on April&nbsp;16,
2015 upon the closing of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Luoxis options that were in the money and all outstanding Vyrix options issued under the 2013 Option Plans were
accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the
option, if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June&nbsp;30, 2015
was $27,000. The company recognized compensation of $422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as
pre-vesting forfeitures and $433,000 of previously recognized compensation was reversed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Luoxis 2013 Stock Option Plan, 1,102,761 shares
of its common stock were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the
model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu
estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar
maturity. The assumptions are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended June&nbsp;30,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">79%&nbsp;-&nbsp;108%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">79%&nbsp;-&nbsp;82%</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.62%&nbsp;-&nbsp;2.09%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.75%&nbsp;-&nbsp;1.53%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.5 - 7.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 - 6.5</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock option activity is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual Life</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Intrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,272,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">430,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available for grant at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Vyrix 2013 Stock Option Plan, 616,067 shares of its common stock were reserved for issuance. The fair value of
the options was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common
stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and
the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. In accordance with the Vyrix 2013 Stock Option Plan, no additional
options were granted during the year-ended June&nbsp;30, 2015. The assumptions are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;June&nbsp;30,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">63%&nbsp;-&nbsp;76%</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.90%&nbsp;-&nbsp;2.02%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 - 6.5</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock option activity is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual&nbsp;Life</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Intrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available for grant at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as
research and development expenses and general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over
the vesting period. The following table summarizes stock-based compensation expense for the years ended June&nbsp;30 2015 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Years Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized expense at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining years to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2015, Aytu&#146;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#147;2015 Plan&#148;),
which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited,
canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the
2015 Plan. As of September&nbsp;28, 2015, no grants have been made under the 2015 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu issued warrants in conjunction with its 2013 private placement. A summary of all warrants is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<BR>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual&nbsp;Life</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants,
certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause
significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the
time of the grant for treasury securities of similar maturity. The offering costs and the additional paid-in capital for the warrants associated with the common stock offering were valued at $313,000 using the Black-Scholes valuation methodology.
</P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#150; Related Party Transactions </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio Loan Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan
agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The
initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under
the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June&nbsp;30, 2014, the amount advanced was $1,600,000
with interest rates from 3.11%-3.32%. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and
the loan agreement was terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend
Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as amended (or
any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio
has an option of converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. As
of June&nbsp;30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11% - 3.32%. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under
the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, Ampio received 4,761,787 shares
of common stock of Aytu for (i)&nbsp;issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of
$8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has service agreements with Ampio which are described in Note 5. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, Luoxis
entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000
per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5
months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 &#150; Litigation </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, Aytu was not party to any legal matters or claims, and none of its property is subject to any legal proceedings.
In the future Aytu may become party to legal matters and claims arising in the ordinary course of business, the resolution of which it does not anticipate would have a material adverse impact on its financial position, results of operations or cash
flows. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10 &#150; Employee Benefit Plan </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu allows its employees to participate in Ampio&#146;s 401(k) plan. The plan allows participants to contribute a portion of their salary,
subject to eligibility requirements and annual IRS limits. Aytu does not match employee contributions. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11 &#150; Subsequent Event </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the
purchase and sale of convertible promissory notes with an aggregate principal amount of $5.2 million. The sale of the notes was pursuant to a private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aytu intends to use the net proceeds of the offering to conduct clinical studies for both Zertane&reg; and RedoxSYS&#153; and for working capital to begin
commercializing FDA-approved ProstaScint&reg;, as well as general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are an unsecured obligation. Unless earlier converted,
the notes will mature 18 months from their respective dates of issuance which will be on January&nbsp;22, February&nbsp;11 and February&nbsp;28, 2017, with an option to extend up to six months at our discretion (provided that in the event Aytu
exercises such extension option, the then applicable interest rate shall increase by 2% for such extension period). Aytu does not have the right to prepay the notes prior to the maturity date. Interest will accrue on the notes in the following
amounts: (i)&nbsp;8% simple interest per annum for the first six months and (ii)&nbsp;12% simple interest per annum thereafter if not converted during the first six months. If there has not been a registration statement on Form&nbsp;S-1 filed with
the SEC for the registration of the shares of common stock underlying the notes by the expiration of the first six-month period then (a)&nbsp;the interest rate will increase to 14% for the remainder of the period in which the notes remain
outstanding and (b)&nbsp;any notes held by officers and directors of the Company will be subordinated to the remaining notes. Interest will accrue, is payable with the principal upon maturity, conversion or acceleration of the notes and may be paid
in kind or in cash, in Aytu&#146;s sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of
Aytu common stock equal in an amount equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of
Aytu&#146;s next public offering of its stock resulting in proceeds to it of at least $5,000,000 in gross proceeds (excluding indebtedness converted in such financing) prior to the maturity date of the notes (a &#147;Qualified Financing&#148;). The
principal and accrued interest under the notes will automatically convert into a number of shares of such equity securities of the Company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the
lesser of (i)&nbsp;the lowest price paid by an investor in such financing or (ii)&nbsp;$4.63. In the event that Aytu </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sells equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert
in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and
accrued interest by the lesser of (i)&nbsp;the lowest cash price per share paid by purchasers of shares in such financing, or (ii)&nbsp;$4.63. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Newbridge
Securities Corporation, Member FINRA/SIPC, through LifeTech Capital, acted as sole placement agent for the institutional portion of the offering. Aytu sold the balance of the notes to individuals and entities with whom Aytu has an established
relationship. For notes sold by the placement agent, Aytu paid the placement agent 8% of the gross proceeds of notes sold by the placement agent and a warrant to purchase shares of Aytu&#146;s common stock equal to 8% of the gross proceeds of the
notes sold by the placement agent divided by the price per share at which equity securities are sold in Aytu&#146;s next equity financing, in addition to a previously paid non-refundable retainer fee of $20,000. The placement agent warrant has a
term of five years, will have an exercise price equal to 100% of the price per share at which equity securities are sold in Aytu&#146;s next equity financing, and provides for cashless exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;19, 2015, Aytu entered into a 37 month non-cancellable operating lease for new office space effective September&nbsp;1, 2015. The new lease has
initial base rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements. The Company recognizes rental expense of the facility on a straight-line
basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2015, the Company entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the &#147;Seller&#148;). Pursuant to
the agreement, the Company purchased assets related to the Seller&#146;s product known as Primsol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trimethoprim solution), including certain intellectual property and contracts, inventory,
work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to the sale and marketing of
Primsol arising after the closing. The agreement provides that for a period of one year after the closing the Seller will not directly or indirectly sell, market, promote, advertise or distribute anywhere in the world any urinary tract
anti-infective pharmaceutical or treatment product containing trimethoprim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company paid $500,000 at closing for the Primsol Business and agreed to
pay an additional $141,694 payable within five days after transfer of the Primsol-related product inventory. The Company also agreed to pay an additional (a)&nbsp;$500,000 payable no later than March&nbsp;31, 2016, (b)&nbsp;$500,000 payable no later
than June&nbsp;30, 2016, and (c)&nbsp;$250,000 payable no later than September&nbsp;30, 2016, for a total purchase price of $1,891,694. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 8,
2015, the Company and Biovest International, Inc. (&#147;Biovest&#148;) entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to the Company. The agreement provides that the Company may engage
Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. The Company expects to use the agreement from time to time for manufacturing services, including without limitation, the
manufacturing, processing, quality control testing, release or storage of its products. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written
notice of a material breach under the agreement. In addition, the Company may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, the
Company submitted a work order to Biovest to provide the Company with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5,000,000, of which the Company paid $1,000,000 upon submission of the work order.
</P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses paid or payable by us in connection with the sale of the common stock being registered. None of these
costs or expenses will be borne by the selling stockholders. All amounts shown are estimates except for the Securities Exchange Commission, or SEC, registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;Paid</B><br><B>or&nbsp;to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,380</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">**&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>**&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Previously paid. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Estimated as permitted under Item&nbsp;511 of Regulation S-K. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors
and Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Section&nbsp;145 of the Delaware General Corporation Law provides that a
Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in
the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another
corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding,
provided that such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#146;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his
conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person
was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including
attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
to the corporation&#146;s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or
otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred. Our certificate of incorporation and bylaws provide for the
indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the
Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of
fiduciary duties as a director, except for liability for any: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transaction from which the director derives an improper personal benefit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payment of dividends or redemption of shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation includes such a provision. Expenses incurred by any officer or director in
defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be
determined that such director or officer is not entitled to be indemnified by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, we have entered
into indemnity agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted by law and advance expenses to each indemnitee in
connection with any proceeding in which indemnification is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an insurance policy covering our officers and directors with respect to
certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15.
Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following transactions do not give effect to the 1-for-12.174 reverse stock split effected on
June&nbsp;8, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rosewind </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On April&nbsp;17, 2012, Rosewind issued Craig K. Olson 20,000 shares of its common stock in consideration of $3,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On May&nbsp;6, 2012, Rosewind issued Ruth Harrison Revocable Trust 11,500 shares of its common stock in consideration of $1,725. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On October&nbsp;23, 2012, Rosewind issued Katherine Gould 33,334 shares of its common stock in consideration for $5,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On June&nbsp;24, 2013, Rosewind issued Sonja Gouak 8,000 shares of its common stock in exchange for services valued at $2,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On September&nbsp;3, 2013, Rosewind issued Craig K. Olson 20,000 shares of its common stock in consideration for $3,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On March&nbsp;17, 2014, Rosewind issued Ruth Harrison Revocable Trust 18,000 shares of its common stock in consideration for $2,700. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On March&nbsp;19, 2014, Rosewind issued James B. Wiegand 600,000 shares of its common stock in consideration of cancelation of notes totaling $90,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On March&nbsp;20, 2014, Rosewind issued Michael Wiegand 100,000 shares of its common stock in consideration of services valued at $15,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On May&nbsp;8, 2014, Rosewind issued Larry Willis 100,000 shares of its common stock in consideration for $15,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On September&nbsp;25, 2014, Rosewind issued Craig K. Olson 100,000 shares of its common stock in consideration of $15,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On March&nbsp;3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment
control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and
related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On April&nbsp;16, 2015, Rosewind issued an aggregate of 154,161,963 shares of common stock to the stockholders of Vyrix and Luoxis in the merger of Vyrix and Luoxis with subsidiaries owned by Rosewind.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any
public offering. The offers, sales and issuances of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and
sophisticated investors and did not involve any public offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to
compensation or (c)&nbsp;under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had
adequate access, through their relationships with Rosewind to information about Rosewind. The sales of these securities were made without any general solicitation or advertising. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vyrix </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2013, Vyrix issued 2,464,268 shares of its common stock to Ampio at a purchase price of $0.0001 per share, and in consideration of the transfer of certain intellectual property assets of Ampio.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Since inception, Vyrix has granted stock options to purchase 117,053 shares of its common stock at an exercise price of $0.70 per share to its officers and directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales and issuances
of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public
offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c)&nbsp;under Regulation S promulgated
under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships with Vyrix, to
information about Vyrix. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Luoxis </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In 2013, a total of 1,026,119 shares of Luoxis common stock were issued at $1.00 per share resulting in $4,653,000 of gross proceeds. Net proceeds were $3,980,000 after placement agent and legal fees. The placement
agent also received 465,250 warrants to purchase Luoxis common stock valued at $313,000 in connection with the closing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Since inception, Luoxis has granted stock options to purchase 625,266 shares of its common stock at an exercise price of $1.00&#151;$1.60 per share to its officers and directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Except as noted below, the
offers, sales and issuances of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did
not involve any public offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their
relationships with Luoxis, to information about Luoxis. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aytu
BioScience, Inc. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In July and August 2015, we issued $5,175,000 of convertible notes in a private placement under Section&nbsp;506 of Regulation D. In connection with the private placement, pursuant to the exemption from registration
provided by Section&nbsp;4(2), we issued to the placement agent a warrant to purchase 58,040 shares of our common stock. The placement agent warrant has a term of five years, will have an exercise price equal to 100% of the price per share at which
equity securities are sold in our next equity financing, and provides for cashless exercise. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offers, sales and issuances of the securities described in this section were exempt from registration under
Section&nbsp;4(2) of the Securities Act, pursuant to Rule 506 of Regulation D, in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section&nbsp;4(2). The sales of
these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:41.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:17.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date<BR>Filed</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:31.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement and Plan of Merger among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind, dated as of April 16, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/09/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/09/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Convertible Note issued in 2015 Convertible Note Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/24/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Placement Agent Warrant issued in 2015 Convertible Note Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/24/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wyrick Robbins Yates &amp; Ponton LLP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, to be entered into between the Registrant and its directors and officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Joshua R. Disbrow, dated as of April 16, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Jarrett Disbrow, dated as of April 16, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Valeant International (Barbados) SRL, effective as of December 2, 2011</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">8-K/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/08/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Manufacturing and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September&nbsp;10, 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">8-K/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/08/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011 (incorporated by reference to Exhibit&nbsp;10.1
of Ampio Pharmaceutical&#146;s Form 8-K/A filed October&nbsp;5, 2011; File&nbsp;No. 001-25182)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March&nbsp;1, 2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">8-K/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/08/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">8-K/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/08/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:41.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s<BR>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:35.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date Filed</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:31.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>Herewith</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September&nbsp;1, 2009</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">8-K/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">6/08/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Addendum No. 4 to Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated March 17, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/27/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Promissory Note issued by Ampio to the Registrant on April 16, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subscription Agreement between the Registrant and Ampio, dated April 16, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Voting Agreement between the Registrant and Ampio, dated April 21, 2015 (incorporated by reference to Exhibit 10.1 to Ampio&#146;s Form 8-K filed April 22, 2015; File No. 001-35182)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement between Jazz Pharmaceuticals, Inc. and Rosewind Corporation, dated May&nbsp;20, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">5/27/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Aytu BioScience 2015 Stock Option and Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Note Purchase Agreement for 2015 Convertible Note Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/24/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated October 5, 2015, between Aytu BioScience, Inc. and FSC Laboratories, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/07/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement between Biovest International, Inc. and Aytu BioScience, Inc., entered into on October 8, 2015, and effective October&nbsp;5, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/13/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;16.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter from HJ &amp; Associates, LLC, dated April 22, 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/22/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">16.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wyrick Robbins Yates &amp; Ponton LLP (included as part of Exhibit&nbsp;5.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.CHL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">S-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">7/01/15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">The company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial statement schedule. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned registrant hereby undertakes: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933 (the &#147;Act&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in this registration statement; and</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining any liability under the Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first
used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such
date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has
been advised that in the opinion of the Securities and Exchange Commission, or SEC, such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The undersigned Registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or
given, the latest annual report to security holders that is incorporated by reference in the prospectus and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934; and, where interim
financial information required to be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
presented by Article 3 of Regulation S-X are not set forth in the prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the latest quarterly
report that is specifically incorporated by reference in the prospectus to provide such interim financial information. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on the 14th day of October, 2015. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AYTU BIOSCIENCE, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua R. Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua R. Disbrow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Joshua R. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">October 14, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jarrett T. Disbrow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">October 14, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Gould</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">October 14, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Macaluso</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Macaluso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">October 14, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d63294dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion in this Registration Statement on Post-Effective Amendment No. 2 to Form S-1 (No. 333-205414) and related
prospectus of Aytu BioScience, Inc. of our report dated September 28, 2015, except for Note&nbsp;11 as to which the date is October&nbsp;14, 2015. We also consent to the reference to our firm under the heading &#147;Experts&#148; in the Registration
Statement and prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ EKS&amp;H LLLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Denver, Colorado</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">October 14, 2015</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>3
<FILENAME>rswn-20150630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:rswn="http://www.aytubio.com/20150630" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="rswn-20150630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DeferredRevenue contextRef="eol_PE731244--1510-K0008_STD_0_20140430_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_58B32303-1D1A-4401-83EE-16CE5E39C28D_2001_0">250000</us-gaap:DeferredRevenue>
  <rswn:PotentialMilestonePaymentsReceivable contextRef="eol_PE731244--1510-K0008_STD_0_20140430_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_58B32303-1D1A-4401-83EE-16CE5E39C28D_2001_2">3025000</rswn:PotentialMilestonePaymentsReceivable>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="eol_PE731244--1510-K0008_STD_0_20150520_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_65D164D5-A74A-4E44-BECC-CA1FC4ACFC6B_1001_3">2391000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="eol_PE731244--1510-K0008_STD_0_20150520_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_65D164D5-A74A-4E44-BECC-CA1FC4ACFC6B_2001_1">1590000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:Goodwill contextRef="eol_PE731244--1510-K0008_STD_0_20150520_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_65D164D5-A74A-4E44-BECC-CA1FC4ACFC6B_2001_2">74000</us-gaap:Goodwill>
  <rswn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="eol_PE731244--1510-K0008_STD_0_20150520_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_65D164D5-A74A-4E44-BECC-CA1FC4ACFC6B_2001_0">727000</rswn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="eol_PE731244--1510-K0008_STD_0_20150531_0_1643960x1985396" unitRef="iso4217_USD" decimals="-5" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_3001_7">2400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance contextRef="eol_PE731244--1510-K0008_STD_0_20150601_0_1639657x1969780" unitRef="shares" decimals="INF" id="id_6457213_F3895328-570E-4DC2-AF9C-D65441667D63_2001_0">10000000</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
  <rswn:OperatingLeasesMonthlyBaseRentInitialYear contextRef="eol_PE731244--1510-K0008_STD_0_20150819_0_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_7001_1">8500</rswn:OperatingLeasesMonthlyBaseRentInitialYear>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE731244--1510-K0008_STD_0_20150831_0_1631478x1962156_1636141x1633766" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6457213_B31FF7A1-8E67-49EF-9158-9A956690C29B_4001_1">4.63</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE731244--1510-K0008_STD_0_20150831_0_1631478x1962156_1636141x1633766" unitRef="iso4217_USD" decimals="-5" id="id_6457213_82654235-D627-4D00-BE44-893333D15348_1001_0">5200000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:LineOfCredit contextRef="eol_PE731244--1510-K0008_STD_0_20131130_0_1631478x1985397_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_2001_0">3000000</us-gaap:LineOfCredit>
  <rswn:CashAdvancesForShortTermLoans contextRef="eol_PE731244--1510-K0008_STD_0_20131130_0_1631478x1985397_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_2001_2">500000</rswn:CashAdvancesForShortTermLoans>
  <us-gaap:LineOfCredit contextRef="eol_PE731244--1510-K0008_STD_0_20140331_0_1631478x1985397_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_2001_0">3000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE731244--1510-K0008_STD_0_20150416_0_1631478x1985397_1633579x1985390_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_2003_3">4000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE731244--1510-K0008_STD_0_20150416_0_1631478x1985397_1633579x1985391_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_2003_2">8000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20150416_0_1642993x1667600" unitRef="shares" decimals="INF" id="id_6457213_1FE5E520-31CE-4B21-A21E-1461CB43B5E2_3001_1">4761787</us-gaap:CommonStockSharesIssued>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE731244--1510-K0008_STD_0_20150416_0_1642993x1667600_1643325x1887167" unitRef="iso4217_USD" decimals="0" id="id_6457213_1FE5E520-31CE-4B21-A21E-1461CB43B5E2_4001_0">10000000</us-gaap:DebtInstrumentFaceAmount>
  <rswn:ShareBasedCompensationShareWarrantsOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_6457213_1AFC4D59-5FE2-42CC-89B6-D55CBC6C0175_1001_2">102613</rswn:ShareBasedCompensationShareWarrantsOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1007_1000001">9811197</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2001_29">2913700</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_F62051D6-64EA-47AF-A1FB-6674BE67F831_1001_2">4.53</rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_1001_2">396994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_1001_2">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1633579x1985391" unitRef="iso4217_USD" decimals="0" id="id_6457213_F677A987-BF65-4EA8-9DE2-1DF0CAF86EAD_1001_2">1272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1640593x1639324_1641766x1676684_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_9447A9EF-D9B7-4B5E-BAF9-B4C367202364_3001_0">615000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet>
  <us-gaap:SharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1001_400002">5437158</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1001_500001">544</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1633302" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1006_900001">-5079247</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1004_700001">4418385</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1642961" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_1003_600001">10471515</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_43">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_40">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_45">7901426</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_42">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_38">50000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_39">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_44">7901426</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_37">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_5">433000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_13">24000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_46">16026554</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_27">4600000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:DueToAffiliateCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_23">150000</us-gaap:DueToAffiliateCurrent>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_2">1427000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_E1F79046-892E-4287-B195-01D0FBAB8CFB_2_0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_3">466000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_49">5369407</us-gaap:StockholdersEquity>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_4">466000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_7BF70ACF-2971-46E3-98EC-8E0EE7F089BA_1002_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_6">430000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_26">561059</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_22">649503</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_25">85714</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_3">13000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_48">-10657937</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_33">6646692</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_50">12016099</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_11">1863000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_31">511607</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_41">790</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_34" />
  <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_10">2779000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1007_1">3222000</us-gaap:ContractualObligation>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_29">6092278</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_36" />
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_32">42807</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_6">3847000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_9">80000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:Assets contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_19">12016099</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_8">190000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:AssetsNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_18">8714247</us-gaap:AssetsNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_9">57246</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_1">32000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_8">3301852</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_6457213_872C7CCE-C401-4A42-816D-E9EB152B673D_1002_0">10400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_15">699563</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_5">521322</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_2">2639650</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_7">18897</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_2_7">482000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_F62051D6-64EA-47AF-A1FB-6674BE67F831_3001_3">4.53</rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
  <rswn:InterestPayableRelatedPartiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_28">46002</rswn:InterestPayableRelatedPartiesCurrent>
  <rswn:ShareBasedCompensationShareWarrantsOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_6457213_1AFC4D59-5FE2-42CC-89B6-D55CBC6C0175_4001_3">102613</rswn:ShareBasedCompensationShareWarrantsOutstanding>
  <rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_14">7500000</rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment>
  <rswn:PrepaidResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_6">121983</rswn:PrepaidResearchAndDevelopmentRelatedParty>
  <rswn:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_2_16">457438</rswn:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1631478x1985397_1633579x1985390_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_2002_3">1600000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1631478x1985397_1633579x1985391_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_2002_2">3000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_5">70000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_2">70000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_3">70000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_4">70000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_6">70000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1003_1">350000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1694714" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1005_2">133000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1694714" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1005_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1694714" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1005_1">133000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_5">3000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_2">35000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_3">36000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_4">36000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1006_1">110000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_5">360000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_2">360000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_3">360000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_4">360000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_6">360000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1001_1">1800000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985413" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1004_2">329000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985413" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1004_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985413" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1004_1">329000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985426" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1002_2">500000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985426" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1002_7">0</us-gaap:ContractualObligationDueAfterFifthYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985426" unitRef="iso4217_USD" decimals="0" id="id_6457213_A2216366-A3E9-4EE4-8327-D2A5653B490B_1002_1">500000</us-gaap:ContractualObligation>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1002_1">180000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1002_0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1002_2">700000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_3001_6">117053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_3001_6">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_F611DB9D-E594-4D8C-9478-7DFB5E8E5974_3001_3">417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_3001_6">430077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_3001_6">4.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985391" unitRef="iso4217_USD" decimals="0" id="id_6457213_F677A987-BF65-4EA8-9DE2-1DF0CAF86EAD_3001_3">1374000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1002_1">33000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1002_2">57000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1002_0">90000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:SharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_3001_400010">7901426</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_3001_500009">790</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1633302" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_3006_900009">-10657937</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_3004_700009">16026554</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_43">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_40">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_45">14259681</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_42">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_38">50000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_39">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_6FE5FF84-F8C5-412F-A4DB-F87A844D6765_1001_1">1718828</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_44">14259681</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_37">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_2CBD4624-C9E9-4FFA-A564-E4AC9010051A_1001_0">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_46">38996367</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_E1F79046-892E-4287-B195-01D0FBAB8CFB_1_0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_49">15616452</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_7BF70ACF-2971-46E3-98EC-8E0EE7F089BA_1001_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_30">664000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_22">1196817</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_25">85714</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_3">64000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_48">-18381341</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_33">2610354</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_50">18226806</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_11">4210000</us-gaap:DeferredTaxAssetsValuationAllowanceNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_31">425893</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_41">1426</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_34" />
  <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_10">2779000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_29">1479034</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_36" />
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_32">41427</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_2">73000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_6">6337000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:IndefiniteLivedContractualRights contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_11">711000</us-gaap:IndefiniteLivedContractualRights>
  <us-gaap:Assets contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_19">18226806</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_8">158000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:InventoryNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_4">39442</us-gaap:InventoryNet>
  <us-gaap:AssetsNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_18">10142947</us-gaap:AssetsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_3">157058</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_9">29706</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_1">32000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_47">5000000</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>
  <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_17">4886</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:IndefiniteLivedTradeNames contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_12">79000</us-gaap:IndefiniteLivedTradeNames>
  <us-gaap:AssetsCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_8">8083859</us-gaap:AssetsCurrent>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-5" id="id_6457213_872C7CCE-C401-4A42-816D-E9EB152B673D_1001_0">17100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_15">628776</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:Goodwill contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_13">74000</us-gaap:Goodwill>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_5">370888</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_2">7353061</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_7">41427</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_8BBE2FD5-30BE-434A-AE2E-9876A0AEC280_1_7">453000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_F62051D6-64EA-47AF-A1FB-6674BE67F831_5001_4">4.53</rswn:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
  <rswn:ShareBasedCompensationShareWarrantsOutstanding contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_6457213_1AFC4D59-5FE2-42CC-89B6-D55CBC6C0175_6001_4">102613</rswn:ShareBasedCompensationShareWarrantsOutstanding>
  <rswn:CoreAndDevelopedTechnologyNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_10">780125</rswn:CoreAndDevelopedTechnologyNet>
  <rswn:AccruedCompensationCurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_24">196503</rswn:AccruedCompensationCurrent>
  <rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_14">7500000</rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment>
  <rswn:NumberOfStockOptionPlans contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="Stock_Plan" decimals="INF" id="id_6457213_6FE5FF84-F8C5-412F-A4DB-F87A844D6765_1001_0">2</rswn:NumberOfStockOptionPlans>
  <rswn:PrepaidResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_6">121983</rswn:PrepaidResearchAndDevelopmentRelatedParty>
  <rswn:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_72BD67D9-859A-4B8F-9EA2-9EE857D496F7_1_16">335454</rswn:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent>
  <rswn:OperatingLeasesMonthlyBaseRentInitialYear contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_2E832CCD-7536-4CB8-B9B7-B5EA85CCB24C_1001_1">2900</rswn:OperatingLeasesMonthlyBaseRentInitialYear>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985413_1635276x1985423" unitRef="iso4217_USD" decimals="0" id="id_6457213_C094E95F-D13B-4922-B38E-6CC6E24A167C_1001_0">329000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985421" unitRef="iso4217_USD" decimals="0" id="id_6457213_730C0480-B6A2-4A17-8029-A994B3E7A06D_1001_0">133000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985426" unitRef="iso4217_USD" decimals="0" id="id_6457213_F7CEC96E-FFDF-494F-9F92-948CA9A6D758_1001_0">500000</us-gaap:ContractualObligation>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1001_1">251000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_2">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_1">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_0">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_5">274000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_4">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1001_0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_92259F9B-C247-4B7E-86A5-08F73201493C_1001_2">629000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886" unitRef="iso4217_USD" decimals="0" id="id_6457213_865ED106-B328-497D-90C4-17F4084BE991_1001_3">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1985399" unitRef="iso4217_USD" decimals="0" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_3001_3">380000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1985400" unitRef="iso4217_USD" decimals="0" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_4001_0">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1985400" unitRef="iso4217_USD" decimals="0" id="id_6457213_9A86736C-38A8-41F9-9142-A20C824CF3C8_1001_0">7500000</rswn:IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment>
  <us-gaap:DeferredRevenue contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1667600_1641811x1638052" unitRef="iso4217_USD" decimals="0" id="id_6457213_BCFEE8E6-C05F-4E81-89E3-947BBFEA126E_2001_0">500000</us-gaap:DeferredRevenue>
  <rswn:PotentialMilestonePaymentsReceivable contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1667600_1641811x1638052" unitRef="iso4217_USD" decimals="0" id="id_6457213_BCFEE8E6-C05F-4E81-89E3-947BBFEA126E_2001_2">3200000</rswn:PotentialMilestonePaymentsReceivable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_5001_11">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_7742D81B-3C58-4A2B-A91E-6E04BBA42E41_1001_0">616067</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_5001_11">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <rswn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_5001_12">0</rswn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_5001_11">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_D436B95C-5B65-4814-96B5-B8146EF911F3_1001_0">1102761</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_5001_11">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <rswn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_5001_12">0</rswn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1001_1">60000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1001_2">30000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1634505x1935108" unitRef="iso4217_USD" decimals="0" id="id_6457213_EE533AB6-16F4-4BEC-9A72-31134DCDF8DA_1001_0">90000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1639657x1986697" unitRef="iso4217_USD" decimals="0" id="id_6457213_5AAD70E7-6932-4BD6-BAE7-98ABC035AF82_2001_1">189000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1639657x1986698" unitRef="iso4217_USD" decimals="0" id="id_6457213_5AAD70E7-6932-4BD6-BAE7-98ABC035AF82_3001_2">422000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:SharesIssued contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_6001_400024">14259681</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_6001_500023">1426</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1633302" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_6006_900023">-18381341</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_6004_700023">38996367</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1644202" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_6005_800023">-5000000</us-gaap:StockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_2">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_1">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_0">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_5">775000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_4">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_6">1570000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_0B4EA470-4E52-4768-8DBE-E8816D10FE24_1001_3">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396" unitRef="iso4217_USD" decimals="-5" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2001_0">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2001_6">664000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396" unitRef="iso4217_USD" decimals="-5" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2001_4">2500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2001_1">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <rswn:BusinessCombinationContingentConsiderationPercentage contextRef="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396" unitRef="pure" decimals="2" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2001_5">0.08</rswn:BusinessCombinationContingentConsiderationPercentage>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE731244--1510-K0008_STD_1_20150608_0" unitRef="pure" decimals="INF" id="id_6457213_19F88C5D-0778-4BF6-A0D1-DE76115B880D_2_1">12.174</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="eol_PE731244--1510-K0008_STD_1_20150819_0_1636141x1633766" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1_0">P37M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE731244--1510-K0008_STD_1_20150819_0_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1_2">318000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE731244--1510-K0008_STD_1_20150928_0_1636141x1633766_1639657x1969780" unitRef="shares" decimals="INF" id="id_6457213_F3895328-570E-4DC2-AF9C-D65441667D63_1002_1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20150930_0_1640593x1641344_1643960x1985396" unitRef="iso4217_USD" decimals="0" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_1002_2">227000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1660852_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_2002_6">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1665043_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_3002_4">141694</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1891336_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_4002_5">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1920370_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_5002_7">250000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_6002_8">1891694</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1643960x1993859" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_6002_3">500000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToSuppliers contextRef="eol_PE731244--1510-K0008_STD_1_20151008_0_1633579x1792882_1634968x1733376_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1003_12">1000000</us-gaap:PaymentsToSuppliers>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE731244--1510-K0008_STD_1_20151008_0_1633579x1792882_1634968x1733376_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1003_11">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="eol_PE731244--1510-K0008_STD_1_20150416_0_1633579x1985390_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_1FE5E520-31CE-4B21-A21E-1461CB43B5E2_1001_3">4000000</us-gaap:DebtInstrumentDecreaseForgiveness>
  <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="eol_PE731244--1510-K0008_STD_1_20150416_0_1633579x1985391_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_1FE5E520-31CE-4B21-A21E-1461CB43B5E2_2001_2">8000000</us-gaap:DebtInstrumentDecreaseForgiveness>
  <rswn:DeferredRevenueRecognitionPeriod contextRef="eol_PE731244--1510-K0008_STD_30_20140430_0_1633579x1985390" id="id_6457213_58B32303-1D1A-4401-83EE-16CE5E39C28D_1001_3">P7Y</rswn:DeferredRevenueRecognitionPeriod>
  <rswn:AgreementExpirationPeriod contextRef="eol_PE731244--1510-K0008_STD_30_20140430_0_1633579x1985390" id="id_6457213_58B32303-1D1A-4401-83EE-16CE5E39C28D_1001_1">P15Y</rswn:AgreementExpirationPeriod>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE731244--1510-K0008_STD_30_20131130_0_1631478x1985397_1642993x1667600" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_1001_1">P1Y</us-gaap:DebtInstrumentTerm>
  <rswn:OperatingLeaseMonthlyRentalPayment contextRef="eol_PE731244--1510-K0008_STD_30_20130630_0_1631679x1706730_1640593x1639324_1641766x1676684_1642993x1667600" unitRef="iso4217_USD" decimals="0" id="id_6457213_9447A9EF-D9B7-4B5E-BAF9-B4C367202364_1001_1">6000</rswn:OperatingLeaseMonthlyRentalPayment>
  <rswn:ManagementFeePayablePerMonth contextRef="eol_PE731244--1510-K0008_STD_31_20150731_0_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_2310DF0A-E254-4FDE-932C-1D57D1AA1801_1_0">30000</rswn:ManagementFeePayablePerMonth>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE731244--1510-K0008_STD_31_20140331_0_1631478x1985397_1642993x1667600" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_1001_1">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE731244--1510-K0008_STD_365_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_485271C5-A656-45B0-9555-8CD5797B8B0C_1_0">313000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="eol_PE731244--1510-K0008_STD_365_20130630_0" id="id_6457213_A4B30D46-F659-4464-8007-576CB872D399_1001_2">P4Y4M28D</rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE731244--1510-K0008_STD_365_20130630_0_1633579x1985390" id="id_6457213_ABEB287C-4A0B-4559-A6D3-A7FC6C8037F6_1001_2">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE731244--1510-K0008_STD_365_20130630_0_1633579x1985391" id="id_6457213_E1FB555A-A23B-424E-A775-32907C4C2853_1001_2">P9Y11M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_15">-5501962</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_14">-0.80</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_4">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="INF" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_0">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_2">-0.0184</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_3">-0.2229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_1">0.0289</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="shares" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_13">6949476</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_2_5">0.1273</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_19">9298</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_12">-5578690</us-gaap:NetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_11">-6098374</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_2">58929</us-gaap:Revenues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_4007_1000006">499690</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:InterestIncomeExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_9">-45553</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_8">-6346834</us-gaap:OperatingIncomeLoss>
  <us-gaap:LicensesRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_1">58929</us-gaap:LicensesRevenue>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_8">497322</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_10">-6392387</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_0">1736139</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_9">-6912071</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_11">-813697</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_2">499690</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_14">191071</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_23">4600000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_5C081779-0B9D-4DA0-B0BC-DB2E6A8ABC5B_2_0">11000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_28">-274050</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_20">-9298</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_27">5237210</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_5">3933619</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_5">-813697</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_2_4">500000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_7">2346557</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_10">46002</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_D492EBEA-C77C-41A7-A3D2-7C659612CB74_2_0">70000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:ProceedsFromContributedCapital contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_26">637210</us-gaap:ProceedsFromContributedCapital>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_11">421870</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:Depreciation contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_F0353E2C-7001-4799-97FA-3F72C2705C80_2_0">27000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_3">97476</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:OtherLaborRelatedExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_4AB24962-5062-474D-8001-CB996FD3F25C_2_0">253000</us-gaap:OtherLaborRelatedExpenses>
  <rswn:ResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_2_6">125587</rswn:ResearchAndDevelopmentRelatedParty>
  <rswn:BusinessAcquisitionsProFormaInterestIncomeExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_8">-45553</rswn:BusinessAcquisitionsProFormaInterestIncomeExpenseNet>
  <rswn:IncreaseDecreaseAccountsPayableRelatedPartyCurrent contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_13">561059</rswn:IncreaseDecreaseAccountsPayableRelatedPartyCurrent>
  <rswn:BusinessAcquisitionsProFormaOperatingIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_7">-6866518</rswn:BusinessAcquisitionsProFormaOperatingIncomeLoss>
  <rswn:BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_10">-813697</rswn:BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit>
  <rswn:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_4">35579</rswn:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>
  <rswn:IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_9">-465000</rswn:IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties>
  <rswn:IssuanceOfCommonStockInExchangeForAcquiredAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_35">6803356</rswn:IssuanceOfCommonStockInExchangeForAcquiredAssets>
  <rswn:PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_2_36">150000</rswn:PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid>
  <rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" id="id_6457213_A4B30D46-F659-4464-8007-576CB872D399_2001_3">P3Y11M1D</rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>
  <rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_3">3933619</rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentExpense>
  <rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_4">125587</rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty>
  <rswn:BusinessAcquisitionsProFormaCostOfRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_2">2054786</rswn:BusinessAcquisitionsProFormaCostOfRevenue>
  <rswn:BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_6">100000</rswn:BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets>
  <rswn:BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_2_5">2388665</rswn:BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985390_1642993x1667600" unitRef="pure" decimals="INF" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_1002_5">0.0332</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985390_1642993x1667600" unitRef="pure" decimals="INF" id="id_6457213_A5FE7440-C23B-4CEA-BB1C-95981DFAC55E_1002_4">0.0311</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985391_1642993x1667600" unitRef="pure" decimals="INF" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_1002_4">0.0332</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMaximum>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985391_1642993x1667600" unitRef="pure" decimals="INF" id="id_6457213_DA2D821B-3FD7-4562-9146-67884D666E7D_1002_3">0.0311</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" id="id_6457213_ABEB287C-4A0B-4559-A6D3-A7FC6C8037F6_3001_3">P9Y6M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="pure" decimals="INF" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1_1">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="pure" decimals="2" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_4001_3">5.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_4001_3">117053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_4001_4">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="pure" decimals="INF" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1_2">0.0090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="pure" decimals="INF" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1_3">0.0202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_4001_4">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="pure" decimals="INF" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1_0">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <rswn:ContributionsFromRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5007_1000003">637210</rswn:ContributionsFromRelatedParty>
  <rswn:UnrecognizedShareBasedCompensationExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_1002_6">0</rswn:UnrecognizedShareBasedCompensationExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1634394x1639948_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_2002_3">104000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1634394x1642216_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_3002_1">38000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1639304x1633605" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_1001_5">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1639304x1643741" id="id_6457213_DBDCE029-91B2-4F67-AEBC-53B72316DC25_2001_4">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5001_400005">2464268</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5001_500004">246</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5004_700004">11108479</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1642961" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5003_600004">-11108725</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <rswn:ContributionsFromRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1642961" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_5003_600003">637210</rswn:ContributionsFromRelatedParty>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" id="id_6457213_E1FB555A-A23B-424E-A775-32907C4C2853_3001_3">P9Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2_1">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="pure" decimals="2" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_4001_3">4.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_4001_3">33083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_4001_4">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2_2">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2_3">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_4001_4">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2_0">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <rswn:UnrecognizedShareBasedCompensationExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_4002_5">0</rswn:UnrecognizedShareBasedCompensationExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1634394x1639948_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_5002_2">152000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1634394x1642216_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_6002_0">206000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1639304x1633605" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1002_5">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1639304x1643741" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2002_4">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_4001_400007">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:NetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1633302" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_4006_900008">-5578690</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_4004_700006">499690</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_99B1CC4E-8ED0-4D46-A574-E20C4649FC33_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 9 &amp;#x2013; Litigation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2015, Aytu was not party to any legal matters
 or claims, and none of its property is subject to any legal
 proceedings. In the future Aytu may become party to legal matters
 and claims arising in the ordinary course of business, the
 resolution of which it does not anticipate would have a material
 adverse impact on its financial position, results of operations or
 cash flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_15">-6634214</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_2D9893B6-A439-4FF0-899F-A84E5CF765B7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 10 &amp;#x2013; Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Aytu allows its employees to participate in Ampio&amp;#x2019;s 401(k)
 plan. The plan allows participants to contribute a portion of their
 salary, subject to eligibility requirements and annual IRS limits.
 Aytu does not match employee contributions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_A8D490E7-A27E-45B4-8F8E-F334300B31FA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The ProstaScint&amp;#xA0;purchase price allocation was based upon an
 analysis of the fair value of the assets and liabilities acquired
 from Jazz Pharmaceuticals. The final purchase price may be adjusted
 up to one year from the date of the acquisition. Identifying the
 fair value of the tangible and intangible assets and liabilities
 acquired required the use of estimates by management, and were
 based upon currently available data, as noted below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company allocated the excess of purchase price over the
 identifiable intangible and net tangible assets to goodwill. Such
 goodwill is not deductible for tax purposes and represents the
 value placed on entering new markets and expanding market
 share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company tests its goodwill for impairment annually, or whenever
 events or changes in circumstances indicate an impairment may have
 occurred, by comparing the carrying value to its implied fair
 value. Impairment may result from, among other things,
 deterioration in the performance of the acquired business, adverse
 market conditions, adverse changes in applicable laws or
 regulations and a variety of other circumstances. If the Company
 determines that an impairment has occurred, it is required to
 record a write-down of the carrying value and charge the impairment
 as an operating expense in the period the determination is made. In
 evaluating the recoverability of the carrying value of goodwill,
 the Company must make assumptions regarding estimated future cash
 flows and other factors to determine the fair value of the acquired
 assets. Changes in strategy or market conditions could
 significantly impact those judgments in the future and require an
 adjustment to the recorded balances. The goodwill was recorded as
 part of the acquisition of ProstaScint that occurred on
 May&amp;#xA0;20, 2015. There was no impairment of goodwill for the year
 ended June&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_5677FBD5-19C6-4C23-BD26-C2C35E55329A_1_0">&lt;div&gt;
 &lt;p&gt;The approximate tax effects of significant temporary differences
 which comprise the deferred tax assets and liabilities are as
 follows for the respective periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current deferred income tax asset:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue short-term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total current deferred income tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Long-term deferred income tax assets (liabilities):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,337,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,847,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Section&amp;#xA0;197 intangible&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;482,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue long-term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;158,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;190,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Share-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Acquired in-process research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,779,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,779,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,210,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,863,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total long-term deferred income tax assets (liabilities)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred income tax assets (liabilities)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_F6FAD3E3-CBC8-480A-9768-65F71ADF7ED3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s allocation on consideration transferred for
 ProstaScint as of the purchase date May&amp;#xA0;20, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Estimated&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,590,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,391,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_943D0090-D075-4996-84B1-239E56606EFD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Pro Forma Information&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The unaudited pro-forma results presented below include the effects
 of the ProstaScint acquisition as if it has been consummated as of
 July&amp;#xA0;1, 2013, with adjustments to give effect to pro forma
 events that are directly attributable to the acquisition which
 includes adjustments related to the amortization of acquired
 intangible assets. The unaudited pro forma results do not reflect
 any operating efficiency or potential cost savings which may result
 from the consolidation of ProstaScint. Accordingly, these unaudited
 pro forma results are presented for informational purposes only and
 are not necessarily indicative of what the actual results of
 operation of the combined company would have been if the
 acquisition had occurred at the beginning of the period presented
 nor are they indicative of future results of operations and are not
 necessarily indicative of either future results of operations or
 results that might have been achieved had the acquisition been
 consummated as of July&amp;#xA0;1, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,371,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,736,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cost of sales - ProstaScint&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,818,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,054,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,065,626&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,933,619&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development - related party (Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;156,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,417,884&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,388,665&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Amortization and impairment of intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,989&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,220,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,866,518&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Interest (expense) income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(114,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,553&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss, before income tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,335,065&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,912,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred income tax benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;813,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,311,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,098,374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="3" id="id_6457213_B4C85572-21E2-4CDF-AF80-C724EC3A7FB2_1_0">0.815</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
  <dei:AmendmentFlag contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_B7BC096B-3F52-4542-83CE-5617C8DFB1F1_1_1">true</dei:AmendmentFlag>
  <us-gaap:BusinessCombinationsPolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_623C702A-950A-4BA2-8FEF-6EEDE380EA2C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company accounts for its business acquisitions under the
 acquisition method of accounting as indicated in the Financial
 Accounting Standards Board&amp;#x2019;s (&amp;#x201C;FASB&amp;#x201D;) Accounting
 Standards Codification (&amp;#x201C;ASC&amp;#x201D;) 805, &amp;#x201C;Business
 Combinations&amp;#x201D;, which requires the acquiring entity in a
 business combination to recognize the fair value of all assets
 acquired, liabilities assumed, and any non-controlling interest in
 the acquire; and establishes the acquisition date as the fair value
 measurement point. Accordingly, the Company recognizes assets
 acquired and liabilities assumed in business combinations,
 including contingent assets and liabilities and non-controlling
 interest in the acquiree, based on the fair value estimates as of
 the date of acquisition. In accordance with ASC 805, the Company
 recognizes and measures goodwill as of the acquisition date, as the
 excess of the fair value of the consideration paid over the fair
 value of the identified net assets acquired.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_50E76B7C-C627-46F9-B2C4-C898BEBC9ED3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future amortization from the year ended June&amp;#xA0;30, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;274,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_373264E5-0381-49AB-9893-7A542AB60771_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;License Agreements and Royalties&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Payments received upon signing of license agreements are for the
 right to use the license and are deferred and amortized over the
 lesser of the license term or patent life of the licensed drug.
 Milestone payments relate to obtaining regulatory approval,
 cumulative sales targets, and other projected milestones and are
 recognized at the time the milestones are achieved. Royalties will
 be recognized as revenue when earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 P&lt;i&gt;roduct&amp;#xA0;&amp;amp; Service Sales&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu recognizes revenue from product and service sales when there
 is persuasive evidence that an arrangement exists, delivery has
 occurred or service has been rendered, the price is fixed or
 determinable and collectability is reasonably assured.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_BD5E3E0B-0E78-440B-B612-FF971EC888E3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following amortization expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amortization expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_AE1CBC54-27DF-44AF-9257-237A41043F77_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounts receivable are recorded at their net realized value. Aytu
 evaluates collectability of accounts receivable on a quarterly
 basis and records a valuation allowance accordingly. As of
 June&amp;#xA0;30, 2015 and 2014, no allowance for doubtful accounts has
 been recorded.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_71A5C36A-D310-4CB1-A0A8-8952E435C7F8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu issued warrants in conjunction with its 2013 private
 placement. A summary of all warrants is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Warrants&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_14">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_77A22042-AD43-42F3-967F-C557264BB2FC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fixed Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="14%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;Estimated&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;Useful&amp;#xA0;Lives&amp;#xA0;in&amp;#xA0;years&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3 - 5&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(60,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Fixed assets, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following depreciation expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Depreciation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <dei:DocumentType contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_B7BC096B-3F52-4542-83CE-5617C8DFB1F1_1_0">POS AM</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_1B2A8693-DBFE-4046-8BE2-A59E3004B7D5_1_2">0001385818</dei:EntityCentralIndexKey>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_ADF1DD67-ECA3-48A1-9F35-D7B10A80F281_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Inventories are recorded at the lower of cost or market, with cost
 determined on a first-in, first-out basis. Aytu periodically
 reviews the composition of its inventories in order to identify
 obsolete, slow-moving or otherwise unsaleable items. If unsaleable
 items are observed and there are no alternate uses for the
 inventory, Aytu will record a write-down to net realizable value in
 the period that the impairment is first recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 When future commercialization is considered probable and the future
 economic benefit is expected to be realized, based on
 management&amp;#x2019;s judgment, Aytu capitalizes pre-launch inventory
 costs prior to regulatory approval. A number of factors are taken
 into consideration, including the current status in the regulatory
 approval process, potential impediments to the approval process,
 such as safety or efficacy, anticipated research and development
 initiatives that could impact the indication in which the compound
 will be used, viability of commercialization and marketplace
 trends. For product candidates that have not been approved by the
 FDA, inventory used in clinical trials is expensed at the time of
 production and recorded as research and development expense. For
 products that have been approved by the FDA, inventory used in
 clinical trials is expensed at the time the inventory is packaged
 for the clinical trial. Prior to receiving FDA approval, costs
 related to purchases of the active pharmaceutical ingredient and
 the manufacturing of the product candidate are recorded as research
 and development expense.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_4">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <dei:EntityFilerCategory contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_1B2A8693-DBFE-4046-8BE2-A59E3004B7D5_1_7">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_9E18279F-E4BA-4D04-B6B0-5CBA46059341_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Research and development costs are expensed as incurred with
 expenses recorded in the respective period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_6E26DE02-56AA-443A-B163-7AEFABBBAE72_1_0">&lt;div&gt;
 &lt;p&gt;Patents consist of the following:&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Patents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(251,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(180,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Patents, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="INF" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_0">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_2">-0.0551</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_6930C5CF-273E-4DF0-88D7-BF21A8791D48_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The carrying amounts of financial instruments, including cash and
 cash equivalents, accounts payable and other current assets and
 other liabilities are carried at cost which approximates fair value
 due to the short maturity of these instruments.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_A1933F56-7FA6-4A62-839A-19D1A66C768D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Note 1 &amp;#x2013; Business, Acquisition of Assets and Basis of
 Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Business/Acquisition of Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu BioScience, Inc. (&amp;#x201C;Aytu&amp;#x201D; or the
 &amp;#x201C;Company&amp;#x201D;) was incorporated as Rosewind Corporation on
 August&amp;#xA0;9, 2002 in the State of Colorado. Aytu was
 re-incorporated in the state of Delaware on June&amp;#xA0;8, 2015. Aytu
 is a specialty healthcare company concentrating on developing and
 commercializing products focused primarily on the urological
 disorders market, specifically sexual dysfunction, urological
 cancer and male infertility.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu&amp;#x2019;s current business was formed through a reverse
 triangular merger (the &amp;#x201C;Merger&amp;#x201D;) in which Luoxis
 Diagnostics, Inc. (&amp;#x201C;Luoxis&amp;#x201D;) and Vyrix Pharmaceuticals,
 Inc. (&amp;#x201C;Vyrix&amp;#x201D;) merged into Rosewind Corporation in a
 multi-step merger on April&amp;#xA0;16, 2015. These historical
 financial statements prior to April&amp;#xA0;16, 2015 include the
 combined financial statements of Vyrix from its inception in
 November 2013, combined with the carve-out financial statements
 related to Vyrix assets acquired in the Merger (the &amp;#x201C;Vyrix
 Acquired Assets&amp;#x201D;) from March&amp;#xA0;23, 2011, the date, its
 parent company Ampio Pharmaceuticals, Inc. (&amp;#x201C;Ampio&amp;#x201D;)
 originally acquired the Vyrix Acquired Assets through its merger
 with DMI BioSciences, Inc. (&amp;#x201C;BioSciences&amp;#x201D;) and the
 financial statements of Luoxis from its inception in January 2013,
 combined with the carve-out financial statements related to
 Luoxis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The carve-out financial statements present the statements of
 financial position of Vyrix and Luoxis and the Vyrix Acquired
 Assets and the statements of operations and cash flows for purposes
 of presenting complete comparative stand-alone financial statements
 in accordance with Regulation S-X, Article 3, General Instructions
 to Financial Statements, and Staff Accounting Bulletin Topic 1-B1,
 Costs Reflected in Historical Financial Statements. Historically,
 financial statements have not been prepared for Vyrix and Luoxis,
 as they were not held in a separate legal entities. Although Vyrix
 and Luoxis have not been segregated as a separate legal entity,
 related revenues, direct costs and expenses, assets and liabilities
 have historically been segregated on Ampio&amp;#x2019;s books. In
 addition, the Company allocated corporate overhead costs based on a
 review of specific labor and other overhead expenses and a
 reasonable estimate of activities related to Vyrix and Luoxis.
 Allocated labor and other overhead totaled $264,000 in 2015 and
 $253,000 in 2014. The Company also prepared a calculation of income
 tax expense and deferred income tax assets and liabilities on a
 &amp;#x201C;separate return&amp;#x201D; basis (see Note 4 &amp;#x2013; Income
 Taxes). These financial statements do not include a carve-out for
 cash as the operations have historically been funded by Ampio. The
 historical carve-out financial statements may not be indicative of
 the future results of Vyrix and Luoxis as a stand-alone
 entities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The &amp;#x201C;Company&amp;#x201D; as referred to in the notes to these
 financial statements includes Vyrix and Luoxis, collectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s activities, being primarily research and
 development, have not generated significant revenue to date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of June&amp;#xA0;30, 2015, Ampio is the majority shareholder of
 81.5% of Aytu&amp;#x2019;s outstanding common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On June&amp;#xA0;8, 2015, in connection with the reincorporation as a
 Delaware corporation, we effected a reverse stock split in which
 each common stock holder received one share of common stock for
 each every 12.174 shares then outstanding (the &amp;#x201C;Reverse Stock
 Split&amp;#x201D;). All share and per share amounts in this Annual
 Report have been adjusted to reflect the effect of the Reverse
 Stock Split.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Business Combination&amp;#x2014;ProstaScint&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In May 2015, Aytu entered into and closed on an asset purchase
 agreement with Jazz Pharmaceuticals, Inc. (the
 &amp;#x201C;Seller&amp;#x201D;). Pursuant to the agreement, Aytu purchased
 assets related to the Seller&amp;#x2019;s product known as
 ProstaScint&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; (capromab
 pendetide), including certain intellectual property and contracts,
 and the product approvals, inventory and work in progress
 (together, the &amp;#x201C;ProstaScint Business&amp;#x201D;), and assumed
 certain of the Seller&amp;#x2019;s liabilities, including those related
 to product approvals and the sale and marketing of ProstaScint.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The purchase price consists of the upfront payment of $1.0 million.
 Aytu also agreed to pay an additional $500,000 payable within five
 days after transfer for the ProstaScint-related product inventory
 and $227,000 payable on September&amp;#xA0;30, 2015 (which represents a
 portion of certain FDA fees). Aytu also will pay 8% as contingent
 consideration on its net sales made after October&amp;#xA0;31, 2017,
 payable up to a maximum aggregate payment of an additional $2.5
 million. The contingent consideration was valued at $664,000 using
 a discounted cash flow. The total fair value consideration for the
 purchase was $2.4 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s allocation on consideration transferred for
 ProstaScint as of the purchase date May&amp;#xA0;20, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Estimated&amp;#xA0;Fair&lt;br /&gt;
 Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,590,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Goodwill&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total assets acquired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,391,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The intangible assets will be amortized over a ten year period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future amortization from the year ended June&amp;#xA0;30, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;775,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Pro Forma Information&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The unaudited pro-forma results presented below include the effects
 of the ProstaScint acquisition as if it has been consummated as of
 July&amp;#xA0;1, 2013, with adjustments to give effect to pro forma
 events that are directly attributable to the acquisition which
 includes adjustments related to the amortization of acquired
 intangible assets. The unaudited pro forma results do not reflect
 any operating efficiency or potential cost savings which may result
 from the consolidation of ProstaScint. Accordingly, these unaudited
 pro forma results are presented for informational purposes only and
 are not necessarily indicative of what the actual results of
 operation of the combined company would have been if the
 acquisition had occurred at the beginning of the period presented
 nor are they indicative of future results of operations and are not
 necessarily indicative of either future results of operations or
 results that might have been achieved had the acquisition been
 consummated as of July&amp;#xA0;1, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,371,106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,736,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cost of sales - ProstaScint&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,818,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,054,786&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,065,626&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,933,619&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development - related party (Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;156,988&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;125,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,417,884&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,388,665&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Amortization and impairment of intangible assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,989&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,220,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,866,518&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Interest (expense) income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(114,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(45,553&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss, before income tax&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,335,065&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,912,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred income tax benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;813,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,311,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,098,374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_3">-0.3095</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_19F88C5D-0778-4BF6-A0D1-DE76115B880D_1_0">On June 8, 2015, in connection with the reincorporation as a Delaware  corporation, we effected a reverse stock split in which each common stock holder  received one share of common stock for each every 12.174 shares then outstanding  (the "Reverse Stock Split").</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_1">0.0279</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_7DF7B99F-7F4A-4B5F-BA08-07C84F92B02F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs of establishing patents, consisting of legal and filing fees
 paid to third parties, are expensed as incurred. The fair value of
 the Zertane patents, determined by an independent third party
 appraisal, is $500,000. The Zertane patents were acquired in
 connection with the 2011 acquisition of BioSciences and are being
 amortized over the remaining U.S. patent lives of approximately 11
 years which expires in March 2022. The cost of the Luoxis patents
 was $380,000 when they were acquired in connection with the 2013
 formation of Luoxis and is being amortized over the remaining U.S.
 patent lives of approximately 15 years which expires in March 2028.
 Patents consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Patents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated armortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(251,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(180,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Patents, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following amortization expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amortization expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future amortization from the year ended June&amp;#xA0;30, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;274,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_531E985A-5300-45E2-89B1-E878DAA43B5C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;Estimated&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;Useful&amp;#xA0;Lives&amp;#xA0;in&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;3&amp;#xA0;-&amp;#xA0;5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(60,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Fixed assets, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following depreciation expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Depreciation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_2E832CCD-7536-4CB8-B9B7-B5EA85CCB24C_1_0">P37M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <dei:EntityRegistrantName contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_1B2A8693-DBFE-4046-8BE2-A59E3004B7D5_1_1">AYTU BIOSCIENCE, INC.</dei:EntityRegistrantName>
  <dei:AmendmentDescription contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_B7BC096B-3F52-4542-83CE-5617C8DFB1F1_1_2">Changes to Note 11 in Post Effective Amendment No 2</dei:AmendmentDescription>
  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_31CCE1A3-83FC-4126-8AB6-AF8EAB0A3C94_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;In-Process Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In-process research and development (&amp;#x201C;IPRD&amp;#x201D;) relates to
 the Company&amp;#x2019;s Zertane product and clinical trial data
 acquired in connection with the 2011 acquisition of BioSciences.
 The $7,500,000 recorded was based on an independent, third party
 appraisal of the fair value of the assets acquired. IPRD is
 considered an indefinite-lived intangible asset and its fair value
 will be assessed annually and written down if impaired. Once the
 Zertane product obtains regulatory approval and commercial
 production begins, IPRD will be reclassified to an intangible that
 will be amortized over its estimated useful life. If the Company
 decided to abandon the Zertane product, the IPRD would be
 expensed.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_257E4A5C-6C44-4588-8099-8764A815A4E4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 4 &amp;#x2013; Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 As previously discussed in Note 2 &amp;#x2013; Summary of Significant
 Accounting Policies, the Company is included in Ampio&amp;#x2019;s
 consolidated tax returns. For purposes of these financial
 statements, the Company&amp;#x2019;s taxes are computed and reported on
 a &amp;#x201C;separate return&amp;#x201D; basis. Ampio and Aytu do not have a
 tax sharing agreement. Accordingly, certain tax attributes, e.g.,
 net operating loss carryforwards, reflected in these financial
 statements, may or may not be available to Aytu. In the event that
 Ampio&amp;#x2019;s ownership interest in Aytu falls below 80% and Aytu
 is deconsolidated from Ampio&amp;#x2019;s consolidated income tax
 return, the net operating loss carryforwards originated prior to
 the incorporation of Vyrix and Luoxis would no longer be available
 to Aytu and the related deferred income tax asset would be removed
 and recorded as a deemed dividend to the parent, Ampio.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Income tax benefit resulting from applying statutory rates in
 jurisdictions in which Aytu is taxed (Federal and State of
 Colorado) differs from the income tax provision (benefit) in the
 Aytu&amp;#x2019;s financial statements. The following table reflects the
 reconciliation for the respective periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Years&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Benefit at federal statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State, net of federal income tax benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Effective tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Deferred income taxes arise from temporary differences in the
 recognition of certain items for income tax and financial reporting
 purposes. The approximate tax effects of significant temporary
 differences which comprise the deferred tax assets and liabilities
 are as follows for the respective periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current deferred income tax asset:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue short-term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(64,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total current deferred income tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Long-term deferred income tax assets (liabilities):&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforward&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,337,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,847,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Section&amp;#xA0;197 intangible&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;453,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;482,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue long-term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;158,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;190,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Share-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Acquired in-process research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,779,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,779,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,210,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,863,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total long-term deferred income tax assets (liabilities)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(41,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred income tax assets (liabilities)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu has recorded income tax benefits in its statements of
 operations since inception, stemming from its operating losses, and
 is expected to incur operating losses for the foreseeable future.
 During the year ended June&amp;#xA0;30, 2015, the net deferred tax
 liability was reduced to zero based upon the operating losses, thus
 Aytu established a valuation allowance offsetting any future net
 deferred tax asset. As such, Aytu would no longer record income tax
 benefits in its results of operations after the year ended
 June&amp;#xA0;30, 2015 because management is currently unable to
 conclude that it is more likely than not that a benefit will be
 realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In assessing the realizability of deferred tax assets, management
 considers whether it is more likely than not that some portion or
 all of the deferred tax assets will not be realized. The ultimate
 realization of deferred tax assets is dependent upon the generation
 of future taxable income during periods in which those temporary
 differences become deductible. Management considers the scheduled
 reversal of deferred tax liabilities, projected future taxable
 income, carry back opportunities and tax planning strategies in
 making the assessment. The Company believes it is more likely than
 not it will realize the benefits of these deductible differences,
 net of the valuation allowance provided.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company has federal net operating loss carryforwards of
 approximately $17.1 million and $10.4 million as of June&amp;#xA0;30,
 2015 and June&amp;#xA0;30, 2014, respectively that, subject to
 limitation, may be available in future tax years to offset taxable
 income. The available net operating losses, if not utilized to
 offset taxable income in future periods, will begin to expire in
 2031 through 2034. Net operating loss carryforwards are subject to
 examination in the year they are utilized regardless of whether the
 tax year in which they are generated has been closed by statute.
 The amount subject to disallowance is limited to the NOL utilized.
 Accordingly, the Company may be subject to examination for prior
 NOLs generated as such NOLs are utilized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of June&amp;#xA0;30, 2015 and 2014, the Company has no liability for
 gross unrecognized tax benefits or related interest and
 penalties.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu has made its best estimates of certain income tax amounts
 included in the financial statements. Application of the
 Company&amp;#x2019;s accounting policies and estimates, however,
 involves the exercise of judgment and use of assumptions as to
 future uncertainties and, as a result, could differ from these
 estimates. In arriving at its estimates, factors the Company
 considers include how accurate the estimates or assumptions have
 been in the past, how much the estimates or assumptions have
 changed and how reasonably likely such changes may have a material
 impact. Aytu has been historically included in the Ampio
 consolidated tax return. Under the general statute of limitations,
 the Company would not be subject to federal or Colorado income tax
 examinations for years prior to 2011 and 2010, respectively.
 However, given the net operating losses generated since inception,
 all tax years since inception are subject to examination.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_D3440764-60B7-483C-876D-7FDE3A37A532_1_0">&lt;div&gt;
 &lt;p&gt;The following table summarizes stock-based compensation expense
 for the years ended June&amp;#xA0;30 2015 and 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years Ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,018,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized expense at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average remaining years to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_8BE43053-50DB-4890-9EBE-353661B0CB0C_1_0">&lt;div&gt;
 &lt;p&gt;The following table reflects the reconciliation for the
 respective periods:&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Years&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Benefit at federal statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State, net of federal income tax benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.03&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Effective tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_D0F74C2E-02AA-4957-BE37-AAF344DBFD04_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu routinely performs an annual evaluation of the recoverability
 of the carrying value of its long-lived assets to determine if
 facts and circumstances indicate that the carrying value of assets
 or intangible assets may be impaired and if any adjustment is
 warranted. Based on its evaluation as of June&amp;#xA0;30, 2015 and
 2014, respectively, no impairment existed for long-lived
 assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_77773170-2E8A-454F-A5D0-B79C38FA2C82_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 5 &amp;#x2013; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Commitments and contingencies are described below and summarized by
 the following table as of June&amp;#xA0;30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2019&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2020&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Thereafter&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Management fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,800,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 ProstaScint Inventory Transfer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Sponsored research agreement with related party&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;350,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical research and trial obligations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;329,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;329,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Manufacturing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Office Lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;110,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,222,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,427,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;430,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Management Fee&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In July 2015, Aytu entered into agreements with Ampio whereby Aytu
 agreed to pay Ampio $30,000 per month for shared overhead which
 includes costs related to the shared facility, corporate staff, and
 other miscellaneous overhead expenses. These agreements will be in
 effect until they are terminated in writing by both parties.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;ProstaScint Inventory Transfer Fee&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu is obligated to pay $500,000 for the ProstaScint-related
 product inventory upon the inventory transfer in July 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Sponsored Research Agreement with Related Party&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu entered into a Sponsored Research Agreement with Trauma
 Research LLC (&amp;#x201C;TRLLC&amp;#x201D;), a related party, in June 2013.
 Under the terms of the Sponsored Research Agreement, TRLLC agreed
 to work collaboratively in advancing the RedoxSYS System diagnostic
 platform through research and development efforts. The Sponsored
 Research Agreement may be terminated without cause by either party
 on 30 days&amp;#x2019; notice.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Clinical Research and Trial Obligations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In connection with the Zertane clinical trials and RedoxSYS
 research studies, the remaining commitment is $329,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Aytu Manufacturing and Commercial Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu entered into agreements with manufacturing companies to build
 its RedoxSYS system. The current remaining commitment is
 $133,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Office Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In June 2015, Aytu entered into a 37 month operating lease. This
 lease has initial base rent of $2,900 a month, with total base rent
 over the term of the lease of approximately $112,000. The Company
 recognizes rental expense of the facility on a straight-line basis
 over the term of the lease. Differences between the straight-line
 net expenses on rent payments are classified as liabilities between
 current deferred rent and long-term deferred rent. Rent expense for
 the respective periods is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years Ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Rent expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_E492E4B7-574A-4CF4-976C-DF7FC824D4B4_1_0">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <dei:DocumentPeriodEndDate contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_B7BC096B-3F52-4542-83CE-5617C8DFB1F1_1_3">2015-06-30</dei:DocumentPeriodEndDate>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_3CED815C-9F78-453B-A9F5-62D2AB518E9E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 6 &amp;#x2013; Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Capital Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 At June&amp;#xA0;30, 2015 and 2014, Aytu had 300&amp;#xA0;million shares of
 common stock authorized with a par value of $0.0001&amp;#xA0;per share
 and 50&amp;#xA0;million shares of preferred stock authorized with a par
 value of $0.0001 per share.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_2F29D3E5-20DE-4691-87BF-842B2A486994_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The preparation of financial statements in accordance with
 Generally Accepted Accounting Principles in the United States of
 America (&amp;#x201C;GAAP&amp;#x201D;) requires management to make estimates
 and assumptions that affect the reported amounts of assets and
 liabilities, disclosures of contingent assets and liabilities as of
 the date of the financial statements and the reported amounts of
 revenues and expenses during the reporting periods. Significant
 items subject to such estimates and assumptions include valuation
 allowances, stock-based compensation, warrant valuation, purchase
 price allocation, valuation of contingent consideration, sales
 returns and allowances, useful lives of fixed assets and
 assumptions in evaluating impairment of definite and indefinite
 lived assets. Actual results could differ from these estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_6487A18C-E477-4A80-AC1E-C217A0D1FA14_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu accounts for share based payments by recognizing compensation
 expense based upon the estimated fair value of the awards on the
 date of grant. The Company determines the estimated grant fair
 value using the Black-Scholes option pricing model and recognizes
 compensation costs ratably over the period of service using the
 graded method.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_A6D8D683-7D3A-4FD5-AC6D-000C5F5E408C_1_0">&lt;div&gt;
 &lt;p&gt;Rent expense for the respective periods is as follows:&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years Ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Rent expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_6CD74130-3AA0-4AE5-B726-8926DFA8D9A1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu considers all highly liquid instruments purchased with an
 original maturity of three months or less to be cash equivalents.
 Cash equivalents consist primarily of money market fund
 investments. Aytu&amp;#x2019;s investment policy is to preserve
 principal and maintain liquidity. The Company periodically monitors
 its positions with, and the credit quality of the financial
 institutions with which it invests. Periodically, throughout the
 year, Aytu has maintained balances in excess of federally insured
 limits.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_6949D91C-2598-4BE2-8B7D-3EA378BA9A4F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 7 &amp;#x2013; Equity Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prior to the Merger, Aytu had two approved stock option plans
 (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan),
 pursuant to which Aytu had reserved a total of
 1,718,828&amp;#xA0;million shares of common stock, both of which were
 terminated on April&amp;#xA0;16, 2015 upon the closing of the
 Merger.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Luoxis options that were in the money and all outstanding Vyrix
 options issued under the 2013 Option Plans were accelerated and
 cancelled in connection with the Merger. Option holders received a
 cash payment per option share equal to the difference between the
 consideration payable per share of common stock pursuant to the
 Merger and the exercise price of the option, if the consideration
 paid to holders of common stock was less than the exercise price of
 such options, no amount was paid to the option holder in connection
 with the cancellation. The cash payment during the period ended
 June&amp;#xA0;30, 2015 was $27,000. The company recognized compensation
 of $422,000 and $189,000 related to the Luoxis and Vyrix options
 that had accelerated vesting as of the Merger date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Luoxis options that were not paid out were terminated pursuant
 to the terms of the 2013 Luoxis Option Plan. The Company treated
 these options as pre-vesting forfeitures and $433,000 of previously
 recognized compensation was reversed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the Luoxis 2013 Stock Option Plan, 1,102,761 shares of
 its common stock were reserved for issuance. The fair value of the
 options was calculated using the Black-Scholes option pricing
 model. In order to calculate the fair value of the options, certain
 assumptions are made regarding components of the model, including
 the estimated fair value of the underlying common stock, risk-free
 interest rate, volatility, expected dividend yield and expected
 option life. Changes to the assumptions could cause significant
 adjustments to valuation. Aytu estimates the expected term based on
 the average of the vesting term and the contractual term of the
 options. The risk-free interest rate is based on the U.S. Treasury
 yield in effect at the time of the grant for treasury securities of
 similar maturity. The assumptions are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;Years Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79%&amp;#xA0;-&amp;#xA0;108%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79%&amp;#xA0;-&amp;#xA0;82%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.62%&amp;#xA0;-&amp;#xA0;2.09%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.75%&amp;#xA0;-&amp;#xA0;1.53%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.5 - 7.0&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.0 - 6.5&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Stock option activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;396,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,272,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,083&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;430,077&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,374,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;195,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(625,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available for grant at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the Vyrix 2013 Stock Option Plan, 616,067 shares of its
 common stock were reserved for issuance. The fair value of the
 options was calculated using the Black-Scholes option pricing
 model. In order to calculate the fair value of the options, certain
 assumptions are made regarding components of the model, including
 the estimated fair value of the underlying common stock, risk-free
 interest rate, volatility, expected dividend yield and expected
 option life. Changes to the assumptions could cause significant
 adjustments to valuation. Aytu estimates the expected term based on
 the average of the vesting term and the contractual term of the
 options. The risk-free interest rate is based on the U.S. Treasury
 yield in effect at the time of the grant for treasury securities of
 similar maturity. In accordance with the Vyrix 2013 Stock Option
 Plan, no additional options were granted during the year-ended
 June&amp;#xA0;30, 2015. The assumptions are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;Year&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;63%&amp;#xA0;-&amp;#xA0;76%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.90%&amp;#xA0;-&amp;#xA0;2.02%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.0 - 6.5&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Stock option activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;417,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available for grant at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Stock-based compensation expense related to the fair value of stock
 options was included in the statements of operations as research
 and development expenses and general and administrative expenses as
 set forth in the table below. Aytu determined the fair value as of
 the date of grant using the Black-Scholes option pricing model and
 expenses the fair value ratably over the vesting period. The
 following table summarizes stock-based compensation expense for the
 years ended June&amp;#xA0;30 2015 and 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Years Ended
 June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;316,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,018,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized expense at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average remaining years to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Luoxis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Vyrix&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On June&amp;#xA0;1, 2015, Aytu&amp;#x2019;s stockholders approved the 2015
 Stock Option and Incentive Plan (the &amp;#x201C;2015 Plan&amp;#x201D;),
 which provides for the award of stock options, stock appreciation
 rights, restricted stock and other equity awards for up to an
 aggregate of 10,000,000 shares of common stock. The shares of
 common stock underlying any awards that are forfeited, canceled,
 reacquired by Aytu prior to vesting, satisfied without any issuance
 of stock, expire or are otherwise terminated (other than by
 exercise) under the 2015 Plan will be added back to the shares of
 common stock available for issuance under the 2015 Plan. As of
 September&amp;#xA0;28, 2015, no grants have been made under the 2015
 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu issued warrants in conjunction with its 2013 private
 placement. A summary of all warrants is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Warrants&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.41&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 These warrants were valued using the Black-Scholes option pricing
 model. In order to calculate the fair value of the warrants,
 certain assumptions were made regarding components of the model,
 including the closing price of the underlying common stock,
 risk-free interest rate, volatility, expected dividend yield, and
 expected life. Changes to the assumptions could cause significant
 adjustments to valuation. The Company estimated a volatility factor
 utilizing a weighted average of comparable published volatilities
 of peer companies. The risk-free interest rate is based on the U.S.
 Treasury yield in effect at the time of the grant for treasury
 securities of similar maturity. The offering costs and the
 additional paid-in capital for the warrants associated with the
 common stock offering were valued at $313,000 using the
 Black-Scholes valuation methodology.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_4E05BDFD-7FEB-46BD-88C5-4516E2CCBE4D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Newly Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In June 2015, the FASB issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) 2015-10, &amp;#x201C;Technical Corrections and
 Improvements&amp;#x201D;. The amendments represent changes to clarify
 the codification, correct unintended application of guidance, or
 make minor improvements to the codification that are not expected
 to have a significant effect on current accounting practice or
 create a significant administrative cost. In addition, some of the
 amendments will make the codification easier to understand and
 easier to apply by eliminating inconsistencies, providing needed
 clarifications, and improving the presentation of guidance in the
 codification. The amendments that require transition guidance are
 effective for all entities for fiscal years, and interim periods
 within those fiscal years, beginning after December&amp;#xA0;15, 2015.
 Early adoption is permitted, including adoption in an interim
 period. All other amendments will be effective upon issuance. The
 Company is evaluating the impact of ASU 2015-10 on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2015, the FASB issued&amp;#xA0;ASU
 2015-03,&amp;#xA0;&amp;#x201C;Interest&amp;#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs.&amp;#x201D;&amp;#xA0;The update requires debt issuance costs related
 to a recognized debt liability be presented in the balance sheet as
 a direct deduction from the carrying amount of the related debt
 liability instead of being presented as an asset. Debt disclosures
 will include the face amount of the debt liability and the
 effective interest rate. The update requires retrospective
 application and represents a change in accounting principle. The
 update is effective for fiscal years beginning after
 December&amp;#xA0;15, 2015. Early adoption is permitted for financial
 statements that have not been previously issued. The Company is
 evaluating the impact of ASU 2015-03 on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2015, the FASB issued ASU 2015-01, &amp;#x201C;Extraordinary
 and Unusual Items (Subtopic 225-20): Simplifying Income Statement
 Presentation by Eliminating the Concept of Extraordinary
 Items.&amp;#x201D; The purpose of this amendment is to eliminate the
 concept of extraordinary items. As a result, an entity will no
 longer be required to separately classify, present and disclose
 extraordinary events and transactions. The amendment is effective
 for annual reporting periods beginning after December&amp;#xA0;15, 2015
 and subsequent interim periods with early application permitted.
 The Company is evaluating the impact the adoption of ASU 2015-01
 will have on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Presentation of Financial Statements-Going Concern (Subtopic
 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s
 Ability to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU
 2014-15&amp;#x201D;). ASU 2014-15 is intended to define
 management&amp;#x2019;s responsibility to evaluate whether there is
 substantial doubt about an organization&amp;#x2019;s ability to continue
 as a going concern and to provide related footnote disclosures. The
 amendments in this ASU are effective for reporting periods
 beginning after December&amp;#xA0;15, 2016, with early adoption
 permitted. The Company is evaluating the impact the adoption of ASU
 2014-15 will have on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606,
 &amp;#x201C;Revenue from Contracts with Customers&amp;#x201D;. The standard
 provides principles for recognizing revenue for the transfer of
 promised goods or services to customers with the consideration to
 which the entity expects to be entitled in exchange for those goods
 or services. The guidance will be effective for annual reporting
 periods beginning after December&amp;#xA0;15, 2017, with early adoption
 permitted but not prior to the original public organization
 effective date of December&amp;#xA0;15, 2016. The Company is evaluating
 the accounting, transition and disclosure requirements of the
 standard and cannot currently estimate the financial statement
 impact of adoption.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_B4EC4CCF-D2D9-426D-AA27-E14E90BDB80C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 2 &amp;#x2013; Summary of Significant Accounting
 Policies&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu considers all highly liquid instruments purchased with an
 original maturity of three months or less to be cash equivalents.
 Cash equivalents consist primarily of money market fund
 investments. Aytu&amp;#x2019;s investment policy is to preserve
 principal and maintain liquidity. The Company periodically monitors
 its positions with, and the credit quality of the financial
 institutions with which it invests. Periodically, throughout the
 year, Aytu has maintained balances in excess of federally insured
 limits.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;License Agreements and Royalties&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Payments received upon signing of license agreements are for the
 right to use the license and are deferred and amortized over the
 lesser of the license term or patent life of the licensed drug.
 Milestone payments relate to obtaining regulatory approval,
 cumulative sales targets, and other projected milestones and are
 recognized at the time the milestones are achieved. Royalties will
 be recognized as revenue when earned.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 P&lt;i&gt;roduct&amp;#xA0;&amp;amp; Service Sales&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu recognizes revenue from product and service sales when there
 is persuasive evidence that an arrangement exists, delivery has
 occurred or service has been rendered, the price is fixed or
 determinable and collectability is reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Estimated Sales Returns and Allowances&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu records estimated reductions in revenue for potential returns
 of products by customers. As a result, management must make
 estimates of potential future product returns and other allowances
 related to current period product revenue. In making such
 estimates, management analyzes historical returns, current economic
 trends and changes in customer demand and acceptance of our
 products. If management were to make different judgments or utilize
 different estimates, material differences in the amount of the
 Company&amp;#x2019;s reported revenue could result.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounts receivable are recorded at their net realized value. Aytu
 evaluates collectability of accounts receivable on a quarterly
 basis and records a valuation allowance accordingly. As of
 June&amp;#xA0;30, 2015 and 2014, no allowance for doubtful accounts has
 been recorded.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Inventories are recorded at the lower of cost or market, with cost
 determined on a first-in, first-out basis. Aytu periodically
 reviews the composition of its inventories in order to identify
 obsolete, slow-moving or otherwise unsaleable items. If unsaleable
 items are observed and there are no alternate uses for the
 inventory, Aytu will record a write-down to net realizable value in
 the period that the impairment is first recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 When future commercialization is considered probable and the future
 economic benefit is expected to be realized, based on
 management&amp;#x2019;s judgment, Aytu capitalizes pre-launch inventory
 costs prior to regulatory approval. A number of factors are taken
 into consideration, including the current status in the regulatory
 approval process, potential impediments to the approval process,
 such as safety or efficacy, anticipated research and development
 initiatives that could impact the indication in which the compound
 will be used, viability of commercialization and marketplace
 trends. For product candidates that have not been approved by the
 FDA, inventory used in clinical trials is expensed at the time of
 production and recorded as research and development expense. For
 products that have been approved by the FDA, inventory used in
 clinical trials is expensed at the time the inventory is packaged
 for the clinical trial. Prior to receiving FDA approval, costs
 related to purchases of the active pharmaceutical ingredient and
 the manufacturing of the product candidate are recorded as research
 and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fixed Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;Estimated&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;Useful&amp;#xA0;Lives&amp;#xA0;in&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;3&amp;#xA0;-&amp;#xA0;5&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(60,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Fixed assets, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following depreciation expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Depreciation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;In-Process Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In-process research and development (&amp;#x201C;IPRD&amp;#x201D;) relates to
 the Company&amp;#x2019;s Zertane product and clinical trial data
 acquired in connection with the 2011 acquisition of BioSciences.
 The $7,500,000 recorded was based on an independent, third party
 appraisal of the fair value of the assets acquired. IPRD is
 considered an indefinite-lived intangible asset and its fair value
 will be assessed annually and written down if impaired. Once the
 Zertane product obtains regulatory approval and commercial
 production begins, IPRD will be reclassified to an intangible that
 will be amortized over its estimated useful life. If the Company
 decided to abandon the Zertane product, the IPRD would be
 expensed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs of establishing patents, consisting of legal and filing fees
 paid to third parties, are expensed as incurred. The fair value of
 the Zertane patents, determined by an independent third party
 appraisal, is $500,000. The Zertane patents were acquired in
 connection with the 2011 acquisition of BioSciences and are being
 amortized over the remaining U.S. patent lives of approximately 11
 years which expires in March 2022. The cost of the Luoxis patents
 was $380,000 when they were acquired in connection with the 2013
 formation of Luoxis and is being amortized over the remaining U.S.
 patent lives of approximately 15 years which expires in March 2028.
 Patents consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Patents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;880,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(251,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(180,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Patents, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aytu recorded the following amortization expense in the respective
 periods:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;Year Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amortization expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future amortization from the year ended June&amp;#xA0;30, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;274,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;629,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company accounts for its business acquisitions under the
 acquisition method of accounting as indicated in the Financial
 Accounting Standards Board&amp;#x2019;s (&amp;#x201C;FASB&amp;#x201D;) Accounting
 Standards Codification (&amp;#x201C;ASC&amp;#x201D;) 805, &amp;#x201C;Business
 Combinations&amp;#x201D;, which requires the acquiring entity in a
 business combination to recognize the fair value of all assets
 acquired, liabilities assumed, and any non-controlling interest in
 the acquire; and establishes the acquisition date as the fair value
 measurement point. Accordingly, the Company recognizes assets
 acquired and liabilities assumed in business combinations,
 including contingent assets and liabilities and non-controlling
 interest in the acquiree, based on the fair value estimates as of
 the date of acquisition. In accordance with ASC 805, the Company
 recognizes and measures goodwill as of the acquisition date, as the
 excess of the fair value of the consideration paid over the fair
 value of the identified net assets acquired.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The ProstaScint&amp;#xA0;purchase price allocation was based upon an
 analysis of the fair value of the assets and liabilities acquired
 from Jazz Pharmaceuticals. The final purchase price may be adjusted
 up to one year from the date of the acquisition. Identifying the
 fair value of the tangible and intangible assets and liabilities
 acquired required the use of estimates by management, and were
 based upon currently available data, as noted below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company allocated the excess of purchase price over the
 identifiable intangible and net tangible assets to goodwill. Such
 goodwill is not deductible for tax purposes and represents the
 value placed on entering new markets and expanding market
 share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company tests its goodwill for impairment annually, or whenever
 events or changes in circumstances indicate an impairment may have
 occurred, by comparing the carrying value to its implied fair
 value. Impairment may result from, among other things,
 deterioration in the performance of the acquired business, adverse
 market conditions, adverse changes in applicable laws or
 regulations and a variety of other circumstances. If the Company
 determines that an impairment has occurred, it is required to
 record a write-down of the carrying value and charge the impairment
 as an operating expense in the period the determination is made. In
 evaluating the recoverability of the carrying value of goodwill,
 the Company must make assumptions regarding estimated future cash
 flows and other factors to determine the fair value of the acquired
 assets. Changes in strategy or market conditions could
 significantly impact those judgments in the future and require an
 adjustment to the recorded balances. The goodwill was recorded as
 part of the acquisition of ProstaScint that occurred on
 May&amp;#xA0;20, 2015. There was no impairment of goodwill for the year
 ended June&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The preparation of financial statements in accordance with
 Generally Accepted Accounting Principles in the United States of
 America (&amp;#x201C;GAAP&amp;#x201D;) requires management to make estimates
 and assumptions that affect the reported amounts of assets and
 liabilities, disclosures of contingent assets and liabilities as of
 the date of the financial statements and the reported amounts of
 revenues and expenses during the reporting periods. Significant
 items subject to such estimates and assumptions include valuation
 allowances, stock-based compensation, warrant valuation, purchase
 price allocation, valuation of contingent consideration, sales
 returns and allowances, useful lives of fixed assets and
 assumptions in evaluating impairment of definite and indefinite
 lived assets. Actual results could differ from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu is included in the consolidated tax returns of Ampio.
 Aytu&amp;#x2019;s taxes are computed and reported on a &amp;#x201C;separate
 return&amp;#x201D; basis for these financial statements. Deferred taxes
 are provided on an asset and liability method whereby deferred tax
 assets are recognized for deductible temporary differences and
 operating loss and tax credit carry forwards and deferred tax
 liabilities are recognized for taxable temporary differences.
 Temporary differences are the differences between the reported
 amounts of assets and liabilities and their tax bases. Deferred tax
 assets are reduced by a valuation allowance when, in the opinion of
 management, it is more likely than not that some portion or all of
 the deferred tax assets will not be realized. Deferred tax assets
 and liabilities are adjusted for the effects of changes in tax laws
 and rates on the date of enactment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The amount of income taxes and related income tax positions taken
 would be subject to audits by federal and state tax authorities if
 Aytu filed these taxes on a separate basis. The Company has adopted
 accounting guidance for uncertain tax positions which provides that
 in order to recognize an uncertain tax benefit, the taxpayer must
 be more likely than not of sustaining the position, and the
 measurement of the benefit is calculated as the largest amount that
 is more than 50% likely to be realized upon settlement with the
 taxing authority. The Company believes that it has no material
 uncertain tax positions. The Company&amp;#x2019;s policy is to record a
 liability for the difference between the benefits that are both
 recognized and measured pursuant to FASB ASC 740-10,
 &amp;#x201C;Accounting for Uncertainty in Income Taxes&amp;#x2014;an
 interpretation of FASB Statement No.&amp;#xA0;109&amp;#x201D; (&amp;#x201C;ASC
 740-10&amp;#x201D;) and tax position taken or expected to be taken on
 the tax return. Then, to the extent that the assessment of such tax
 positions changes, the change in estimate is recorded in the period
 in which the determination is made. The Company reports tax-related
 interest and penalties as a component of income tax expense. During
 the periods reported, management of the Company has concluded that
 no significant tax position requires recognition under ASC
 740-10.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu accounts for share based payments by recognizing compensation
 expense based upon the estimated fair value of the awards on the
 date of grant. The Company determines the estimated grant fair
 value using the Black-Scholes option pricing model and recognizes
 compensation costs ratably over the period of service using the
 graded method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Research and development costs are expensed as incurred with
 expenses recorded in the respective period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The carrying amounts of financial instruments, including cash and
 cash equivalents, accounts payable and other current assets and
 other liabilities are carried at cost which approximates fair value
 due to the short maturity of these instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu routinely performs an annual evaluation of the recoverability
 of the carrying value of its long-lived assets to determine if
 facts and circumstances indicate that the carrying value of assets
 or intangible assets may be impaired and if any adjustment is
 warranted. Based on its evaluation as of June&amp;#xA0;30, 2015 and
 2014, respectively, no impairment existed for long-lived
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Newly Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In June 2015, the FASB issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) 2015-10, &amp;#x201C;Technical Corrections and
 Improvements&amp;#x201D;. The amendments represent changes to clarify
 the codification, correct unintended application of guidance, or
 make minor improvements to the codification that are not expected
 to have a significant effect on current accounting practice or
 create a significant administrative cost. In addition, some of the
 amendments will make the codification easier to understand and
 easier to apply by eliminating inconsistencies, providing needed
 clarifications, and improving the presentation of guidance in the
 codification. The amendments that require transition guidance are
 effective for all entities for fiscal years, and interim periods
 within those fiscal years, beginning after December&amp;#xA0;15, 2015.
 Early adoption is permitted, including adoption in an interim
 period. All other amendments will be effective upon issuance. The
 Company is evaluating the impact of ASU 2015-10 on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2015, the FASB issued&amp;#xA0;ASU
 2015-03,&amp;#xA0;&amp;#x201C;Interest - Imputation of Interest (Subtopic
 835-30): Simplifying the Presentation of Debt Issuance
 Costs.&amp;#x201D;&amp;#xA0;The update requires debt issuance costs related
 to a recognized debt liability be presented in the balance sheet as
 a direct deduction from the carrying amount of the related debt
 liability instead of being presented as an asset. Debt disclosures
 will include the face amount of the debt liability and the
 effective interest rate. The update requires retrospective
 application and represents a change in accounting principle. The
 update is effective for fiscal years beginning after
 December&amp;#xA0;15, 2015. Early adoption is permitted for financial
 statements that have not been previously issued. The Company is
 evaluating the impact of ASU 2015-03 on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2015, the FASB issued ASU 2015-01, &amp;#x201C;Extraordinary
 and Unusual Items (Subtopic 225-20): Simplifying Income Statement
 Presentation by Eliminating the Concept of Extraordinary
 Items.&amp;#x201D; The purpose of this amendment is to eliminate the
 concept of extraordinary items. As a result, an entity will no
 longer be required to separately classify, present and disclose
 extraordinary events and transactions. The amendment is effective
 for annual reporting periods beginning after December&amp;#xA0;15, 2015
 and subsequent interim periods with early application permitted.
 The Company is evaluating the impact the adoption of ASU 2015-01
 will have on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Presentation of Financial Statements-Going Concern (Subtopic
 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s
 Ability to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU
 2014-15&amp;#x201D;). ASU 2014-15 is intended to define
 management&amp;#x2019;s responsibility to evaluate whether there is
 substantial doubt about an organization&amp;#x2019;s ability to continue
 as a going concern and to provide related footnote disclosures. The
 amendments in this ASU are effective for reporting periods
 beginning after December&amp;#xA0;15, 2016, with early adoption
 permitted. The Company is evaluating the impact the adoption of ASU
 2014-15 will have on its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606,
 &amp;#x201C;Revenue from Contracts with Customers&amp;#x201D;. The standard
 provides principles for recognizing revenue for the transfer of
 promised goods or services to customers with the consideration to
 which the entity expects to be entitled in exchange for those goods
 or services. The guidance will be effective for annual reporting
 periods beginning after December&amp;#xA0;15, 2017, with early adoption
 permitted but not prior to the original public organization
 effective date of December&amp;#xA0;15, 2016. The Company is evaluating
 the accounting, transition and disclosure requirements of the
 standard and cannot currently estimate the financial statement
 impact of adoption.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_1B2A8693-DBFE-4046-8BE2-A59E3004B7D5_1_0">RSWN</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="shares" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_13">9207917</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="pure" decimals="4" id="id_6457213_BF1ABB66-559F-4EA4-9B76-B26D2C16BFB7_1_5">0.0030</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_E2B0259C-E7BE-4FCE-B7CF-A0F327A4F799_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu is included in the consolidated tax returns of Ampio.
 Aytu&amp;#x2019;s taxes are computed and reported on a &amp;#x201C;separate
 return&amp;#x201D; basis for these financial statements. Deferred taxes
 are provided on an asset and liability method whereby deferred tax
 assets are recognized for deductible temporary differences and
 operating loss and tax credit carry forwards and deferred tax
 liabilities are recognized for taxable temporary differences.
 Temporary differences are the differences between the reported
 amounts of assets and liabilities and their tax bases. Deferred tax
 assets are reduced by a valuation allowance when, in the opinion of
 management, it is more likely than not that some portion or all of
 the deferred tax assets will not be realized. Deferred tax assets
 and liabilities are adjusted for the effects of changes in tax laws
 and rates on the date of enactment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The amount of income taxes and related income tax positions taken
 would be subject to audits by federal and state tax authorities if
 Aytu filed these taxes on a separate basis. The Company has adopted
 accounting guidance for uncertain tax positions which provides that
 in order to recognize an uncertain tax benefit, the taxpayer must
 be more likely than not of sustaining the position, and the
 measurement of the benefit is calculated as the largest amount that
 is more than 50% likely to be realized upon settlement with the
 taxing authority. The Company believes that it has no material
 uncertain tax positions. The Company&amp;#x2019;s policy is to record a
 liability for the difference between the benefits that are both
 recognized and measured pursuant to FASB ASC 740-10,
 &amp;#x201C;Accounting for Uncertainty in Income Taxes&amp;#x2014;an
 interpretation of FASB Statement No.&amp;#xA0;109&amp;#x201D; (&amp;#x201C;ASC
 740-10&amp;#x201D;) and tax position taken or expected to be taken on
 the tax return. Then, to the extent that the assessment of such tax
 positions changes, the change in estimate is recorded in the period
 in which the determination is made. The Company reports tax-related
 interest and penalties as a component of income tax expense. During
 the periods reported, management of the Company has concluded that
 no significant tax position requires recognition under ASC
 740-10.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_0535CD8C-EB7B-4AE4-8B6C-04A0D2954B2E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 8 &amp;#x2013; Related Party Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Ampio Loan Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In November 2013, Vyrix entered into a loan agreement with Ampio.
 Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an
 aggregate amount of $3,000,000 through cash advances of up to
 $500,000 each. Unpaid principal amounts under the loan agreement
 bear simple interest at the &amp;#x201C;Applicable Federal Rate&amp;#x201D;
 for long-term obligations prescribed under Section&amp;#xA0;1274(d) of
 the Internal Revenue Code of 1986, as amended (or any successor
 provision with similar applicability). The initial term of this
 loan agreement is for one year, subject to automatic extension of
 successive one-year terms. Vyrix may repay any outstanding balance
 at any time without penalty. Ampio has an option of converting any
 balance outstanding under the loan agreement into shares of Vyrix
 common stock at the fair market value per share of Vyrix common
 stock, as determined by the Ampio board of directors, as of such
 conversion date. As of June&amp;#xA0;30, 2014, the amount advanced was
 $1,600,000 with interest rates from 3.11%-3.32%. On April&amp;#xA0;16,
 2015, in connection with the closing of the Merger, Ampio released
 Vyrix from its then outstanding obligation of $4,000,000 under the
 loan agreement as consideration of its share purchase, and the loan
 agreement was terminated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2014, Luoxis entered into a loan agreement with Ampio.
 Pursuant to the loan agreement, Ampio agreed to lend Luoxis
 $3,000,000. Unpaid principal amounts under the loan agreement bear
 simple interest at the &amp;#x201C;Applicable Federal Rate&amp;#x201D; for
 long-term obligations prescribed under Section&amp;#xA0;1274(d) of the
 Internal Revenue Code of 1986, as amended (or any successor
 provision with similar applicability). The initial term of this
 loan agreement is for one year, subject to automatic extension of
 successive one-year terms. Luoxis may repay any outstanding balance
 at any time without penalty. Ampio has an option of converting any
 balance outstanding under the loan agreement into shares of Luoxis
 common stock at the fair market value per share of Luoxis common
 stock, as determined by the Ampio board of directors, as of such
 conversion date. As of June&amp;#xA0;30, 2014, the amount advanced was
 $3,000,000 with interest rates from 3.11% - 3.32%. On
 April&amp;#xA0;16, 2015, in connection with the closing of the Merger,
 Ampio released Luoxis from its then outstanding obligation of
 $8,000,000 under the loan agreement as consideration of its share
 purchase, and the loan agreement was terminated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On April&amp;#xA0;16, 2015, Ampio received 4,761,787 shares of common
 stock of Aytu for (i)&amp;#xA0;issuance to Aytu of a promissory note
 from Ampio in the principal amount of $10,000,000, maturing on the
 first anniversary of the Merger, (ii)&amp;#xA0;cancellation of
 indebtedness of Luoxis to Ampio in the amount of $8,000,000; and
 (iii)&amp;#xA0;cancellation of indebtedness of Vyrix to Ampio in the
 amount of $4,000,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company has service agreements with Ampio which are described
 in Note 5.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Sponsored Research Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In June 2013, Luoxis entered into a sponsored research agreement
 with TRLLC, an entity controlled by Ampio&amp;#x2019;s director and
 Chief Scientific Officer, Dr.&amp;#xA0;Bar-Or. The agreement, which was
 amended in January 2015 and provides for Luoxis (now Aytu) to pay
 $6,000 per month to TRLLC in consideration for services related to
 research and development of the Oxidation Reduction Potential
 platform. In March 2014, Luoxis also agreed to pay a sum of
 $615,000 which is being amortized over the contractual term of 60.5
 months and is divided between current and long-term on the balance
 sheet; this amount has been paid in full. This agreement is set to
 expire March 2019 and cannot be terminated prior to March 2017.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_5D986C9B-21A1-43CD-B836-674A017B4236_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 11 &amp;#x2013; Subsequent Event&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 During July and August 2015, Aytu closed on note purchase
 agreements with institutional and high net worth individual
 investors for the purchase and sale of convertible promissory notes
 with an aggregate principal amount of $5.2 million. The sale of the
 notes was pursuant to a private placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Aytu intends to use the net proceeds of the offering to conduct
 clinical studies for both Zertane&amp;#xAE; and RedoxSYS&amp;#x2122; and for
 working capital to begin commercializing FDA-approved
 ProstaScint&amp;#xAE;, as well as general corporate purposes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The notes are an unsecured obligation. Unless earlier converted,
 the notes will mature 18 months from their respective dates of
 issuance which will be on January&amp;#xA0;22, February&amp;#xA0;11 and
 February&amp;#xA0;28, 2017, with an option to extend up to six months
 at our discretion (provided that in the event Aytu exercises such
 extension option, the then applicable interest rate shall increase
 by 2% for such extension period). Aytu does not have the right to
 prepay the notes prior to the maturity date. Interest will accrue
 on the notes in the following amounts: (i)&amp;#xA0;8% simple interest
 per annum for the first six months and (ii)&amp;#xA0;12% simple
 interest per annum thereafter if not converted during the first six
 months. If there has not been a registration statement on
 Form&amp;#xA0;S-1 filed with the SEC for the registration of the shares
 of common stock underlying the notes by the expiration of the first
 six-month period then (a)&amp;#xA0;the interest rate will increase to
 14% for the remainder of the period in which the notes remain
 outstanding and (b)&amp;#xA0;any notes held by officers and directors
 of the Company will be subordinated to the remaining notes.
 Interest will accrue, is payable with the principal upon maturity,
 conversion or acceleration of the notes and may be paid in kind or
 in cash, in Aytu&amp;#x2019;s sole discretion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The notes are convertible at any time in a noteholder&amp;#x2019;s
 discretion into that number of shares of Aytu common stock equal in
 an amount equal to 120% of the number of shares of common stock
 calculated by dividing the then outstanding principal and accrued
 interest by $4.63. A holder of notes will be obligated to convert
 on the terms of Aytu&amp;#x2019;s next public offering of its stock
 resulting in proceeds to it of at least $5,000,000 in gross
 proceeds (excluding indebtedness converted in such financing) prior
 to the maturity date of the notes (a &amp;#x201C;Qualified
 Financing&amp;#x201D;). The principal and accrued interest under the
 notes will automatically convert into a number of shares of such
 equity securities of the Company sold in such financing equal to
 120% of the principal and accrued interest under such note divided
 by the lesser of (i)&amp;#xA0;the lowest price paid by an investor in
 such financing or (ii)&amp;#xA0;$4.63. In the event that Aytu sells
 equity securities to investors at any time while the notes are
 outstanding in a financing transaction that is not a Qualified
 Financing, then the noteholders will have the option to convert in
 whole the outstanding principal and accrued interest as of the
 closing of such financing into a number of shares of Aytu capital
 stock in an amount equal to 120% of the number of such shares
 calculated by dividing the outstanding principal and accrued
 interest by the lesser of (i)&amp;#xA0;the lowest cash price per share
 paid by purchasers of shares in such financing, or
 (ii)&amp;#xA0;$4.63.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Newbridge Securities Corporation, Member FINRA/SIPC, through
 LifeTech Capital, acted as sole placement agent for the
 institutional portion of the offering. Aytu sold the balance of the
 notes to individuals and entities with whom Aytu has an established
 relationship. For notes sold by the placement agent, Aytu paid the
 placement agent 8% of the gross proceeds of notes sold by the
 placement agent and a warrant to purchase shares of Aytu&amp;#x2019;s
 common stock equal to 8% of the gross proceeds of the notes sold by
 the placement agent divided by the price per share at which equity
 securities are sold in Aytu&amp;#x2019;s next equity financing, in
 addition to a previously paid non-refundable retainer fee of
 $20,000. The placement agent warrant has a term of five years, will
 have an exercise price equal to 100% of the price per share at
 which equity securities are sold in Aytu&amp;#x2019;s next equity
 financing, and provides for cashless exercise.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On August&amp;#xA0;19, 2015, Aytu entered into a 37 month
 non-cancellable operating lease for new office space effective
 September&amp;#xA0;1, 2015. The new lease has initial base rent of
 $8,500 per month beginning in October 2015, with the total base
 rent over the term of the lease of approximately $318,000 which
 includes rent abatements. The Company recognizes rental expense of
 the facility on a straight-line basis over the term of the lease.
 Differences between the straight-line net expenses on rent payments
 are classified as liabilities between current deferred rent and
 long-term deferred rent.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On October&amp;#xA0;5, 2015, the Company entered into and closed on an
 Asset Purchase Agreement with FSC Laboratories, Inc. (the
 &amp;#x201C;Seller&amp;#x201D;). Pursuant to the agreement, the Company
 purchased assets related to the Seller&amp;#x2019;s product known as
 Primsol&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;(trimethoprim solution),
 including certain intellectual property and contracts, inventory,
 work in progress and all marketing and sales assets and materials
 related solely to Primsol (together, the &amp;#x201C;Primsol
 Business&amp;#x201D;), and assumed certain of the Seller&amp;#x2019;s
 liabilities, including those related to the sale and marketing of
 Primsol arising after the closing. The agreement provides that for
 a period of one year after the closing the Seller will not directly
 or indirectly sell, market, promote, advertise or distribute
 anywhere in the world any urinary tract anti-infective
 pharmaceutical or treatment product containing trimethoprim.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The Company paid $500,000 at closing for the Primsol Business and
 agreed to pay an additional $141,694 payable within five days after
 transfer of the Primsol-related product inventory. The Company also
 agreed to pay an additional (a)&amp;#xA0;$500,000 payable no later than
 March&amp;#xA0;31, 2016, (b)&amp;#xA0;$500,000 payable no later than
 June&amp;#xA0;30, 2016, and (c)&amp;#xA0;$250,000 payable no later than
 September&amp;#xA0;30, 2016, for a total purchase price of
 $1,891,694.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On October 8, 2015, the Company and Biovest International, Inc.
 (&amp;#x201C;Biovest&amp;#x201D;) entered into a Master Services Agreement,
 pursuant to which Biovest is to provide manufacturing services to
 the Company. The agreement provides that the Company may engage
 Biovest from time to time to provide services in accordance with
 mutually agreed upon project addendums and purchase orders. The
 Company expects to use the agreement from time to time for
 manufacturing services, including without limitation, the
 manufacturing, processing, quality control testing, release or
 storage of its products. The agreement has a term of four years,
 provided that either party may terminate the agreement or any
 project addendum under the agreement on 30 days written notice of a
 material breach under the agreement. In addition, the Company may
 terminate the agreement or any project addendum under the agreement
 upon 180 days written notice for any reason. In conjunction with
 entering into the agreement, the Company submitted a work order to
 Biovest to provide the Company with active pharmaceutical
 ingredient for ProstaScint over a four-year period at a total cost
 of $5,000,000, of which the Company paid $1,000,000 upon submission
 of the work order.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_24">27476</us-gaap:PaymentsOfDistributionsToAffiliates>
  <us-gaap:NetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_12">-7723404</us-gaap:NetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_11">-8311155</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_2">261782</us-gaap:Revenues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8007_1000020">1017938</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:InterestIncomeExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_9">-114994</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_8">-7632320</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_7">39442</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:LicensesRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_1">85714</us-gaap:LicensesRevenue>
  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_18">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_6">157058</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_34">664000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_8">-150434</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_25">20013</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_10">-7747314</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_0">1371106</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_9">-8335065</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_11">-23910</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_2">1017938</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromContributionsFromParent contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_22">5000000</us-gaap:ProceedsFromContributionsFromParent>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_14">-85714</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_23">7400000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_2E832CCD-7536-4CB8-B9B7-B5EA85CCB24C_1_2">112000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_5C081779-0B9D-4DA0-B0BC-DB2E6A8ABC5B_1_0">51000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_28">4713411</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_20">-1004886</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_27">12352511</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_5">3219361</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_5">-23910</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_1_4">1018000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_7">4382640</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_33">4600000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_10">-46002</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_D492EBEA-C77C-41A7-A3D2-7C659612CB74_1_0">71000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_11">547314</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:Depreciation contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_F0353E2C-7001-4799-97FA-3F72C2705C80_1_0">27000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_3">118202</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:OtherLaborRelatedExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_4AB24962-5062-474D-8001-CB996FD3F25C_1_0">264000</us-gaap:OtherLaborRelatedExpenses>
  <us-gaap:CostOfRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_4">88109</us-gaap:CostOfRevenue>
  <us-gaap:GoodwillImpairmentLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="INF" id="id_6457213_2268A969-7E8A-4180-8F1F-5782406D0494_1_0">0</us-gaap:GoodwillImpairmentLoss>
  <rswn:ResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_6">203992</rswn:ResearchAndDevelopmentRelatedParty>
  <rswn:IncreaseDecreaseInAccruedCompensation contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_12">196503</rswn:IncreaseDecreaseInAccruedCompensation>
  <rswn:BusinessAcquisitionsProFormaInterestIncomeExpenseNet contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_8">-114994</rswn:BusinessAcquisitionsProFormaInterestIncomeExpenseNet>
  <rswn:IncreaseDecreaseAccountsPayableRelatedPartyCurrent contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_13">-561059</rswn:IncreaseDecreaseAccountsPayableRelatedPartyCurrent>
  <rswn:LicenseAgreementTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_109A6C62-159F-49F4-8C7A-7600801E2953_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 3 &amp;#x2013; License Agreement/Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 During 2011, Ampio entered into a license, development and
 commercialization agreement with a major Korean pharmaceutical
 company which was assigned to Vyrix when it was formed in 2013. The
 agreement grants the pharmaceutical company exclusive rights to
 market Zertane in South Korea for the treatment of premature
 ejaculation (&amp;#x201C;PE&amp;#x201D;) and for a combination drug to be
 developed, utilizing Zertane and an erectile dysfunction drug. Upon
 signing of the agreement, Ampio received a $500,000 upfront
 payment, the net proceeds of which were $418,000 after withholding
 of Korean tax. The upfront payment has been deferred and is being
 recognized as license revenue over a ten year period. Milestone
 payments of $3,200,000 may be earned and recognized contingent upon
 achievement of regulatory approvals and cumulative net sales
 targets, which may take several years. In addition, Aytu may earn a
 royalty based on 25% of net sales, as defined, if the royalty
 exceeds the transfer price of the Zertane product. No royalties
 have been earned to date.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In April 2014, Vyrix entered into a Distribution and License
 Agreement (the &amp;#x201C;Paladin Agreement&amp;#x201D;) with Endo Ventures
 Limited, which recently acquired Paladin Labs Inc.
 (&amp;#x201C;Paladin&amp;#x201D;), whereby Paladin has exclusive rights to
 market, sell and distribute Zertane in Canada, the Republic of
 South Africa, certain countries in Sub Saharan Africa, Colombia and
 Latin America. The Paladin Agreement expires on a country by
 country basis upon the later of fifteen years after the first
 commercial sale of the product in that country or expiration of
 market exclusivity for Zertane in that country. Paladin paid
 $250,000 to Vyrix upon signing the Paladin Agreement and is
 obligated to make milestone payments aggregating up to $3,025,000
 based upon achieving Canadian and South African product regulatory
 approval and achieving specific sales goals. The upfront payment
 has been deferred and is being recognized as license revenue over a
 seven year period. In addition, the Paladin Agreement provides that
 Paladin pay royalties based on sales volume.&lt;/p&gt;
 &lt;/div&gt;</rswn:LicenseAgreementTextBlock>
  <rswn:BusinessAcquisitionsProFormaOperatingIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_7">-8220071</rswn:BusinessAcquisitionsProFormaOperatingIncomeLoss>
  <rswn:NoncashOrPartNoncashCapitalContributionFromParent contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_32">5000000</rswn:NoncashOrPartNoncashCapitalContributionFromParent>
  <rswn:CommitmentsAndContingenciesDisclosureTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_E4567F2F-291A-4F90-B967-E4A98E6EF3B7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Commitments and contingencies are described below and summarized by
 the following table as of June&amp;#xA0;30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Total&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2016&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2019&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2020&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Thereafter&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Management fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,800,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;360,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 ProstaScint Inventory Transfer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;500,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Sponsored research agreement with related party&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;350,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical research and trial obligations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;329,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;329,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Manufacturing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Office Lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;110,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,222,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,427,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;466,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;430,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</rswn:CommitmentsAndContingenciesDisclosureTableTextBlock>
  <rswn:ProductsAndServicesRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CF8E6A73-0438-4C22-895B-A0738D4B119B_1_0">176068</rswn:ProductsAndServicesRevenue>
  <rswn:StockSubscription contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8007_1000014">5000000</rswn:StockSubscription>
  <rswn:BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_10">-23910</rswn:BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit>
  <rswn:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_4">121984</rswn:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>
  <rswn:IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_9">-150000</rswn:IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties>
  <rswn:EstimatedSalesReturnsAndAllowancesPolicyTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_AAF4C134-E151-49F5-A718-A138E822870F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Estimated Sales Returns and Allowances&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Aytu records estimated reductions in revenue for potential returns
 of products by customers. As a result, management must make
 estimates of potential future product returns and other allowances
 related to current period product revenue. In making such
 estimates, management analyzes historical returns, current economic
 trends and changes in customer demand and acceptance of our
 products. If management were to make different judgments or utilize
 different estimates, material differences in the amount of the
 Company&amp;#x2019;s reported revenue could result.&lt;/p&gt;
 &lt;/div&gt;</rswn:EstimatedSalesReturnsAndAllowancesPolicyTextBlock>
  <rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" id="id_6457213_A4B30D46-F659-4464-8007-576CB872D399_4001_4">P2Y11M1D</rswn:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>
  <rswn:AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8007_1000015">20013</rswn:AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid>
  <rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_3">3065626</rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentExpense>
  <rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_4">156988</rswn:BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty>
  <rswn:BusinessAcquisitionsProFormaCostOfRevenue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_2">1818690</rswn:BusinessAcquisitionsProFormaCostOfRevenue>
  <rswn:BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_6">131989</rswn:BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets>
  <rswn:BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_CA55AD5A-2A19-42E7-BCB7-FDC78B600341_1_5">4417884</rswn:BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses>
  <rswn:PaymentsForDepositsInvestingActivities contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_6457213_9D226746-5A9B-491C-869A-AED1CCED766B_1_17">4886</rswn:PaymentsForDepositsInvestingActivities>
  <us-gaap:DebtConversionDescription contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1631478x1962156" id="id_6457213_B31FF7A1-8E67-49EF-9158-9A956690C29B_1002_3">The principal and accrued interest under the notes will  automatically convert into a number of shares of such equity securities of the  Company sold in such financing equal to 120% of the principal and accrued  interest under such note divided by the lesser of (i) the lowest price paid by  an investor in such financing or (ii) $4.63.</us-gaap:DebtConversionDescription>
  <rswn:AgreementTerminationNoticePeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1632127x1640093" id="id_6457213_3032F6F1-1230-493F-A878-B9D27F197386_1001_0">P30D</rswn:AgreementTerminationNoticePeriod>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985399" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_1001_4">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <rswn:FiniteLivedIntangibleAssetsExpirationMonthYear contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985399" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_1001_5">2028-03</rswn:FiniteLivedIntangibleAssetsExpirationMonthYear>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985400" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_2001_1">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <rswn:FiniteLivedIntangibleAssetsExpirationMonthYear contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985400" id="id_6457213_27A1DECE-46EB-4A37-8A29-CDAA47176BD1_2001_2">2022-03</rswn:FiniteLivedIntangibleAssetsExpirationMonthYear>
  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1667600_1641811x1638052" unitRef="iso4217_USD" decimals="0" id="id_6457213_BCFEE8E6-C05F-4E81-89E3-947BBFEA126E_1001_1">418000</us-gaap:ProceedsFromLicenseFeesReceived>
  <rswn:PercentageOfRoyaltyRateOfNetSales contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1667600_1641811x1638052" unitRef="pure" decimals="2" id="id_6457213_BCFEE8E6-C05F-4E81-89E3-947BBFEA126E_1001_4">0.25</rswn:PercentageOfRoyaltyRateOfNetSales>
  <rswn:DeferredRevenueRecognitionPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1667600_1641811x1638052" id="id_6457213_BCFEE8E6-C05F-4E81-89E3-947BBFEA126E_1001_3">P10Y</rswn:DeferredRevenueRecognitionPeriod>
  <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1792882_1634968x1733376" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1004_9">P4Y</us-gaap:LongtermPurchaseCommitmentPeriod>
  <rswn:NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1792882_1634968x1733376" id="id_6457213_964FEAEC-3C5A-440D-B722-B09E315624AC_1004_10">P180D</rswn:NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_7001_9">117053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_7001_9">5.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" id="id_6457213_97E931B2-5366-4D74-93E5-A32680A56C81_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Stock option activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&amp;#xA0;Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;417,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(117,053&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available for grant at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_09A0ECC8-157C-4B28-AC47-7C6BE07DBDBB_7001_8">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" unitRef="shares" decimals="INF" id="id_6457213_EE79E0B7-9DE6-4EC3-83BD-AEF433D73B69_7001_8">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" id="id_6457213_CA07E61A-E2B5-48B1-A268-99898E847300_1_0">&lt;div&gt;
 &lt;p&gt;The assumptions are as follows:&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;Year&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;63%&amp;#xA0;-&amp;#xA0;76%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.90%&amp;#xA0;-&amp;#xA0;2.02%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.0 - 6.5&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_1001_8">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <rswn:UnrecognizedShareBasedCompensationExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_1001_6">0</rswn:UnrecognizedShareBasedCompensationExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390_1634394x1639948_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_2001_3">183000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390_1634394x1642216_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_3001_1">92000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_7001_9">625266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_7001_9">5.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1_1">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="pure" decimals="2" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1_6">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="2" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_7001_7">7.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" id="id_6457213_896110A2-0E6D-4DBC-B141-96EE8B8DF32E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Stock option activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&lt;br /&gt;
 Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&amp;#xA0;Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual Life&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;396,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,272,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,083&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;430,077&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;4.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,374,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;195,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(625,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available for grant at June&amp;#xA0;30, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_7001_7">195189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="iso4217_USD_per_shares" decimals="0" id="id_6457213_86A8E254-848D-4DDC-9F53-439B7F04CD74_7001_8">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1_2">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1_3">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_DF257789-8CA2-4E14-A99C-AAE8F90E0644_7001_8">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="pure" decimals="INF" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1_0">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" id="id_6457213_65BB442D-AA28-45C1-9FB2-6E2A5B8684C4_1_0">&lt;div&gt;
 &lt;p&gt;The assumptions are as follows:&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;Years Ended June&amp;#xA0;30,&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2015&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;2014&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79%&amp;#xA0;-&amp;#xA0;108%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79%&amp;#xA0;-&amp;#xA0;82%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.62%&amp;#xA0;-&amp;#xA0;2.09%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.75%&amp;#xA0;-&amp;#xA0;1.53%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.5 - 7.0&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.0 - 6.5&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_4001_7">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <rswn:UnrecognizedShareBasedCompensationExpenses contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_4001_5">0</rswn:UnrecognizedShareBasedCompensationExpenses>
  <rswn:AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9007_1000016">-27476</rswn:AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9007_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1634394x1639948_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_5001_2">316000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1634394x1642216_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_057A6FDA-710E-47BA-9C7E-B101B9178603_6001_0">427000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1639304x1633605" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_1001_5">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1639304x1643741" id="id_6457213_CE79E486-A297-4D73-8660-B3ACD707EB7A_2001_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9001_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1633302" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9006_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9004_700016">-27476</rswn:AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1641496" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9004_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1642961" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9003_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1644202" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_9005_17">0</rswn:AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1634505x1935108_1639304x1633605" id="id_6457213_0A670C3C-1AD9-4402-9E28-70CFA82F49DA_1002_0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1634505x1935108_1639304x1643741" id="id_6457213_0A670C3C-1AD9-4402-9E28-70CFA82F49DA_1001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1639657x1986697" unitRef="shares" decimals="INF" id="id_6457213_73E158FD-0E47-4986-80FB-D611D91A4167_1001_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <rswn:ReversalOfAllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1639657x1986698" unitRef="iso4217_USD" decimals="0" id="id_6457213_C2F38B34-4B5B-4194-8BD2-401C889C74C6_1001_0">433000</rswn:ReversalOfAllocatedShareBasedCompensationExpense>
  <rswn:LeaseAgreementsMaturityPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1640593x1639324_1641766x1756965_1642993x1667600" id="id_6457213_9447A9EF-D9B7-4B5E-BAF9-B4C367202364_2002_3">March 2019</rswn:LeaseAgreementsMaturityPeriod>
  <rswn:PrepaidExpensesAmortizationPeriod contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1640593x1639324_1641766x1756965_1642993x1667600" id="id_6457213_9447A9EF-D9B7-4B5E-BAF9-B4C367202364_2002_2">P60M15D</rswn:PrepaidExpensesAmortizationPeriod>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1642755x1633925" unitRef="iso4217_USD" decimals="0" id="id_6457213_5AAD70E7-6932-4BD6-BAE7-98ABC035AF82_1001_0">27000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8001_400013">2597339</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8001_500012">260</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <rswn:ReverseMergerValue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1632657" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8001_500018">160</rswn:ReverseMergerValue>
  <rswn:ReverseMergerShare contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8001_400019">1596468</rswn:ReverseMergerShare>
  <us-gaap:NetIncomeLoss contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1633302" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8006_900022">-7723404</us-gaap:NetIncomeLoss>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8004_700020">1017938</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8004_700012">11999740</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <rswn:AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8004_700015">20013</rswn:AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid>
  <rswn:ReverseMergerValue contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1641496" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8004_700018">-160</rswn:ReverseMergerValue>
  <rswn:StockSubscription contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1644202" unitRef="iso4217_USD" decimals="0" id="id_6457213_21153704-EA55-4B73-836D-4C5A6F08E772_8005_800014">5000000</rswn:StockSubscription>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643960x1985396" id="id_6457213_B74567C3-F158-4356-AD4D-8E21C1E14441_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Future amortization from the year ended June&amp;#xA0;30, 2015 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;775,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,570,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons contextRef="eol_PE731244--1510-K0008_STD_365_20150630_0_1643960x1985396" id="id_6457213_B57DD78A-A8BD-4DF8-B1C7-1D82270F00BF_2003_3">Aytu also will pay 8% as  contingent consideration on its net sales made after October 31, 2017, payable  up to a maximum aggregate payment of an additional $2.5 million.</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985513_1636141x1633766" unitRef="pure" decimals="INF" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_1001_6">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985514_1636141x1633766" unitRef="pure" decimals="INF" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_2001_7">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985515_1636141x1633766" unitRef="pure" decimals="2" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_3001_8">0.14</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_0">2017-01-22</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" unitRef="pure" decimals="2" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_5">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <rswn:DebtInstrumentMaturityDateTwo contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_1">2017-02-11</rswn:DebtInstrumentMaturityDateTwo>
  <rswn:DebtInstrumentExtensionPeriod contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_4">P6M</rswn:DebtInstrumentExtensionPeriod>
  <rswn:DebtInstrumentMaturityPeriod1 contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_3">P18M</rswn:DebtInstrumentMaturityPeriod1>
  <rswn:DebtInstrumentMaturityDateThree contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" id="id_6457213_8016207C-638B-4444-833A-9593ACF6922A_4001_2">2017-02-28</rswn:DebtInstrumentMaturityDateThree>
  <rswn:ConvertibleNotesEqualToPercentageOfCommonStock contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766" unitRef="pure" decimals="2" id="id_6457213_B31FF7A1-8E67-49EF-9158-9A956690C29B_2001_0">1.20</rswn:ConvertibleNotesEqualToPercentageOfCommonStock>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766_1639304x1643741" unitRef="iso4217_USD" decimals="INF" id="id_6457213_B31FF7A1-8E67-49EF-9158-9A956690C29B_3001_2">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <rswn:PrivatePlacementWarrantTerm contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766" id="id_6457213_F1681F2A-B28C-410E-BEAF-59511CBCC53F_1001_3">P5Y</rswn:PrivatePlacementWarrantTerm>
  <rswn:NonRefundableRetainerFee contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766" unitRef="iso4217_USD" decimals="0" id="id_6457213_F1681F2A-B28C-410E-BEAF-59511CBCC53F_1001_2">20000</rswn:NonRefundableRetainerFee>
  <rswn:PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766" unitRef="pure" decimals="2" id="id_6457213_F1681F2A-B28C-410E-BEAF-59511CBCC53F_1001_0">0.08</rswn:PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold>
  <rswn:PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766" unitRef="pure" decimals="2" id="id_6457213_F1681F2A-B28C-410E-BEAF-59511CBCC53F_1001_1">0.08</rswn:PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes>
  <rswn:PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold contextRef="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766" unitRef="pure" decimals="INF" id="id_6457213_F1681F2A-B28C-410E-BEAF-59511CBCC53F_1001_4">1.00</rswn:PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985515_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rswn:IfNotRegisteredCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985514_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rswn:IfNotConvertedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_62_20150831_0_1631478x1962156_1632270x1985513_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rswn:IfConvertedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1644202">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1640593x1639324_1641766x1756965_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rswn:FirstInstallmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1639657x1986698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:LuoxisTwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1639657x1986697">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:VyrixTwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1634505x1935108_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rswn:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1634505x1935108_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rswn:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1644202">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1642961">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1634394x1642216_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391_1634394x1639948_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390_1634394x1642216_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390_1634394x1639948_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1792882_1634968x1733376">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:BiovestInternationalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rswn:MasterServicesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1633579x1667600_1641811x1638052">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:AmpioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rswn:ZertanePatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1632326x1985399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rswn:OrpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1632127x1640093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0_1631478x1962156">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1634394x1642216_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391_1634394x1639948_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1642961">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1634394x1642216_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390_1634394x1639948_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985391_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0_1631478x1985397_1633579x1985390_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20130630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20130630_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_365_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_31_20140331_0_1631478x1985397_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-03-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_31_20150731_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_30_20130630_0_1631679x1706730_1640593x1639324_1641766x1676684_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rswn:SecondInstallmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rswn:AfterAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_30_20131130_0_1631478x1985397_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_30_20140430_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150416_0_1633579x1985391_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-16</startDate>
      <endDate>2015-04-16</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150416_0_1633579x1985390_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-16</startDate>
      <endDate>2015-04-16</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151008_0_1633579x1792882_1634968x1733376_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:BiovestInternationalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rswn:MasterServicesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-08</startDate>
      <endDate>2015-10-08</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1643960x1993859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:PrimsolBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-05</startDate>
      <endDate>2015-10-05</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1920370_1643960x1993859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:PrimsolBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">rswn:PeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-05</startDate>
      <endDate>2015-10-05</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1891336_1643960x1993859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:PrimsolBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">rswn:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-05</startDate>
      <endDate>2015-10-05</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1665043_1643960x1993859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:PrimsolBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">rswn:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-05</startDate>
      <endDate>2015-10-05</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20151005_0_1636141x1633766_1637070x1660852_1643960x1993859">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:PrimsolBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">rswn:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-05</startDate>
      <endDate>2015-10-05</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150930_0_1640593x1641344_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150928_0_1636141x1633766_1639657x1969780">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-28</startDate>
      <endDate>2015-09-28</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150819_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-08-19</startDate>
      <endDate>2015-08-19</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150608_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <startDate>2015-06-08</startDate>
      <endDate>2015-06-08</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_1_20150531_0_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-05-31</startDate>
      <endDate>2015-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1644202">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1639657x1986698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:LuoxisTwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1639657x1986697">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:VyrixTwoThousandThirteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1634505x1935108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rswn:LabEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1633579x1667600_1641811x1638052">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:AmpioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1985400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rswn:ZertanePatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1985399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rswn:OrpMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632326x1636886">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985426">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ProstascintInventoryTransferFeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985421">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:AytuManufacturingAndCommercialDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0_1632127x1985413_1635276x1985423">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">rswn:ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ResearchAndDevelopmentArrangementClinicalResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1634505x1935108">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rswn:LabEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632326x1636886">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985426">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ProstascintInventoryTransferFeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1985413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ResearchAndDevelopmentArrangementClinicalResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1948085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ManagementFeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1888177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:OfficeLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1694714">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">rswn:ManufacturingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1632127x1640093">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1631478x1985397_1633579x1985391_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0_1631478x1985397_1633579x1985390_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1642961">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1640593x1639324_1641766x1676684_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rswn:SecondInstallmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0_1633579x1985391">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150416_0_1642993x1667600_1643325x1887167">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rswn:PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-16</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150416_0_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-16</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150416_0_1631478x1985397_1633579x1985391_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:LuoxisDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-16</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150416_0_1631478x1985397_1633579x1985390_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-16</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140331_0_1631478x1985397_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20131130_0_1631478x1985397_1642993x1667600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:AmpioLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rswn:AmpioMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150831_0_1631478x1962156_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rswn:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-31</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150819_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-08-19</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150601_0_1639657x1969780">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rswn:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-01</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150531_0_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-05-31</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150520_0_1643960x1985396">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rswn:ProstascintBusinessMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-05-20</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20150520_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
    </entity>
    <period>
      <instant>2015-05-20</instant>
    </period>
  </context>
  <context id="eol_PE731244--1510-K0008_STD_0_20140430_0_1633579x1985390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rswn:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-04-30</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Stock_Plan">
    <measure>rswn:Stock_Plan</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rswn-20150630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
  xmlns:us-types="http://fasb.org/us-types/2015-01-31"
  xmlns:rswn="http://www.aytubio.com/20150630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.aytubio.com/20150630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
        <link:definition>108 - Disclosure - Business, Acquisition of Assets and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock" id="Role_NotesToFinancialStatementsLicenseAgreementTextBlock">
        <link:definition>110 - Disclosure - License Agreement/Revenue Recognition</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>113 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>114 - Disclosure - Equity Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" id="Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
        <link:definition>116 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" id="Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
        <link:definition>117 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>118 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
        <link:definition>120 - Disclosure - Business, Acquisition of Assets and Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>121 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>122 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>123 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>124 - Disclosure - Equity Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation" id="DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation">
        <link:definition>125 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint" id="DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint">
        <link:definition>126 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Company's Allocation on Consideration Transferred for ProstaScint (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense" id="DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense">
        <link:definition>127 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Future Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation" id="DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation">
        <link:definition>128 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Unaudited Pro-forma Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fixed Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense">
        <link:definition>131 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents">
        <link:definition>132 - Disclosure - Summary of Significant Accounting Policies - Schedule of Patents (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense">
        <link:definition>133 - Disclosure - Summary of Significant Accounting Policies - Schedule of Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense">
        <link:definition>134 - Disclosure - Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation" id="DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation">
        <link:definition>135 - Disclosure - License Agreement/Revenue Recognition - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxes">
        <link:definition>136 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities">
        <link:definition>137 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>138 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies">
        <link:definition>139 - Disclosure - Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>140 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense" id="DisclosureCommitmentsAndContingenciesRentExpense">
        <link:definition>141 - Disclosure - Commitments and Contingencies - Rent Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation" id="DisclosureCommonStockAdditionalInformation">
        <link:definition>142 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation" id="DisclosureEquityInstrumentsAdditionalInformation">
        <link:definition>143 - Disclosure - Equity Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions" id="DisclosureEquityInstrumentsSignificantAssumptions">
        <link:definition>144 - Disclosure - Equity Instruments - Significant Assumptions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity" id="DisclosureEquityInstrumentsLuoxisStockOptionActivity">
        <link:definition>145 - Disclosure - Equity Instruments - Luoxis Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity" id="DisclosureEquityInstrumentsVyrixStockOptionActivity">
        <link:definition>146 - Disclosure - Equity Instruments - Vyrix Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense" id="DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense">
        <link:definition>147 - Disclosure - Equity Instruments - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures" id="DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures">
        <link:definition>148 - Disclosure - Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>149 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation" id="DisclosureSubsequentEventAdditionalInformation">
        <link:definition>150 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="rswn-20150630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="rswn-20150630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="rswn-20150630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="rswn-20150630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedCompensationCurrent" id="rswn_AccruedCompensationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" id="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" id="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" id="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AfterAmendmentMember" id="rswn_AfterAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementExpirationPeriod" id="rswn_AgreementExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementTerminationNoticePeriod" id="rswn_AgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" id="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmpioLoanAgreementMember" id="rswn_AmpioLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmpioMember" id="rswn_AmpioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AssumptionsUsedToDetermineFairValueOptionsLineItems" id="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AssumptionsUsedToDetermineFairValueOptionsTable" id="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="AytuManufacturingAndCommercialDevelopmentMember" id="rswn_AytuManufacturingAndCommercialDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BiovestInternationalIncMember" id="rswn_BiovestInternationalIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" id="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaCostOfRevenue" id="rswn_BusinessAcquisitionsProFormaCostOfRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" id="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" id="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaInterestIncomeExpenseNet" id="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaOperatingExpensesAbstract" id="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaOperatingIncomeLoss" id="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" id="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" id="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationContingentConsiderationPercentage" id="rswn_BusinessCombinationContingentConsiderationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" id="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAdvancesForShortTermLoans" id="rswn_CashAdvancesForShortTermLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" id="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureTableTextBlock" id="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesLineItems" id="rswn_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesTable" id="rswn_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ContributionsFromRelatedParty" id="rswn_ContributionsFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleNotesEqualToPercentageOfCommonStock" id="rswn_ConvertibleNotesEqualToPercentageOfCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePromissoryNotesMember" id="rswn_ConvertiblePromissoryNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoreAndDevelopedTechnologyNet" id="rswn_CoreAndDevelopedTechnologyNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentExtensionPeriod" id="rswn_DebtInstrumentExtensionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentMaturityDateThree" id="rswn_DebtInstrumentMaturityDateThree" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentMaturityDateTwo" id="rswn_DebtInstrumentMaturityDateTwo" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentMaturityPeriod1" id="rswn_DebtInstrumentMaturityPeriod1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueRecognitionPeriod" id="rswn_DeferredRevenueRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="rswn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedSalesReturnsAndAllowancesPolicyTextBlock" id="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FiniteLivedIntangibleAssetsExpirationMonthYear" id="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstInstallmentMember" id="rswn_FirstInstallmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IfConvertedMember" id="rswn_IfConvertedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IfNotConvertedMember" id="rswn_IfNotConvertedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IfNotRegisteredCommonStockMember" id="rswn_IfNotRegisteredCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseAccountsPayableRelatedPartyCurrent" id="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInAccruedCompensation" id="rswn_IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" id="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" id="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestPayableRelatedPartiesCurrent" id="rswn_InterestPayableRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssuanceOfCommonStockInExchangeForAcquiredAssets" id="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LabEquipmentMember" id="rswn_LabEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseAgreementsMaturityPeriod" id="rswn_LeaseAgreementsMaturityPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementTextBlock" id="rswn_LicenseAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LuoxisDiagnosticsMember" id="rswn_LuoxisDiagnosticsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LuoxisTwoThousandThirteenStockOptionPlanMember" id="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManagementFeePayablePerMonth" id="rswn_ManagementFeePayablePerMonth" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManagementFeesMember" id="rswn_ManagementFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingMember" id="rswn_ManufacturingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MasterServicesAgreementMember" id="rswn_MasterServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashOrPartNoncashCapitalContributionFromParent" id="rswn_NoncashOrPartNoncashCapitalContributionFromParent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableRetainerFee" id="rswn_NonRefundableRetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" id="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfStockOptionPlans" id="rswn_NumberOfStockOptionPlans" type="xbrli:positiveIntegerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeLeaseMember" id="rswn_OfficeLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeaseMonthlyRentalPayment" id="rswn_OperatingLeaseMonthlyRentalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeasesMonthlyBaseRentInitialYear" id="rswn_OperatingLeasesMonthlyBaseRentInitialYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrpMember" id="rswn_OrpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsForDepositsInvestingActivities" id="rswn_PaymentsForDepositsInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" id="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfRoyaltyRateOfNetSales" id="rswn_PercentageOfRoyaltyRateOfNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" id="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" id="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodFourMember" id="rswn_PeriodFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOneMember" id="rswn_PeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodThreeMember" id="rswn_PeriodThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodTwoMember" id="rswn_PeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMilestonePaymentsReceivable" id="rswn_PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidExpensesAmortizationPeriod" id="rswn_PrepaidExpensesAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" id="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidResearchAndDevelopmentRelatedParty" id="rswn_PrepaidResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" id="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrimsolBusinessMember" id="rswn_PrimsolBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementWarrantTerm" id="rswn_PrivatePlacementWarrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductsAndServicesRevenue" id="rswn_ProductsAndServicesRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PromissoryNoteMember" id="rswn_PromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProstascintBusinessMember" id="rswn_ProstascintBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProstascintInventoryTransferFeeMember" id="rswn_ProstascintInventoryTransferFeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryAssetsAbstract" id="rswn_RegulatoryAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentArrangementClinicalResearchMember" id="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentRelatedParty" id="rswn_ResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionLineItems" id="rswn_RevenueRecognitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReversalOfAllocatedShareBasedCompensationExpense" id="rswn_ReversalOfAllocatedShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseMergerShare" id="rswn_ReverseMergerShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseMergerValue" id="rswn_ReverseMergerValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfEstimatedFutureAmortizationExpenseLineItems" id="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfEstimatedFutureAmortizationExpenseTable" id="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfRevenueRecognitionTable" id="rswn_ScheduleOfRevenueRecognitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SecondInstallmentMember" id="rswn_SecondInstallmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" id="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" id="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" id="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" id="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationShareWarrantsOutstanding" id="rswn_ShareBasedCompensationShareWarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" id="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockSubscription" id="rswn_StockSubscription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="rswn_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesTable" id="rswn_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TwoThousandFifteenStockOptionAndIncentivePlanMember" id="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UncategorizedAbstract" id="rswn_UncategorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnrecognizedShareBasedCompensationExpenses" id="rswn_UnrecognizedShareBasedCompensationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VyrixPharmaceuticalsIncMember" id="rswn_VyrixPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VyrixTwoThousandThirteenStockOptionPlanMember" id="rswn_VyrixTwoThousandThirteenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" id="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ZertanePatentsMember" id="rswn_ZertanePatentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>rswn-20150630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxes" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSignificantAssumptions" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsLuoxisStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsVyrixStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLicenseAgreementTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AccruedCompensationCurrent" xlink:label="rswn_AccruedCompensationCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CoreAndDevelopedTechnologyNet" xlink:label="rswn_CoreAndDevelopedTechnologyNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="us-gaap_IndefiniteLivedContractualRights"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="us-gaap_IndefiniteLivedTradeNames"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_InterestPayableRelatedPartiesCurrent" xlink:label="rswn_InterestPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedParty" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="rswn_CoreAndDevelopedTechnologyNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IndefiniteLivedContractualRights" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IndefiniteLivedTradeNames" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.3500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToAffiliateCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="rswn_AccruedCompensationCurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="rswn_InterestPayableRelatedPartiesCurrent" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.3000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.3200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" order="1.3300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProductsAndServicesRevenue" xlink:label="rswn_ProductsAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentRelatedParty" xlink:label="rswn_ResearchAndDevelopmentRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostOfRevenue" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="rswn_ResearchAndDevelopmentRelatedParty" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="rswn_ProductsAndServicesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicensesRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInAccruedCompensation" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PaymentsForDepositsInvestingActivities" xlink:label="rswn_PaymentsForDepositsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="us-gaap_ProceedsFromContributionsFromParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromContributionsFromParent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfDistributionsToAffiliates" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromContributedCapital" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="rswn_PaymentsForDepositsInvestingActivities" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="rswn_IncreaseDecreaseInAccruedCompensation" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_Goodwill" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:to="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:to="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" order="1.0400" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>rswn-20150630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxes" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSignificantAssumptions" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsLuoxisStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsVyrixStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLicenseAgreementTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ContributionsFromRelatedParty" xlink:label="rswn_ContributionsFromRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerShare" xlink:label="rswn_ReverseMergerShare"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerValue" xlink:label="rswn_ReverseMergerValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_StockSubscription" xlink:label="rswn_StockSubscription"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ContributionsFromRelatedParty" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_StockSubscription" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ReverseMergerValue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ReverseMergerShare" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationContingentConsiderationPercentage" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLaborRelatedExpenses" xlink:label="us-gaap_OtherLaborRelatedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rswn_BusinessCombinationContingentConsiderationPercentage" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OrpMember" xlink:label="rswn_OrpMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertanePatentsMember" xlink:label="rswn_ZertanePatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rswn_ZertanePatentsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rswn_OrpMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LabEquipmentMember" xlink:label="rswn_LabEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rswn_LabEquipmentMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementExpirationPeriod" xlink:label="rswn_AgreementExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioMember" xlink:label="rswn_AmpioMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DeferredRevenueRecognitionPeriod" xlink:label="rswn_DeferredRevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_KR" xlink:label="country_KR"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfRoyaltyRateOfNetSales" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PotentialMilestonePaymentsReceivable" xlink:label="rswn_PotentialMilestonePaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_RevenueRecognitionLineItems" xlink:label="rswn_RevenueRecognitionLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfRevenueRecognitionTable" xlink:label="rswn_ScheduleOfRevenueRecognitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_AmpioMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_ScheduleOfRevenueRecognitionTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_PotentialMilestonePaymentsReceivable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_DeferredRevenueRecognitionPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_PercentageOfRoyaltyRateOfNetSales" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_AgreementExpirationPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="us-gaap_StatementGeographicalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_KR" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesLineItems" xlink:label="rswn_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesTable" xlink:label="rswn_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeesMember" xlink:label="rswn_ManagementFeesMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManufacturingMember" xlink:label="rswn_ManufacturingMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OfficeLeaseMember" xlink:label="rswn_OfficeLeaseMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintInventoryTransferFeeMember" xlink:label="rswn_ProstascintInventoryTransferFeeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ManagementFeesMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ProstascintInventoryTransferFeeMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ManufacturingMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_OfficeLeaseMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementTerminationNoticePeriod" xlink:label="rswn_AgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AytuManufacturingAndCommercialDevelopmentMember" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesLineItems" xlink:label="rswn_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesTable" xlink:label="rswn_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeePayablePerMonth" xlink:label="rswn_ManagementFeePayablePerMonth"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintInventoryTransferFeeMember" xlink:label="rswn_ProstascintInventoryTransferFeeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_ManagementFeePayablePerMonth" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_AgreementTerminationNoticePeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_OperatingLeasesMonthlyBaseRentInitialYear" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ProstascintInventoryTransferFeeMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_AytuManufacturingAndCommercialDevelopmentMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfStockOptionPlans" xlink:label="rswn_NumberOfStockOptionPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReversalOfAllocatedShareBasedCompensationExpense" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_VyrixTwoThousandThirteenStockOptionPlanMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_NumberOfStockOptionPlans" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ReversalOfAllocatedShareBasedCompensationExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_UnrecognizedShareBasedCompensationExpenses" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_UnrecognizedShareBasedCompensationExpenses" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AfterAmendmentMember" xlink:label="rswn_AfterAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioLoanAgreementMember" xlink:label="rswn_AmpioLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioMember" xlink:label="rswn_AmpioMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CashAdvancesForShortTermLoans" xlink:label="rswn_CashAdvancesForShortTermLoans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FirstInstallmentMember" xlink:label="rswn_FirstInstallmentMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LeaseAgreementsMaturityPeriod" xlink:label="rswn_LeaseAgreementsMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeaseMonthlyRentalPayment" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidExpensesAmortizationPeriod" xlink:label="rswn_PrepaidExpensesAmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PromissoryNoteMember" xlink:label="rswn_PromissoryNoteMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SecondInstallmentMember" xlink:label="rswn_SecondInstallmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rswn_AmpioLoanAgreementMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rswn_PromissoryNoteMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rswn_SecondInstallmentMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rswn_FirstInstallmentMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rswn_AmpioMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rswn_AfterAmendmentMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_CashAdvancesForShortTermLoans" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_OperatingLeaseMonthlyRentalPayment" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_PrepaidExpensesAmortizationPeriod" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_LeaseAgreementsMaturityPeriod" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementScenarioAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BiovestInternationalIncMember" xlink:label="rswn_BiovestInternationalIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertibleNotesEqualToPercentageOfCommonStock" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertiblePromissoryNotesMember" xlink:label="rswn_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentExtensionPeriod" xlink:label="rswn_DebtInstrumentExtensionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateThree" xlink:label="rswn_DebtInstrumentMaturityDateThree"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateTwo" xlink:label="rswn_DebtInstrumentMaturityDateTwo"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityPeriod1" xlink:label="rswn_DebtInstrumentMaturityPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfConvertedMember" xlink:label="rswn_IfConvertedMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotConvertedMember" xlink:label="rswn_IfNotConvertedMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotRegisteredCommonStockMember" xlink:label="rswn_IfNotRegisteredCommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_MasterServicesAgreementMember" xlink:label="rswn_MasterServicesAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NonRefundableRetainerFee" xlink:label="rswn_NonRefundableRetainerFee"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodFourMember" xlink:label="rswn_PeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodOneMember" xlink:label="rswn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodThreeMember" xlink:label="rswn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodTwoMember" xlink:label="rswn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrimsolBusinessMember" xlink:label="rswn_PrimsolBusinessMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrivatePlacementWarrantTerm" xlink:label="rswn_PrivatePlacementWarrantTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rswn_MasterServicesAgreementMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_PrimsolBusinessMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodOneMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodTwoMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodThreeMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodFourMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfConvertedMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfNotConvertedMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfNotRegisteredCommonStockMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rswn_ConvertiblePromissoryNotesMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_BiovestInternationalIncMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityDateTwo" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityDateThree" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityPeriod1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentExtensionPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_ConvertibleNotesEqualToPercentageOfCommonStock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionDescription" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_NonRefundableRetainerFee" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PrivatePlacementWarrantTerm" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_OperatingLeasesMonthlyBaseRentInitialYear" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>rswn-20150630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6457213_1642737_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_6457213_1642737_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1645860_1_1">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1645860_2_1">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1645519_1_1">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1645519_2_1">Payable to Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6457213_1649249_1_1">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6457213_1649249_2_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AccruedCompensationCurrent" xlink:label="rswn_AccruedCompensationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AccruedCompensationCurrent_lbl" xml:lang="en-US" id="id_6457213_1770120_3_1">Accrued Compensation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AccruedCompensationCurrent_lbl" xml:lang="en-US" id="id_6457213_1770120_1_1">Accrued Compensation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AccruedCompensationCurrent_lbl" xml:lang="en-US" id="id_6457213_1770120_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AccruedCompensationCurrent" xlink:to="rswn_AccruedCompensationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6457213_1647288_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6457213_1647288_14_1">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_6457213_1644587_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_6457213_1644587_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6457213_1641496_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_6457213_1641496_2_1">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid_lbl" xml:lang="en-US" id="id_6457213_1985414_3_1">Adjustments to additional in capital business combination liabilities paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid_lbl" xml:lang="en-US" id="id_6457213_1985414_1_1">Adjustments To Additional In Capital Business Combination Liabilities Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid_lbl" xml:lang="en-US" id="id_6457213_1985414_14_1">Liabilities paid pursuant to the merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" xlink:to="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" id="id_6457213_1645853_1_1">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" id="id_6457213_1645853_2_1">Issuance of common stock to Ampio in exchange for Aytu debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6457213_1645027_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_6457213_1645027_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985502_3_1">Adjustment to additional paid in capital options paid pursuant to merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985502_1_1">Adjustment To Additional Paid In Capital Options Paid Pursuant To Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985502_2_1">Luoxis options paid-out pursuant to the merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985503_3_1">Adjustment to additional paid in capital shares options paid pursuant to merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985503_1_1">Adjustment To Additional Paid In Capital Shares Options Paid Pursuant To Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger_lbl" xml:lang="en-US" id="id_6457213_1985503_2_1">Luoxis options paid-out pursuant to the merger, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AfterAmendmentMember" xlink:label="rswn_AfterAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AfterAmendmentMember_lbl" xml:lang="en-US" id="id_6457213_1706730_3_1">After Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AfterAmendmentMember_lbl" xml:lang="en-US" id="id_6457213_1706730_1_1">After Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AfterAmendmentMember_lbl" xml:lang="en-US" id="id_6457213_1706730_2_1">After Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AfterAmendmentMember" xlink:to="rswn_AfterAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementExpirationPeriod" xlink:label="rswn_AgreementExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AgreementExpirationPeriod_lbl" xml:lang="en-US" id="id_6457213_1872589_3_1">Agreement expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AgreementExpirationPeriod_lbl" xml:lang="en-US" id="id_6457213_1872589_1_1">Agreement Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AgreementExpirationPeriod_lbl" xml:lang="en-US" id="id_6457213_1872589_2_1">Agreement expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AgreementExpirationPeriod" xlink:to="rswn_AgreementExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementTerminationNoticePeriod" xlink:label="rswn_AgreementTerminationNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_6457213_1697378_3_1">Agreement Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_6457213_1697378_1_1">Agreement Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_6457213_1697378_2_1">Sponsored Research Agreement termination notice period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AgreementTerminationNoticePeriod" xlink:to="rswn_AgreementTerminationNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6457213_1650010_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6457213_1650010_2_1">Stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" id="id_6457213_1644832_1_1">Allowance for Doubtful Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" id="id_6457213_1644832_2_1">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" id="id_6457213_1639450_1_1">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" id="id_6457213_1639450_2_1">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6457213_1633423_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6457213_1633423_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1650884_1_1">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1650884_2_1">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985386_3_1">Amortization of prepaid research and development due to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985386_1_1">Amortization Of Prepaid Research And Development Due To Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985386_2_1">Amortization of prepaid research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioLoanAgreementMember" xlink:label="rswn_AmpioLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AmpioLoanAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1985397_3_1">Ampio Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AmpioLoanAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1985397_1_1">Ampio Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AmpioLoanAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1985397_2_1">Ampio Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AmpioLoanAgreementMember" xlink:to="rswn_AmpioLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioMember" xlink:label="rswn_AmpioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AmpioMember_lbl" xml:lang="en-US" id="id_6457213_1667600_3_1">Ampio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AmpioMember_lbl" xml:lang="en-US" id="id_6457213_1667600_1_1">Ampio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AmpioMember_lbl" xml:lang="en-US" id="id_6457213_1667600_2_1">Ampio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AmpioMember" xlink:to="rswn_AmpioMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6457213_1632222_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6457213_1632222_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6457213_1648873_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6457213_1648873_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6457213_1636242_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6457213_1636242_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6457213_1650014_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6457213_1650014_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6457213_1643954_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6457213_1643954_2_1">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1649246_1_1">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1649246_6_1">Total non current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems_lbl" xml:lang="en-US" id="id_6457213_1856449_3_1">Assumptions Used To Determine Fair Value Options [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems_lbl" xml:lang="en-US" id="id_6457213_1856449_1_1">Assumptions Used To Determine Fair Value Options [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems_lbl" xml:lang="en-US" id="id_6457213_1856449_2_1">Assumptions Used To Determine Fair Value Options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable_lbl" xml:lang="en-US" id="id_6457213_1801566_3_1">Assumptions Used To Determine Fair Value Options [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable_lbl" xml:lang="en-US" id="id_6457213_1801566_1_1">Assumptions Used To Determine Fair Value Options [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable_lbl" xml:lang="en-US" id="id_6457213_1801566_2_1">Assumptions Used To Determine Fair Value Options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="rswn_AssumptionsUsedToDetermineFairValueOptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1642755_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1642755_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AytuManufacturingAndCommercialDevelopmentMember" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember_lbl" xml:lang="en-US" id="id_6457213_1985421_3_1">Aytu Manufacturing And Commercial Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember_lbl" xml:lang="en-US" id="id_6457213_1985421_1_1">Aytu Manufacturing And Commercial Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember_lbl" xml:lang="en-US" id="id_6457213_1985421_2_1">Aytu Manufacturing and Commercial Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_AytuManufacturingAndCommercialDevelopmentMember" xlink:to="rswn_AytuManufacturingAndCommercialDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BiovestInternationalIncMember" xlink:label="rswn_BiovestInternationalIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BiovestInternationalIncMember_lbl" xml:lang="en-US" id="id_6457213_1792882_3_1">Biovest International Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BiovestInternationalIncMember_lbl" xml:lang="en-US" id="id_6457213_1792882_1_1">Biovest International Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BiovestInternationalIncMember_lbl" xml:lang="en-US" id="id_6457213_1792882_2_1">Biovest International, Inc. ("Biovest") [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BiovestInternationalIncMember" xlink:to="rswn_BiovestInternationalIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_6457213_1641952_1_1">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_6457213_1641952_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_6457213_1643960_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_6457213_1643960_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_6457213_1634680_1_1">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="id_6457213_1634680_2_1">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632644_1_1">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632644_2_1">Unaudited Pro-forma Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" xlink:label="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1986464_3_1">Business acquisitions pro forma amortization and impairment of intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1986464_1_1">Business Acquisitions Pro Forma Amortization And Impairment Of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1986464_2_1">Amortization and impairment of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" xlink:to="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaCostOfRevenue" xlink:label="rswn_BusinessAcquisitionsProFormaCostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaCostOfRevenue_lbl" xml:lang="en-US" id="id_6457213_1986463_3_1">Business acquisitions pro forma cost of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaCostOfRevenue_lbl" xml:lang="en-US" id="id_6457213_1986463_1_1">Business Acquisitions Pro Forma Cost Of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaCostOfRevenue_lbl" xml:lang="en-US" id="id_6457213_1986463_2_1">Cost of sales-ProstaScint</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaCostOfRevenue" xlink:to="rswn_BusinessAcquisitionsProFormaCostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" xlink:label="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="id_6457213_1986498_3_1">Business acquisitions proforma general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="id_6457213_1986498_1_1">Business Acquisitions ProForma General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="id_6457213_1986498_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" xlink:to="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl" xml:lang="en-US" id="id_6457213_1647979_1_1">Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Changes in Accounting and Extraordinary Items, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl" xml:lang="en-US" id="id_6457213_1647979_6_1">Net loss, before income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1925184_3_1">Business Acquisitions Pro Forma Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1925184_1_1">Business Acquisitions Pro Forma Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1925184_14_1">Deferred income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" xlink:to="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1737647_3_1">Business Acquisitions Pro Forma Interest Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1737647_1_1">Business Acquisitions Pro Forma Interest Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1737647_2_1">Interest (expense) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" xlink:to="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1644705_1_1">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1644705_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6457213_1986465_3_1">Business acquisitions pro forma operating expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6457213_1986465_1_1">Business Acquisitions Pro Forma Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6457213_1986465_2_1">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1831507_3_1">Business Acquisitions Pro Forma Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1831507_1_1">Business Acquisitions Pro Forma Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1831507_2_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" xlink:to="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6457213_1986461_3_1">Business acquisitions, pro forma research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6457213_1986461_1_1">Business Acquisitions, Pro Forma Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6457213_1986461_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" xlink:to="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1986462_3_1">Business acquisitions, pro forma research and development related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1986462_1_1">Business Acquisitions, Pro Forma Research And Development Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1986462_2_1">Research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" xlink:to="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" id="id_6457213_1647513_1_1">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" id="id_6457213_1647513_2_1">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_6457213_1645516_1_1">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_6457213_1645516_2_1">Total purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" id="id_6457213_1646739_1_1">Business Combination, Consideration Transferred, Liabilities Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" id="id_6457213_1646739_2_1">Additional cash payable in business acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" id="id_6457213_1646739_12_1">Business Acquisition, liabilities incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xml:lang="en-US" id="id_6457213_1645964_1_1">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xml:lang="en-US" id="id_6457213_1645964_2_1">Contingent consideration related to the ProstaScint purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xml:lang="en-US" id="id_6457213_1645964_12_1">Value of contingent consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons_lbl" xml:lang="en-US" id="id_6457213_1637894_1_1">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Reasons</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons_lbl" xml:lang="en-US" id="id_6457213_1637894_2_1">Restructuring payment, contingent consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xml:lang="en-US" id="id_6457213_1646523_1_1">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xml:lang="en-US" id="id_6457213_1646523_2_1">Business Acquisition, future contingent payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1645846_1_1">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1645846_2_1">Contingent consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationContingentConsiderationPercentage" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage_lbl" xml:lang="en-US" id="id_6457213_1990440_3_1">Business combination contingent consideration percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage_lbl" xml:lang="en-US" id="id_6457213_1990440_1_1">Business Combination Contingent Consideration Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage_lbl" xml:lang="en-US" id="id_6457213_1990440_2_1">Contingent consideration percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessCombinationContingentConsiderationPercentage" xlink:to="rswn_BusinessCombinationContingentConsiderationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_6457213_1650898_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_6457213_1650898_2_1">Total fair value consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" id="id_6457213_1650898_6_1">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_6457213_1650892_1_1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="id_6457213_1650892_2_1">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1749432_3_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1749432_1_1">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1749432_2_1">Tangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1636690_1_1">Business Combinations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1636690_2_1">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US" id="id_6457213_1637070_1_1">Business Combination, Separately Recognized Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US" id="id_6457213_1637070_2_1">Business Combination, Separately Recognized Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xml:lang="en-US" id="id_6457213_1643584_1_1">Business Combination, Separately Recognized Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xml:lang="en-US" id="id_6457213_1643584_2_1">Business Combination, Separately Recognized Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" id="id_6457213_1633439_1_1">Business Combinations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" id="id_6457213_1633439_2_1">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_6457213_1637900_1_1">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_6457213_1637900_2_1">Business, Acquisition of Assets and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CashAdvancesForShortTermLoans" xlink:label="rswn_CashAdvancesForShortTermLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_CashAdvancesForShortTermLoans_lbl" xml:lang="en-US" id="id_6457213_1691079_3_1">Cash Advances for Short Term Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_CashAdvancesForShortTermLoans_lbl" xml:lang="en-US" id="id_6457213_1691079_1_1">Cash Advances for Short Term Loans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_CashAdvancesForShortTermLoans_lbl" xml:lang="en-US" id="id_6457213_1691079_2_1">Amount advances on loan agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_CashAdvancesForShortTermLoans" xlink:to="rswn_CashAdvancesForShortTermLoans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6457213_1651160_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6457213_1651160_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6457213_1651160_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6457213_1651160_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6457213_1648882_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6457213_1648882_6_1">Net change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642769_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642769_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1643590_1_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1643590_2_1">Non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_6457213_1985406_3_1">Class of warrant or rights weighted average remaining contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_6457213_1985406_1_1">Class Of Warrant Or Rights Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_6457213_1985406_2_1">Weighted Average Remaining Contractual Life, Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:to="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6457213_1646952_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6457213_1646952_2_1">Commitments and contingencies (Note 5)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1640697_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1640697_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1850022_3_1">Commitments And Contingencies Disclosure Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1850022_1_1">Commitments And Contingencies Disclosure Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1850022_2_1">Summary of Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:to="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1641131_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1641131_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesLineItems" xlink:label="rswn_CommitmentsAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1904563_3_1">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1904563_1_1">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1904563_2_1">Commitments And Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_CommitmentsAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesTable" xlink:label="rswn_CommitmentsAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_6457213_1852432_3_1">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_6457213_1852432_1_1">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_6457213_1852432_2_1">Commitments And Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="rswn_CommitmentsAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6457213_1640698_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_6457213_1640698_2_1">Shares of common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6457213_1632657_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_6457213_1632657_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6457213_1637092_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6457213_1637092_2_1">Common Stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6457213_1633455_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6457213_1633455_2_1">Common stock, authorized shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6457213_1641977_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6457213_1641977_2_1">Common stock, issued shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6457213_1641977_12_1">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6457213_1635113_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6457213_1635113_2_1">Common stock, outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6457213_1646846_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6457213_1646846_2_1">Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 in 2015 and 7,901,426 in 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" id="id_6457213_1631869_1_1">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" id="id_6457213_1631869_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642400_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642400_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_6457213_1638725_1_1">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_6457213_1638725_2_1">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_6457213_1647381_1_1">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_6457213_1647381_2_1">Contractual obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_6457213_1647381_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xml:lang="en-US" id="id_6457213_1645952_1_1">Contractual Obligation, Due after Fifth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xml:lang="en-US" id="id_6457213_1645952_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" id="id_6457213_1645236_1_1">Contractual Obligation, Due in Fifth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" id="id_6457213_1645236_2_1">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" id="id_6457213_1644464_1_1">Contractual Obligation, Due in Fourth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" id="id_6457213_1644464_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" id="id_6457213_1644820_1_1">Contractual Obligation, Due in Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" id="id_6457213_1644820_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" id="id_6457213_1644928_1_1">Contractual Obligation, Due in Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" id="id_6457213_1644928_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" id="id_6457213_1645123_1_1">Contractual Obligation, Due in Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" id="id_6457213_1645123_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ContributionsFromRelatedParty" xlink:label="rswn_ContributionsFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ContributionsFromRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1663202_3_1">Contributions From Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ContributionsFromRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1663202_1_1">Contributions From Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ContributionsFromRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1663202_2_1">Investment from Ampio in Vyrix</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ContributionsFromRelatedParty" xlink:to="rswn_ContributionsFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_6457213_1650519_1_1">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_6457213_1650519_2_1">Ampio unpaid debt converted to stock, received prior to 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertibleNotesEqualToPercentageOfCommonStock" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock_lbl" xml:lang="en-US" id="id_6457213_1985436_3_1">Convertible notes equal to percentage of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock_lbl" xml:lang="en-US" id="id_6457213_1985436_1_1">Convertible Notes Equal To Percentage Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock_lbl" xml:lang="en-US" id="id_6457213_1985436_2_1">Convertible notes equal to percentage of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ConvertibleNotesEqualToPercentageOfCommonStock" xlink:to="rswn_ConvertibleNotesEqualToPercentageOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertiblePromissoryNotesMember" xlink:label="rswn_ConvertiblePromissoryNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_6457213_1962156_3_1">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_6457213_1962156_1_1">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_6457213_1962156_2_1">Convertible Promissory Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ConvertiblePromissoryNotesMember" xlink:to="rswn_ConvertiblePromissoryNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CoreAndDevelopedTechnologyNet" xlink:label="rswn_CoreAndDevelopedTechnologyNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_CoreAndDevelopedTechnologyNet_lbl" xml:lang="en-US" id="id_6457213_1729243_3_1">Core And Developed Technology Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_CoreAndDevelopedTechnologyNet_lbl" xml:lang="en-US" id="id_6457213_1729243_1_1">Core And Developed Technology Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_CoreAndDevelopedTechnologyNet_lbl" xml:lang="en-US" id="id_6457213_1729243_2_1">Developed technology, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_CoreAndDevelopedTechnologyNet" xlink:to="rswn_CoreAndDevelopedTechnologyNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" id="id_6457213_1651911_1_1">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" id="id_6457213_1651911_2_1">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US" id="id_6457213_1632270_1_1">Debt Conversion Description [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US" id="id_6457213_1632270_2_1">Debt Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionDescription_lbl" xml:lang="en-US" id="id_6457213_1643984_1_1">Debt Conversion, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionDescription_lbl" xml:lang="en-US" id="id_6457213_1643984_2_1">Debt conversion description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionDescription" xlink:to="us-gaap_DebtConversionDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" id="id_6457213_1643615_1_1">Debt Conversion, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" id="id_6457213_1643615_2_1">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_6457213_1631478_1_1">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_6457213_1631478_2_1">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_6457213_1635896_1_1">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_6457213_1635896_2_1">Debt Instrument, convertible, Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" id="id_6457213_1649014_1_1">Debt Instrument, Decrease, Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US" id="id_6457213_1649014_2_1">Cancellation of indebtedness amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentExtensionPeriod" xlink:label="rswn_DebtInstrumentExtensionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DebtInstrumentExtensionPeriod_lbl" xml:lang="en-US" id="id_6457213_1777380_3_1">Debt Instrument Extension Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DebtInstrumentExtensionPeriod_lbl" xml:lang="en-US" id="id_6457213_1777380_1_1">Debt Instrument Extension Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DebtInstrumentExtensionPeriod_lbl" xml:lang="en-US" id="id_6457213_1777380_2_1">Debt instrument maturity, extension period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DebtInstrumentExtensionPeriod" xlink:to="rswn_DebtInstrumentExtensionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_6457213_1646840_1_1">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_6457213_1646840_2_1">Aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_6457213_1646840_12_1">Debt instrument principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" id="id_6457213_1633097_1_1">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" id="id_6457213_1633097_2_1">Debt instrument interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="id_6457213_1639881_1_1">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="id_6457213_1639881_2_1">Debt instrument interest rate, increase during period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl" xml:lang="en-US" id="id_6457213_1635898_1_1">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl" xml:lang="en-US" id="id_6457213_1635898_2_1">Loan agreement interest rate maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl" xml:lang="en-US" id="id_6457213_1636715_1_1">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl" xml:lang="en-US" id="id_6457213_1636715_2_1">Loan agreement interest rate minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_6457213_1635899_1_1">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_6457213_1635899_2_1">Debt instrument maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateThree" xlink:label="rswn_DebtInstrumentMaturityDateThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DebtInstrumentMaturityDateThree_lbl" xml:lang="en-US" id="id_6457213_1934628_3_1">Debt instrument maturity date three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DebtInstrumentMaturityDateThree_lbl" xml:lang="en-US" id="id_6457213_1934628_1_1">Debt Instrument Maturity Date Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DebtInstrumentMaturityDateThree_lbl" xml:lang="en-US" id="id_6457213_1934628_2_1">Debt instrument maturity date, three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DebtInstrumentMaturityDateThree" xlink:to="rswn_DebtInstrumentMaturityDateThree_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateTwo" xlink:label="rswn_DebtInstrumentMaturityDateTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DebtInstrumentMaturityDateTwo_lbl" xml:lang="en-US" id="id_6457213_1719875_3_1">Debt instrument maturity date two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DebtInstrumentMaturityDateTwo_lbl" xml:lang="en-US" id="id_6457213_1719875_1_1">Debt Instrument Maturity Date Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DebtInstrumentMaturityDateTwo_lbl" xml:lang="en-US" id="id_6457213_1719875_2_1">Debt instrument maturity date, two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DebtInstrumentMaturityDateTwo" xlink:to="rswn_DebtInstrumentMaturityDateTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityPeriod1" xlink:label="rswn_DebtInstrumentMaturityPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DebtInstrumentMaturityPeriod1_lbl" xml:lang="en-US" id="id_6457213_1807362_3_1">Maturity period of term loan facility under subtranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DebtInstrumentMaturityPeriod1_lbl" xml:lang="en-US" id="id_6457213_1807362_1_1">Subtranche term loan maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DebtInstrumentMaturityPeriod1_lbl" xml:lang="en-US" id="id_6457213_1807362_2_1">Debt instrument maturity period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DebtInstrumentMaturityPeriod1" xlink:to="rswn_DebtInstrumentMaturityPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_6457213_1632266_1_1">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_6457213_1632266_2_1">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_6457213_1635902_1_1">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_6457213_1635902_2_1">Term of loan agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xml:lang="en-US" id="id_6457213_1634298_1_1">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xml:lang="en-US" id="id_6457213_1634298_2_1">Common stock, shares authorized for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1649535_1_1">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1649535_2_1">Deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6457213_1645505_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6457213_1645505_2_1">Upfront payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6457213_1646286_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6457213_1646286_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1635910_1_1">Deferred Revenue Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1635910_2_1">Deferred Revenue Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1646837_1_1">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1646837_2_1">Long-term deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DeferredRevenueRecognitionPeriod" xlink:label="rswn_DeferredRevenueRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_6457213_1814274_3_1">Deferred Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_6457213_1814274_1_1">Deferred Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_6457213_1814274_2_1">Deferred revenue recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DeferredRevenueRecognitionPeriod" xlink:to="rswn_DeferredRevenueRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_6457213_1649017_1_1">Deferred Tax Assets, Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_6457213_1649017_2_1">Deferred revenue long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1651917_1_1">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="id_6457213_1651917_2_1">Section 197 intangible</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xml:lang="en-US" id="id_6457213_1649638_1_1">Deferred Tax Assets, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xml:lang="en-US" id="id_6457213_1649638_2_1">Deferred revenue short-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl" xml:lang="en-US" id="id_6457213_1642002_1_1">Deferred Tax Assets, Net, Classification [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl" xml:lang="en-US" id="id_6457213_1642002_2_1">Long-term deferred income tax assets (liabilities):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xml:lang="en-US" id="id_6457213_1651676_1_1">Deferred Tax Assets, Net of Valuation Allowance, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xml:lang="en-US" id="id_6457213_1651676_2_1">Deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent_lbl" xml:lang="en-US" id="id_6457213_1651676_6_1">Total current deferred income tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl" xml:lang="en-US" id="id_6457213_1642816_1_1">Deferred Tax Assets, Net of Valuation Allowance, Current Classification [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl" xml:lang="en-US" id="id_6457213_1642816_2_1">Current deferred income tax asset:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6457213_1648153_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6457213_1648153_2_1">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6457213_1648766_1_1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6457213_1648766_2_1">Share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_6457213_1648015_1_1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_6457213_1648015_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl" xml:lang="en-US" id="id_6457213_1646399_1_1">Deferred Tax Assets, Valuation Allowance, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl" xml:lang="en-US" id="id_6457213_1646399_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1646720_1_1">Deferred Tax Assets, Valuation Allowance, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1646720_14_1">Less: Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_6457213_1644576_1_1">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_6457213_1644576_2_1">Net deferred tax liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_6457213_1644576_19_1">Total deferred income tax assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_6457213_1647267_1_1">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_6457213_1647267_14_1">Acquired in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1647829_1_1">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1647829_2_1">Noncurrent deferred tax liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1647829_19_1">Total long-term deferred income tax assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1649776_1_1">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1649776_2_1">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6457213_1651565_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_6457213_1651565_2_1">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAbstract_lbl" xml:lang="en-US" id="id_6457213_1634309_1_1">Depreciation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAbstract_lbl" xml:lang="en-US" id="id_6457213_1634309_2_1">Depreciation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_DepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="us-gaap_DepreciationAndAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationAbstract_lbl" xml:lang="en-US" id="id_6457213_1631501_1_1">Depreciation, Depletion and Amortization [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortizationAbstract_lbl" xml:lang="en-US" id="id_6457213_1631501_2_1">Depreciation, Depletion and Amortization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationAbstract" xlink:to="us-gaap_DepreciationAndAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6457213_1651566_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_6457213_1651566_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6457213_1640297_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6457213_1640297_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642836_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642836_2_1">Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DocumentAndEntityInformationAbstract" xlink:label="rswn_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6457213_1666892_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6457213_1666892_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6457213_1666892_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="rswn_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6457213_1642039_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6457213_1642039_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6457213_1634742_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6457213_1634742_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToAffiliateCurrent_lbl" xml:lang="en-US" id="id_6457213_1644688_1_1">Due to Affiliate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToAffiliateCurrent_lbl" xml:lang="en-US" id="id_6457213_1644688_2_1">Accrued liabilities-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToAffiliateCurrent" xlink:to="us-gaap_DueToAffiliateCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6457213_1634329_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6457213_1634329_2_1">Basic and diluted Aytu net loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1644010_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1644010_19_1">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="id_6457213_1638766_1_1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="id_6457213_1638766_2_1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6457213_1636341_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_6457213_1636341_14_1">Benefit at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6457213_1637967_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_6457213_1637967_14_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6457213_1636342_1_1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_6457213_1636342_14_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_6457213_1635549_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_6457213_1635549_14_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6457213_1638361_1_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_6457213_1638361_14_1">State, net of federal income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_6457213_1648664_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_6457213_1648664_2_1">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6457213_1633925_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6457213_1633925_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6457213_1634753_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6457213_1634753_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6457213_1640311_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6457213_1640311_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6457213_1635557_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6457213_1635557_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6457213_1639155_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6457213_1639155_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1636759_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1636759_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6457213_1644027_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_6457213_1644027_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:label="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1985402_3_1">Estimated sales returns and allowances policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1985402_1_1">Estimated Sales Returns And Allowances Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1985402_2_1">Estimated Sales Returns and Allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:to="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_6457213_1636375_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_6457213_1636375_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_6457213_1645583_1_1">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_6457213_1645583_14_1">Less accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" id="id_6457213_1649907_1_1">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" id="id_6457213_1649907_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="id_6457213_1649656_1_1">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="id_6457213_1649656_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633960_1_1">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633960_2_1">Schedule of Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="id_6457213_1649908_1_1">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="id_6457213_1649908_2_1">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="id_6457213_1651200_1_1">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="id_6457213_1651200_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="id_6457213_1648913_1_1">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="id_6457213_1648913_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="id_6457213_1648914_1_1">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="id_6457213_1648914_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_6457213_1632326_1_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_6457213_1632326_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl" xml:lang="en-US" id="id_6457213_1973789_3_1">Finite lived intangible assets expiration month year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl" xml:lang="en-US" id="id_6457213_1973789_1_1">Finite Lived Intangible Assets Expiration Month Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl" xml:lang="en-US" id="id_6457213_1973789_2_1">Intangible asset, expiration month and year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:to="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="id_6457213_1631943_1_1">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="id_6457213_1631943_2_1">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_6457213_1650431_1_1">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_6457213_1650431_2_1">Costs of establishing patents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_6457213_1650431_12_1">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_6457213_1638797_1_1">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_6457213_1638797_2_1">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_6457213_1631944_1_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_6457213_1631944_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_6457213_1650931_1_1">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_6457213_1650931_2_1">Patents, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_6457213_1650931_6_1">Patents, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" id="id_6457213_1641213_1_1">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" id="id_6457213_1641213_2_1">Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" id="id_6457213_1641213_12_1">Remaining amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FirstInstallmentMember" xlink:label="rswn_FirstInstallmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_FirstInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1756965_3_1">First Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_FirstInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1756965_1_1">First Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_FirstInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1756965_2_1">First Installment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_FirstInstallmentMember" xlink:to="rswn_FirstInstallmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6457213_1650296_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6457213_1650296_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6457213_1639948_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6457213_1639948_2_1">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_6457213_1650936_1_1">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_6457213_1650936_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1633530_1_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1633530_2_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" id="id_6457213_1631951_1_1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" id="id_6457213_1631951_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="id_6457213_1651947_1_1">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="id_6457213_1651947_2_1">Goodwill impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfConvertedMember" xlink:label="rswn_IfConvertedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IfConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985513_3_1">If Converted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IfConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985513_1_1">If Converted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IfConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985513_2_1">If Converted within First Six Months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IfConvertedMember" xlink:to="rswn_IfConvertedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotConvertedMember" xlink:label="rswn_IfNotConvertedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IfNotConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985514_3_1">If Not Converted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IfNotConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985514_1_1">If Not Converted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IfNotConvertedMember_lbl" xml:lang="en-US" id="id_6457213_1985514_2_1">If Not Converted within First Six Months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IfNotConvertedMember" xlink:to="rswn_IfNotConvertedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotRegisteredCommonStockMember" xlink:label="rswn_IfNotRegisteredCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IfNotRegisteredCommonStockMember_lbl" xml:lang="en-US" id="id_6457213_1985515_3_1">If Not Registered Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IfNotRegisteredCommonStockMember_lbl" xml:lang="en-US" id="id_6457213_1985515_1_1">If Not Registered Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IfNotRegisteredCommonStockMember_lbl" xml:lang="en-US" id="id_6457213_1985515_2_1">If Not Registered, Shares of Common Stock Underlying Notes by Expiration of First Six Month Period [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IfNotRegisteredCommonStockMember" xlink:to="rswn_IfNotRegisteredCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640809_1_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640809_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_6457213_1647034_1_1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_6457213_1647034_6_1">Net loss, before income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6457213_1631567_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6457213_1631567_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6457213_1634394_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6457213_1634394_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6457213_1635998_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6457213_1635998_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1638039_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_6457213_1638039_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1639962_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1639962_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1648041_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6457213_1648041_14_1">Deferred income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644088_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644088_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent_lbl" xml:lang="en-US" id="id_6457213_1756930_3_1">Increase Decrease Accounts Payable Related Party Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent_lbl" xml:lang="en-US" id="id_6457213_1756930_1_1">Increase Decrease Accounts Payable Related Party Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent_lbl" xml:lang="en-US" id="id_6457213_1756930_2_1">(Decrease) increase in payable to Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" xlink:to="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6457213_1651075_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6457213_1651075_2_1">Increase in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6457213_1645919_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6457213_1645919_14_1">Increase in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInAccruedCompensation" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" id="id_6457213_1727510_3_1">Increase Decrease In Accrued Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" id="id_6457213_1727510_1_1">Increase Decrease In Accrued Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" id="id_6457213_1727510_2_1">Increase in accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IncreaseDecreaseInAccruedCompensation" xlink:to="rswn_IncreaseDecreaseInAccruedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6457213_1648681_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6457213_1648681_2_1">(Decrease) increase in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" id="id_6457213_1650822_1_1">Increase (Decrease) in Interest Payable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" id="id_6457213_1650822_2_1">(Decrease) increase in interest payable to Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_6457213_1645450_1_1">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_6457213_1645450_14_1">Increase in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_6457213_1646372_1_1">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_6457213_1646372_14_1">Decrease (increase) in prepaid expenses, other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985387_3_1">Increase decrease in prepaid research and development due to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985387_1_1">Increase Decrease In Prepaid Research And Development Due To Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US" id="id_6457213_1985387_2_1">Increase in prepaid research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="us-gaap_IndefiniteLivedContractualRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedContractualRights_lbl" xml:lang="en-US" id="id_6457213_1648559_1_1">Indefinite-Lived Contractual Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedContractualRights_lbl" xml:lang="en-US" id="id_6457213_1648559_2_1">Customer contracts, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedContractualRights" xlink:to="us-gaap_IndefiniteLivedContractualRights_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6457213_1794598_3_1">Indefinite Lived Intangible Asset In Process Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6457213_1794598_1_1">Indefinite Lived Intangible Asset In Process Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="id_6457213_1794598_2_1">In-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:to="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" id="id_6457213_1632356_1_1">Indefinite-lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" id="id_6457213_1632356_2_1">Indefinite-lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="us-gaap_IndefiniteLivedTradeNames"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTradeNames_lbl" xml:lang="en-US" id="id_6457213_1649929_1_1">Indefinite-Lived Trade Names</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedTradeNames_lbl" xml:lang="en-US" id="id_6457213_1649929_2_1">Trade names, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTradeNames" xlink:to="us-gaap_IndefiniteLivedTradeNames_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_6457213_1639579_1_1">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="id_6457213_1639579_2_1">In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="id_6457213_1638422_1_1">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="id_6457213_1638422_2_1">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1645084_1_1">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1645084_2_1">Interest (expense) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_InterestPayableRelatedPartiesCurrent" xlink:label="rswn_InterestPayableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_InterestPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1695379_3_1">Interest payable related parties current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_InterestPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1695379_1_1">Interest Payable Related Parties Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_InterestPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1695379_2_1">Interest payable to Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_InterestPayableRelatedPartiesCurrent" xlink:to="rswn_InterestPayableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_6457213_1649181_1_1">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_6457213_1649181_2_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634812_1_1">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634812_2_1">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets" xlink:label="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets_lbl" xml:lang="en-US" id="id_6457213_1985389_3_1">Issuance Of Common Stock In Exchange For Acquired Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets_lbl" xml:lang="en-US" id="id_6457213_1985389_1_1">Issuance Of Common Stock In Exchange For Acquired Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets_lbl" xml:lang="en-US" id="id_6457213_1985389_2_1">Issuance of common stock in exchange for Vyrix acquired assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets" xlink:to="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_6457213_1650553_1_1">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="id_6457213_1650553_2_1">Warrants to purchase common stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_KR" xlink:label="country_KR"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KR_lbl" xml:lang="en-US" id="id_6457213_1638052_1_1">KOREA, REPUBLIC OF</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KR_lbl" xml:lang="en-US" id="id_6457213_1638052_2_1">KOREA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LabEquipmentMember" xlink:label="rswn_LabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_LabEquipmentMember_lbl" xml:lang="en-US" id="id_6457213_1935108_3_1">Lab Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_LabEquipmentMember_lbl" xml:lang="en-US" id="id_6457213_1935108_1_1">Lab Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_LabEquipmentMember_lbl" xml:lang="en-US" id="id_6457213_1935108_2_1">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_LabEquipmentMember" xlink:to="rswn_LabEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LeaseAgreementsMaturityPeriod" xlink:label="rswn_LeaseAgreementsMaturityPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_LeaseAgreementsMaturityPeriod_lbl" xml:lang="en-US" id="id_6457213_1985395_3_1">Lease Agreements Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_LeaseAgreementsMaturityPeriod_lbl" xml:lang="en-US" id="id_6457213_1985395_1_1">Lease Agreements Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_LeaseAgreementsMaturityPeriod_lbl" xml:lang="en-US" id="id_6457213_1985395_2_1">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_LeaseAgreementsMaturityPeriod" xlink:to="rswn_LeaseAgreementsMaturityPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_6457213_1648807_1_1">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_6457213_1648807_2_1">Total base rent over the term of the lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6457213_1633579_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6457213_1633579_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" id="id_6457213_1631586_1_1">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" id="id_6457213_1631586_2_1">Litigation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_6457213_1638834_1_1">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" id="id_6457213_1638834_2_1">Operating lease period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6457213_1646694_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6457213_1646694_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1646695_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1646695_6_1">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1636826_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1636826_2_1">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1647463_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6457213_1647463_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6457213_1639229_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6457213_1639229_2_1">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LicenseAgreementTextBlock" xlink:label="rswn_LicenseAgreementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_LicenseAgreementTextBlock_lbl" xml:lang="en-US" id="id_6457213_1765566_3_1">License Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_LicenseAgreementTextBlock_lbl" xml:lang="en-US" id="id_6457213_1765566_1_1">License Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_LicenseAgreementTextBlock_lbl" xml:lang="en-US" id="id_6457213_1765566_2_1">License Agreement/Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_LicenseAgreementTextBlock" xlink:to="rswn_LicenseAgreementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_6457213_1645561_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_6457213_1645561_2_1">License revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_6457213_1647932_1_1">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_6457213_1647932_2_1">Total amount agreed on loan agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" id="id_6457213_1644771_1_1">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" id="id_6457213_1644771_2_1">Line of credit, remaining amount outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1643325_1_1">Long-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1643325_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1640415_1_1">Long-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1640415_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_6457213_1646801_1_1">Long-term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_6457213_1646801_2_1">Master services agreement, total cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" id="id_6457213_1642932_1_1">Long-term Purchase Commitment, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" id="id_6457213_1642932_2_1">Master services agreement, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_LuoxisDiagnosticsMember_lbl" xml:lang="en-US" id="id_6457213_1985391_3_1">Luoxis Diagnostics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_LuoxisDiagnosticsMember_lbl" xml:lang="en-US" id="id_6457213_1985391_1_1">Luoxis Diagnostics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_LuoxisDiagnosticsMember_lbl" xml:lang="en-US" id="id_6457213_1985391_2_1">Luoxis Diagnostics [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_LuoxisDiagnosticsMember" xlink:to="rswn_LuoxisDiagnosticsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986698_3_1">Luoxis Two Thousand Thirteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986698_1_1">Luoxis Two Thousand Thirteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986698_2_1">Luoxis 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" xlink:to="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeePayablePerMonth" xlink:label="rswn_ManagementFeePayablePerMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ManagementFeePayablePerMonth_lbl" xml:lang="en-US" id="id_6457213_1761589_3_1">Management Fee Payable Per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ManagementFeePayablePerMonth_lbl" xml:lang="en-US" id="id_6457213_1761589_1_1">Management Fee Payable Per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ManagementFeePayablePerMonth_lbl" xml:lang="en-US" id="id_6457213_1761589_2_1">Management fee payable to Ampio per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ManagementFeePayablePerMonth" xlink:to="rswn_ManagementFeePayablePerMonth_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeesMember" xlink:label="rswn_ManagementFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ManagementFeesMember_lbl" xml:lang="en-US" id="id_6457213_1948085_3_1">Management Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ManagementFeesMember_lbl" xml:lang="en-US" id="id_6457213_1948085_1_1">Management Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ManagementFeesMember_lbl" xml:lang="en-US" id="id_6457213_1948085_2_1">Management Fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ManagementFeesMember" xlink:to="rswn_ManagementFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManufacturingMember" xlink:label="rswn_ManufacturingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ManufacturingMember_lbl" xml:lang="en-US" id="id_6457213_1694714_3_1">Manufacturing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ManufacturingMember_lbl" xml:lang="en-US" id="id_6457213_1694714_1_1">Manufacturing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ManufacturingMember_lbl" xml:lang="en-US" id="id_6457213_1694714_2_1">Manufacturing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ManufacturingMember" xlink:to="rswn_ManufacturingMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_MasterServicesAgreementMember" xlink:label="rswn_MasterServicesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_MasterServicesAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1733376_3_1">Master Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_MasterServicesAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1733376_1_1">Master Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_MasterServicesAgreementMember_lbl" xml:lang="en-US" id="id_6457213_1733376_2_1">Master Services Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_MasterServicesAgreementMember" xlink:to="rswn_MasterServicesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6457213_1633605_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_6457213_1633605_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6457213_1643741_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_6457213_1643741_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1649336_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1649336_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633620_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633620_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1649062_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1649062_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1638471_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1638471_2_1">Cash flows used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1631616_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6457213_1631616_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1639627_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6457213_1639627_2_1">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1644530_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1644530_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1644530_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642952_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642952_2_1">Newly Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NoncashOrPartNoncashCapitalContributionFromParent" xlink:label="rswn_NoncashOrPartNoncashCapitalContributionFromParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_NoncashOrPartNoncashCapitalContributionFromParent_lbl" xml:lang="en-US" id="id_6457213_1841447_3_1">Noncash Or Part Noncash Capital Contribution From Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_NoncashOrPartNoncashCapitalContributionFromParent_lbl" xml:lang="en-US" id="id_6457213_1841447_1_1">Noncash Or Part Noncash Capital Contribution From Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_NoncashOrPartNoncashCapitalContributionFromParent_lbl" xml:lang="en-US" id="id_6457213_1841447_2_1">Ampio stock subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_NoncashOrPartNoncashCapitalContributionFromParent" xlink:to="rswn_NoncashOrPartNoncashCapitalContributionFromParent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NonRefundableRetainerFee" xlink:label="rswn_NonRefundableRetainerFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_NonRefundableRetainerFee_lbl" xml:lang="en-US" id="id_6457213_1985439_3_1">Non refundable retainer fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_NonRefundableRetainerFee_lbl" xml:lang="en-US" id="id_6457213_1985439_1_1">Non Refundable Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_NonRefundableRetainerFee_lbl" xml:lang="en-US" id="id_6457213_1985439_2_1">Non refundable retainer fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_NonRefundableRetainerFee" xlink:to="rswn_NonRefundableRetainerFee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US" id="id_6457213_1644631_1_1">Notes Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US" id="id_6457213_1644631_2_1">Notes to Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice_lbl" xml:lang="en-US" id="id_6457213_1900179_3_1">Number Of Days To Terminate Agreement By Delivering Written Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice_lbl" xml:lang="en-US" id="id_6457213_1900179_1_1">Number Of Days To Terminate Agreement By Delivering Written Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice_lbl" xml:lang="en-US" id="id_6457213_1900179_2_1">Master services agreement, period upon which company may terminate agreement with written notice for any reason</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" xlink:to="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfStockOptionPlans" xlink:label="rswn_NumberOfStockOptionPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_NumberOfStockOptionPlans_lbl" xml:lang="en-US" id="id_6457213_1931397_3_1">Number of stock option plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_NumberOfStockOptionPlans_lbl" xml:lang="en-US" id="id_6457213_1931397_1_1">Number Of Stock Option Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_NumberOfStockOptionPlans_lbl" xml:lang="en-US" id="id_6457213_1931397_2_1">Number of stock option plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_NumberOfStockOptionPlans" xlink:to="rswn_NumberOfStockOptionPlans_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OfficeLeaseMember" xlink:label="rswn_OfficeLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_OfficeLeaseMember_lbl" xml:lang="en-US" id="id_6457213_1888177_3_1">Office Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_OfficeLeaseMember_lbl" xml:lang="en-US" id="id_6457213_1888177_1_1">Office Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_OfficeLeaseMember_lbl" xml:lang="en-US" id="id_6457213_1888177_2_1">Office Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_OfficeLeaseMember" xlink:to="rswn_OfficeLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6457213_1632029_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_6457213_1632029_2_1">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1645424_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6457213_1645424_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeaseMonthlyRentalPayment" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment_lbl" xml:lang="en-US" id="id_6457213_1882760_3_1">Operating Lease Monthly Rental Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment_lbl" xml:lang="en-US" id="id_6457213_1882760_1_1">Operating Lease Monthly Rental Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment_lbl" xml:lang="en-US" id="id_6457213_1882760_2_1">Monthly equipment lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_OperatingLeaseMonthlyRentalPayment" xlink:to="rswn_OperatingLeaseMonthlyRentalPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear_lbl" xml:lang="en-US" id="id_6457213_1985420_3_1">Operating leases monthly base rent initial year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear_lbl" xml:lang="en-US" id="id_6457213_1985420_1_1">Operating Leases Monthly Base Rent Initial Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear_lbl" xml:lang="en-US" id="id_6457213_1985420_2_1">Lease initial base rent per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:to="rswn_OperatingLeasesMonthlyBaseRentInitialYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1648832_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_6457213_1648832_2_1">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6457213_1650466_1_1">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_6457213_1650466_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6457213_1641734_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6457213_1641734_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OrpMember" xlink:label="rswn_OrpMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_OrpMember_lbl" xml:lang="en-US" id="id_6457213_1985399_3_1">ORP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_OrpMember_lbl" xml:lang="en-US" id="id_6457213_1985399_1_1">Orp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_OrpMember_lbl" xml:lang="en-US" id="id_6457213_1985399_2_1">ORP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_OrpMember" xlink:to="rswn_OrpMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" id="id_6457213_1635276_1_1">Other Commitments [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" id="id_6457213_1635276_2_1">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" id="id_6457213_1641731_1_1">Other Commitments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" id="id_6457213_1641731_2_1">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLaborRelatedExpenses" xlink:label="us-gaap_OtherLaborRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US" id="id_6457213_1651859_1_1">Other Labor-related Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US" id="id_6457213_1651859_2_1">Labour and other overhead costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US" id="id_6457213_1642961_1_1">Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US" id="id_6457213_1642961_2_1">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" id="id_6457213_1636886_1_1">Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" id="id_6457213_1636886_2_1">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PaymentsForDepositsInvestingActivities" xlink:label="rswn_PaymentsForDepositsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PaymentsForDepositsInvestingActivities_lbl" xml:lang="en-US" id="id_6457213_1987273_3_1">Payments for Deposits Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PaymentsForDepositsInvestingActivities_lbl" xml:lang="en-US" id="id_6457213_1987273_1_1">Payments for Deposits Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rswn_PaymentsForDepositsInvestingActivities_lbl" xml:lang="en-US" id="id_6457213_1987273_14_1">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PaymentsForDepositsInvestingActivities" xlink:to="rswn_PaymentsForDepositsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates_lbl" xml:lang="en-US" id="id_6457213_1644512_1_1">Payments of Distributions to Affiliates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates_lbl" xml:lang="en-US" id="id_6457213_1644512_14_1">Luoxis option payout pursuant to the merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="us-gaap_PaymentsOfDistributionsToAffiliates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" id="id_6457213_1646786_1_1">Payments of Merger Related Costs, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" id="id_6457213_1646786_14_1">Liabilities paid out pursuant to the merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" id="id_6457213_1645892_1_1">Payments to Acquire Businesses, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" id="id_6457213_1645892_2_1">Business Acquisition, acquisition cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" id="id_6457213_1645892_12_1">Cash paid to acquire business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US" id="id_6457213_1645892_14_1">Purchase of ProstaScint Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6457213_1644389_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6457213_1644389_14_1">Purchase of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" id="id_6457213_1645058_1_1">Payments to Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" id="id_6457213_1645058_2_1">Master services agreement, cash paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold_lbl" xml:lang="en-US" id="id_6457213_1985517_3_1">Percentage of amount paid to placement agent based on notes sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold_lbl" xml:lang="en-US" id="id_6457213_1985517_1_1">Percentage Of Amount Paid To Placement Agent Based On Notes Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold_lbl" xml:lang="en-US" id="id_6457213_1985517_2_1">Percentage of amount paid to placement agent based on notes sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" xlink:to="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfRoyaltyRateOfNetSales" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales_lbl" xml:lang="en-US" id="id_6457213_1755400_3_1">Percentage Of Royalty Rate Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales_lbl" xml:lang="en-US" id="id_6457213_1755400_1_1">Percentage Of Royalty Rate Of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales_lbl" xml:lang="en-US" id="id_6457213_1755400_2_1">Royalty percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PercentageOfRoyaltyRateOfNetSales" xlink:to="rswn_PercentageOfRoyaltyRateOfNetSales_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold_lbl" xml:lang="en-US" id="id_6457213_1985519_3_1">Percentage of warrants exercise price equal to equity securities sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold_lbl" xml:lang="en-US" id="id_6457213_1985519_1_1">Percentage Of Warrants Exercise Price Equal To Equity Securities Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold_lbl" xml:lang="en-US" id="id_6457213_1985519_2_1">Warrant exercise price percentage equal to equity securities are sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" xlink:to="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes_lbl" xml:lang="en-US" id="id_6457213_1985518_3_1">Percentage of warrants to purchase shares of common stock equal to gross proceeds of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes_lbl" xml:lang="en-US" id="id_6457213_1985518_1_1">Percentage Of Warrants To Purchase Shares Of Common Stock Equal To Gross Proceeds Of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes_lbl" xml:lang="en-US" id="id_6457213_1985518_2_1">Percentage of warrant to purchase shares of common stock equal to proceeds of notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" xlink:to="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodFourMember" xlink:label="rswn_PeriodFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PeriodFourMember_lbl" xml:lang="en-US" id="id_6457213_1920370_3_1">Period Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PeriodFourMember_lbl" xml:lang="en-US" id="id_6457213_1920370_1_1">Period Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PeriodFourMember_lbl" xml:lang="en-US" id="id_6457213_1920370_2_1">Payable no later than September 30, 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PeriodFourMember" xlink:to="rswn_PeriodFourMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodOneMember" xlink:label="rswn_PeriodOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PeriodOneMember_lbl" xml:lang="en-US" id="id_6457213_1665043_3_1">Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PeriodOneMember_lbl" xml:lang="en-US" id="id_6457213_1665043_1_1">Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PeriodOneMember_lbl" xml:lang="en-US" id="id_6457213_1665043_2_1">Payable within five days after transfer of Primsol-related product inventory [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PeriodOneMember" xlink:to="rswn_PeriodOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodThreeMember" xlink:label="rswn_PeriodThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PeriodThreeMember_lbl" xml:lang="en-US" id="id_6457213_1660852_3_1">Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PeriodThreeMember_lbl" xml:lang="en-US" id="id_6457213_1660852_1_1">Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PeriodThreeMember_lbl" xml:lang="en-US" id="id_6457213_1660852_2_1">Payable no later than June 30, 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PeriodThreeMember" xlink:to="rswn_PeriodThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodTwoMember" xlink:label="rswn_PeriodTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PeriodTwoMember_lbl" xml:lang="en-US" id="id_6457213_1891336_3_1">Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PeriodTwoMember_lbl" xml:lang="en-US" id="id_6457213_1891336_1_1">Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PeriodTwoMember_lbl" xml:lang="en-US" id="id_6457213_1891336_2_1">Payable no later than March 31, 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PeriodTwoMember" xlink:to="rswn_PeriodTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6457213_1639657_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_6457213_1639657_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6457213_1637683_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_6457213_1637683_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633657_1_1">Postemployment Benefits [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633657_2_1">Postemployment Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PotentialMilestonePaymentsReceivable" xlink:label="rswn_PotentialMilestonePaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PotentialMilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_6457213_1804462_3_1">Potential Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PotentialMilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_6457213_1804462_1_1">Potential Milestone Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PotentialMilestonePaymentsReceivable_lbl" xml:lang="en-US" id="id_6457213_1804462_2_1">Milestone payments that may be earned and recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PotentialMilestonePaymentsReceivable" xlink:to="rswn_PotentialMilestonePaymentsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6457213_1642594_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6457213_1642594_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6457213_1639289_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6457213_1639289_2_1">Preferred stock, authorized shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6457213_1640465_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6457213_1640465_2_1">Preferred stock, issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6457213_1634872_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6457213_1634872_2_1">Preferred stock, outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6457213_1647540_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6457213_1647540_2_1">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_6457213_1651110_1_1">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_6457213_1651110_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidExpensesAmortizationPeriod" xlink:label="rswn_PrepaidExpensesAmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrepaidExpensesAmortizationPeriod_lbl" xml:lang="en-US" id="id_6457213_1985407_3_1">Prepaid expenses amortization period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrepaidExpensesAmortizationPeriod_lbl" xml:lang="en-US" id="id_6457213_1985407_1_1">Prepaid Expenses Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrepaidExpensesAmortizationPeriod_lbl" xml:lang="en-US" id="id_6457213_1985407_2_1">Contract term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrepaidExpensesAmortizationPeriod" xlink:to="rswn_PrepaidExpensesAmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" xlink:label="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid_lbl" xml:lang="en-US" id="id_6457213_1985392_3_1">Prepaid research and development and accrued liability related parties unpaid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid_lbl" xml:lang="en-US" id="id_6457213_1985392_1_1">Prepaid Research And Development And Accrued Liability Related Parties Unpaid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid_lbl" xml:lang="en-US" id="id_6457213_1985392_2_1">Related party research and development liability included in prepaid research and development-related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" xlink:to="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1985384_3_1">Prepaid research and development related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1985384_1_1">Prepaid Research And Development Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1985384_2_1">Prepaid research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrepaidResearchAndDevelopmentRelatedParty" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1985385_3_1">Prepaid research and development related party noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1985385_1_1">Prepaid Research And Development Related Party Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_lbl" xml:lang="en-US" id="id_6457213_1985385_2_1">Long-term portion of prepaid research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrimsolBusinessMember" xlink:label="rswn_PrimsolBusinessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrimsolBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1993859_3_1">Primsol Business [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrimsolBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1993859_1_1">Primsol Business [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrimsolBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1993859_2_1">Primsol Business [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrimsolBusinessMember" xlink:to="rswn_PrimsolBusinessMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrivatePlacementWarrantTerm" xlink:label="rswn_PrivatePlacementWarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PrivatePlacementWarrantTerm_lbl" xml:lang="en-US" id="id_6457213_1775010_3_1">Private Placement Warrant Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PrivatePlacementWarrantTerm_lbl" xml:lang="en-US" id="id_6457213_1775010_1_1">Private Placement Warrant Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PrivatePlacementWarrantTerm_lbl" xml:lang="en-US" id="id_6457213_1775010_2_1">Warrant term of placement agent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PrivatePlacementWarrantTerm" xlink:to="rswn_PrivatePlacementWarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" id="id_6457213_1650987_1_1">Proceeds from Contributed Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" id="id_6457213_1650987_2_1">Contribution from Ampio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="us-gaap_ProceedsFromContributionsFromParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromParent_lbl" xml:lang="en-US" id="id_6457213_1648586_1_1">Proceeds from Contributions from Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributionsFromParent_lbl" xml:lang="en-US" id="id_6457213_1648586_2_1">Ampio stock subscription payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromParent" xlink:to="us-gaap_ProceedsFromContributionsFromParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_6457213_1648717_1_1">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_6457213_1648717_2_1">Proceeds from convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_6457213_1648717_12_1">Proceeds from convertible note from Ampio converted to stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US" id="id_6457213_1649362_1_1">Proceeds from License Fees Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US" id="id_6457213_1649362_2_1">Upfront payment received, net proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProductsAndServicesRevenue" xlink:label="rswn_ProductsAndServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ProductsAndServicesRevenue_lbl" xml:lang="en-US" id="id_6457213_1862303_3_1">Products And Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ProductsAndServicesRevenue_lbl" xml:lang="en-US" id="id_6457213_1862303_1_1">Products And Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ProductsAndServicesRevenue_lbl" xml:lang="en-US" id="id_6457213_1862303_2_1">Product and service revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ProductsAndServicesRevenue" xlink:to="rswn_ProductsAndServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PromissoryNoteMember" xlink:label="rswn_PromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_PromissoryNoteMember_lbl" xml:lang="en-US" id="id_6457213_1887167_3_1">Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_PromissoryNoteMember_lbl" xml:lang="en-US" id="id_6457213_1887167_1_1">Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_PromissoryNoteMember_lbl" xml:lang="en-US" id="id_6457213_1887167_2_1">Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_PromissoryNoteMember" xlink:to="rswn_PromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_6457213_1643397_1_1">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_6457213_1643397_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1634505_1_1">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1634505_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6457213_1651381_1_1">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_6457213_1651381_2_1">Fixed assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6457213_1642195_1_1">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_6457213_1642195_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6457213_1649598_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6457213_1649598_2_1">Fixed assets, net (Note 2)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6457213_1649598_6_1">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634506_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634506_2_1">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6457213_1638511_1_1">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_6457213_1638511_2_1">Schedule of Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1637279_1_1">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1637279_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6457213_1634075_1_1">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_6457213_1634075_2_1">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_lbl" xml:lang="en-US" id="id_6457213_1648964_1_1">Property Subject to or Available for Operating Lease, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_lbl" xml:lang="en-US" id="id_6457213_1648964_2_1">Equipment lease payments net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ProstascintBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1985396_3_1">Prostascint Business [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ProstascintBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1985396_1_1">Prostascint Business [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ProstascintBusinessMember_lbl" xml:lang="en-US" id="id_6457213_1985396_2_1">Prostascint Business [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ProstascintBusinessMember" xlink:to="rswn_ProstascintBusinessMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintInventoryTransferFeeMember" xlink:label="rswn_ProstascintInventoryTransferFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ProstascintInventoryTransferFeeMember_lbl" xml:lang="en-US" id="id_6457213_1985426_3_1">Prostascint Inventory Transfer Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ProstascintInventoryTransferFeeMember_lbl" xml:lang="en-US" id="id_6457213_1985426_1_1">Prostascint Inventory Transfer Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ProstascintInventoryTransferFeeMember_lbl" xml:lang="en-US" id="id_6457213_1985426_2_1">ProstaScint Inventory Transfer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ProstascintInventoryTransferFeeMember" xlink:to="rswn_ProstascintInventoryTransferFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xml:lang="en-US" id="id_6457213_1641766_1_1">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xml:lang="en-US" id="id_6457213_1641766_2_1">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xml:lang="en-US" id="id_6457213_1638127_1_1">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xml:lang="en-US" id="id_6457213_1638127_2_1">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6457213_1639304_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_6457213_1639304_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6457213_1634888_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_6457213_1634888_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_lbl" xml:lang="en-US" id="id_6457213_1649705_1_1">Receivable from Shareholders or Affiliates for Issuance of Capital Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_lbl" xml:lang="en-US" id="id_6457213_1649705_14_1">Ampio stock subscription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:to="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US" id="id_6457213_1644202_1_1">Receivables from Stockholder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US" id="id_6457213_1644202_2_1">Receivables from Stockholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634083_1_1">Receivables, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634083_2_1">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_RegulatoryAssetsAbstract" xlink:label="rswn_RegulatoryAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_6457213_1942371_3_1">Regulatory Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_6457213_1942371_1_1">Regulatory Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_RegulatoryAssetsAbstract_lbl" xml:lang="en-US" id="id_6457213_1942371_2_1">Regulatory Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_RegulatoryAssetsAbstract" xlink:to="rswn_RegulatoryAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_6457213_1634903_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_6457213_1634903_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_6457213_1631679_1_1">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_6457213_1631679_2_1">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_6457213_1641333_1_1">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_6457213_1641333_2_1">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_6457213_1641778_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_6457213_1641778_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_6457213_1640485_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_6457213_1640485_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_6457213_1642993_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_6457213_1642993_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644230_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644230_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember_lbl" xml:lang="en-US" id="id_6457213_1985413_3_1">Research And Development Arrangement Clinical Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember_lbl" xml:lang="en-US" id="id_6457213_1985413_1_1">Research And Development Arrangement Clinical Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember_lbl" xml:lang="en-US" id="id_6457213_1985413_2_1">Clinical Research and Trial Obligations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:to="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US" id="id_6457213_1640093_1_1">Research and Development Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US" id="id_6457213_1640093_2_1">Sponsored Research Agreement with Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6457213_1649370_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6457213_1649370_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6457213_1642216_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6457213_1642216_2_1">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6457213_1635712_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6457213_1635712_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentRelatedParty" xlink:label="rswn_ResearchAndDevelopmentRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1695246_3_1">Research And Development Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1695246_1_1">Research And Development Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US" id="id_6457213_1695246_2_1">Research and development-related party (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ResearchAndDevelopmentRelatedParty" xlink:to="rswn_ResearchAndDevelopmentRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6457213_1646649_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6457213_1646649_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6457213_1633302_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_6457213_1633302_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_RevenueRecognitionLineItems" xlink:label="rswn_RevenueRecognitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_RevenueRecognitionLineItems_lbl" xml:lang="en-US" id="id_6457213_1953889_3_1">Revenue Recognition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_RevenueRecognitionLineItems_lbl" xml:lang="en-US" id="id_6457213_1953889_1_1">Revenue Recognition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_RevenueRecognitionLineItems_lbl" xml:lang="en-US" id="id_6457213_1953889_2_1">Revenue Recognition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_RevenueRecognitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633725_1_1">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633725_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6457213_1644847_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6457213_1644847_6_1">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReversalOfAllocatedShareBasedCompensationExpense" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6457213_1725690_3_1">Reversal Of Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6457213_1725690_1_1">Reversal Of Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6457213_1725690_2_1">Reversal of share based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ReversalOfAllocatedShareBasedCompensationExpense" xlink:to="rswn_ReversalOfAllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerShare" xlink:label="rswn_ReverseMergerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ReverseMergerShare_lbl" xml:lang="en-US" id="id_6457213_1986472_3_1">Reverse merger share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ReverseMergerShare_lbl" xml:lang="en-US" id="id_6457213_1986472_1_1">Reverse Merger Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ReverseMergerShare_lbl" xml:lang="en-US" id="id_6457213_1986472_2_1">Reverse merger, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ReverseMergerShare" xlink:to="rswn_ReverseMergerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerValue" xlink:label="rswn_ReverseMergerValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ReverseMergerValue_lbl" xml:lang="en-US" id="id_6457213_1986470_3_1">Reverse merger value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ReverseMergerValue_lbl" xml:lang="en-US" id="id_6457213_1986470_1_1">Reverse Merger Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ReverseMergerValue_lbl" xml:lang="en-US" id="id_6457213_1986470_2_1">Reverse merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ReverseMergerValue" xlink:to="rswn_ReverseMergerValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US" id="id_6457213_1633309_1_1">Sale of Stock, Percentage of Ownership after Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US" id="id_6457213_1633309_2_1">Percent of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_6457213_1641344_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_6457213_1641344_2_1">Scenario, Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" id="id_6457213_1639324_1_1">Scenario, Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" id="id_6457213_1639324_2_1">Scenario, Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6457213_1638535_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6457213_1638535_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_6457213_1637306_1_1">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="id_6457213_1637306_2_1">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640497_1_1">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640497_2_1">Summary of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632086_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632086_2_1">Schedule of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640501_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640501_2_1">Reconciliation of Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems_lbl" xml:lang="en-US" id="id_6457213_1837539_3_1">Schedule Of Estimated Future Amortization Expense [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems_lbl" xml:lang="en-US" id="id_6457213_1837539_1_1">Schedule Of Estimated Future Amortization Expense [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems_lbl" xml:lang="en-US" id="id_6457213_1837539_2_1">Schedule Of Estimated Future Amortization Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable_lbl" xml:lang="en-US" id="id_6457213_1702466_3_1">Schedule Of Estimated Future Amortization Expense [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable_lbl" xml:lang="en-US" id="id_6457213_1702466_1_1">Schedule Of Estimated Future Amortization Expense [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable_lbl" xml:lang="en-US" id="id_6457213_1702466_2_1">Schedule Of Estimated Future Amortization Expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:to="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633722_1_1">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1633722_2_1">Schedule of Future Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_6457213_1632487_1_1">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_6457213_1632487_2_1">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1636123_1_1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1636123_2_1">Future Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_6457213_1634922_1_1">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_6457213_1634922_2_1">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6457213_1636513_1_1">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_6457213_1636513_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632492_1_1">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1632492_2_1">Company's Allocation on Consideration Transferred for ProstaScint</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_6457213_1632493_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_6457213_1632493_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642619_1_1">Schedule of Rent Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642619_2_1">Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfRevenueRecognitionTable" xlink:label="rswn_ScheduleOfRevenueRecognitionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ScheduleOfRevenueRecognitionTable_lbl" xml:lang="en-US" id="id_6457213_1817936_3_1">Schedule Of Revenue Recognition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ScheduleOfRevenueRecognitionTable_lbl" xml:lang="en-US" id="id_6457213_1817936_1_1">Schedule Of Revenue Recognition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ScheduleOfRevenueRecognitionTable_lbl" xml:lang="en-US" id="id_6457213_1817936_2_1">Schedule Of Revenue Recognition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="rswn_ScheduleOfRevenueRecognitionTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6457213_1643015_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6457213_1643015_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640512_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1640512_2_1">Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1643831_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_6457213_1643831_2_1">Stock Options Valuation Assumption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634114_1_1">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1634114_2_1">Warrants Issued in Conjunction with its Senior Convertible Debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SecondInstallmentMember" xlink:label="rswn_SecondInstallmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_SecondInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1676684_3_1">Second Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_SecondInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1676684_1_1">Second Installment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_SecondInstallmentMember_lbl" xml:lang="en-US" id="id_6457213_1676684_2_1">Second Installment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_SecondInstallmentMember" xlink:to="rswn_SecondInstallmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6457213_1642624_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6457213_1642624_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6457213_1648110_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6457213_1648110_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6457213_1638565_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_6457213_1638565_2_1">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6457213_1631722_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_6457213_1631722_2_1">Expected term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" id="id_6457213_1638237_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" id="id_6457213_1638237_2_1">Expected volatility, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" id="id_6457213_1643441_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" id="id_6457213_1643441_2_1">Expected volatility, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_6457213_1642254_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_6457213_1642254_2_1">Risk free interest rate, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_6457213_1641796_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_6457213_1641796_2_1">Risk free interest rate, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6457213_1637335_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6457213_1637335_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_6457213_1985410_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_6457213_1985410_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_6457213_1985410_2_1">Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_lbl" xml:lang="en-US" id="id_6457213_1807600_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_lbl" xml:lang="en-US" id="id_6457213_1807600_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_lbl" xml:lang="en-US" id="id_6457213_1807600_2_1">Number of Options, Available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6457213_1637337_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_6457213_1637337_2_1">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1642255_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1642255_2_1">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6457213_1633736_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_6457213_1633736_2_1">Number of Options, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_6457213_1640581_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_6457213_1640581_2_1">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6457213_1651525_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6457213_1651525_4_1">Aggregate Intrinsic Value, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_6457213_1651525_5_1">Aggregate Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward_lbl" xml:lang="en-US" id="id_6457213_1876388_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward_lbl" xml:lang="en-US" id="id_6457213_1876388_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward_lbl" xml:lang="en-US" id="id_6457213_1876388_2_1">Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6457213_1632583_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6457213_1632583_4_1">Number of Options, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_6457213_1632583_5_1">Number of Options, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_6457213_1641361_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_6457213_1641361_2_1">Number of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_6457213_1641361_12_1">Number of Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1634132_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1634132_4_1">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1634132_5_1">Weighted Average Exercise Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6457213_1826654_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6457213_1826654_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6457213_1826654_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_6457213_1633321_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_6457213_1633321_2_1">Warrants, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_6457213_1633321_12_1">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6457213_1634936_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_6457213_1634936_2_1">Weighted Average Remaining Contractual Life, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6457213_1644249_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_6457213_1644249_2_1">Weighted average remaining years to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6457213_1634939_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6457213_1634939_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1641363_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1641363_2_1">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1635427_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1635427_2_1">Weighted Average Exercise Price, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1638569_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1638569_2_1">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding_lbl" xml:lang="en-US" id="id_6457213_1721729_3_1">Share Based Compensation Share Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding_lbl" xml:lang="en-US" id="id_6457213_1721729_1_1">Share Based Compensation Share Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding_lbl" xml:lang="en-US" id="id_6457213_1721729_4_1">Number of Warrants Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding_lbl" xml:lang="en-US" id="id_6457213_1721729_5_1">Number of Warrants Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="rswn_ShareBasedCompensationShareWarrantsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1659852_3_1">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1659852_1_1">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_6457213_1659852_4_1">Weighted Average Exercise Price, Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6457213_1637341_1_1">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6457213_1637341_4_1">Ending Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_6457213_1637341_5_1">Beginning Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6457213_1643028_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6457213_1643028_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6457213_1643450_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_6457213_1643450_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6457213_1641811_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6457213_1641811_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6457213_1641812_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_6457213_1641812_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6457213_1643038_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6457213_1643038_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6457213_1640591_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6457213_1640591_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1643451_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1643451_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6457213_1640593_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6457213_1640593_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6457213_1632950_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_6457213_1632950_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1644941_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1644941_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1644941_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6457213_1644941_6_1">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1634143_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6457213_1634143_2_1">Stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642264_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6457213_1642264_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_6457213_1642265_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_6457213_1642265_2_1">Reverse stock split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6457213_1638248_1_1">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_6457213_1638248_2_1">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6457213_1632112_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_6457213_1632112_2_1">Issuance of common stock to Ampio in exchange for Aytu debt, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" id="id_6457213_1638249_1_1">Stock Issued During Period, Shares, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" id="id_6457213_1638249_2_1">Issuance of common stock in exchange for Vyrix Acquired Assets, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_6457213_1640611_1_1">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_6457213_1640611_2_1">Stock-based compensation, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6457213_1642361_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_6457213_1642361_2_1">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" id="id_6457213_1646543_1_1">Stock Issued During Period, Value, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" id="id_6457213_1646543_2_1">Issuance of common stock in exchange for Vyrix Acquired Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_StockSubscription" xlink:label="rswn_StockSubscription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_StockSubscription_lbl" xml:lang="en-US" id="id_6457213_1865396_3_1">Stock Subscription</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_StockSubscription_lbl" xml:lang="en-US" id="id_6457213_1865396_1_1">Stock Subscription</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_StockSubscription_lbl" xml:lang="en-US" id="id_6457213_1865396_2_1">Ampio stock subscription payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_StockSubscription" xlink:to="rswn_StockSubscription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_6457213_1639792_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_6457213_1639792_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6457213_1633766_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_6457213_1633766_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633767_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_6457213_1633767_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644261_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_6457213_1644261_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_6457213_1631799_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_6457213_1631799_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1636141_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_6457213_1636141_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1633768_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_6457213_1633768_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1961765_3_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1961765_1_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_6457213_1961765_2_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6457213_1858129_3_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6457213_1858129_1_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_6457213_1858129_2_1">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="rswn_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6457213_1639366_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6457213_1639366_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6457213_1643125_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6457213_1643125_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" id="id_6457213_1969780_3_1">Two Thousand Fifteen Stock Option And Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" id="id_6457213_1969780_1_1">Two Thousand Fifteen Stock Option And Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US" id="id_6457213_1969780_2_1">2015 Stock Option and Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:to="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6457213_1634968_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6457213_1634968_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_UncategorizedAbstract" xlink:label="rswn_UncategorizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_6457213_1652489_3_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_6457213_1652489_1_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_6457213_1652489_2_1">Uncategorized [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_UncategorizedAbstract" xlink:to="rswn_UncategorizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xml:lang="en-US" id="id_6457213_1641075_1_1">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xml:lang="en-US" id="id_6457213_1641075_2_1">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_UnrecognizedShareBasedCompensationExpenses" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses_lbl" xml:lang="en-US" id="id_6457213_1878275_3_1">Unrecognized Share Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses_lbl" xml:lang="en-US" id="id_6457213_1878275_1_1">Unrecognized Share Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses_lbl" xml:lang="en-US" id="id_6457213_1878275_2_1">Unrecognized expense at March 31, 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_UnrecognizedShareBasedCompensationExpenses" xlink:to="rswn_UnrecognizedShareBasedCompensationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_6457213_1645139_1_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_6457213_1645139_2_1">Liability for gross unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" id="id_6457213_1632127_1_1">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" id="id_6457213_1632127_2_1">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6457213_1642359_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6457213_1642359_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_VyrixPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_6457213_1985390_3_1">Vyrix Pharmaceuticals Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_VyrixPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_6457213_1985390_1_1">Vyrix Pharmaceuticals Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_VyrixPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="id_6457213_1985390_2_1">Vyrix Pharmaceuticals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_VyrixPharmaceuticalsIncMember" xlink:to="rswn_VyrixPharmaceuticalsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986697_3_1">Vyrix Two Thousand Thirteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986697_1_1">Vyrix Two Thousand Thirteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_6457213_1986697_2_1">Vyrix 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_VyrixTwoThousandThirteenStockOptionPlanMember" xlink:to="rswn_VyrixTwoThousandThirteenStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6457213_1643551_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6457213_1643551_2_1">Weighted average number of Aytu common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember_lbl" xml:lang="en-US" id="id_6457213_1985423_3_1">Zertane Clinical Trials And Redoxsys Research Studies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember_lbl" xml:lang="en-US" id="id_6457213_1985423_1_1">Zertane Clinical Trials And Redoxsys Research Studies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember_lbl" xml:lang="en-US" id="id_6457213_1985423_2_1">Zertane Clinical Trials and RedoxSYS Research Studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" xlink:to="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertanePatentsMember" xlink:label="rswn_ZertanePatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rswn_ZertanePatentsMember_lbl" xml:lang="en-US" id="id_6457213_1985400_3_1">Zertane Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rswn_ZertanePatentsMember_lbl" xml:lang="en-US" id="id_6457213_1985400_1_1">Zertane Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rswn_ZertanePatentsMember_lbl" xml:lang="en-US" id="id_6457213_1985400_2_1">Zertane Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rswn_ZertanePatentsMember" xlink:to="rswn_ZertanePatentsMember_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>rswn-20150630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 1 -->
<!-- Creation date: 2015-10-14T17:54:28Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxes" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommitmentsAndContingenciesRentExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSignificantAssumptions" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsLuoxisStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsVyrixStockOptionActivity" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLicenseAgreementTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rswn-20150630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DocumentAndEntityInformationAbstract" xlink:label="rswn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AccruedCompensationCurrent" xlink:label="rswn_AccruedCompensationCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CoreAndDevelopedTechnologyNet" xlink:label="rswn_CoreAndDevelopedTechnologyNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="us-gaap_DueToAffiliateCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="us-gaap_IndefiniteLivedContractualRights"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="us-gaap_IndefiniteLivedTradeNames"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_InterestPayableRelatedPartiesCurrent" xlink:label="rswn_InterestPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedParty"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="rswn_CoreAndDevelopedTechnologyNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedContractualRights" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedTradeNames" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="rswn_PrepaidResearchAndDevelopmentRelatedParty" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToAffiliateCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="rswn_AccruedCompensationCurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="rswn_InterestPayableRelatedPartiesCurrent" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProductsAndServicesRevenue" xlink:label="rswn_ProductsAndServicesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentRelatedParty" xlink:label="rswn_ResearchAndDevelopmentRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="rswn_ProductsAndServicesRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="rswn_ResearchAndDevelopmentRelatedParty" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" xlink:label="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" xlink:label="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ContributionsFromRelatedParty" xlink:label="rswn_ContributionsFromRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerShare" xlink:label="rswn_ReverseMergerShare"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReverseMergerValue" xlink:label="rswn_ReverseMergerValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_StockSubscription" xlink:label="rswn_StockSubscription"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ContributionsFromRelatedParty" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_StockSubscription" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ReverseMergerValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rswn_ReverseMergerShare" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_2" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" xlink:label="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInAccruedCompensation" xlink:label="rswn_IncreaseDecreaseInAccruedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets" xlink:label="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NoncashOrPartNoncashCapitalContributionFromParent" xlink:label="rswn_NoncashOrPartNoncashCapitalContributionFromParent"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PaymentsForDepositsInvestingActivities" xlink:label="rswn_PaymentsForDepositsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDistributionsToAffiliates" xlink:label="us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" xlink:label="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="us-gaap_ProceedsFromContributionsFromParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rswn_NoncashOrPartNoncashCapitalContributionFromParent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromContributionsFromParent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfDistributionsToAffiliates" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromContributedCapital" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="rswn_PaymentsForDepositsInvestingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="rswn_IncreaseDecreaseInAccruedCompensation" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationContingentConsiderationPercentage" xlink:label="rswn_BusinessCombinationContingentConsiderationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLaborRelatedExpenses" xlink:label="us-gaap_OtherLaborRelatedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rswn_BusinessCombinationContingentConsiderationPercentage" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" xlink:label="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaCostOfRevenue" xlink:label="rswn_BusinessAcquisitionsProFormaCostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" xlink:label="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" xlink:label="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" xlink:label="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" xlink:label="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" xlink:label="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaCostOfRevenue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" xlink:label="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OrpMember" xlink:label="rswn_OrpMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_RegulatoryAssetsAbstract" xlink:label="rswn_RegulatoryAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="rswn_SummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertanePatentsMember" xlink:label="rswn_ZertanePatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rswn_ZertanePatentsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rswn_OrpMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RegulatoryAssetsAbstract" xlink:to="rswn_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rswn_FiniteLivedIntangibleAssetsExpirationMonthYear" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="rswn_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LabEquipmentMember" xlink:label="rswn_LabEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rswn_LabEquipmentMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="us-gaap_DepreciationAndAmortizationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAndAmortizationAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:label="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfEstimatedFutureAmortizationExpenseTable" xlink:to="rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementExpirationPeriod" xlink:label="rswn_AgreementExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioMember" xlink:label="rswn_AmpioMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="us-gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DeferredRevenueRecognitionPeriod" xlink:label="rswn_DeferredRevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_KR" xlink:label="country_KR"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfRoyaltyRateOfNetSales" xlink:label="rswn_PercentageOfRoyaltyRateOfNetSales"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PotentialMilestonePaymentsReceivable" xlink:label="rswn_PotentialMilestonePaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_RevenueRecognitionLineItems" xlink:label="rswn_RevenueRecognitionLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ScheduleOfRevenueRecognitionTable" xlink:label="rswn_ScheduleOfRevenueRecognitionTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="rswn_ScheduleOfRevenueRecognitionTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_AmpioMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_PotentialMilestonePaymentsReceivable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_DeferredRevenueRecognitionPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_PercentageOfRoyaltyRateOfNetSales" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_RevenueRecognitionLineItems" xlink:to="rswn_AgreementExpirationPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="us-gaap_StatementGeographicalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ScheduleOfRevenueRecognitionTable" xlink:to="rswn_RevenueRecognitionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_KR" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="us-gaap_DeferredTaxAssetsNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesLineItems" xlink:label="rswn_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesTable" xlink:label="rswn_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeesMember" xlink:label="rswn_ManagementFeesMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManufacturingMember" xlink:label="rswn_ManufacturingMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OfficeLeaseMember" xlink:label="rswn_OfficeLeaseMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintInventoryTransferFeeMember" xlink:label="rswn_ProstascintInventoryTransferFeeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rswn_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="rswn_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ManagementFeesMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ProstascintInventoryTransferFeeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ManufacturingMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_OfficeLeaseMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AgreementTerminationNoticePeriod" xlink:label="rswn_AgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AytuManufacturingAndCommercialDevelopmentMember" xlink:label="rswn_AytuManufacturingAndCommercialDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesLineItems" xlink:label="rswn_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesTable" xlink:label="rswn_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ManagementFeePayablePerMonth" xlink:label="rswn_ManagementFeePayablePerMonth"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintInventoryTransferFeeMember" xlink:label="rswn_ProstascintInventoryTransferFeeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" xlink:label="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" xlink:label="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rswn_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_ManagementFeePayablePerMonth" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_AgreementTerminationNoticePeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="rswn_OperatingLeasesMonthlyBaseRentInitialYear" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_CommitmentsAndContingenciesTable" xlink:to="rswn_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ProstascintInventoryTransferFeeMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_ResearchAndDevelopmentArrangementClinicalResearchMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="rswn_AytuManufacturingAndCommercialDevelopmentMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfStockOptionPlans" xlink:label="rswn_NumberOfStockOptionPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ReversalOfAllocatedShareBasedCompensationExpense" xlink:label="rswn_ReversalOfAllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixTwoThousandThirteenStockOptionPlanMember" xlink:label="rswn_VyrixTwoThousandThirteenStockOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_VyrixTwoThousandThirteenStockOptionPlanMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_LuoxisTwoThousandThirteenStockOptionPlanMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_NumberOfStockOptionPlans" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ReversalOfAllocatedShareBasedCompensationExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="rswn_AssumptionsUsedToDetermineFairValueOptionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_UncategorizedAbstract" xlink:label="rswn_UncategorizedAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_UncategorizedAbstract" xlink:to="rswn_AssumptionsUsedToDetermineFairValueOptionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_UnrecognizedShareBasedCompensationExpenses" xlink:label="rswn_UnrecognizedShareBasedCompensationExpenses"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rswn_UnrecognizedShareBasedCompensationExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationShareWarrantsOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="rswn_ShareBasedCompensationShareWarrantsOutstanding_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AfterAmendmentMember" xlink:label="rswn_AfterAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioLoanAgreementMember" xlink:label="rswn_AmpioLoanAgreementMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_AmpioMember" xlink:label="rswn_AmpioMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CashAdvancesForShortTermLoans" xlink:label="rswn_CashAdvancesForShortTermLoans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_FirstInstallmentMember" xlink:label="rswn_FirstInstallmentMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LeaseAgreementsMaturityPeriod" xlink:label="rswn_LeaseAgreementsMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeaseMonthlyRentalPayment" xlink:label="rswn_OperatingLeaseMonthlyRentalPayment"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrepaidExpensesAmortizationPeriod" xlink:label="rswn_PrepaidExpensesAmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PromissoryNoteMember" xlink:label="rswn_PromissoryNoteMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_SecondInstallmentMember" xlink:label="rswn_SecondInstallmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rswn_AmpioLoanAgreementMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rswn_PromissoryNoteMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rswn_SecondInstallmentMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="rswn_FirstInstallmentMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rswn_AmpioMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rswn_AfterAmendmentMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_CashAdvancesForShortTermLoans" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_OperatingLeaseMonthlyRentalPayment" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_PrepaidExpensesAmortizationPeriod" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rswn_LeaseAgreementsMaturityPeriod" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementScenarioAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_BiovestInternationalIncMember" xlink:label="rswn_BiovestInternationalIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertibleNotesEqualToPercentageOfCommonStock" xlink:label="rswn_ConvertibleNotesEqualToPercentageOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ConvertiblePromissoryNotesMember" xlink:label="rswn_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentExtensionPeriod" xlink:label="rswn_DebtInstrumentExtensionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateThree" xlink:label="rswn_DebtInstrumentMaturityDateThree"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityDateTwo" xlink:label="rswn_DebtInstrumentMaturityDateTwo"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_DebtInstrumentMaturityPeriod1" xlink:label="rswn_DebtInstrumentMaturityPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfConvertedMember" xlink:label="rswn_IfConvertedMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotConvertedMember" xlink:label="rswn_IfNotConvertedMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_IfNotRegisteredCommonStockMember" xlink:label="rswn_IfNotRegisteredCommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_MasterServicesAgreementMember" xlink:label="rswn_MasterServicesAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NonRefundableRetainerFee" xlink:label="rswn_NonRefundableRetainerFee"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" xlink:label="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="rswn_OperatingLeasesMonthlyBaseRentInitialYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" xlink:label="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" xlink:label="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" xlink:label="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodFourMember" xlink:label="rswn_PeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodOneMember" xlink:label="rswn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodThreeMember" xlink:label="rswn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PeriodTwoMember" xlink:label="rswn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrimsolBusinessMember" xlink:label="rswn_PrimsolBusinessMember"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_PrivatePlacementWarrantTerm" xlink:label="rswn_PrivatePlacementWarrantTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rswn_MasterServicesAgreementMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_PrimsolBusinessMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodOneMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodTwoMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodThreeMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="rswn_PeriodFourMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfConvertedMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfNotConvertedMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rswn_IfNotRegisteredCommonStockMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rswn_ConvertiblePromissoryNotesMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_BiovestInternationalIncMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityDateTwo" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityDateThree" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentMaturityPeriod1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_DebtInstrumentExtensionPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_ConvertibleNotesEqualToPercentageOfCommonStock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionDescription" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_NonRefundableRetainerFee" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PrivatePlacementWarrantTerm" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_OperatingLeasesMonthlyBaseRentInitialYear" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_ProstascintBusinessMember" xlink:label="rswn_ProstascintBusinessMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rswn_ProstascintBusinessMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:label="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock">
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LicenseAgreementTextBlock" xlink:label="rswn_LicenseAgreementTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="rswn_LicenseAgreementTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rswn_CommitmentsAndContingenciesDisclosureTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRentExpenseTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_LuoxisDiagnosticsMember" xlink:label="rswn_LuoxisDiagnosticsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="rswn-20150630.xsd#rswn_VyrixPharmaceuticalsIncMember" xlink:label="rswn_VyrixPharmaceuticalsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_LuoxisDiagnosticsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rswn_VyrixPharmaceuticalsIncMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g63294cov1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294cov1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 00"Z P$1  (1 0,1 ?_$ ,T  0 !!0$! 0$
M       )!@<("@L%! $# 0$  00" P               0('" D#"@0%!A
M  8! P(#! $,#0T      0(#! 4&!P 1"!()(1,5,2(4"D%1,B/55Y<86'@9
M.1J14K*STW0UM18V=I;684*TU%5UE::V%S=WMQ$  0,"!0$$ @H."@,
M 0 " Q$$(1(%!@<Q05$B"&$3<8$R4F)RTB,8"9&QP4+",T-SDQ0T5)05H8*2
M4],D)35%%E47&?_:  P# 0 "$0,1 #\ W^-$4?//WF6XXJTRNM::E#2F3KC(
MCZ1&S":[EC'P$<9,\Q+OFS99NJ8#"JFW0#S"[JJ=6Q@(8-7=XEXW9OS4II-2
M,D>B6S/&YE YTCO<,:2".PN=@<!3"H6&?G%\STOEZVO96^V6VUQOS4YOF8I@
MY[([>.AFFD:US3C5L;!F%7.S4<&D*)?\[]R>_P!AXQ_X%+?;K5__ */.Q_[V
M]_ML^0M<W_TJY[_=-!_03?XZ\.>[T/(2LLS/9IGBMDCL(ID/"2QG"X^SI;MR
MS0JJB(^'@&P#[1#7%-P!L*W9GFFO0/SC*^T,B]EI?UB?F,UFX%MIVGZ'))VD
M6\V5OQG>OH/;Q[@LI.!W<TS9R-OR3W*L-3JSB9VLI Q#J,BGK.6?S"@@4LJY
M7<R#M)O%M%C$3,4I1ZNL1ZO=VUK<\T_._%G O,.U^*+%[W2ZG,?YE/-('"RC
MF8YMG7*&AKI)J.D+LV2)IP!<TK<9Y,-O\\<[\1ZYS#R$VQATFW<(=.AM8'QF
MZEC<'W;\TCWE\<4=&,RAH?*[ ^!P,\VKF=<1T5QTT1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31%X5GLD-3Z]-6FQ/D8V#K\:[E91\X.5-%LS9(F66
M4,8XE+OTEV -_$P@'TZ\JQLKG4;R*PLVE]U,\,:T=2YQH%ZG7M<TO;.BW6X-
M:E9!I-G ^:61Q :UC 7.))]C#O- M-CE;R%D.0>7[=E.== Q@U%ACJPS=*BB
MA#U6..H2,0Z53;)KKIB*ZW^<*B@AX[!K8UL?:UKLK;,&CQY?6M;FE?[Z5V+C
M7N'0>@+K*<]<LZSSQRI?[SF;(;:63U5G"*GU5K&2(FAO87#QO^&X]P4>USSL
MS:>:QJ"17S@.HAY9R0?@R#[.IJCN N-OH,/NB&O9W6LM;5EJ,Q]\>GM=Z]9M
M[C&XGI<Z^XQ18$1-/C/H<?O?8&*L]3:]:LRW^%K@.W4C*3;TB:KI<QU$V+(G
MONW1@ !*@W;( (^ ;!X .K*\R<K:%P_QUJO)>ZY/]/TVV<\-)%993A#"P$BK
MI'D  8TJ>Q9@>7O@_5N9>3M&XDV1;B.ZU*Z:QSFM.6&%OBFGD(!HV.,%Q<<*
MT':MA/$%8B:3'1E6@$2M8R"B$V;0J8=)A%-0IU7)Q#Q%=PX,90P^WJ-KIO>8
M7D#<?*.X-0Y"W1,Z37]4U$SO=7W%?Q<;>YL3 UC:>]KVKN@[,XZVQQ-QQI/&
M^T(&P;<TFV9!$T#W5 3)([O?-(7R/)ZN<5L \6\M%R7CYNPDG(*6FHD;Q,N"
MAP%=XU(F)8R5$!'K/\2@F)%##XBJF81^N#6X7R0\\MYDXGATO69L^]] :RUN
MLQ\<L8;2WN>M3ZQC<CW'$RQN<?=!:_><M@G9>[7W5DRFAZ@72Q4'A8XGYR+N
M&5QJT>]<!V+)K69ZLHOP1 H"8P@4I0$3&$0    W$1$?   -$7-2[\'S(?*I
M3G);L,]OO/M@Q9A+C^5UCN7L]'48F-E')#%P<;S.*NU478+0==D4_2F0%V*8
MS-=<!$JQ=$4H/RN_?8RORZNF1.&7-O*LA?\ -3_XB_X)OMG^$1D;1",VQ0MM
M =ND2-TG$I#"4KYB E\Q5LHJ0H#Y.B+=-M-LK%'@9"TW*P0]6K40D#B5GY^0
M:Q4/&-Q.4GQ#^1>J(M&: ', "=0Y2AOXCHBLPPY<<5Y1\RC(WD?@U](2+I!B
MP9-,ITI=T\>.E2HMFK9%.:,HLNNL<"D*4!$QA  \=$60X" @ @.X#X@(>("
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MI<14+LL?5*>5^/C_ (W?S_NJW:-V;FBRZ?G:"^WTT$_.-.-#>&CZ@@F(-:X
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MSD#_ &9GYX?:*\36/V9OQ_N*1CAUB0+C;U;U,-04K].6(+$BR8&1?V(Y>ML
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M>/E;/.VI=Q-JMRM3N"OIYX]=)$\@@% A3 4-O9HBS;T1-$4'>>?EVNUIR3Y
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31-$31$T1-$31$T1-$31$T1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g63294tx056a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx056a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 9P*\ P$1  (1 0,1 ?_$ (\  0 " @(# 0
M       ("08' P4!! H" 0$                     $   ! 4! 0X#! <%
M!0@#   $!08'  $" P@)$1(3%%25U1876)C8&5F9(=(5,5>7UT$B(QBX.7E1
M<22W.&&1L0HZ,D+",T.#-R@T)2<1 0                    #_V@ , P$
M A$#$0 _ /J!S(RLS@(,X6'PJPN(\4?KKG8VO!D,I59E"'=X25@036N W"&D
M1$-MIS<$+D*,JW"MWMHBS71N0]?Z],Y2IJ#U]ZU]./Z0').9_/4 WK7TX_I
M<DYG\]0#>M?3C^D!R3F?SU -ZU]./Z0').9_/4 WK7TX_I <DYG\]0#>M?3C
M^D!R3F?SU -ZU]./Z0').9_/4 WK7TX_I <DYG\]0#>M?3C^D!R3F?SU -ZU
M]./Z0').9_/4 WK7TX_I <DYG\]0#>M?3C^D!R3F?SU -ZU]./Z0').9_/4
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M<=TA.2<T>=8!TNUX..Z0G).:/.L Z7:\''=(3DG-'G6 =+M>#CND)R3FCSK
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M3==?5=TRZOM]5?5)]<Z\NJ;@^^_7.EGTC@/^)V<.W[?OANMS^K 7N7"0FNG
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M.R<]D!QP" 0'[E;KJHJN2HKG;HG3*NN5,YT43JGLIE55LV4SJG]FW[8#\0"
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M\FC9[#Y))YRUF:K9#(XXR,2]U%/2+2Z=.:;U\L"+M*"A((073%W"FS(8)OV
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M 0" 0" 0" 0%.6E_.<\GM:24YSG*6I('V2G/[/\ ZAXQR_X2E_N@+C8! (!
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M]:3^I('_ (1,9("XZ 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0" 0"
M0$2&4QR736/D_KL*)]EDX:<> ZD9IUN3RLRF1M_9E<L7;5@KX2>#@M=0(-1P
M"S.0>G< K%JFB=JF55J EO (! (! ?, ZSW9/(K_ )C%UV5Q41#"*I>/%IE,
M@JS4SR#6;B(Y*$2=:)YG<HOV"V^W"-6YL..3@8X=G<T70MNS1:#53WR54Y4U
M!9_]:UHONTTO_P <<K?#U /K6M%]VFE_^..5OAZ@'UK6B^[32_\ QQRM\/4
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M:7_XXY6^'J ?6M:+[M-+_P#''*WP]0#ZUK1?=II?_CCE;X>H!]:UHONTTO\
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M(;.,365$%0U +UNEZUZD.!+JF]L0HK-M5II5)T3*@< KJJIL@. W0GDYV.R
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M),+HHW-'F=H%9'K47?KKOJ:U:H#C*J[-,J)!J2K3YL"LG5"L:CM1$K%F*)R
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MZE&X:AZ0J,;;!A;((-*_>L!"PJ"TV@UBF4Z 8,+;KKW5VNFJ[7<N5!L6 0"
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MQ==V6[G7:%6YRJGMEL@+ B@F)T^7!"<A*BTD* %JFP!*R@"%+2X%8HELHLA
M(*U9#![5$I;)4T4RE* [* 0" 0%..E]_J?UI/ZD@?^$3&2 N.@$ @$ @$ @$
M @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$ @$!34T7\^/-7^G%A9_G9
MD] 7*P" 0" 0" 0" 0" 0" 0" 0%.+Q_SU\'/Z>.</\ G#BM 7'0" 0" 0"
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ME^HE@WW ESXJ(!U"ZY?J)8-]P)<^*B =0NN7ZB6#?<"7/BH@'4+KE^HE@WW
MESXJ(!U"ZY?J)8-]P)<^*B =0NN7ZB6#?<"7/BH@'4+KE^HE@WW ESXJ(")B
MLPTU0#3-5F'A46J9@. RD2#!O0A6P;J[AT;@391-"L5<V!LYZI"MV)RHZ4*$
M(G5&F" /<- O^$+IC:;5[]851M"6?4+KE^HE@WW ESXJ(!U"ZY?J)8-]P)<^
M*B =0NN7ZB6#?<"7/BH@'4+KE^HE@WW ESXJ(!U"ZY?J)8-]P)<^*B =0NN7
MZB6#?<"7/BH@'4+KE^HE@WW ESXJ(!U"ZY?J)8-]P)<^*B =0NN7ZB6#?<"7
M/BH@'4+KE^HE@WW ESXJ(!U"ZY?J)8-]P)<^*B =0NN7ZB6#?<"7/BH@'4+K
ME^HE@WW ESXJ(!U"ZY?J)8-]P)<^*B =0NN7ZB6#?<"7/BH@'4+KE^HE@WW
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g63294tx056b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx056b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ <P*\ P$1  (1 0,1 ?_$ (H  0 !!0$! 0$
M       %! 8'" D# @H! 0$                     $  !! ,  0,# 0,'
M!PD&!P $ @,%!@$'"  1$@D3%!4A(A87,5$C)+@Y"D$S="5U-AAA<9'!,K<X
M>'FR<S0U)AF!H6-4958G$0$                     _]H # ,!  (1 Q$
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M'E!6 V/OM,N$N2MG'#D FST1V28!H&[VIERECZB?#V<&"01?706K3);[RT=
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M'VM+A,DX3'Y2/@/26M/7ZXN:1 SW-#$VNN[G:KCTO4-J$13%M-V7'D\[%SC
M5O8,)K<!IQ)8EV9'6V5)6=;)$6X( E8Z@J9>U=9+DIQ4!-\YL1#D[M)RLM3%
M3V<1)C5DJ@QP^DQIYX&VL"%3\/M-)95K='0V,=7ELL1Z!S$K>4%5%6OJ5$U$
M+G)CGUZNHME">GQXFK;(8FWZ*/JPX7:(4.29:7@![=);N4,;7R'VUA"U-+HQ
MC3T@I!. H(:U==(CZZFQ3G-K\JW":$1;G82H[2'CB[(!=Y5_J,BMLGVX@D.#
MLNME@CZ^:*6Z1%3J"'IA9HBFV4A0&V?LU44:B.L7+K<XJN7MJ.?.IFVG8ENW
MO[98+UB6<P/<VS7*U&Z)PZ%/LMK245;\H*$<9CL9&R%;+VGKQ;MBS 3W-;##
MCN[LU+$Q4-ID.B,G0L4CFW%D4#;V$&.UZQH.<O61<-)DP5L(B?M'4N+4$Z/;
M>E<3H[A<IHE=8Q>(=\H8:M["1/JUJC2CX5@CARG;,N-1>G^CLM2 12FLQ[='
MPH-UE4KG!> A(FT]=('KF)Z=YL?+;CN?4V]414=I#C%2T<;+*ZM=K*#;>^Z'
M&VB-6 G72"\O.Q+Z"%32C4*;PD(O-G[4_$Y1BQ\L?G?W<4WA_-*V[^(_>_\
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M6'ZM["Z@W+\'VM*_V'==&L][?&MM39G14]JN,U\<2=M*L:F1-,7>FP5CA)F
MJ][%LJB,YRRUAEA33B4L(=90IH,S:YZ#WO?_ )#^C^3K[\@LSSC;>)=I\+,Z
MGJ=^AJ%@/LOG0O7*AM[R]EJ<CFN#[%V#T3>9H-Q<O$9=75"G FHX5KU(P\')
M72G0&Y>:M\;;V'I_=ULJ4/MW_%8[!YBV?JQHVK$:POVL=G@>MO<M$<5!O3TC
M8EKC16 2TR+34=EC*F&DON+<R'[HG4^QQQ&/7T0M:?U_E_95G'Z_\OZ>!\>
M\!X')/D'^]A^9S_9_P :_P#9HM?@=;/ _'+1..Y'Y#N^O\1]R,1N.)U7JG:'
M0?%9&XI:+IC5YV5*UJC+MMO"A]=E2%KBJO43R9VMI'+DSXV84.C/L:92OW>H
M=!:.UT;LWY;^I>#J#VSN_1?-G,O,O$&P:'4*<G7]IL0Y0B*5%3M858;Q6I>2
M%JUR@1'&IU*58)?=*:6EQMCZHY :P<W_ "&=NW3</%%PG[/:+%?NE?DP[MY;
MWKR*^]"-U#7&E-*PPC]9B*]5FXQN6HTYI,<1B1*G\NI-D\'N?DW262!TMAX\
M$]]]M[FV?\4YE_V/>)^R=]7'Y/JCV)IM"8T"+YYA.>KD?$:SG]=P3,0@_24I
MI90HT:LE]2L3#AG]?P26XPXD-M?\-+6P!?C[L,Y^<FK0?*=?]4QF7YV6 EW8
MX2/V:Y[AX@](3)4<BS..H.D,*=6T69E)'M3^F/ U3Y"^0#MO9>W_ (Z9^X7Z
MXR5W[#[C^0_GGICFS*X9N TMJS1:A!JB33*PS%(E=:6#G\<=@Q^74O[J54<O
M$FLK) OTPVA_PX=:BX_F[K2<?LEAMA:ODFZ[@5EV29!L! 04;9JTZ5(!E-@#
MF"RMQP2V5+NX=^G)/,,._31]/'J%E?"I.R&M^T?FJHO4$X!5^RK/V4G93[UW
ME082S7GEM8MC8TM/T8J6(&?GM45T%Q21<@K=#C1RA4.?3S[,8"^^PND[!6NJ
MM Z-YZVBYHSE';?+OR+]7S6X--R\)6A-H])ZOA[9.D"1MZ,!, >B*G8AW;9(
MC1Z\ 6 @G+Q7W0"5H6&B:>Z>XMVF?$XBY;_VESK*]5_%UVGO?>D'K15,J;UM
MOND-:W^Q:HVE%B6*I3S5*-N(T"'/+5&-"MJ&(]C.&D(PI(5VI?D6Z4WSKCXC
MM6;EZ]D^51.S^"NFK69U^&JHUE-L[+U]/35&U0-<IZ89C*RH*JA0+<U)0#9,
M6/99619&)5E"T-9#-QG87:][[VW5S%6^K-0TZ?YIH_QU7C3\]L*XQ>H=6=8Z
MYM<+'3'5^STZMBZ->C-Q?QTDIS$+#A14F.BGOX!_'YR^X\]D-1=E]Y]FT.'[
M[VS3^O\ ;%DV3RG\VU2Y;T#S-,2VOI6N[*TA=+D)7W-.6>HYJ>+A=!Y:.*)1
M'%_=9,"7%K<%=2[@AS(=-OBR^_+^2SYNW+;N38UFLU9ZSJ%/KE'N-\&D6":$
M%KQU^#-Q5" V9!V-HP>6X^&?&^D" "1]+"5*<PM0=_O Y)\#?^/[YOO_ #6<
MJ_V*M9>!UL\!X#P'@4IQP48$9)218L?'1PA)\A('$-"! @ALK(+-,*?6VP*(
M*.VI;CBU)0A"<J5G&,9SX&-JOO31]YJT[>J/N?4EUH]72ZNS76G[)I=HJ%=0
M.U]<A4]9X*;/@X=(S&?J.?</M_31^TKTQ^O@7C!SM1V!7X"TUN8J][JDFPU-
M52RPA\/:ZY(BO9SEB9K<V [(198[^4>K90CJD+]/5*L^!9\UNC2$4?L "Q[;
MU''2^KX%-KVH!.7ZE"R^N:O]-!#=EV$"?+(D*?7U-DI6@V20,,K#F,I7GW8]
M0GIN[ZWK=.=V-9+=0J_KS$6!./7^=GZW$4A$))MCNQDT];9$L:OMQ$BT2RM@
MI1&&'D.(RE6<*3G(3D/(5VR1$78J\; 6" GXX*7A)^#?BYB%FXB08:,C9:'E
MXY1,?)QAXJVW6"&'%M.MY2M"LI],^!*.N,,8))?4*QAUK+AI+WT&?K#@LYPI
MPU]SVY='"&5GU4YG*&F\_KG"<^!;--N5%V35X6[Z]M%.O]*G@L+KMOI<Q!VJ
MK3,: 8^,G\+/P;YT3( @2 SK>,,.K;9?;6GT2M.<8"Z$H0A.$MH0VC&<YPAM
M"6T8RK.5*]$(QA./<K.<Y_3]<Y\#Z\!X#P/5C_.H_P"?_JSX'(CX'_[I?D#_
M &;NS^TONGP.N7@/ J!,MX*&R[[/I8?9RY]3&5-^S#B<J^HE/ZJ1[?Y<8_7.
M/ _-9_A_[*;K6=^5#7/3EC J'<#/?FP=D;Q;V!/!05ULNLI6 B,:MOD>_.F"
MF2>I67&9E4.6PI<6(.1A3:D-O-^X*+IDO5XOS ?&I(:1E(*%H<EP+\GMRJ4M
M1"68R)_)62*OUMEK75G<H2,EF7MCYTDP2RVH,C*E/,^]C.,Y#23E#KCJ78VG
MO\.O2A^HM@:O [,BOD(K?0[^IQM64MRTQNGCKS(T5^,AD4(NJT^9KCXZ1FC(
MZ/&<1E:5JPHA*',!.\G=Z]0;PUC_ (</9VQ]K.WN_P"^.E.SM;;>*DXNDDG;
M1CM4/SU>I+YA)T"017;B3'(9CR9:(7'%FH(]I"W/J?J&>N+.[-N[EXPVCW/L
M_P"2J-U+M2H<_=N072'+MMUY5]CM\\[XHFQ[-)ZIV;3], DQ]ZK,+I77+L7'
M.0.!"&+5EX99SZS%NY6&EAO=FZ>B>4OG%U%L'=)>SM8P'Q><W[IUF+9;O3[S
M.Q=IVEJV*=V9+1\Q63)5, '>9HEF4-J*9:;&J!Q28QHG"FW$J#]&M<B96U?"
MK"0-7")G9NQ_%.!$0$9$HR8;,RDIR&V''1T:RQE2BS#RG4M--H]5..*PE.,Y
MSC'@:)?%3=:I8?A0^+BH5VV5V;MI>RM"59FLQ4X ?/8GJ#V 7=[Q#DQ A+DB
M,33J?6CI*40XVG[$(93KOL1Z9R'/V^WJ[:_K_P#BF=E#]!;)5M34^R(:,UY7
M;E<:Y90'ZC&UV";@')#7=K@9 "PUNLQ9>(>.9<%5%,QAN1_HK6XE?@0&X=KV
MZ-Z1[UW'%6YH/9,?_A<=([+!L0XM;>;=M[+U&LSA#U?*C2JM(1<E(%8P3&N
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M<L"B+E:[3&R8-U%5@9.,;2.2&!@<9]C&&UH4C]/ ^(O2VF8,JI'0FGM40QU
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MY3NZ=^C_ !OR-+OM?YYSUW\:?872FU(P33]+NV =J\TUN^D05JUTB]"R),'
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M AX;G'<X#5:1*=8V^=<B1N>FIYU_56J ,VM_6#DPK=I12 ()E$2KIM!PJ9)
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MA2'&W$94A:%ISZXSC.<9QX'&CX[O[QGYR_\ S2\K?V(-,>!V;\!X#P'@/ >
M\!X#P'@/ > \!X#P'@/ XT?X?3^Z$Y!_T;>/]I/<?@=E_ > \!X#P'@/ > \
M!X#P'@/ > \!X#P'@/ > \!X'D\\V.RZ0\KV,L-./.K]JE>UMI&5K5[484I7
MM2G.?3&,YSX&-M3[JU'O>N'V_3.R*9L^LQ-FGJ7+S5(L$=808>XU<K 5EJDN
M['/O_B[)7S%8:-!(PV4,O.,.(3G./ L1[K;FEN,V=,L[KH$G%Z6V!#:HVR;
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MP'@/ > \!X'&C_#Z?W0G(/\ HV\?[2>X_ [+^ \!X#P'@/ > \!X#P'@/ >
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MS&UB*^14B-FRFO*B?L%^IEBO E59ZYE1#MC=K9(9#C;@"B<B+0M6,MY]<^!
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M!-K:5/-O,N&/9RRG'JEH+=@YJ  AMB[*TYJDB;U58B7(GNOX_)T)]%AI$S[
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M(.QVHMJ":?LPP,:'3'CI";E;.:@N" 9;6788'"Y>.;(CD*)P%9+]6:XA#9\
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MASQ&QN9#E'H..:&(Z:%ERZ Y-/&:]9:@@ZZU"NXN#Y>66:4XMI$TH)3S>%!
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MU;@2R#SANV0DG8O3VW1-*V@4&+#I#Q\A/2UL-09 QS+:S;%7L+F8YLF,0HK
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MZ)5]XLIM87/)\;B1T!N&,6,STRN710$3;9U.87 DUW,*[^^#1>&7*3A;69O
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MV_+?D_H?L_:?1^X^K_1^SW_L^!-^ \!X#P'@/ > \!X#P'@/ > \!X#P'@/
M> \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X
M#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/ > \!X#P'@/
) > \!X#P/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g63294tx057.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx057.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!9@'4 P$1  (1 0,1 ?_$ 0L  0 !! ,! 0
M       '!08("0$"! ,* 0$  04! 0$             !@$" P4'! @)$
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MBWFL[D'.G[R"F?JR\YWX"R_=7CTY@'GU-X1YD]'XMYK.Y!SI^\@IGZLO.=^
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M81,(F$3"+HL@W=(+M':*+EHY2.@Y:N$B+-W*"I1(JBNBJ4R:J2A#"!BF 2B
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M33IKYHG3)CXZP+!L$-2GM!,F298)E,8V&@$F)VGA4FB.HB;301'4=.KX !Y
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M [C5.>439 _-#3)__(5@(6)DC"'7W0%U!:2A.C7C:++ET\H9[:7&:"KLES&
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M(54Z9E"E4, #TY>V8\-W<290T#85>QUTN<X S'"$>!5H1$>L1'X.6DQ,58+
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M;B XA<954@5SA$PB81<"(  F,(%*4!$QC"!2E*'2)C&'0"@ >4<)I,-:YZP
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M-EURJ+Q2<G'PD9(3,JZ391D4T7?OW2FHE0:MDS**J 4NIU# 4NA2E 3&,(%
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M,V%SM,(F$7BD(Z/EF_=)-DW?MN,%"I.2 <$U2=)%D#]"C=<@^Y4()3E\@Y;
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M9'?9U5XKG6%WSN1XQ9MGT**AS&*0A.T.<YS%(1,A.(3J*',(%(0A0$1$1
M-1Z,Y('- O.[D*:%T+!&)6*+J9"WV69N*?'Z,=(M(&KB<#%%6NQ*CA490$S
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M[-BG]%4.I*IM0S3>M'?1L@=L5CK"27IF(C)3N_=#2+1-R#;B$P%$P>W%N<P
M9PT.(<:*FG]8B8I^C7.1.;&:]K1W!A8N@/<"\2@?CKH);[IL=$6Z1U0K0W=E
M9:"VFW1FX%TJQG(7;J[RT,^1 AEF4K'5J3=Q[M(JA#IF4;.T2'*!@$NI>D!#
M+I<N\\7[&1$5(LF45%7YUP;#<3EF9056*4LB:UQ(9N9DY@FET"TGM;!!P,";
M;53ZWL!#)<K$/S 6K?#FJGG;382/W=L$5 ;E0;!637;[?HW&7CX=!.H(IHJN
MU2*$0*8^A1,4!'HSN=!T=Y=J:"34S]\Z8^6'&#H:1L 7ISUTT.P#.^,X#AN4
M\GMH:'%:NFE_W*>XF7(J)DJ67%U:>V+&B,( FV$5%JZW+"PL,U S6^O.$F6-
M"O*MIR'W5D[)7W;&<J>WUF>2KZ7J5?=,H&+@7&YL.Q=*NC%$%W13D*9+B,&P
M;T;97@.TG'CF%1)_3YB9,!EK*3>+#W>W4GLJFJV;D:85,UGGN9#FS069HU L
MY"-=T=TI.3B9:],C253B%B,(9L"CBS12*[^,. $)(Q[=1PCQ$#IJ>C[*XLW4
MT@?UBL/KZS$#\7@F6&MU0PR48#_2<3RD\:\LO8.3N,0C%@OW.@X)9'=R:4Y]
M8=VMSZY!6]2ARJ4//^BW@/U)@"G=@L#4AF!7"X-SG[,B0=IE6]'^5;UDB9'W
M[N>"O]?^;8?%X;EAKM4,(I21X4LCEBKXVNB^3_<^4B:XE,\XE?MLK7+=<PJU
MGWFW>,_9TVD2<Y!66SO'54O$W%^BXRQ01HQ8B:YW:4FY;MCH@=8FN?U?99%I
MIW^$>=6/_$#GX-.[ILNMXL&PSLNI7*E;=PW*UO%NAMSM_MO"\S<U'6Z/N,Q9
M+78>83>%A'U>-KM5J-I@TB)1^X$HE)2=L979D<B JIJQY"J)O$T7.B(4&0<K
MG33N\(\ZM'XA.D9O<,R\.+!\)CUJ-71OMLE4-@M_N4<=N93<=FROEAWA@K;'
MV'=+<2Y1DRWC-L'DQ"E=1ELL4NQ!1C(("JF<B93@;R]&07/N6\+P.@DU.&RP
MP.F0=$Q)T0A$F&N/478<CYUQ;I(Z+<\SLU2\);58;2X7-IYLC#J.GG2K]>63
M1+F4TB4X;QI#'Q)BV T*=M1 0$!T$H@(#Y0$!UUZ-,Y6]L)CMA*Y3,A?+F@B
M6^#@"8G19'8=-FJ)43.=A-BGCAP[>;*[4.G3M==TZ<K[>5)5=RZ=*&7<N5E5
M(@RBJ[A8XG.8PB8QA$1'4<N;-F,$&.($8V&%NWC4R]8W2-VI&/XP UC6-_O<
MZQC&W6-';V-8WM6C0T6" 7P_-ZV!]XW:/\'%/_N?+O*)_?NY2KO61TD_S#C'
MTN=\-/S>M@?>-VC_  <4_P#N;'E$_OW<I3UD=)/\PXQ]+G_#6,_-SLELQ!;*
MK2$'M%MG#2 ;D[+M ?15%K$>\!K(;KU%D^:@Y:1B*X(/F:YT52<7"HD<Q# )
M1$,J)\XD O=".TKL701GK/6(](8I<3QG$ZFD]#XLZY-J9KVWI>&U+V.NN<1>
M8]H>TZ6N <+0LGE^7K8 %U@#8W:'0%E0  VWIX   <>@ ]#= 98VIJ._?RE<
M6I^DSI+?*879@QF.ZEGYW/TEHC[O3'3PKX_F][ ^\;M'^#BG_P!SY=Y1/[]W
M*5F]8_20=.8,8^ESOAI^;UL#[QNT?X.*?_<^/*)_?NY2J^LCI)_F'&/I<[X:
MNFK[9;:T=XO(4G;RD4]^Z:BR=/JO58* >N68JD7[HNZBF#595J*Z93]F81+Q
M% =-0RQTV9,<'O<2YN@DQ(XEJ<8S;FK,-,*+'\2KJVD$P3+D^?,FLW@;=#[K
MW$7PWM0Z$0+(P5[Y8H\G\FO\7G^!C@UH+3 6E<85"0TP=84PJ7V;1RIA+[-H
MY4PE]FT<J82^S:.5<XT:54$.,&VE<:^8?\. (VZE>QF][2%X.LAICKZNU8IV
MAZQ+SL;,M3/617AN7G>DH,S.FY7?&M<-O542 W%0%A.LD@H8@<.IBIF$-0*.
ME3&Z5VO#:6L9^'',=1+E313',N&Q>&.N=K2U>ET+O:D@&VPD;0LK1_Q?RY8W
M0N*S?SA<.Y-TCBNB!'Y%R!C!H &,  &@  B  'L>;+M5WW,8]7;QK&[MHWK8
MZ8Z^-<]H?^F?_.'^7"0"C+>C<R)V?VGOVYMB:34G"U"N/9%\P@&HOY9T54",
MDDVC83D)T+NBBHH<Q4TDP,<P@4HXA%33HYR=B&?\]85D["IE-)KZZL8UKZAU
MR2VZ=XXO=J[5C@W6770+2L9O#IW5A=S^57;TL&QG(X: U4V^F/2K4&[9Y+0W
M [5?PCE-11&1BW"4B0.T*("14IR' #%Z1$8.X%V#\6.0\0R/TWXO-Q&?0U#<
M7N5TETA[WO#)Q<-W.CW+I=T ,=: ;+"LYN,_],W^</\ +E(",=87S7 1#H"(
MT+KKEQ)<8FTJIM)<>Z)B>$[3PJ)MIJG"WWG#YA:-8T57%>N?)C0:K8&[=TX8
MN'$)8;_NA$2B*#UHHDZ9KJL7AP(LF8ITS"!BB @&=9Z)FQGUA(L('M*<=(C+
M_P"&[!7N$2,XUS8\'D,@P'!&V&U3)O#R?;>O=L'#G=7?C=6+J&U=#F4F]GC%
MZ;3E:G0(-.HSTDC++4BF0R]BBD6&W;<'J3LJY7;<5$Q)H8H!V@" @%\HMB
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M[78F561,(NIR$4(=-4A%4U"F(HDJ0JB:A#@)3$43. D.0Q1T$! 0$, PT("
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M3:MQ1,/;H%."I.%(IBP3-\NC9/8X&-81UM:D.7&U,N4Z4>VI&GM20V+2=0(
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ME;-N1<]Q>75I<:]8%MP=_%E]P]YE+BQA2T,Q:O9%X]@[?1,F5Z(\*(@D0YP
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MPDGB"Z%@.%Y1E='V/Y^S7*KYDC"JN@I6LIITF3%U<9X:_P".ES+6[KW(TFV
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M;+KE43")A%\UDD7*"S5R@@Z;.$SH.&SE(B[=PW5*)%D%T5 ,FJBJF80,4P"
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M:J@(\.HZ=7DSB\UIE.<QP,6KHK -Y $%HMCJ5Y[>D%7<]0Y#=EW3;Y\+@HF
M!>E?6:,(T(!0]V6/.Q5,(_S1< '\[)?E*6&XA4/)$2QMFM:3,/:4<J1I+7$Q
MU6K(OA*H4Z9R%434(8BB9R@9-0A@$#$.0P"4Y# .@@/0(=>3\-8]X:\ L)M4
M,F&ZV^(Q&Q8HN(]M!6^^03)NDSCVD\QDHQBW("35FPGZ_&/Q29MRZ)MVHRB;
MH03( )E.)N$ ZLY1CLH2L2F-:T-9&Q3["_C:)DR]%Q%L=4%Z@$0$#%$0$.H0
MZPT$>H=>CKS3$+8QNV*VUZM'"Y4>1RSZ =KF,=TO!.",DWIS=:CU@HBYBW:P
M?+#H=K_EZ=&4@E\)Z*L*7^KVU933^;)P40\ 1]D[$D0H/P]<75=>D]Z5QP7%
M+J<55^ ?+&<Q%*&TZ?=)/)=,HCU>YTQ!+\GO2J;+-;7-(M(MQ&Q[!@M*QBDL
M_C;*\[48IFZ([>M42A%QKWM'X(E1'@4* $.;4<74+Y?N0054_59BF/\ HTC9
M60=0%;6:;$H!YNS=O7:>G1Y2CB!03W,[D#JKY+PTTV)VT19Y)5TF(&(SL!&4
ME%NBAUMG*C:/;2K<% Z 525$R8](D. "40:5>'MF=M,';<"]L+.)2H+MUVZL
M9,L 3"5AG(E,X9BH)BI.4%2Z)/XIV)#"W=):IJ  @/"<#$+6,+%B<R)B+ J\
M4PD.4P=93 8->D-2CJ&H>4-0RO$L$QM]CF6&((MT6C7"V&V%L% -.V6MVV\;
M(0&W',GOI2*P_LMHM9:W$&VN=1K"5N$Z]L<WW)::VXE)(&ZLI(*F(51<XD*.
M@#DFH<X9BP^G\EIJ@B2-$6M,.J1%=/S!T@8+FNKEXAF;*^"5V(RJ:GIQ,<ZN
M872J:0R2P$2ZMHB T6B%D%=7JEO1^M_S#_,=F_R4YZ?O[FOSK^PWF6B],Y _
MDG+_ .OQ3ZZGJEO1^M_S#_,=F_R48^_N:_.O[#>9/3.0/Y)R_P#K\4^NIZI;
MT?K?\P_S'9O\E./O[FOSK^PWF3TSD#^2<O\ Z_%/KJ>J>]'ZW_,-\QV;_)1C
M[^YK\Z_L-YE7TSD#^2<O_K\4^NIZI[T?K?\ ,-\QV;_)1C[^YK\Z_L-YD],Y
M T_<G+_Z_%/KJ>J>]'ZW_,/\QV;_ "48^_N:_.O[#>94],Y _DG+_P"OQ3ZZ
MGJGO1^M_S#?,=F_R48^_N:_.O[#>9/3.0/Y)R_\ K\4^NIZI[T?K?\P_S'9O
M\E&/O[FOSK^PWF3TSD#^2<O_ *_%/KJH*NSL[-7S;R_W_?+=S<^0VO>V&1J,
M7<3T)&'9/[-!+UV4<JI5:D5UXY.>-<"!0.L)2F !TZ]=;B>9,7QJ4R3BDW>,
M8^(L AMT"U;$YZP^BROBV5,MY>PC"Z'&I,J74ODOJWO<)$W>RH>43YUVZ^WM
M;L=<;(3AFB-KW.U%Q(XES]W=$@DM)LCIT:.6*81,(F$3")A$PB81,J-(XU11
M!LQMA7MW^8/G,I%F6DVD>O5^3JP,I&%=(M):(L-.>WRUUB98*.FKYBJO$S\.
MW< BZ0<-5NSX%DE$S&*/:.BGYI5^.]LJ2]+/_P )Y+/_ )IC_P#WU&IZD?#S
MVRG;-!VZQ[G[\S$[$2%VE%7 ;EO8=L[?7M8SJ3791L RBV-7.S=',9OZ*(ST
M*82'XR"!0ZTOF10!O)RO;$[0P4U#DM]^]>66TNX.[4/+6%HTGZC$4W9VR[6V
M&]IHTBNLJ]6TE)E)O&-G$>FS%I-%6=G>I+'76,<BLS;C:CE!J"^QZ\CS57>?
MLVTFX[6:?/&%RC*S4 O3%NBV<)3T(\: ]94Y=QMVO#JMV;A=J!DW3=<R8%5,
MB15&[;5^')N/;MQ%$^8]9A==R+4:2M)*CN8"TBZG[7?(.:8Q<3&)Q<BDFV<S
MAF;=Q&M" E(MEVBDBFX,@P71(HJW&VOY07#MQ-T#FHMZ4G<&E8K$?+7&1EMT
M]J"1]>JFXL6@C(5^-BU04DZ_7Z-+O$92PI*,VPM040< L4BJ!%E9M'X?7+9*
M0KF9B-SMQ=V8]PO'PDO*O[\M/5V2L%&A)>F2)FZ1R.T%DV4L[6<(IBNZ)&NV
MR2;90J20D$BFS;CD5VLVKW/A-UZI9;\WF8*3N$T,6I)001,Y)7J$8Q-F<6<[
M:N-I6?4D'+$'XJ.')E^^FU[3LBE2 -(XU5O=!1_LG^D1SU_]=.VWXC*1G,L2
M^W*GC'8"^D<__P#Q7T<?\AQ'_P#FJU939@7'4PB81,(F$3")A$PB81:]?%2_
M0:W7^?\ M3^-"JY(\L?Q!*]Y[2TF8?LEWOQV5M=^Q7[7_J=DRU]5:I:T_$N^
MN;D%_;;VX^DECS([[.JO%<ZPGYW(\8LVS^Z-\</Q1SDHT*;+KE43")A$PBY
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MK93<:I@P&0+TS6"KT/L]7!C^Q3E[2E,\(CZR#.N57QG&GM5%8DXA6U&Q3?\
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M;O&KHT5.QX'"+F44P54;E5$HJLWK<1*62B'0E#MFQQ !TXR"10"G"TQ5[9A
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M4-0Z0'01#4!Z.@1#(&I(N<(F$3")A$PB81,(F$3"+C0.GV0T]CX7E#*05P?
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M,(F$3")A$PB81,(F$3")A$PB81,(F$3"+7AXJ*Z8\EUTA2B!Y2V7_9JK5YD
MB*\G.R6YE<6:1[5,/;*+*HM%3Z  B!2"/DR1Y1[;'6EUI#;.1:7,0_X?=]R2
M#UUMK[JMZ![CPAWCT1W7@U#3MNY=CP\75IQ]&N3+7%:E1+S(;"4_F:V7O.RU
MW,Y;0]QC"HM9EAPA*UF?8.$I&NVB'4,)>SDX"9:HN4NDH'X!((\)C9=+?<=>
MTC6-HUA6N;>;#6M?>V',[9-CY"(Y>N>E1OMSN;$E3@J5OJ_*=MLMS!Q#( ;1
M4]%W)4A(NJWMTT(09&(DU&ZO>.(Z8CQ<(1+&\!>R::_#@7RW]TT"):.+4MG0
M8@2!(K+'-T.T#CBM@#-1.0:HOHY5&08N"%4;O6"R;UFX3, &*H@Z:F5;K)F*
M.H&*80$,BLSXIUV9%KN$+>M<UXO,((X"%Z.[N/E"WS,_R.8][+&DA70*=W<?
M*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%O
MF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_
MD<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;
MV7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7WP2"=W<?*%OF1_D<;V7W
MP2"H=GEF58KLM.S35RM&1[83.VR33O"SXKA1-FE'MVZHII.%Y!=P5 I#F*01
M4#B$"ZCF&IJ9$JEFOJ(&GN:>'G661)G39[&RG $F$(K%NNQ;^-A6+%VV,W4;
M%<$39E4.Z"/9F>.%8Z,[V)0%T,5'G2;"IU'[+4-0$!SC+I]/,>7R(B428 Z=
M*Z&)4R6 Q]KP!$]15OL5?E2G^8;^3+=XS:ETIV*ORI3_ ##?R8WC-J72G8J_
M*E/\PW\F-XS:ETIV*ORI3_,-_)C>,VI=*=BK\J4_S#?R8WC-J72G8J_*E/\
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M0CWT_$4^AWB'?DXQ>;WM/\GSI<G=_/Z_P4]4.0CWT_$4^AWB'?DXQ>;WM/\
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&O4F$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g63294tx058.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx058.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!C0&0 P$1  (1 0,1 ?_$ .D  0 " P$! 0$!
M       &!P$%" 0" PD* 0$  04! 0               @$#!08'! @0  $$
M 0($ @4%"0D+"0,("P,! @0%!@ 1(1(3!S$402(5" GP46%Q%H&1H=$R(U,7
MM['2DR34ECAX.4)2DC/3E%9V5W<8P>'Q5"5UU9<H<B<W8J/$-2:&&2F"LL)#
M@S1D196'IQ$  0,"! (#"0P(!00" P$  0 " Q$$(3$2!4$347$&88&1P2(R
M4Q05\*&QT>%RDB,S-38'0J+")#1D="7Q4J-E)F*"0Q:R"&-$5(/_V@ , P$
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M]1\.:&;9\;];7=ZQZ+^+//5W:H_D9/+OMU8JR7JQWBU7<->K<?NBY^:/&O&
M3>P4SUGX%UAKFPR"VU-51-$31$T1-$31$T1-$31$T1-$31%G46D.KIQIFCO(
MIJPKDL:-<UPJTU"J6EN#A0IJ2HFB)HB:(FB)HB:(FB)HB:(LZB7-:*DX*K07
M8-Q7R[P<J[(UJ*]SE5$:QK4YE<YR[(UJ(GBO#57.#(Q*XTC.1X%7&$5Y?_D&
M8XKG[NSF?L"SPQV.Y'91+*R+*GDKL:JL>M@Y1706!4;;J=-*R:^O!U5<,,)S
MY4H:E06SFM5,'NF[6MJ *M<XMJ.*SVVV,TS75;1H/'Q>X+F*UO<US'VK%NY3
MLE%:4LA^31<;I*D1,9Z"R8H:>MA6D;JP*FXC.98G@+)=927(HWL$[UM<^O-_
M?/)H:RH!K@%LUO:,A())QPS]\_&MOBC[C%J<-@E:)V*K9R 38T/')P;\M8Y%
M=&RCR[CGM2Q125Z#(I&/D-A;$5V_-K&SSRW-)7FA;D"LD]L,+QRW"ASHM+<+
MDAR9%:Y1=Y+"C6>%S,IQC%J^<D&-2'J$<!(D]\8 K"7;0_/1I9F]10\_,U6N
M8-->?7)T*X'-</)H5?,-[TB0AFD DRFQ(3I!H[O5.=0-8^0-O,I%!(>BN&O@
MJ+XKJ_4*QI=T%1,TNVR2RF0*BRD4M+33'Q+"WAC ^SL[D+$23 K?/19,2/"K
M'<C))G#(0I-QL1O*Y^H'-4R6F)=WN-6A:*=;AM"V1Z!V/6^1BBP((66%@"HR
M-T\M2&&,$6G),$9H7(-SAO<JD5$X5B;SYA;O<&1'B30*C@^)ANF N(%*#N*]
MNU<JAII=D&1W!P>YM<WL S*VHQFR82(4U3#]FRY,5),A\L]A.=&_/-5&[=%&
MHCE17+TO8HK&Q:61W,<CG@ -#JG!:;O NKSZ[D/:&><:=/2KXUM3F/934"*K
M6P-0+AB!FFHHFB)HB:(LZFPAOE<0IM/DEAR*IOO-VX^W6-RI-0"(S,*R*3V+
M*,V0KY &%29(IAJ"5&8 UD02- =W,H#.1R;;JJ8'>=N]=C,C164$+*;5?"TG
M$1-(3FN;<,F>U\6L<>R>5(A3A'FPI==>SPID%-$+TA)%FK(*\S_9EGU Q9#W
ME>48Q.([G=NO.[R*6REUM:X%IKX%NT<;96M$)#]1H:94/3WLUTKVF[FQ<V%,
MQZ3+A3LFQF,)EG-KI I-;;Q@R25B6\?HJI(DDDJ,K940K6/ 97<JO9LJ=([.
MWCKRU!EZ.*T[=+-MG=D.RJKA^XJ<5X.X*FVRJBI\Z(J;_7K,Z'$%P%6CBL))
MY#J.P)R6-6PX$5&2%KAF%4_>:@%9898WH5G"O,1AS+:EEUTU\(\;G8,=HLA&
M>K.@-KF.,2,]%85P6IK!]H(XI=N>]Q%6A9+:9WQW(:SS2155L,HCC&<!&% 8
M;2A*B(K"C>U'C(B*JHB.:Y%^[KEMG0O868@2$X?-<NA,!Y\>K,N'@HJ;[!O?
M%^)AE(0+TQ6WN:54BP1N_P#&C5O=9 07F7P>Z.&0]K-_!JJB:^@_RFFDG[%3
M&0'R;YU%R7MC'#'VA>(B#48T5J>^7_2Q^')_O.[U_LJUNNX_=%S\T>-:W%_'
MV_SRNLEUS5OFCJ6U.\X]:QJ2HFB)HB:(FB)HB:(FB)HB:(FB)HBT=SE&.8Z>
M!&O[^HICV;S,KQ6<^/!=+<!J/,HWR"L'RA:NSE543F<B;HO#5A][!:G0::G?
M"K@LY[H:Q6C?$MP \>4$4F*<$J,<;"@DQC#D1SB>B*PH3B<\11N3TM54^G5U
MI81JC\TJ!#P=+\Q@OTU)431%G9?'9=OGVT18T1-$31$T1-$31%E$5>"(JK\R
M<=$6JN[NIQNLDW-Y-#75D/D\Q*-SN1KS/:&.$8A-(8YSG>UC&,:Y[G+LB*NK
M<T\-F-5QYH588)KPZ;?SES=EF4%SF5(?++:X[@ 8PHD>OGS/83\HEGF$:69>
MA84$T-6X3!BCPC/$XJE5Q1^#-<^[1=H9))"RV)%N#A[O"MTVG960Q-?=T,YS
M^55?)K:29:.A8=BE06QHYZODW)V/J:2EM8Z"DQXC"0AO/=RXAB,*D03?+!1O
M%6JJ+K5)KR24M$GG$>\MD?'''1L8\FBL&AJH]!45]/'7JI!!RR)/(,3IDHCU
M-*F$1B-<X\F2]SW/=NNZ^*^*QY0;]9Q*M/RJMONO-S)NB^._#?F_OO#;??CX
M:H[)6'9*#Y\P8*0=H!C?:]7812T*;=5\VRG'' ?2/"Y7>8CWT,Q %8OJN1>=
M?R$U +UV_FE>2P[=5?4CEQL[L/*C20[(M.-6&L:>06,^15K*0S#P^7RK6 *Q
MWYA'.Y43?2JM>LN[BE,*%4XO5G"%S8-9%6;/ER9LLAN1YGOE3)DR;-(0A-S*
MKG.>_P /3JJF':AJZ55%+A<KN 67EF>FEDK+F,0%1B#9\X,*)2'F-D^6MAM%
M"9*60Z#'<K6-1"HB.>KM]DMG[0*?-T,H,U(;+"*NK!5-JHUS$Q^'9EM<DCXT
M<'VDL#OE1I27B2IX)4FVL8;A$<K5(V0C7JX#D>U&+E;.2VBF9)=2&, X=T_(
MO!-'-=Q20PTK3%=A8WG&,9<Z0.ELVDFQ=UEU,X4BNO(H]]FGD5=@.-.\N]?
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MX<AC6=YF:1ST4"H19Y"UTM[Q1[F2HN$2H*<:B0S_ !+NW;=%VSK]RM-<3('
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M5]_32&UF15@RN(./,02%C3H;R_G#5%O$5IXKUW7INY'*KV.UU;9MRBW6"CR
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M6P[+R9]OD=;$B8BO?HK5R;[-X#A9K'MS$H<>LLMEXY55DZLC1D*=MQ+"$4P
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ML8G917YA<_:%TNHE1C6D6<2*&*ZNFU-E,ALZ058O1/&>K7#(O51JL15T/?\
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MI8UQE,J#-="-6XQ'+LX220%9('/O9;4 !C.5R,:]ZKRM7?*;3M,F[WC: ^K
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M:5!.8%QU>HD3GAO.^PR636- )(IU)L^QRLO7/<:!N./%:V*)XP1@EDEF%$$
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M<&J1[!\R_,G4<W==61I__6U/=Q!X#I4Q#$?.?1?F4P8X"29)A1XP1.,:08K
MQQ"8F[B$.1S!,8UO'=7;;?1J98^A<X4IP32UI\G%JKF[S"=*K7&H(5C'K9<B
M+7#RF1!>\QRV4ED&*F+T3NG+M9LHS^0!Y"1H;'JA'*]B(BP:"YP;TFB.TM!<
M<@*^!2B/B%SVZA8^:X%6Q*_*+!T&;6";SV%!>'$615NN+]_Y[(9UL".0$F05
MS4;-5C1(YG!<YN.P7%C#ZPVK@ L/9[U%?2\@@,<<BI"U45$5/!4WX;;<>._#
M9./T<-8%CB]@<<"0LJ]FAQ96M.*^M344T1-$31$T1-$31$T1-$31$T1-$31$
MT187P75ZV_B&=9^ J47V\?S_ !%4[V'_ +2S(?ZF-=^UK7T!^4GX(G_K7+D7
M:S\12*T??)_I9?#H_P!XW?#]E;-;KN/W1<_-'C6"B_CX/G+K!/!/JUS49+:C
MF>M-55$T1-$31$T1-$7XRHT6=&+#FQ8TR&=CA2(LL Y$<XG*BN&8)FO80;MN
M+53E7TIH\B1NAX!%%)KWM\TD*K<Z[=&N24MKB"45)>U+Y$,SY48T>#8T4T*C
M-!ECK&C<=\.8@I0.9/RQ*SG&USG:P&Y;#;WK:AM.K!9&TW:6V=I<XFJJG*Z>
M3@\RI!F%O4V]%<"*Z/<S*.+4P:N]@/$45?)(:7,A#\Z%Q"17G<(G,%S6J[FV
MUI&Y[1/ML8$0/+<:'O8K;;*>/>(I()7M;:M =(TG%[:X!IX&N>:@&1]Z^U.)
M9WBO:_)L_P <I^X6<":7$L5GV#4M+D15*V.^*U>9K62B"<T'.YO7(CD:B[:P
MK2&,,=*//3UK>=G_ "Z[<=H-AW+MSV7VB5W9JRC:)Y&M\D-U- <>@ D$]Q>W
M">Z_;7N//R:LP'.L9S&QPNR=599 H;*//E8_8-<0:Q; 3'+R*I O:CDYQJ]C
MF\VZ;:CB#50[1=B>VG9,Q7G:/:[FRVB^LV2V4D@(%P[51^FH%0T8TX+;9+35
M185C=F#'BVU?6%D0L@Y6ML*PM8CIT&1&E?XP2QY0E=LG!S7.&N['*W4[6>6.
M^YD%0^JUFXA;,WE7%-'<P76U%,E6-'2V$X7EYL^FJITP*-Z:"F2X0#R1HS9.
M1&E([U?[GPUV:T>^2UCDD^T<P$]=,5S:Y8V.YDC9BQKR!U K:+KTJVUH(JGS
MIZ4]&BHYH&2RFI- )H504X]"@W<ZWL*/M_DUG53G5T^-""T$T;FCDQF2)L:-
M(? <1',)9* [_+LVW<;EVXZPV[W1MK24.P)C=3IR.2].VPF>Y:'BK=8^%<]O
MFT6*QX%1S&")H%;"BAAS[2600';ED%#"!+D+U#GW<4B(CSEVYN9=EY:R*YOV
M:&$:NG]+PKHP<&1\H4#%*^TD:_NLI=FL6+$KL;)1S*2TY+VJN3V<ALIDFKA&
MB5W4-16M&<QEEC*1'LYT&J.7BW=.REC<V (E+:D\5K>];A;F,LB#N8WX1@:*
M6]XU:@<#1Q&(QV;,:X/.U"&+]GKM8[F#5>H9L8OKO7BC4<F^R:]7;%TDEB&D
MCO8+P=F"^2YUS#R#6G2H)KF[70NC:(ZZAG5;F\^61^CP7GFRX]?$E3YI.A$A
M1RRI)E15Z81#<1RHQ/6(]R)LUJ<7JJ(G%=1>USRUK?.+@I,D9'5[\J*?8/VW
MJ)=,2YSC&ZRQO<E.&S=#N(H; F/U@F-93T;.NU[ NC ;U)#1^JZ4=Z+NC4VZ
MGL6R#U+F7 ;YM<0M&W3<BZ?5!70#[W2KF& 480PA$.. 0QA"$3&B&(06-&(0
MAM1K6#&-$:UJ(B-39$36?#.6SE,H&]S!8;7S'\QH.KN]*_7C\WA_S)X?0NIR
M<Z6<.A(TCI5NK(CJDJ5$8^=XC+R.?AP+<?VCKTDI,@%CRPM&V+%BS):LF'CC
M@$\K"EL*_E(O*QV_H7:,FXV3;F2WN2.8W.F R"]IMKJ6".Y@%(795'=I\*IJ
MWG]@[:RDS]K-)4J0\]C?8G&S.#5RRE<Y2K)M*$8X$U9:\'D:A&O7CS>G6LS7
M/9SG%LK2Z0G,GY%FH[;?1"'1T$8'1\JFF*X9V9OH);#'J"AOQ,*^+,-;,E75
MG$E-:U[H]B/(7R;"))1CVJWJ,&Y6JBINB[ZR%I:[5(ZMJU@J,>I8ZXGW$$,F
M<:@UPP6LROW?\#O8JOA0[BH=%')E@J*G(+&NQV?/2.1(+K"K>X\(#!G:U4*%
MHW,XJG'CJSN79C;I/*!<'D<'47NLMXW%CA#Y)C)QJW'O*D)4UMAB<RCGDD@R
M5,8E D1[2)(CG-85M:UDN7'.@UBV(A31(1'@*5-G(3==M]<RFMGVM]RG_8@X
M>'I6XVTC96'F$:J<%U#?2*"Y[73I>0GB1Z*TPQLR9,M3"<"(.;4C)&FR)+QJ
MU#19QV$85NR]5$5GK:ZU=RPR;(X$CF:5SJ*UN6;F)17/"G3T*B,?DR9E#22Y
MC"CER*FN-*:<;A&22^()3J0;VM>U[R[NXHBKOOKCYK4USJNAK;ZHB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(L+X+J];?Q#.L_ 5*+[>/Y_B*IWL/_ &EF0_U,
M:[]K6OH#\I/P1/\ UKER+M9^(I%:/OD_TLOAT?[QN^'[*V:W7<?NBY^:/&L%
M%_'P?.76">"?5KFHR6U',]::JJ)HB:(FB)JB+6W5F.DIK:Z-'E2PU%;-M#QH
M0T+,."#'))(.,)SFH0SV#5&ING%?FW5+-U.+2$RN%:<%<9$Z2Z%LW(FE?D4
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MR.:Y>;6V;[?;E!&RVM&N8'BA/17"M%JVV6UC(99IB"QH)#>GN55C]L\#NL0
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MS58=?F?M;M]&KRYE<8/E7;^-B-OETFV@PR6%E7U!8BV P!=)*.TI\FZ1(;9
M7H]3O1%17>JO2X-UL]PVPRL>1)&=)J"#4 'CPQS6DR6M];7O*E8WRJD4((H>
MK(X9*.]F.>GS%16)Y%,7+,>?/;7=,A8^09(6PE7$\LX[WO$/(**L*P36<J&E
M 5^[G]%$3&=E[A[]RN6R.^KT"E3QU+W;S;O%G"0!4.(-*='P+J(4R#(*6.&5
M D2 KT9,04N-(,%=E1XS@81Y&M;NJ*CD^C6\M='(=/DOKP)%"M<=%-&W7Y3>
MZ!5<^=QX.'1,C!34_;;"K/)F0XUU<R[:*:OK*^O/)D @!F J&#/8SK4P"HT+
MF=-!,5Y>9$8W6G[_ +E86+@UENWFU%:"M,>E9C:[7<+L'G3NY5",UN*OOO#D
M^>#983E40E)+6MMBTPZZ_K13&1 2S-KW@FQ;"8&.*2WF:V*A!NW9R\R;:NVO
M:ZS:?KBX=325;N>S4SL(:4ZP%&IO?JTO,QR##L"HH9:RGK*>:G<&X=-)3F);
MQF25CU]2$<0\TR(5O27S#!NY'[JB-V=XK[MA(7.%KBVN%13#AFO39=GJ,'/\
MD\:&N2@-Y2Y#:6Y+6QE,RR=94LNK?,NY+8,2BF'ZX8]E$I(,5\:7$KX<P_EH
M;7L1DQS2D<]R<S-7DW>ZO+DRW?FEM.E;#ZA!! UEJ?*#JG#/N5^'N+R99:4S
M:J;AL,X[;)25L:NIJ@(TD3A3RPVLJY[W;*&"D-!-D&-U&N"-O/P7E1?$Y[GR
M%X<0!DO28VO8!(!4+:45=E6'3ZJUQF;52K@U=;0LML+5TP(+V;9-8<%I)B@9
M(=8^S+-7% TBC*HT02D1CG;Y>PWJYM'U)JW25XKS;[>ZB;&YOD![2:= .([X
MP7.GO0]G>^W>_MOGF,X=W4B81FE[=8I,K,RA/GT!+&@HHQ R\=M4I.4].(CW
MH]I(SR=5R*A%Y'*U,7<3NW"9SKQVEAIEC\&*[7^0O;?L=^5W;IO:3MAM[=W[
M-LRLWMUM::>< [R21G0_"K#[3X'W:B]KL+['G+3=SI>*.KXN==XK])L6P]K%
M*.QOZB7U'NG7:VAGL89X'H;R3D0R.>C=;;M<5]N5K[,MQ&;0"FIS@T]\'%<Z
M_,7M#L.]_F7O/:>TMAMFV3!TT%K&*QZ#D!3R6X '3TU74V%=O+I]S%R#/)>/
MDE8[*D/K,:QM\F=5P[%G2%'O;2PE-CE?/ )5?&C/CL;%0W-N]Z(Y,CMG9N.W
M<[UPL#FG#$'+J7+=RWZ>\E8VT8]L+F ^4"QNDCI.%**/Y-VPB8^*5.L\V@5'
M;1;3VI?Q;BO.MC'ARK5MG*J8=Q#EC67!N)DA0.4PE,P!7(CB;NVI=;#8Q77K
MKS]4ZF6.6'!>NWWF>YBY=N6OD&%0:C#/'*H\2M:P[;=O;FN"R)C]56-)Y:;
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MZVKZ%5$7C].O,:9#)2Z\U [G"(I93;[' P*W*8]E[7CS)4<LJ-,DK'E D09
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M*-P"C^6Y-8QL?F0;[&/+RYJQJQ+,L<60X<TMA.C5LBP/(89#5\4<*:4S?.L
M-CF\KG_/&@K7BJZG-RK5676PV5]= @#,>4.%"BQ!S)+FN/*''CB",[U8JC<X
MK6<RJU5:NZ;+JXO,O!<9'6X^Z(LWSII$TKV0(%9!D65E,*!K"%\O$BC(YK -
M>Q7%)R!9S)S.3?43FKS!A7BH91X#72X$FPR:I6)=75A-N"Q(D^:#[.K--N.M
MJY$&P<V*K ,:^2X"M0T@A%7ALFJ*N>:]>2X-#D5[C8O'6FO:Z &)4&JIQZ09
M61GA6,"P6$X8YXXC1*X/F$>C2;<W,SF162KK:P>7B#@MQ5WMFZX?39%7PJB9
M+BOL*5(4TTV-+CC<B3(!#DCQA^UJ\;1D>T>['C,KF)LQ5TXUX*R^,GZP>:I9
MJ:BFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+'R_ NIP_P 1'\[]DJ4?
MVS/G#QJGNPG]I9E']3.J_:TNOHC\J_P7+_6N7(NU?XBEZEM?B)1Y<[O][A5;
M#*(#[/-^]E?(.92(T=;*[=01VS6])%>I)%;U1M1/'FV7@NLMVP>YG9>ZT] \
M:\&RM![06M>DK=91CSIY(=_3L4.34(VCJ>4PQ@E0EF1CSJR0TXS &.;%"X3'
M-:QS'.39S6[Z^7'$O(<[-=P8P1M+65TGNK8T>0)<%L84FOD4MM6&&DNGFGB2
M908TH?5ARQF@E+&/$D#\'M7E81KV<51-5+B34YJ3HV"+4,U(51."[<4\%].W
M!53?Q1%5$W^?;4:DBG%>9I-2MOV^R@.(6A,7NY8(F+W,F1.Q>PE%9'C5-K(>
M27;8W+DF5!1@S2<TF YZHWF<4/CT]^@]G-R8V/U:=WE 8+7=ZVYC@+B(?6$T
M*Z)W14W3;9W%NR^JK7-YVJU=UYFJSBB\45-;JQO,9S&GR:+59&.8ZA6-1454
MW=[N1%P+')S8HA6>0RZ^42+5)*&!T2M09A2K^P>\4ED>O@.3U%>Q6R#\H4WY
ME5,-N^XQ[=9&!Y!)&2RNU6LM_>";( XX8=2HKM_ @UF%8U&KHJ1(Y:F+/(-6
MC0A)EB-LV;(.\;!H0QI1GNWV1$141$1$1$Y2Z1LKC*W!KC5;[(W3(6YT4PU%
M031$T1-$6-D^7[GU+JE I:W*#7RSJ&W3, QO:=:VICT]Y":A%GUM?$FDE,N:
MMHQE\R.,DTCI4?;G>)G.QV[534  #49J]74VAR7+7O$47OAY#W?[$6_NZYCC
ME1V?BSH\ON?%F2*Q&6<0ED \B1,25$D2K>LDX\]S(PHKFO8?BJ[[+JZ'5J3F
M13W#BOH+\IM]_(#9_P O.U4'YE6EQ/V]EMV#;9&R2AL1((J&,<(R:FIU@X"G
M%=F,I*0-O-O(])41KFP"R-,N 5T,5O+AB7^+Q)EFP+9LJ.#9.1CR.1NR>E-1
M#CD":+Y^EW*1UC'V;COKZXV^"DO+DD?RPYY--+*Z>&(I1;/ZD^O;Z_%?F1-#
MTJRY[Y)'R8![P :  >3E@,$WV\>"[[<?'?ZEU$$UQR5&<QCP]OG U&'0LM:K
MEV1%55>UBJU%7BY=E3=$7CQU<^KZ/?7G=;!S&1FNB.7F@ D>7T]T=S)0G#.:
M<R[OY12&L+&ZLZU4(]%9 JZ"SFP*RI$%C48!8@^9Y-E<I"%<Y7+P1+961N'.
M>-;_ #B:GK.?OJ:ZDW)>)OFIJJDL:("1DFR<>'H75" IM<XE:RX.D6GMY#A#
M.T%58R%CG5BBD>7A2"]!["[BZ9D:K7<R<NSM15U5]CC\[J\;H*J'5T%PQU/4
M.@7BS9E;!@QRQV$*RXJY+S6LAXANW%Y541RJC51B(JZ5*K2W6[H:W)G9+<7>
M4MJN8%?$I\?)4%,L189"FEVI6PY"/DQB3#LCH[K/>Y.14:O+MN5#IKY'FJ<[
M\R<>/%?P[>'S)OJH5MY(R1$VT<,%:>2Z@.55"+$A)^=X[6O161J&KL\D7KO<
MT<N3/1]-$?7B8W\\>LYR==SW(T;)3=FJKD5*!>H86Y[JG&IKS)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HBQ\OP+J</\1'\[]DJ4?VS/G#QJGNPG]I9E
M']3.J_:TNOHC\J_P7+_6N7(^U?XBEZE)O?Z_I*?#Z_U_[V?LTCZRG;+\+774
M/&O#L?W_ &W65NKG)*VA)7BG,L#GLEDNBQJNNE6<E00@A/.DD#&8YXH\09V<
M[]E3=VR(J\-?+HR7<%'<>(ZSS"^O@P[8E9(I:^!"G6];+J"1#0YA72:JLB3V
M@+*K9/42820H6JTJ\B.7=&H52:LTJP]]TU5@TOUYTX+SEND]:_(\>/* 6-*C
M@E1S-49H\D(Y$<K%3BTH3->,C/H5-4>).;S8WEO<56ACJA^5%).VN3DQF9&P
M.U#-+6V]I)9AEN^P=.C0QI7CEMQ:6R45UA#<%8IG1%W*%S50:.:J;:Z%V;WN
M.5HLYG?7' =WW46I[QM^AKKEGFM%2**X\FR.LQ.DF7MN1S8T9$'' '9\NRL#
M;LA54 *+SFG3CJC!HB+MQ5=FHJIMEY=6MG%KD?Y5%KUG!<7<NAK<*KE"UQ^1
MF,:_-F$EWM'+I%;+M@U70CCKH=6T#(&.1)'3,Z17Q AY"O?NXY"$(WE1S=N0
M;A>S;A)KEP%<ET:WACMH>5$*'IXJ6,:T;!C8U&,&,8V-;P:U@V-8UK4X[(C6
M\->.@& R5P5 Q-2OK1531$T1-$3Y>&HZE&KNA0>7+L\CL)%32R#U--7R)$*]
MR 702=,E!1O5J*!"M*@W!4W+(FJS8;D48D5[7*VA7J(TQA_2I; @Q:N#"K8(
MD!"@10Q(H4<]_3 !B#$U2$<\A'(C>+G*KG+Q557==*5%589-,-186@$<6@T/
M37Q+UZD!118^Y,(9=R"64$^7I#30Y TX#@M9=2&1::WDDFK6M!632K9-'UG0
M%9'(Y); HCE*\"INUJ)ZSMDT.2O0?:=Y0?'\4L)%)3RI.29O2S)=7%+:5Z7S
M)RMEN8TO,,]G#G2(B,.KB=,;VM5'\CT5&HB0..'2KDDY8ZE <5^UI@<N2D"5
M79;DJ6]3+C2JV1=V4FT@ 1AF.E*2OBK 220[$1/SG.-$39&M15U'DCI*CSST
M!>G 'NA4[L9G.<R\QV1+#9L,/HR)XY=A/D1+Y$XLDBO&*Z0X@EZ+2JYB(WE1
M-2IP4GNY@ R4[WWXZF,EYM.GR5G5431%A?!>.W!>*^"</3X<-4.2JWS@H/FM
MU!C5EC1-5L^^MZR5#KZ2.R1)D%6>C(+9)VQ1D6-$'YE7=4O38[E79W!=15]3
M*(!8D2'#4G7\I$C1>LJ;*98X! 4VWH4O2WTT]U>4@])7[*FZZKI5QKM(HB<-
M5 HJ.=J3?;1V2H&ZC10O*3-J;/%<B>\70C63L<F *Y@D0&5.BQQS %>K1M+$
MF10N?SJC7BYT14<WC%>@&C-'2IDCO'96N3T*U=T5/G1?!S7>*+Z475:JWR^Z
MOO4E;31$T1-$31$T1-$31$T1-$31$T1-$31$T1/'9$\5X)J0'DDJE<:*%$SV
MB<\@:\-W<R1R#1F@J:2PE>9=%>0,XT*4\0:^7$@'"]AB(9$:1JL1'.V180/K
M=QM_Z_V2O3'$.9&ZOZ0\:KGW;)5K.^)+ELRRKFU*']SNK?"@$*TM@" G=7E"
MZTZ;WQQ3C/W<X8U<T:;)S*NZZ^C/RK_!4O\ 6N7'^UK0.T$A[BF'Q#[.)3^\
M![AEE+(T8X&8=])?KO:)I'B[91NB)'O:].J<ZM$-$154A$1$551%RG;+\+71
MX4'C7@V)I=V@M@.DK<8]56IY[LLR%8X[:;50XL"KB>;:#'JZ0UDV7$<DGE<^
MQERD9YA_*FZA1$VXIKY> P7;"\ E3)>9=]U5=UW7=57=?G7YUTHFL=U$X)JH
M4'$')9^KQU1P<:4I2N/4K3PXCR<ZKR3H0+"/T#*87(>+-!)B27Q)D29 +YB-
M,B3![%C2@/W5CVKZNZHJ*BJFKH+()V75N2)F&HZU=9'!*WE7 ):[ T47QZ9;
MW\J?.RNYL<FL,8O[C'Z699/ ,$>-%Y>>7$@18T1@K51G\N>45KS&:-7L<@G[
M.]-_N-S?1AKW'4K$5E!:RE]L!I/2IG^/?;[R?N)KQJZFB)HB:(G_ $)]*^A/
MK5=5 J:!4."T5S>BJ2PH@H-C;VEBDDD2JJ1"),?&AM$LJ:1\DT6+&A@<=C>H
M0C4<]R-;S+PU!S@TT*N,878BE HFZFSO(UK[*=D'V%;':Z0"EHP#M9BD,YK&
MI?2[%4@3.G#:]$CC%TF%(CU<]S$W45[F0]!6H2?EO;^GKZ]<.^T-3 (=]WD=
M-8ND3WQ&/(:7?R*1T=UD>TG]5"/"%Y4<5"KNC>5$JYI:*GH4C]<W2Q6107M7
MDU6"WJ#/)"-NG(<!(DJ.1J-<Z/)B%_.A.QKVN5.**CD5%5%34&O%%Y'M,1T.
MS6X7AJ8-<D;Y62\-E7LN*VPJ2$< =G"DU[SL:Q[P-F"='ZS&$]1ZB4G-LO#A
MH<E=:>4=;LEJ\0L3VV.5LN4U@IPAFKK$+6D&@+&J.2OE!Z1MRB7J1N9&*KN1
M%VW5$15A7%6I'A[ZBN:D/-]>IU4]!579@.7!RG'<C@TLNZE1:RUK:R+7@Z"O
MO)) "BBO+&/&D&!4DKI!W;%5D=A&<^RNU%>@1NIP4UQ_(861U[)L5"@(-_E;
M"#)&04NKLF#&25731E&(C3@<5-G*U&D:J.;NBZJ"K+XSJX+>(N^JUJK9:6YK
M.JJB)MXN_)3=5^I$W5/!?';5#D@-,55U;>X]49CW!<EK APQ>P9-HA#!65]H
MR",&9&"$;EM#M\JV&Q M:0;"EV'LJJW4:KTN&F/F'(J6U^7XU:R&PX=L!)Q'
M\@ZZ:*35V)%5%5BC@V8(DDK2(U5:K6JBHFI5"LZ"5(N9%\.*?>^M%3Q147@J
M>A=*IH/<6?'55$@C-87PU0J3,U7DO)3295O&FXBZ^QN)92Z&0.$-MO9NLX<6
M)*%[0I7@:(%78+*Y GZBH-S6D?R-57)%70*FBWV(0K.NQRNK[870D04D1(X7
M2&2CBK R"-JPRI DZ)9887(PBL5S%<W='*G'17.7W6^%2?4UXTT1-$31$T1-
M$31$T1-$31$T1-$31$T1-$647;9WS+O][;5=0 +>*B?."Y_AV!>W>3W\&">^
MRNCD26%2HA2?-,I)MM.2=9>>$&K<GMR5-D.Z ^J/J!)L]>?9=0@:?7(W'+4?
M_B5[V$!T9/\ F'C6]["?VE>4;^*^YG4[^/#_ -[*[M5%XHK?#;T>&OHW\J_P
M7+_6.7&^UK@>T$@'0I%[_D:-+]Y;X?0Y0!2!CSSO6=C#,:1C3@[<PR *C7(K
M><)6HYJ^AR(J<4364[9_A6Z[R\.P$#M%;5RJ58/,NVRK\^^_%555W7=?%>.O
ME\9+LSO./6L:JJ)HB:(L?/\ 4O[FJ%5;YP4!L%?C64#OR!<''L@C1:J[D!*-
MH(N0+,#'JK:RCE*-K(YH;O*..)%5%5B%]5&JVE"KZGZ\%5%X*BJGWE5/O;IP
M^?4JA6-)Z$T5$T1-$3?;CJ32 ZIR5""109JG^Y-;CU/&L,N+-FP<BG"KZFJ,
MRTLA#;)'($P9(<:&1C>K"B/(9S"KY-$:KBHB*YZ6)*EPHO3%@PU5DV&14-;6
MMN)UW!94N>, ;/JI(BR'N<1C&@+$ZHS/=TG*J,5W*B*J[-15U<JK38WNP:"2
MO+DUC=P,9MK3&*SV_<AKR2*6M1Z-982"";T>5%(/KCY'\W3:YJE1%8BHJKJ4
MA!8 ,Z*_$0PT>:$?&JKQN'DU#409>$ABWD.SHHDR\982"0P0\AJR3%L@1JIK
M4F0)5A'5L&,%$48>@Q"*JINMA@HW'-7'B*1VHD*=P>Y&$S013/R&!!61'60\
M5D1\-(;QB8Z57S9$@8(P;*$[F:0._.CFN7EV1=KC316S&T?9XKU6.2V/M"75
M8Y0+>2HD"OE%EDM85=7";;CD+7E:4CG&G V KBN S9&<$57KMJIQ"IH'Z>#5
M'*M^6XG/R MS5$R4>03(UK!)AE<@8T2>Z*E?-AS@6MHXL4LU0B.Z5_B>92<_
M+PU&B%L Q#@I-3WUD2>&FR>G!1VLL#I=8D*>ZSK[,3$<Z5#!,6-'5+>N%LXH
M5:K7L]<;G-1R(41Y7FXJ6<O]RJ>AB*S9%W1JJK6N1O!Z>JN_H5/HU3%6R^:M
M*%00H2XSD\)81>I49E:R0V\&0JN2NOW0#3 6\.2FQ1.LVPD"6.17-*[E>-S>
M56NJ%<8U[@"0:J=(B\>'@NR_6GBGW-5&"A*---6"^M5J%;&.2RW=%1R(BHCD
M\=^7?T;[<?1H3@A:XC *N<3KJXUSF<TM;$DRX^;3I,:Y+7@87K'K:UA10WD#
MY@):X8F (1CE:5S4>URHO""];R#;Z1YU,E,K>IK[R&6!9Q6R@$<U[7J]XY4>
M0-R/!,ARV*V1$F1RM1["L>US'(B\?!:T5JH432PO,5-T[Y]KD]&2/%8"[A5#
M#6E?-4A0^5M(-6KY,T<H?25L@8/\;S(]$W14K0JM0<ENZS,,7MW1P0+N"28<
MA@-KS%\I9I)CLZLB,6ME=*8&3'%Q(Q6</1NG'51AFHN8YV(&"]MQ<P::.$\Q
MTA[I,D<.%$AQBS)MA.*Q[Q0HD8+7/>8C!JY=^5K6M57.:G'0E59&\'(JM(F9
M1X&4Y*\U%DZ65JF/1JVC]C+"L+.+75D\UA;L204,22VN(UX2D&5[N1H&)NKF
MHL2I.C):=6#3Q4RAYE"D2H<8]1DU0EG(9&KI=S2$A1)D@C7+' XJ%,Z&>2T;
MNFV0T3WJFS=UX:HHMMFG%KZJ8:N*RFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB_&1)CPHY9<LX(L6.UQ3R))6! (;$17/*0CFL:Q$^==0=FJ:27"BA& O>V+
M=L!YHU0Z^G3J>YF@+$F7PK3:7/F2&R$&>2V/->H!25&-L@36\J*C-UN0?Q,?
MSO$5[*BL8XZQ\!49["*B_$MRGCQ_X-*I5^?=>[*KQW]*Z^BORK_!<O\ 6N7&
MNU?XBEZE*??U_I,?#]_UV[X?LWAZRG;+\*W7>7@V/\0VW65.E\5U\OC)=J=F
M>M-55$T1-$3\2_N:*K<UY942+/BR8,V..5#F +%E1RIS"/'.Q6%&]J_WS5X*
MFSFKQ14794JKRJ]9(.WV15$.;?7UE39'%D@/[8E.LW49X!H$2HEL5HF.AU)F
MS&0G.;U%<;D>_P!97/6VJJV]E1=ME143P7Q39-U1R>AR>E..WSKJ8R5AV97E
M),AB<)A9<4;SD00&/E 8\Q5X]((W$1Y2JG@UJ*JZ*B].B(B(JM15V:KD1SO'
ME15XKMZ=DU0Y*3/.591)=OEUS#*6DC5M9BF57@#GE68Y1I3 UTRI2.6I\L(T
M:9,9.:<;G.Z+HY$=NJJFT5=.1/<7MN\!HI,#(C5]8-UI95EJ.%&)+E#K(UA/
M@O :17P&O6!62IZM8AR#&CBHBHO!SM4[BA;SFJCGE>Y3*V+FR#\QD,6CE1/L
M$4QHD0L=(2""]S8A"PY62'FC\PJJU (Q>BQS=O6+WB:W_2&/'K7FQ3",QKI$
M_(4O:JMMK\4-9P/82-BMAR(R2#OFU$4T>"F3P[<Y40S"O$1BJUR*W9-57GD<
MQSJQX-HI; M+QV01L1R2DIIC"5,^Y9=PS*6-)6%.%$9))3S(JMB3I3YC.9@B
MF4?%RNV<W2M%:=*8\N*]F*89&Q,]V>+)(85O,88,9P 1@54,9)9X];#$!RLZ
M(BS2JBHC6HW9-M]U6H.*@9B\:3DIGJIR5LY+3WU547$!\>ZA.GPXSVS^B,IP
M2&DBL>[FB'C$#(#)>)7,16.:KFO5J\%74 O1:^)5IBMCE5UC>/TH(=U1MDC/
M)L,E*L:8./CANK)J@45JX[DEV\B&4,92/9U(W(Y[DYVHJU4CF5*I';3#);([
M#U)4."4&<VR'96:6Y9(51R$E6GF_.3>?=R*CW*BHY4;RIMM2M%;,Y8=(.2U%
M1)RK%*Y(,K%9,^EJYLR,*1!MAV=LRJ)8RW5CJZO1AIMM#KZ]P1O4I1R4<J^J
MYK%<K-5:#<8G@IC4Y'773C@CMFPIT0(Y$RLMX9:VPBA,]PQ%( Z=,H%<Q44H
MGD&CDY=T75:*7)$?E!:5+*URM[V8_*6GQQC^F3)6CYK.V<U'=<&,BDB0(H;%
M1&K8/8_G7?HL5&J]"*155/!I@&#"20Y94HLV9)F2C39DV:9&-))E23N<\A',
M&UJ(FS6M:B-1$31%M]37G.:SSN3P545$VW1=EV5-E;X<6K\R[ZJKK?-4:O,5
MJ,A=&+-&:/+BRH\ED^L-[.L'MCCD!'#+/ Q);H2AED:K$>BHB[M5KDWU!QHJ
MF4QX#BM;!Q"9$O*^42[),QZE2T+3ULUQY=G!DVD>-$*P]E(D&6='@C$1(SB(
MX[&F<QSU:B:C54]:<IKXJCMMEX^LK6\Z-7E7E:J)ZC=V-79.'#2J@^X+F%O2
MH)W \\^!11:I\<=U,RVD'3'FJ1:^//$LJ8AK (6$-*C="*1%&B;J]Z+S-VYD
MJ%?MS1I4]5KFHG.U6NY6;\-FJY6[OY$7CR([@FIKS+&B)HB:(FB)HB:(FB)H
MB:(OR*>. 13F.$( ,<0YRE&P0&,:KGO,]SD:-K6HJKNJ:(OR@S8=I$!/K90+
M"%)'U8\N&1#QCCW5.<16<'LW3QX:(O3HBSHB;+\RZ(M9<T]?>UTJHMHR2J^:
MQ@Y %<\2J@RC.-XRB<PH3"*-KF/:J.:J;IQU$YJXS)0JWB91BM-9VE?E:V42
MFK9TQD'(:@%@=(\(1)( #M(LB!**7IMZ9#R>NY6KU$]9%WG!_$Q_._9*F/M6
M?/"T/N]*XGQ),J,4;!F?[F..O>P;NHP;B]T7O(QA%1JO:CN".V3F1-_3KZ*_
M*O\ !4O]8Y<>[6&O:*0]Q2SW]?Z3'P_?]=N^'[-X>LIVR_"MUWEX-C_$-MUE
M3I?%=?+XR7:G9GK3551-$31$T1/1XI]6Z;K\^V^R+MHBC>0XS R6/&')5L:P
MKY0;&GMVQ(DN54644XY 949LL)&/&I!-Z@'>H5NZ+Z%2"]"U>,GL,DS##<#S
M2IGUXK$-U)MI<*7';5Y,?'8#"MAQ9-9,?-@09ARH9P2=)Q1C<-55&JBY_LW9
M-W.Z,4OF-*\&[2/MK3FP^>0NBKSM)@]A33Z^JQRBQVQ**.6MNJNHB GUMI7F
M;,K)C#M&IE9'FB8XC$<G58CFNWWX=(O-DLQ8NM8*:\\.FBT2TWF]-SSIJZ0:
M8JDHTG(8F1VN*Y76P:^YKZZKM8YZR5(FUUK737'BDFQCFBQD P4^.YBC=LK5
M<B<=E<O*+ZQFL)3'(/(K@M^AFAN8A/&:O.?<6TEI(\I,2(J>;\I)\HJ\NR2T
M _RRKU/4V0_+OS>K\_#7A.2]$/V@40[?$K"T0FPI!9%JKQDRCSI)#[9N1FC@
M\\VU;+1IV'5S-A(C4$@6-0?J(FH*-QY^&55-W-5J[*BIZ=E39?3Q5/%/N\=7
M%%?/_1HBSX^/'1%'[RE-9D@3*Z9[,NZQTAU?.<#S<8@I3&#F5MC"YQNEUTYK
M6\[6/81KVM<QR.1-4*N1\5IL.S1N1M?$F1'5]H-M@8'*PWLK(*ROF.AOO\<D
MF:QYZY2-V(,FQ@*J*Y%:YKEC12+-8TA34)Q2 LDQGBDQR(JL. C2@>C=^96F
M&Y1JU$:NZHNR;:I10]5<JZMI.49/>3ZS$[EN/UU $\"TLWAA3FSKFQA0)44
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M-+NA3YD9- 0<*X8_ K\155$<O-ZS6.5'_EL5S&JHW;*K5<)55JJBJBJG#AJ
MJHO((P6=54$T1-$6JNJMEY4V=04KX[+.%(AND#1KGA0S-D)TU]4S6.:GJ*J(
MY.&Z:C0JZ'-HHB^+F&,P&6LG(WY:."A)-Y5/J*^O?)A>N286B/'8PX#04W>
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M<BH[Z-T5-1XJUHT2Z>I4Y2X^8-K9UT&W)19)0).&570H%Q4V6-9'?6EY5/\
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MZTGLRVEY)35MBT<^(JQ9[*_R\_RIT89"#85^Z<.;E7=$T^X[56<[I+9I\NA
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M$3'0K(#]G,,SE<CD3=53@L9X(KZR,<C&B4\:"JA:SOCE$VHA@[OB7.][77N
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MP8;/"S$J%LRV@RI46JK@V!UMHLU1RGQA*C)4IIU;YE6N1%Y]GJY.*N\5K5"
M<U+6D:]K7L<Q[')NU['(]CD3Q5KFJK7(GT:5*IH:L/*,;%(4@Q#;MS$(]K&-
MW5$3=[U1J;JJ)Q^?0NH*E4,9<-,?GG):24K,AM:G$ 6T.KA9,:=46-[PF^6(
MD=CVT$1@7J %[= >1L=\AS1L5BJB.?RM=D]N@M[K=(K26O)>,:&A\*\>XOEV
M^#61J?[L5US' .+'CQ HK 1 !C &KN;IA )@1CYN'-RL&GW=U].NP4:  T
M"F"YY+*^4G5D2OVT"M 4P"QJJJLZH154I58U5I+7!PX*IHYND@>-9^Y^[JCQ
MK-79J3'NC%&K&I..KN=2B,(^5^BOAS4>CF*B*Q_,TC%1%8\;O\:Q[53E>QS4
MXHOCX>E=1+6EI:14%3@C;"!HJN6,TJ0]J'2+$RD;VXDD,>-,8$T@>%32.ZGL
M24@&/?\ 9^:1ZI!(B-Z!5Z#O5Z>_.^T>S\F7G6;3I+<>..*W3:;]LT7*G^WU
M8=6"U%9EV/6YUB1)[13T:KG5E@&3660T14:J.B6(HIB+Q1?S:/1-TW7?6G"9
MKAH (E;FLY);RQL$E1I<I']2<>'S^E=OG].VI DFA5MK75\K)81=]O#9?3^+
MCJ5%<T!9T5M?G(&.0$H3L$4)6*PHCB&8)6*K=VE$5A!D1$;P14U4$AP<W A5
M:XM!' J==F)4H,?*<2>H%K\5L89:)S4(TXZW(02;9*X@NH5C8U89'B ]KMG-
M3EV16KKIW9.[-S9/9<&KF5(6F[_;Q03,DCP=(<>CHP5T_+]S6?BU/C;*[.I6
M"D%)'1?HBGC4:S'&8^98W:X\<C8Q)T=GD9Z!:4E99QBMDUME':NW*>+-&UZ<
MNRN7Z5U;W"W9?V[HGM;6E:@4.'=5ZUNY+*1KXSQXXYYKFNFN$LQR8\AT(=S5
M2YE9=0(DILCRLZNG2*Z01C=TD)"E2(KG@>1K5>Q4\5W77'+B-MI/)"X'50AO
M7P71VM?/;LG@(Z7=7%;I=_F^7C^XNO/$U^4JJFJHHE?J@,@P>=OLBVMO2%V_
M1W%+(.!')Z4\]5"3;YW)J)S5]KB8]'!2U-U3P\?R?I^KY]1RP5AP#7 #BH//
MSBOAY"?'HU;;V\V!&C3;E*F.&6ZIA34VBR'1FG=.GO>]/SC(XRO$WBY?1J47
MDW$;N.KQ%7Y(F" SBO,8 X==0,?#DH/[M%O N_B-YO.K3=8"^Y[0 >CQ/CR8
MQQ=UCM/$F1C-9)B2A$9ZXB(CV[?5KZ*_*EY/8J5IR]=<5R+MP-':ML;:Z#:A
MQ^<3CWE;WO>_TQ/AW_ZW]^?V9Q=;MN/W)<+6H_O*#K76">"?5KF0R6VG,]::
MJJ)HB:(FB)HB:(FB)HB:(FB+\9,D,.-)F27*R/#CGER'HU7JP$83SF<C&^LY
M6C&J[)Q74'NT,<__ "M)\ JJM&IP;TFGA5%U7?.*]%GY'C-G1T-@&'84UM"Y
MKL0*N6]6^9RKH#%[&*(#QF>K%.)@WJBNW8Y=:U:=J+2XEY<C>7W:U\06;FV.
M:.+F,=J[WRJ^6.:1C"#<THR,:]A!.0HGL>G,Q["L51D8]%396JJ+OK:8P)@'
M0N:X'+%80QSM=1[*#I]P6'G!%&23**./&CC=(D2#/8( 0B:\A"&*1S1B8-H]
MW*Y41&\=3?&8&.=-0&G357&,.L!F+JKB?J4TZKNROM H2'EV;6E3=5=D)91K
M"%=6\P%SCTP<AOGB, 9JITU<-Z;C=S,5R+QZ[EE9O1DM3J\K&BZ7;MC&T@3B
MFIN%>X.A=/QX<S..VD>!>'9#G9;A<8%E)@[&8&3;5;'&,%J*QCDW*UZLWY51
MSFHO#?74(==_MIBGR+:>[J7.YI!;7H,8J&NKX%^F%84+$Z2?6GGDMK"YE2YU
MW:-%[.\W(DQ&0&-AQQE)[/!$KPC$%$>YS$;OS;\4\^V;;%MEHZW>[6PDDFE/
MC7JOMR-_=MN S2X4 %:U]Y<HQLHQ_& 6&/0;%F5!Q^U^S]$;& ^U95NTD.18
MU\,T>"U4!;Q(<=S)JNY6-<-3;[$US/<(;?;[^5]L>8)#U4^&JW/;(WS68YPY
M9\*^Z_"H5H2?>Y?6UDV\OWP)9A!C. ^G2'7)$CUX;1A4LI1 B7ED$0K1%?\
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MMMCE#2"B63T,-#4PIC03&'?U0#"I'HX:HNN9WNRW5ENFJWBD?;EY\UI( KW
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M?/D--)(/O*JLOQ;/;[L_D-%F+'9;EH9:2:I.WUL;#9UH*'8B?4F;,*K!P;$
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M%>M2Q_>3'TC\P\>SDD]=T96+CBB*KD\.><:6RI&)?[_S#OJUD?\ V_9O\S_
ML7_ZUN5:49X5$)W<#N!;NYX:4V$PD5>D-8R9/>[)NK"3#E+$I8QG+M^:$R1R
MIQZF_AKUQVIN97G0QHCKAB<N'O+)0;!;Q.#WN)<!B*85^%1>LA2H;)SY\U)T
MVSM9]Q+,**.!&9+LB#*=D2$(AAQ0N<Q7.:CG;D>YR\5UKMU.;N=UPX .=3 =
MP46?CI&P1M'D@4"V6O.!1'.U)\OP+JY#_$1_._9*K']LSYP\:J'W>O[2?/\
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M.9_^-B<N+_/)[N^LZ@B:(FB+'R_ NIP_Q$?SOV2I1_;,^</&JA]WK^TGS_\
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MR"\N]T)A=/)5K>.?0I@/)+B]8T.,T\N [9&V%ME$ L*-4&:YS218]>KT/>V
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?CS/LZ\,L.JO>5Z/E<TZM7K'_ %UU4[Z_IAKP+TK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g63294tx073.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx073.jpg
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M P,# P,# P,# P,# __  !$( 6<"Q@,!$0 "$0$#$0'_Q #6  $   8# 0$
M            !08'" D* 0($ PL! 0  !P$! 0             ! @,$!0<(
M!@D*$   !@(! @0"! @*" 0$!@,! @,$!08 !Q$2""$Q$PE!%%%A(A5Q,B,6
M&)A9"H&10B35MM87=QKPH5(SN#EY.K'!8AGA@D-3T?%R-&0EE38W$0 " 0,"
M! ,%! <%!@0$!P   0(1 P0A!3%!$@91$P=A<8$B,I&A% BQP=%"4B,5\&)R
M,Q;A\8*2) E#4R47LF,T57.#P],U5AC_V@ , P$  A$#$0 _ -_C & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & =#' /I\!^C^#Z?+)+C<8]75&*7%OA0BN
M)0V_]RNCM9"JC;]CU]G((@;KAF#@\U,]9?-(T9#$?.DE/J4*4,\GN7>_;&TU
M6;N&-&:_=KJZ<HZ\2>%N5S2*+2[1[F.I(XQTZO3;U:3%-TE<.4XVN,SC_M$.
M\<NW8$^L4 'GX9KG.]=>W,:<HX-C)OM<^"?NXU1<0Q)R\"D;_P!T:8,<?NO3
MT>DG_(^\;BY54XY'CK*UA$BB(A] \9YNY^8#)G*N/MS5O^]6I4_!2_M0\#?W
M0[: \NM1UXY.?)O:Y-,W3S\#*Q*@=64H^O\ N#O=/]/C3X_M'X*7Q)_@?="K
M*QTT[-JBQ1Q!$ 4<0=AC)<H<CXB5L^:1!^"E\?\ >>.9K$]?-OD^C<,*]":X
MN/#X$'ARY%R%)[Z^W&YJ)-U+FO4GRW2!6ERC'4.F!Q$ Z1DR?-1  !OB+@H9
M[C:/57M'<X_-?EBS?.]I'X.O#["C+&FGIJ781,S%3S%&3A9-A+QK@H&;R$6\
M;OV2Y1 !ZDG+915%0.!^ YL'&S,7+M?B<6XKEEKBN'O+=Z,BN79 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M1110PG4544,)U%53F$QU%#F'D3"(B(CXYSO==Z[=ED9%WS+TW5\2Z&2$!@#
M& , 8 P!@#(QIU*NBJ30IU+J^FI<1H#N5OW;].D=03E27J+MR12P4AZL?[K?
MIC]E9Y'<B;[IFBI_B+I!TG$.E4IR\<>W[0]0=[[3S8R\QSVE2^:WRDJ-?<VG
M\"GE6(7&_*UER-@?4FW*7N>FQ]TI<C\TP=AZ+UDN!4Y*%D2%*9Q%2S8ICBV>
M(=0?$2J$$#D$Q1 <[([;[CVWN?;([GMTDXM+J5&G%^#3H_CP,5<MSMNDU0JA
MGH$TU5%(9$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M%8A54CE'X@8AP'._<>\K]J%Z'^7<MJ2_XE4Q+T=.1ZLKD!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , X$ 'SP
M#7:[Z)D\QW.; *8PF3AD:Y!H\FY A&L"P<*%#X!_.'AQ$/I'GXYQ7ZL9$<KO
M?*MQ_P#"BDO9IK0RF,J8W6OKJ6C9K(N!@# & <#Y9+&*E?@GX2?V)$47+U9@
MRM_;P[J#*UTB%L3;<X68\7;;9$U=9Q"_F46/%ZS&453*Z+\Z()\$Y'J ?HSW
MNW6K>9V'>@KUJ.[2R(N,9T3G%)IM?X>'Q*<W)-4\"IM>J%"LM:?S"3:M7N>I
M&CM6*H,[EL&585.-N4E<9>&E(=_)%EV*+!N5AT>BP^8;M04$O2*?6(CZ7&VK
M9+^'<O-6<Z_8VVWU)-M69]<^IZ-:I4>I3ZY/F?-Q"]OB4G)UX]M2C:>YVWJ<
M)J)BKA)NX!FS<TV54OWW285522T##6D$F:<P=-99LV4$$U!#Q&@\#M&619PY
M7XPPWD8U-=+CN6E*Y;]W55.FI'KE3B2INQW76FHJ35XUMKJ#F&>T;W-O:OKJ
MYK7*.:13Z%@F$1+KNEY28.W4DD6/ E!<0,) ,)4SF,F%CW==VZWV];PMK>+;
MNQR91Z*ZJDVDG5UX4YD+4Y2NN,G4M+S7%U25V2G3K4G6G"OL]A</B,ID!@#
M& =#E Q#E$.>2F#^,!#_ ,\@^B,'=FJJ%)?8T*)\>%#:"T!-JV/2>J9I8W6J
M^U_5S+'YZNI=&+0;JF$?B83I#S]>?0#M+)67VSA9"_>L1^Y4_48>ZDIOWE8,
M]$4Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#CD/I#
M'(!YB ?PY"J  0'R$!_ .1X<0<X P#CJ+_M!_&&0E*,?J:5?$#D/I#^/(\=5
MP!S@# & , UP.])JHT[G=K)J ("O*P[U/P$.I)U7(8Y#!SY^0A_!G$/JK%Q[
M[S>3:5.5?=XF5QG_ -+3G4M?S7A7& >N/;@\D&#,R@I%>/V3,RA0 3)E=NDF
MXJ% W@)DP4Z@^D0ROB6H9&;8Q)I]%^]"VZ<NMTK\/$EG)P74M2\79_:LWK!I
MN.J#RY.K/'7V'HU<@+6VJS939)Y91VFK*T@(B3,^!I$ V!1T+Q!-,B)NH3EX
M$,V5O?I_CXO59PKB>79NQMJ-5U24HM]2C6KU2U]O$A#(:=9+2A1M3MZV@$E'
MQJ$;"NPDX2PV%I*HV2() FC*FJBA9E%9ETNU9MUH-1RGZY%#%'H.!R"<H@(^
M?AV/W#+)CB9;A:M3C.2<J1IT*NK=.-?B5/Q<?8>9MH;8#Y@608HUMZ9VTFI&
M"CD+5!GG+;$5Y1T26FJA#"Z^\)^'1^16,FLD0/F"I&%(#\#EM:[9W>]MBW-3
MM^;)S2C55Z8.CDH\>GQ:5 \J+THB(P^J]DQL?"G?)/&NO]FRM,A0/!66 *A?
MDI603=QL? BX>BQF7\4N03+%.421CD !SZ8^&7>W]L[Q@PC=G<C;Q,I:-2Z5
M<;_=3T4W[%4AYL)_-HOL)MH/;;+6&W-&ED,C7JI(.-@!'M7=FKC.[2;&EMIY
M([^,A156/)LF,S$E;N5FZ0I*=*@I<E 3%OMJ[%R<G<8SNSC&Q%3E&$FE-RC6
MK47K5>*52C._&$NG1HI1"ZCN<]4C7.*3@581N#520$T_'MG,2R=2B4*64F$'
M!TTHV-1DER%6454 Z*9@4.4$QZLP=KL[<MRQH7+4H>5+)JG)JM%*E6WKQ7%E
M2&5%*M%6GL*A6SMWL=2=7.O%(>X6&!G*!"QCJGRT$\B3+W===!HPEXP[E2=0
MEGSD@)-4R   4OJ+ "9R&S*[AV=DXMZZNN%S=87%&'2U*$7/_+C.FBE)4Z4]
M9<JE*65J].9+JG;[L[[PA8U@QK\\YF["YJ*)ZY;J_-LH^ULV+F2<UR<?-'WR
ML/*IL62J@%6,"9P3,!3F$! +"YV?O,)*-FQ9G-NC<;D71\VZ-TH^->!764FJ
M47W$F7/7UDH8PAIT(E=I9(U:5@Y2"FHZ?AY-HU>JQC[Y63C5E6YEX^10.@NF
M(@8BA?B'CF.W?8MSV5K\;*$H2X2BTT_<UH1H21F%(# .IOQ1_!DMS6S->*7_
M ,2(KG[C9H[7FBK'MZTZW7+TJEH%>,8HAP(>LT!<OA]950SOKLF/1VI@QI3^
M1'0PUW_,?O*\YZDIC & , XY#Z0_CR":;HFFP.H.>.0Y^CD.<FHR-&!$0$ X
M$?K^C($#G ..0#S$ _A#%&*/B.0^D/X\@I1;HFJ@YR(& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M=RU#=]&C[I47 ^DM_-I:(<')]Y5^73(4SJ)D4R__ %$A,!DU2AZ:Z0@<G@/
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M&:&]9N]I;79EV[@3<<R<%*4H\4FVNEOX5?O+[%M)IS?%,PQAX  !Y!X!QX>
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M&[9^^YLMWW*77=O2DXP=:0C71)-U5>)E[=J-J/RMNI*&8DG& , 8 P!@# &
M, 8 P#C"]JJO!\ 7']L&_)70.QV4WZJZU-FSH1=XAR\G3<11E  LNW1 0#[T
M@Q.*R1@^T=/K3'P/X>^].N[,GM7?%)37X*^TI1E7I2Y]*JJ/GK74M\BU&4.I
MUJ;(,7(LY:/8R<:Z0?1TBT;OF#UN<%$';1VD1PV<(G*(@=)=!0#%$/ 0'.VL
M/*LYV+;S,=]5BY%23\4S%]/3\J(AER!@# & , 8!KBR/_=9U[_HHR/\ Q9KX
M!L=8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ML!RZ[KYOO>/;M$'2B315=$J364:>F_.DQ]!\S45DR* /2FH!VR/VAX*!)/\
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M>P@TI*CX&<GVZ-MK7#6$EKJ7="M,:V=((QHJFY57J4L996,('5R<Y(MZDNW
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MEFVI2EZDT.P[H*SLLC^_;SD]D-=!)[GUSM)'5$=H5+;$'7$H_4MFV@Y;2,S
MR-R3:MU6['[O*@N],H9 "NS'W%=D2N_^[#2<94],LM@]OU4W18ZAVW;+NECT
MMO+9$#KV#;O=9[;KMTV!%-=16S1.X9$X@[L,4LHVI2*Z!))1=Q\RDV I',^[
M!M6MU[N>LHZRU3>*;V=[I[4XG>&SJ[8;W!5=OVT=Q]#HELMV^:A N:[996Q)
MZ&5M#UY(I$=EC9NLQIY1H\1'EK@%6.Y?W'+SH^%=7HU>UC3]%O\ N,MFDX?N
M;V"CLV?TU3XBB4M122M>Z'%"@UWNNZY;-V,G])86)592O1JL>=^]7$%VS-4#
M*E0IUW:*-3+-('KRC^Q5.NSKY2HS9++5#NY>'9R#D]8L:2:*<_7C+.#"R>E(
M0KIMT*@  ;C ,-/:K3:K[@&_O<MMW=A ?WC-=!=YEI[/M)ZJLDA*A4-1:MUE
MJG5=C1NM2KC9TR0B-C[;L-_>S;JT$#[Y%H#%LU=(M6B1  MIT7[C^^.UGMGN
M]HVS$%WCVY=KON0]TG8?>]_V^\/U=OP.I:+L)_4.W39DR608#&[6:1]LF(BB
M6R:=2K)\R%$TV\.Z(A)+)@7C]R/=J\[<M[=JE[[E]0:_"0@>QWOW[B[U<==W
M^\6&3U:30E2TO<MJT>C1#N-K%9OT-;(:78)-Y2323=_,19O0;M2.#&,!:FCN
MKNGKON&O][6S7NJW5UF?9FV-N:D:JA-Y350UH#P.XG2SV-K>S;ALE5K0J_)T
M!C)&2D;BU:LVTBR66$&S<J)"* 51N_N7;]L$';:_K5GJB/M&LO=,[,.S"=OJ
MD'>"5C8VINXL>W^\FM-6K,ZX2FZC,.X';9X9P=PM*ME&J"C]@J(N6QFX$P0O
M?1(:NV#W0TJ!TOK^&WALKW5=?=D]*?)7B\RM'N^P;AVC:CV\&XMB'F&Q']?;
M5/4$4Y36@H)NW1D'<,W;)+D6?*R!0/L3W.^X9#8-5[?Y#3&H6^\8/W$6G8+N
M5\>YW-'7X)7;M;L_=;J3>6M4$Z\]F'$+9Z!#)$DH"2=%>Q<CZC4CIRF)'N 5
M/U%[NFAV.J=92O=W8HG3.W;_ +O[E>WR+KU*INWMAT^W7/MF[A+)V^V.>K4I
M6J18W%;K]EEHED_;(3JK99LG(>D*JX-U%Q R[X P#6)]OK_G6?O!W^,'M;_U
M/4P#(U[I#I0L)IMCU#Z*\S<79R?R16:1T*BB8?K*F]4 /_U9SK^8&5S^GX4(
MI]#G*K^,3(87"7P,/><TSMQMW)*/-U^Y%X<Y # & 3[*WT):ETJE_FG4(T::
M]D7GYSQ<8+:V6+[P=>N*-@D15,1XBV\DP H!]D#>'&9>6_2R]LP=HC8Q[65"
M;D[[5$XIU:K3C3[R-"H36[4-6UV:=D828%M:W4Q90-864.[!B]^Z+@5DTC6Q
MD7C233/-2;44U5R>F59L G#CRS,=UV>>3=S[]FEB<7T-K23IHE[^&I;<>!!E
M]@T=5N[(G0D2K';JI*'%I H_?CU6*CF+::?&09 K /8Z2:K/4V\4*;991<2'
M 2\F&TN;]LR@W^&Z?;X$SBUJ^! K79:_96Z81E<=PB",DL^E463.&62!!Y*R
M"HO3316P2I7J[9^FW!!90695$"='\D M\O.Q,^=N6-8?3&DNJFFFM-?$C"BE
MJ3A*;<JLX1@A)4,6:5?+*1U060?H3@U^!D&2+5JU&/L#8\4[5B7#)-R@D8OR
MWKNW9A ICD$,I+N?;LRVK=S$E*Y!4JM=":XTUH?.%VC5(AVP>DJ2H/F")4C/
M46M>.XDP"+E& H.!<LQ) HI+OB.2F8=!Q.3T_$I2<4;'<.UPRX^7C./RR3?A
M540M\74H04O20I>0'I*!>0\.>  .?X<\IQK+AU3DZ>%63G; & , 8!F(]KIZ
MH>K[@8F'\DWLE7=IEX'@%'D2]15'GR$3 Q+_ !9T[Z#W;CP,U-:=2?V&/RHN
MNIE7SH0LQ@# & , ^)B> @'/ AXCE.<.JO\ A:%:-27%2,"ON#HGH?<$J](<
MR#:\5>(LB8  E(H]:"M"R)N0\ $QX\AA^LV=M>@-R>\=BSA*3=S"R'":3UA"
M2BX-^QMR2]QRIZMV8[9W6[M.FSD6XS3?.3;37W%D!+RZ7.FW16,99=5)N@4I
MS]1EUU"HHE+R''(JG#P^.;JS-ON8>->RKCDO(LSK7DZ5-9XV?'(R(X,*-WKL
M53QHTG]AM*:TK*=/U]2:H0H$" J\+'*@'AU.6[! KHX\\\F4<B<PB/B(CGS2
MWK-GN.[Y.=-MRNWIR^#;I]U#N79\2&!M>/AP^FW:BONJ3R!0#Q#G,89([8 P
M!@# )'V:[.PUQ?GR9A*HSIEH=)F#GJ!1"$?*$$O'CR!B\AQF%[BN>7L67/PL
M2_03V_K1JJ)?[I+QY_)D\_/\4/,?B(Y\^KMYWK]R7[OF,S*^A'TR4# & <"(
M  B(@  '(B(@  'TB/D&0;2N*U_XCC5+G3Q!5K6^W9?6U=V-&5P[ME,W>.K4
M>QL4>[116@P@IT9AR8$56SD'(2" ^CP'0).>>?AGJNW>Z,C9</*P\-.&1DPZ
M87W6,5+^&KIJN!0:J_B1,V\;4I2'M:?OY:5FI;:,9L>9GI*:<KEGB1<&2(1K
MLVU$2KR3)0Z)3"4R@I"B $ GEQ5L]Y;O8VE;?E2=Z_:NQE._JX:23Z9>_A[B
M?\-%E39SN;9+NY.5@(6Y)3%HV/4=D3J5EN82L3".*F_,_/"T1!JQ:NHIC)@N
M=LHJH<3D8B#?I,0,]'D>HBM=>=ML<UYF/F6KEVS+7'C%R3CY']Z7[GM(+%BB
M-Q?=1!Q,A8W#>MV=9%]L9SM*"D9"2K<I8F,Z]9$04AGCR6AGK0(2.6*4&!TD
MP6;H=:9B& P@%3 ]1\+&S+MJQ#)47)78N3^7K<DY)^Y58_"1YE._TAGA:JK
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M[?UK>*/-PD984K6E0[AK*92G6\S6I^L3,1:J/?I9B^2/'%4(#L56BC5<B:I
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MJ$6QVRE4HX\+5)VV0-\HNP8)G>ZY7S_=K6R1#>+L'W<1%LH\41:M"( >./\
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MJ-Y-N;Z5J]==3<D9SD.Z5!%K*1SE4P'$J+=^R75$I! 3""22YU!*0HAR(!X
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M%02!=ZS9.!(W<+@W$6_K'2XZA3'H$W(@'&>"WW"QL#=;EC#GU8Z2H5ZW']?
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MPE3*!AYX+P'/CYY5>1?D^J=[(E)>,]/B.F'@<BNN*H+F77,X*8#E7%=85RG
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MN)1K^2H-0D8N-O=FTY-:%N6NDX=LI%?-4R3UW-&^27774D6$HD5R=5RGU-A
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M1?;6I]PUZP5M5Q^:5<[<;ZBH.P)F$J2;II&"UCG@?>!I)T@W=) 2^]]I-O\
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M$7KR'/3];1'6#XRZXO2+K H +^F0"Z/ & , UB?;Z_YUG[P=_C![6_\ 4]3
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MFVYVW[A&4HRAD69V'%Q='%N:HW%IIN-5H3^53JXXX\>/I^.5C!GVP!@'43
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M<TS2* "J[CB(N"AR8S=8>1S9O;WJA*5^.#O5MRM\/Q"I&/Q227V4/FMZ]?\
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MSN[AGFM]:[6V6RE^V^+?Q<=-;6BW]%I$^QD(&O+2R9I))%0[V.3*<SE!+H'
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MKY<J:P?^\K0O2@J+@8>=S=@6W=>*.Y2B)CL^K)F,<GW4B5O;&* "(]+R $P
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M4BE^RJBXX_WG&;5])N[MYPKSVS$R+F*XRK:E"3C.J3?R4:;T/FG_ -S;\O\
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M.PVG;T7J"$H6[X^G/-/UO[@J<RGK JSVO&?+/(DK@_2[="5-(0.]^]NOOPW
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M*+VT3W;EH/O0U>QG)+<>W&L<:M(:RE-FTYQKV!4U;79"&I,:G?V+*P6 ;&\
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M'XJC9RF59!4HAX""B:@"''P'.L(],EYJ_?C%_<?E;G8GC9$K%]4OVW.VU_\
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MBZ($1MC8#FE3UHA%*[8Y:88::B64--+W_:+9Q'M%$(A0&;4T?\VNJZ2%$A5
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M'DHUA('8.2/&)GK-N[,R=I_[MTT,NFH+9R3X')P8/@. >_ & , 8 P!@# &
M, 8!K$^WU_SK/W@[_&#VM_ZGJ8!L[8 P!@# & , 8 P!D*^.B Q5/@!D0, 8
M P!@# & =3_B&\OQ1\_+RR#X"K6JXFG%[S1US]_DJ583BBAJ?6Q&7)A$I&YB
M32JI$P'P HNSG$1^GG.?/4WK_P!4U;T\B/Z$??S_ +<BM0_+$G9<?,EO^=U^
M/"%"SVEAP1 /H*3_ ,L\M8584]ITQW(_YDO?^LO.T_=)?7UGB[7")L'#Q@#U
MJLQE&YG49*1DJP<1DM%2#<ATCJ,I)@[424Z#$.4#=13 8 '/3[3D7<"_#)MQ
MA.G%254T^*7M.;_5'M# [[[8R^V-RE.%C(<&IP?3*$K<U.,HR56FG%/G7@U2
MI=-7MGUN*C"P$#K&'BJM(SL18+?#N;-.3+FV*P"BSF(A5Y60)ZT76&CM<RIF
MJ!/45$.#JB&>CAO%JW"F-CQA?E<<I=/!I\(_!Z^TYRW7TLW3+SKN^[SO5R[O
M]G%GC8EZUC6[$<6S<A&W.<O+J[M]PC3S)N*2X):E8&&\;;)V"MVJ>K*5@M=:
M<S[B+FBH/6*BM9GHY^Q2K*C9DT.@I!P*TB8\>H7D6Z8BB')! 0REO=;U^4;=
MZQ*5VFC32HO!K]!KW</2SMO;]KS-EV;=+>/V[F6<>-ZVKMMQ\^S.,I9*;G52
MNI/S4_JG22YGM;[1>M'$++QVN2-[U7*5&4^.M#EU./ACFC.)4A$9EK7/E6[1
M*4.R,?H55,JF4XB8"B)0XK/-E*\VK5R.5&*2EU:=*K33QU983].L7+>3MF3O
M#EV?D[E^,C:MNU!79QN>9&W<ON;4HPT<K<4F^/!H^[+=U@;LF<,VHT&O2F5-
M<4!>'2A5'3QS"N4#FDC+6Q-BI)-GCJ:'[P/Q]E-P4 XX#))[KN$[?1TQ_"*O
MR\'[=?:]2.1Z5[)>RKVX?U/(7=%W._%QO7[\(6U<ZEY4;>/*3C.U&TE;23K*
M.I)J.U92/FJW:1@$%#5S7:^M&I5'3HK1^R5A9B"&34=BAT%>E1F3'%$G)0.0
M"\@ Y0AF2_$V[T(25N%GIZ7Q?'7[3U;]/\.]M>1VV\FZ[&1NUO<IN$+:E&Y&
MY;N-*VIZ69=#I)/I5=>!)=@V=/+:K9ZI<QJ"#5LZ(?\ .!8BZ,T]K:+QQ+QU
M56!4A4SP;"=>JO$^/$5#@'D 997-VS/Z>L)QZ<I77U3\;==(4XU2TJ>DVOL#
M8<COG)[]QLJ%R=^QT2M0_F1C><5;N7X^6Y)7)VEY3T^FKXMDF[TWDIM-BX0?
M0D[&O57$4X IMA3DO5VIXQ@E'&&.I[UD2-8'<-TAX,13\F8QA !Y'+#?]WM[
MA!1A;E"B7&55P/2^D?I#/L'/CFV\K$O6HNXZ+#A&\U-MI?B:^;2->#6M#'U<
M #H<AP'\L?+X]'G^'/&2^AG8_;GTKX%GNQ1$&CL0#DP-W E#Z3 4>G_7GG<N
M71.,J-TN0T_XD;X[=A;N6I0N_P"4[<Z^[HE4W^M'*N5M0:<5= /S"^J*$JY$
M?$1<*52(.MU"/B)O4\_KSK_$:EBQDZJ71#3X'Y1.](VH=^[O;QZ?A(9V4H4\
M/Q,_U4*O95, , 8 P!@# & , 9+5^ &1J_ #(@8 P!@# & , 8 P!@# & ,
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MS>X] DA'MWRC660;*E(\:-E@,F $_P" , 8 P!@# & , 8 P!@# -8GV^O\
MG6?O!W^,'M;_ -3U, V=L 8 P!@'7J#GCD.?A_ISD*OP="--*E*;_O'5&K43
M*7R^5ROK@ B2-7?$<S"O@(@",,Q^:DU>>/ 02X^O/.;IW;V[L<'+<\RQ&7@I
M)OW43>OO)E;D^6A9K;?<NU!$JG2JE5N5Q.0PE*Z.BSK<<IT\B!B*R*R[\2B/
MQ%L'A\,UCNGKOVWB?+A6,B\_:J?HJ5ECR<DGP*&2WNAV]54P06I:XT1$3 4T
MQ9)-^IP \D$2LX^.3\O/[7GGDK_K_GW9=.#M\5;?[TW-4^QEPL.WSDR6?_<W
MV_ZG4-!UOZ75^)U64#]/T>H,KQ_#TY;_ /OKO4=;N+BN/^*Y^TC^#M_Q/[B:
M(GW1+8DJ0)W4M==H\_E#0]EDF2@!X?B$>QT@3R^DP!]>7.)Z]9:N?]1A6G;I
M^XYU^]M4(2PE3Y6VRNE4]RO3DN=-&UUFYTU4Y@ SD&K2QQJ?/'VCK1BZ;X"@
M(CX_+#P 9Z[;O7;MO*FK63CY-N7-I5BO?X(HRQ)Q+R:!N[56T$B*42^5NPJF
M*!S1[9^FA,(@(<_EX9X+>32$OQY2X#Z<V5M?=W;N]T>VYN/-Z5@Y)33?!4;7
MZ&496IQXIE5 'GGQ#P'C_3Q'/2IM\4U^OVE-IKB=LB0& , 8!T4$0(<0X 0*
M80YYXYX^/'CQD&Z*I!]=/Y='<Y5X5]IJG>_#KAY7NX32FVD$E30]ZUY(4MVZ
M],WIISU+FW$DDB=4 Z1,O$V0!( CR((F^@<TAZKX%RWN&/NL%57(=$O!47%<
MZ\#[5?\ :U[NQ]S[![C]/I7(_C-OS?QEN+^J5J^HPN-+A\LXZ4Y/4Q=TM]SZ
M0=7ET^'AX<\9KW&NOH6AWMW+B2C*3U_LRZ"KO@Z2@!_'D.<S]F\XP5$C3&\X
MTZOCQ*_5*1]&3AG JLR"UDV#H#R3;YI@7Y=TBKR^0*1159D7IY6(0!,=/D.!
MYXS+X=[R<JUD432EP?#XTXFF.[=N5_;<F5[\9Y"LSC)8]QVY-3CTZI:2:_=K
MHGJ9 YK:T4:[ZSM+/9#Q"7-=/5ND95[C9)FBQ%35DX=RHO%.)B-CG\0TD2)*
M^K$!\RB@FD0 $..D/;Y.9C/(MY4)1C-UJHZQX^VC^'@<<=L]A;O=[8WW:;FR
MX\L"&%.6'>R<>"S+UYU^6;C)PDXK6-Q)/J?-$7IVYZ^U'9;BX7"TR!9S;%4/
M&N(BTRT7/DIC21M1W#Z/?(@HNM#QB3UN8S+K3*J4_ <" <38^=C1N2N3^>K:
M\-/9["RWOTRWK*P>W8=N8&/YEC8\UW^NQ&5EY$H04(RM]2BKLFII7/JK%/6E
M".SFQX>6J<JS;W.K,IAS>-ER;YM ;$GZ'%+L9K[N^YGC6,9PSTL\T?H('-Z;
M@Y#@?J _B<V5Y7<=XE;?EN59:5I]GB>?V#M#>,'?+%][1GW]K>W85OKGM\,Q
M^9;MTN]+G<2MM2TK#A33@2-);%A7%1I3IY<:NC8JY*:_"$@(V3L4C1'[6%'A
M\^N](<PI&]?7B4B *JK)10SU8QA!,?QLH?BL>:LSN=$;MKI^55<73^)/7WTX
MZGJ-L[-W*'<&YX6)L^Y3V#)QKSNW[EN-K,M7)+2&-<C.CMNBI:GHE2KTH4,[
MC;/7[(YKLC&6IU/S2S67&R1I+++72M0"BLD"K!.M3<_'QTD+>00$RJC0Q52-
M."D*H/D&,WV]AT\RQ)=;3;47HFW6B9MKT$V+?\2QG[9F8:PMJA;B[%V%M8N3
M<:BE2\K;<>I<'))-NKI0LOL+P@@;J-^*' >7 >7\7EGB<K7XG6.RXT^E)UK1
M5_W_ *RW*WO>2N/M#XB;Z/\ 9XS#Y+\I-+70V_V[ARC"NNA;S%U.2VELFAZT
MADE'4M?;M6ZBS02#DYS3LRT8J'\/$"(MU#G,/\DI!'X98X&)/<-RL8\%6<[L
M4E\4_P!1L?N+>\7L;TYWCO+=IQMX>#MF1=U=*M6I*"_XIRBOB?H*0$4T@HR+
MA6/V6<3&M8MFGY DT8($:MR%#P\"(H@'\&=9))+I7&,8I_8?E+O9%S,R[N7=
M_P V[<NW'_\ FW'/[JZ$>P2C & , X$Q2^8@&0E)159:($%F['!5J/6E;#-1
M,'&( (K2$Q(-(UDF !R83.7BR20<!\.>1^&6F3GX>'9>1F7;=FQRE.22?VM$
MRC)O1:%G]X[^^W6H**MV%@E+P^3$Q?1I\4L\9B</(OWL_/'QIB"/\I-10/PY
MKC>/5WM+::J%W\9-.E+'S</C^@JJQ-JI;7/>Z(F G+5-0J'+X]"UCM)$#C]
MG:Q<6Z*4//P!4<\'E?F"Q)?_ ,;@W)?XZK]!<K"C3YI.I3AS[G6V%#F^4UUK
MULGSR4%W-B>&X^("<CUH43__ "\9AO\ WYW>3HL7'K[[G[2;\';\6>IE[GFS
M4S%&0UI1'1.0Y*SD9]B?CGQX%95^7G^#)[?KMOD)UGAXTX^"E<J_=J/P=O\
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M]MH;0J&HZA)76ZR01T/'$Z2)D %'\F^4 ?E8J*: 8#O)%X<O20@> !R8PE*
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M# & :XLC_P!UG7O^BC(_\6:^ ;'6 , 8 P!@# & , 8 P!@# & , 8 P!@#
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MB($0="!@X!0_&\/2CON6T7EL>Z/JVN4J6G_!.;JZ^"<G]A:Y-MSUBM3. 4?
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M3&]+-@L-7LN5Z_D/ZM5&-?%?#V&JNZ?^YWZR;C;=GL_9=AV/7Y;K5W-OM?\
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M$$?,>"A\ S=OH;N][%[CN[5*7_2WK74H_P![Q+7*A\G49TLZT,:, 8 P!@#
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M -)X _3._>-_V,?;A^OMJ_\ I/ 'Z9W[QO\ L8^W#]?;5_\ 2> /TSOWC?\
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M]!14E^).MG4,!0X+/,$P^4*8_( +E%$H?$V;4V+UF[<W=*.?"_BW:I<^EO\
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M " #E]MNY9NTW9W<%MRFJ27)KP?L'2JUIJ3D]W=?'BD 5#\UH:*K,T%DB:U
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M).0:HO6)E#I"=,/F6K@ARASR(&#X^&0NXF7::5R,FVJIT? @Z'D%%8!, HK
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M5XF4Q&J.-=3&AFAY1E&73)-2\'QUX%XTUQ0R! 8 QPX XP#G'.O,'&0H@,4
MQ1 YPDEJN(&1 P!@#P#Q'P /$1^H/$?]6*/H<Z?)%JKY*O"KY5Y$:.E>1G/]
MNS42M)U:_P!@R[0S><V:Z1>,BJIB59O4XH5$(@!Z@ Q/O)THNYX\C)F3'.M_
M1CMM[1VU+=)J2OYUQ3HTT^FM.>M'0Q^5)2?2GHC(AFZBR& , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#J
M8O/T^7&2M4EUK5I QD^X)VXKW"%2W-38\[BRU2.*UM\>U1 SB9JS<QU$Y1(B
M1?47D*_U&$P>(G:&-_\ :*&:']8NQY[KB?Z@VV+65:@HRA&FJ3D^K[Z/W%]B
M32E1^)A7 0$ $! 0'Q*(#R @/D("'@("&<MT<U71..C7M6CT,E=UEIPHB::5
M<+-0K3#VZG/C1UEAG!U8MV1HW?BFLN@JU4+\FZ1<MW *H+F+TF(/GX>.7VSY
M>=MF5^,VGICE-UK<CUQJO[J3:^PITJJ/@R+P#VWSTU<)9E'#8)2P1,ZA9'BX
M(-&K8EG<IB\D7+DRK&.8J+/1 $RJ'33,<W0 "/ 9?6WN63FY6?2,LB[!];C2
M,7<>LJ1=&E6M$TJ(F*I(;+V)&2%K(\HY5Y-Y,N;+*#*EDP!BG"JP=B(R1%=0
MS86L&RC4#M?1$#%;.#B4% 4((91;QOT89">+9I*,:?*M:+7XEKS)49[LG&\>
M#-Y%1TPH48@PO)%S(K+*O8B75EFCMUPL!WCWA0&Q ,H*96Y2@*9OL]-BNY<B
M;Z(XDNI^PGZ)'P#<<X0Z)E8QHZ5+$Q,*LLO(2IG!&41'S\4U/&+BY]:"?$93
MY^%FQBF(LB10H /4 PCW-DVIU\B,IP_=E2GQ3XD.B1Y9W;<]/,7L6NS9MXUU
M%OXLS-%=ZH53YM2OG1E'BB[A0TA.-25U(/FU>5%#K*G'@3 &4<ON++S<>=J[
M;LQMRB_EBJ.O+4FA%J56>F&W198*-B(QHPB54H-O"M6#A8C@SU!K%N#KR3=J
MY*J0S).TE(W3D 3_ -XFV(!>GDW5<6>Y\O'QK%K&A!3A;I+J55Q6A4E"%Q4E
MP/2ONR?<1;:(^ZXUFU3KSNNNRQ:SR,^<:NH1O">N061DU&*I$FI%CD(8R:Z_
M48Y...*EWO'<K]OH\G'@X\^E?-[/A[2D[48?1Q(;;]JO[?$'AUX2*C6QHYE&
ME,Q.[.LF@RE1ED"$,X.8?ET5S&(FF83BFD/'4)N1&3.[DO;EC6\>];MVU!.O
M0J5?BR>"<:U/>CN>:1 W,-$*&#[*8"O) S434AX.$7^\XXCDK.96(U@4SM%'
M!1,R54,9/D.D"TK7<>;8@K5I6W!+]Y5?^XA--O3P/DON2>>,)YA(1[*0&P,G
M[%TX=.Y ZA$WLK.2J*QQ]7U7*D4:>42:D$X)IIID Q3%Y+D\NY;U^S/'OVXJ
M37U1T7V<=">.D=>)1\/+QX#@/B/T!Y\C]0<YYN$)S?2M9OES?N7$FE%I=3^D
MS8]@';BO2(!3<5RCS-[5;F((U2/=I 5Q!51P/6+]5,X=:+^Q])3@'@8C4I '
MQ.8,ZH]'NPULV)_7-R@UFWDIVTVFU&2ZD].'&E'JN:,7DW(R=(F2S[)/,?/^
M'R_ &;XKS9:E,]M[6J6G*3*7FWO!0CF"?IM&B(E%_,2:I3?)1$8B?CUGKM0.
M Y^R0@"<P@4HY@.XNXMN[:VJ>Z;A*D%!N$:.LY)54%IIU<*O15U)K:\QKIX5
M-=?>6];KOJW*V6UN10CFIE4JW5VRJ@Q-;8'$.E%LF8>EP^4( >NZ,'6L;_9(
M!2%XN[O[QW+N[<)Y.7-K"3_EV^4/<9BS:MVX?WRB^>.)ADT(2N35N&LY.B R
MFI2E/R[<+DY=37RPE*C7&M$Z>]Z XQ<D[5SRKL9QN>#C)?J R:2E%5:?V,#(
M*KCU4=/<P<Y-TRZ>JCI[F#C(13FZ1X@YP!@'J8OGL:]9R,:[<1\C'N$G<?(,
MUU6SQB[0/ZB+EJY0,19%9(_B42B&5L>]DXV1#)P[KLY4'6,UQB_AKJJKXBB:
MZ9?29R^S3N^3VZT0UUL)RV:[-C&?,;(F$B"%WCFR?Y5PF0!!-.PLTB@9TD7@
MJI1]4@?CE+UOZ:>H\>X[,-LW=*SNL(M1KKYJBM9554GSHVF_>8V_C.#\R*^4
MR$ 8!\/CQXA_X_Z\W&G557 M.I5Z>937;NL8#;] L- L9#?(3K0Y$'9"E,O%
M2B(E6C)=ISQTN8YX0J@?[10,4? V8+N38L7N79[VR9B_E7H.DOX)+6+7/B5+
M<W;EU(UH]BZ]LNK;G/42V-#-)F =G04/T&*WD&AN3,99@<X%!9A)-P!1(WGP
M/2/V@$ X4W[9\[M_-EM^YQ:O0E)*3UZXIT3TKR,K"^KJ2?%$D9AVFOB5I1<7
M1C!*, 8 P!@# & , 8 P#C()IRZ?W@7,=K';_);]V.TC%D7"%'KJC:5N\J4@
ME2^0*IU(0+580Z1DYLR8D .>4D0.H/D'/O\ T_[/R.[=]LXUU2CLUM]=U\I.
M+TC[? M[^2XQ\M<5^LV.X]BTC63-@P;I,V+%J@R9M$"%30:M&J94&[=%,H !
M$D4DP*4 \@#.W<>U;L6(V+,%"U!=*BJ:):+@8QNKJ^)[<K$!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8!\%D@5*<I@*8AR"0Y#@!B&*("!BF*("4Q3%'@0'P$,I2LPE*4I+J4H=+3X
M4UY?$5FI55*&%;O'[,7E/=RNU-311WE1<&6D+34HYN95U5USB*CB5AVR0"=6
MNJ&$3JHD 3,AY$ %+\3ECU.]*9X$Y[[V[!SL.75.W&O5'G)TI3IKPU,I8R%-
M*,OJ,?-)ND_KRTQ%SJCILVG8195>.=.&;22;D.LW5:J"HS>)+-E@,@L8 ZB\
ME$>0$!#-,[7N=[:LUY>.[:O=7T3Y-<J4:+EJFC/>A=UEPMB-BCD9YG=)5I/S
M2*2XP;C[\9.G[I"08N(] [=H4#2C@AD!;J("13P*4Q2F"YM;O/S+U^^OYEZY
M*;4>"<G6BX::BI.([PL@1RD8V:_=[=LS?1E?382\FFE 1KVH-::5-))4ZHOI
M!FP9$63=',13UQ.80X,!291=U9"BH]$:)%+H;>I$$=\R;=$$TJG7$U?O\L^H
MJDF0H.' R#&34^:349+&6>?-,Q!-T4Z:B::AB<"'/,J[HNII^5;T]B*U2ACE
MRX>.5W;M=5RZ<JG7<.5SF46<+*&$ZBRIS"(F44.(B(CGG,G(EE7Y7[B2;Y(@
M?'*! 8 P!@# ..0#S$ X 1$1\   \QYQ&DYJTO\ ,EP7B_83.-(=;:H9.NS?
MLM?6AY$[5V[%*,JLV.A)5.GR2)DG5E6*8JS.8FVA^#H0*0\'1;J !W8@!C@"
M7@IT%Z8^EGXJY;[E[BA*'1K:MNM6JOZEPY<JEA?R)/Y(\C-"1,I"E*!2E*4I
M2@4H 4"E   "E    * !X 'AG2]FVH:P24.27)<E\"Q>O'B?)TX1;I*+KJ$0
M00355665.5-))%(GJ*JJ'.(%*1-,HF$1\  ,C/)M6K5R_=?3:M)N3?@E5D5&
MIKJ=W'<&^WOL=P,<[5#7U2<.HRFL>HQ4GA2F]%_97"7!>7DN8@>GR'Y-L!0#
MS-SQ9ZB]ZW>Z]]N6<>;_ *3;581_:EI]YE+-B-J/S<?86JYK@K# .,C;ZO.@
MX?4I5^Y@O!T?5:@\TQ<+9-UZN24XSV?"UYG*3U N6Q2M8IU574DX8H0M-D6#
MUKUND 4^85$4PX$@^)BYM+M#!VJ_VODY.3"U+,5U_7:G=\>"@TU[:\>1)<N=
M#54Z$*J>A8*\IQ4@]M;VMRVP;GL^LU*#C*4LC",7]#C$IWKDR2DRC*PT2_:N
M"I)M_27<MAXZS&Z3#EAA]G8.9*$W<<;^1=<(JU:E;2:BY5FKLJOV.-:<&2?B
M(\:,\R&@ZHVJ6M;+:+O::<XV-+1#%FPG**@9!I#R(BU<7-9XSL3@&M72D#D3
M;K/"-%WA!%1-+I#)KG8N%#"LYN3DY-F[D790MJ73^ZZ5=&^+K0FC>C+6C/HM
MVUIUI679["M+^OS%7U[:MF6R#BH%&9?1E?@;2UK,,W1,K+1Z2TA:DSJ/$>L4
MTT6XI&-U IR$'V!A8F5<L[OG78Y=O!N93@J5=NW+I455KYY_5%<&N+1+*_%.
MB39')'M>@UW[Z!JVP)!Y.QS_ % =R:R5EM!PR4'N=9J2O+F?-)A^L>4B$WB9
MGB8IIHJ"(E1.(YDGZ>X5^YY>V9=]7'&$JSZ5'YX1DN#;T4J/3C6F@_$+^%E,
M-PZAB=:-8=Y%6XL\+Z8L$"]C'2<4E)LW=?.@122($+)RS/[M>F6,3TE%".FR
MJ8D5+R(#GG^YNV,?MW&MWH74\B<^F3;T<UQ?N;*]I^;].GO*%YX@AP.< XR:
M+2E5\ 1*&F96O2T9.P;]>+F85\VDHJ1:G%-PR?M% 6;N$CAX_84+XE'[)R\E
M$! 1#*MC,R\7*MY6/-P\N:EIH]'6GQYDT8J;Z7PH;(G;)O%CO?6,9:Q]%"QL
M1"&N$:B( #*?:IIBLNDGU<D8RB(E<(? "G$G(B0<[C[$[I7=FS0SY_+DQ73*
M.G_-0Q.1:5N>A<2( /GGMFM:KBBW+3>Z?M?@NX.LIK-3M878D W7&KV,Z?Y-
M=,P^J>!F^@HJ+Q+M4H"4X<J-E!ZR> G*?6_J'V+A=W[>VHQAN]N#\N7"+KJU
M*BKQ6CH5[%U6Y5EJJFOQ<:=:-?V22J-RA7<#88E847D>\* #TB;A)TV6*(HO
M&#HO!D5TS&34*(<#\,XWW3;,[9<AX6YQ<+\-.#HURDM.#,Q&:R5UQT2TU_LR
M6LLIPZ)4JGHGI[2$H]+HQDA*, 8 P!@# & , 8DXPMNY)JB?Q)XP<^%"LVC]
M$WC?5M1K51:&18MU$3V*SND3C#UMB<WVEW2@"0'#Y4@#\NU(;U%C!_)(!CAZ
MCM#M#<^[]TACXD5'"5'*Y*JC[8U2>M*?:4+UV-B71+5TKH;$FGM0U'2U(C*3
M3VGILV8"M(2*Y2C)3LJJ4H/)>46*4OJNG)B!P'XJ28%3( %* 9VSVYVY@=L;
M;;V[ C'Y:UES;;J]??P]AB[MSS)N7B55S/I45"F,B!@# & , 8 P!@# & ,
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MP  '3VT;/MFRXGX+:[,;5F+UIQ;HDY/WEI.<KCZI<2><RI(, 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M<<K")E34"O)G,(\B((-/ER^/_P"E'.^^RFWVK@M\?(B8:ZDKCH5[SU!3& ,
M9!I25'P!P)0$.!#D,DG:MSCT27R^]K] J<=)?H\OP\_Q^>3J*CHB-6<\!D15
M@0 ?,.?PX%6<"0H^8?Z!E.=J$U22=/>U^ABK.>D ^&3=$:=--$0.<F P!@#
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MC_A.W<+%?&./'[]3#W=9M^TJ_GHBD, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# ,.WN<T!9&7UWM!J@(MWK1
MY29A4"&X3=-55I>$.L<O@(KH+.B%\O%, ^.<U>O.T1C>Q>Y4M+*Z9O\ AKHO
M;K7D9'#FM4S%3G.9=C & <#D8SA&<5/C)T7OY J#(4'842SUY(SL;*Q,->3)
M#0I20<G%DX04?-D1<1P(N%U6"22[LBHE B9C%."@ /(#GIKFU]P8D\2[EJ'X
M?(E+RG-Q:T2ZJ4;:XJM:$WNXE4YF)W=!S($B9AU8)'TWRC]:+A6<=($6930,
MQ5G6,G%M'3QY(R<019BLL"R[P4O41,(E-QD[^/W%B9BG8E&[=H]+?[OL?#5D
MLI*/%DJ(CNUD1R"19I WW<@1QR2%,Z49N6LI+-$.%"F=N'Q8Z3=KII%ZG:35
M<XE*5(P996WW'C7Y7XPN>;/B134E5'V*KNP&_P @NO-=95(V09Q;IA&NS/DG
M#EVLS?$5,T50+$)G9*N4U%C@T5*4ZJ8B &-DL+O<EE.W!W(QJW2CYZD3M:(C
M<DLS/&2+B5M3-1G!V.33;"Q?%9+6E1-\Q:BLD)W*J8O7H'_(',TZU@,7CJYQ
ME0[DR+2A-7+MNXOF5.'VE.5ZW%T;^9$B?W;WO^?@6K2B@QCKY)[Z*:*_I.^&
M@G0)Z"Q_F#MP?H"KZ76"(*E]02\YAOZ-N2BY1L3\N+IP)//M?Q$MR\1)0,BY
MB9=H=C(LS@FZ:J'24.BH)"G ACH**I";I,'( 8>/(?'+3(Q;^)?_  V1%POT
MK1TX?!T*O*O(AV4 , XP"HNHZ,ZV7LZBT1HF93\Y;'',G@E*)P1BDU0=R[E0
M \020C&RIA',_P!K[2]X[DPMLG%NS=OI3YTBJNK]E:%.[*,(UD;239%)NDF@
M@F5)!!))!%,@ !2))$!-,A2AX 4A"@ 9WSBVHV;:LQ5%;2@O\,>!AWK*O(].
M7(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@%%M_:G9[IU7:: X%)%W),_FH)XH <1]BC3 [AGG(@(E3^:3!
M-7CQ%%0X?'/*]W=NP[EV')VV<8N_<C6%>%5PKI^HK69JW*K-9F7B). E9*#F
MF:T=,0[YU&RD>X(9-=F_9*F0=-U"F /M)JD$.?(0\0\,X.R<:_A7[V)E1<,N
MQ<Z)P?U5\4N<?;]QE+<U<58\"'Y1)A@'&0^7JBG]3>GOY4!41[5=GQ+?74A)
M1-E;L[(L@IK%>3.L>/?F^\&ID2U]-TLHU024?N4C] %3*;J*?@2CR/H[NW=Q
M8ZQI9\+MO'O-JQ*?TMJG5TT;?AR(IUT7$G:OU_9*+VT%H-LAI^4=R/RMU91#
MTA2HR'7*/$GKDT]'Q[!RBBZ1=D2>-#'(FL82E$ 4*8UWC8._8^3.6)D-/]^F
MJKRI5>!'JMK_ #$SPNFFX860031*_DEK&UBIEF_;QD>]("R]/8F!VR=NFAQA
MI1G65P;KN$Q;F.B01ZS% #A%R[NLWI6HWI2K\U:?=]PK!ZP^DA4O:-MP@,WL
MXO,QH*BI&,E)2*8("JVB5'K-6$(@X: 96&C?F7#?Y02"T2(H=(H 01+EI>W7
MN/&@IY-R:JZ5Z5R!"!VE>_E5V(31"L5V[9F=FE%PJ+8K)JU:,DF2*"485)LT
M!HP1(9,@ 4X)AS\>::[EWN.D<AT_PHINW!NKXG=[M6_R+5RS>61RNT=G045:
MF:1P-B"W;L&I4VZ)6A2-4#MHQ!-0B?210B0=8&\>:7^H]^\J</Q#K)NFB'E6
MO E:>L$O9Y$TM.//G9 S=JT];T&[8I6K%$K9F@FBU21132;H$ I0 OD'F.8[
M*R;F5-7[KK?IQ)R#9;$!@'&*J*;=.#_M[R#=%5F6[VW=)K)_?>\IQH*9'"#F
MK4<%B&*91$5"!89U#JX^P<Z16:)R^!@!;Q\<Z5]$.T[=JW_JB]"7G.+@E->+
M3ZE]E/B663>C-*"KHS+@4O3_ *OK\LZ)BFG)RXMU+)T.V3D!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!P(
M /GQD'6FG$&*?OY[6G4V#K>6OHTSF59M _O"A6:0F6DF#0A2I6AF@F'4J]CF
MY (\*')E&X IP)DS<\\>L/8ES,NKNG:+2>5"S+SE%?6DOJTYI>\O+.3T+II6
MIAX 0$ , \E'CI'Z0'X_@SF:DEI)-37%/2ADH1Z[;GX'."4XR#=Q4=II23YJ
MOV>#]H(PK8)Y=*(0<3<PY1KP %>0<23M9"!*#@CH"PZ*BIB1H Y3*I^1Z/ME
M ?AEV\W,FH*[>O7.AUBI2;C&O'I7*O,C4F4VS+AZQ'"3R-:+#)!,/3,J_!LR
MS4F5!TW![/IMF*2<VIZ3Y?DK@#DZECF  .839>2WK.BDL:71_%SJ^3Y4H2R7
M4<,=EW.+<*.8Z6*U.L1JBX(FQ9@@X;-( M809K( B"9V9(0A4/3\"B!0$0Z@
M <FM=P;Q:GU>:FJ4X?[1%=*H2_/6.;LSEN[G'HOEVJ+EN@H=)-,Q$'4@\E54
M^I,I1.'ST@J8O//24P%#@ #BVRMTS\VRK.1--)M\/%DU2"98:<N! 8 P!@'&
M302E*C=%XDT4FZ/1%PW;;V^V+N"O:4&T(X8U&'4;O+I9")F]*-C1.!BQK10Q
M13/.RI2&(@GX]!>53!TE\?8]B=HY7>.YP=B,OZ7:G6<VM*QU4:<^IZ5J6]^[
M&VFEJ;'E:KD-4X*'K5?8(1L)!1K6+BF#<@$3:LFB1$44P_VC<%Y,8>3',(F$
M1$<[CP<;&P,6W@8T5"W;@J17Z3%R?4^HCV79*, 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , ^2A.L!*)0
M,4Q1*8! ! 2F 0$!*;D! 0'R$,DFDX2C)*4&FFGJFO!KP8YU,1W=KV*N3NY+
M96CHKU2KBN_LNNV12E."INM9S*5!(3$3'U3<F5CPXY.(F0\_3SF_U(])\G+N
MSWKMN-+E.J5MZQ]O2DD_O9>VLRY&/ENE.?B8F5DE&ZZS==-1!P@J=!=NLF=)
M=!9(PD41715*15%5,Y1 Q3 !BB' @&<Z=-Q.Y:O6KEF_:E22GS?]W0R$)6YV
M^J/U'3)" P!@# & , 8 P!D8Q<Y**XMD52JKP+ENWGM>OO<%,)FC458&CM'!
M23EV>MC&9)$((&690B1A($Q+*%^R!2#Z2(CU*F#@"F][V=Z>[QW=F12A.QML
M)?S)RT;7]QTI5OV/2I0R+T8-QM\38!U;JNFZ@I\92J1%ECHI@43KK&$%7\J_
M4*4',K+.^DIGD@[$H"8X@ %#@A *0I2AV/LNQ87;^%;V[;K<;=I)=32HY-+B
MW[3&3;DZOB5' ./XN/',XTG+JI\Q+4YP0& , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , ZF* AXAX_7^
M'P_UX]PI4M*WUV=ZNWF+B77;#4+R=/A.XP*"15G:H /06P1IO3:3:9?]HXD<
M 'DJ !QFMN[O3C8^[*Y'RV<U?O15-?:DZ:^ZI7M796W[#$'MSLSWCJ55RY5K
MJEUK2 F,6RTU%:33*B'B"DE$%*,O&F*7\81241 ?)0<YNW[TK[EV*])J%S(Q
M$])02>GCHN!?V<B$I?,M*%J9N2G.F8!*HF;I43,'2HF8/ 2J$-P<A@'X" 9K
MFXE:O2QY1N1O1XJ:I]A<.=N7T*@R!*, 8 P#CD \1\ R%4N(*BZ^U)LK:KXK
M#7U,F[(<5 35>M&IDH=ISQ^4?33H4(MJEX_RE>H?@ YZ':>V=YWV26UXN1.K
MI7I^55YM^'-^PI?B+9E#T;[<,7$JLK!O"70L+LADER4B 563@TS\@8$IJ8_)
M.Y4"^1DD"H(B(<"8Y?/>_:OHE9Q;D<ONNXKLE)-6[;?0VGPDUK1\Z/AS1:SR
MJQI'BT918B&BH&.91$+',XF*CD"-6$;'-TVC%DW3  (BV;(%3113* >0%#QS
MH/%Q<?"QXXF+"-O'@J**Y)??]I9MN3J^)$\K\" P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MX<<?5QQ_JRZAT]*\NG1[.'W$-#G)@, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
/ P!@# & , 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g63294tx076a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx076a.jpg
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M P,# P,# P,# P,# __  !$( +4!X ,!$0 "$0$#$0'_Q #7  $  00" P$
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M@^[CU-_K44#[/>KO^=_TX/NX]3?ZU%!Y&/>KMJ-=W_3AT[].G#J;UT[]/_\
M5%!EKH(WZW"ZE^E? -W]UK=AEKW$NV1[P8EE<;;N)?8&%.W+:K>O<3:?ZRQV
M!DUVOM^@P+Q'PAN6&94R0XTM]2><@"@W$H% H% H% H% H% H% H% H% H%
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M.GRXP\AOF"@WS*TY$Z[VQVNXP9)ME^&8\=6EOMUM\^.*XOBBWAIP<3U#G[C
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M=(TG24WVZVQL/K;].3#+/N3-*<ZN>RF$[E6+-9C!=N=BW'MN&P[U'OZEI"9
M%S?+C$WDT4Y'DN:#FY=/2M_TROJ3TACQ[R?^5;;4R5O/;7)%(GF_3QBWC$R_
MFUZ&^96X_+E^;?J'4/1^/7TUA]1[SI^;9TMICS;#)N[8K8-)UK_MQRWP\VL5
MR8Z:\-==1/0YVT<S';C->L+<3([GG^[6?WA_;.-D>3RW[W?++B."1;5!9MK5
MVN*Y$QM$D-,HY$+2 Q'0#KKH.!\M-G_D;/)Z@W5[9=]EMY<6M/-,4I$1IK/'
MCP_1$/>/_)+ZP_\ S_J_IWR!]+;/#TKT-TK;QU"VWV](P8<VZWMLMYR3BI%:
M_9UO.LQ/V[VF--..(]_=E.A6W]2V_.8P/4PS;IPS[-,ZN$O='!L,O\VTJ@9A
M%<6F[0;A)MQ@/RDQKDZ^XVTZ7!'+RTI4023H]5Z;Z7KUC=;BO6<FSW>3+,Y:
M4O-=+QVQ.FFNDZ\)UTU???*SYA_F<W/R>],= S_)OIWJ[TMT_IE*].WN[VU,
MT9-K:(G%?'7)&2M>;'%*VM7E\R*5FT:PQSL+GYVGZ_\ I<P7ISZX]TNKS -T
M49-9]X(N4WG(,FLF,6YN*Z_;B[$ERI4&))D.QPXW*4E*HY;TYM'-#I=*W4;#
MU7LMKT?J>?J&US\T98M:UZUC3APF9B.SM[M/:^M^:7I?+ZY_*SZT]2_-SY:=
M$] ^I^BVV^7I=]MM\&US;G)-HB^EZ4I>U:Q;EMBB9B\6UY=::QVCZ]M?Q61L
M>D>HKZ$MOEG356[O5\HZ=FJNL??TG3MX<:"2>@4"@4"@4"@4"@4"@4"@\*/*
M"?9[M?W!QXT&,,MWCV[PF0J'?\DB-3T\H5;8;<BY7!LJU(#T:"V^6/\ =E-!
M:#74WL^YH59%*9]H>L5W;(]Y_DJM!05-KJ)V><T_NSB)U/ .6^\-GC\L @\/
M?05-O?+:=Q/,G.K'I_;+DM]VIUYV 01KWB@YC6\FV#W+R9UC9YNPFX);'XW$
MIUUH*@C=';IS3R\WQ@DZ<#>(8[?E=!%!46L[PQ_3R<LQMP$:CEO,#C^$O@=E
M!RV\KQEPZ(R.P.:Z:!N\0%G_ '7*^=*#FHO=G7IRW:V*U&HY9\16H]HT?.HT
MH.4B=!<',W,BN)UTYD2&5#4=VJ5D:T'U2^PKYKS2O]JX@_U#0?0$'L(/R'6@
M\T"@4 ]AH/5)U''@==/9_5H/3G/N_=_LT'T2=0#0>:".;;__ %L/5-_F%=%'
M^/?KCH+S]3'_ "!NJS^]#D/]6-6ULO\ MX_ZFMO/^K?^E!SZ7?29AG6CT/;V
M;+YWD>28M85;\89EINF*IM"KK\;C]@G?#1M+W;KG"^&>^,5S_1<_ :$<:Z>^
MSVVVYKDK$3/),<7,V6WKN=K;':9B.?7@VI_\/'TS?GIWM_XK;K\C:U_Q;-]V
MOU_O7?A.'[UOJ_<CQZ<<$R+H0]8;&>G? \SN-WQ6X9A:\'NK\K^3G(\)S3!D
M97!BW^%&2Q"?NEI<D-$+0@-IDL^8V$C1(W,UJ[KI\YK1]K37W3$Z-7#2VUW\
M8:3]G73WQ,+>ZP7]J\;]9K+YO4+;TN[.2=P< <SEF:S-5$7BUYVIQJVMW.2F
M /K!5O@S742'%1P7"AA03WUG;^9/3X\G^YI.GOU1W')'4)\W^WS1K[M(2=D^
M@R"1]=[1</9-W)T_]G6GS=5_F^IN_P#Q?C'UN3#G^@Y;Y");=WV:<4UXN26Y
MN'*8/*0KQLOL+;4 1KV5B?Q6>'VOJ(GI<?=^MBOUZU63+.F?I,SW!GX,W 9&
M:2UX]-MK*X\!ZQ97MXFY8Q)@L%ED1X#ULM?T:"E!2E21RCCI/I>M<V2E_CT_
M5/%#JFEL..]?AUX?IC@VOZ-O4WZ++-TN;&8WF^]N/8/F.)[<8QB>3XQ?H-_;
MG6R]8[:X]JFI2Y&M,F+*AON1O-8=;<4E;2QKHKF2*-QLMS.>UJUF:S,S$K]O
MO=O&"L7MI:*Q$]O<S7G_ *F_0?=,#S:V0.I+")4ZX8ADL&%&:C9&79,N599K
M$=AL&Q@%QYY82D:C4FJJ;+=1:)Y)[?8MMO=K-9B+QKI[?W(8_0QAR9FV77I;
MXS*W9DK:;&(;##:2MQV2_CVYK#3*$I!*EK=4$@#4DFNCU.8Y\4]W-/['-Z;Q
MC+'\D?M8]]$#JOV)Z9;KOU:-\LY@;>M9O9=NYEANUXCW%RW2I.)NY+$N-KY[
M?"FN-3N7($.)#B4)4AM6A)! GU/!ESQ2<4:Z3/UH]-SXL'-&6=-=-/T:NP9_
MI1N@3_M,X)_\ODG_ $%7)_PMU]R?J=7_ #MI]^/K_<Z]/45OQMOU)>L1T\YO
ML]?$9?A=NW1Z<<9B9'$C3(T2\3;-E5ME7=^ U/CQ)2X4)V66?,4VD.*:64ZI
MY5'KX<5\'3[TR1I;EM.CE9LM,^_I;'.M>:L?6G$]3SU#K1T6[<,8WA;MKOG4
M!N)"FL878GGFY",/M1:=CO;@Y% ;*G5P8DPI:@1G/*$^4%!*BVP^!S-EM)W-
M^:W]J.WV^QT][NXVU-*Z3EGL]GM0>[(>C]O#U ]+>X/49EF0W-K>+/;1#S[9
MS&+M))FY@N5-E7R_7#.)4Z,X^B9G5L>3]5*#J")+OFO\K2DZ]/+U#'BSQAK'
M^W$Z3/A[O<YF+I^3+@G+:?\ <F-8]OO][.'I%^H))V,R&7T6]34^3BMFB7^9
M:-NKUE:I4:3@^9O7=B!/VUR%4L<MJLLJ:ZZ[$==+;,.0E;:CR.H**M_M/-K_
M ).#C.G'3OCQA;T_=^5/^/FX1KPU[I\'9'W,V,VBWE59E[I;?X[G"\?$Y-E5
M?8JI)MJ;E\*9XBE+C?()1A-<_;KY8KY3>]+Z?U'E_P [#3+R:Z<T:Z:]NGOT
MAZKZ,^9GK_Y>1N*^B.K;SID;OD\[R+\GF>7S<G-PG7EY[:>'-+&#/1'TF,/-
M/M[![=^8PZAUOS+.7V^=M06GS&7GG&7FR1Q0M*DJ' @CA6E7TST"LQ:-IAUC
M^5]IE_,E\^,V.V+)ZKZSR6K,3IGF)TGA.DQ$3$^$Q,3';$ZMFU08:H*K88K
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M&]"M#3BT)4= I0&IZ4=6QZ<:3K[W-GI-]>%XT]RHXM_1YMP/KF.<TZ@,*^H
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MQ?!['$LUO0M<9,RY3E(4[=+[>'@ Y<+_ 'ZX..2IDEP<SCKIT"4A"4AL8[-
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MGCV _CK,HQ$S.D,1WF/S/.(2>*5%) [.  ('M[*Q[TXI:)B9\6)<E:"6Y!T
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M%VE0' KCXOH'V7%$=FM5#--AWZW@L)0JR[IYI&2@>!!R*1/8 &@U#4_XUD:
M=G+09FPSK9ZFEWJS8Q8,B@YQ?KU<X-IM5JO>-6R69LJ?*:C(9??@-PGPPCS.
M=2M3RI23W4$^<&5/7'@L/!"YCD>(W,$,K4VN<IEM,AN$?&XXPY+*DMCM*2*#
M;[I!Z>3U/[I"U7>/\1L;M#=[=<-UIJ%#X+</<" XB99-J8;Z%#XJQV&242+R
M6BI#KO*R>PT'9:8<##3##"$-,,-(9;9;"$---,H2RRTTTVE+:&VF6TI2 -
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M*K$[-J3C>V^'0$QK4XQCV,Q+=CU@QVTM*,V]7)P-PL<P^RLL_2S;MD$I*6O
ME2@7%N*X:F@[#OIZ]+,_8C!KGN9N7'B/[][N-0;IFCS24+1AN/-H2YC&VMG
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M-S=B+P\RM+K*LYF*;>;4%M.)78+"OF:<25-NM^+@I)((J(D1H% H% H% H%
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MQK3A<-]YBW7RYVJQRI*01Y#-R=><G*4I*P0W$LL22\3V I2#VB@[OVV>>6+
M<6QW#,;99MF.XO9[=8[-#8Y$MQK;;V$QV&N1 0CS-&^=:@/$IPGO-!G:U[U,
MK2G66#J$C0* (]W%0TH,B6[=^$X4\[Y*0 2-4GO[00N@S5CV5)FVM3D=Q0?N
M/T1> Y2S$XJ44:<0\L'2K,?>(!_5LZQ$WZZL]*VW]RUL.-3(5WW<GQ'-6KKD
MC*$/VG"TO((YX>/)<3*FI.H5,6AL\6JM$%LJ;RJ4$^[YNI(3IH"= 2 3PU/?
M075@FV^XFZET39MN\,R',9Y/EK18[>]+C,%2DI*I5QT;MT (/$K>?0E(!UUJ
M//7Q$I.Q?I!;K9R_!F;IWZ/B4)XM+=QW%6DW_(EH40"U)NKP38K8M0[5-B60
M>ZG-7Q$\G3)Z2&W&WZH,W'MOH;=T0E"AE&1).19(5 A*RBX7-I2+<%Z:Z1&6
M$E7LISU\1,3MST=XGCR(\NZQT29:"DE3J$K<T2G0!*EI*D@=P[JKO,3V#;.Q
MX5CN.M);M=MCM\N@"BVVHCAQ()3VFH"ZD("4A(2E(]@  X=G <*#WTT[*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#U4D*[2>S3A0>OEC^$
MH?)IV_PCPXJ([Z"BWS&<=R.*Y#R*Q6>_PW4E#D2]6R#=(RVU<%-J8G,/ME!U
M[-*#4/<+T[.BO<]3SV2]/6 QITA2EN7+&(#N(3RM8T*R_C3ULYE \1S C44&
MD.?>A7TPWY3S^!9[NUMR^I*PS'%WM^7VME1*E ?"WV#\86>8]GQ.H'810:/[
MA>A#OI:$OO;:;V;>YFTDN&-;LJL]YP^XN)2/HVC*AJOUN+BCVDAM-!I#GOIB
M==FW!=<N&PUSRZ''YE&?MY>[)EC#J$G4."+%F,W1"2GCR_#$]Q(H-/LMPS.<
M!D/1<ZV_S/"Y#*BEQK*<6OEA\LC@4J=N,-EE9"N\*Y3PXT%C*NMODM*##S;B
MB#_%*2>('$:A2D\-:"/'U![FMK9:VVM"TD7?-+0V^RHZA;4%J=-(*=-1JIM!
M[?WM!"VJ"VL$%IOCH>';V:#3M]E!1I-D86D\K>AUXZ =G'L\/M-!0WL:"PHE
M Y=-="!K^'@.^@I3V-)21RM#LXZ ^WW T%/..R "4@)('[WF&ONXT' -KF()
MYFEK"===#P/MT[Z":GTM\88MKRLI<0D/QHE\N"%<H\U$F[36L>MVJBDZ:VRV
MR"GV!Y1[Z"=>'F4AH)!>6H<.PI!^4^W6@NB#GJVU ^:2HGL*P#KQX=GMH,AV
M'/YDV="AL.GS94AIA"?-&BN=0!TT&O,=:#=#J9WR/2KTT9'GL71[,VX%NQ+!
M8!07Y$W/<D1\-:E-1FT./2DVHK7-6VA"E%N,0>WC9C[9'71VAZ%NJKJ"G.9%
M(Q>?B=OOTU^ZW+,=R%R+?.NTFX/KDW&Y1[*&W;]=94B0YYBBIMI*CIX@*M$T
MW3CZ)^%QWK?<=P(]]W4O" VIU%U0[9,09<X$ABQPG4RIB5JT.DN0I)3^\/96
M)GA[3]:>[97T_<?Q*UQ+<U8[58+-"0A,:T6>WQ;9 :"$H'*(D-AIAT^TK2M2
MN\DUKC?W#]C,(Q!EI,:V1G'6@$I4&4@#W$E/<>R@S#$A18C:$1V&V@A(2"A"
M0=!P ) H.90*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0>JAJ-/?0>H0?;^(G^MI04Z[6.T7Z*N#>[7;+S"=!2[#NUNAW&(XD
M_O5QYC+S2D^XB@U(W)]/GHPW6^)=S3IVVV?F2BHKNEDLB<7N@<6/$XF9CKEL
M<Y_>2KY*"'+K@_HTW31U.8Q:;?M!O!N-T^WBRW>1>6T2D,;G8M/6[#<BM1';
M9?95ONEM9:*R>=F8HE)TY>^@Z]^\_P#1*?4%PE$V1L_NMT_;Y0F@MR+!D7&_
M[9Y')0E)*6RS?(=PL33JNSE$L)![Z"(S>GT9/5)V%$Q[/NBG>*;;(/.I^_[=
M6ZW[GV)*&]>=T3,+GW226 ./,6!J.Z@C;R?&<CPNX.VG-\8R7#;JRM3;]NR_
M'KSC,QM:"4E*XM\@P'!H4]AT/NH* E+"TA:%MK00"'&E!312H:@A8)!U'LH/
MG\&T?G#A[CW_ (J J!$4DI\LZD=OL]I^0=M!,]Z;]N0WMWD,Q7AY;C;[6V#\
M[RX48O!/LU#LM1H)+#S_ +Q6GMH/JA]]'+XP0!IW^S2@S)L1$5>-U<0C/E2H
MZ+G'?<2 2D)97YA4H=I3X0*#L%;7=.[F_KZ+G.M\:9 Q.[-*AR)4-B4(5YEQ
MPZJ5#6^#\--:M[I:#K9#B$+(![J"1[;WI)PW&&VWKE%1(DI2#JYR.%2B=5*(
MTU )H-HK)B=BL;(;M]NBL ) !0TD$\OM.G>107*D<H    [AP ^2@\T"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M::]M!XT'L'XA0.5(UX#CKKP[=>W6@\$:#PC3CW</_)08TW!V8VBW9M[EMW2V
MKVZW(@NH+:X>=87CF51U).HTY+W;9R4^$]VAH(K]Z_Z/SZ2V^1ERKUTBX=@M
MXEE:EWW:*Z7W;.XH<7KJMJ/C5PC68%)5J J*I(]E!$CO1_0^NE;(C,F;#=3F
M]FUDE?.J%9LVMN-[F6-I7:AMR5Y6.7SRAP!/G+5IJ:");>C^B1^H+@@D2MG]
MT]@M\X#27%,15W.^[9Y$\WHHI28F00[G95O$:#03D@G@#QH,@]-?HR>I7TZ;
M8SD;@=.,N2_<;Z]<Q:\'S#$<RN4&,B,U'UEPK3=G7U%]U@K2&O,*4D:Z:Z /
M7+=O]RMO7UP]P=M\_P (E-*4EQO*,3OUH Y5%.H>E0$,*3J.!"B#06>Q<(4@
M?1R65$<H("P3S$:Z:#4F@V5Z7D)<W2M3Y4 EIAYQ.IUX:%/,4\2D@]Q&M!V[
M.@*,VG9J[S$M)"IF<WC5[EXNHBP+4PWXNU7ED*'N)(H-X]![!Q[:#S0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*#Y_1_[.:@]SIH->SA[?:-*#Y>#Q<O/S:\>777\'-X>7Y.%!;^
M0?9GZM?^UOU']4<BOB?M+]6_5_E]_G_6O\G\K7V\*"*CJ)_T.7\M_GE_1J^N
M-'?.^QYBC*_-YCYG+_-J#<_B>?7YW?01F8:WZ4*MTV#LC*ZJ&%#S>=NRP+;*
MQ1QG7Z41'<^N4/(F>&FA2A:]-.4:T'9&Z??YL_YJ\;_FBY_L-Y4CX#XCS?C_
G (WXM_ZT^MO/^F%V^-YO/YN_33AI09JH% H% H% H% H% H%!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g63294tx076b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63294tx076b.jpg
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M P,# P,# P,# P,# __  !$( '(!X ,!$0 "$0$#$0'_Q #W  $   8# 0
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MN5O5]*KT_?H;\Z*H8J;C1Z15%&T\VI^F>TUNUO14HZN+!K!DRE,%T<.H D>
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M&+Z@8ID-]NUYR2F]36VEH+3:KM55U3.JK$J=4A!#3*5N*DE),36MO,+EA+'
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M ;$_=B@B?5!WB?:M;F?8!L3]V*")]4'>)]JUN9]@&Q/W8H(GU0=XGVK6YGV
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MIPNL53@],FK<"GM?Q4S*U*XIG%.\6RJ+:YKM5L=6ZC!7].\J<IL.KV4(LU<
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M7Q#M(G%LLAJX[#7FYU@'O+TJO><VVQY#B&-KO^1X]6>KKA1TB&W[C58W7)4
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M,HXJ+5S1NO WAKUZUVL'VT0$;7&5K= =RTV[=>M<UNXMR/2I7PDH6"8IW7D
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E\W!%'Q^=_3^;S'W8(H?FX(I!S_K?_P KSOV((I_SD$52"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868853078832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 19, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear', window );">Lease initial base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total base rent over the term of the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember', window );">ProstaScint Inventory Transfer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Sponsored Research Agreement with Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AgreementTerminationNoticePeriod', window );">Sponsored Research Agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember', window );">Clinical Research and Trial Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_AytuManufacturingAndCommercialDevelopmentMember', window );">Aytu Manufacturing and Commercial Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember', window );">Zertane Clinical Trials and RedoxSYS Research Studies [Member] | Clinical Research and Trial Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ManagementFeePayablePerMonth', window );">Management fee payable to Ampio per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease period</a></td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear', window );">Lease initial base rent per month</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total base rent over the term of the lease</a></td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ManagementFeePayablePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Management Fee Payable Per Month</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ManagementFeePayablePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases monthly base rent initial year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_OperatingLeasesMonthlyBaseRentInitialYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_AytuManufacturingAndCommercialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_AytuManufacturingAndCommercialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=rswn_ZertaneClinicalTrialsAndRedoxsysResearchStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868923865568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,259,681<span></span>
</td>
<td class="nump">7,901,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock</a></td>
<td class="nump">4,761,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Scenario, Plan [Member] | Second Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet', window );">Equipment lease payments net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Scenario, Plan [Member] | Second Installment [Member] | After Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_OperatingLeaseMonthlyRentalPayment', window );">Monthly equipment lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Scenario, Plan [Member] | First Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PrepaidExpensesAmortizationPeriod', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_LeaseAgreementsMaturityPeriod', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument principal amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Ampio Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total amount agreed on loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CashAdvancesForShortTermLoans', window );">Amount advances on loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Cancellation of indebtedness amount</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Vyrix Pharmaceuticals [Member] | Ampio Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit, remaining amount outstanding</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Loan agreement interest rate minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum', window );">Loan agreement interest rate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Cancellation of indebtedness amount</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember', window );">Ampio [Member] | Luoxis Diagnostics [Member] | Ampio Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit, remaining amount outstanding</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Loan agreement interest rate minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum', window );">Loan agreement interest rate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_CashAdvancesForShortTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Advances for Short Term Loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_CashAdvancesForShortTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_LeaseAgreementsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Agreements Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_LeaseAgreementsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_OperatingLeaseMonthlyRentalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Monthly Rental Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_OperatingLeaseMonthlyRentalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PrepaidExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PrepaidExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(f))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, by major property class, net of accumulated depreciation, subject to or available for lease as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6454179&amp;loc=d3e41551-112718<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rswn_AmpioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rswn_SecondInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rswn_SecondInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rswn_AfterAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rswn_AfterAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rswn_FirstInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rswn_FirstInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rswn_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rswn_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rswn_AmpioLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rswn_AmpioLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`$B*3D<P0O^NY`$``)(>```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR
M@ADJG4U^>J[O.<EUODW/'YX]Q<G&]D.<5UU*_HRQV'1D=:R=IR$K"Q>L3ODV
M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[
MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL<P^D"ZC1U1
MLGT=TW-/<9__5GESOJ*%?NS3EXQ?WUT=J!]K8F?\J]7U)G>)^;=YE=7X*8?=
MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^
M<YM0>:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[
M_]OXO>!P.<I<Q^N/ACZ*D8VG`T+B2SD$2`X)DD.!Y#@&R7$"DN,'2(Y3D!P_
M07+P&4H0%*)R%*1R%*9R%*AR%*IR%*QR%*YR%+!R%+(*%+(*%+(*%+(*%+(*
M%+(*%+(*%+(*%+(*%+(*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*%+)*
M%+(J%+(J%+(J%+(J%+(J%+(J%+(J%+(J%+(J%+*J=[*R\:_HBQ=02P,$%```
M``@`2(I.1TAU!>[%````*P(```L```!?<F5L<R\N<F5L<ZV2RV["0`Q%?R6:
M?7%*)1818<6&'4+\@#OC/)3,>.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<
M4M?'5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SG
MVL7.U49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//
M>997'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C
M@KN_V/P"4$L#!!0````(`$B*3D=AI.76UP$``"`>```:````>&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'/%V<UNFT`8A>%;L;B`#-^/[<2*L\HFVZ8W@.RQ
ML6(#8J9J??>A7E1NDCG*PM+9@`#IFW?U@(;'+M6K'_'8Y$/?I?8PI-F?T[%+
MJ^G^NFIS'E8AI$T;3TVZZX?834]W_7AJ\G0Y[L/0;-Z:?0Q:UXLP7L^IGAX_
MSIZ];-?5^+*5:O:S&?<QKZO?_?B6VAAS"I>3W$T+3(_/0_S.\OUN=]C$YW[S
MZQ2[_$5%^+=`%<I!6@Y22I"5@XP2Y.4@IP3-RT%S2M"B'+2@!"W+04M*T'TY
MZ)X2]%`.>J`$20UDK#E)"&N.U@*X%H[7`L`6CM@"R!:.V0+0%H[:`M@6CML"
MX!:.W`+H%H[=`O`6CMX*]%:.W@KT5M*W-OK8YNBM0&_EZ*U`;^7HK4!OY>BM
M0&_EZ*U`;^7HK4!OY>BM0&_EZ&U`;^/H;4!OX^AM0&\C[96@S1*.W@;T-H[>
M!O0VCMX&]#:.W@;T-H[>!O0VCMX&]#:.W@[T=H[>#O1VCMX.]':.W@[T=M)>
M-]KLYNCM0&_GZ.U`;^?H[4!OY^CM0&_GZ.U`;^?H/;_2.[7-&+>O>3QT^W3K
MFO^&PZ(KO%,^'^/M4RY38<.5UGE:*8;+\>:OCLO4OR'AT\_@IW=02P,$%```
M``@`2(I.1P8YJZ82`P``O`P``!````!D;V-0<F]P<R]A<'`N>&ULO5==;]HP
M%/TK%B_KI+7A:]V*:"1*F5:)J:BP]G%RG1MBU;%3VV&P7[\;I]#0ABSD83PY
M-_?<KW-LAZ$T[<%,JP2TY6#(.A;2#-!XV8JL30:>9U@$,35GZ"+Q;:AT3"T^
MZJ6GPI`SN%8LC4%:K]MNGWNPMB`#"$Z37="6/\RRC))$<$8M5]+_P9E61H66
M3-8,Q-![Z^`0&'D.+-7<;OQV[E,T.9\YHP+&F,L/J3"0>[T:G<]8Q0F5&R]_
MFG+Y9'XF"W5-+111^R_RZ!'5$&#2O>@[H_/YOL$^188=1U0N(2CZOG^YG<4]
M:)-UVNF>M?&W&\'6GL<&&G"YG%&NC3]<V<$*F%7ZA::5;<I2H%A&NKE?8'VF
M11ZI@6QYV5I1S:FT+6+X'WSLMO*TN=6M16*L]A^4?C(1@#5#;V=TRZ)O<<W[
M?O_">>!JW]/;=>:_C&VO[\RRX%:`N0UG5-O_-`K7TW80_8M6H?MM"$)E0";2
MHAS)C<Q3(7G%D>Q65U10R8#,WTWM@`LYP68Q2006MX7X6`J96Q1K5HHA*B2W
MJ#9707G\?>>Y5>PI4B)`Q7T@D^>T!F9,342^"?7[0`.IX1*,^41&[#GEAF>U
M9+B1,8>:GJ=Q3/7&5<27DB-%*`H,P%2*DRW%3)%&:8",EAI<<;_N8`4R!7('
M3"U+,3>2J1C(@JZAO!`\)F)N\U8S7L<*T^.>E8Q7(+`_-\A2!QQJ+@U\<((I
MCW,'`H<<D$S<&[+05!K*#M,XQ;$N#PMM$B=";0#(%4@(N24S5-6!T3\:>$XS
M(4]P?/9X?CI?C]=!Y^+X/-WV/SDE)POZB&=$^3ZI))><U&2O.D=EU]U^`\SG
M!ICS!I@O#1@I9[X:TX#Y7CGSU9A.`TRW`:9W_.G4*]?!GI)/W3&&TA2<YCS5
MP<SQX@M2`5FMUQ!"'<PH")P2J,COKP9[Y_1X3*]<!Y68?KD.BD=PW7Y*]G41
M61_SJHCZF&FJUMQD!=?'W&\T7[L>CZAM)]SZF`>J\>[!Y<V1UY2;7ZTKY@U'
M[SX>BU^!;[[YO/W_*OY?4$L#!!0````(`$B*3D?E^F6K/@$``&D#```1````
M9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+L_&EJ.L!$"<F(3$$XA82
M;PMK/I1XZOKOR;*NW8#+;MSJVN_CUW%2"L>$]?#LK0./"L+%5M<F,.&FV0K1
M,4*"6('F810K3$PNK-<<8^B7Q'&QYDL@XZ*X)AJ02XZ<[("YZXE954K!A`>.
MUG=X*7J\V_@ZP:0@4(,&@X'0$259]6K6QC:F)(.^*J/CF@><6:D6"N1=.Y3]
M3L7."%Z'O1QDWS[]_=-#RI"LJ]P&U5<U33-J)JDN#DS)^^SI)9U-KDQ`;@1$
M55`,6P?3[-#Y;7+_,'_,JG%!KW):Y/1R3F\8O65T_+&;[,3?8%AW0_Q;QP>#
M:;NHL(8S=YLT,BTW?2:0A""\<JBL.0N7,$?B!`N;SR\0>#ZH$Z;+MH:VL5Z&
M*MVO(=J]G+BRI?7M/O4C.GE5U3=02P,$%`````@`2(I.1YE<G",0!@``G"<`
M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/`0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103`9IZ_PP`JE3%ZU6FD`PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW`<!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK`:?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG`
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E`<`J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5`9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_`>KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+`.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_`[/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z`=-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI`&$P'-E,E$\`*"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW>`,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M`5!+`P04````"`!(BDY'[-<6Z6D"``#)"P``#0```'AL+W-T>6QE<RYX;6S-
M5EMKVS`4_BM"&:.%4=LI2=O5-HQ"8+"60O.PMR+;LBW0Q9/E+.FOGRZ.[9AE
M:;-UQ"\Z_LXYW_ETL8_"6FTH?BHQ5F#-**\C6"I5??:\.BTQ0_6%J##7GEQ(
MAI1^E8575Q*CK#9)C'I3WY][#!$.XY`W;,%4#5+1<!7!60<!EW\G,AS!Y[./
M/QJA;C\`-TX^32;^\_GM&#^SCG,(',?7+(+!?`:]UY->^/K9RVR](_KY&^G_
M1#ZBOMI#W6G17+VP4?+U`5WW2*;EGO4<^GZ[IC>&W&LW+PYSP?L]G$('Q&']
M`E:(ZOC`A*>""@F4/B1:A44X8MA%W"%*$DD,F"-&Z,;!4P/8<]7&,<*%M+5=
MA7&="[^O)(LD@G[[O+Y<TK/;P4R/4+H[/0W$8864PI(O]`MH[>6FTI/C@F,G
MTL8=B"XDV@33V2#!#KIN(F2&95<Y@%LH#BG.E4Z0I"C-J$1EI`NE!--&1E`A
M.**&<IO1&IHVQ90^F:_X>[[#O<Z!BS%[[$-@5&Q-O1"MV1\#NZC>D,UQ#VFG
M1_&"==X5T-FHJNCF"R4%9]B)==!"M&^'Z(,]]'&(MJR@%)*\Z'AS$%(-8`G!
M"DM%TB'R4Z)JB=>J/<'>.M^G\-@IOZ>F?[]JO1I]!/_W\AQ=W$(/#4NP7-A?
MX]LE75X=WC+[=<*1S'=79CK>R4J;GZZT$][0ZU.5=GESJLK,'>7OI'EM+QLT
MS)UVV:$@:0A5A&\U('/!>3"ZZ4XGZUNEYLS6?9>T7H42?:_>J:+),IRCAJI'
MLA+*.B/8V]^,_&#>12T[B@CV]CW.2,/<C:V_O,>_`%!+`P04````"`!(BDY'
MA0!S;$H$```K$```#P```'AL+W=O<FMB;V]K+GAM;)67:T_C.!2&_XJ5+\M(
MR[9QTG+1="1NLUN)W4$4,1]')G%;"R<NML-E?OT>)S#S!DR`3TW2^+&/_?CD
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M$")QS"S9MXVTG:Q`R(&0OT58>%-<KXTNR9$_V,E-`Z`)@"9O@8Z$6[.OI"\.
M90J$:612&J=JZ=R?[*"X:6A-0R@!=N!<?W9W`+03&4I35<(^M`&I5:UH5PM:
M[(.B,`TM-H!V`;3[$G1*Z:!VDAVLK&QC^W$N;V7=2'8N"[,"T!Z`]EZ"YG5A
M*LDNQ+W$.-(QZC5^V>[(5)7RW:P&5X]H^]!^DW6A^J">IQ%1`X@FLUU?;(>>
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MX6SKVF[HG%2$`R_]=(5L/@GU3[C_EP[!LR2<5.E0VFA]1,^^U:=&M.>YCOQT
MQ/WR/U!+`P04````"`!(BDY'!M\`@`P"``!F!@``&````'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;'U5VV[B,!#]%2L?T-PAH!"I=%5U'U:J^K#[;,*01+7C
MK&U(]^_7EQ"<RO""[?$Y<V8\S*0<&?\4+8!$7Y3T8A>T4@[;,!1U"Q2+)S9`
MKVY.C%,LU9$WH1@XX*,A41(F4;0**>[ZH"J-[9U7)3M+TO7PSI$X4XKYOST0
M-NZ".+@:/KJFE=H05F4X\XX=A5YTK$<<3KO@.=[N8P,QB-\=C,+9(QW\@;%/
M??AYW`61C@$(U%*[P&JYP`L0HCTIY;^3TYNF)KK[J_=7DZX*_X`%O##RISO*
M5D4;!>@()WPF\H.-;S#ED&N'-2/"_*+Z+"2C5TJ`*/ZR:]>;=;0W63K1_(1D
M(B0S(4],X%;(A/D#2UR5G(V(V[<=L"YAO$W40]1(&".WV:M`A;)>JJ@,+]K-
MA$@,8N\BXAD1*M^S0.(3F.B)0T_\]-1'3VU\J4-/_?3,1\\L/7/HV3(]B]B[
MB-POD#\0R!WZRBO@(M9^@=4#@95#+[P"+F+C%U@_$%B[]8V\"@O(G?]`\4"B
M</F)5V(!N5/HS0.)C<OW5WH!N5-JW<=W-?3ES<.W:N=3MUA,/R52Y$5<W)'R
MMN55:M%U:V\^2\QWE="9`Q1X8\:=0#4[]V:Z.M9YI#[;.7*#5^6`&_B%>=/U
M`AV85-/(C(X38Q)4$-&3RKM50W\^$#A)O5WK![%CT!XD&ZY3??ZT5/\!4$L#
M!!0````(`$B*3D<WCTZEP00```X7```8````>&PO=V]R:W-H965T<R]S:&5E
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MI:FZZ7/U\M[U37T-6:_JXN?\?3Q-WY?Y'Z>6,#D`EP"\!8!.!M`20'<!F]G9
MU*\O15_LMFUS6;7S8)R+<<SA@88G][+JIIOM_+B&GG7#W8\=^.WF8VQGD>`D
M>>(2E!1YH%`WR6;(?S.!D@F:32"/!SF>I'@]QQ./O[-HYT[,DM,DR<B0LB#I
M<JY#2]Z:2']TPH_F?BC,8V8_FN4!DRGCY#0FD<;P-%I,8U@:\EJCG,4FLEB>
MQ8A9+,^2*>><),NYS"`01MQD"3<9=V-%-QE_M`C>B2.0)V2!&Y=PX[B;3'3C
M6!H-6E;E7`7.^4SVXA->//<B#L"39UF<<N2,%]UP'9$"9R(C-7(R:FC\\Y<C
M,=/3HEG>-Y\I<4CS0&8RU#;B1T3=U0_'%"G9#W!..`5LQH>91)Y=,W&@$<B9
MD&<"4"H"&DB1#SCZ".5,`?M\/%$*:<"91C+3@$,MT_%$*:@!IQK)5`..M<PH
MQ5,%\R8E##VE$`B<@20S$#C=++HLBTSE0.>]L1'N0`J#P#E(,@<A"UYCHXWX
M-/-`ITVF*;(600J%P%E(,@LA@*%SL;<XA3G@G".9<\`!!FJ@KM<R=P.ERP:E
MCJ`74ZA#CCJ248<J8#RB=1':A4I48)7W$5<B\*YE%0>>CM5E*9`A!YF6088<
M9`#>.I"?=2"TVAL5F?F8(AYRXFF1>#ERXH&)O_680AYRY&D9>1C4<6.U&.M3
MBGG(F:=EYB%'F3/#5)6['I>%?E*\0\X[+?(NQZ":LZ!,;(JF.(:<8SKR.@1\
ML@F(8PI0R`$5P0&ZNU21N@=3A$).*"T3"@-"Z6%5EI>Z/!`.'$#,(G2F%*"(
M`TK+@"*.'6OCZS>EJBSBT#%RE46\RM)HG)=+]$!G8.!@!,Z4@AAQB!D98L39
M%"_30QFZJ)_D;I43S$2VJ^$^%!3=+][7_2J%@V:MC\Q92K&...O,W6CHQ5.@
MT9(FCVE")R(+ET6+.`M-I/JF%+V(T\M8N2_V?_0EH@F=I.A&G&XFDT<ZV(?J
M^SWM=9BY:J!%Q$R*?\3Y9V0L$><?.>\MV<B;$.Q8K4)KHH\H!4OBL)2WHT_$
M&?AIKN)CIS(I"&H.02NC27,(?H)ACPPD%S[YG519DWF*`$&GD*DY,N_/I:Z^
M.`IA6&^MOD?'U58`3;)>QRBE4]34G)I6II0.2C^QI%WF;ZB42]H-.[D\%V_E
M7T7[=CQUJ^>F[YMZ.K%\;9J^'-I3GX?.'LIB?[NHRM=^_)F-3V$^KITO^N9\
M/7V^'8'O_@-02P,$%`````@`2(I.1S-D4<TG`@``E0<``!@```!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R-E<N.FS`4AE\%\0"QN8>((#6,JG91:32+=NTD
M3D!C,&,[8?KV]84PIG+=88%O_W_.=\"RJXFR5]YB+(+WG@Q\'[9"C#L`^*G%
M/>(;.N)!KEPHZY&00W8%?&08G;6I)R"&,`<]ZH:PKO3<,ZLK>A.D&_`S"_BM
M[Q'[?<"$3OLP"A\3+]VU%6H"U!58?.>NQP/OZ!`P?-F'7Z)=$T$ET8J?'9ZX
MU0\4_)'25S7X?MZ'4#%@@D]"A4"RN>,&$Z(BR<QO<]"/G,IH]Q_1O^IR)?X1
M<=Q0\JL[BU;2PC`XXPNZ$?%"IV]XKB%3`4^4</T.3C<N:/^PA$&/WDW;#;J=
MS$J:SC:W(9X-\6*(_(9D-B1_&8`ATW4](8'JBM$I8.9GC$C]\VB7R"]W"KB>
M9.9SR<JXG+W7>5*!NXHS2V(M.=B2V*5H5@JX2(#,OT#$+HC$0,0V1.KV)RY_
M:OR)[<_6B(4IPD@&+8$;"&'DDC4>V8HF]="D-DV^3I,9FM1*DT'SN(2-5[@B
MRCQ$F4U4.(DRNW`GBENQ8L@]#+G-L'4RY/]E<"M6#(6'H;`92N<^*3ZW3SRR
M%<W60[.U:`IGO8>ME2:!OHWB5ZZ82@]3:3-%3J;2RA2E<5;F6Z>PL85%":4V
M=P.IT_:?1&KQ`REV(LV:3S"ME&XH8!V@([KB'XA=NX$'1RKD6:P/S@NE`LMP
M<"/#MO*.7`8$7X3J%BJ?N37,0-#Q<0DN-W']!U!+`P04````"`!(BDY'\@V0
MQB(#``"<"P``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(U638^;,!#]
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M<V5>]>6[&FM@+N%65UW_&VW/G='U%!)'=?$Y7,NFOUZ&-TR,87``'@/P-0#Q
MQ0`R!I!;`.TK'93U=7TM3+%>M?H2M<-FG`JWY^B1V,YMHZY?;(=VV<HZN_JQ
MSL@J^7!Y1@CN(1L?@JZ(Q":_,F"(80S'7CB&"/(`D<(,!&(@0PW$KX'"\12*
MIT,\]>-9*)$/10R09NA!QE,N8!JV0,-\&A[2L(&&>32"98A"8G(?Q83$$M;"
M%[1P7TL&:N$>"^8H$QB"Y?S_Q&0+^Y?Y8F8:*Q:*$7Z\!(L1?F,%2F=4R@46
MZ;&(%&21'@O!2!*.P)X%.$DL;$:/\Z%90>[E31'(M!DQXRZF1$IX%P,<PHR)
M;$81:":3(M\JX/.R&3$#$R4"<PHV,P^`F%#.V)PFT'XF3;Z["`)KPA[5EXP3
M3/",J`#)K2I!9AP'@98UJ?(]2U!8%?&Y$*)2@L`\!%+&&)F1M.2"R+=!P6!)
M-&A41C-R[U&3)AHV2F(R>Z263!/YKBE@UT0L."D2S>Q=X*Z(<#DG:,DYD6^=
M(@._%HB';;*G-X6M/$3:$RZXG/D"(M!")U6^APH!MRGSN"1.,XE`Y\\#()=4
M4N]S%6I:LF7D^[*X\V4Q:O*-^4OZ</]7$*.B>]B=G,0;>FK5'OIAL(NV^MP8
M-V9XJ]>!\QF[H>EN?>,&T7Z8NJ59KT[%0?TLVD/9=-&;-G8DZ^>GO=9&67GI
M@VW<T8[*UX=*[8V[S5Q'A^%Q>##Z-,W"UX%\_0]02P,$%`````@`2(I.1_9-
MEB!Y!```%!4``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R%F%M3VSH0
MQ[]*)N_47ETM)F2FW`JET-"'TV=##,G4CG-L0WJ^_9'OVLQ:X8'$SF^U*^WJ
MO[(7A[SX4VZ2I)K]S=)=>3'?5-7^/`C*UTV2Q>67?)_L["]O>9'%E;TLWH-R
M7R3QNC'*TH"%H0JR>+N;+Q?-O56Q7.0?5;K=):MB5GYD65S\=YFD^>%B#O/^
MQJ_M^Z:J;P3+13#8K;=9LBNW^6Y6)&\7\Z]P_LQXC33$/]OD4#K?9W7P+WG^
MI[ZX7U_,PSJ&)$U>JWJ(V'Y\)E=)FM8C6<__=H../FM#]WL_^FTS71O^2UPF
M5WGZ>[NN-C;:<#Y;)V_Q1UK]R@]W23<'60_XFJ=E\W_V^E%6>=:;S&=9_+?]
MW.Z:ST/[BX;.C#9@G0$;#(![#7AGP`<#[O<@.@,Q&+#(:R`[`SD:,*^!Z@S4
M8"#]!KHST(.!,%Z#J#.(QE527@/3&9C1@]^@SGF;N7`T\6<"AF2/V>8GO/3I
MAC'?ZH1)GW`8,ZY.!-:G',:<<W_.H4\ZC%E7TF_2IQW&O#-_&J%//(R9E\WT
M@W9?-;OR.J[BY:+(#[.BE9)]7"L6G%LK._BL;.X6[6ZW&[.T=S^7)EP$G_5`
M'<(:Y!(A0"%7"&$4<HT03B$W"!$4<HL022'?$*(HY`XAFD+N$1)1R'>$&`IY
M<!$(R>7]@1ER?1\Q0R[P$V;(%?Z)&7*)5Y@AU_@9,^,B![;DAKIC9-V)MNX8
M&N$H!ZHMO);9=3D`@.-<M=R-RTDA*.;.9>S,-4B0%/C@@D)`Q".26[G<F0RU
M84+3Z\!]Z\#1.AP5FFSGQ]'\N(T]HCT)GR>!/!EJ4E?"\:2X9A!2V+T'0_%(
M7SS2C8=V="L=1TPH,AB7.;-%$D::D2G[X9(-*+2A`U>^P!4*'*B4W2H<N&!J
M(F7:YTDC3XSR=*G=>C5&'8MXBSUX,!1/Y(LG0O%PLE@CQ]&$#^/S81P?D2:G
M;-#6DSJ:F/3*"Z*0ZB/+=$SUK\[$!1E5!W7;E"LC:%F[0:">R!>"0(5,24GZ
M72'RS*JQU(9/2!'09X%^FDC6C_6QRV\'#=&#K>T)9]X&`*@#`+FW;\!56:8F
ME@II.QACM)A*LU>+`8DQD,5W`ZX:,VDTYQ,B`EXY!J3'0"K_);A**\/FCUJH
M)R^(H_**,F!5-G142'+M8RTM!0\^#L?DU5M`@LO(!;@&A7QIH<F*>O1Q.":O
M,@.29D8V@6O0I!8ZR+?3R/?3R.-IY.=IY'D"P:OB[0^`&@1C])Z.L++1I1,A
M45-3X7A;"1@4#MVOP&T2((T24ZV:>7L$PSV";M8,J7H(5JG)C?_@!7%47DEG
MKJ1/M%/F*OJ9UHR+XT>#KM7X21R6__2/Q)^11_9+AG1=*E!"TB6%2;<AH9.]
M2_'('H*X(COT$SLZW$_J[@J3]=,"<`$32^)M/@PUG^,3;%>LC..)VG*-CKT%
MSAN`??R>/,;%^W97SE[RJLJSYL'_+<^KQ(X7?K'C;I)X/5RDR5M5?]6UP_:E
M77M1Y?O^'>3P(G3Y/U!+`P04````"`!(BDY'G[G7;G8$```?%0``&````'AL
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M7ZO^1W/]PR]CT&/`?5-UT_]L_]KU37WKLLKJ\M=\/9VGZW5^DHNE&]\!E@YP
M[R!-L@,N'?"]@YI&.CN;QO5;V9?;3=M<LW8NQJ4<:RX?<)BY?=9-C>T\7</(
MNJ'U;2O!;-9O8Z!%`Y-F1S1WQ7J(?D\!7(JE.P3=@4M0$(7@,R"7`>=!(!F$
MY0,H+H":`Z@@0&ZI1S./8I:<)\D7:P&54)RP($*M;6Y<9$@ZX4B3(>4TDYXM
MZ2"3%-(Z9'5%J%/.1?V8A!]#_#C6CPG]R!P$L'9"F;/*&MZ-3;BQH1L4K!L;
MN@'I<L6Z"64XE,OQ;O*$FYRXD:R;/%P5@$ZRI@LBRR4:%UG-+N''$3]L$78N
M3"2U%3KG$XTHC&8:'P:ID$VUB)9<Z)2"2"H65+=4A$+(%G.WB):B:Z%X74%T
M7Y2S"#%/+-ENGH!XTKPGH%,MAC_>%!$JHT,A-<7"\&:*T!`-;PII+A'YKA(=
ME5%'*;I*11Q9WE'(3:TLRDCI0IT"F=O8)*7P*@E?>6[N)`&L&PJ"D50I<DJ"
M3N31*0UY:Q@I-"LLB/"#CGI*\5,2@"H>H-(2&&D;JP@A[4`V&]DDR!1$):&H
MXBDJ"1^-P6$!1$P1I=9BJ%]L[;(L7;86DL`T1BY(01)"2$96/Q!&JCR/O!0A
MA4@@B%0\C8&@3PHAHIB!%/N`L$_Q50""-`<N\I*!%-"``$WQE`7\,"PRA\03
M?M(3B[1E60!!FHI5*X4@(`B2/((@1)!.%BO%("`,4I$U&*+%*A%]41'A^%*(
MFTI!""B$(A-`(`3Q[2*DX`(4+CR#@>[1A)`1W$-J\P4$&#HR@^'VRZ`%&?O5
MDP(+DMV7YI&)(5DDH`8M665!E!I2KE(40D(AS6\_,:20LL-^+F9*?JB_T#%3
M*5HAH97FT8@AK<#@^,;G31&A&[8TL2\`IL"&!&R:W])BB"N+&H6)S!0FW%-3
M*;(A(9O6D1`ILF%(-GX?L\-/@PU38$,"-LUO=O'3O,(4KY#P2O/'!!CRRA@5
M3Y7B%1)>:?YG/8:\,KE`U!$V8@I82('EN&$5&`+KPV^8.=4Z.'>J??LRG<=U
MV;YY/??C04_0>C_S^P;CN=6']IU\*.:3N_<PV\VE?/%_E>W+Z=QE3TW?-_5T
MA/7<-+T?#(JOPZ0<?7FXWU3^N1\_VG&VYO.[^:9O+K?CR/N9Z/9_4$L#!!0`
M```(`$B*3D>Q9CU!H@$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#<N
M>&UL?5/+;MLP$/P5@A\0RK*=!H8L($X1M(<"00[MF996$A&2JY"4E?Y]^9`5
MN5![$7=7,[.S?!0CFC?;`3CRH:2V1]HYUQ\8LU4'BML[[$'[/PT:Q9U/3<ML
M;X#7D:0DR[/LGBDN-"V+6'LQ98&#DT+#BR%V4(J;WR>0.![IAEX+KZ+M7"BP
MLF`SKQ8*M!6HB8'F2!\WA],N("+@IX#1+F(2O)\1WT+RO3[2+%@`"94+"MPO
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M\(N/3;I2*7'87Q_(_$K+/U!+`P04````"`!(BDY'$]MBG:(!``"Q`P``&```
M`'AL+W=O<FMS:&5E=',O<VAE970X+GAM;'U3VVZ<,!#]%<L?$+.&I-6*1<JF
MBI*'2%$>VF<O#&#%%VJ;)?W[^L(2-J)]P3/#.6?.^%).VKS;'L"A#RF4/>#>
MN6%/B*U[D,S>Z`&4_]-J(YGSJ>F('0RP)I*D(#3+[HAD7.&JC+574Y5Z=((K
M>#7(CE(R\^<(0D\'O,.7PAOO>A<*I"K)PFNX!&6Y5LA`>\#WN_VQ"(@(^,EA
MLJL8!>\GK=]#\MP<<!8L@(#:!07FES,\@!!!R#?^/6M^M@S$=7Q1?XS3>O<G
M9N%!BU^\<;TWFV'40,M&X=[T]`3S"+=!L-;"QB^J1^NTO%`PDNPCK5S%=4I_
MBGRF;1/H3*`+X7L6C:=&T>8/YEA5&CTAD[9V8.$$=WOJ-Z)&-A9-FMX;M;YZ
MKG9W>4G.06C&T(@Y7F$6!/'J2PNZU6*FTQ6=;M/S+7J>'.97#O_1O]@2*))`
M\;\1$^9XC2F^-"&K/95@NGAU+*KUJ.)%7567VWE/XYE\PJMR8!V\,--Q9=%)
M.W^R\1A:K1UX$]G-+4:]?S]+(J!U(?SF8Y.N5$J<'BX/9'FEU5]02P,$%```
M``@`2(I.1V#DF'^C`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q]4]MNG#`0_16+#XA9[R71BD7*IJK:ATI1'MIG+PQ@Q?90VRSIW]<7EK`5
MZ@N>&<XY<\:78D3S;CL`1SZ4U/:4=<[U1TIMU8'B]@%[T/Y/@T9QYU/34ML;
MX'4D*4E9GA^HXD)G91%KKZ8L<'!2:'@UQ`Y*<?/G#!+'4[;);H4WT78N%&A9
MT)E7"P7:"M3$0'/*GC?'\RX@(N"G@-$N8A*\7Q#?0_*]/F5YL``2*A<4N%^N
M\`)2!B'?^/>D^=DR$)?Q3?UKG-:[OW`++RA_B=IUWFR>D1H:/DCWAN,WF$;8
M!\$*I8U?4@W6H;I1,J+X1UJ%CNN8_FR?)MHZ@4T$-A.>\F@\-8HVOW#'R\+@
M2$S:VIZ'$]P<F=^(BMA8-&EZ;]3ZZK7<'/8%O0:A"<,BYGR'F1'4J\\MV%J+
MB<X6=+9.WZ[1M\GA]L[A85U@MR:P2P*[_XV8,.=[S.,_3>AB3Q68-EX=2RH<
M=+RHB^I\.Y]9/)-/>%GTO(4?W+1"6W)!YT\V'D.#Z,";R!_V&>G\^YD3"8T+
MX:./3;I2*7'8WQ[(_$K+OU!+`P04````"`!(BDY'*:ZT$J0!``"Q`P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q]4]MNHS`0_17+'U`3DUXV(DA-
MJZI]6*GJP^ZS`P-8]87:)G3_?GTAE%2H+WAF..?,&5^*49MWVP$X]"F%LGO<
M.=?O"+%5!Y+9*]V#\G\:;21S/C4ML;T!5D>2%(1FV0V1C"M<%K'V:LI"#TYP
M!:\&V4%*9OX=0.AQCS?X7'CC;>="@90%F7DUEZ`LUPH9:/;X?K,[;`,B`OYP
M&.TB1L'[4>OWD+S4>YP%"R"@<D&!^>4$#R!$$/*-/R;-KY:!N(S/ZD]Q6N_^
MR"P\:/&7UZ[S9C.,:FC8(-R;'I]A&N$Z"%9:V/A%U6"=EF<*1I)]II6KN([I
M3YY/M'4"G0AT)MQET7AJ%&T^,L?*PN@1F;2U/0LGN-E1OQ$5LK%HTO3>J/75
M4[FYN2O(*0A-&!HQAPO,C"!>?6Y!UUI,=+J@TW5ZOD;/D\/\PN&O=8'MFL`V
M"6Q_&C%A#A>8V^Q;$[+84PFFC5?'HDH/*E[4176^G?<TGLD7O"QZUL)O9EJN
M+#IJYT\V'D.CM0-O(KNZQJCS[V=.!#0NA+<^-NE*I<3I_OQ`YE=:_@=02P,$
M%`````@`2(I.1]H,\W6B`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL?5/;;J,P$/T5RQ]0@Y-LJX@@-:U6NP\K57W8?79@`*N^4-N$[M_7
M%T))1?N"9X9SSISQI1BU>;$=@$-O4BA[P)US_9X06W4@F;W1/2C_I]%&,N=3
MTQ+;&V!U)$E!:);]())QA<LBUIY,6>C!":[@R2`[2,G,_R,(/1YPCB^%9]YV
M+A1(69"95W,)RG*MD('F@._S_7$;$!'PE\-H%S$*WD]:OX3D=WW`6;```BH7
M%)A?SO``0@0AW_AUTOQH&8C+^*+^,T[KW9^8A0<M_O':==YLAE$-#1N$>];C
M+YA&V`7!2@L;OZ@:K-/R0L%(LK>T<A77,?W9T8FV3J`3@<Z$NRP:3XVBS4?F
M6%D8/2*3MK9GX03S/?4;42$;BR9-[XU:7SV7^6U>D',0FC`T8HY7F!E!O/K<
M@JZUF.AT0:?K],T:?9,<;JX<?B&P71/8)H'M=R,FS/$:L_G4A"SV5()IX]6Q
MJ-*#BA=U49UOYWT\1/(!+XN>M?"'F98KBT[:^9.-Q]!H[<";R&YV&'7^_<R)
M@,:%\-;')EVIE#C=7Q[(_$K+=U!+`P04````"`!(BDY'T^SE5*(!``"Q`P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q]4]MNHS`0_17+'U`3A[15
M1)":5JO=AY6J/K3/#@Q@U1=JF]#^?7TAE*S0ON"9X9PS9WPI1FW>;0?@T*<4
MRAYPYUR_)\16'4AF;W0/RO]IM)',^=2TQ/8&6!U)4A":9;=$,JYP6<3:LRD+
M/3C!%3P;9`<IF?DZ@M#C`6_PI?#"V\Z%`BD+,O-J+D%9KA4RT!SPPV9_S`,B
M`EXYC'81H^#]I/5[2/[4!YP%"R"@<D&!^>4,CR!$$/*-/R;-GY:!N(POZK_B
MM-[]B5EXU.*-UZ[S9C.,:FC8(-R+'G_#-,(N"%9:V/A%U6"=EA<*1I)]II6K
MN([3G_N)MDZ@$X'.A/LL&D^-HLTGYEA9&#TBD[:V9^$$-WOJ-Z)"-A9-FMX;
MM;YZ+C=W>4'.06C"T(@Y7F%F!/'J<PNZUF*BTP6=KM.W:_1M<KB]<KA;%\C7
M!/(DD/]OQ(0Y7F-N_VE"%GLJP;3QZEA4Z4'%B[JHSK?S@<8S^8&71<]:^,M,
MRY5%)^W\R<9C:+1VX$UD-SN,.O]^YD1`XT)XYV.3KE1*G.XO#V1^I>4W4$L#
M!!0````(`$B*3D>);*P4HP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;'U3VVZC,!#]%<L?4!.'-MV((#6MJO9AI:H/N\\.#&#5%VJ;T/W[
M]850LD+[@F>&<\Z<\:48M?FP'8!#7U(H>\"=<_V>$%MU()F]T3TH_Z?11C+G
M4],2VQM@=21)06B6W1')N,)E$6MOIBSTX`17\&:0':1DYL\1A!X/>(,OA7?>
M=BX42%F0F5=S"<IRK9"!YH`?-OMC'A`1\(O#:!<Q"MY/6G^$Y+4^X"Q8``&5
M"PK,+V=X!"&"D&_\.6E^MPS$97Q1?X[3>O<G9N%1B]^\=ITWFV%40\,&X=[U
M^`+3"+=!L-+"QB^J!NNTO%`PDNPKK5S%=4Q_=OE$6R?0B4!GPGT6C:=&T>83
M<ZPLC!Z125O;LW""FSWU&U$A&XLF3>^-6E\]EYO=KB#G(#1A:,0<KS`S@GCU
MN05=:S'1Z8).U^G;-?HV.=Q>.;Q?%\C7!/(DD/]OQ(0Y7F-^_-.$+/94@FGC
MU;&HTH.*%W51G6_G`XUG\@TOBYZU\).9EBN+3MKYDXW'T&CMP)O(;FXQZOS[
MF1,!C0OASL<F7:F4.-U?'LC\2LN_4$L#!!0````(`$B*3D>Y974^H@$``+$#
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U3RV[;,!#\%4(?$,JT
MTQJ&+"!.4+2'`D$.[9F65A(1DJN0E)7^??F0%3E0>Q%W5S.SLWP4(YI7VP$X
M\JZDML>L<ZX_4&JK#A2W=]B#]G\:-(H[GYJ6VMX`KR-)2<KR_`M57.BL+&+M
MV90%#DX*#<^&V$$I;OZ<0.)XS#;9M?`BVLZ%`BT+.O-JH4!;@9H8:([9P^9P
MV@5$!/P2,-I%3(+W,^)K2'[4QRP/%D!"Y8("]\L%'D'*(.0;OTV:'RT#<1E?
MU;_%:;W[,[?PB/*WJ%WGS>89J:'A@W0O.'Z':83[(%BAM/%+JL$Z5%=*1A1_
M3ZO0<1W3G^U^HJT3V$1@,V&?1^.I4;3YQ!TO"X,C,6EK>QY.<'-@?B,J8F/1
MI.F]4>NKEW*SSPMZ"4(3AD7,Z08S(ZA7GUNPM183G2WH;)V^7:-OD\/MC<-_
M]-^M">R2P.Y_(R;,Z1;SV25=[*D"T\:K8TF%@XX7=5&=;^<#BV?R`2^+GK?P
MDYM6:$O.Z/S)QF-H$!UX$_G=?48Z_W[F1$+C0OC5QR9=J90X[*\/9'ZEY5]0
M2P,$%`````@`2(I.1_"J$>VC`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL?5/;;IPP$/T5BP^(62_;1"L6*9NJ:A\J17EHG[TP@!7;0VVS
MI']?7UA"*MH7/#.<<^:,+^6$YM7V`(Z\*:GM*>N=&XZ4VKH'Q>T=#J#]GQ:-
MXLZGIJ-V,,";2%*2LCS_1!47.JO*6'LV58FCDT+#LR%V5(J;WV>0.)VR778K
MO(BN=Z%`JY(NO$8HT%:@)@;:4_:X.YZ+@(B`'P(FNXI)\'Y!?`W)M^:4Y<$"
M2*A=4.!^N<(32!F$?.-?L^9[RT!<QS?U+W%:[_["+3RA_"D:UWNS>48::/DH
MW0M.7V$>X1`$:Y0V?DD]6H?J1LF(XF]I%3JN4_IS8#-MF\!F`EL(#WDTGAI%
MFY^YXU5I<"(F;>W`PPGNCLQO1$UL+)HTO3=J??5:[1[V);T&H1G#(N;\`;,@
MJ%=?6K"M%C.=K>ALF[[?HN^3P_VZ^_T_!(HM@2()%/\;,6'.'S'%7TWH:D\5
MF"Y>'4MJ''6\J*OJ<CL?XR'2=WA5#KR#[]QT0EMR0>=/-AY#B^C`F\CO#AGI
M_?M9$@FM"^&]CTVZ4BEQ.-P>R/)*JS]02P,$%`````@`2(I.1UU4J!*B`0``
ML0,``!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5/;;J,P$/T5RQ]0
M$R=IJX@@-:U6NP\K57UHGQT8P*HOU#:A_?OZ`I2LT+[@F>&<,V=\R0=MWFT+
MX-"G%,H><>M<=R#$EBU(9F]T!\K_J;61S/G4-,1V!E@525(0FF6W1#*N<)''
MVK,I<MT[P14\&V1[*9GY.H'0PQ%O\%1XX4WK0H$4.9EY%9>@+-<*&:B/^&%S
M..T"(@)>.0QV$:/@_:SU>TC^5$><!0L@H'1!@?GE`H\@1!#RC3]&S9^6@;B,
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M-U!+`P04````"`!(BDY''1#N%Z0!``"Q`P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q]4]N.FS`0_17+'[`F3K9-(H*TV:IJ'RJM]J%]=F``:VV&
MVB9L_[Z^$)94J"]X9CCGS!E?\A'-FVT!''G7JK,GVCK7'QFS90M:V`?LH?-_
M:C1:.)^:AMG>@*@B22O&L^P3TT)VM,AC[<44.0Y.R0Y>#+&#UL+\.8/"\40W
M]%9XE4WK0H$5.9MYE=3068D=,5"?Z-/F>-X%1`3\E##:14R"]POB6TB^5R>:
M!0N@H'1!0?CE"L^@5!#RC7]/FA\M`W$9W]2_QFF]^XNP\(SJEZQ<Z\UFE%10
MBT&Y5QR_P33"8Q`L4=GX)>5@'>H;A1(MWM,JN[B.Z0\_3+1U`I\(?";LLV@\
M-8HVOP@GBMS@2$S:VEZ$$]P<N=^(DMA8-&EZ;]3ZZK78[/<YNP:A"<,CYGR'
MF1',J\\M^%J+B<X7=+Y.WZ[1M\GA]L[A85U@MR:P2P*[_XV8,.<[S"'[IPE;
M[*D&T\2K8TF)0Q<OZJ(ZW\XG'L_D`U[DO6C@AS"-["RYH/,G&X^A1G3@360/
MCY2T_OW,B8+:A?"SCTVZ4BEQV-\>R/Q*B[]02P,$%`````@`2(I.1S.YB86'
M`@``(@H``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL?5;;CILP$/T5
MQ`<LV%R2K`C29JNJ?:BTVH?VV2%.0`N8VD[8_GUM<UD&V;R`;<Z<,[9GALEZ
MQC]$2:GT/INZ%4>_E+)[#@)1E+0AXHEUM%5?KHPW1*HIOP6BXY1<C%%3!S@,
MTZ`A5>OGF5E[XWG&[K*N6OK&/7%O&L+_G6C-^J./_&GAO;J54B\$>1;,=I>J
MH:VH6.MQ>CWZ+^CYA$,-,8C?%>W%8NQIY\^,?>C)S\O1#[4/M*:%U!1$O1[T
ME=:U9E+*?T?2+TUMN!Q/[-_-=I7[9R+H*ZO_5!=9*F]#W[O0*[G7\IWU/^BX
MAT03%JP6YND5=R%9,YGX7D,^AW?5FG<_?$GBT<QN@$<#/!OLS4D$@Y!Q\QN1
M),\XZST^G&U']!6B9ZP.HO"$6>3#[I6C0JT^<G1`6?#01",&&\P)8&9$H-AG
M"6R3&,WQPAS;S2.;>31X&"W54X=^;".(!X(8;!'#+0Z8$\1$=I%D0R0!!+%5
M!&(2NTBZ(9("@M0J`C$[N\AN0V0'"/96$8@YV$7V&R+[94R$H54$8AP7?]@0
M.0`"^\5#C./B=78[5?3'!87]ZE<@Q]TC:Z9..@A0V&]_!7)</[*FZZ0#\C6T
M!\`*Y(@`9,WK26>9V%%DEUEB,`H=,EO9CV)`@>PZ$.2H4FBK`""0W:GCV!*@
MXPJWK1J`4D#A"#<(<H7;5AE`.T#A"#<(<H7;5B5`(,V1X]P@R!5N6\4`@4S'
M]I*S`KE^=EOE`(-,Q_:JLP*MXR!8_,,;RF^F51%>P>ZMZ8P6JW,[]()-#_`%
MS[..W.@OPF]5*[PSDZJ3,+_]*V.2*B_")Q6-I6K8YDE-KU(/=VK,AQ9FF$C6
M31W9W!;F_P%02P,$%`````@`2(I.1W.D!-:Q`0``%@0``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL?53+;IPP%/T5BP^(&<\K&C%(F515NZ@49=&N
M/7`!*S:7VF9(_[Y^,`0BV@VV+^=UL4TVH'XS#8`E[TJVYIPTUG8G2DW1@.+F
M`3MHW9L*M>+6+75-3:>!EX&D)&5I>J"*BS;)LU![T7F&O96BA1=-3*\4UW\N
M('$X)YOD7G@5=6-]@>89G7BE4-`:@2W14)V3I\WILO>(`/@I8#"S.?'9KXAO
M?O&]/">ICP`2"NL5N!MN\`Q2>B%G_'O4_+#TQ/G\KOXU=.O27[F!9Y2_1&D;
M%S9-2`D5[Z5]Q>$;C"V$A`5*$YZDZ(U%=:<D1/'W.(HVC$-\<SB.M'4"&PEL
M(CRF(7@T"C&_<,OS3.-`=/RT'?<[N#DQ]R$*8D)1Q^Y=4..JMYRQ749O7FC$
ML("YS#&;"4&=^F3!UBQ&.IM;K-.W:_1M3+B=NQ_^X;];$]A%@=VBQ?VRQ8BY
M+#&'=9/]?TSV"X'CJLD2\_C)A,XV3H&NP_DTI,"^#;=A5IVNP!,+&_\!S[..
MU_"#ZUJTAES1NN,3]KI"M.!"I`\N1>,NZ;204%D_/;JYCN<V+BQV]ULX_0KR
MOU!+`P04````"`!(BDY'$H>;,]<!``!%!0``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6R-5-UNVR`4?A7D!R@.B9,T<BPUG:;M8E+5B^V:V,<_*A@/
M<-R]_0`[KJF8M1L#Q]\?QIQT$/)-U0`:O7/6JG-4:]V=,%9Y#9RJ!]%!:]Z4
M0G*JS5)66'42:.%(G&$2QWO,:=-&6>IJ+S)+1:]9T\*+1*KGG,H_%V!B.$>;
MZ%YX;:I:VP+.4CSSBH9#JQK1(@GE.7K:G"Y'BW"`GPT,:C%'-OM5B#>[^%Z<
MH]A&``:YM@K4##=X!L:LD#'^/6E^6%KB<GY7_^IV:])?J8)GP7XUA:Y-V#A"
M!92T9_I5#-]@VD)B!7/!E'NBO%=:\#LE0IR^CV/3NG$8WR1DHH4)9"*0F7",
M7?#1R,7\0C7-4BD&),=/VU%[@IL3,1\B1\H5Y;A[$U29ZBTCY#'%-RLT88C#
M7):8S8S`1GVV("&+B4Z6%F'Z-D3?C0FW2_HV]A..F(N/^4?&W8K)SA,@01,?
MLPV;)"LFB2>P"YKXF"1LLE\QV7L"^Z")CSF$30XK)@=/X!@6.*X('/_C4'W,
MXR<3O/C/.<C*76>%<M&WKGDLJG/'>'(7"W_`L[2C%?R@LFI:A:Y"F]OFKD8I
MA`83(GXP!U*;GC8O&)3:3@]F+L=K/BZTZ.Y-:^Z<V5]02P,$%`````@`2(I.
M1T-R^7.R`0``%@0``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL?53+
M;IPP%/T5BP^(P<.DZ8A!RJ2*TD6E*(MT[8$+6/&#VF9(_SY^,`0BV@VV+^=U
ML4TQ*OUF.@"+W@67YIATUO8'C$W5@:#F1O4@W9M&:4&M6^H6FUX#K0-)<$S2
M]!8+RF12%J'VK,M"#98S"<\:F4$(JO^>@*OQF&3)M?#"VL[Z`BX+//-J)D`:
MIB32T!R3^^QPVGM$`+PR&,UBCGSVLU)O?O&S/B:ICP`<*NL5J!LN\`"<>R%G
M_&?2_+3TQ.7\JOX8NG7IS]3`@^*_66T[%S9-4`T-';A]4>,33"V$A)7B)CQ1
M-1BKQ)62($'?X\AD&,?X)K^;:-L$,A'(3+A+0_!H%&+^H):6A58CTO'3]M3O
M8'8@[D-4R(2BCMV[H,95+R7)TP)?O-"$(0%S6F*R&8&=^FQ!MBPF.EE:;--W
M6_1=3+A;NM]^WQ;(MP3R*)"O6LS6+4;,:8WY1\K]?TSV*X'=ILD:DW\QP8N-
M$Z#;<#X-JM0@PVU85.<K<$_"QG_"RZ*G+?RBNF72H+.R[OB$O6Z4LN!"I#<N
M1><NZ;S@T%@__>;F.I[;N+"JO]["^5=0?@!02P,$%`````@`2(I.1^P/TK^R
M`0``%@0``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL?53+;J,P%/T5
MBP^HB1.:-B)(34?5S&*DJHMV[<`%K/I!;1,Z?U\_"(41,QML7\[K8IM\4/K=
MM``6?0HNS3%IK>T.&)NR!4'-C>I`NC>UTH):M]0--IT&6@62X)BDZ2T6E,FD
MR$/M61>YZBUG$IXU,KT05/\Y`5?#,=DDU\(+:UKK"[C(\<2KF`!IF))(0WU,
M'C:'4^81`?#*8#"S.?+9STJ]^\6OZIBD/@)P**U7H&ZXP"-P[H6<\<>H^6WI
MB?/Y5?TI=.O2GZF!1\7?6&5;%S9-4`4U[;E]4<-/&%L("4O%37BBLC=6B2LE
M08)^QI'),`[Q349&VCJ!C`0R$>[2$#P:A9@_J*5%KM6`=/RT'?4[N#D0]R%*
M9$)1Q^Y=4..JEX+LLAQ?O-"((0%SFF,V$P([]<F"K%F,=#*W6*=OU^C;F'`[
M=]__0V"W)K"+`KM%B[?+%B/FM,3LUTVR_YAD"X&[59,EYOXO$SS;.`&Z">?3
MH%+U,MR&676Z`@_AI.!O>)%WM('?5#=,&G16UAV?L->U4A9<B/3&I6C=)9T6
M'&KKIWLWU_'<QH55W?463K^"X@M02P,$%`````@`2(I.1R0--*CO`0``[04`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC53=;ILP%'X5BP>H@03R
M(X+4M)JVBTE5+[9KAYP`JHVI;4+W]K,-H;ARV&YB^_C[LXE/UG/Q)BL`A3X8
M;>0AJ)1J]QC+H@)&Y`-OH=$[%RX847HI2BQ;`>1L28SB.`Q3S$C=!'EF:R\B
MSWBG:-W`BT"R8XR(/T>@O#\$47`KO-9EI4P!YQF>>.>:02-KWB`!ET/P&.V/
M46@@%O&KAE[.YLB$/W'^9A8_SH<@-!F`0J&,!-'#%9Z`4J.DG=]'T4]/0YS/
M;^K?['%U_!.1\,3I[_JL*ITV#-`9+J2CZI7WWV$\0V($"TZE_45%)Q5G-TJ`
M&/D8QKJQ8S_L;,*1YB?$(R&>"%M+P(.1C?E,%,DSP7LDAKMMB?F$T3[6%U$@
M:8MB.+T.*G7UFL=)F.&K$1HQL<4<YYAH0F"M/EG$/HN1'L\M_/25C[X>$JZ<
MA)&;<,`<7<P=D_6"R=H16'E-7,S:;Y(LF"0S@=W*ST\7^*D3(/&&=#&IWV2S
M8+)Q!#9>$Q>S]9ML%TRV\YNX\[EV"_S=?]R$B]GY3<R[O>MB-O]Y%RXH#;_X
MX-ES9"!*VW4D*GC7V"8WJTZ=[3&VS_D3GF<M*>$G$67=2'3B2C<%^X(OG"O0
M*<('_=^J=.^=%A0NRDPW>BZ&;C0L%&]OS77J\/E?4$L#!!0````(`$B*3D?"
M/0D?W0(``$(,```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U7VW*;
M,!#]%88/"*RX.F-[IHF3M`^=R>2A?99MV68"R$5RG/Y])024=86*'PP2Y^S9
ME?9@>7GES;LX,2:]SZJLQ<H_27F^#P*Q.[&*BCM^9K5Z<N!-1:4:-L=`G!M&
M]RVI*@,2AFE0T:+VU\MV[K59+_E%ED7-7AM/7*J*-K\?6,FO*Q_\?N*M.)ZD
MG@C6RV#@[8N*U:+@M=>PP\K_`O<OA&A(B_A1L*L8W7LZ^2WG[WKP;;_R0YT#
M*]E.ZA!473[8(RM+'4DI_^J"_M74Q/%]'_VY+5>EOZ6"/?+R9[&7)Y5MZ'M[
M=J"74K[QZU?6U9#H@#M>BO;;VUV$Y%5/\;V*?IIK4;?7JWF2AQW-3B`=@0P$
M`DY"U!&B@0"QDQ!WA'BN0M(1DKDUI!TAG:N0=83LAA"8U6WW9D,E72\;?O4:
MTU!GJOL6[C.U^SM/M).-V7*U.T+-?JQ)"LO@0P?J,*3%/&`,L6$>,2:R8388
M$]LP3QB3V##/&)/:,"\8DPV80*W)L##$MC"161B"`N3V`)$M0&P"1"C``F>9
MFFH-INY7)`Q#&^P9P9)H#$/IQ(YTXG$ZV8V.P3QA#-A%$H=(@@(0JPC&1':1
MU"&2H@`W;;0P[9B.5@S('8Q@2"=SZ&1()[%N8#;6"=N/72AW".5(*+4*Y2.A
M%'<*TEDX=!9()[/IO"S&K18M8%)(O^8GE?3#D51N;80;T&)"Q_KVZG60S:,)
MEX++YS#+Z.!R.D3_[Y0-1'-;!5PV!N31_,;'2:<5C[02EY3+S("<FH-]$S&(
M3.BX_`S(T'ED7[X4O0-=-;D\#<C4>6RK:7,#2B9T7):&&9[>P%Q3@\O5,,/6
M&T"^CAW+1UR^)LBR>3H1PFK9_G<5YOB-6"W;9T%<'C`5/W2@KF+UB_=/P<'H
MI'2F1_:=-L>B%MZ62W7H:D](!\XE4]'".]7F)W6@'P8E.TA]FVG+F2.N&4A^
M[D_LP]^&]1]02P,$%`````@`2(I.1T_FK0$(`@``<08``!D```!X;"]W;W)K
M<VAE971S+W-H965T,C4N>&ULC57;;ILP&'X5Q`/4Y@P105J#INUB4M6+[=H!
M$U`-9K83NK>?#X1!!S0W,;:_T__'F'2@[(W7&`OKO24=/]JU$/T!`%[4N$7\
MB?:XDSL592T2<LHN@/<,HU*36@)<"$/0HJ:SLU2OO;`LI5=!F@Z_,(M?VQ:Q
M/\^8T.%H._9]X;6YU$(M@"P%$Z]L6MSQAG86P]71_N(<<@<JB$;\;/#`9\^6
M"G^F]$U-OI='&ZH,F.!"*`DDAQL^84*4DG3^/8K^\U3$^?-=_:LN5\8_(XY/
ME/QJ2E'+M-"V2ERA*Q&O=/B&QQH")5A0PO6O55RYH.V=8ELM>C=CT^EQ,#LQ
M'&GK!'<DN!/!\7<)WDCP'B7X(\'_0`"F%-V('`F4I8P.%C/_7H_4(7$.OFQU
M87&]R$Q_92NX7+UE;AREX*:$1HRK,<\+S!KBM%2)US#Y$I-,&"!33E'=M:B>
MB>K.!<)X7<!;$_"-@#<3\+QER-"4:B"=AD0^A'#=Q=]Q\><Q$[AFD_LS&]=+
MG$VC8,<HF!MY&_T(=QH:/M+0:"=!M"C5698:F%*C>4?=:+/2>,<G7OBXJS[Q
MS,<)$KAIE.P8)9^>D#QY[(2H*V?31FU^=D9.(V@\),KI/R\P>]=[=,$_$+LT
M';?.5,AK0[_C%:4"2SGX)/M4R_M_FA!<"?48J0::&]%,!.WO%_STE<G^`E!+
M`P04````"`!(BDY'9R?J$R`"```=!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6R-5=N2FR`8?A7'!U@0XVG'.-.DTVDO.K.S%^TU24AT%L4"B=NW
M+P>UN"4V-T'@^[\#!"@'QM]$38@,WEO:B6U82]D_`R".-6FQ>&(]Z=3,F?$6
M2]7E%R!Z3O#)%+44(`A3T.*F"ZO2C+WPJF1729N.O/!`7-L6\]\[0MFP#:-P
M&GAM+K74`Z`JP5QW:EK2B89U`2?G;?@I>MY'2$,,XD=#!N%\!]K\@;$WW?EV
MVH90>R"4'*6FP*JYD3VA5#,IY5\CZ5]-7>A^3^Q?3%QE_X`%V3/ZLSG)6KF%
M87`B9WRE\I4-7\F8(=&$1T:%^0V.5R%9.Y6$08O?;=MTIAWL3`[',G\!&@O0
M7!!M5@OBL2#^4`"L,Y/K,Y:X*CD;`FXWH\=ZSZ/G6*W<,1!FD-OE4LF$&KU5
MJ(A+<--$(P89S&Z!\2'V"P2<(4`9F%T@GXO8ND`+%QL_0>PCV%B"V"&(DZ7'
MU*:PD,Y`4I1G6>J#[1>PHDC2V.]FL^)FX\:)<S]!LK(>R2/KD?H($DN0.BD0
MC#Y$M:"="XJ2`L([.Y>M"&5+H<PKE#THE*\(Y4NAW"N4/RA4K`@52Z'"*U0\
M**0ODKM*>M*1<@Z.*[5`K6IYS_GXEXR6!SWQ2T6.5)8E]Z6\AWF20O\_C"-F
M"I7!?Z6`<Y'U^$*^8WYI.A$<F%1WHKG`SHQ)HNC@DPI0J[=J[E!REOHST\GL
M[6T[DO738S2_B-4?4$L#!!0````(`$B*3D?IDYV+[`(``$$*```9````>&PO
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MW+11S6021TWY/ERKMK_>AR<\'<U@`SP:X-D`L54#,AJ0#X.LSW0@Z_/Z6IIR
MM^G4/>J&Q;B6;LW1([&5.T2ZG^R&<MG,M)U]VV'!-LF;<S1J<*_9^QHT*Q+K
M?0Z!H1"C.?9#0`&*0)'"$0@4@0Q)D"")'':000ZRP4'F.<CSD)$-60R2=B@"
MR1%*&:0K`EU.&"("YJ$K"5&?A\/V;"4?%A2$AZ!T2(CYH!QQ)E)(5_@ZG-(L
MYPP&RE>`<@^(@W'VN1>'I(PRS$">0">(K?!"@?D*#_=Y$,C#_?I0)CA8QB*0
M84KYPNLG5FB$3X-!&N&%R3*4<YZ!.+X.$\X9HS"/:W&+0.ZA]P()$&D439\$
M$AS4%:$N=;\%)+!134A^%^($)D)>I"\<VRTK!Q>W")7,E0DM?&<([&T3E=^Z
MX"79CYHQ%D*9$/#:A<*,4DH6D,!F."'YW9!3&(D$A2*$I@Q4%J&2"83]DH94
M:QT6^2V6@U_V'F7!RRL0W)`"&4>$+75\!+;8"<COL1SN^:-F+A-"B%*PZX=*
ME@I.\NP35>+MS(WLSOV)14<'=6N-VPJ]V?E4](3=SOYI?N].2_V._^%FM[F6
M9_FS[,Y5JZ,79>RYH=_D3TH9:1'3!XMXL>>Y>5#+DW&WN:OK<,(9!D9=IP/;
M?&K<_0=02P,$%`````@`2(I.1Y*QX5]W`@``9PD``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&ULC5;;CILP$/T5Q`<L&,(E$4':I*K:ATJK?6B?'>($
MM("I[83MW]<7(#@R7O(0?#DSYXS'8SOK,?F@)4+,^6SJEN[=DK%NYWFT*%$#
MZ0ON4,MG+I@TD/$NN7JT(PB>I5%3>X'OQUX#J];-,SGV1O(,WUA=M>B-./36
M-)#\.Z`:]WL7N./`>W4MF1CP\LR;[,Y5@UI:X=8AZ+)W7\'N"%(!D8C?%>KI
MK.T(\2>,/T3GYWGO^D(#JE'!A`O(/W=T1'4M/''FOX/3!Z<PG+='[]]EN%S^
M"5)TQ/6?ZLQ*KM9WG3.ZP%O-WG'_`PTQ1,)A@6LJ_YWB1AEN1A/7:>"G^E:M
M_/9J)O4',[-!,!@$DP&(K0;A8!`^##8R4J5,QO4-,IAG!/<.4<GHH,@YV(5\
MY0J'RD&BEHM'1OGH/0]]/_/NPM&`"23F,,>`">%Q[Q-%8*(8S(.9>6`B.&H(
MW\P0FAA"%42H!;$@<6-RL%$.-IJ#)Y&Q"D-A6HGQ38BC&:&)B"PBHKF(C5%#
M-&-((E_\C$IL.$U/;-$3:XL2ZD0*<YAC@F1K)DDL)(E&8HXZ^7I=4PM%JE%$
M9@=;R_;:KME>XLA8E"`F%W,;#57FKTT:,!;T2*57=&Q<T0&DN*Q4QL(>J8(5
M.^0)E"SP&,M[Y-'K.S7SZ*"%K0ALIP#0C@&PM"3&&AZV"HA6[15;V8%X30+C
M60+#U))`6_&!9$T"-1!8"LE6@2!=DT`-!((G'F]VKS6(7.5]3YT"WUKYO)B-
M3F^*UT#>BP]XGG7PBGY!<JU:ZIPPX[>KO`HO&#/$5?@O/($E?_5,G1I=F&@F
MHDS5.T!U&.[&9\WTMLK_`U!+`P04````"`!(BDY'2DC$O%\"```U"```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R-5LN.FS`4_17$O@/8/$)$D&:H
MJG91:32+=NT0)Z`!3&TG3/^^?@#!4X.21<#FW'//,;Z^9`.A[ZS"F#L?;=.Q
M@UMQWN\]CY45;A%[(CWNQ),SH2WB8D@O'NLI1B<5U#8>\/W8:U'=N7FFYEYI
MGI$K;^H.OU*'7=L6T;\ON"'#P0W<:>*MOE1<3GAYYLUQI[K%':M)YU!\/KC/
MP;X((@E1B%\U'MCBWI'BCX2\R\&/T\'UI0;<X))+"B0N-US@II%,(O.?D?2>
M4P8N[R?V;\JND']$#!>D^5V?>"74^JYSPF=T;?@;&;[CT8-26)*&J7^GO#).
MVBG$=5KTH:]UIZZ#?K+SQS![`!@#P!P0Q)L!<`R`]X!0.=7*E*^OB*,\HV1P
MJ'X9/9+O/-A#L7*EP]0DU<LEG#$Q>\MA`#/O)HE&#%"8ER4FF!&>8)]3`%N*
M,1PLPH$M06$@?'L&:,L`M0EHF`CM!*&-(-0$H4$0F2)C;4-C.BTR3?S8ABJ6
MJ"@!86P7$VV(B0PQ*P3QQG+$CRQ'LJ$@,0@2TVBDER-9&$U]\;.ABG64(6:W
M(69GB-E9Q>P6:;[$JVH,&(2K<M(-.>D#6R5=Y('_JQFW2FILE54Q\BQ:52,?
M+N2D*Q36$V#<+4'PR'8)K!4^J5@6,`2?[(;C*6*"5@Z2P%KG4QZCT`%8H;!6
M^N0V?,CM5GT&T2-N31#\E,=;G-(MIA?5O9A3DFNGFN5B=NZ0ST"=\G=XGO7H
M@G\B>JD[YAP)%[U"'>QG0C@6*OPGH:(2/7P>-/C,Y6TB*T)W-3W@I)^:]/RE
MD/\#4$L#!!0````(`$B*3D?J`V#1QP$``$4$```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;'U4R6[;,!#]%4(?$%*+G<"0!<0JBN10(,BA/=/2:$&X
MJ"1EI7\?+K(L%VHO(CE\[\T;#JE\DNI#=P`&?7(F]#'JC!D.&.NJ`T[U@QQ`
MV)U&*DZ-7:H6ZT$!K3V),YP0LL><]B(J<A][4T4N1\-Z`6\*Z9%SJOZ<@,GI
M&,71-?#>MYUQ`5SD>.'5/0>A>RF0@N88/<>',G,(#_C9PZ17<^2\GZ7\<(O7
M^A@19P$85,8I4#M<H`3&G)!-_'O6O*5TQ/7\JO[=5VO=GZF&4K)??6TZ:Y9$
MJ(:&CLR\R^D%YA)V3K"23/LOJD9M)+]2(L3I9QA[X<<I[#R1F;9-2&9"LA#B
M_7\)Z4Q(;P1_=#@X\W5]HX86N9(34J$7`W4MCP^I/;D*:1]4X;AL9=I&+T6:
M9#F^.*$9DWC,:8V)%P2VZDN*9"O%3$]6]&0K07F'(-L9TJT,:2@BO2MBMRV0
M;0ED02"[$]C?F]R',@)&!)./A)`M5/EO5#"#5^WAH%I_;36JY"B,.X]5='D9
MSXEK[U_QDWTQX8+?9(I\H"W\H*KMA49G:>SE\9UNI#1@[9&'780Z^Z:7!8/&
MN.FCG:MPS</"R.'Z:)<_1_$%4$L#!!0````(`$B*3D=ZM8[4]P$``.0%```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(U42X^;,!C\*XA[UV#"(Q%!
M:JBJ]E!IM8?V[(`):&U,;2=L_WW]("QL779SB.V/F?&,7_G(^+-H,9;>"R6]
M./JME,,!`%&UF"+QP`;<JR\-XQ1)->07(`:.46U(E``8!`F@J.O](C>U1U[D
M["I)U^-'[HDKI8C_.6'"QJ,?^O?"4W=II2Z`(@<SK^XH[D7'>H_CYNA_#@]E
MIA$&\+/#HUCT/>W]S-BS'GROCWZ@+6""*ZD5D&INN,2$:"$U\>])\W5*35SV
M[^I?35KE_HP$+AGYU=6R568#WZMQ@ZY$/K'Q&YXBQ%JP8D28?Z^Z"LGHG>)[
M%+W8MNM-.]HO63#1W`0X$>!,"'>;A&@B1&\(P#HSN;X@B8J<L]'C=B\&I+<\
M/$1JY2I/F"*WRZ62"56]%1%,<W#30A,&&LQIB8$N1+E"!#,$*`.S"^AR$5D7
M<.4B<PM$+H&=%8B6`O':8V)36$AO(`G,TC1QP<H5;+^/D\CM9K?A9K>*LW<+
MQ!OK$7]D/9(-!\EJ0]XDC>V")(ND61:HGPM6;L!6=M(-.^DR3^2<YY0NYOD$
MX_!_?E:X<,-0MF$H>_^\9*OSLO_'SG1>EK`T<+@!BPLYH`O^@?BEZX5W9E+=
M;7,1&\8D5F+!@\K8JB=W'A#<2-U-=7C["MF!9,/]39T?]N(O4$L#!!0````(
M`$B*3D=$`>!+QP$``$4$```9````>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;'U4V6ZC,!3]%8L/J`VDZ2@B2`U5U3Z,5/5AYMF!RZ)ZH;8)G;\?+X1`A?J"
MKZ_/.7>SR4:I/G0+8-`79T(?H]:8_H"Q+EO@5-_)'H0]J:7BU-BM:K#N%=#*
MDSC#"2%[S&DGHCSSOC>59W(PK!/PII`>.*?JWPF8'(]1'%T=[UW3&N?`>89G
M7M5Q$+J3`BFHC]%C?"AV#N$!?SH8]<)&+O>SE!]N\UH=(^)2``:E<0K4+A<H
M@#$G9`-_3IJWD(ZXM*_JS[Y:F_V9:B@D^]M5IK7)D@A54-.!F7<YOL!4PKT3
M+"73_HO*01O)KY0(<?H5UD[X=0PGO\A$VR8D$R&9"?'^1T(Z$=(;P;<.A\Q\
M74_4T#Q3<D0JS**G;N3Q(;6=*Y'V3A7:92O3UGO)TS3.\,4)39C$8TY+S`V!
MK?H<(MD*,=&3!3W9"E"L$&0[0KH5(0U%I*LBDFV!W9;`+@CL5@+I.LE]*"-@
MA,<\Q(20+52Q0I$E*B2#%^/AH!I_;34JY2",Z\?".[^,Q\2-]YO_9%],N.`W
MF3SK:0._J6HZH=%9&GMY_*1K*0W8],C=?81:^Z;G#8/:.//!VBI<\[`QLK\^
MVOG/D?\'4$L#!!0````(`$B*3D?7_97)*`(``#\'```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;(U5RXZ;,!3]%<0'#,:\(X+4I!JUBTJC6;1K)W$"
M&H,9VPG3OZ\?0,W4H=G@U[GGG&MS[7*@[(W7&`OOHR4=W_JU$/TF"/BQQBWB
M3[3'G5PY4]8B(8?L$O">873202T)(`!IT**F\ZM2S[VPJJ1709H.OS"/7]L6
ML=\[3.BP]4-_FGAM+K50$T%5!G/<J6EQQQO:>0R?M_Z7<+,/H8)HQ,\&#]SJ
M>\K\@=(W-?A^VOI`><`$'X6B0+*YX3TF1#%)Y?>1]*^F"K3[$_NS3E?:/R".
M]Y3\:DZBEFZ![YWP&5V)>*7#-SSFD"C"(R5<?[WCE0O:3B&^UZ(/TS:=;@>S
MDH,QS!T`QP`X!X3Q:D`T!D2?`@+C3.?U%0E4E8P.'C.'T2-UYN$FDCMW]+B>
M9&:[9&9<SMZJ*(K+X*:(1@S4F)V-@2[$?H$`,R20!F87T.4B,B[@PD7B)HA<
M!+$AB&R"9.DQ-5D82*<A*<RS+'7!]@M8421IY'83K[B);3>P<!,D*_N1/+(?
MJ8L@,02IE04$X:=4#6AG@[(0@#L'EZWH9$N=S*F3/::3K^CD2YW<J9,_IE.L
MZ!1+G<*I4SRFHRZ1NT)JT5*RBL966J#6I)PE/OZ-X:(ZB\2M%-I^LOB^E+..
M)RGX_SH<,5,A%K:278@+7`;`OXX"ZZKKT07_0.S2=-P[4"%O37W%G2D56+*!
M)YEG+5^S>4#P6:ANIC;`W.]F(&@_/5?SFUG]`5!+`P04````"`!(BDY'!;R8
M/%\"```V"```&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R-EMMNHS`0
MAE\%\0`%FV,B@M1D574O5JIZL7OM$">@`F9M)W3??GT`@BM#FHN`S3_SS>"Q
MAZPG](.5&'/GLZE;MG-+SKNMY[&BQ`UB3Z3#K7AR)K1!7`SIQ6,=Q>BDC)K:
M@[X?>PVJ6C?/U-P;S3-RY775XC?JL&O3(/IOCVO2[US@CA/OU:7D<L++,V^R
M.U4-;EE%6H?B\\Y]!ML#B*1$*7Y7N&>S>T<&?R3D0PY^GG:N+V/`-2ZX=('$
MY88/N*ZE)T'^.SB],Z7A_'[T_J+2%>$?$<,'4O^I3KP4T?JN<\)G=*WY.^E?
M\9"#BK`@-5/_3G%EG#2CB>LTZ%-?JU9=>_TD]0<SNP$<#.!D,''L!L%@$-P-
M8I6ICDSE]0-QE&>4]`[5B]$AN>9@&X@W5SA,35+]ND1F3,S>\B"(,^\F'0T:
MJ#1[4Y/8-(>Y!DP*3T0PA0%M80P(:"!2*V*N@79$8$.$.M/`0&SL#D*;@T`[
M".<.0M_N(%J)(#(<`#/)6">I-:W21+[\V3GQ"B<V.-#D1)H3SS@A2!<YR0HG
M,3B!-9]DQ@G@2D+I"B@U0*$)TIK#7`.3A>7=K$`V!B2R0DQ-;(?(PV.1(A].
M+C8+90RL.W8H0P"^4X?`NMO&(.#C2MP/(KUT,%I>.;"VZT#PN$CV@VBH$E_!
M%EC6#3JRPL=ULO\B2A8X:_L8F!LYM7,,$?AZ)GJS8[K!]*+:%W,*<FU5MYS-
M3BWR&:IC_B[/LPY=\"]$+U7+G"/AHEFHD_U,",<B"O])1%&*)CX-:GSF\C:1
MYX!N:WK`23=VZ>E3(?\/4$L#!!0````(`$B*3D=&!"F&'@(``.X&```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;'U5VXZ;,!#]%8L/6*XA%Q&D3:JJ
M?:BTVH?VV2%#0&MC:CMA^_?UA1"\<GB)[>&<,V=@,BX&QC]$`R#1)R6=V`>-
ME/TN#$75`,7BA?70J2<UXQ1+=>274/0<\-F0*`F3*,I#BMLN*`L3>^-EP:Z2
MM!V\<22NE&+^[P"$#?L@#NZ!]_;22!T(RR*<>.>60B=:UB$.]3YXC7?'K488
MP.\6!C';(^W]Q-B'/OP\[X-(6P`"E=0*6"TW.`(A6D@E_CMJ/E)JXGQ_5_]N
MJE7N3UC`D9$_[5DVRFP4H#/4^$KD.QM^P%C"2@M6C`CSBZJKD(S>*0&B^-.N
M;6?6P3[)XY'F)R0C(9D(<;Y(2$="^B!DIE+KS-3U#4M<%IP-B-MOT6/]R>-=
MJMY<A80)<ONZ5&5"16]EFFV+\*:%1DQB,(<Y)IX0H5*?4B2^%",]F=$37X*C
M@XC\&5)?AM06D<Z+6#T1R'P"F17('('8-6DQ!Q>3^##'9QC'R&K!R,H12+U&
M7$SF->)B5GXC^8*1?/[-8V^UA]Q)DGN-N)BUW\AZP<C:$=AXC;B8K=>(@\F?
M],AFP<C&$?#WB(OQ]\@SC&-DNV!DZPCX>\3%^'O$Q7SMD7`V1RCPBYFO`E7L
MVDG]QYU%IQ'^FN@Y]"5^4*/=3N*'3%GT^`*_,+^TG4`G)M64,R.I9DR",A>]
MJ`YNU.4S'0C44F_7:L_M/+8'R?K[[3)=<>5_4$L#!!0````(`$B*3D?H[IQ<
MFP(``.0)```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;'V6T9*;(!2&
M7\7Q?E=!%,PDSC3I=-J+SNSL17M-$I(XJV*%Q.W;%\2DL`O>1,'_G/,=)#^N
M1SZ\B0MC,GIOFTYLXHN4_2I)Q.'"6BJ>><\Z]>3$AY9*-1S.B>@'1H]34-LD
M,$V+I*5U%U?K:>YEJ-;\*INZ8R]#)*YM2X>_6];P<1.#^#[Q6I\O4D\DU3IY
MQ!WKEG6BYETTL-,F_@)6.Y!KR:3X5;-16/>1AM]S_J8'/XZ;.-4,K&$'J5-0
M=;FQ'6L:G4E5_C,G_5]3!]KW]^S?IG85_IX*MN/-[_HH+XHVC:,C.]%K(U_Y
M^)W-/4R$!]Z(Z3<Z7(7D[3TDCEKZ;JYU-UU'\X2D<Y@_`,X!\!$`T&)`-@=D
M'P(20S;U]95*6JT'/D:#>1D]U>\<K#*U<H=(3).#62[5F5"SMRHKBG5RTXEF
M#9PT6UL#?8J=HT@?DD0!/"B@CR(S%-"AP/X$F2\!,@DR)P%Q(0O3AM%T1J-V
M<^I3[<(J!P8MP"`'IG3+Y`8&665P%BR3+Y3)[3(X]9;)K3)/!?K4M)'M'!D(
MXQ0+.(6#`[PXA54'`02QE\96`4+*P'[`"QL*.S#0GX`L=$.<!)FW&V)Q%IEZ
M!8'5M74903BXO.4"4.D`(2]0:2]OGH5X'!D)[W'M@D$>_=`"RKU`LVA^E3D)
M$;FZ,@TC>;WLCN28&2[\I8!5BBQ4\OK5O9)C6-B[C;>S:/Y708S+8/N+2A=K
MR06!8X.8^+%LAWM"$*1!+$<)2!$V!K#DA\`Q1.PW1(`<K*`Y?-!!D@;L`2QY
M)W#,DWB/@BVP;=%_6CB2)X@^+U!BG<<]/;.?=#C7G8CV7*JC?3J'3YQ+IK*E
MSRK;17UR/08-.TE]BW7SYB/$#"3O[]]4CP^[ZA]02P,$%`````@`2(I.1Q!;
M9US,`0``QP0``!D```!X;"]W;W)K<VAE971S+W-H965T,S<N>&ULA53;CILP
M$/T5BP]8FUO21@2I2[5J'RJM]J%]=F`(:&W,VD[8_GU](=2L:/J"/>-SSIRQ
MC8M)R%?5`6CTSMF@CE&G]7C`6-4=<*H>Q`B#66F%Y%2;4)ZQ&B70QI$XPPDA
M.\QI/T1EX7+/LBS$1;-^@&>)U(5S*G\_`A/3,8JC6^*E/W?:)G!9X(77]!P&
MU8L!26B/T9?X4.46X0`_>YA4,$?6^TF(5QM\;XX1L1:`0:VM`C7#%2I@S`J9
MPF^SYM^2EAC.;^I/KEOC_D055(+]ZAO=&;,D0@VT],+TBYB^P=R"<U@+IMP7
MU1>E!;]1(L3INQ_[P8V37\GW,VV;D,R$9"'$V5U".A/2#P3LG;F^OE)-RT**
M"4E_%B.U1QX?4K-S-5(N*?UVF<Z4R5[+]%-<X*L5FC&)PSR&F&0+4:T09(%@
M8V!QD6RY2+V+).#'N\_;`NF60.8%TE4;'TSN?!L>,S@,V4)4(2+)"/E')]D=
M(]G*2+HNDWLC65`FWL>$A)4"8+4"DFP-7%G*[UC*5Y:RS;W)_[LWVPAO`@=W
M;J1G^$'EN1\4.@EMKJ^[:ZT0&HP.>3!"G7E5EH!!J^UT;YOV/YH/M!AOS\;R
M=I5_`%!+`P04````"`!(BDY'']YJ"+L#``!/%0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6R-F-MRFS`0AE^%X0$*.G#*V)YIW.FT%YW)Y**])K9L
M,P'D@ARG;U\.PI4::;TWP<"O_5<LGY9H=97=:W\20@7O3=WVZ_"DU/DABOK=
M231E_TF>13O<.<BN*=5PVAVC_MR)<C\-:NJ(QG$:-675AIO5=.VIVZSD1=55
M*YZZH+\T3=G]>12UO*Y#$BX7GJOC28T7HLTJNHW;5XUH^TJV02<.Z_`S>=@F
M\2B9%#\K<>V-W\&8_(N4K^/)]_TZC,<<1"UV:@Q1#H<WL15U/48:G'_KH/\\
MQX'F[R7ZUVFZ0_HO92^VLOY5[=5IR#8.@[TXE)=:/<OK-Z'GD(P!=[+NI[_!
M[M(KV2Q#PJ`IW^=CU4['ZWPGC_4P]P"J!]#;`,+!`4P/8/\-B.;,IGE]*56Y
M677R&G1S,<[E6'/RP(8GMPOZZ6(W/ZYA9OUP]6W#\F05O8V!M(9.FD=30UV*
MK:6(;Y)H2."6!75EP>8LJ)5%Z@[`7`'X'(`9`0IBYYC..<Z2=O:@='B=/8ER
MET\R^W`C"(U):CO-HJTI(IQF7J<$<$ILI\SI9(IXFGJ-4L`HM8URIU&*-,H`
MH\PV*IQ&IH@SYC7*`:/<,C+>1],HMXQBKU$!O'6%^=H7B=.G,'P\%N-JX_48
M;QIL9)X03L8U781@\").0)<L*`"8GJG6Z/<^C_W/E#A1UM4C#,.8I6(IX`7A
M3#B&,DL%>D%`DP0#FJ4"O2"F28IAS5*!7A#6),/@9JE`+R?9RVN8(X@C.0(Y
M"&M26+SDGG[FI'9I:#$&.>JD5F=!R=V>]J@U\U03FSCSD4`Z.R/G(J`K32F&
M3$L%>D$-G3)$I2F[7VGJY']QX5:9"D\()]9+I1-4I9VT+EFD]Q=7:K&:`$\5
M8I5FJ`J:J@RP@IHPS3%+JZ6"K)R\+E8%9F6U5(`5<W*MK5B,65@M%63EY'^Q
M(IAUU5)!5E!W9Q0!&Z/W86/@-[J)-"M\(9R\:M@8Q\#&G+PN623W86-6$Z:%
M_ZE"39BE&-@L%>CE!'N958:I8(:H(-1^66Y5D'A".%E=*EA@*LBA+V(>WZ\@
M-PDDP/\1'$*0$TP%+17H!3'(,0QR!(,<8I#;#%)/"(A!CF*00PQR!(/<9)`0
M_\K&(08YBD'^H;EZK*#>RC-,P^,?OH,]5E!OY3FFX5DJR`KJK;S`-#Q+Y0<@
M@;!.8@@`O8F3Q```D;'U=2Z/XD?9':NV#UZD4K*9MKP.4BHQ!(H_#9F?1+F_
MG=3BH,:?V3BE>;]O/E'RO&Q?WO90-W\!4$L#!!0````(`$B*3D=8-OZ0Y0(`
M`-8,```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;(U7T9*;(!3]%<</
MJ'(5HSM)9IID.^U#9W;VH7UF$Y(XJY(*V6S_OB":PA:H+S'BN>?><^&`+F^L
M?^5G2D7TWC8=7\5G(2X/2<+W9]H2_HE=:">?'%G?$B%O^U/"+STEAR&H;1)(
MTR)I2=W%Z^4P]M2OE^PJFKJC3WW$KVU+^M\;VK#;*D;Q-/!<G\Y"#23K97*/
M.]0M[7C-NJBGQU7\&3T\0JD@`^)'36_<^!^IXE\8>U4WWPZK.%4UT(;NA:(@
M\O)&M[1I%)/,_&LD_9M3!9K_)_8O@UQ9_@OA=,N:G_5!G&6U:1P=Z)%<&_',
M;E_IJ`$KPCUK^/`;[:]<L'8*B:.6O.MKW0W7FWY2IF.8.P#&`+@'H#P8D(T!
MV=R`?`S(YP;@,0!_"$BT]J%S.R+(>MFS6]3KZ;X0M:K0`Y9SLX_X,-CK"9&]
MXW+T;9U5V3)Y4T0C!@;,QL;D+LS6QF`79F=BP(5XM!#I'9)((7<UX%*3:35@
M5E$6;H+,19!K@LR24=A%%KI(C>DT!D`ZSU-I'DB46XD6=B*-V=F8TIT$!Y)@
MBZ!RJ=EA0PU4/BE%($MA9,D-@@&#=9;"R(*0OV6+0)Z%-;F>=I2!U5'.61U5
MH(+J_ZMC5QE*<9JF[H8\!F!6.6JO\]:C'AJ**@^%T_]C3Q":TQ3D--U4!83:
M,NH=0:-K<$!PR)XHL]8:<MKF`P@\>4+N1+;U?*4ZO3<U%L]J;,A8J)BQ&Z'"
MVHXJ?V-#WD(+JV>9AR+D+C3+7BCD+S3'8,BT#LHRKV`(60=22W#NH0A9!V99
M!T+6@:!U1L$`,V<80M8!VQ780^%TQ20XGR4X="(!MJIP"MZ">29E_JT"0N8!
MVSS.$W;S`>0Y4R#D'+".)?<ANQE!6E&)O8*<_IH2E5;K4G>BTFP=*O_M76*\
M'U[(B7XG_:GN>/3"A'S5'-X+CXP)*MG23W(BSO(CXW[3T*-0?Q=J5]>OW?I&
ML,OT%7'_E%G_`5!+`P04````"`!(BDY'Y_5MS,H!``!%!```&0```'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6Q]5,ENVS`0_15"'Q!2B^W"D`7$*H+V4"#(
MH3W3TFA!N"@D9:5_7RZR+`="+R(Y?._-&PZI?)+J77<`!GUR)O0IZHP9CACK
MJ@-.]9,<0-B=1BI.C5VJ%NM!`:T]B3.<$++'G/8B*G(?>U5%+D?#>@&O"NF1
M<ZK^GH')Z13%T2WPUK>=<0%<Y'CAU3T'H7LID(+F%#W'QS)S"`_XW<.D5W/D
MO%^D?'>+G_4I(LX",*B,4Z!VN$()C#DAF_ACUKRG=,3U_*;^XJNU[B]40RG9
MG[XVG35+(E1#0T=FWN3T`^82=DZPDDS[+ZI&;22_42+$Z6<8>^''*>SLLYFV
M34AF0K(0XOU_">E,2.\$GP$'9[ZN[]30(E=R0BKT8J"NY?$QM2=7(>V#*AR7
MK4S;Z+7(R"''5R<T8Q*/.:\Q\8+`5GU)D6REF.G)BIYL)2@?$&0[0[J5(0U%
MI&N#AV1;(-L2R()`]G`*WQY-[D,9`2,\9A<30K90Y1H5/Z""&;QJ#P?5^FNK
M425'8=QYK*++RWA.7'N_Q,_VQ80+?I<I\H&V\(NJMA<:7:2QE\=WNI'2@+5'
MGG81ZNR;7A8,&N.F!SM7X9J'A9'#[=$N?X[B'U!+`P04````"`!(BDY'2Y5O
M#=L!``!H!0``&0```'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R-E,V.FS`4
MA5\%\0"Q^8T:$:0.HZI=5!K-HET[<`EH;,S83IB^??U#J!DAU"R";<XY_NY%
M=C%Q\28[`!5\,#K(<]@I-9X0DG4'C,@#'V'0;UHN&%%Z*JY(C@)(8TV,HACC
M'#'2#V%9V+4741;\IF@_P(L(Y(TQ(OX\`>73.8S"Q\)K?^V464!E@19?TS,8
M9,^'0$![#K]&IRHW"BOXU<,DO7%@V"^<OYG)C^8<8H,`%&IE$HA^W*$"2DV0
MWOA]SORWI3'ZXT?Z-UNMIK\0"16GO_M&=1H6AT$#+;E1]<JG[S"7D)G`FE-I
M_X/Z)A5G#TL8,/+AGOU@GY-[D^/9MFV(9T.\&*)TUY#,AN23`3DR6]<S4:0L
M!)\"X;[%2,PGCTZ)[EP=2+LH7+MT95*OWLL4?RG0W03-FMAJGGQ-O*6H5@J\
M2)`&6"CB+8K$4<2>/SIFVP')5D#J`A(OX(C7C)FKPDD&*TGP_-M25OO*%5.Z
MPY1Z3/FGSAX=4^KMA`]ZEVA+5NW(5C39#DWFT^2;'<J\;;*]!NT*5T3Y#E'N
M$V6;_<G_KS\[,D>#O$,QDBO\).+:#S*X<*7/EST,+><*=!@^Z.HZ?>TM$PJM
M,L.CJ=[=!&ZB^/BXUY;+M?P+4$L#!!0````(`$B*3D<7GK"E)P,``$8.```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;(V7T6Z;,!2&7P7Q`,4^!@-5
M$FEM&FT7DZI>;-<T<1)4P!DX3??V,V"H7=D>-R'`?\[O<^S/P.K&V[?NS)@(
M/NJJZ=;A68C+?11U^S.KB^Z.7U@C[QQY6Q="GK:GJ+NTK#@,0745`4(TJHNR
M"3>KX=ISNUGQJZC*ACVW07>MZZ+]^\`J?EN'.)PNO)2GL^@O1)M5-,<=RIHU
M7<F;H&7'=?@-W^_((!D4OTIVZ[3_03_X5\[?^I,?AW6(^C&PBNU%GZ*0AW?V
MR*JJSR2=_ZBDGYY]H/Y_RKX;RI7#?RTZ]LBKW^5!G.5H41@<V+&X5N*%W[XS
M54/2)]SSJAM^@_VU$[R>0L*@+C[&8]D,Q]MX)\U5F#T`5`#,`8"\`40%D#F`
MI-Z`6`7$GP[^@$0%))\!V!M`50#]4D,T-FMH];80Q6;5\EO0CNOC4O3+$-]3
M.9G[H!LNMN,,RF9W\NK[)L9H%;WWB90&!LV#J<$VS:.I`9MF:VJ(3?-D:F*;
M9F=JDED3R7KGHL%6-!F+!B,!M2<@M@3QF(`8"5)SE,G8D5'3#!JP6\0>B]BP
MR*P6L6:!4YQED-F-$H]18ACEIA$=C1+=".$,(633;75=@I`N,\9#/>.A^GC`
MZO-$-1^"B=,G]?BDA@^V)\@\JRA;LHIRSPAR7^?5%.?Z*DJ=A?9[J-.GOZF5
MZEB,V+I-J%HQ7E(LMD(WC<*@#HAUH2F16FE9[B[8AR<V^(38VEFL`^IR\1&*
M#43!L0]A*WM36Y-%;?7A@NF2MNK`R!7@;JN/&&PB0^U6J6Y%W&QB*UN3E0$7
MI(X45KJFWN9+>@L^<,`$Q[H)[Y1HVAR19]L#*V*3F8$8Y(X4WN?:H@<;^-"!
M!>@\P`)TP(<.Z.CDQ)'!1PXL(@=\Y(!!CN,1"SHY&"-(J>-1`3YT(%VP(X&.
M#LX3N?_9=%M#)PG+7`WT$08Z8;GCF0`^P&`18,0'&$$+IH#H@%%,$75L!\2'
M%\'_GX&M$DVSG:+D:VLC[?7Z4IS8SZ(]E4T7O'(AW]2'U^HCYX+);.A.9CW+
MC[KYI&)'T?]->[OQ,V<\$?PR?;7-GXZ;?U!+`P04````"`!(BDY'A=9!;NP"
M```U#0``&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5]N.FS`0_17$
M!RS80"`K@K2AJMJ'2JM]:)^=Q$G0`DYM9[/]^]I<L@RR'5ZXF#,S9^PY@YW?
M&'\79TJE]]G4K=CX9RDOST$@]F?:$/'$+K157XZ,-T2J5WX*Q(53<NB,FCK`
M8;@*&E*U?I%W8Z^\R-E5UE5+7[DGKDU#^+\MK=EMXR-_''BK3F>I!X(B#^YV
MAZJAK:A8ZW%ZW/@OZ+G$F89TB-\5O8G)LZ?)[QA[UR\_#QL_U!QH3?=2NR#J
M]D%+6M?:DXK\=W#Z%5,;3I]'[]^[=!7]'1&T9/6?ZB#/BFWH>P=Z)-=:OK';
M#SKDD&B'>U:+[NKMKT*R9C3QO89\]O>J[>ZW_LL*#V9F`SP8X+L!2IT&T6`0
MS0R"GEF7US<B29%S=O-XOQ@7HM<</4=JYO:>Z`9Y/UTJ,Z%&/XHX"O/@0SL:
M,+C#;*<8=$<$ROL]!#:%&,SQQ!R;`I0`$9HC1*8(<9]$-+%?1V;[V&0?]?8Q
MF`1+BHF#0`(<S)+L,5N(B4R8TH8!1%8.(BO@(#82@9C$2`1B5F8BJ8-("ARD
M1B(0DQF)0,S:3"1S$,FF#N+02`1BD)$(Q&`SD;6#R!HX,*[_%F*,RU?:,("(
M;F!6)OKCEUXLJ2!CUQ@$@]`2Q2!C5QA)X,>:*2$H3BQQ7+T!18\E44)0;*EW
M9.PA8YSX<<67$!2GECBN5H.2QP5=SD"9)8ZKDZ#5XWHM9R!;,;H:!0(*CRT*
M1T:)C]68+:I&ES@14%5B;A,SD+E/`%"$+3T<N_2)0Q#'(E#L$BA>)%#L$BC&
MCZ>D!"![MBZ!8J"]Q.;"]?_&BW[@V"4KG"PH``"*8K/&9YXLFL`N[6$@J\32
M]K!15N.4I(NFQ/7GQ-F2`LB<V0:3W6A#^:G;I0MOSZZMU-N_R>C])/#2[9=G
MXUMU0NCW\U]NBOQ"3O07X:>J%=Z.2;57[C:V1\8D5>S")[469W6&N;_4]"CU
M8ZJ>>;^K[U\DNXR'E/M)J?@/4$L#!!0````(`$B*3D=4>6LQ*`,``/<,```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;(U7P6ZC,!#]%<0'!&S`ABJ)
MU!*M=@\K53WLGFGB)*B`4^PTW;]?&QQJ1X.;2PGFS;PW@_TZ+"^\?Q-'QF3P
MV3:=6(5'*4\/422V1]968L%/K%-/]KQO*ZEN^T,D3CVK=D-0VT0XCDG45G47
MKI?#VG._7O*S;.J./?>!.+=MU?][8@V_K$(47A=>ZL-1ZH5HO8RFN%W=LD[4
MO`MZME^%C^AA@[&&#(@_-;L(ZW>@Q;]R_J9O?NU68:PUL(9MI4Y1J<L'*UG3
MZ$R*^=TD_>+4@?;O:_8?0[E*_FLE6,F;O_5.'I7:.`QV;%^=&_G"+S^9J2'3
M";>\$</?8'L6DK?7D#!HJ\_Q6G?#]3(^R6,3!@=@$X"G`$2\`8D)2+X",F]`
M:@+2*0`/#-%8RM"(326K];+GEZ`?W]ZITIL$/:2JU=M`#(O]V%_5"J%6/]9I
M1I;1ATYD,'C`/-D8-"$BE7VBP!"%"<=6.(8(2@<10Y`-=G126$4"J4C&0A,G
M00XG2*$$Z9@@=1(4KLIL+'7$=",FB6-*(5AIPY*"%$4*R\D\<C);#DY!.9G%
M@XH,Y:#JTH8E29PGL!KB44-L-20&U1"+!D24,,(103TBJ","@2*H14%PA@F!
M>7(/3^[P8+"4_*Z=L,GOW`F%1T[AR$G`LHOO.ZM-<I9#/[1(X.UF0'X6T(S,
M&46.&Y%L)@5H-E>ACE&0&T/+C5!LOYU%ED"H<A[ER@%=YRK'L1URLPETPP8]
MB<5$%S@#8:4#\PCRN1AR;(SD\(M,OSVJ,Q!7B,^_D&-@I)CIC.U-V6+F=""?
M-2''FV@,OVMRQX[8S*-<.3Z30HY+T1N7(J9L>D=W08NZGB3'HRB>2>&S%>3X
M"KWI2&KZYH)2"+2Y`<T<:PSZCZD'._Y#9TP;@^9BZL&.N=SZL6F\`9E_F0E-
MXSB&@*4+Q!3;0%>4SZZP8U<TA[GP?:(V+A`4%5GC8<OZPS!GBV#+SYW4PY:U
M.LWRC\,H?[/^I&;\<2+_2K->GJH#^UWUA[H3P2N7:G@=)LT]YY(IA?%"G>>C
M^@J9;AJVE_HGU;XRSN7CC>2GZV?&]*VS_@]02P,$%`````@`2(I.1Z$B)6#I
M`@``O`L``!D```!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC5;!;J,P$/T5
MQ`<4;,`F%4%JB%:[AY6J/>R>W<1)4`%GL=-T_WYM8RB.C)-+`?-FWIL)\SK%
ME?7O_$2I"#[;IN/K\"3$^3F*^.Y$6\*?V)EV\LV!]2T1\K$_1OS<4[+706T3
MP3A&44OJ+BP+??;:EP6[B*;NZ&L?\$O;DO[?AC;LN@Y!.![\JH\GH0ZBLHBF
MN'W=TH[7K`MZ>EB'+^!Y"Z&":,3OFE[Y[#Y0XM\8>U<//_;K,%8::$-W0J4@
M\O)!*]HT*I-D_FN2?G&JP/G]F/V;+E?*?R.<5JSY4^_%2:J-PV!/#^32B%_L
M^IV:&C*5<,<:KO\&NPL7K!U#PJ`EG\.U[O3U.KS)8Q/F#H`F`$X!`'D#$A.0
M3`$P\P:D)B#]8DAU:X92=".V1)"RZ-DUZ(=?[TS41P*>4]GJ7<#U83_T5[:"
MR]./,L6K(OI0B0P&:LQFC@$3(I+9)PKHHC#A<!8.7025A8A=D.T<DF;8K2)Q
MJ4B&0A,K0>Y.D+H2I$."U$IPTZEL*'7`=$.G`(ZSQ,V3>7BR.0],73Q5]B`/
M\O"@.0^*G?6@&8\34;D1E@CL$8$M$<`I`C]8;.[AR2T>Z"PE?Y!GY>%963R)
MLY[5_98IPUKD4"]G),XO9&-`?A:G,9AY`98SH&PAA7/P1Z'6T")D"\V-4#@3
MFCVAA<D$SMD>B:SA1MA%5!G072*?!P#+!&8IK-:G=Z=F`6(+\9D$L%P"W;B1
M^O&UDNRQDGTV`2R?P+&[M^@Q(I\5`,L+\(T7(%,1?J!Q3B,8/VO+"3!<2.&;
M<6`-.;X9\M1TQ`+EL0NTO0$M_6]UFH&I!UIF@-%""N>DFWJ@O0-@9^,-:&A\
M*MTQ7N@^]#D"M!P!YRZJ"L)[5-%LQVEI?]3+(@]V[-()M3',3J>%]$7OHS?G
M&[FH#FOE5YJR.),C_4GZ8]WQX(T)N8'I=>G`F*!28/PDQ^HD5^GIH:$'H6ZQ
M&N]AN1P>!#N/N_*TL)?_`5!+`P04````"`!(BDY'34)S]NP"``!Z#```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R-5]N.VC`0_94H'["Q)U=6(=)"
M5;4/E5;[T#X',!!M$M/8+-N_KQTGK+VUW;P0XIR9.7/@,$-YH\,K.Q/"@_>N
M[=DZ/'-^>8PBMC^3KF8/]$)Z\>1(AZ[FXG8X1>PRD/HP!G5M!`AE45<W?5B5
MX]GS4)7TRMNF)\]#P*Y=5P]_-J2EMW6(P_G@I3F=N3R(JC*ZQQV:CO2LH7TP
MD.,Z?,*/6\@E9$3\;,B-:>\#27Y'Z:N\^7Y8ATAR("W9<YFB%I<WLB5M*S.)
MRK^GI!\U9:#^?L[^=6Q7T-_5C&QI^ZLY\+-@B\+@0([UM>4O]/:-3#VD,N&>
MMFQ\#?97QFDWAX1!5[^K:]./UYMZ4J`IS!X`4P#<`W#F#8BG@/@C(!D[5<S&
MOK[4O*[*@=Z"07T8EUI^YO@Q%LKM`S8>#DHNT1D3IV]54D`9O<E$$P9&S$;'
MX#LB$MGO)<!68@H'+=Q:8&L@D+U";*L0JR9BO0F<V1,DM@2)2I`8*L0FR4RU
MH3"]4@'A`B%DPVUU7(J0#C/XI!X^J<9G%=OC,X\@V1)!<@^!W!`DL0J2:XU^
MDB)54M@1!HG"0Z(P2*1F"879F!C'MW/E*;+2I09[O/PY<&HM'_Y?;&PUX<0!
MXP5R3R"?W@Z(2<1JU9D(+)#\$\BA.;8:=JYC.!9<*:R6G65/%LGN<QE.%]A^
M`BE-(7?:&5O].%<R#%FXR%H=.?>;+^K7YR=<^/I-IWX+K=_$;-CXKNDX0)E;
M&)_[\,J@E#NFB\]_L,A_X/,?X`7"@&ZN%;AT,6!QX90%?#X$TV*%(X5O)L*B
MH0B^J0C>L3C+HL^[&&=.78SYF8);&)]EP;3LRI'"-QMAT7`$WW2$?,$/!^C3
M#Q>Q:U\P<2CY5YA(6^DZ,IS&59<%>WKMN=RAM-/[.OT$<B7\=+X1:[9:BC_2
M5.6E/I$?]7!J>A;L*!<+Y[@='BGE1!!$#T+SL_@C<+]IR9'+M[G\:-5JK&XX
MO<R;_OWO1O474$L#!!0````(`$B*3D?!R@WO,`(```H'```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0W+GAM;(U5W8ZB,!A]%<(#6(0B:I!DA$QF+S:9S,7N
M=<4J9`IEVBJS;[_]0:2F0[RQ]..<TW-J^9KVE'WR"F/A?3>DY3N_$J+;`L#+
M"C>(+VB'6_GF1%F#A)RR,^`=P^BH20T!81"L0(/JUL]277MG64HO@M0M?F<>
MOS0-8O_VF-!^YR_]6^&C/E="%4"6@I%WK!O<\IJV'L.GG?^RW!8;A="`/S7N
M^>394]X/E'ZJR:_CS@^4!4QP*90"DL,5YY@0)207_AHT[TLJXO3YIOZJTTKW
M!\1Q3LG?^B@J:3;PO2,^H0L1'[1_PT.$6`F6E'#]ZY47+FASH_A>@[[-6+=Z
M[,V;=3#0W(1P((0C(82SA&@@1,\2X$"`=X).`DP4O1$%$BA+&>T]9OZ\#JDS
MLMQ"N=6EQW61F?V56\%E]9K!39""JQ(:,*'&[*>8Y8@`4GU<(G0M,=##"3UT
M+9!;"*>'8@J!<>)V$;E<1"9H9`7](09T"4`C`"V!AR"QB6HPK=FI(%PM(Q>L
MF(%9=N(9.[%EQ[G./G[*3CX#L^RL9K9W9=F!;H%D)D]B"<2VT;7)DTR,PD4<
MN4#Y,Z#B1Y#E=ST3>#WUFX1N@<U,X(T5>&7;-)B]C4E<F-S&K%V8PL9L'LR"
M2<MH,#OKWLN]DEY:H3[`275L[R^A:CD/];UL^Z9+WV6RM$-G_!NQ<]UR[T"%
M;&BZ^YPH%5B:"Q;R_%7R8AHG!)^$>DS4^32]VDP$[6XWSWC]9?\!4$L#!!0`
M```(`$B*3D<`)+(7F`,``.D1```9````>&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;(U8VW*;,!#]%<8?$%A)W#*.9VJ[<?O0F4P?VF=BRS$30"Z0./W[<A$.
MZY&V\H,!<?9RI#TK8'E1]6MSDK+U/LJB:AX6I[8]W_M^LS_),FONU%E6W9VC
MJLNL[2[K%[\YUS([#$9EX;,@B/PRRZO%:CF,/=6KI7IKB[R23[77O)5E5O]=
MRT)='A:PF`9^YB^GMA_P5TO_:G?(2UDUN:J\6AX?%E_@?B>"'C(@?N7RTLS.
MO3[Y9Z5>^XOOAX=%T.<@"[EO>Q=9=WB7&UD4O:<N\A_M]#-F;S@_G[P_#G2[
M])^S1FY4\3L_M*<NVV#A'>0Q>RO:G^KR36H.8>]PKXIF^/?V;TVKRLEDX979
MQWC,J^%X&>\D@38S&S!MP*X&($@#K@VXJX'0!L+5(-0&H:M!I`VB3X.$-(BU
M07P3P1]G=UB;;=9FJV6M+EX]%M0YZ^L6[N-N]?=>,PS6XY)WJ]-TH^^K,`B6
M_GOO2&/8@%EC#)@P&XQA)LP68[@)\W6.$6%LPCS.,<9(.X3X).5W$W*=%6::
M%3[."D.9"K,#;G(@1@<<.0AQDN%(8\14`P8$"],H`1-P-P?&:=!A(W-&@LA(
MH(PL#D)B3D*7.8F(#*+_S\DZFE$5<01Q$IL#Q42@&`6R.$@(JHD+U93(($4.
M$DPU&BL]G5&-H-.>I4[[?FH-U-^<14HM+HP=0),%<&$+1KE,62"]0&#DJT&:
ML)TN)2M`N@*PN##J8*(KG.@:E3!E@:0`-RU(Z":%0=P2AQ(,(,6`P'$`=*"Y
M9E@`MAJ@%`-(,A!:7%":`2?1`*4:0+*!R%1&:YCK!H+Q9^GPE'(84@Y8N@2C
ME,.<E,,HY3"L'&.GV+"Y<O@-XQEP2P)Q4I3*&%99:JKO#0:QP`3:6D$X&6K?
M8DBO#,S$Q8QX2/&F=,V09!FSN#!*=BJ)R*DD*"TRI$7&C?ND!NF-DEQIHVBG
M6$BTS):N4;03X]2%,:>DR)$4F?G)0(/,C&>UL$-`B(BIX49Q3TDA<;/(5-^[
M&Y"EB7"J`W#4`5ABCH-!EA;/R2=2)$5NFQ)JZ^1.6R>G),9#A^+6H'$%$ZJX
M.;5]<J1%;GE8X$8M3HQC)\:4Q'A"%;?>U#3(S!@5=^+:X3FUT_+4I;A3E^(6
ME+)%X%#<-Z#;XO9G+[3G[$7^R.J7O&J\9]5V[\;#B^Q1J59VKH*[KG).,CM<
M+PIY;/O3N"^M\4O$>-&J\_1AY?IU9_4/4$L#!!0````(`$B*3D?B8&W,K@0`
M`"(;```9````>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;(V9VW+B.!"&7X7B
M`6);:LEFBE"U24AV+[9J:BYVKIV@!&ILS-I.F'W[]4$0MZ>[1[D(8/X^2?K4
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M>C@.K^?QFRSV9K2!\@;J:I"`:*"]@0XU`&\`H0;&&YA/`RL:6&]@0XM.O4$Z
M2RD:1W>8FX>\S3?KNCHOZG%!G?)^W29?TF[V7Q;-<+$>I[R;G::[^K$Q6JVC
MC]Z1UZA!<X<UFM+<8PU0FH>I1J](S1;[,93F<:HA,WY"BO@JB;H!N8Z*HD9%
MCZ.B4!:6=J`I!S`ZT,A!BI.T8QFCYCAH4HC[/TKW--6!Q3J4$`@)`1K[64*C
MYA%K,CJ($8(8Y&!%5FTFU:@55XH5HMA)%)B/F1FCV$F4)%'LD*5"G!3-8496
MDT[CQ,+<9$*@#`5:T0Y6PG)=A2S7?E]F4^B__'0!,;D^9J*$B4-N-Y<XB&]0
M=!PLTDP<$N!+'$0P`.."1-@/:J*#1E6"+@&4A:&KQ2(NCL1=8A`2AG%!0G6I
MU@95*_&2(&"`W&.V2*0R+E4)EP3Q`AD=)PN*0U)UB8.P`G([VWJ1W\]X_I5$
MGT)@&9*^+1)IQ5"A)/H4`LLD=!PL4DP<B3ZE?M]M'F8BIMTHJ<LJ_?N&\Z"F
M_3,S[`1)("N0>LXE$$P"Z23CUX+$LC)H^+EIEEA602PKB645T/SNU;3[&:'Y
M*0EGA7`VLV.A\:&R::/-5HE=,7NZDI!6"&G#[`J:9-4/KHY#!E=+&&I,F"4K
M]B)?,?`%:XE$C?J@21D74A_407U02_AH""D8`E>3EO#1&!]F5]$2/CH('RWA
MH].0@D/QT1(^&N/#G!ZU='S40>='D#H8Q%+!?K_P(M\KC7`C(]$#B![+N9!N
M[R#H_@ZDU@.("IM0!=^!_F6&N73%>S>$CU5TK"D^XJT(2/P`XL<R[0<D?B"(
M'Y#X`<2/!:KB+2!^E%2Q!!`@@"QY2-_.1%Q-4N\!1)FEC\<S$7</+J%H$(IV
M1<;!HI09-R-Q:!"'*7V8G(F8PZ216IA!L*::CH-%3*LT$M$&$9W2ZV`F8M:!
MD6@VB.:47@<S$;<.Q!]C$,GI;!UD/L[TYQBXX7@WTN\Q!O&><6N)Y-UO&28-
MV3*,A+%!A&;,<@RZ*S02Q@81FC$KVDI'2!MTA+02?#8)J'8F8N;62O!9Q%7&
M<&6E\Z,-.C]:"1D+(=5B$3.W5D+&(F0R+E6I^=F@YF>EYF<Q#.2/QUO[Z^%Q
M#EXT>1)PRM_<WWG]=C@VB^>J;:MR>`+P6E6MZ]S%-UWE>Y?OKA\*]]KV;]/^
ML#H^PAD_M-7I\D3J^EAL\S]02P,$%`````@`2(I.1W[W_[B,<```)J`!`!0`
M``!X;"]S:&%R9613=')I;F=S+GAM;.V]VW(<278M^"S_BK`R\!S0+)"5%V0B
M42VU&7CKPQ:KR"'([M'(QL8"F0$@NA(94$0F293-0S_,'XQ>9';F93Y`'Z%/
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M/`DC_50FX][%O,NKHL2=6"8OLDUK/KJ7[F_^IFLW/U39LEC?))</=U?EJOG7
M]Y=__*GY.]GR]_E-@?N,T\ONVMOP#Q\^)L]>O[U\_OKE3\]?ILGKGYX/>H9Z
M#LNHLA6<XC+_DOQ]_M#SW*MBE5?)<UCD35FU'KJ\RU;X]_?Y?5EM<$W/R[O[
M;-UZ\%FVRM:+/+E$:JZ3D^3CY8OD^.CI+BH\;9W@MJJ(WNL:!FG]-:MOZ2HL
M\(?\G[;%IVP%C[<>O%@L\#K6294O<GCH:M7:R=?K3_!FQX+?5?E]5BR3_`O<
MUSIOC:U_K_(ZSZH%3VB9?\I7Y3U2SDF5KV`OE\E]5L'N'A,ESEO;\"*_SF&M
MRV23?>'EMFBHW,#I+7;NR*OB"PS!?TN3=;Z1[XT[OD<SQ`_FB]MUN2IO'NB-
M]A'4F_(.3GQ1KNG"UYV/(87GR1IHM/OOORO+Y>=BU:+]U^N3^ZI<Y'7=NX.M
M'8?M7/=,XTVYOCG9Y-5=0N0)C*J\3NY_K2.Z+^NBO>E\,&OXUN[#X>=Z2%G>
M7!795;$J-D6;T#P1WV</2,&TBFRQ`.ZXW/->\Y$#%ZQO+N"&`^UWRAA/MQ7L
MY[K-J-_)9($'7]S=%V7S[_CINO>OK]=PECGPZ_L]P\278\=N/`<J!JZ%3P%!
MU\4RKSK7%0AIN6>%/Y5K_>[27F*=1(NC\%QWSO'NKM@@9=;,WG3."WA83FO:
M/"W4,GZH[[-%_G??W2.E5Y_R[WZ;M/CWIES\?%NN8-WU?R6>V9X@L#19!SV=
M(IDDP%JW>7(T&`Z'H]\DTV$*/^#_DOHV@\\EV79S6U;%+_GR-W@7\J2HZVU;
MZ<"UP4WI'7@RW#FR_(K'ILTIMYMZ`S^@*!J=IN/I>3J;DZ!'04R/G*7GPU%Z
M.I[);UMBYF*Y+)`(X%B049S`8XOLOH!C:NL=0'Q)C;-/ZNU5K^H!5V=[M^5+
M!E11+(H>?MY]`BT2H75T/]L0M,?O,J3%VWQ3+++54Q"\1\GWLF]M8H`)DGH#
M7/)5L89Q"OCN.V1SNY6\0")UXR3W/AF.LV=6K3?DM`]\VA)$]RL]--CSV*'3
MCA_?.>?XT?T3]N=4XT&]O1>>M4.K>KT&I@TTX0]XUU&6R^V";0KD&@704@^K
M>P-_`QVH[\],M3U_?-FC/SU'=1Q658/JUOKC^P-5@K[G#A1TO\O7.:K&)%&7
M=\6:=&XT#]IB`125ZZJ\2TI_"KU"ZUATQJ?`=_`X6I(#]+,5#)@F5SE85KD\
MAM*C5\R&1^"E-7"6UE[HJ,W?_S$O;FYQ+[)/,/,;4-:V=U>@U\'>7SQLMBCE
MB2B9PQJB;#.<NECP3A>K+8Y([Z_EN\D]*8MAL-W4'`NDE\3B^NF:2*SYRS\\
M5,67Y!U\ZP[$WY887YW\XX\YKJ]%[V^VY9>B3EX4V<T::*]8]#]J&<7C'GK<
ME#J'>,0\F>4?^N?'S:WQ\B-F9:3J.Y&JSUFJ?LLKCYO]`0,^8D7OO?DH3,`0
M[[>]])AM-:K%"U8MONK91WSR67Y3K-<HGU39R#:)-=PG>]](O3:WYTTTQ&M2
M?GFW6.."<Z.#;ST-8I8F!)QD8:0JOI!_69`#*`'>RF\G%PO@+\A&+SJML&\;
M+>V5WC#$R556[S&E^I[K&_<EJPP]1])2<N/'^\ZC]5KOGJ@IUMH<D@;+_*HE
MF;YAJ+X]Z-/'T6#L4A3>&)6:?`+WVPHGM<$Y@-*<W.7535[UR(SRGM4N,A)`
M0OY5WNY;ZGM0:ZJZ[QOQ7[^.9%INR\-(IO5:+.#)2_=J57[>H:[2,]?TC%6N
MX-L9>FD[K>2^ZZ*>N@[W396#?4//D*9WARZB7SKOXH7YVZ_J0@H.@O:*0&FO
M<E@/7H/L$)=E>+SH<U^^R.6AXT(>1VW4KT>]FF"%``6VJ,I^XE?:@F.=$6G%
M9@$'>GHZ-TE>VO/L7F=6S]SV3:GGM;V.(U"8R7.]K4FQ/XCJS4W1UPJ2F+M?
M>[>%$\-Y`2V#P0>J_>4"MCQYMJV+==XV%NSSU\:IO'<-ATRF>=NOV?.P>P'H
M),Z7\L:BA,_`!<5362.=&55!_H:73"3#3GZ,I_L(5MZ4'X>_BI['JKC:TD?#
M?'MW]+XJ/Q5+6,;5PT$[1"^RZ"3_U8&QD=X@"K+Y*Z_&(0^D$-BCWL_10=?W
MYD_E^H1>POA6C0L#Z?A#MX3?KFFW417H..!4N"0R'_A2A7_H$DQ]SM]$69<<
MH+TA]W(3OE%7S%17[+Y'[R/>V<=B@T\9&<UJN^0[]SC.W%+5A06DK,^*ZP^]
M`C13&@Q-_IIY!WQCO>F6F<R-D5K>E:N"G-7];B>.R"9_^?/_G3QF!L[.P.F;
MWW>^Z$A]?%:4<)(Y*3`@$`;)\5_^_-_Q+W_Y\_^3(*W<Y@Y^(V%,^.73Y'-6
MDZ.ENB\KVCCX]_NRSC\7,)/G\FOZU-I=;&^V(+;.414:CO$XD()(!2+MIUS!
MP\MRP+HLC.RJ_"0:7%ZI]947<%J?0=&"T5'/`B'*:A8/X6`;LJ2^1U5F!81P
MF\-_;A?X_(*7@+2]H&`OG46Y5EH@_K%>.B37O,+WBU_P=_?L`03>6BZ(C\,E
MNLNJ8O6`+^/<MA4&"-'4=LNB+BMTUB3PR,\Y:N8XEVO\([Q0YU^V8%PO'^KK
M[7K!YHMY>X%7IJ(3O0,V`6N_1CZ.)#UPG53F^*C^I?;1G2LY=#HF1"3@Q;VM
MRNT-4#X)6U"$'?!:N()@^U;"CY-C7`F<](_T3SIHV/K/MP7<&!8)SAC#AECX
MC_0"3KS3`Y$Z_SC]G9ZF#^,!`U_II!_42QP8Z)OBI-[D]SI3^,L%G,$J&<WT
MZ#_<PI8DMP7PF(IV\MJ[Z^N@;GON%[^NW()H'4[_"O9OF72.`+O/ZR,)56SH
M(N3W,EOW4_F)7`1DNJ>)'^MSL;DE2@%"_)23==,UO#.,5OBB7'%ECW(9?HR/
MC)YU#7N;MIBF^2-QO?&$5CM*:80E?"?%!;A[]F#I[6"!TCP^PQKP[SBV@YT&
M\4=D[>>'0W=:_YX$<<_X'!WMRHL?7QL>9+]D?NN)"T^H[V!$;^D\F>3WV7J;
M50]\,.ZQ!V,DH.//#-R'_6_=\T4-_$OG:M9P7P:^+&<.ZY2UR)(;6^H,XV\-
M;3SO0>\0;1*('^0U?#&O'5MM.#WD<7CZJWPC3)*=^PEYN$^R%88K.\E5;(QJ
M29*>]O)]CDR%%G1Y\K^"R`+VM0!.!L2G8837:Y!Y6]9G'%!ZB*P%RSBEN<._
MKT%:!<'Y;+N"6<)G/P"[7B2CDV>CU&&(!`10?KW*%R(P_IMG!)VC#\P#JX>T
MFZ)NLT^D/8.6EXL2@>1L=!9_3JG+D,#SA^0S6&GTTFV^HIF`+,II0_-DE=]@
M1!-A1"#[05R!8*(KP=?7''O\Z3J_J>!5$;3=`\(BE$3%G((M7`*Q+/!FUT(L
MP9S-`@69,*JC#]^:O6G-`'DO<P`0.5=E^3,LY/7:9>)(9N8BRD("(Y0+>LW+
M\P0X9`5">2G38@<%NAQ@`9^*_#,%NT1D)JOLJF1Q2/9W>%E7PIX*AT9EN28K
M%,VK.U$5@C60M#FKW^Z!N_#S[/W@!B,K\,#1>'9*T7<307='X^G$_/*4Y)'9
MA;H,])/!C5PM]([`)#EDY3!D):L2!;4=TNH^-=X]8)B>,*I\LZW6J,!=D<YP
M7.<Y8_Q.2:/D\*?[@%Z6IRH\.R_!LB0Z5`&968Y75H[-**)]RW=ZR`A4'C'8
MB(3HPRX\MH^;WF4/<BE@/DMX@Y@4,%/\^O46EHPKKT%=J+N9*5V>P-.<OXK$
MRR,E%Q_VD?--J7)WK7"<#6Y9-]^0O:K;7`)(?K5B7.7J@3_JO_@OM:%6C'BR
MYJF*IK5=G+%=TL`K;HB](A'7Q<V:-$X0/<(-<,XH\H'6:7-(<58'9:KN93[(
MN^Q/<""@.Y,_4R(QL,WST6#Z1..A-&,;FK=&WL"]C77SE&SN<KW.B>T'L5OE
M0=<GQR-L@_,:OOE+"JPUR0F62I=(]%CU;=_#5?#JJLLSV*G(ZI15>#L811HM
MKV6?(EG3^_B!AV0T'HS.3M6U"U->1ZM6#4S]R^1U=9<X'=19D,FOY$-("!C[
ME7_=L6N."`LV_F(-^LG*,6Z4#Y7N3+;\$]A/3(05BSC:.-X*G#W^2S[O.$1*
MGQ]XZP^)#+0=VL:__/F?C?4.2CDHAP]*!&B!Y>1H%*6<](=5J1QZS0S(V_PN
M`['`^`DZT-]GO_S2ISF*&7F9(SR6M^9=PR_D1Y.IZ&>63OA>PPVA8_U+K29:
M\O.Z_(RS=-9%\6__2E=-A\-;M<C9PU$SJR`;[AX4Q_5&(R/XZZ/18)C<%:L5
M;-R`K67BY311F@8\3-L2PJA'4T%GJ5<4=P8.^1K(SBVS!Z#O:]AA=NH`?R%]
MHN%4"0X)699W7Y.2<#0>GT6?0%T+-%VV//12)\=LNE6YJ'EXLPSJ$^S,3083
M>_7B(KG.20Z$%2(4E18W?X)7TB/L-BYV#*%N#0,CMH$`*L`[4$K0"M\N-B5-
M:$03.DN=SG=[CWN7P<-?BKOM'>RGJ!=V\QO;.AY,G1X%2==%G[,*S5X"+"W1
MQ78T$WF-E^'&9:`4U:1.YD8UYA%)Q"?76:&@NWA<.2CGZ0@_!/,Z#232XNBL
M5\A.Q<,I`8A.&5%LYJG2?PR9M]Q5-5I1HKEK$"F@V__@7HK>LTQ>P0I`MJ]O
MR/\K=^<H.6.J@3N_:?QME$[/B6B=PI"3,]HT9S&YP<@[2L;IY'S$3]RB-&Z.
M2&-<Y1I#0O[Q"?T:R098V@-(,O%Y#MPKEMLVV,06'*Z>GLQ):8@$5G/M\+L9
MS&HT/:<Y(;79?\SM/\[-/\9#_P]8!RB11+AG9U/ZU1%NS!EO#)Q.\@JS.VR6
M!RU^N\ZV0*9\6T_H;UX+D9N'.@\([,_6SR`,G.RPID\U,]XZ=+6!CH@BH6:)
M@&2TO;M3>P`$\^^WH"'P+0,SBU@QBPU62."NW:"F)"(#V1:LAF;J4#L@XQRN
M"HHE-AG0HM^P-UXC.\2@S;Q8T'I=QWZOP::S1JQ0R<BUR(:O8;2A2;RAHHZ*
M('2H78>H$*RO('_!`_HM[TN$P:-NAH8&L*=/\$PM_BQ4)7E,YXD-][5<%4L_
M47,D`S)"*Q3Y8"^R]A<FZMH3Q;T,IX^LHPAT@U:_F.'`%W"S0:G+Q'`$%0ED
M-FM]D9H+4\\V<@Z;+2$)5==U7O=6ON$='.K6^5QNP2`->D5!SSE[I+=@YI0+
M<B,2Z\1QH@@',21.]/%K<VNTEZJ<S=]XPFV=O.&;D#6[_C7G!9EA.T<"YJE_
M(#J^0R"?5:$6MT6.2A\NL$G'^(1K7:G$7JF!^P?@0S4S(J>,R!$C0FO/1<!.
MY$/IY&R4CH;$D]*SR2P=3<Z=(CQ=!.E,3J*K/TKGHWDZ.Q\"BQU.3].S^<SU
MH3<3L#EGTW0VGL%/YY-).AN=]S]\DG0'H($#SM+S.?#(\32=SL]</]HS.4U/
M08[/YZ<H`.8PS]G415``?*<`@BLJ%>-MV3`"A>!\#FR8%277A1E-CN?I&"3=
M\&R4/$V.9^E\-DNGP,B?NE[X:'(\&IVFY^>G^,8IK&4Z@<=W@$CQ(Y/)%#>1
M/W(^&O,7W0X\*?I1ST?#9`Z\=G9^YC\`9XWCC>#@ISC>$8XX/(=?@?G0"O-?
M(KF!>8$(3V.M=<2(.@-#8S+C]P[B=!#GPY#TP\L0AG0";F75A%06L-QO;H'\
M5P4\AEN`[CIQ:*I*+E)F[9W`P%+ABJ+52(P"%.3DCI,K@3^LT`H!<7"5M\*@
M`YZ:#8R*9F[#+-<X&/`7CJF0(\$5'@E7#X))&GX+$@`6_T!6;9EHS@?P:CC3
MXEX('/-'20WFQ6*<)?+=,+L3)P;,H0`MO':H\ZK?MJ:M2+TS=@%D`U3R3\"A
M_6X8YXK#[2PVV_"JB*1B(W.'U;PS7TW5<XY^$639J!2)A80Z@:X`E0P&(M42
M8\5-1RZ<H\ZY(M9:;U'PKHJ[`G?^O7"L]_FB!/(AE48Q[!=JC#&G?E\^9"MR
M$;YC%;T.MO3V'HUG)$`6$RL9(C-#5+G7GRMBSW`DVYHU(?^\2`3O^3(H)-4@
M<0"D)@9FV[<I&0GE/J6_P:^O\\8CP`^K[<W`_5C`"!OT`-R'M2!KQ$F55[B9
MN)**/=E@=279/:(-LE7J!"]*WG%BWYNLNLG57\T^0WCV3^RFN-,O>7$'DHKV
M^I<@8D%MYWVP3Z-*+&)K$#:?]&IWA8(PC%)[R?,9O1-`'4`+`_<N$>/QOV1W
M][\!`Y%3%RYQUGSI_2!A!&+#]QT9#[Q8^@"N,<<P*]P-L-]K4BT1BH$Q`%8D
M01!4%4;XZ1[F7]#.3N%<5P7Y5(!LG5<TX,CT(U[%K5#4PA_9F\SV.D9V"&D#
MXGZ9XVD7:Y_G)XXU'_W'%8E'^`'E#I+]P)A(M`M`]^@FY;-!%_!GNCUA<ZIE
M[=W)Z%=?2M`"[Y??L4C59,>K!%<D:GSUD"PD210959VHEIC"W5UGLDEW&"6_
MRW[.G7Z1+F\86E0@/9S*S)W)+@LK,!JX1H6]WJ:OT_31=X]?I=R:+7K.]./1
MY."GU0/2B7'6R@12_P78L'5Y5RS<!H]/@D^28H[>/TV47>9W=!DX/3._WRA,
MI-Q63G<-)G9M9T!Q%5@.[A`8*6#)T#?_M%W>2."K2K88*/\E=^'/T6J`9'`?
M]:_")\5"V:[5E^:L`5^1.RX$58#04(WF\QLXGW,:0.RN(YF:KC,3E+_V145>
M$R#3%5UC\C@(A"''?Q`%-.B:K*?V\*AXH<"!F5:K!\<^?]Q?)>(LX1%)15,R
MD=`=F31$EV1)6BL;AT`%-P4EW;R')+\LMU>;Z^TJS`<OM5Q>7NC`:=(XB@WS
M<]=V@`KUF7DZ66OP!85/D(C$7_I;+]Y(8`=5O3DIUJG\A`*2UBZ>+"N[);A4
MJW%DHZX<*P[30Z@A0CC([[_$ZW?]X,HK,`YSC)G7,-63N_(32;N*+]_G@NQ!
MY))T(F`5WC$-AU\Z^B4M'@9#762I2D.5BRD$NPQK7*,LVJ)UJ#+3.P!%\)-_
MA;<0-N(SZ%WYR1)=GS#E0%8T%79E%6MGK+>-6I)&5R?^"MMH9,O`_?&6PC;$
M>2PL1N`9M5<<V5J_\@PYA&2<\@6O0,-KJ+HOA$.1..-;D/IPH`MWGRZB7G19
MOZ2?DNP"S>YDE6W7J$-Y/RD'%SW>HT.6`Y&8%*]KL*G+BD]G`SQF[<@!'KGL
M4O'?X,$3&0GCP]C/UC.3\"FGGTHDA3\U[!QV'O1$[Z`A-M1\W"%+1@%?9]?Y
MAKP:Y./(%@^H;VP*U&.9.W4;?;`(H')25\0V9OZ%QRYQ!#6W&27!JJB_(ZAF
MJRL/D4]I\JDPO*A-$:Q2X\6]7V6+7$3!`%UG7O0L,'2R)/9&4XJ#W;P)'"5$
MRG_UXB(-Y^IQM(L5+`W%$.*85K72%&EY5J\"GB;?U>D%QM-?4D''HHE[F62F
MVS75I'NJ[M"I\FGHVZA?98N?X0XLG88(XI'`3`CDC;(`Z1*]^5Y;Y1"[U0;4
M?O/^Y8RKO-Q'01N8Q@U:,2SZEXZ#@NLM7A*P\8PSJ'FD#=8>=MCU[;#CFAR"
M2+0%.EIB`E<#MY9\M!(?12(C>A`5,N58<'.4I>8VH+52Z_U%MP;:(B>PK8A*
MWMR62T=61E#ZX!!1RJ'BBF1L!U8S5=0&=D;#V-85[YU%'WF<-W03"_:!UTEP
M(;W)KL@&%L=.<I),$_;)RW_<&S3GLBAOWB1L',_XX:?)\82A"$]=N]K)$<X%
M_WB43#D88'1=06_Y=<0?4&B"YW*(T4#:<2Q3ZA_(2\:EE)(.)]F+KM&.$@EE
MZ0^@)YR\DX(GD2OKA>%J!Q1%(0#9ZW?O7Q!RC&\`,EIGX"DD6/XW#(.M\\CH
MB>\9AEXR9Q%X78%L1-9%CD4@"P-@X]C0T5FJX4&_YQA%"B`8Y,*P[VC_H+#;
MW!:5..Q(FF0%:!/>IQ`B57J;XT`-*""P`\!*G!'3\HEK%`T@.,F";SKIV(^'
MB%?_"2\'\(&:>!=%K-E[32H(QG9("<&`!2D6.(6W;!;FKKG3;&G77;)9;#J5
M+I:%DT,:H\JX,IT3;.8*YE5<%\SF:(U^2<BV74]$"A?9<=NO<U+>#+&`]KF@
M=`,<_@KF)]#?QJK88N7)D:B]`@5(N#W8Y%R:1Q!KZ-ZN,<!2U+?$S;1PCW`6
M=:<0R@MWY!HD+_P.H[6.$.VD."B%$&X$N5V0+@1&(3.;O5H1Q;AH^OIMHV1?
M/33HL9L<L9B##WOS=QJCLO5F;I#[BAODW4/$^EW;+P14<">NFX^#RT%P!'UB
M<4?$]85.&GW[(\<\F%4>V+.B8M8L:-GA>*R!9L_D%4DDZW(4`9[,^4:K<^2A
MM=P^AC%QH6!<P*_2W:M%PNU=IMNSS&FR;YES3Y<-D988D=;!T/6EHV0^5ZDB
M/[6%510$/!Y/1RJM1O+N4V?K5L%0L_&Y#'HF@8)=LBH:_YMEU477:#"1D9\1
M3>C7C%WSV!RZ#C_/S<_GX>?Q4'\V8>NQQ.S]UG4"@&H+4@C6.T4HT5FEKYB+
M6">(VZM:\4+6F(Q3@@ZB5I,BH-4]!->9^,8E0J@R]$X\*^$_)(Q1:+^ZN'Q&
M0MN$,<*SS\&@OU:#A>#HE\_IZ?EPFB(02]?L[)KAB311.`Q=RSH$`DFA91`M
M)QSX/5B$(43+9L.X0_IBV(2EK]<4TKA`45UO[_"7[/M")./ZA&K&`2'@#'R&
MIYCJ,LQO&+BK<L).7(Z!]>ZZ,2EWEV?H]I1(2&<,VY.!\00W%M'"FLHZ<*>Z
M]@F,UF`D&XA.#W(5_]W8"&<VPAQ2G@?G0'/_@\>4\1`;R6_P:`/>*7)V-O'J
M0#],.U;6V_U`BY:WLDYN%!Z3&0,J/HE4CL*%`$RWKA:C@3A94ED\/NVBI\4/
MA?H-LL>FHN>!.W2[N_+SQ(MN$$E!\:0`3K9VY.:5'*/="F;S&!720=RO"P8H
M^D<AV`<[)<1BH&(F0$?'Z#`,SQ`+]0Q53[2QZW"JXJ,3N\ZUIQVTVW5;V6VC
MX#WQ"[-@8;/E=-]`;%</QD/-%QLEOS.;*BXB5)(_9<6*W&-H3A"5()A8D$&#
MF"M[.#H!A3PA-3;.!\24.-CUN(Y6B]327"\"@H1>!LDENOT]81<T+=`"2=_&
M=\CYD'T)B!5VHGA0(4Z`-UNL<129>(7Q.-;Y9_$'^00$`<[R;QV!8>/5;S`&
M2L+(SXJD4W!5JN61HD<,U2Y$ORJ4"7YEHPY%!4I(O=&X*$LFTFO#>$B!Z-;Q
M0:F4@C:4">.=?5E5$87Q6M$UC+.\NU_AG0P7%L@Q'IAC!43&*:H*J-13O`9A
MH3?`+TGC+DS*FSAJ23>4T(CA@TO/=V&X)<-^)2P.+(4!D^%/=B]`,US!\O%0
M5]EGP<UHMH[HU["\JLC9O<?3C':PPRH2<T$Q9-'&8D`O["F[?L.=*EV7!UO9
M8[S?$DRJ;O*&WQHS;S);&Z"A_'F/=^Y-&^^\1K`J9:](P$7/&J>%1<""I[-C
M1O!;I<_4>A5")(]EI50U08`KR5YC;JIC/:MO'6=HA6B>.J01MZ][W,>4E?LJ
MBNYY.'."[N0W#R&B8JB$O<'.I`L@2$!]PW#937Q-ME.FS#R`/DN"PZ/_U)?M
MU73%)+``\#?Z,_D&O9\0DQ`W72*U48^!:"R$CM?.(F+I$Q7C<M=E`X<4\1+5
MSUV'?CY`7QV^H5X\UI@Y?\?;:CV9'TWU0L%4L*\7%.M$5Z?!^#`6915"D1_7
MA'RD5#7292[N<HRWDJ[[NXN+=^+/$B761$@U..KE$[E<+0GR!140*)V1!#<U
M%P'5)2\1G9&(*:&F5R5K0>3YWZO9M32Q"`9CMTWC11WS<9K,%J6O)<MM%>ZJ
M%MH6VVY@L5`2<ZNW5W\2Z"N%5(S"V-@C1>CZ>*D+8?64,T0Z2U!])L##)KR7
MABR)IN:5FFALO)>-<!.!+IR-]-O)6-=TLPX)(TJC=26&R<570YV!HAWI/QW[
M!I6I7,2@4PXD<3#=ZVBU(3\,_Q)VCK+,V'@O_`9[VS"@;G.N"ZS+Q3PCRA(+
M&>Y4%2C15'XJK2C*"-,-185-'IQKYL')W>])=ALD<?TAQR!>*3-B$V`LL3^H
M'?P9F0_H#;;*L6N$,@2S0Q'TH&+!]S'-J7J(P`EXA$&L$<20;@KLD6#,2"+A
M8)_)-HZR!O'CT7ULSP`>R7H_#SI9]ZP8ZAO][BK??,[S=72)72=3:1E_C(0@
M>"6&I>(CB'</MDN<DIUH!M0#4Z4J+.;`U\M9%9TUD#N$@:Z*G]$_!CQQ31HO
M,<<:Z=7GR!"DQG.Q5@%ZR7*0C$0-8<<K\.9T<^E5,'B\1)*,`.()08)3K6Q0
MUVB,BL7".C*(\C4(;%P@Z]$!S1+`JUYM7XE?QJ-:`XR1P][JM;8\DV#N9.\(
MEI"A8520@Q;)M7]I9<4U7_7K8L7V2ZT3**-D:`%J6,4?M<5L6=X3]00A>;,M
MEAYWLEUKWE(\>7;NR&5E4><LCB/X;N"\XT$$EI"*I0@6R@.\@UH<(NTZB07!
MV_!W<<.2FBDS\3C0R/\BTL\`(#0'F+WT^,<5*K>@.<KQ\0J$6.G#T^$3/Y$(
M-2$`S'RS69ED/)P#K(9\<G(^#6PK6)X(,!3%0%),UJ6'2KF>S8Y&X?0[B[15
MI=X%#JD4'IA&Q#-D7TP:RA4HP1%4,GAAXIJ$Z"TD'\[9Z?!D-$PQQ]`H6/CA
MC[H*]N]9J?27/_]SMF:'$^AW&R^2:=10'/JG<I",AN<H1\3EZ/ASH2R%V1^^
M2`36B%$N\GMV[P511]N)B?.EF/N;7#5==;G4M9(1J2_(&@/I"Z]@^@T5KGP>
M?&$T[<@H<A'@H\<ZL@3#O)WDL*8H!F\=I[>N!:A*N=:$(5GG3684T!4O2(\S
MR*2`N(OPAV5D=!*=8A$?5B3HI@#9VJSGZ#R\MEP%G+.XM,-1#CAW]N09*7?/
MC7(GB9_64\XIO*P'>@SQ5?"C:D4-/X0:I<8U1&<=3,&V5<="G9]TRNMO4,N,
M3R4RP>V8]*SU)0;HP[-5!FN]7-R6:'MHI3?04\DU4R[SE<?*L!_4124D&5T%
M?)SPM=YM*;8VDJD@>OT7W0TV0%F*KC1PO;']WOP5J6+1$]]D:\L;"$V"#R&@
MD'B(._X'W?%0)>1U2'?0$B]L]AN%)FB/)CG"PL.TO)QKICNDK:*,QN:/^Z.P
M`DA_:*H..*<B@&+D%IO(7Q2Y7VY]!E]]B]GE<:I&3LX2OPS0VR/K@#I]O"%3
MP)8-J\HM<%@41N*J(C<,>^:\J1'RT6*7BB8]METJ*`56^$5K?,1.$-`PT#DB
M`.-N_Y[GGNTOB$9&&7E-QZBXHA6\P`;1-85KC(NCP,`OF7NH[CW3H`1!"8QF
MVJZS0"?*@-I`D.C&C+T5A)<7O3#LA7IWW$_Y9]CUU]Q`(7(FE.L213;3[FNI
MP,"Y_12&0ZE6M-X+P;6/]\AF',NXCR3<\&V4JVA6?<!.2(2+>5Y65;[P;D.D
M&$3"T8?A->9/F78.JX.[V"NVB*T$C0>1M6P%AK`>XA]H>&P5!WM,+AKQ72I)
MJ4Z('F!';@\@#782^XDHS=NQ@X:!:IS*9RQ"1+"^+!(B6F+!-"X*NW:/5?O(
M"U\YK&FZ:;[=2)UC\-KKD-2>LK4AZ#&S6615T)I:LP<-J&!]EL075:&@`PA_
MP(UZ0%F48Y;/6NS]M43VN4=.*HHR>^ASS&KDPY#O2#8+;Z;7<$W1.7L$PF*=
MG6B+`&C;U6%(F>\LA?T@F!J3^Z9SUV)[Y5*@A7YQ7=1(>P1G2#62`\S\3G4'
M)Z46V'49/Q[R6#E8_B)?<+D$O!SL]GN951BG68HTY`27.X0U+2UK#P\(7(OF
M(,@"KO<A^1B-([U2"P]72"I`(34RN1".RO.B3AK^:'')HD?D\J->264Y(;/,
M>#+P]G.-NY[K?_F1X`XGPPE=;9]4>8+ABVTXY9!M>;F]VF#1+3>?3$\FPZ<_
M))<4_?!QMZ@L84*%&J\VB=8!9<S3`'5HI(TML9J@FE'E4MT/U2]$Q:1:$<88
MH&>#<7%E,ZU%WHO7.:%>D>A?SK08UE*S>$)@L2'A@\A2G.75QMG*HG"-,M)R
MM$B/?IQ#$<2G![QZXS9E!)JM``!2K)%[TER:VI*!;KRZC4;TH',KP:JH2H]X
ML8RS$;G+C+40<39Q2C-9RO!(E=']M/>K>;U<^WHE.ZZ7C->FXZ0#('Z/F1SE
MML90!1%SK`V#<-Y_>X:3O;?'U`OLOC\RTHCNS\LOP-0(6Y%)D9:/ZVV-JM!K
M<D#[VY.,Q].3<?/V--L1155<D9F_-,R<+2&J;4AABNC3]#E_RR1FR]2%N"/?
MS)--=9416OG2#YK;036;)4I=R]:*F1$OF$-5A9#9-L3G'3YP7(+1?$A]7432
M\?F*(&#"?E.BN70#3/WCAF2)R))P\J*!ML("^R4`'1LV28#9T]"Q=&&O2LY4
M;"Z5I^(XBMW+Q<FVTUL0$>6(6021>Y,\DR9SY[*ZK$QV42?Z+/"O)[`\=(HT
MF7-76<23WY7<L10])FO#\L?#Z<DI$NT+S\]PC.!9(</D"A.P@"Y>$EV@8\A=
M"",#0N#BTMN<70/1EX)CA:02SEF*9_'>X"\X=B#:(-D#L#=Y,TT(U6K4=,)G
M-9<._<,2=L<8(;`)/.I-QMDXE,X65E!6-]E:$'U<R"<,N)!U4.`YN2D%Z$0[
M1M1:JAO22Y#KLMQ0&78C#IBY&AW!%P*#-9.5&W';%CV[??0\2R.*%8IS@5R3
MKR57/:/D<'*5(F,]M$KC#<]-C!P]>ESB<S:<$?V^MQG*S[77*B]1>[`&VZ,6
MF\9YC_!]"+7R?@9/C4WE)=><EN;BY*&[`@T\C!_7)EF931C]L*DC&Q=Y*EWP
ML`F_9*M#ZR'0+U>LN41UT5F+I<\Z\UF)HZO>W-8LNYB@.Y0)GNTAFN0*+@B*
M8I]91]$6K0%QO[T"OAA='Z.[J`^K1:D[2%&@D*J<I-9X,-*#B\.0U/%U<%&D
M*1VPKP"V!:8>,%G>1=H3FG9!=="M:'6/;M5+^+ZCJD*K31O(NN39BMJ9[:X`
M/Z%"'P=]Q+$W56H\<T7'/*KFIX40TLBQEC5*GHNN&)?VR[@J9/+W)=BZZT:^
MF/-%AHC6$7^!DOYFG9MZJP2/+S:V*CE72YT(*_0?)+\E.S,;>6GZ';@HJRT5
M'J!B$I38(^@633V`L2^!F]_RC,W=!E-=75OW"*7G'-4_9;XD*TJB=R^]:Y_N
M4P0%QBH2?'NU$B=:B)Q]C@>@4V#C/,G)58+`OU#TG2M1)!]!6#E3.8.(W51!
MI#/T=3:R4%Q0BA4Z<3XS6T6HW[WV`:%Z470:*.Z.3D=S>I&O/1XI5L3$"P8/
MRJ%NLB]J4<2E$'U=AJ@RA^8H1'&:VM?C4*[:4_@M\54XG/>@8\G%23J6-8HS
MCNM9Q.[HI05-H"GMI%B&GFQ'3I'X"T/]#E^TT/D:'J$X&,9J@.=^HF@GV3@-
MYPTY0?%)G!]6(*8:'0\!HSSF6JG^*P3Y9*T%_0EB8_);!!;&4XO$CZ`\^<E&
MGM$`%#QYV]=MIB.2[?+E7JTC`,0OW\4&6WB!;BIMO4+U:OD,G><WOL[I.S"L
M@6P")^*&$,@B7JZ7<-?A5V3MOL$:,[A2A=TO!`>K*$8=Z4UV55.-4/([RF]Q
MU-0C*O11I,/^JY_">:U6*A5X0;GE!\]!5UQF?%?>YRJKKAWSB8MKQ%FEOBXF
MB1RM!P":<'*9`3.":Z(/8NL*8`H9,=`W**T2`6OQ+6IME<^^H4@XCX^N.N=_
M))"*CPZA\LC)Z07<VER31J5^*(FLJMX8WDV$ULS-+<3IJ1_AN&3AH6S*.'5C
M-5YK-LZ^/_#K0L@Z5K[FV^KY?%0-:-.Y#\P]7`D'<*.9R>+$;57FT=J@.!HC
MPX%%#,=<H='"UXD!D%&!QUQD3,GV;->F^DD[1Y_KD>@@O@(Y%[ZY*3V&O<$<
MW6[FF!S"'!TRF@9[C)A-]S;&:(=P+`^!,01VQ.OX5*ZV=WE+B;$Q\?Z_6>MO
MC]IBRXPK`*RVKAO4V[:U)//O+6GF.NJBQ1DL#629+U'O^O!E4I/`EV'42%B7
M0RCZU(%(-!<AT9(&$FT@LITJ#U$31RYLR5$(J@6/,692U/6\&_D[%IJAQ3IQ
M5_+!S2!U*'8:X#%R<RI8#"-0IE_"KK6CD"/TL*^^'G(9L)4*3)_(E4R<3XI=
M<*%+0/EY#2;2;7%O<YQXV=?9:E5+<=3Y\(G?#T2^+//H[$)+,.YV8_\6L`4"
M^0L*T:Y-4,.%:XVR04,&1UR3O.RH)<\PJ769!*^7WQ4GNV*`K;[3?7=)?Y\K
MC,F=)07[&I4J,G@Y1YUY65"I+5]=E;NWI(J5?-VN5\@>.T+#X!92@(A8')8M
M(16)467%VOT)+(AZ680J5RR\%;N)5+],CE\9$)@V<G+:R.FI@'SJX%^W:#-D
M635IV3*]IQH_\BC/;F@FLMZ0[LEE:86$.0<%=PM>6Q51M>9VY%^2/^O^[,]G
MLG$@]!3O%N]5<CPY'6#.ZI/PDZ.=X.354'2OJW[D\7AP=D[OC@?S<WZUIU7G
M=#`=)4^2T6!^FCQQS[VWO@O_.!D.SJ?P\'@\&)_#TV_)VS4<#"?P2_Z/>^EM
M<>*$M)3A8,(K&<&\)CB=CN*7Q.RPQA$?:B<R5,[1@FS*4&:<@=A<"#<0_]JV
M63+N"F'+XNT-N`:&#P6<9(3YT5DY.RNF8-Q5FO^F!\K92@&KR%$I6;H[J2D0
MSG,)$_?>\Q_"WJH&0(B,$RI>>)1,QI)@S#^@V*.FG![7<D:U/=Q?_OS/[@\=
M-'`LM<XQKUJK@'!QVL6^J26GG-P\.I>BK.L;GM6./B3'9L>>_D"54'>PVV26
M3B9<[6.2SD^YW,>EI,6/SL\L'N-4^JF<SGDC6MNV\O,;3><R<4[*OD1LUHZ^
MM[AYB:2I7X0<_0,JBHS3L[-SW5_S#\IV_R'I/)#3=#SRE5E&Z7P6'\OJT=L,
M0_K<^=-XL(.'.*(].()%"+DX7TW4`*>:C(MN./XG[F1EBO;6!>,!I.T6YDOD
M=W=>\N"[,7WD',AWC8I@!.IJ/>HO(9;QK7,NM,;Y2`/U?6UN^Q/O@T[0"9)_
MD)PDAIG#+'[)J[()V&M/?W.[%414R-%>]D#4R^MK1.F25@<ZJ^12P8Q<FR51
MN`W1GEKQK:%P",K6:#[-8^HIN^VMQ[!/C;)_5_DBPV17`\`L:N,VW:Y%]W,*
MPO0(XIWH^LR+0/%:.P^:1S<%`UU#7@]7L/,I>!U<VV)$?8F;VD=Z'HGV=XSV
M[Q41W6A_,@E7[$>6]7BML6L44FRUGHJG*^G=@U[<TM=-U_P,.6-)>E)7O@'O
MEG7>(_W@*.E5GVLR2'X,IQJVC+"!"Z#<[0K(@7OK<*&A:`U12E@H<QO/U_%\
M4TE/N<H6/P,!XCYOUR;Q`[7!5<;!",E29&>+DWJD,?BY![K>?<:.>E9MM$PB
MG56,-/?VGDG#,1LG!A030]=5UK2@..B+'%0UO_W&Q[6+:[4<C<X&(VTF0IMT
M-!J&]B(-1*'S)3KM[6U`"XG04Y/+P;6?!6>GF??>G"O6YBS%W82Y^,2W&N<K
MNIE_M[U>))+BFJZ,E&:EI-]X-*7N\&DA\%2YQ$U!U3?8>8;T,1Y.1HFVDX1_
MG`Z2/:H'F^IF%_(O68"ZKP,[W&#Y'GS63YACDBO)P#=!9*=;%-5-Y+=#*Z[0
MM8/;*%T]B"V11\DZ)MEFB365E,P*=!F1(U7MO9_>OO&3XP*TG14]Y&C-N';)
M5+08#5X'P]5FNAG+G(1^;?>ALV^8*1"[:=P"%%0V_</=5'@HV[7QAT6Z!<5D
M-3LII!0XGU(P<*;D^3+G:C7X5%0OV9L;1@5BW+8K&IF'W7;F10PTW30*`EN<
ME#9QE@(M6FGXMOR,_!,+H7PJ5Y\4EO\%?;2,Q=&L:GI3RDK89,V,O-IR';8Q
MR&*]3-D?H$"<GD3,4,F9?8E5Q04B24[7=KX^TSP<H1&F"EB#55%!ITKCI6;;
MJVCV5$F!>XQ(MDE6;VA;DKNMAL)WOLQ1<':IX6NFEK<P>2)2Q1)K^08*4DKJ
M$D=N!Z%,/DTH:DG8I`?RH/3Y"P?)1ZV!)-=%G0)T>H&KUG$Q`%7;-HW;J%("
MEJ^>$ZO+F<O*>B_S8MN]?:2W;QBS_('[;T*`U/5GW>,)R^NH86"LN),J%$1`
MX\\-9FHY2\NS#/L`.Q/RO'V+^:[6%CL?/LC[G'RY6_U0P]'G?_>==GSXCEW2
M4_(O[_R$:_YU$4V`*XG6BZJXRK6C$V/&T&=-+.V*X>Q-1U4[%^#T!S':J/P7
M5?VB<E]4YXL*?'WPE;V<4=FN<VXP,Q]JR;7)[)$_D??`%E5X[8O.?M#0H\:9
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M]71'H4G<,8^\V-&NT=TWVS4&`R_\RH?W"W.J`W.;?`;<17R;WLN>OZ/RFQU4
MD.P?`Q:[O<M"DMV;-\\)[_+A/?S$0?<LOK8ISY,3B28#%\0@[KHO%;;KTVE"
MPTO;3(R.?"ZKGZFW`79;SL14013Z\A.J9&+\O<^7Y9?+?[A,+A_0D00Z3G:S
MAETO%@XLQPV"B+P9T%_)^_H:<U;96O&S=!T;)"JS(2;<,D2$LCL$<VJX&QD7
M0(63G0P3;.D)FB&*>&`8@\"VHD3&#\2VW@:VA7>ZJRJH1MV;1<-Q$-T/YQ=;
M;[9+'PH-=4$77HQ1:5;AC*)`Q[R09:`'$-A,S/U\)JX)SN"L@I&15]MBM:0^
M2?X4:SI%J:DJ[NB>.;LCX<V#B!$W<MJZKL#D3%B9T7;P5?PLC$L_DS[(E?%7
MY.!+*H$-'8W3<P1)\1B"A>2VH/XYY]-=N>.0M!BB@5OE5X]&HW$HB]M17A!'
MQ(1)R0_VA?<6XO>BF@E1G7**'^^8Q``4I>[2'-$XY.#P<07*D@Z@!@EMAYK*
M!%T(.:@RJFM%%2JU:CH<VQ5Y<=[GH?@[&8;=816NDIKX*JDF9-=5BS8:]2B9
M:J'6$?_0I6C"DBGNUOP;]D:#G=\#<)AY;5+'<<^Y)X7\ZV+3:RN+3;*$O_GV
MPMI@NKQV43=J*=WP2ZX=UY#YA&36H^$`UC<*?:4I<#SM&!;!%W(0.T9V_2.W
M5'O9*),OW7PBSA:P.?5>F%%66)K8H(UO,+;G",[H"-JS<&_9EG3O+$;YQ[RZ
MR2NS^9O/9>C@P%NB>?"@G-3N6"+]*/;X3!,>.'FW$G`1HP*Z'WB:.ENGP@32
M\>-BFF"@@-D+G/LH/1O-T_EXWG%XEB925FLB@*<S4JM4Q!^F`!#I>2T$3R-`
M31WO"3NB9+6EK15&T%&QCKG_GM2@BEJ@TRXX?5%@_;YB,&^/V1A?#1RT0/4Z
M4:+\&M7"O+=>MDQ6A^*&[J8+7<:Y]HI91;J5\^1J#3EVY%-JZ"Y$TFANK0GZ
MH6E[XR2B2B1A0SWNP_M\(B1G*<&QHJ,.K"_KKLMK?A%C5-Q-$4,9G1_AKC%R
M'MRZB9V,^&XH&Z\3D4_%V^Y"/@.?BTGKC;;95&*3Z@]=$27NE'T6).'"5Q0Q
MB%Y3+P,9T*F84>P(GY]+VX3(\#`ET_DRRK*=)`XN(SK#[HI2HUK.0@Z,H;([
MKP$E/5"1WJUV(PM73NG`R;0BU9@N@(QK[D$<T"!<>DZM5NK<?S[C[D8Z;Q"7
MUZ""4A$^VA6U'YF]"[;.]6RJQ#>I+"CV(HAI-]G)[M($^]F.T[/9R$BJ@NK`
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MQOC,>#`\1RC7V91>'DPG3\+@M)/'Y*]]BK@Q>.)L,(2?AO#3;#!U+V+R&<)(
M@CS36T6]H*1]IEW?3[Y+VA]SM!_@:_Z'"SGP"X%IY^ZM40VL%)@DD_,9M6<^
M2DYA[LGYX)P;9(_/&.3S.RZIDB!3FT_D,5@AR[<E@U;(/_:*&6&^_/ZYJ@WF
MKWTS.&4OV]E9F`$HN-RN^S2:P>A\FH+$P;8,@_'TT"DDQ[/Q-!W/9M3]>3HX
M'?9.96I&DM'94;SI?>S"1UJ1>)F,NQYO,?9=6FJ:S$!+',[.C*X)7-W])U?_
M3Z[^/SE7[^@%L>.V.+XMJ$Q+5@8:;4KF>$%NA'<L8R3:28<^?)A(Z9`HW<)D
M-D%Y<#;KER##P?E0),BX7V;T2HK_H6+"L+SPDV?,(S`BIA-BK[/YKRH;XJ%!
M-DQ)4HW.K&1HL^W]0D$'?JJS_O<0"KT0<W6:-0RKF-\19XNX>C-X'F%"([SA
M_AZ0;,QH5)U<#''MK/!<[1`ZA![]6_TR1UBYBX;DTH069HVEM(N2\Y8]MC!B
M*#38^$"K)*+R2DWK^F`[1<K<??RX[BTP;CVFQ%8Y,!^A7&,WXP$NT]V]3^OH
MUM=.[$.X$J%EXY`"F8YYYCF;ZY,Y7YC]Q]G]@<F(HZ.CZ=@,/II+S':H3:Y&
MZ5!RFH]\F/JCA1?IEK7N@ZZ$8?0T//_LV94*O!">\%@X/%`9(;S/K$6"$Z/4
MQ"<(-$2GJAX=[W,4W\#415H9[M?K-2;+XE:1JU%S;^GL\#<4J'.-DL<:F*2Z
MH?[2!LU(O+[WH0NGXPQ:@H]L@,0WP3?L2U+F[%Z58J14@?F>.RPZS<RD>\01
M<CJ.;J^EU.7H]G(;78IJ+?+7?*V^:V6KJ;BCX"?$VOJ&*`_2\%L=OG+KL(+^
MIJ@I@J&Q/$X6E)IDNDNIH@L1C83_V6A/;^/D.=:V+1F69'+J=WL:^SKYA'S,
M&K0%G"!B8&VLO,/1'W%R7PFM8VSMU7Z)[21(Y([G2G*@GTCUA)`13JIO/`YI
M,P/W1ZYBZ8OSD^=62EO6XA#\DU8L(`T)/3ZD&\%6?T(Q3CU_)#M1&!FWJ:<>
M'SK2HQ6%'58DNJ%F(S4/X?].1[ND>OST9'`^[I>_S:?'^#3#$?Q:2-<C9O_7
MM&?T<ZE30*/5%FD.!UHTIAV;C0!$'ND^4\;UZ.L'F3*I%Y3TQ[^"$6/]I\%2
MRZQJS-A&%VIS9+!Y#2;/C`KS=,G9O]4<#C\,(L/0PYICB5X-<C_>H'%JT"1?
M9="XR*!)NMU4)88U^!SKT%G%&9L%?=@G>+4E6JEBPQ,XG$DIK;)]'?F(4_EO
MV*L`2SB:2,Y9*/H<7XN`H^<JT.6JO'EHA14CF`NC<Z3VV^%/[@L=SBETV/\^
M)R\G;\K,Y-LC^N`G+"Y++!=844\UC16^U4#"279NTS43/ZH%7P)6:Y7[P$:'
MV`VE(X\F7OHJ((8K4!.>A@F&!G`>QP32\Q9!K133D.)8J*Y)D>L@+^(YNBNT
M3&NL76AH7@@82[B%'F.:)OP>Y@H:B_/EC-D]8"!\B-045"5_UV<%CL].CY=/
M56FG8J1KPM9P%N!S8'&D?9S/9PR+OF.5^)B*8!%.&)/Z@`6$S&,Z$+T^VA.-
MV,53OD0*#0EN#$2.Q*<JS62T2V$:M\O8E-C5=\&U_&NILR%S*:A<6G["^088
M*!K($7.W.$2;X=1MB%7*F;J,]1=B%*K0,$#^02L*W&H_-)^`6ZZ!T6G2F=/*
MJ';XOL-FB@[Z'.NZL=JR"1),"HE(,T`;-.7U\8M.-"ZJAF-[36\4@YU<E:+"
M<LW6LN+B.26W/W"\(MI6"MPE[=0$R4B0&R+7@'JMNZ-1.I,[P"J-9=R2M3X9
MC$9/3B:#R?@)-C`/\73':E9/B#H.KP?(@91Q(GC.4BP.GQ&YP;I8]C3"S:"K
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M9.ULS!S\J5`+<0>CMH=-FL.R<&J,ZLRH7AP-W*560@TJLC7)\*YK'YB^#`5J
M6V+3:IR6@]H#B;=0X$F?C*IW9*@PPHF`Z;:8M38B%Z^2+S>D-YVV\OEMD5\G
MEXLBI[;+BX1!RG!T+RIL"%*=O*TDQA.DGJ^-Z50.%'&5<>Z@9-UYLJKC=?F9
M2/*I9".XHUDC<0-^SQA[OO?FGEW;DK7!R1\PY$WWKQ#CVR^8`\=03:V8_Z[$
MUE287J?X>_)J="@+V:JV$IZD!KJ'B%W,1IQ'PSOB*Z4!D8$@^"4W?="[@HJS
MX6#J:-6U5EICQ\/20_E\NXX(B%Q&K0$<M0;X32)UT8F^?9X@Z1V4D8P=LC_0
M(U:Z4OXR9A&3T]"O_]R6F8U3";QKTC]\UE%*=B-<M=-H/9=2L/I05T:N%HO@
M[N*2>$5VXP.H63<9-A;9P+2HI/!BE15WTDICC<J"\&2@0:`L#O!9S4''<%)D
M%`ZM]I6_)%O5E\64R@-^!O'7:9_H\U17"(]?.S=J`?A%N:T8$1_Z76^HOE!=
MKK;*OX2&-LFRS'G-6-$;^3&6_":74C,U5#MC:W'?9NGJT,JONX(&-GQ!XYHZ
M-K=1T:!\E@]YGF@5*72U-A]Z5V(J!#Y(%/5,DZ#WN"U&0X8\=WU"NI1QN2+*
M\)6G:KZ`E=\56QXO.1V.CG]^BO=9'&KW!&[F8?Q;XGNCZ\AE-;-0.(/X10%Z
M-URLZB%2-G-0$[06>U2>F4OC4I'JU^\O.7U6,[S]2<*)8:]>7:W_.N$)FAMT
M&0KWO\14JWU_W[_9(RE(&+^GE68H=8O*U?E*_'K[)-6_I%(CP?YR32&(G42*
MS58<<Y3L7-S<4J[N9XEP$F?;8C[S&F,:F*:M#CL=EE-0I?"GJM/DR8Q5%VZ/
M0PU*O`>I4W>9#L:*0)>@3:@JZF@D1A(;*R_3>$`2X@$25*"2_40]6RF_U2Q3
MO+%^2Z8R%#C.IT!)EA.MG*#ODB3U;_\:I47]Y?_Z?[5@L\,$,W*#BI>3JC7?
MD'`,A:[Q@5<O+DXT(F<3!/_M7TFE_TP596L?G`YYC;Y$&>D\O"V$XL#6@N2J
M11+P>C):LX3;QLKJ!3F2Z:0PDK7Q`TCK)^*DHWDB4DZ3^HO*)LHLI>2!\XJK
M:!@2>2J-=C%.P>"]JN@?G#CN_+\E>*25WX-U1IG=>'KB>ZS1144S0DL/N#,5
M\:QR>OC8]TGF4D"V'"2#C21<Q@4FG#$^!0Y/'G`T-+)@I<=.=5#DN8-.1<E@
MH)^-G[!^0SV]_8@<:W^J:`!E)R0'-K=2.!CE]SW;LV'_HZKVODL>&W&^$Q)M
M<$:5V9SH%/RVUI7PX7WQ5_Q`]L7\2=-MBF7UB0O>A=)69!N$G2:")GM@--;W
M`ZPLO+_QR>):<<73EP4D^>%%@8)57?.[4K1#>NQ@#NB-!.S)EA9P!P+"7F':
MY>7)2#K\>M/R\N5S4R;/O"U7G,TPUTQH,+&GL)-B;4=UBL,"'"S@A/5>R3D@
MNCG.GM(S,=%HUR6B&3STT>D3,T^,[R\Y&$E,E<>+&J/RE/A19ZU@.INKIZ08
M\4.W&->Y0H..[`%IR:U.`NUZZ&M#R$T%@<E:C\'?!.0!C3QP7>274A<ER5+Q
M!Q&8.N7]*!FGUB^!AHPF1ICM%3:&S78Y&58586"F2U1\*'!4WZ9:P)7A#>4J
M-[R@R1&M3+(N(@QJTF.,C*!JO8:CD`U'S&3MX\7!E&=!:PF)\WL0^KE6:>93
M?D;CX1._QH[1[$#.`%:QFWLAC?(\?[(D8`0HE8^F<HWA@L+[1Z>#V02#XY)F
M4UY;7H]\VJ::RUXI7_%Y)'ZOU]@YPI<N%Z&IOA2:?BCW6JR#G,6J>MS(8D-I
MHAN0\]YK`P]2>1[G'S^F:N!+'L5X"`)7@7>([8K>O+YY*A6%NKAG3%_'5!KY
M?X&SH>12]TJ'X*8_'V*G2MC7<+.#)]SLI?=L4G47F:FZ`KI.G041`USBX*J]
MI4#=':OUM.4L;1TT;1I(V@&1R'3"[E`_X#FBO&`OV&?B\Q2LI[MXA4IGHMH@
MDGMC7N3-@M>%[EIUF?GF8*7\NF/M5'Q1-<W(GWN+'2PV]F)'O)`N<YB%:=DE
M"H$89TG'L:=\KW1P!4J%[D(;C_`V=P37_AD#R_SG?9?2Q`-\=QCC#6WLX@ZJ
M8<[#>J6X$KD3Y(%,!S\DLG`'IWD<D]E)/9ROQR3DTX25F-2*X%1#666+VJG-
MJB$K[$%[517+FQRC(4H\ST/-[#3YD>/DKU[_]/[B^\O7[YZG&IIV;XKK''O)
M)I(QC3V1M?@8GJ>W(<!2R14%<8MZC[678OO3,T/1^NC6&G=/;+\0F:MM)06\
MM-4HR5$@K+M0.RI;V^*>CKQH:(3>%O=<1IY'I6_*:336()8A9U_>&MB4+''N
M*87KI%G[J#5XZVTB"T5PD+FOMF%,ME(0OR4TX8U=$PBW7B;A.E88G'`/R@HM
MP2$S896*F8Y%LU`Y*>&RL:`3!F7H$.6[@%G4\/0]!6AWU^7ZI,JO@=5*B7!$
M3V%EM)QR8X_&PY"%VER"[B"=N7<X7J.U)6UDD2=QLQ6DB3CS-ES\8201&MO@
M[#8DC]@&9[:AY2K&2\[VI4R*8R3LFQB=1][!GI(9#K=.XP.X=XT2&O2==?Y9
MM-N$RFR9[HL!CSBR:0[XQNZR&QA`FD;N[-"F#/;B+2C/`KF9ID'-#64Y'(_S
MF+(<$X$.-XH;L=?X*JXZ_[R9J]Q1M8.K?NVKVK%CC@-W4-6.9&?5#G=0U8YV
M+7!UEKN^JAU(2WH,4UM-V</O(I(BYZ[ZP-`U207&WRE3:M0D>G7Y')L`H>0H
M*ZIF@]V`"/7L0$^\Q#2*BE7#)K+`A%?,;'PXT?>/;R0WZ)#_4ON.,#^OR\\(
MLL2B$7=P"Y-_^]<HF$6\Q8.GL!V.Z`ZA'A2_]TR<U;2?C0C(VB8/'8U.1^GL
M_#0RX##FP,Z=!RG5[$PW0ONA$U^EJ5ET*J9:C,3LG`>:S7YA.A<LWYEM!.WL
M.&8Q&6E?231Z][QBHQ(SYE?'"WA+VP5UOQ582'B5^Z_Q;?=RS=<Z.!JE\W/:
MQXA(YUU$BI-X5I2HWBJ4C/<@#?VGY._4U:K!)W\$JXG@'\VH9U>E#_T.AVBU
M(6A<,,ETDK0U(QN1P[C-3[0@:C^VOD&\M'Z/?86HL2.MRW_U\_Z#12OWS=UM
M,<J&/FVF%?(=2(EG0K&OE]L[5I7\*1"<N8Z[EYONENKP#4MISPZ=M=V[8GNN
M*YK$%B]&]A"]F292PI]^1F%L`KK`<24E0%`.J-&BF2,(8(E[X4VJFP?04`?0
M\\GJ@(N=GK8Z&#>1T_A?8QL8_^.:NVO0$^997V6,"MMA&STN-492S6E4*[G"
M?(C;KB$Z>DD9`G*[)]DB@:XO."*6T;Q[GM<R$E=QI=DT\PH<735O>/6S=O25
M22?2C*O(*:3>WP!#[[&S#9W;4F,J[EX)WX5K7JBI8<L$2O-"//,3TYZ+3&/A
M28BTIGHETP#Y\(')34N$C`)6AAJEX7KJ6FJ>X.-A51TQKJ[F6$E'<ZSD6']Z
MVJI]1<!@+/N&/V#YI$_9JJMZ4^^#3IQO6B(8O?(8N:+RO/#8DB);4HTI"<)8
MX@O.MXOU/B):.J+HQ>N-2&$J<D,M<LF`S</W!^YYXS<\&?:48"K=BH;DDD4"
M^T*+0*)H6NE9=>SP6Z[I_."Y-N>\N]@`1\<LI63P8CWVWI\SD8BXH6`.!?E^
MB<%(9)F-S`!V6B#Y;3S+\KYN[<9E#%]OGTK8F^<.JWEGONI-;>29&\D63(,]
MJRN@S*15IMU[L`DEHX"D.C$59<3R74LG$=HV!']OK]NN3K6M?K92X-#WL_0U
MP#R>*VHK6%[[3GHFJ"JI8HP2D!B/%T+^>;25JSSNUM>&GKC@3K%OLQ!`'H](
M&$IJ:3RRY-:N[L=V*T/6V*B@_M5&O/L=C4I39YJ4<ML^WZ`T).:%[@N^:6*M
MBXLZLIK<$O++FJ>I#!?U35T.PN:SD4M-+FSK0NV\0WU\N<OHP+U+1/O\+]G=
M_6]4-THNJ:TJT5MD-9D6WJJV4O1:7N/%?A9G(*P#PQLYJE8$3,TIO6@AW48R
M*FJ.Z422M5I0);EEOD)<'<'/7+D@6V=I^G8'D$^%**P*DPJ#H8ZHQ^(+O>`4
M_<DYV%0->H7MQK2J?5';PN28R@2#M?$@/C&)-@6N`;4?9.B`UOEO\=[#W@H[
MC.F2(06J4L0676O;WOQ>$5S:!I$2FT3O0=>-[VA.J-509=[T@KE#EP*VZPPE
MYO$.A*&UCX-OMAGFSK2;A148RTS-4A&QX76:/ND-TAF$'?>A@KV9'/RT>D!B
M"Z7>=0*I_P)VBBOOB@785@1.H,.5S#2,<,D>`"W=,5"%RXC=;]23".J`"]KB
MZVL[`ZX-)@U-M<[<QM?\)^$F715<^'.T&E'IVLW5#$QCTVA,X%M/ZG%S/AV?
M7XLJ165`PD+^BB1^P"/._Z[ROR,N$CH5;@2H@'X*;9+#D&L6N$Y:NU,EZ>@Z
MH3K;,3SY4D`RPMJJ%0+$:ZGWIF3?W6HI"XTQ-%^VKQPGUO3P[^$E69;;J\WU
M=A7F@[Q$>`8OM*.#*EO?'57MS9^<^;EKX\AE7W%$LMYPUTUN;4Q2GU1-`THO
M.>A2U9N3`C1[_@EEOO88)9^S40RPLT^1?^:R!90Q6OM&?=PY*DRO,.FJR'<W
MQ?6#*Z_00X\9H#5,]>2N_"0QIY`QO5TC&V?X!O;\H_L1?NFX$2`A[Z^T"";K
M0143$YT'6^<YBN_:!`#$Q:$P1V[O0XVP,C([\I,E^G%@RH$`:2J,^B^XGHU'
M#<BN(Q*PJ'SJ!($D@O`;N#^B1!*N9@%$TC\F0-O9'7/E)<;&`R.=\AS?`ZO1
M\\PTE4I#]9W`5^B2*Q-)HR@4"5>L$[C*P*BZ#9X@QUF@'M72H6Q@9#H$I[05
M"!55!_ZU=F2/18AB:Y<3&0E3I6X8GE%U=5@6\SPUH@)V'E1?G]Q++*[Y.$<X
M,3B47><;;F"-'NAL\9`:M*<%><>09L=.9]2GQ(G"O%$`H(P966K3EPC[07<$
M+0>-U@,]POE\*@S7:E,$6PEX<2G"(&)&.@Z+6%M@<&\IU9<R02<%`(X6B9"(
MSZL7%ZDM*R^-DYM5PH6F2`V-DXI57.GT;&_9_MKI/!9-W,L[,]VNJ2;=4W6'
M3I5/0]\F?,OB9[@#2Z>>UGBD0?(ND#=*#4'U!76:<Z&MIJ$FJ8]N=?H%$N,7
M0&<NHQJLJ\K'>!I'VF#M^RO@M,3)*U)"R6_>E"?=+4[L"X[_H9U-&V(&=P-N
M/6'%&'A/1,H8!]:1&9)XW1QEF4OMD*CT01R?X,QN+D\>%%(@`I2GJ)GC-;`#
MJ^4N*HT'S_W@@@[LJ]=\Y''>T$TNUE*5)=2T>9-=D5N`-W>2G"33A-N"RG^H
M52?U,;K;:D_F4!`E.9[Y7IT3[:UI9\OM?8\2;=:13+DZE-'#M>B0!P%&']"(
MD>>2"N=T47/B_F*2+[I&.TI"29ZSSH+GK]<G[Z2_:53WQ]3[_XI70)TYH&WJ
M7_[\WU^_>_^"7.I\"9L>;Y)MVOG`&H;Q54<H4>:RT+.U,\6-6R/A0T&W>5:4
ME*VS4+SNT5FJ\0M_;`AJ]D4;"&3C&S6BB5A4TA&#!%I62']$#OPUZW?HK9&Y
M@@X$.Y`4M3.:@GSB&J43R&[R<I@6N-R5ES)<,#W!?\*+(NZ-F"N07N#HZGPE
M/:BX%MT&I_"63>?<-7>:O1%UEWH@=J\*."M%*$:+P3I<F<X)-C.$'RD4:)=$
M?>']]&.?BVU*9A@&%@UY'0&R0`%>L,^]Q%#M>BE8N<:JV*KGR4ES=:W:U=;>
MWY$[IZ6YRZ\=%:G'H_4H$&*;_-=469@ZIBC1A8#HH")@A#`'Q3_4W58ZHD@G
M%2;W8I#*JI'#HJ.PIHL6J=^.4U1CJNTF6@*-:O2.O],850NT^WOFON*>>4<;
MR1C7D=P5(*Y4[M&[U#ZQ7(XC]J.1E#P3]`1E7I$,T(2J\5A+BWMIHMEHLBY'
M9<@G<TFN%3?30VNY?6QE@BK(G0?,FMKCNW+8XF6Z/<N<)ON6.1\XH<N&[$R,
M[.R0'/K243*?J_B2G]I2$?0@6HB(Q?'4]YP>R<M/=4"5B3/IPW64G$DUMEU2
M,;/C?[-4O.@:#28R\C.B";UB$R[ZMB97]+:-YNI5SE>OHH9M.K:CSFWAY[GY
M^3S\/![JSQ\"4']\IJ7L9.N:[,=#"8#S76DWP(,>BJ`+WHM!A<70S><A"N'V
MFJ(*SEYJUN>,<T;JYXO!E/L"D*]\M,*$HRX1PDBUW)YARCS)>=0'7EU</B-]
M(#SKPK//RR6%MICVL&[#)?6F2N;#:8K085VSLVN&)S3)5E+-:M'M\1\$V>44
M7PQ^.[\'BS"$V!!L]G<(]HQR@4C#5FZ11@`;*F>5<^4KR0I8GVA&L40W&;,I
MC@@9YC>,0/000S-Q.0:V*IKE)MT=E882F$!94!6VOHZPQA'?6`3GR;;7@3O5
MM4^U+2KF6R1NO-+3'(W32^U&.+,1YI#R/(W+9IG]#[[F=A%/LU.==7V!?IAV
MK!IA]P/M==[*.KDIRR7CR8UY&)]$*D?A0L2L6PUL]A,IC%S`IUWTM'C94'5"
MEMK4(9LW_W<R4;KL-FC=0,F@<W,1.D"8CO98!0;]Y01-VZ?*-D]5IL45$7Z?
M_?)+\BXRGP5&<4V1WL:4M/$TE7:#,3C!3.N5!)YL<P?B0Q:'I!8::T\[Z-'K
MMEK=6DZX"\([6%Y);]Y`>U</QM7/]YS:[YA-%7\8JN.^I",:+D0T"*.5UJ%Q
MYW`YI%P;QRA=-1%/&IY46M$T.;O:-777CM<+VZN$/4@N,7[BZ5R@^:81.GE:
ML#^[Y#B*QXB\#6NN!R*4*ZZ#<IUX!`?B/=GY)<#J+_>"8^??.NXF%:T>P3F<
MM>QG1<(J^&75QD$D.JENV,?$Y9\THF+#-T4%BDR]T;@V"RK2C<-XVC/8APA3
MBGY1'4#OV<0.XO@/7BNET-0XR`JO:+B_0([QP!QT(3).4=M`PV##M4,Q9SYE
M'WXA6'E?2"2O2+\,:/6@E(84>,E>=P)KP&390BJ\:F*[V0N32[G*/E/NNEAY
M7)R9@..?8,DY^S)YFM$.=MA?8G)HA=9H8S&\&O:4_=SA3I6NRUVOW#+>;XG*
M53=YPTGOM(B0PI,;^F-("O3FD??48]5,E!$:A]*SQFEA/<C@UNV8$?Q6Z3/N
M\NQ#HE%%RU"<T_01D"A"5M\Z*B!@PJ*^$7<9S+H^IJS<EZ]W**R)3CQ,O,QO
M'D+XR%`)N[Z=*;")(`]UA,-E-X'*(JKLP#R`/DN"PY?E#"F+HNDKIH0%@+_1
MW'[(.T4=VJ5=$A9^9:49T5@(Y",:%>NE&(AYE4O!"TN'YJP\1A>%B^M0\5NB
M]2/S??5`MI3NYM^)F5$V<<BG[&HOWP6\E$+9<`P7%&-&-ZX!=#'T:!5"P!_1
M7;1$U5KROR_N<HQSDZ;\NXN+=^)H$Q781*8U*.W%&;FC+<7R?>:BI'RD$E36
MRFOEM1&@S@C0E!)`N=F?I%3NU0M;>ER$>K+;IK&TCODXB7=[8</0>)/TS"^%
M(NQ`EP8])_%(4[2"L\F#NMG8(TD6"%%G%^`,:6\!]]0GE_CWTE`9HJFHI2:F
M'>]E(Q1'B!EG$19V,M;MSB1I/?KKI8O7E1B>&-\D]5**,J7_=.RT5!YTP85Z
MM&H*!]D8Q.!5NMJ07T<0G6K&?,B^Y+XF==+L-(`[4*XHSK(D+457CTE.7(#0
M(_LV.)(D(=_=;Z778"`C"J##M:GYYN:RDU@0D($&PCGJ;KH<)"\4149?HOP+
MCPEF+W)PXZY\T%",:FW0O32#N$;41O!7!$L("AH6CP'MH7J(,")XHB9GIZSE
MXL`>"<*0Y!D.Q@76V55O/AY=S_8,X)&L]_.@T77/JF(AMNS);]'#<)T\IF5)
M,KP$UX27K'$$\>[!=HE;M!,B@EIDZLL.W0-%<Z4UJ^"S_G)75HCO^QD]=%3^
M'?5EXI4UU3C23,2*>V,*4S/ST@61-)+B4!KMCU?@;?/FTJM@+GEYQKE7S&Z#
M_,=14-FC,;AHH)C3RF?S-8A[+M+R(0(5%7P!Y=K035F)DT?_8$"LC!!0[WI<
M9')9,)Y,D*0,\]L0_!$7R;UG:67%-5]U+B?!EXTGP&E4<C45TV+-!@+F+\M[
MHIX@,V^VQ=*#>;9KK:`>3[[1/8%"$Q;R$AQ!5-'%#B((#BE9DH%]\X"9:W`V
MB)KL)!9*_*T5]$E*JJ\RI46ZK3-'A*'!BIA<8?$#K5`UQGQF/CY>@1`K?7@Z
M?.(G$@%,!$R;;S8KDX>%<X#5D(-/SJ>!;`:[%<&BHB<4&RD:$DIK]6QV-`JG
M75F<M9H$+G!(I?#N/JVZ+Z9%!-8%BF"OP:6SC$H5H>N1'$)GI\.3T3#%%#.C
M;^&'/^HJV%EHI=)?_OS/V9J]5_>86JH2FD:]]&52?BH'R6AXCG)$_)>./T>Z
MF3)EC[ZBBT2XEA@0)+]G7V$0=;2=F,E1BK-@DZN>K`Z;NE8R(FT&66,@?>$5
M3+_\#Y+^(I?98A,]/3*I7(2-Z;&M+,$P;R<YK/EJP?5'J414'E:TP2PT,8B9
M40"B</$M`^(*P,<(!MJHX7#+Y4=%D:";LBYMEX'X/+SR7`7,NOC'PU&VLS-(
M]7M&JI_M=7WH<U+!S7KK.6>8M4D/([\*OEQM_."'4$O8^*.(1';TL9-F*U*<
M-.J+%!]F9/?;,:570?!G/K:=DO%-NZCK$>/76DV5Q,!'ZA90=V@Y`)/!,V85
MJR-?X3#P0R_BH;=KDC1<Z(GG2I:36B?-ZV7*>DFCJ!8@",_M#WIN/MBRJ_OZ
M`:^0^/=.#J.`!6W7I/)8Y-]"DH-<,SDG#12L.9[!P^$+<P83A/_05'5P3D7`
M*VFEV!`KC1`12_;.X4[6(+<VC<2BG%Q#?AEMLR.R==Y@#O0;,FPZ\5?['I>P
M9[D%>8*B5]QZY+*2DH=Y9-VUW4^:"M9V/Z',HR1M:WG%#B/0I]"1)*CV;E^H
MEQ7M+XC^2;5EFDYD<=LKI(2MP6N*=!EW4(&!]HK[Y6$U7(GG$,##Z.'MXJ5$
M#XS)#A<"7;ZQ9X<R/40+#GNAGK!6+<?\,QS":^YM%#E6RG6)^DKGW3GL+5N$
M6*)+I`@4K?="<//C/;)8QVK!1]('\&U41=`2Q;HH#'EZ7E95OO!^6@=DASA+
M^C"\)DFJ6$I8LXO$/^]M`43N@I*(N&TVG$-8%4$K-#R(-2[1B,?)SF*E2U6C
MJ?@+.8Z`OM@K[R>BU\Z.'90RU'Q],U-L:L^56*W<E0XXI2G:&W;M'JMS4MBC
M<@MJD-YXN]%8CJ&-4;8K&6B"+32;)846?\[;LP>EL6`3@"0^5>&A`PA_P(UZ
M0#F<8UK<6CPF:X%C@+9*#C&V+3@DDF.9)SX,^8XD<_%F>J.`3[!U!"(GG)UH
MBP!HV]5#2U4#6''Q@V!FF"_7P6FYL`NY%K[!7UP7-=*>5#N1T!E(I#M5MYQ4
M*6!?<?QXJ-K!`(<7^4+J@4C-B(%[F548&%N*)L#Y79S0:Z5+>$"0>#0'ITT4
M+]#*)KG1/-(K4Y"$U9^H5;'/4B_JI!$`T&K`UZ#B?=0KV2H.[(SS!V\_%Z'O
MN?Z7'PFB<C*<T-76"GY@0[Q&9Y0_9?V#.[[<7FW*^V*1S"?3D\GPZ0_))86;
M?*`3&%!,(2_RJPWQ*:II34"U`9H=2!M;8C5!F\4Z;J',O>A6HI53A0-C/]&S
MP1Z[\K09E!:MK$2%M-&AGTFI0_54671-0\D(<D]1N%<;8_ZAM,XSTO`$HNP_
MSK$?8O8#7KUQ/#NM]D@>6@Z=+!I94\VEJ?D=Z"8J(#GHW$HPQ*K2HY0LXVR$
M2C-C8$6<3=SZ3)8R/%)E=#_M_6I>+]>^7LF.ZR7CM>DXZ4@_,$65F)AC2P`D
M_/[;,YSLO3VV^GWG_9&11G1_7GX!IJ;EP<FY]7&]K:F$-+GPP^T9CZ<GX^;M
M$3/>&^DNNDK`S%\:9L[&XQKC,13HB3Y-G_.W3(+D3%U%'5B2>#=41N3"P?V@
MN1U4<Z6BI,O0ED`<AU2@AW#[-J;J?618]I#AMP^I7ADV5/B*(&#%?E/"YW0#
M3/>SAF2)R-)Q-8<U._H;@97]$H".K0XEM1O2A1U1.5.QN52>BF/80"\7)[MV
M&;K,&%)RH:Q@J_)[D[G[RMZGW=2);A[\ZPDL#_U(3>8<;"Y/=?7)[TJ<+!%7
MM0Y$"Z)B>G**1/O"\S,<(SBCR#:ZXAZFR4NB"RKH=B&,#`CA.06*N-%QED1?
M"KXHDDHX9ZZI)'N#O^!PBVB#9%3`WN3-)#34S5'3"9_5G$YTJ0O.`8.RP";P
MJ#<9YWI16F5805G=9&M!8=*X61AP(>N@2']R4PK0C':,J#74^%`)<EV6&RFJ
MZ<4!,U>C(Y#D@D7BFLE4C[AMBY[=/GJ>I1'%"L6Y0*[)UY*KGE%R.+ER7+R/
M5FF\X;D!):`3]`/QR]EP1O3[WB;H/Y?>&W(IGVMBN+<]:K%IG'>BWX=@->]G
M\%+9)'3R9H:J5HX+U:,CJ40>8!N64%JX?-AT,8I@=9O2!:>D\$M3A>A*?KEB
MS27_(@*99X*<FS[KS&<%N*!Z<UNS[&*"[E`F>+:':)(KN"#4O<-6(_=%4[3X
MK[D^1G=1_UV+4G>0HD!153E)K?%@I,>V\E)'$MG9K%(Z8(<#-S\)(#CO5>X)
M[KN@.NA6M&SX9Q[]=!'C1"Y"G/!9)BC&B`D??T`/5$<1'-Z'_UI3-06U>==(
M](:R/@B15J(^&5A*<\!F@".+AFT0;#RL;3M@0*<>^4=':D$O341Z2)1#EY_[
MT/#:'"5GG!6&-<0;?QNE4TF,4S1I(JCT#U3<J(%!Q02S='(^ZD*K?UQ3U`\>
M@O6<$)(-="Z?,='*K:E*3"N-'R+IOO4#W?N!%%,0[`#"4$:JOD1#U7D6[:HA
M&_3*7FOPBK1=/!VLK"3F!94*P%R,5)I+<=VBN`WQ#14D$:0,2:.$9JJ01.\#
M89,(+_J&NY=P!+ULP9X:I2CM]QKE"Z/\!84_5QQ:B<]7C!>[H4F\H<N26$V5
M7V,M!D>M_0*N#M.L,9V'L&0A:YM<LG6&;@L-I`;8HPLVGT=JM&%=;:!Z;2;J
MVA-E:(6>/J%#`]TPPIBQJN6:,^&<>J#6.8)IN2J4YGE_RKE&EX;,8N0*4(#O
M]Q.@W(A_%U0/%10+S86(B@IQ,IDCO4435I%K\JD@'?2>:[D369M;2Q/Z#>8F
MQ1,6*%YW7R)-N((UN_XU2Y&ZG2,12I3_0'1\1\643,JW%`VB!3;I&)]PK2N5
MV"LUH'2>FK-MNG*5F/FHSG`$[TW.1NEH.*.?SR:S=#0Y=R\EG$)N#XH&4:V<
MD^CJC]+Y:)[.SH?`N8;3T_1L/NL/XDS2X6R:SL8S^.E\,DEGH_/^AT_\O>2*
M?\?<6OHIB-Q9>CZ?)Z/Q-)W.SQ3AQP<4>RQ/TU/0!^;S4^2K<YCG;!HG,XF/
MT`0<VF[YT60$WSO'NL.<S87('[J%YDR/Y^D8:Q^?C3"+:Y;.9[-T.IHG3T-G
MB6.)3SW5T.OQ"+3)\_-3?.,4UC*=P.,_Y1O"%J&_[QJQ!B9."Q^93*:XB?R1
M\]&8O^@\QL4\K>B&,6SV:)C,@=?.SL_\!^"L<;P1'/P4QSO"$8?G\*LSF-&W
MU,;K40HD/2S:?Z&QGLS0OV8&WK<GX+6V:'&;+[<K"0=^58&!_ZPI\)\U!;K(
MZ8`[TTU6_]%R1'>N\A$,XO]GJ:8L,6N2F#ZC]!^YAT.K/=ZON;;1]#PLSOQC
M;O]Q;OX!Z]-_F`6>G4UE@6#1G'5R/POCZA4!6*1RC57<37`FO-9E]`5RW4C#
M`=*D:Q_6-\/YXI1-N(<0;]U/O=KJ$9BM0BJIX!)5:R!\Y/'D=(#,Y4GXR9';
MD1E,J.K9)8*/QX.S<WIW/)B?\ZO=0/9D.IB.DB?):`!*RQ/WW$<WNB"VD^'@
M?`H/C\>#\3D\_99TS^%@.(%?\G_<2^^[((0;+64XF/!*1C`O4#J>[+J57K6`
M,[(>@3<!4])U<`9,PABS`*:-@&%=H&9Q..&^5(44&.W"^W:B>/TE,&W(VO00
MCOYYLUR_.3_ZS@]!NU*5F6`P7,D?),M86!S_@`G:U!''PY'.2"ZYO_SYG]T?
M.D[Q>';JE0^58*RAMSH)-*>6G#)['9V+9MKJ+]!\`^ZFV;&G/Y`ZV$"U4S!1
M4.S)#%1.%E"3='[*LO-2JC>,SL^LOGPZY>F?SGDC6ML6^A^,IG.9.,OX2T3B
M=5T'V43<O$1TN8M02N*`\CCC].SL7/?7_(/4BA^2S@,Y3<<CKU6`A3.+CZ6C
MC<.>;88AO8)Y&@]V\!!'M`>@I8^%7#J<;G?%)F3T/->TEIU:N5'L=PZP[VN+
MZ&M1TW%Q)G%L"K]&(7#I<]-D\&W@TND/LE4DTTB2D00CR442*T@J]V,`J6)+
M&A18\Z&J?I/9(W^B.VO-W=>^=)HZ+Q,M="3_I5>:_[O<T2F=_5^QK3N1-@YG
M>_]#PS_7.D[1->"B3J%':@T,BHE?_MLYU1^C$FPCT:GEOYUO<'?VY`V5_1_)
MQ9EP#_+)+/I/-`;L,]C,RCQ'Z:G7B$]GL_9/,A/\R9Q.6\/`3L*/T)#?YZ%.
MW`Z)P?I5XO4KHT]TV:+1J&!SJ!8\&G5JP2^Y6Y&!CAYR7_N0SH]:?Y>2Y6]I
MW9MPYQFS3?ZL8\TTK@1[P)[MKI-8L](D,.?:28$@((A@2@V)7-P?'JKB2W+.
MM#69LP>^WTVT^P.3$=/@:#HV@X_F<C.&JOO#T4K;HR//##ZN#>A'Z0&4S$AW
M]RMA%8&&YY__F*.9CK8LHE=O;+4CWN]-F6"!>ADAO$^RHDDZ?V38:*W`RX("
M,E&G"`J!7N9KC(P]-XU%7^2@RJ)9<I@W0Y(+Z2N?]:M%NS$%?0Y=EMK@.O1>
MP\JI=:#UC#*<=:3X+O[D"ZSZ_?(_7/#&N;>FX9_=_`D<X#B=P7^!C@;3"?S?
MZ:CWZ=/FTY/!^;CWZ6GSZ3$\W;:`B>;>2IIHT$<N?/)HIWIM4DM9[>WD35VV
MSDO-@OE48J$"`@6<G3])3F"Z\R?RXWS\Q+TOZI_!\LR;/7]'@]D8GQD/AN=H
M9YQ-Z658X9,P..E'QT2E3]&H@2?.!B`EX7\GR6PP=2^HH1U<QH<"V_H.8:2V
M'6+V!O-?X97-0_=#$M[/Y*&OH)'D0ANW[Z"6R?F,7+9RHN>#<W::C\^8.?R.
M@=D)2JNY'CSL"G>-6[(.1_?T55E=YQB-^?XY-X6+_MI/@23^SL["#(8C<>&?
M1C,8G4_3$1B;1[#OX^FA4P!K9#Q-Q[,9>82G@]-A/WF;D63T3)H0]SUVX4NV
MH-C@Q):NQ[^&XCL(OIO69Q,DU[-9/X&#63T4`A_WDW0O(?][$JC9[/"3)XD1
M",KIA`YV-O]5J3(>&JAR2G=D=&9ILDTP^\E1!WZJL_X/0(Y?#Y@X22Y":S@3
MF4^.7V`GS55;W<OO!WXN'R]?),='K6=@OH-D*#W9FG_\,7L8:&^YG0,<\A$]
M[IYGZ%OCW>-X]Z?=NG]\@X$(`GZVW*'8NW!;F2PG#%3<(GR9(-8M5RN<O(3R
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MWSTS`I";K;L_&+:O_LX03?)_)I<P&-C$98JPJGR1@:[0%\#Y%O'PS<@Y+TE@
ML%UL6D7"3A[>?9$:J+760S%^HATHVNQ^X%NV;T<(\8"-><6UPCG=U,Q3/KQ+
M2@47Y*^YG#V@OP.6U%F_-OG'BZN:T,>M=418GY,=B,S'PFB^`5"R5VGJ7[Y^
MY>W^K^PZ7=\3K+N!49N9JY<F"N+>=\H2CPP-&]A\1`N(*\*EC_'L+*3>DF&C
M;AG6O)\IE\GF)7#_<#QN?+?Y*E8)/QE.6EK2^W>]4]:*W!U#S3N&>A35]`%R
M#J`;('PXK<U#FKQ;99+E\]*C5':12@M[TJ'/VJ'Z0`#1,#=P#UM;M!,7<]A7
M0:[]"(2*<KQO(B\[$4'-IR;=I]C_5=$>^K[:0Q5???P1!N=P@1"]UL\TNQ`^
MO]K4]=+OG^WK9KN+QXFP?=QE)X;N5UON5XIN>P0I'O<J]Y(I&K+_%+L03+\>
M__DFQ<2/]#94Q5SN''.G1=UL#_M]1Q/9;Y&ZH^1';C1,+KG6/M]7P9/0/H3[
MHK2<XN_?OG]YT65@-N>[:\4?[Z^K,A@1WCP^]#G&^!#8H/U21RM:AG5S.0_N
MY1K7X6F-T8)*V-)(W7H#-Y1],'8.TIDWYUH"==IE]9QU\UE/&5;V=T\CPGV=
M)+L17KUNKH!2"H\G[]&JC`=,$_7O]-_CO5BNY@L,Z'K2OG4'PKM:XR':JST<
M8;_:OT;`5^M<$/[5^N5.,%A+(B,VK#4$(<5:OR7<6/.7B!]K/=E&D[56B>"R
MCL43U*S]^P;Y/!)X=@`OV@_OVGL7`]JK=4\:4*\N3]6><SH0Z=7BX8^'>C6'
MV(/\:GNBNT!?>S?/@Z5:X^V!?+7W^G#85Y?JTHGUZCZ-QP.\NL?YVK<;E^*K
MY3"><(2;]&4Y'DD+;<4^*B5)YDFRM5@'PQ[W0L=BH!HP@0,A:8?<?O/^1>O]
M72J#`9*]RO->I7@/.*SOM0`(\ZB7BQ@0]EX`8>\($-9K\2OR*P+/?"#DUUN#
M_.I[/T9[]3T5(;SZG0^[3_6KJ?AB>S-`A&NG1_+WVU6_+U-S[+<1#JZUND#W
MM,!N/6=RQLZ/#C,\H[R)@G(WD9\EVF>=W^CF#>%!7W>1.(ZD.M%4'D4UMEKH
MNJ2Z7CTK&2;+[*&M\V$((:8'/D;M3F@+-?92@;JJ/&%^X'ZT.-3[?%E^N?R'
MRS#[R\UV21<QZ/O?2M&7H?K)RT^[9MI`BFJ`8U-RF?/^\]M'Z!:">`!Y6ZA@
MUZ?@.#G:=L@5.DJ^EQ!>2W-K0PR_+A@]EF!G]V>Z0LDT_?\#'6G[W]'0\OXG
M)SNCX:-=D[2J1P2<O$"`F1#%U4-BGWLG)N$%H>)W28Z`Y*@M\.,>UH]Q)+\9
MG;.J6W%:`=5)4K:4%VN;*KMAFC5\^:CYDL<#FI[-T;=3J6_:\6Z,6NN[8XQE
M).!4WR,10K)KZEU?#ULL,T@3@9BTN#-#*W=.@</5W&_6E@0^=#8$K8N@:L@6
M0(G#?'XPE?"P=XK-L-\2?I<"X;_L.?5'?1AI[U#>V,DL(H>7`6/U<0O[S$?<
MSP\EB!"MHVK*YWHJVG&I.H!<*1;,1"]RRZEQWN7JZ!Z!_=`M\WO8&2.>C[M^
MVX,BZYT>P2?;UO99VUKO'[E[V@3(;']NVK;C8\Q:A^G?7N9LTNE`FG7]E@!T
M';-KK[L9?@`JE2O[HLANUJ!<%XM^_M()S>N))22S'@6N8PK,MQH-]W9H$E^^
M80VS?=-KC_ZXZ75>9IE@)\#6*A0[%M*OTD1B>B_O/H"Y/_-5/9YQ5<P#WO$(
MPP.>[4`>'O(%AD8]>DI9A]^DX^D.=&)+@C<1HKIH;&S5GM*>QP_8Y[TC](CA
MO>_UGM;>-P\XN_U?WWF2K2R,7%^_CR;?=:ZM3P=L@+5.WQ37W_)JFAA4;'.<
M<V$PIYUFG_YU-!+^DXQFW?:A!WJ]AH\7Z[I8L/P^^,$#Z&O'N[O/J)/),9_<
MR^-VL]-^-G?>X-S87KQKYWK`@MU*UN'I78?$#?>9!3NU<9.OQ.W1^_PLAZ8I
MM17O[C80(8II=-=.@^-QHO97^=[CA*_-.KN(L\[^2HO\E;[X*^@8OTJ^V6'>
M#9,]H1_=P1%W/_TH=:-[@#WR1-Y)VQD>WRB_;6[$@3+M$.%RR)Z.VW($F6'+
M^7C88Z=>9LE3XWDG:XV]Y!],E>5O\C@C0@&KSW8#9"OO<6[!%WXJ/_5KOKV3
MW6GY=KN%6E..<!.[_QJAF5L^`HRW+^DF9ZO53E]O0':)XUSA#QVHMU]G!O!7
MKH)UX:MG]QIE2#=8(+5GDM\PP5=%56\.VB&]2DE7`'0VW*,W<&3!(#"6'?'V
MUKS?4;G?&L-05#&O;VY4W#_T[='JPB@YJ)[_W@_Q+]Z4L#DA"M'W-4&.<Z<`
MJGU`76M6^+8OA=!Z20(BNY\:=6)1+^13RT_<G&?OQUKK>YP$%./#PUZPC>L5
MW'8"7Q^XHWL4T4=N.?$49!O4G#0U2IDV;.CGYF^BK6JD1_;XM2:#41O(LGN@
M;C?69#!I.XI:F_4(E>@Q[SYVEUL^U6^0.V\7F_Y$/O[CM/N/%"/M4\_;;M]=
M*%`&N4F%RX71R9">VU1?WP)++:AXKB2$)%>2<]!\^%E1HA7`#5G64EDV17_U
M(#G^3O[ZW=,8)UPCN[_4@N7[ST/>\"7./>VEG4SXM-LVVS&*%)2E[C>A3A6U
MJ<\>?!0V;Q9X^5QA]7$?FN42YUC4-ZO;(>G1O#M&:U7D!I_OIWYB]'R0-4F1
M_GQ&:K@1Y`!6RA"$D[^XW*<10]1K^BJE+F#`HD0R7U"G=:$:?`E3Q=8A(.9U
M&>X"SE9#G2^VTJU6HM^^D'I=KKC*)3XNY<VQ<O(_H7(*@X_&PR>^TF_GQ)LS
MIY&DDP$WDKYZD(A[7?,LCXNG_)OR,[['W<.)R.%1;IB$E$HUDILS@U\>%_#^
MT>E@-FDEN[V+L)K"AO7Z^-(70#H4@-36;KS1N!6[Q],6Z#:<5W<'%?T&WNMU
M1^PH?J>MT6+#SFO8/*F_A\TRL,)QWF?7>!Q#8T%]C\?>-(MG];-L$PI&Z;IV
M9#3L#%[T1KY(82KN8*C]A1E9A_%;>]]EHGW5A_!O`C^0_E_7W&S@H9:$3-//
M08<Y\26CJA+[01%5,ORH5PX&P;1@QLT?A0\JS[;)M[_VVM9E@C.NN'URY%*:
M/1[/\54?M:G]_Z.^>9G?;[A9Q#=]^-]=>C)0M2,?>\=+"]4/'K/2KY)RP7.\
MSY!I&CZ^FVF7>?7[;#U(QN/4_<W?8"+TH\:"/?O<2GE_E5\-L`S85PYX6[7Y
M+@TYGC]ZR&YXV&C>$XCL&R?E%MEU?XY`7VBS.6(CR@W'6)$)O)2L^,[!.V/R
MEH18?`:)%\G,73X54"ZZQN:>@'[6J5624R%>WHS'"HB#"!^>>WVMC^9+E1CL
ME+@$^U%R;PZU^Z--_RO-%G[W#3,>=1[QKSBU]_D--A:M,-$GN-LB\-U'5!Y7
MU.F.1\&.=L$S0QFFT7*D<D3_HD[_6HOJS^C\OJXWO_W_`%!+`0(4`Q0````(
M`$B*3D<P0O^NY`$``)(>```3``````````````"``0````!;0V]N=&5N=%]4
M>7!E<UTN>&UL4$L!`A0#%`````@`2(I.1TAU!>[%````*P(```L`````````
M`````(`!%0(``%]R96QS+RYR96QS4$L!`A0#%`````@`2(I.1V&DY=;7`0``
M(!X``!H``````````````(`!`P,``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L!`A0#%`````@`2(I.1P8YJZ82`P``O`P``!```````````````(`!
M$@4``&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````"`!(BDY'Y?IEJSX!``!I
M`P``$0``````````````@`%2"```9&]C4')O<',O8V]R92YX;6Q02P$"%`,4
M````"`!(BDY'F5R<(Q`&``"<)P``$P``````````````@`&_"0``>&PO=&AE
M;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`$B*3D?LUQ;I:0(``,D+```-````
M``````````"``0`0``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`2(I.1X4`
M<VQ*!```*Q````\``````````````(`!E!(``'AL+W=O<FMB;V]K+GAM;%!+
M`0(4`Q0````(`$B*3D<&WP"`#`(``&8&```8``````````````"``0L7``!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"%`,4````"`!(BDY'-X].I<$$
M```.%P``&```````````````@`%-&0``>&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L!`A0#%`````@`2(I.1S-D4<TG`@``E0<``!@``````````````(`!
M1!X``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(4`Q0````(`$B*3D?R
M#9#&(@,``)P+```8``````````````"``:$@``!X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"%`,4````"`!(BDY']DV6('D$```4%0``&```````````
M````@`'Y(P``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`A0#%`````@`
M2(I.1Y^YUVYV!```'Q4``!@``````````````(`!J"@``'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+`0(4`Q0````(`$B*3D>Q9CU!H@$``+$#```8````
M``````````"``50M``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"%`,4
M````"`!(BDY'$]MBG:(!``"Q`P``&```````````````@`$L+P``>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L!`A0#%`````@`2(I.1V#DF'^C`0``L0,`
M`!@``````````````(`!!#$``'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M`0(4`Q0````(`$B*3D<IKK02I`$``+$#```9``````````````"``=TR``!X
M;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`A0#%`````@`2(I.1]H,\W6B
M`0``L0,``!D``````````````(`!N#0``'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"%`,4````"`!(BDY'T^SE5*(!``"Q`P``&0``````````````
M@`&1-@``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(4`Q0````(`$B*
M3D>);*P4HP$``+$#```9``````````````"``6HX``!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`A0#%`````@`2(I.1[EE=3ZB`0``L0,``!D`````
M`````````(`!1#H``'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"%`,4
M````"`!(BDY'\*H1[:,!``"Q`P``&0``````````````@`$=/```>&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+`0(4`Q0````(`$B*3D==5*@2H@$``+$#
M```9``````````````"``?<]``!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`A0#%`````@`2(I.1QT0[A>D`0``L0,``!D``````````````(`!T#\`
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"%`,4````"`!(BDY',[F)
MA8<"```B"@``&0``````````````@`&K00``>&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+`0(4`Q0````(`$B*3D=SI`36L0$``!8$```9````````````
M``"``6E$``!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`A0#%`````@`
M2(I.1Q*'FS/7`0``104``!D``````````````(`!448``'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"%`,4````"`!(BDY'0W+Y<[(!```6!```&0``
M````````````@`%?2```>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(4
M`Q0````(`$B*3D?L#]*_L@$``!8$```9``````````````"``4A*``!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L!`A0#%`````@`2(I.1R0--*CO`0``
M[04``!D``````````````(`!,4P``'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"%`,4````"`!(BDY'PCT)']T"``!"#```&0``````````````@`%7
M3@``>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(4`Q0````(`$B*3D=/
MYJT!"`(``'$&```9``````````````"``6M1``!X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L!`A0#%`````@`2(I.1V<GZA,@`@``'0<``!D`````````
M`````(`!JE,``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"%`,4````
M"`!(BDY'Z9.=B^P"``!!"@``&0``````````````@`$!5@``>&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;%!+`0(4`Q0````(`$B*3D>2L>%?=P(``&<)```9
M``````````````"``219``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!
M`A0#%`````@`2(I.1TI(Q+Q?`@``-0@``!D``````````````(`!TEL``'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"%`,4````"`!(BDY'Z@-@T<<!
M``!%!```&0``````````````@`%H7@``>&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;%!+`0(4`Q0````(`$B*3D=ZM8[4]P$``.0%```9``````````````"`
M`69@``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`A0#%`````@`2(I.
M1T0!X$O'`0``100``!D``````````````(`!E&(``'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"%`,4````"`!(BDY'U_V5R2@"```_!P``&0``````
M````````@`&29```>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(4`Q0`
M```(`$B*3D<%O)@\7P(``#8(```9``````````````"``?%F``!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L!`A0#%`````@`2(I.1T8$*88>`@``[@8`
M`!D``````````````(`!AVD``'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"%`,4````"`!(BDY'Z.Z<7)L"``#D"0``&0``````````````@`'<:P``
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(4`Q0````(`$B*3D<06V=<
MS`$``,<$```9``````````````"``:YN``!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L!`A0#%`````@`2(I.1Q_>:@B[`P``3Q4``!D`````````````
M`(`!L7```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"%`,4````"`!(
MBDY'6#;^D.4"``#6#```&0``````````````@`&C=```>&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+`0(4`Q0````(`$B*3D?G]6W,R@$``$4$```9````
M``````````"``;]W``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!`A0#
M%`````@`2(I.1TN5;PW;`0``:`4``!D``````````````(`!P'D``'AL+W=O
M<FMS:&5E=',O<VAE970T,2YX;6Q02P$"%`,4````"`!(BDY'%YZPI2<#``!&
M#@``&0``````````````@`'2>P``>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM
M;%!+`0(4`Q0````(`$B*3D>%UD%N[`(``#4-```9``````````````"``3!_
M``!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!`A0#%`````@`2(I.1U1Y
M:S$H`P``]PP``!D``````````````(`!4X(``'AL+W=O<FMS:&5E=',O<VAE
M970T-"YX;6Q02P$"%`,4````"`!(BDY'H2(E8.D"``"\"P``&0``````````
M````@`&RA0``>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+`0(4`Q0````(
M`$B*3D=-0G/V[`(``'H,```9``````````````"``=*(``!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L!`A0#%`````@`2(I.1\'*#>\P`@``"@<``!D`
M`````````````(`!]8L``'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M%`,4````"`!(BDY'`"2R%Y@#``#I$0``&0``````````````@`%<C@``>&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(4`Q0````(`$B*3D?B8&W,K@0`
M`"(;```9``````````````"``2N2``!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L!`A0#%`````@`2(I.1W[W_[B,<```)J`!`!0``````````````(`!
M$)<``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@`````Z`#H`R`\``,X'`0``
!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920750560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 1,018,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember', window );">Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_UnrecognizedShareBasedCompensationExpenses', window );">Unrecognized expense at March 31, 2015</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining years to vest</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_UnrecognizedShareBasedCompensationExpenses', window );">Unrecognized expense at March 31, 2015</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining years to vest</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">427,000<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">92,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">316,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_UnrecognizedShareBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Share Based Compensation Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_UnrecognizedShareBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920801264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems', window );"><strong>Schedule Of Estimated Future Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 628,776<span></span>
</td>
<td class="nump">$ 699,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems', window );"><strong>Schedule Of Estimated Future Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 629,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Estimated Future Amortization Expense [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ScheduleOfEstimatedFutureAmortizationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917899424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation - Company's Allocation on Consideration Transferred for ProstaScint (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>May. 31, 2015</div></th>
<th class="th"><div>May. 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917736704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>Stock_Plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_NumberOfStockOptionPlans', window );">Number of stock option plan | Stock_Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,018,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrants to purchase common stock, Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rswn_VyrixTwoThousandThirteenStockOptionPlanMember', window );">Vyrix 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rswn_LuoxisTwoThousandThirteenStockOptionPlanMember', window );">Luoxis 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ReversalOfAllocatedShareBasedCompensationExpense', window );">Reversal of share based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember', window );">Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,189<span></span>
</td>
<td class="nump">33,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ReversalOfAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal Of Allocated Share Based Compensation Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ReversalOfAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rswn_VyrixTwoThousandThirteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rswn_VyrixTwoThousandThirteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rswn_LuoxisTwoThousandThirteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rswn_LuoxisTwoThousandThirteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rswn_TwoThousandFifteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868853042240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">17,100,000<span></span>
</td>
<td class="nump">10,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Liability for gross unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868929993648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">102,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">102,613<span></span>
</td>
<td class="nump">102,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Warrants Outstanding</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 4 months 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920876400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement/Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_LicenseAgreementTextBlock', window );">License Agreement/Revenue Recognition</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note 3 &#x2013; License Agreement/Revenue Recognition</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 During 2011, Ampio entered into a license, development and
 commercialization agreement with a major Korean pharmaceutical
 company which was assigned to Vyrix when it was formed in 2013. The
 agreement grants the pharmaceutical company exclusive rights to
 market Zertane in South Korea for the treatment of premature
 ejaculation (&#x201C;PE&#x201D;) and for a combination drug to be
 developed, utilizing Zertane and an erectile dysfunction drug. Upon
 signing of the agreement, Ampio received a $500,000 upfront
 payment, the net proceeds of which were $418,000 after withholding
 of Korean tax. The upfront payment has been deferred and is being
 recognized as license revenue over a ten year period. Milestone
 payments of $3,200,000 may be earned and recognized contingent upon
 achievement of regulatory approvals and cumulative net sales
 targets, which may take several years. In addition, Aytu may earn a
 royalty based on 25% of net sales, as defined, if the royalty
 exceeds the transfer price of the Zertane product. No royalties
 have been earned to date.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In April 2014, Vyrix entered into a Distribution and License
 Agreement (the &#x201C;Paladin Agreement&#x201D;) with Endo Ventures
 Limited, which recently acquired Paladin Labs Inc.
 (&#x201C;Paladin&#x201D;), whereby Paladin has exclusive rights to
 market, sell and distribute Zertane in Canada, the Republic of
 South Africa, certain countries in Sub Saharan Africa, Colombia and
 Latin America. The Paladin Agreement expires on a country by
 country basis upon the later of fifteen years after the first
 commercial sale of the product in that country or expiration of
 market exclusivity for Zertane in that country. Paladin paid
 $250,000 to Vyrix upon signing the Paladin Agreement and is
 obligated to make milestone payments aggregating up to $3,025,000
 based upon achieving Canadian and South African product regulatory
 approval and achieving specific sales goals. The upfront payment
 has been deferred and is being recognized as license revenue over a
 seven year period. In addition, the Paladin Agreement provides that
 Paladin pay royalties based on sales volume.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868926980992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Significant Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember', window );">Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions Used To Determine Fair Value Options [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AssumptionsUsedToDetermineFairValueOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868929998752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fixed Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 29,706<span></span>
</td>
<td class="nump">$ 57,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rswn_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rswn_LabEquipmentMember', window );">Lab Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rswn_LabEquipmentMember', window );">Lab Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rswn_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rswn_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917479296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_ZertanePatentsMember', window );">Zertane Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Costs of establishing patents</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_FiniteLivedIntangibleAssetsExpirationMonthYear', window );">Intangible asset, expiration month and year</a></td>
<td class="text">2022-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_OrpMember', window );">ORP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Costs of establishing patents</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_FiniteLivedIntangibleAssetsExpirationMonthYear', window );">Intangible asset, expiration month and year</a></td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_FiniteLivedIntangibleAssetsExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets expiration month year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_FiniteLivedIntangibleAssetsExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite Lived Intangible Asset In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_ZertanePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_ZertanePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_OrpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rswn_OrpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868927090896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Luoxis Stock Option Activity (Detail) - Luoxis Diagnostics [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">430,077<span></span>
</td>
<td class="nump">396,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">195,189<span></span>
</td>
<td class="nump">33,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="nump">625,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,077<span></span>
</td>
<td class="nump">396,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant', window );">Number of Options, Available for grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">7.25<span></span>
</td>
<td class="nump">4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">5.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 days<span></span>
</td>
<td class="text">9 years 11 months 16 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="nump">$ 1,374,000<span></span>
</td>
<td class="nump">$ 1,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,374,000<span></span>
</td>
<td class="nump">$ 1,272,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930868480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869041392448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Patents (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 628,776<span></span>
</td>
<td class="nump">$ 699,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(251,000)<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 629,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869111236144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 2 &#x2013; Summary of Significant Accounting
 Policies</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu considers all highly liquid instruments purchased with an
 original maturity of three months or less to be cash equivalents.
 Cash equivalents consist primarily of money market fund
 investments. Aytu&#x2019;s investment policy is to preserve
 principal and maintain liquidity. The Company periodically monitors
 its positions with, and the credit quality of the financial
 institutions with which it invests. Periodically, throughout the
 year, Aytu has maintained balances in excess of federally insured
 limits.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>License Agreements and Royalties</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Payments received upon signing of license agreements are for the
 right to use the license and are deferred and amortized over the
 lesser of the license term or patent life of the licensed drug.
 Milestone payments relate to obtaining regulatory approval,
 cumulative sales targets, and other projected milestones and are
 recognized at the time the milestones are achieved. Royalties will
 be recognized as revenue when earned.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 P<i>roduct&#xA0;&amp; Service Sales</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu recognizes revenue from product and service sales when there
 is persuasive evidence that an arrangement exists, delivery has
 occurred or service has been rendered, the price is fixed or
 determinable and collectability is reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Estimated Sales Returns and Allowances</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu records estimated reductions in revenue for potential returns
 of products by customers. As a result, management must make
 estimates of potential future product returns and other allowances
 related to current period product revenue. In making such
 estimates, management analyzes historical returns, current economic
 trends and changes in customer demand and acceptance of our
 products. If management were to make different judgments or utilize
 different estimates, material differences in the amount of the
 Company&#x2019;s reported revenue could result.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Accounts receivable are recorded at their net realized value. Aytu
 evaluates collectability of accounts receivable on a quarterly
 basis and records a valuation allowance accordingly. As of
 June&#xA0;30, 2015 and 2014, no allowance for doubtful accounts has
 been recorded.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Inventories</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Inventories are recorded at the lower of cost or market, with cost
 determined on a first-in, first-out basis. Aytu periodically
 reviews the composition of its inventories in order to identify
 obsolete, slow-moving or otherwise unsaleable items. If unsaleable
 items are observed and there are no alternate uses for the
 inventory, Aytu will record a write-down to net realizable value in
 the period that the impairment is first recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 When future commercialization is considered probable and the future
 economic benefit is expected to be realized, based on
 management&#x2019;s judgment, Aytu capitalizes pre-launch inventory
 costs prior to regulatory approval. A number of factors are taken
 into consideration, including the current status in the regulatory
 approval process, potential impediments to the approval process,
 such as safety or efficacy, anticipated research and development
 initiatives that could impact the indication in which the compound
 will be used, viability of commercialization and marketplace
 trends. For product candidates that have not been approved by the
 FDA, inventory used in clinical trials is expensed at the time of
 production and recorded as research and development expense. For
 products that have been approved by the FDA, inventory used in
 clinical trials is expensed at the time the inventory is packaged
 for the clinical trial. Prior to receiving FDA approval, costs
 related to purchases of the active pharmaceutical ingredient and
 the manufacturing of the product candidate are recorded as research
 and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fixed Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">Estimated</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Useful&#xA0;Lives&#xA0;in&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">3&#xA0;-&#xA0;5</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(60,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Fixed assets, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following depreciation expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Depreciation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>In-Process Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In-process research and development (&#x201C;IPRD&#x201D;) relates to
 the Company&#x2019;s Zertane product and clinical trial data
 acquired in connection with the 2011 acquisition of BioSciences.
 The $7,500,000 recorded was based on an independent, third party
 appraisal of the fair value of the assets acquired. IPRD is
 considered an indefinite-lived intangible asset and its fair value
 will be assessed annually and written down if impaired. Once the
 Zertane product obtains regulatory approval and commercial
 production begins, IPRD will be reclassified to an intangible that
 will be amortized over its estimated useful life. If the Company
 decided to abandon the Zertane product, the IPRD would be
 expensed.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Patents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs of establishing patents, consisting of legal and filing fees
 paid to third parties, are expensed as incurred. The fair value of
 the Zertane patents, determined by an independent third party
 appraisal, is $500,000. The Zertane patents were acquired in
 connection with the 2011 acquisition of BioSciences and are being
 amortized over the remaining U.S. patent lives of approximately 11
 years which expires in March 2022. The cost of the Luoxis patents
 was $380,000 when they were acquired in connection with the 2013
 formation of Luoxis and is being amortized over the remaining U.S.
 patent lives of approximately 15 years which expires in March 2028.
 Patents consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Patents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(251,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(180,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Patents, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">700,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following amortization expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amortization expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future amortization from the year ended June&#xA0;30, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="87%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">274,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Business Combinations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company accounts for its business acquisitions under the
 acquisition method of accounting as indicated in the Financial
 Accounting Standards Board&#x2019;s (&#x201C;FASB&#x201D;) Accounting
 Standards Codification (&#x201C;ASC&#x201D;) 805, &#x201C;Business
 Combinations&#x201D;, which requires the acquiring entity in a
 business combination to recognize the fair value of all assets
 acquired, liabilities assumed, and any non-controlling interest in
 the acquire; and establishes the acquisition date as the fair value
 measurement point. Accordingly, the Company recognizes assets
 acquired and liabilities assumed in business combinations,
 including contingent assets and liabilities and non-controlling
 interest in the acquiree, based on the fair value estimates as of
 the date of acquisition. In accordance with ASC 805, the Company
 recognizes and measures goodwill as of the acquisition date, as the
 excess of the fair value of the consideration paid over the fair
 value of the identified net assets acquired.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Goodwill</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The ProstaScint&#xA0;purchase price allocation was based upon an
 analysis of the fair value of the assets and liabilities acquired
 from Jazz Pharmaceuticals. The final purchase price may be adjusted
 up to one year from the date of the acquisition. Identifying the
 fair value of the tangible and intangible assets and liabilities
 acquired required the use of estimates by management, and were
 based upon currently available data, as noted below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company allocated the excess of purchase price over the
 identifiable intangible and net tangible assets to goodwill. Such
 goodwill is not deductible for tax purposes and represents the
 value placed on entering new markets and expanding market
 share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company tests its goodwill for impairment annually, or whenever
 events or changes in circumstances indicate an impairment may have
 occurred, by comparing the carrying value to its implied fair
 value. Impairment may result from, among other things,
 deterioration in the performance of the acquired business, adverse
 market conditions, adverse changes in applicable laws or
 regulations and a variety of other circumstances. If the Company
 determines that an impairment has occurred, it is required to
 record a write-down of the carrying value and charge the impairment
 as an operating expense in the period the determination is made. In
 evaluating the recoverability of the carrying value of goodwill,
 the Company must make assumptions regarding estimated future cash
 flows and other factors to determine the fair value of the acquired
 assets. Changes in strategy or market conditions could
 significantly impact those judgments in the future and require an
 adjustment to the recorded balances. The goodwill was recorded as
 part of the acquisition of ProstaScint that occurred on
 May&#xA0;20, 2015. There was no impairment of goodwill for the year
 ended June&#xA0;30, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The preparation of financial statements in accordance with
 Generally Accepted Accounting Principles in the United States of
 America (&#x201C;GAAP&#x201D;) requires management to make estimates
 and assumptions that affect the reported amounts of assets and
 liabilities, disclosures of contingent assets and liabilities as of
 the date of the financial statements and the reported amounts of
 revenues and expenses during the reporting periods. Significant
 items subject to such estimates and assumptions include valuation
 allowances, stock-based compensation, warrant valuation, purchase
 price allocation, valuation of contingent consideration, sales
 returns and allowances, useful lives of fixed assets and
 assumptions in evaluating impairment of definite and indefinite
 lived assets. Actual results could differ from these estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu is included in the consolidated tax returns of Ampio.
 Aytu&#x2019;s taxes are computed and reported on a &#x201C;separate
 return&#x201D; basis for these financial statements. Deferred taxes
 are provided on an asset and liability method whereby deferred tax
 assets are recognized for deductible temporary differences and
 operating loss and tax credit carry forwards and deferred tax
 liabilities are recognized for taxable temporary differences.
 Temporary differences are the differences between the reported
 amounts of assets and liabilities and their tax bases. Deferred tax
 assets are reduced by a valuation allowance when, in the opinion of
 management, it is more likely than not that some portion or all of
 the deferred tax assets will not be realized. Deferred tax assets
 and liabilities are adjusted for the effects of changes in tax laws
 and rates on the date of enactment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The amount of income taxes and related income tax positions taken
 would be subject to audits by federal and state tax authorities if
 Aytu filed these taxes on a separate basis. The Company has adopted
 accounting guidance for uncertain tax positions which provides that
 in order to recognize an uncertain tax benefit, the taxpayer must
 be more likely than not of sustaining the position, and the
 measurement of the benefit is calculated as the largest amount that
 is more than 50% likely to be realized upon settlement with the
 taxing authority. The Company believes that it has no material
 uncertain tax positions. The Company&#x2019;s policy is to record a
 liability for the difference between the benefits that are both
 recognized and measured pursuant to FASB ASC 740-10,
 &#x201C;Accounting for Uncertainty in Income Taxes&#x2014;an
 interpretation of FASB Statement No.&#xA0;109&#x201D; (&#x201C;ASC
 740-10&#x201D;) and tax position taken or expected to be taken on
 the tax return. Then, to the extent that the assessment of such tax
 positions changes, the change in estimate is recorded in the period
 in which the determination is made. The Company reports tax-related
 interest and penalties as a component of income tax expense. During
 the periods reported, management of the Company has concluded that
 no significant tax position requires recognition under ASC
 740-10.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu accounts for share based payments by recognizing compensation
 expense based upon the estimated fair value of the awards on the
 date of grant. The Company determines the estimated grant fair
 value using the Black-Scholes option pricing model and recognizes
 compensation costs ratably over the period of service using the
 graded method.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Research and development costs are expensed as incurred with
 expenses recorded in the respective period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The carrying amounts of financial instruments, including cash and
 cash equivalents, accounts payable and other current assets and
 other liabilities are carried at cost which approximates fair value
 due to the short maturity of these instruments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu routinely performs an annual evaluation of the recoverability
 of the carrying value of its long-lived assets to determine if
 facts and circumstances indicate that the carrying value of assets
 or intangible assets may be impaired and if any adjustment is
 warranted. Based on its evaluation as of June&#xA0;30, 2015 and
 2014, respectively, no impairment existed for long-lived
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Newly Issued Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In June 2015, the FASB issued Accounting Standards Update
 (&#x201C;ASU&#x201D;) 2015-10, &#x201C;Technical Corrections and
 Improvements&#x201D;. The amendments represent changes to clarify
 the codification, correct unintended application of guidance, or
 make minor improvements to the codification that are not expected
 to have a significant effect on current accounting practice or
 create a significant administrative cost. In addition, some of the
 amendments will make the codification easier to understand and
 easier to apply by eliminating inconsistencies, providing needed
 clarifications, and improving the presentation of guidance in the
 codification. The amendments that require transition guidance are
 effective for all entities for fiscal years, and interim periods
 within those fiscal years, beginning after December&#xA0;15, 2015.
 Early adoption is permitted, including adoption in an interim
 period. All other amendments will be effective upon issuance. The
 Company is evaluating the impact of ASU 2015-10 on its financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2015, the FASB issued&#xA0;ASU
 2015-03,&#xA0;&#x201C;Interest - Imputation of Interest (Subtopic
 835-30): Simplifying the Presentation of Debt Issuance
 Costs.&#x201D;&#xA0;The update requires debt issuance costs related
 to a recognized debt liability be presented in the balance sheet as
 a direct deduction from the carrying amount of the related debt
 liability instead of being presented as an asset. Debt disclosures
 will include the face amount of the debt liability and the
 effective interest rate. The update requires retrospective
 application and represents a change in accounting principle. The
 update is effective for fiscal years beginning after
 December&#xA0;15, 2015. Early adoption is permitted for financial
 statements that have not been previously issued. The Company is
 evaluating the impact of ASU 2015-03 on its financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2015, the FASB issued ASU 2015-01, &#x201C;Extraordinary
 and Unusual Items (Subtopic 225-20): Simplifying Income Statement
 Presentation by Eliminating the Concept of Extraordinary
 Items.&#x201D; The purpose of this amendment is to eliminate the
 concept of extraordinary items. As a result, an entity will no
 longer be required to separately classify, present and disclose
 extraordinary events and transactions. The amendment is effective
 for annual reporting periods beginning after December&#xA0;15, 2015
 and subsequent interim periods with early application permitted.
 The Company is evaluating the impact the adoption of ASU 2015-01
 will have on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15,
 &#x201C;Presentation of Financial Statements-Going Concern (Subtopic
 205-40): Disclosure of Uncertainties about an Entity&#x2019;s
 Ability to Continue as a Going Concern&#x201D; (&#x201C;ASU
 2014-15&#x201D;). ASU 2014-15 is intended to define
 management&#x2019;s responsibility to evaluate whether there is
 substantial doubt about an organization&#x2019;s ability to continue
 as a going concern and to provide related footnote disclosures. The
 amendments in this ASU are effective for reporting periods
 beginning after December&#xA0;15, 2016, with early adoption
 permitted. The Company is evaluating the impact the adoption of ASU
 2014-15 will have on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606,
 &#x201C;Revenue from Contracts with Customers&#x201D;. The standard
 provides principles for recognizing revenue for the transfer of
 promised goods or services to customers with the consideration to
 which the entity expects to be entitled in exchange for those goods
 or services. The guidance will be effective for annual reporting
 periods beginning after December&#xA0;15, 2017, with early adoption
 permitted but not prior to the original public organization
 effective date of December&#xA0;15, 2016. The Company is evaluating
 the accounting, transition and disclosure requirements of the
 standard and cannot currently estimate the financial statement
 impact of adoption.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917435168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Amortization Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationAbstract', window );"><strong>Depreciation, Depletion and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930801536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Rent Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917491248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,353,061<span></span>
</td>
<td class="nump">$ 2,639,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">157,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">39,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">370,888<span></span>
</td>
<td class="nump">521,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PrepaidResearchAndDevelopmentRelatedParty', window );">Prepaid research and development-related party (Note 8)</a></td>
<td class="nump">121,983<span></span>
</td>
<td class="nump">121,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Deferred tax asset</a></td>
<td class="nump">41,427<span></span>
</td>
<td class="nump">18,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,083,859<span></span>
</td>
<td class="nump">3,301,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net (Note 2)</a></td>
<td class="nump">29,706<span></span>
</td>
<td class="nump">57,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CoreAndDevelopedTechnologyNet', window );">Developed technology, net</a></td>
<td class="nump">780,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Customer contracts, net</a></td>
<td class="nump">711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, net</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">628,776<span></span>
</td>
<td class="nump">699,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent', window );">Long-term portion of prepaid research and development-related party (Note 8)</a></td>
<td class="nump">335,454<span></span>
</td>
<td class="nump">457,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non current assets</a></td>
<td class="nump">10,142,947<span></span>
</td>
<td class="nump">8,714,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,226,806<span></span>
</td>
<td class="nump">12,016,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,196,817<span></span>
</td>
<td class="nump">649,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Accrued liabilities-related party (Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">196,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">85,714<span></span>
</td>
<td class="nump">85,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable to Ampio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes to Ampio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_InterestPayableRelatedPartiesCurrent', window );">Interest payable to Ampio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,002<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,479,034<span></span>
</td>
<td class="nump">6,092,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">425,893<span></span>
</td>
<td class="nump">511,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Noncurrent deferred tax liability</a></td>
<td class="nump">41,427<span></span>
</td>
<td class="nump">42,807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 2,610,354<span></span>
</td>
<td class="nump">$ 6,646,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 in 2015 and 7,901,426 in 2014</a></td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">38,996,367<span></span>
</td>
<td class="nump">16,026,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock', window );">Ampio stock subscription</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(18,381,341)<span></span>
</td>
<td class="num">(10,657,937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total equity</a></td>
<td class="nump">15,616,452<span></span>
</td>
<td class="nump">5,369,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 18,226,806<span></span>
</td>
<td class="nump">$ 12,016,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_CoreAndDevelopedTechnologyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Core And Developed Technology Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_CoreAndDevelopedTechnologyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite Lived Intangible Asset In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IndefiniteLivedIntangibleAssetInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_InterestPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest payable related parties current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_InterestPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PrepaidResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PrepaidResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph 3<br><br><br><br> -Article 6<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a)(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from owners or affiliates of the reporting entity related to issuance of the entity's capital stock before cash payment is received (does not include amounts due from officers or directors). This element would also include the receivable for proceeds from the issuance of shares under employee stock option exercises which proceeds have not been received as of the reporting date due to the timing of the transaction date versus the settlement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29,30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868915056112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments - Vyrix Stock Option Activity (Detail) - Vyrix Pharmaceuticals [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">117,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="nump">117,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant', window );">Number of Options, Available for grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months 15 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="nump">$ 417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868852375872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,723,404)<span></span>
</td>
<td class="num">$ (5,578,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,017,938<span></span>
</td>
<td class="nump">499,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">118,202<span></span>
</td>
<td class="nump">97,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties', window );">Amortization of prepaid research and development-related party (Note 8)</a></td>
<td class="nump">121,984<span></span>
</td>
<td class="nump">35,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="num">(23,910)<span></span>
</td>
<td class="num">(813,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(157,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(39,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease (increase) in prepaid expenses, other</a></td>
<td class="nump">150,434<span></span>
</td>
<td class="num">(497,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties', window );">Increase in prepaid research and development-related party (Note 8)</a></td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(465,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">(Decrease) increase in interest payable to Ampio</a></td>
<td class="num">(46,002)<span></span>
</td>
<td class="nump">46,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">547,314<span></span>
</td>
<td class="nump">421,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IncreaseDecreaseInAccruedCompensation', window );">Increase in accrued compensation</a></td>
<td class="nump">196,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent', window );">(Decrease) increase in payable to Ampio</a></td>
<td class="num">(561,059)<span></span>
</td>
<td class="nump">561,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">(Decrease) increase in deferred revenue</a></td>
<td class="num">(85,714)<span></span>
</td>
<td class="nump">191,071<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(6,634,214)<span></span>
</td>
<td class="num">(5,501,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PaymentsForDepositsInvestingActivities', window );">Deposits</a></td>
<td class="num">(4,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Purchase of ProstaScint Business</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,298)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(1,004,886)<span></span>
</td>
<td class="num">(9,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Ampio stock subscription payment</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible note from Ampio converted to stock</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Luoxis option payout pursuant to the merger</a></td>
<td class="num">(27,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Liabilities paid out pursuant to the merger</a></td>
<td class="num">(20,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Contribution from Ampio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,352,511<span></span>
</td>
<td class="nump">5,237,210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">4,713,411<span></span>
</td>
<td class="num">(274,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,639,650<span></span>
</td>
<td class="nump">2,913,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">7,353,061<span></span>
</td>
<td class="nump">2,639,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_NoncashOrPartNoncashCapitalContributionFromParent', window );">Ampio stock subscription</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Ampio unpaid debt converted to stock, received prior to 2015</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration related to the ProstaScint purchase</a></td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets', window );">Issuance of common stock in exchange for Vyrix acquired assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,803,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid', window );">Related party research and development liability included in prepaid research and development-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of prepaid research and development due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Accounts Payable Related Party Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IncreaseDecreaseAccountsPayableRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accrued Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid research and development due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock In Exchange For Acquired Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_IssuanceOfCommonStockInExchangeForAcquiredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_NoncashOrPartNoncashCapitalContributionFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Capital Contribution From Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_NoncashOrPartNoncashCapitalContributionFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PaymentsForDepositsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Deposits Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PaymentsForDepositsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development and accrued liability related parties unpaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 6<br><br><br><br> -Section I<br><br><br><br> -Subsection 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868929987312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Benefit at federal statutory rate</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal income tax benefit</a></td>
<td class="num">(2.79%)<span></span>
</td>
<td class="num">(2.89%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">30.95%<span></span>
</td>
<td class="nump">22.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.03%<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(12.73%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930855888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesDisclosureTableTextBlock', window );">Summary of Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Commitments and contingencies are described below and summarized by
 the following table as of June&#xA0;30, 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2019</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2020</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Thereafter</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Management fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,800,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 ProstaScint Inventory Transfer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Sponsored research agreement with related party</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">350,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Clinical research and trial obligations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">329,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">329,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Manufacturing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">133,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">133,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Office Lease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">110,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,222,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,427,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">466,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">466,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">433,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">430,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Rent Expense</a></td>
<td class="text"><div>
 <p>Rent expense for the respective periods is as follows:</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years Ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Rent expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">51,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_CommitmentsAndContingenciesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies Disclosure Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_CommitmentsAndContingenciesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868927113968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract', window );"><strong>Current deferred income tax asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossCurrent', window );">Deferred revenue short-term</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent', window );">Valuation allowance</a></td>
<td class="num">(64,000)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Total current deferred income tax asset</a></td>
<td class="nump">41,427<span></span>
</td>
<td class="nump">18,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract', window );"><strong>Long-term deferred income tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">6,337,000<span></span>
</td>
<td class="nump">3,847,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Section 197 intangible</a></td>
<td class="nump">453,000<span></span>
</td>
<td class="nump">482,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue long-term</a></td>
<td class="nump">158,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Acquired in-process research and development</a></td>
<td class="num">(2,779,000)<span></span>
</td>
<td class="num">(2,779,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent', window );">Less: Valuation allowance</a></td>
<td class="num">(4,210,000)<span></span>
</td>
<td class="num">(1,863,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Total long-term deferred income tax assets (liabilities)</a></td>
<td class="num">(41,427)<span></span>
</td>
<td class="num">(42,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (24,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31938-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Deferred Tax Asset<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917681584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 08, 2015</div></th>
<th class="th">
<div>May. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May. 20, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Labour and other overhead costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percent of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 8, 2015, in connection with the reincorporation as a Delaware  corporation, we effected a reverse stock split in which each common stock holder  received one share of common stock for each every 12.174 shares then outstanding  (the "Reverse Stock Split").<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business Acquisition, acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total fair value consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business Acquisition, acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Acquisition, liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons', window );">Restructuring payment, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aytu also will pay 8% as  contingent consideration on its net sales made after October 31, 2017, payable  up to a maximum aggregate payment of an additional $2.5 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Business Acquisition, future contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessCombinationContingentConsiderationPercentage', window );">Contingent consideration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total fair value consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember', window );">Prostascint Business [Member] | Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Acquisition, liabilities incurred</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessCombinationContingentConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessCombinationContingentConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the reasons causing an amount of any change recognized during the period in the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityReasons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payroll tax expense, compensation, postemployment and benefit-related expenses not elsewhere specified in the taxonomy (such as health plan, profit sharing, incentives, tuition reimbursement, other fringe benefits and perquisites) incurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Stock Split<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930302752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business, Acquisition of Assets and Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <b>Note 1 &#x2013; Business, Acquisition of Assets and Basis of
 Presentation</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Business/Acquisition of Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu BioScience, Inc. (&#x201C;Aytu&#x201D; or the
 &#x201C;Company&#x201D;) was incorporated as Rosewind Corporation on
 August&#xA0;9, 2002 in the State of Colorado. Aytu was
 re-incorporated in the state of Delaware on June&#xA0;8, 2015. Aytu
 is a specialty healthcare company concentrating on developing and
 commercializing products focused primarily on the urological
 disorders market, specifically sexual dysfunction, urological
 cancer and male infertility.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu&#x2019;s current business was formed through a reverse
 triangular merger (the &#x201C;Merger&#x201D;) in which Luoxis
 Diagnostics, Inc. (&#x201C;Luoxis&#x201D;) and Vyrix Pharmaceuticals,
 Inc. (&#x201C;Vyrix&#x201D;) merged into Rosewind Corporation in a
 multi-step merger on April&#xA0;16, 2015. These historical
 financial statements prior to April&#xA0;16, 2015 include the
 combined financial statements of Vyrix from its inception in
 November 2013, combined with the carve-out financial statements
 related to Vyrix assets acquired in the Merger (the &#x201C;Vyrix
 Acquired Assets&#x201D;) from March&#xA0;23, 2011, the date, its
 parent company Ampio Pharmaceuticals, Inc. (&#x201C;Ampio&#x201D;)
 originally acquired the Vyrix Acquired Assets through its merger
 with DMI BioSciences, Inc. (&#x201C;BioSciences&#x201D;) and the
 financial statements of Luoxis from its inception in January 2013,
 combined with the carve-out financial statements related to
 Luoxis.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The carve-out financial statements present the statements of
 financial position of Vyrix and Luoxis and the Vyrix Acquired
 Assets and the statements of operations and cash flows for purposes
 of presenting complete comparative stand-alone financial statements
 in accordance with Regulation S-X, Article 3, General Instructions
 to Financial Statements, and Staff Accounting Bulletin Topic 1-B1,
 Costs Reflected in Historical Financial Statements. Historically,
 financial statements have not been prepared for Vyrix and Luoxis,
 as they were not held in a separate legal entities. Although Vyrix
 and Luoxis have not been segregated as a separate legal entity,
 related revenues, direct costs and expenses, assets and liabilities
 have historically been segregated on Ampio&#x2019;s books. In
 addition, the Company allocated corporate overhead costs based on a
 review of specific labor and other overhead expenses and a
 reasonable estimate of activities related to Vyrix and Luoxis.
 Allocated labor and other overhead totaled $264,000 in 2015 and
 $253,000 in 2014. The Company also prepared a calculation of income
 tax expense and deferred income tax assets and liabilities on a
 &#x201C;separate return&#x201D; basis (see Note 4 &#x2013; Income
 Taxes). These financial statements do not include a carve-out for
 cash as the operations have historically been funded by Ampio. The
 historical carve-out financial statements may not be indicative of
 the future results of Vyrix and Luoxis as a stand-alone
 entities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The &#x201C;Company&#x201D; as referred to in the notes to these
 financial statements includes Vyrix and Luoxis, collectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s activities, being primarily research and
 development, have not generated significant revenue to date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As of June&#xA0;30, 2015, Ampio is the majority shareholder of
 81.5% of Aytu&#x2019;s outstanding common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On June&#xA0;8, 2015, in connection with the reincorporation as a
 Delaware corporation, we effected a reverse stock split in which
 each common stock holder received one share of common stock for
 each every 12.174 shares then outstanding (the &#x201C;Reverse Stock
 Split&#x201D;). All share and per share amounts in this Annual
 Report have been adjusted to reflect the effect of the Reverse
 Stock Split.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Business Combination&#x2014;ProstaScint</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In May 2015, Aytu entered into and closed on an asset purchase
 agreement with Jazz Pharmaceuticals, Inc. (the
 &#x201C;Seller&#x201D;). Pursuant to the agreement, Aytu purchased
 assets related to the Seller&#x2019;s product known as
 ProstaScint<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> (capromab
 pendetide), including certain intellectual property and contracts,
 and the product approvals, inventory and work in progress
 (together, the &#x201C;ProstaScint Business&#x201D;), and assumed
 certain of the Seller&#x2019;s liabilities, including those related
 to product approvals and the sale and marketing of ProstaScint.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The purchase price consists of the upfront payment of $1.0 million.
 Aytu also agreed to pay an additional $500,000 payable within five
 days after transfer for the ProstaScint-related product inventory
 and $227,000 payable on September&#xA0;30, 2015 (which represents a
 portion of certain FDA fees). Aytu also will pay 8% as contingent
 consideration on its net sales made after October&#xA0;31, 2017,
 payable up to a maximum aggregate payment of an additional $2.5
 million. The contingent consideration was valued at $664,000 using
 a discounted cash flow. The total fair value consideration for the
 purchase was $2.4 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s allocation on consideration transferred for
 ProstaScint as of the purchase date May&#xA0;20, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Estimated&#xA0;Fair<br />
 Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">727,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,590,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,391,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The intangible assets will be amortized over a ten year period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future amortization from the year ended June&#xA0;30, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">775,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Pro Forma Information</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The unaudited pro-forma results presented below include the effects
 of the ProstaScint acquisition as if it has been consummated as of
 July&#xA0;1, 2013, with adjustments to give effect to pro forma
 events that are directly attributable to the acquisition which
 includes adjustments related to the amortization of acquired
 intangible assets. The unaudited pro forma results do not reflect
 any operating efficiency or potential cost savings which may result
 from the consolidation of ProstaScint. Accordingly, these unaudited
 pro forma results are presented for informational purposes only and
 are not necessarily indicative of what the actual results of
 operation of the combined company would have been if the
 acquisition had occurred at the beginning of the period presented
 nor are they indicative of future results of operations and are not
 necessarily indicative of either future results of operations or
 results that might have been achieved had the acquisition been
 consummated as of July&#xA0;1, 2013.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,371,106</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,736,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cost of sales - ProstaScint</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,818,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,054,786</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,065,626</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,933,619</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development - related party (Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">156,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">125,587</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,417,884</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,388,665</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Amortization and impairment of intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">131,989</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">100,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,220,071</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,866,518</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Interest (expense) income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(114,994</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(45,553</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss, before income tax</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,335,065</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,912,071</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred income tax benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23,910</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">813,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,311,155</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,098,374</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid"></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868927884288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">14,259,681<span></span>
</td>
<td class="nump">7,901,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">14,259,681<span></span>
</td>
<td class="nump">7,901,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868918022832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 11 &#x2013; Subsequent Event</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 During July and August 2015, Aytu closed on note purchase
 agreements with institutional and high net worth individual
 investors for the purchase and sale of convertible promissory notes
 with an aggregate principal amount of $5.2 million. The sale of the
 notes was pursuant to a private placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Aytu intends to use the net proceeds of the offering to conduct
 clinical studies for both Zertane&#xAE; and RedoxSYS&#x2122; and for
 working capital to begin commercializing FDA-approved
 ProstaScint&#xAE;, as well as general corporate purposes.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The notes are an unsecured obligation. Unless earlier converted,
 the notes will mature 18 months from their respective dates of
 issuance which will be on January&#xA0;22, February&#xA0;11 and
 February&#xA0;28, 2017, with an option to extend up to six months
 at our discretion (provided that in the event Aytu exercises such
 extension option, the then applicable interest rate shall increase
 by 2% for such extension period). Aytu does not have the right to
 prepay the notes prior to the maturity date. Interest will accrue
 on the notes in the following amounts: (i)&#xA0;8% simple interest
 per annum for the first six months and (ii)&#xA0;12% simple
 interest per annum thereafter if not converted during the first six
 months. If there has not been a registration statement on
 Form&#xA0;S-1 filed with the SEC for the registration of the shares
 of common stock underlying the notes by the expiration of the first
 six-month period then (a)&#xA0;the interest rate will increase to
 14% for the remainder of the period in which the notes remain
 outstanding and (b)&#xA0;any notes held by officers and directors
 of the Company will be subordinated to the remaining notes.
 Interest will accrue, is payable with the principal upon maturity,
 conversion or acceleration of the notes and may be paid in kind or
 in cash, in Aytu&#x2019;s sole discretion.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The notes are convertible at any time in a noteholder&#x2019;s
 discretion into that number of shares of Aytu common stock equal in
 an amount equal to 120% of the number of shares of common stock
 calculated by dividing the then outstanding principal and accrued
 interest by $4.63. A holder of notes will be obligated to convert
 on the terms of Aytu&#x2019;s next public offering of its stock
 resulting in proceeds to it of at least $5,000,000 in gross
 proceeds (excluding indebtedness converted in such financing) prior
 to the maturity date of the notes (a &#x201C;Qualified
 Financing&#x201D;). The principal and accrued interest under the
 notes will automatically convert into a number of shares of such
 equity securities of the Company sold in such financing equal to
 120% of the principal and accrued interest under such note divided
 by the lesser of (i)&#xA0;the lowest price paid by an investor in
 such financing or (ii)&#xA0;$4.63. In the event that Aytu sells
 equity securities to investors at any time while the notes are
 outstanding in a financing transaction that is not a Qualified
 Financing, then the noteholders will have the option to convert in
 whole the outstanding principal and accrued interest as of the
 closing of such financing into a number of shares of Aytu capital
 stock in an amount equal to 120% of the number of such shares
 calculated by dividing the outstanding principal and accrued
 interest by the lesser of (i)&#xA0;the lowest cash price per share
 paid by purchasers of shares in such financing, or
 (ii)&#xA0;$4.63.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 Newbridge Securities Corporation, Member FINRA/SIPC, through
 LifeTech Capital, acted as sole placement agent for the
 institutional portion of the offering. Aytu sold the balance of the
 notes to individuals and entities with whom Aytu has an established
 relationship. For notes sold by the placement agent, Aytu paid the
 placement agent 8% of the gross proceeds of notes sold by the
 placement agent and a warrant to purchase shares of Aytu&#x2019;s
 common stock equal to 8% of the gross proceeds of the notes sold by
 the placement agent divided by the price per share at which equity
 securities are sold in Aytu&#x2019;s next equity financing, in
 addition to a previously paid non-refundable retainer fee of
 $20,000. The placement agent warrant has a term of five years, will
 have an exercise price equal to 100% of the price per share at
 which equity securities are sold in Aytu&#x2019;s next equity
 financing, and provides for cashless exercise.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On August&#xA0;19, 2015, Aytu entered into a 37 month
 non-cancellable operating lease for new office space effective
 September&#xA0;1, 2015. The new lease has initial base rent of
 $8,500 per month beginning in October 2015, with the total base
 rent over the term of the lease of approximately $318,000 which
 includes rent abatements. The Company recognizes rental expense of
 the facility on a straight-line basis over the term of the lease.
 Differences between the straight-line net expenses on rent payments
 are classified as liabilities between current deferred rent and
 long-term deferred rent.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On October&#xA0;5, 2015, the Company entered into and closed on an
 Asset Purchase Agreement with FSC Laboratories, Inc. (the
 &#x201C;Seller&#x201D;). Pursuant to the agreement, the Company
 purchased assets related to the Seller&#x2019;s product known as
 Primsol<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;(trimethoprim solution),
 including certain intellectual property and contracts, inventory,
 work in progress and all marketing and sales assets and materials
 related solely to Primsol (together, the &#x201C;Primsol
 Business&#x201D;), and assumed certain of the Seller&#x2019;s
 liabilities, including those related to the sale and marketing of
 Primsol arising after the closing. The agreement provides that for
 a period of one year after the closing the Seller will not directly
 or indirectly sell, market, promote, advertise or distribute
 anywhere in the world any urinary tract anti-infective
 pharmaceutical or treatment product containing trimethoprim.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 The Company paid $500,000 at closing for the Primsol Business and
 agreed to pay an additional $141,694 payable within five days after
 transfer of the Primsol-related product inventory. The Company also
 agreed to pay an additional (a)&#xA0;$500,000 payable no later than
 March&#xA0;31, 2016, (b)&#xA0;$500,000 payable no later than
 June&#xA0;30, 2016, and (c)&#xA0;$250,000 payable no later than
 September&#xA0;30, 2016, for a total purchase price of
 $1,891,694.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 On October 8, 2015, the Company and Biovest International, Inc.
 (&#x201C;Biovest&#x201D;) entered into a Master Services Agreement,
 pursuant to which Biovest is to provide manufacturing services to
 the Company. The agreement provides that the Company may engage
 Biovest from time to time to provide services in accordance with
 mutually agreed upon project addendums and purchase orders. The
 Company expects to use the agreement from time to time for
 manufacturing services, including without limitation, the
 manufacturing, processing, quality control testing, release or
 storage of its products. The agreement has a term of four years,
 provided that either party may terminate the agreement or any
 project addendum under the agreement on 30 days written notice of a
 material breach under the agreement. In addition, the Company may
 terminate the agreement or any project addendum under the agreement
 upon 180 days written notice for any reason. In conjunction with
 entering into the agreement, the Company submitted a work order to
 Biovest to provide the Company with active pharmaceutical
 ingredient for ProstaScint over a four-year period at a total cost
 of $5,000,000, of which the Company paid $1,000,000 upon submission
 of the work order.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868915103472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Changes to Note 11 in Post Effective Amendment No 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RSWN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOSCIENCE, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920681872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu considers all highly liquid instruments purchased with an
 original maturity of three months or less to be cash equivalents.
 Cash equivalents consist primarily of money market fund
 investments. Aytu&#x2019;s investment policy is to preserve
 principal and maintain liquidity. The Company periodically monitors
 its positions with, and the credit quality of the financial
 institutions with which it invests. Periodically, throughout the
 year, Aytu has maintained balances in excess of federally insured
 limits.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <i>License Agreements and Royalties</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Payments received upon signing of license agreements are for the
 right to use the license and are deferred and amortized over the
 lesser of the license term or patent life of the licensed drug.
 Milestone payments relate to obtaining regulatory approval,
 cumulative sales targets, and other projected milestones and are
 recognized at the time the milestones are achieved. Royalties will
 be recognized as revenue when earned.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 P<i>roduct&#xA0;&amp; Service Sales</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu recognizes revenue from product and service sales when there
 is persuasive evidence that an arrangement exists, delivery has
 occurred or service has been rendered, the price is fixed or
 determinable and collectability is reasonably assured.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock', window );">Estimated Sales Returns and Allowances</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Estimated Sales Returns and Allowances</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu records estimated reductions in revenue for potential returns
 of products by customers. As a result, management must make
 estimates of potential future product returns and other allowances
 related to current period product revenue. In making such
 estimates, management analyzes historical returns, current economic
 trends and changes in customer demand and acceptance of our
 products. If management were to make different judgments or utilize
 different estimates, material differences in the amount of the
 Company&#x2019;s reported revenue could result.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Accounts receivable are recorded at their net realized value. Aytu
 evaluates collectability of accounts receivable on a quarterly
 basis and records a valuation allowance accordingly. As of
 June&#xA0;30, 2015 and 2014, no allowance for doubtful accounts has
 been recorded.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Inventories</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Inventories are recorded at the lower of cost or market, with cost
 determined on a first-in, first-out basis. Aytu periodically
 reviews the composition of its inventories in order to identify
 obsolete, slow-moving or otherwise unsaleable items. If unsaleable
 items are observed and there are no alternate uses for the
 inventory, Aytu will record a write-down to net realizable value in
 the period that the impairment is first recognized.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 When future commercialization is considered probable and the future
 economic benefit is expected to be realized, based on
 management&#x2019;s judgment, Aytu capitalizes pre-launch inventory
 costs prior to regulatory approval. A number of factors are taken
 into consideration, including the current status in the regulatory
 approval process, potential impediments to the approval process,
 such as safety or efficacy, anticipated research and development
 initiatives that could impact the indication in which the compound
 will be used, viability of commercialization and marketplace
 trends. For product candidates that have not been approved by the
 FDA, inventory used in clinical trials is expensed at the time of
 production and recorded as research and development expense. For
 products that have been approved by the FDA, inventory used in
 clinical trials is expensed at the time the inventory is packaged
 for the clinical trial. Prior to receiving FDA approval, costs
 related to purchases of the active pharmaceutical ingredient and
 the manufacturing of the product candidate are recorded as research
 and development expense.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fixed Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="14%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">Estimated</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center">Useful&#xA0;Lives&#xA0;in&#xA0;years</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">3 - 5</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(60,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Fixed assets, net</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following depreciation expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Depreciation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>In-Process Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In-process research and development (&#x201C;IPRD&#x201D;) relates to
 the Company&#x2019;s Zertane product and clinical trial data
 acquired in connection with the 2011 acquisition of BioSciences.
 The $7,500,000 recorded was based on an independent, third party
 appraisal of the fair value of the assets acquired. IPRD is
 considered an indefinite-lived intangible asset and its fair value
 will be assessed annually and written down if impaired. Once the
 Zertane product obtains regulatory approval and commercial
 production begins, IPRD will be reclassified to an intangible that
 will be amortized over its estimated useful life. If the Company
 decided to abandon the Zertane product, the IPRD would be
 expensed.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Patents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs of establishing patents, consisting of legal and filing fees
 paid to third parties, are expensed as incurred. The fair value of
 the Zertane patents, determined by an independent third party
 appraisal, is $500,000. The Zertane patents were acquired in
 connection with the 2011 acquisition of BioSciences and are being
 amortized over the remaining U.S. patent lives of approximately 11
 years which expires in March 2022. The cost of the Luoxis patents
 was $380,000 when they were acquired in connection with the 2013
 formation of Luoxis and is being amortized over the remaining U.S.
 patent lives of approximately 15 years which expires in March 2028.
 Patents consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Patents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated armortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(251,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(180,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Patents, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">700,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following amortization expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amortization expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future amortization from the year ended June&#xA0;30, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="87%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">274,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Business Combinations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company accounts for its business acquisitions under the
 acquisition method of accounting as indicated in the Financial
 Accounting Standards Board&#x2019;s (&#x201C;FASB&#x201D;) Accounting
 Standards Codification (&#x201C;ASC&#x201D;) 805, &#x201C;Business
 Combinations&#x201D;, which requires the acquiring entity in a
 business combination to recognize the fair value of all assets
 acquired, liabilities assumed, and any non-controlling interest in
 the acquire; and establishes the acquisition date as the fair value
 measurement point. Accordingly, the Company recognizes assets
 acquired and liabilities assumed in business combinations,
 including contingent assets and liabilities and non-controlling
 interest in the acquiree, based on the fair value estimates as of
 the date of acquisition. In accordance with ASC 805, the Company
 recognizes and measures goodwill as of the acquisition date, as the
 excess of the fair value of the consideration paid over the fair
 value of the identified net assets acquired.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Goodwill</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The ProstaScint&#xA0;purchase price allocation was based upon an
 analysis of the fair value of the assets and liabilities acquired
 from Jazz Pharmaceuticals. The final purchase price may be adjusted
 up to one year from the date of the acquisition. Identifying the
 fair value of the tangible and intangible assets and liabilities
 acquired required the use of estimates by management, and were
 based upon currently available data, as noted below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company allocated the excess of purchase price over the
 identifiable intangible and net tangible assets to goodwill. Such
 goodwill is not deductible for tax purposes and represents the
 value placed on entering new markets and expanding market
 share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company tests its goodwill for impairment annually, or whenever
 events or changes in circumstances indicate an impairment may have
 occurred, by comparing the carrying value to its implied fair
 value. Impairment may result from, among other things,
 deterioration in the performance of the acquired business, adverse
 market conditions, adverse changes in applicable laws or
 regulations and a variety of other circumstances. If the Company
 determines that an impairment has occurred, it is required to
 record a write-down of the carrying value and charge the impairment
 as an operating expense in the period the determination is made. In
 evaluating the recoverability of the carrying value of goodwill,
 the Company must make assumptions regarding estimated future cash
 flows and other factors to determine the fair value of the acquired
 assets. Changes in strategy or market conditions could
 significantly impact those judgments in the future and require an
 adjustment to the recorded balances. The goodwill was recorded as
 part of the acquisition of ProstaScint that occurred on
 May&#xA0;20, 2015. There was no impairment of goodwill for the year
 ended June&#xA0;30, 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The preparation of financial statements in accordance with
 Generally Accepted Accounting Principles in the United States of
 America (&#x201C;GAAP&#x201D;) requires management to make estimates
 and assumptions that affect the reported amounts of assets and
 liabilities, disclosures of contingent assets and liabilities as of
 the date of the financial statements and the reported amounts of
 revenues and expenses during the reporting periods. Significant
 items subject to such estimates and assumptions include valuation
 allowances, stock-based compensation, warrant valuation, purchase
 price allocation, valuation of contingent consideration, sales
 returns and allowances, useful lives of fixed assets and
 assumptions in evaluating impairment of definite and indefinite
 lived assets. Actual results could differ from these estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu is included in the consolidated tax returns of Ampio.
 Aytu&#x2019;s taxes are computed and reported on a &#x201C;separate
 return&#x201D; basis for these financial statements. Deferred taxes
 are provided on an asset and liability method whereby deferred tax
 assets are recognized for deductible temporary differences and
 operating loss and tax credit carry forwards and deferred tax
 liabilities are recognized for taxable temporary differences.
 Temporary differences are the differences between the reported
 amounts of assets and liabilities and their tax bases. Deferred tax
 assets are reduced by a valuation allowance when, in the opinion of
 management, it is more likely than not that some portion or all of
 the deferred tax assets will not be realized. Deferred tax assets
 and liabilities are adjusted for the effects of changes in tax laws
 and rates on the date of enactment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The amount of income taxes and related income tax positions taken
 would be subject to audits by federal and state tax authorities if
 Aytu filed these taxes on a separate basis. The Company has adopted
 accounting guidance for uncertain tax positions which provides that
 in order to recognize an uncertain tax benefit, the taxpayer must
 be more likely than not of sustaining the position, and the
 measurement of the benefit is calculated as the largest amount that
 is more than 50% likely to be realized upon settlement with the
 taxing authority. The Company believes that it has no material
 uncertain tax positions. The Company&#x2019;s policy is to record a
 liability for the difference between the benefits that are both
 recognized and measured pursuant to FASB ASC 740-10,
 &#x201C;Accounting for Uncertainty in Income Taxes&#x2014;an
 interpretation of FASB Statement No.&#xA0;109&#x201D; (&#x201C;ASC
 740-10&#x201D;) and tax position taken or expected to be taken on
 the tax return. Then, to the extent that the assessment of such tax
 positions changes, the change in estimate is recorded in the period
 in which the determination is made. The Company reports tax-related
 interest and penalties as a component of income tax expense. During
 the periods reported, management of the Company has concluded that
 no significant tax position requires recognition under ASC
 740-10.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu accounts for share based payments by recognizing compensation
 expense based upon the estimated fair value of the awards on the
 date of grant. The Company determines the estimated grant fair
 value using the Black-Scholes option pricing model and recognizes
 compensation costs ratably over the period of service using the
 graded method.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Research and development costs are expensed as incurred with
 expenses recorded in the respective period.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The carrying amounts of financial instruments, including cash and
 cash equivalents, accounts payable and other current assets and
 other liabilities are carried at cost which approximates fair value
 due to the short maturity of these instruments.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu routinely performs an annual evaluation of the recoverability
 of the carrying value of its long-lived assets to determine if
 facts and circumstances indicate that the carrying value of assets
 or intangible assets may be impaired and if any adjustment is
 warranted. Based on its evaluation as of June&#xA0;30, 2015 and
 2014, respectively, no impairment existed for long-lived
 assets.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly Issued Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Newly Issued Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In June 2015, the FASB issued Accounting Standards Update
 (&#x201C;ASU&#x201D;) 2015-10, &#x201C;Technical Corrections and
 Improvements&#x201D;. The amendments represent changes to clarify
 the codification, correct unintended application of guidance, or
 make minor improvements to the codification that are not expected
 to have a significant effect on current accounting practice or
 create a significant administrative cost. In addition, some of the
 amendments will make the codification easier to understand and
 easier to apply by eliminating inconsistencies, providing needed
 clarifications, and improving the presentation of guidance in the
 codification. The amendments that require transition guidance are
 effective for all entities for fiscal years, and interim periods
 within those fiscal years, beginning after December&#xA0;15, 2015.
 Early adoption is permitted, including adoption in an interim
 period. All other amendments will be effective upon issuance. The
 Company is evaluating the impact of ASU 2015-10 on its financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2015, the FASB issued&#xA0;ASU
 2015-03,&#xA0;&#x201C;Interest&#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs.&#x201D;&#xA0;The update requires debt issuance costs related
 to a recognized debt liability be presented in the balance sheet as
 a direct deduction from the carrying amount of the related debt
 liability instead of being presented as an asset. Debt disclosures
 will include the face amount of the debt liability and the
 effective interest rate. The update requires retrospective
 application and represents a change in accounting principle. The
 update is effective for fiscal years beginning after
 December&#xA0;15, 2015. Early adoption is permitted for financial
 statements that have not been previously issued. The Company is
 evaluating the impact of ASU 2015-03 on its financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2015, the FASB issued ASU 2015-01, &#x201C;Extraordinary
 and Unusual Items (Subtopic 225-20): Simplifying Income Statement
 Presentation by Eliminating the Concept of Extraordinary
 Items.&#x201D; The purpose of this amendment is to eliminate the
 concept of extraordinary items. As a result, an entity will no
 longer be required to separately classify, present and disclose
 extraordinary events and transactions. The amendment is effective
 for annual reporting periods beginning after December&#xA0;15, 2015
 and subsequent interim periods with early application permitted.
 The Company is evaluating the impact the adoption of ASU 2015-01
 will have on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15,
 &#x201C;Presentation of Financial Statements-Going Concern (Subtopic
 205-40): Disclosure of Uncertainties about an Entity&#x2019;s
 Ability to Continue as a Going Concern&#x201D; (&#x201C;ASU
 2014-15&#x201D;). ASU 2014-15 is intended to define
 management&#x2019;s responsibility to evaluate whether there is
 substantial doubt about an organization&#x2019;s ability to continue
 as a going concern and to provide related footnote disclosures. The
 amendments in this ASU are effective for reporting periods
 beginning after December&#xA0;15, 2016, with early adoption
 permitted. The Company is evaluating the impact the adoption of ASU
 2014-15 will have on its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606,
 &#x201C;Revenue from Contracts with Customers&#x201D;. The standard
 provides principles for recognizing revenue for the transfer of
 promised goods or services to customers with the consideration to
 which the entity expects to be entitled in exchange for those goods
 or services. The guidance will be effective for annual reporting
 periods beginning after December&#xA0;15, 2017, with early adoption
 permitted but not prior to the original public organization
 effective date of December&#xA0;15, 2016. The Company is evaluating
 the accounting, transition and disclosure requirements of the
 standard and cannot currently estimate the financial statement
 impact of adoption.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated sales returns and allowances policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_EstimatedSalesReturnsAndAllowancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)-(d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section CC<br><br><br><br> -Subsection 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.15)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 206<br><br><br><br> -Paragraph b<br><br><br><br> -Subparagraph i, ii<br><br><br><br> -Chapter 2<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3-5<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868927785696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ProductsAndServicesRevenue', window );">Product and service revenue</a></td>
<td class="nump">$ 176,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue</a></td>
<td class="nump">85,714<span></span>
</td>
<td class="nump">$ 58,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">261,782<span></span>
</td>
<td class="nump">58,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">88,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,219,361<span></span>
</td>
<td class="nump">3,933,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ResearchAndDevelopmentRelatedParty', window );">Research and development-related party (Note 8)</a></td>
<td class="nump">203,992<span></span>
</td>
<td class="nump">125,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,382,640<span></span>
</td>
<td class="nump">2,346,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,632,320)<span></span>
</td>
<td class="num">(6,346,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (expense) income</a></td>
<td class="num">(114,994)<span></span>
</td>
<td class="num">(45,553)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss, before income tax</a></td>
<td class="num">(7,747,314)<span></span>
</td>
<td class="num">(6,392,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">23,910<span></span>
</td>
<td class="nump">813,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,723,404)<span></span>
</td>
<td class="num">$ (5,578,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of Aytu common shares outstanding</a></td>
<td class="nump">9,207,917<span></span>
</td>
<td class="nump">6,949,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted Aytu net loss per common share</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.80)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ProductsAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products And Services Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ProductsAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869044423952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note 6 &#x2013; Common Stock</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Capital Stock</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 At June&#xA0;30, 2015 and 2014, Aytu had 300&#xA0;million shares of
 common stock authorized with a par value of $0.0001&#xA0;per share
 and 50&#xA0;million shares of preferred stock authorized with a par
 value of $0.0001 per share.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869044423952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 5 &#x2013; Commitments and Contingencies</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Commitments and contingencies are described below and summarized by
 the following table as of June&#xA0;30, 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2019</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2020</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Thereafter</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Management fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,800,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">360,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 ProstaScint Inventory Transfer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Sponsored research agreement with related party</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">350,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Clinical research and trial obligations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">329,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">329,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Manufacturing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">133,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">133,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Office Lease</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">110,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">35,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,222,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,427,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">466,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">466,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">433,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">430,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Management Fee</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In July 2015, Aytu entered into agreements with Ampio whereby Aytu
 agreed to pay Ampio $30,000 per month for shared overhead which
 includes costs related to the shared facility, corporate staff, and
 other miscellaneous overhead expenses. These agreements will be in
 effect until they are terminated in writing by both parties.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>ProstaScint Inventory Transfer Fee</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu is obligated to pay $500,000 for the ProstaScint-related
 product inventory upon the inventory transfer in July 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Sponsored Research Agreement with Related Party</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu entered into a Sponsored Research Agreement with Trauma
 Research LLC (&#x201C;TRLLC&#x201D;), a related party, in June 2013.
 Under the terms of the Sponsored Research Agreement, TRLLC agreed
 to work collaboratively in advancing the RedoxSYS System diagnostic
 platform through research and development efforts. The Sponsored
 Research Agreement may be terminated without cause by either party
 on 30 days&#x2019; notice.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Clinical Research and Trial Obligations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In connection with the Zertane clinical trials and RedoxSYS
 research studies, the remaining commitment is $329,000.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Aytu Manufacturing and Commercial Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu entered into agreements with manufacturing companies to build
 its RedoxSYS system. The current remaining commitment is
 $133,000.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Office Lease</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In June 2015, Aytu entered into a 37 month operating lease. This
 lease has initial base rent of $2,900 a month, with total base rent
 over the term of the lease of approximately $112,000. The Company
 recognizes rental expense of the facility on a straight-line basis
 over the term of the lease. Differences between the straight-line
 net expenses on rent payments are classified as liabilities between
 current deferred rent and long-term deferred rent. Rent expense for
 the respective periods is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years Ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Rent expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">51,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868932444464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div>
 <p>The following table summarizes stock-based compensation expense
 for the years ended June&#xA0;30 2015 and 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years Ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">427,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">183,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">104,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,018,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized expense at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Weighted average remaining years to vest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Issued in Conjunction with its Senior Convertible Debentures</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu issued warrants in conjunction with its 2013 private
 placement. A summary of all warrants is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Warrants</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember', window );">Luoxis Diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Stock Options Valuation Assumption</a></td>
<td class="text"><div>
 <p>The assumptions are as follows:</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center">Years Ended June&#xA0;30,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2015</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;108%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;82%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.62%&#xA0;-&#xA0;2.09%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">0.75%&#xA0;-&#xA0;1.53%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.5 - 7.0</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.0 - 6.5</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Stock option activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual Life</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">396,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,272,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,083</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">430,077</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,374,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">195,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">7.25</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(625,266</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">5.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available for grant at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Stock Options Valuation Assumption</a></td>
<td class="text"><div>
 <p>The assumptions are as follows:</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Year&#xA0;Ended&#xA0;June&#xA0;30,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">63%&#xA0;-&#xA0;76%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">0.90%&#xA0;-&#xA0;2.02%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.0 - 6.5</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Stock option activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">417,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(117,053</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available for grant at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917506944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Company's Allocation on Consideration Transferred for ProstaScint</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s allocation on consideration transferred for
 ProstaScint as of the purchase date May&#xA0;20, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="84%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Estimated&#xA0;Fair<br />
 Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">727,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,590,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Goodwill</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">74,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total assets acquired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,391,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Unaudited Pro-forma Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Pro Forma Information</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The unaudited pro-forma results presented below include the effects
 of the ProstaScint acquisition as if it has been consummated as of
 July&#xA0;1, 2013, with adjustments to give effect to pro forma
 events that are directly attributable to the acquisition which
 includes adjustments related to the amortization of acquired
 intangible assets. The unaudited pro forma results do not reflect
 any operating efficiency or potential cost savings which may result
 from the consolidation of ProstaScint. Accordingly, these unaudited
 pro forma results are presented for informational purposes only and
 are not necessarily indicative of what the actual results of
 operation of the combined company would have been if the
 acquisition had occurred at the beginning of the period presented
 nor are they indicative of future results of operations and are not
 necessarily indicative of either future results of operations or
 results that might have been achieved had the acquisition been
 consummated as of July&#xA0;1, 2013.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,371,106</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,736,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cost of sales - ProstaScint</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,818,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,054,786</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,065,626</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,933,619</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development - related party (Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">156,988</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">125,587</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,417,884</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,388,665</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Amortization and impairment of intangible assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">131,989</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">100,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,220,071</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,866,518</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Interest (expense) income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(114,994</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(45,553</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss, before income tax</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,335,065</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,912,071</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred income tax benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23,910</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">813,697</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(8,311,155</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,098,374</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid"></p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930877856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note 9 &#x2013; Litigation</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2015, Aytu was not party to any legal matters
 or claims, and none of its property is subject to any legal
 proceedings. In the future Aytu may become party to legal matters
 and claims arising in the ordinary course of business, the
 resolution of which it does not anticipate would have a material
 adverse impact on its financial position, results of operations or
 cash flows.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869044444144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 7 &#x2013; Equity Instruments</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Options</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Prior to the Merger, Aytu had two approved stock option plans
 (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan),
 pursuant to which Aytu had reserved a total of
 1,718,828&#xA0;million shares of common stock, both of which were
 terminated on April&#xA0;16, 2015 upon the closing of the
 Merger.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Luoxis options that were in the money and all outstanding Vyrix
 options issued under the 2013 Option Plans were accelerated and
 cancelled in connection with the Merger. Option holders received a
 cash payment per option share equal to the difference between the
 consideration payable per share of common stock pursuant to the
 Merger and the exercise price of the option, if the consideration
 paid to holders of common stock was less than the exercise price of
 such options, no amount was paid to the option holder in connection
 with the cancellation. The cash payment during the period ended
 June&#xA0;30, 2015 was $27,000. The company recognized compensation
 of $422,000 and $189,000 related to the Luoxis and Vyrix options
 that had accelerated vesting as of the Merger date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Luoxis options that were not paid out were terminated pursuant
 to the terms of the 2013 Luoxis Option Plan. The Company treated
 these options as pre-vesting forfeitures and $433,000 of previously
 recognized compensation was reversed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the Luoxis 2013 Stock Option Plan, 1,102,761 shares of
 its common stock were reserved for issuance. The fair value of the
 options was calculated using the Black-Scholes option pricing
 model. In order to calculate the fair value of the options, certain
 assumptions are made regarding components of the model, including
 the estimated fair value of the underlying common stock, risk-free
 interest rate, volatility, expected dividend yield and expected
 option life. Changes to the assumptions could cause significant
 adjustments to valuation. Aytu estimates the expected term based on
 the average of the vesting term and the contractual term of the
 options. The risk-free interest rate is based on the U.S. Treasury
 yield in effect at the time of the grant for treasury securities of
 similar maturity. The assumptions are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center">Years Ended June&#xA0;30,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2015</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;108%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">79%&#xA0;-&#xA0;82%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.62%&#xA0;-&#xA0;2.09%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">0.75%&#xA0;-&#xA0;1.53%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.5 - 7.0</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.0 - 6.5</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Stock option activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual Life</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">396,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,272,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,083</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">430,077</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,374,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">195,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">7.25</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(625,266</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">5.40</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available for grant at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the Vyrix 2013 Stock Option Plan, 616,067 shares of its
 common stock were reserved for issuance. The fair value of the
 options was calculated using the Black-Scholes option pricing
 model. In order to calculate the fair value of the options, certain
 assumptions are made regarding components of the model, including
 the estimated fair value of the underlying common stock, risk-free
 interest rate, volatility, expected dividend yield and expected
 option life. Changes to the assumptions could cause significant
 adjustments to valuation. Aytu estimates the expected term based on
 the average of the vesting term and the contractual term of the
 options. The risk-free interest rate is based on the U.S. Treasury
 yield in effect at the time of the grant for treasury securities of
 similar maturity. In accordance with the Vyrix 2013 Stock Option
 Plan, no additional options were granted during the year-ended
 June&#xA0;30, 2015. The assumptions are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Year&#xA0;Ended&#xA0;June&#xA0;30,</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">2014</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">63%&#xA0;-&#xA0;76%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">0.90%&#xA0;-&#xA0;2.02%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.0 - 6.5</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Stock option activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Intrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">117,053</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.54</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">417,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Forfeited/Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(117,053</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available for grant at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Stock-based compensation expense related to the fair value of stock
 options was included in the statements of operations as research
 and development expenses and general and administrative expenses as
 set forth in the table below. Aytu determined the fair value as of
 the date of grant using the Black-Scholes option pricing model and
 expenses the fair value ratably over the vesting period. The
 following table summarizes stock-based compensation expense for the
 years ended June&#xA0;30 2015 and 2014:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Years Ended
 June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">427,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">38,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">316,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">152,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">183,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">104,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,018,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">500,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized expense at June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Weighted average remaining years to vest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Luoxis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Vyrix</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On June&#xA0;1, 2015, Aytu&#x2019;s stockholders approved the 2015
 Stock Option and Incentive Plan (the &#x201C;2015 Plan&#x201D;),
 which provides for the award of stock options, stock appreciation
 rights, restricted stock and other equity awards for up to an
 aggregate of 10,000,000 shares of common stock. The shares of
 common stock underlying any awards that are forfeited, canceled,
 reacquired by Aytu prior to vesting, satisfied without any issuance
 of stock, expire or are otherwise terminated (other than by
 exercise) under the 2015 Plan will be added back to the shares of
 common stock available for issuance under the 2015 Plan. As of
 September&#xA0;28, 2015, no grants have been made under the 2015
 Plan.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Warrants</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Aytu issued warrants in conjunction with its 2013 private
 placement. A summary of all warrants is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of<br />
 Warrants</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted<br />
 Average<br />
 Exercise&#xA0;Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted&#xA0;Average<br />
 Remaining<br />
 Contractual&#xA0;Life</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2013</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.41</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding June&#xA0;30, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">102,613</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 These warrants were valued using the Black-Scholes option pricing
 model. In order to calculate the fair value of the warrants,
 certain assumptions were made regarding components of the model,
 including the closing price of the underlying common stock,
 risk-free interest rate, volatility, expected dividend yield, and
 expected life. Changes to the assumptions could cause significant
 adjustments to valuation. The Company estimated a volatility factor
 utilizing a weighted average of comparable published volatilities
 of peer companies. The risk-free interest rate is based on the U.S.
 Treasury yield in effect at the time of the grant for treasury
 securities of similar maturity. The offering costs and the
 additional paid-in capital for the warrants associated with the
 common stock offering were valued at $313,000 using the
 Black-Scholes valuation methodology.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868923157024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 8 &#x2013; Related Party Transactions</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Ampio Loan Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In November 2013, Vyrix entered into a loan agreement with Ampio.
 Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an
 aggregate amount of $3,000,000 through cash advances of up to
 $500,000 each. Unpaid principal amounts under the loan agreement
 bear simple interest at the &#x201C;Applicable Federal Rate&#x201D;
 for long-term obligations prescribed under Section&#xA0;1274(d) of
 the Internal Revenue Code of 1986, as amended (or any successor
 provision with similar applicability). The initial term of this
 loan agreement is for one year, subject to automatic extension of
 successive one-year terms. Vyrix may repay any outstanding balance
 at any time without penalty. Ampio has an option of converting any
 balance outstanding under the loan agreement into shares of Vyrix
 common stock at the fair market value per share of Vyrix common
 stock, as determined by the Ampio board of directors, as of such
 conversion date. As of June&#xA0;30, 2014, the amount advanced was
 $1,600,000 with interest rates from 3.11%-3.32%. On April&#xA0;16,
 2015, in connection with the closing of the Merger, Ampio released
 Vyrix from its then outstanding obligation of $4,000,000 under the
 loan agreement as consideration of its share purchase, and the loan
 agreement was terminated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In March 2014, Luoxis entered into a loan agreement with Ampio.
 Pursuant to the loan agreement, Ampio agreed to lend Luoxis
 $3,000,000. Unpaid principal amounts under the loan agreement bear
 simple interest at the &#x201C;Applicable Federal Rate&#x201D; for
 long-term obligations prescribed under Section&#xA0;1274(d) of the
 Internal Revenue Code of 1986, as amended (or any successor
 provision with similar applicability). The initial term of this
 loan agreement is for one year, subject to automatic extension of
 successive one-year terms. Luoxis may repay any outstanding balance
 at any time without penalty. Ampio has an option of converting any
 balance outstanding under the loan agreement into shares of Luoxis
 common stock at the fair market value per share of Luoxis common
 stock, as determined by the Ampio board of directors, as of such
 conversion date. As of June&#xA0;30, 2014, the amount advanced was
 $3,000,000 with interest rates from 3.11% - 3.32%. On
 April&#xA0;16, 2015, in connection with the closing of the Merger,
 Ampio released Luoxis from its then outstanding obligation of
 $8,000,000 under the loan agreement as consideration of its share
 purchase, and the loan agreement was terminated.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On April&#xA0;16, 2015, Ampio received 4,761,787 shares of common
 stock of Aytu for (i)&#xA0;issuance to Aytu of a promissory note
 from Ampio in the principal amount of $10,000,000, maturing on the
 first anniversary of the Merger, (ii)&#xA0;cancellation of
 indebtedness of Luoxis to Ampio in the amount of $8,000,000; and
 (iii)&#xA0;cancellation of indebtedness of Vyrix to Ampio in the
 amount of $4,000,000.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Services Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company has service agreements with Ampio which are described
 in Note 5.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Sponsored Research Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In June 2013, Luoxis entered into a sponsored research agreement
 with TRLLC, an entity controlled by Ampio&#x2019;s director and
 Chief Scientific Officer, Dr.&#xA0;Bar-Or. The agreement, which was
 amended in January 2015 and provides for Luoxis (now Aytu) to pay
 $6,000 per month to TRLLC in consideration for services related to
 research and development of the Oxidation Reduction Potential
 platform. In March 2014, Luoxis also agreed to pay a sum of
 $615,000 which is being amortized over the contractual term of 60.5
 months and is divided between current and long-term on the balance
 sheet; this amount has been paid in full. This agreement is set to
 expire March 2019 and cannot be terminated prior to March 2017.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph b<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001193125-15-343845-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-343845-xbrl.zip
M4$L#!!0````(`!R*3D?X?`0[%^P``(-%"@`1`!P`<G-W;BTR,#$U,#8S,"YX
M;6Q55`D``TC&'E9(QAY6=7@+``$$)0X```0Y`0``[%U9;^-*=GX/D/^@^"%(
M@-!F[57&[1YP'1CIV]UP]RS)BT!+M,V,3#HDY;;GU^<4M9B2*8FD1)I&9A[N
MN$52JN^KLQ9/U?GM#\\/L]%3F&91$G\Z0^?FV2B,)\DTBN\^G<TS(\@F470V
MRO(@G@:S)`X_G;V$V=D?/O_S/_WV+X8QNKX>N4D<A[-9^#+ZZR2<A6F0AZ.K
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MN&/]W5E4]<UP*[KXZ^]??DSNPX?`V$8`DG(7!(_K)V^#[*9X;GGAHI@'$QD$
MK1Z9AJ\_5(PH"R?G=\G3!5S0M]/-V]/L5[PQL.`EG]]$22$M^MM-3LS2</*7
MQS"K'$]QI6)`>A#3?'-,2^CL8G%QX]:H\E:^N#5:W9KECVDU3GU%#P-M#F,"
M,IVG+]7/+"_JQ\C68_,T!<W=]=SR:@6QX?/DOOHA?:6"ISB()EGU$\6E"DQ1
M_!1F>?4SBVL5B+)HLH.X:%+Q&W%X!QH_W2GIZB)-9N'%\K;U4_.'ZB>F>7JA
M)>4"[@C3:+)^`(S"X6>2V-AZ;IZG>X8&5\_`?(Q&A0&976:%FEV'MZ-"FR_U
MMWXZRZ*'QYG6N>*S()UH1/7L1O'$?1K>?CK3FF2L-.;\.9NV,"OU+=;%`M;2
M#ERZX6T(HCB]#I_">!Z.)DF<A\_YM1Y8F,S&WSU!$*;4,!`#L_V?IFG*\8^?
M[M@<:]$U*3'A3\0)84(](R494:#V\SA:?,?2FHW_],,]&TW#2?00S$!8X98(
M1".:CCEE`B,R9M(FF)C$0"ZR#$I!EB3Q/`-QQV,>40Z6[EA;O;%Y]ADS&(?Y
MV\4.%`N(FM?+[TD.WBX*9K]',Q!K<)C?@Q?M`+/K<!)&3\'-[$.`QF>?B5G`
M_NVB-K#-J;;G612'609>\R:*"Z<,MR9W<?3W<'HUU=]V&^G'K"P+\\R:_.\\
M`DZM>/H%/HYF41Z%&5P#/9HN;FE('#,9!N+:$,69BSAUF6$)"D1Y\!.VYSB&
M8R'?H9;C.]P>(TT4`>D@"FV(Q^F1=\?L50R._"Y:W_PMOP_3G_=!_,<DF?Z*
M(-)I13I(*R6*FTMIY9U-0B&MZ.PS8LKL;!(.DK0Y/Q^).E!T03>(V\14*/\I
MN?RYP>1'H`@<@,#BU11VQ\;P#"A!;=@VV!NZ;29<5TC+L*3M&M3UI6$C1X`G
MDAC(]4W3]L=$TRW`HFJ)[-.BKARZSO#"."M^P$I3F)Q0^[B_1/G]53R-GJ+I
M/)C]N`]2^+9Y?I^D^O?])+V"KR[RW:8$<W-!,-#*!!#,E9!ECY45OU7F]NJK
M_X9<GTC%")8&$Z8'Y#K8L'SE&"YGE"+.A<O)6I:1:9K5X<RQZ$L6X]NC7@B(
MXKLO(82!V>]`R_WLQ8:_K^$;KP`>A!+_%09I8\8D4@O&.*+H60=%@K<R`(I3
MW[,\QR`.*X(AU[`%QH9M*H\@QC$8@;%8NA?)UNI?&]JVB-WD>EDD+=9#G`32
MGC37JK_X4R]Q?(=\(43-&5DJ*4%42"U#&$9?CZ$Q8!G7DS&;(-\7%D2,'A<&
M59YO*,2DH2S%.%>F@Y4]IDNZZ#DG9?FJ"7T?8WXP":T'G?_V2=`!JR8Q:!@F
M##0-`RFN:8(3@8%(1>!_+F*$RD6<"(H'KFM;[ZH!;M+P!2S?MUL']#-J"IT@
MM$H=EM"U`1?:H&.ER+,V#=QL%2%;S/<$*(WA8&(;U/$LPP:#;BBF)')]RV',
M6YL<LFUQRIA*5L,)LGMK^J1M209VY0>8F/QGF#Y\28*XJ?,:!':(KM@2^F&`
M)YMV:I(MB3\9=-?"X+"1;1#?!8$'*PE6@'*#"RFIRSGWA-MDVJNN@")HC_UR
M'3X$40R&UD[2-/D%?SC!(US+7QI;`'""E7QL9-1]B@;1B2/=Q\]A%@;'(.I3
MPHA6+GE*!B'\>4CB'WDR^=LBR-%Q33AM3=4N*NKY6^1[S`.781#D0$QG8V18
M&'D&<($<FQ*;>7@1,&M_*S@24KSRL`-+1PZV$G&1-A#,GI&4`G'11AAJD4#W
M!+;['&QAD0MV=/"V$?T6G_XET#$P9/OSO'C_!8+3D!FLEUC'+>;>@A349<H`
M:X(-BB$ME<KFALN88SO<,9%@B[`":]B8([)T,,W@;(I#(2WWR6P*(9D'"51C
M*T'>P*T]T1A!K"1,:G@68S#1@AB2<$@4(3;GOBD](;!&+,:+60:9!X.*D"K)
M_-OQ;^FW=K[Q5/^?OOP4S/3RI94[0,P+L/'G8-9X1?H(R,K%F`NP;,Q2X"H4
M>`G)%23(GHL<QW,A)EVMT2A(B14"?DJR70M-:T'_2ZC?;T*R#/%Y<!=ZSV$Z
MB;*P"--/2=&.!`2_37$Y-AERP0]0\*E46+YA(=\VP-90&S(27P?Y*Y6@YZR=
M0NR#O:4LE=];RIKME]=;EDOEUJ\@G7Y[U#>6?_3K_.$F;)H(+UG=]L"-38WK
M8R:$5(9T+#`U'J*&I91C6)8G?65Z)J=TS2M17"E:TKA3D]`9QZ>7YSW,MY%O
MR2WI80:I(Y5Z?<R%F-%GQ*!$V<(WJ>,*NB7?/=/4V=Q<Q7D:Q5DT.<(`UYN-
M_0;9YT)82@K#]CGX(,^2AG+!_T+<;CJ6+[EGN:]>%PN\$6MT1L@F[]_3!$0J
M?_DQO_F?<)+_3+ZEUE,0S?3B)V24FXM37\/&*P9K.JG)BEB.*(*I_C<"AP3_
MAO]*>HI`7U&PXGH9R04)!Y?//,.V?&78U"$<R,6$TT6`"[$=1VR#[:8T5`AO
MN_"^1!"AS-0$8<Y$8[M;-^!!XR)+U`L)E`C$Y);$50;VIXKD]J`\>62'QFP9
MV#%*ZP=U74`E!/CN$"H?JR54@YE"8=H@B.T`+T6TW2NTNGBI7D8O\%**))'L
M?>%BQ5OYA[IPR9@OX2*3@LJB!GC?Y.VO+UH:+P*VRST%METN7`@(&20CU):^
MH3P(#97G229<$!5?C"'I)NOUO8VL9/?XM_W8\J53Z=[VB7;78,$#;3B?O6,_
M,*/#1<G./@L%/X/YG@FM`_1[D'Y+?^2ZT*X(8;Z':?'PT7C;O;JJBQ^<K'FN
M-;<2_BY0A^5ZJ#I,Y.KUA'E`NIMH<:NPJFNDZJ`"5\51IUD1[EIM:1VUK8*W
M2</'5%HBWBIM/5S;4PU)5S#)Y\'LV\TLNBNR-W<>7L5^,D_S^Q:U"GN9./`:
M"6/]>IH;%O$4I*(>A5`#"\/%%N.,V%29]F(Y%&PV)63+!Q^&4EW^\C-X+M7+
M]`=7VK:'?9<9Q+0]`P(UO0J*/0.2<6Z9EN=@"3\Q1F19&O2V=&5SY)OHK.DT
MTA0$L^]!-+V*G>`QRH-9247Z0UI7ISD$C]R$G(N5<J'#0#:!?TWR,/L>O.BD
M^#J<:0T`9=`$.;,@RZ+;*)PZQ<Z`YF^8NV8`@UY3ON6:&@#:$O!Y^#.Q;F]!
M/N"AP6(FNHYUZQ56U<CKFJZO@.[GKW#V%!952CUJ='T#IM?2Z+*\LCFB+4V?
MS9)?NKC"3U(WF=_DM_.9-2DVS1Q3?U^3A2HOYB$??#/EAE1@SRC6JXM(Z1TU
MKNG;EBT=WX:9W\POZL&H*P0_0L`[':K_TF40G-><_5<H)UXEZ,&B0P3*"%?4
M;/+&<B<3/^^C=+!S2IO,Z1K))O0_Q>FZP!><NQW&X6V49U?Q)'D(X8/O(;C!
MHJHWUN7Y(424.>A(>HKPO(%^"]L7IN7X!E8"&91[!((6SS&D9WJ>\$VI;$N3
MLJWB1\"K';=&M\,-6[D.6[>7C@XBV;+V2Y-8'1`,U<<#<L:1R53)WM<`LA<Z
M",E2.$I!\&`9`(_/J6(FV<G`/CSUQ-^Z!9T9M`:(#7M0#\?>O92#G6^FR^<%
MHF^SMLV1[\Q)%SLV=/*^>*>Z"H]Z1UPS3]5A/-F5IAX`LTG"=9@'41Q.O2#5
M!8P9:,7\85Z8!_C*:-*B-+CS0$>>?3:0R9E0I!3J'$:R7<[Z#NL0==><8((Y
MAQ!'X7+EZ8[EA_(.I'CZ`4)5IFLIX9>XJ50EODH8C;7W:Q)/!JK`2+^[D[RQ
M#K]"VFNIWP-Y7='6[]\13+W8::UW@2PM0[4IY.G!,J%BH;QRD;RBTD9?C?)B
MB[NNLP0P8+?">')RB_2<19=Q-/MTED/$TWKBZ,ZS%C;71E>?>L^Z2"E<KB'J
M/$2?91.D$UU5ZL)4SY+'Q7:MK/'&T1XT5)_*((2JL1C<"G"-*'.(025(.,$8
M'\ZK=KJHP4:1"GRNJ3`6LM(G589/FR^".K!*IU%=7E-UA^PW=%4JJ&:%V]B%
MX4#`\%K"EV194=1^FZ2Z7G)XQ@A2>B*IV!\M[,9S@`CX8]N$E0M,X^EJ\:BZ
M`E6;L\$QII9;M_;P=0+86VLF;8Y`Z%YSD*J*MO<=4K"F:/7!8M5P<),,B2!2
M!V9Y$T+5A`W8Z"%`*`6B&P6<VZ.N+M_^/@OB'(18YTY%U-&\5+M[?/J5A<"T
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M&([J$L(NRR?[)>/X<LH3ON3O%[I>O&8U!.'=7(:B`M*3#CE@Q2ZBVML@V_F,
M$^M$#Z0,52=Z@(YJRD/_(:64$HE6)^G41<]U2'GLEN#^S$,?A."EB?P8$64?
MC.CC6X[==M=#1-D'%;0!%0TCRM/ZC#[(&*C/Z`.Z]AGHA''4Z7R&HM*4K$OT
MJ/`9_..L0_1!"6Y"R?N[C3XH(4TH>4>_T0<7M`D7[[<4T0<5O)'Q>,^UB#[8
M&*@/[0-ZL7'*/*$3/;G?D(RB3A=D:.$WL.K4;YQ8*7H@9:A*T0-T5%,>WE,G
M<*L38.MR@,N=D#Z.3G1-RH!UHFOHJ*8\U*[8+6THMQZ2-(_^?BP7!.OSS@F7
MLEU_08R9\I5M.)CJ\\V%9TAN,<.4OB#ZIQ1QUER@K>TPS8'6)JHH9/\(M)AG
MGV5]6@I8W==W]TO!ZDUX/0JJS[E_QR8E)<YVM"ZO5QWH>4)YIBUT/P8.9L71
M)V_;KF%Y/B7$%<3F:E$SJDN^D#`[:H_Q<9J4'&:^3>VNJ2S3<QP)/RD<W8Y+
M&I8#(BP<;GNF<&W7MM?SP,[Y=K."_Z]-2AK-QJ$F)0BYMG(-CREJ4%<ZAJ)"
M&L+U;>9)^%30U_)IM+DIM:<>)<,T.QWU1EJ)NS[.3(A_F)WWZHVTGH=_]$9J
M-1LGZ(VT,CN("/H>=F?C3*G'%.`L4JCP<18N-XV7(^:=FUG;TTR9R8!F`G?)
M-C1['B/$LKF!N`_6W?9`TBV!#=W,F+J.ZTO76N<,6_4-IT+?]8;E?GG2ZPZ;
M3K#^'N:==QZ90O6''E*HK1WX^S&=K$W6*]H>VF2159LL?2K0FU8(';;).HSR
MM,V%R+I-EMHZRJKS/DH54#MMDT76;;)4Y7F"[P"XVSY99-TG2U6=_=]?XRC6
M9;L2-+#&45V#'4;CJ*Y1LN(,?Z:XK&Z=U'OGJ+>`.VQ"@P;8.:KC&1]0YZBN
MD1[=.6IYX.#B7KWE,GT*IWZ2^O-\GH;Z87UT:$^HN>\QWY?4\*4#K@AAW["H
M:\,_A24I!48X>WV3+Y"46%;*=#U47;33ZMJ8T5K&K+=^6CV;LE/UTSI)2ZF]
MV`_$7([M4HZIX2C])M+W+<-B'$(P:CF0(9@F0]9"T#==]+LTE#H"9UVI+LXH
M5(H37CZKK&%#J4[ZZ]0&W[J_SO8<M^FO<W0^T<,<Z\2!<4A4RF=]'4H<^FNT
M<M1$UVVTLCW7)VNT8L^S*`ZS#)3C)HJ79TPNSX3.X:\LFA:GCB7QRFZT/Q*B
M>UDA9G&$_4;X=A3"OOJ3=$^-[D^"D';_8F-QM5V#DI,TZ>@!],":=!R!N-:!
M7,5["KZSE^3[-NGHP54433HDD8C04J#77Y..'BR<;A;*D4G*JVA]->GH'E[1
MI$-BS*7)*_&]<Y..[A58-^F`+S2;ZG#733IZ$.T".9.*[+36'37IZ,$RH2+]
MKFYEW6F7C@/83G#4/QI6EXX>5+37+AT?(;;4*1H%0DBU4^JHBT4OHMUY%XL>
M#*ON8J&[$9^LB\7;+@;+M=)LE4+`B-^F$H/39%V(?*`=5DNH?;4!Z9XC#AD%
M(2=J`[)U>F=I;\2U+D,;7KRMPS%1[)]_17\(Q`D:=/0`3%5%VMTWZ.A>8'6#
M#B;WR^N^!AU7,<2:>9*^-*\%ZR&0//M,%*6X+(VOPSUIIY$>9%!/E:YK4O5;
MC;Q=T6Y]+'P/GE>+HC"9?+OD5C7^SFH4NT<*U@0K8;Y[4Y4>HO]CFJJ\SKJ?
M)@_%"\;E2L:WU+J]A>`AR,/,3]+5J^9OMZM7TL-\`2?6%1/E];:C0&X+QV.2
M19`&#]Z8%;T0)"_+1?70]X9$/]-@&GX-'@:X]HAP49ZY)Q1Z'?SI>@EUCTOW
MNS(ED>Q-I[)N>PG51G9$+Z'BQ2$2:$M%WZ674`\2JGL)82E$20N;["Q=M2H9
M'C!]5/+F>YW56$_?#:F'97[PH<*44I;#A7?IAM3#XIA>8V#$Y.6ZJ_?LAM0]
M9+%OO>G=NB%U'QIJW.S`>M+`NR&UJ<MKV0V)+4\;Z[H;4J>=@=J6;=;J#,27
M#)VF,Y"3I.'KVP80R7!R'R>SY&Z0"QW%IB=I(LR6N/<.OP1SN1:[T35WH'82
MZ[G5??)6<[M[[._4X:F'>>ZLP]-B?_FWVR*I7&RYU6L1Q[N-X@O'^KM.5Y>N
M7RDN\>\:=P_-J[J?[H_1O*H'L=>5RX117<9S7/.JXNG7?"X$SY`5YXO-7K27
MN(8;KP!%%,Q:G!]V3*FZ)PFX-=<0C'"#.K8T;&4+PV:>)9GCV)@ZZST9^ARY
M)1&UH9S^R#!6?8R>_C?#@B^/$&MUK)YC*NHIYALNTBVY%,:&3:1G<,?A'J86
MXL)96X)3':MW"OBXU<$*@IB.2:5IV%R?,6(A84@3*WW0"+6))RR3EY8G3M32
MX"1P6VV%]87C.>K_V+O6WK:1)?M7A"PPV`6&N>QW=X(=@,^[ODCB(/$LD/T2
M,#)M\XXL&GHD\?SZK6J2$D7)$JFWDWP)9$6BNDY75U=U59^2D1/'80RSRV'1
MQP86/=>!9SP9*J%GXIXC05P=BR/1@!7K7BRF5@]($%?_4GG*@%;DZFZ4;ADD
M[0,M+444$E>"-:`:-$>%CG$#[A`5<U=#L&2PH5U)VZW:@[5&V)T1^Y8_![S(
M/O#ZEN^"UHZ,IB>!S=T1MO4DI]V>92E"<1YB^,)S`$]@82#?`;T%B7==J,\%
M-;Z'E=H)KVV(;DZR0YX75^A)(*"8T3%M(5C*Z&RA2?ETRRCIN*N&[6/5@*S'
M7366J\UL%4\JCX11$.$M28B@/`8AA0<A11!Z'E=$23\D,ZXV=JA5LR\0^'9]
MB5N!P)\(--J!<*HSQGW`8SPM%9.!P[0'JX?$!MLV4\>C;J`I#V(6S..PO9\Z
M/G%I97LX"GK#HHLU,C8130@:%^V*K2BJ_"".(AU))W`%A*F1)HXV>.68*]^/
M(X]0:?N"K]2>AE3U\[A\`AADR>!M-DC'DWR8EF2'.]^>/RT(M*STFNE(&T'W
MRYE9YK1LF>`VG+%+.!Z2JMHF]+!@>H\<F4L`G(209F?\E.(TU-A//A!@F#SJ
M.YXAD2,CE_N^QVG$Y_&7)-*M\UGLR$^SQRG8?Z)Y)RKOY<7=BLK[P'JZ4UJZ
M_2]Z7Y-L8(LL\]$_,>U[_J:!6L@/(_USL+L'XNK^:>SN%OAQ)GTC`D?X2/"L
M`3\C?>'X\$I&L2$D9O,\!'&IDJOIL7YTP]N-S'Q5W-J"S/R7X3V1;3B>X3T1
M67D-TV/14-L,0Z,[Y-F3E9\$)UI2XYZ<K/PDTN]&5A[=/PSRQS3]"!L.F+'5
MJ_==/OP*\2A8/EO"?Y47;'?S&K)\/'F73SZE(&3%&K8]=$8*FRR7TFS%"2X\
M+U1NI!QI&-@M/Y2.[\&?1GM^X#+AQ9H6`;CM(+9X]GLP/)X3[%MI;"O86;E>
M.:6G@'UW_M3C4//+BIJ?KJ15/2`W_V8Q]\O?+BMN?LJ:##8'YZI?(>M!R?EE
M1<Z/LJ[@$3N!P(<EYY<5.3]EJWA43R$OIX>=8/%95Q.\=&]UD[S'+BZ"V$FZ
M97BPE1*X/H\\KEP(#@28?"6UHT,_<B*-=P6)&T>4SUPT(EIG6<^UNNB(@)&]
M`'8FY45'Q,W=%;?SJR\Z(GKBQ1_*IBV??WW1$5'C^UBKG0#;)3`_(C"RH"=Y
M+L4U1T2&[45EEJIKJG3Q5>[UP<&`&*HDITZ[%I:0`AK!R#;0K"`4\(4*0Z4]
MQ],^'N#&VO%)H!P2:DJ5&[NN'\]J`TC3==HDV+:DX[5SR7%PAR\OAH#V=#BY
MO'GJ*S@EY%A(KJ@O:`VDW(6L?&MD]CD55W?I!WQU>7,YG2"3UG@3M;J]V?X_
MV>W=LU!UCC<4&JI^,L3:3-S\^U?PV^.B8J=&2WA1W!WK<+ARNN5!EFN0=A.Z
ME@-J/XGOTU$?WDMN.[@Z+3%[F([2]??HVX,E;'\;729YMA%O4VS_+I^D1:>@
M!X`UP+.^T1B>\`&?T]W>2OC370/&RDOS)M8Z$*'C*J4AR(^EX[DA<<)(28C_
M?:W=\+-M(DOH2Z+6]AE<+TZ#@A<WLA3O(P*"]57=N*MXE8[N"^N+][DZ0Z*)
M*8YZ)>&VQ(TI*9=K'"6/(R\*L)3(<SAW0\=7>)W0-1$C0E+N!45OF/=,O:WQ
M\6XE1!,(^(0WO,:;F,F@='7V)><6Y9[MH,#\$UDDA%PIR'ZS]S8Y"K8'5EB6
M7V_GWAFJEY&J)0.D4;I[Q4[,M!%87@Z^?P16):".%YO`":7@'"LM0\EF[9CW
MF*I?@<A)]S13Q16N,,P>MC+.C[;'57V<\9U][W&G`13;CZU65^4J/-T%FR]H
M#6"#G&L'6_@4`9:'<2+.%6#A<G8T@!D";!-@1!K^,P"L#6%,'@U@C@"+GTF#
M#77AU=$`%@BPJH*\DP/<V8M^$L[CP"<1/FV+-+:V`.2P)V3G@!!;7L'=SLOF
MG_XX?8!P!2*5+7#0]9I#!:ZEIK82RD@-?S,$YGA.N>LR6Y:XYB1Q)FLC!LF'
MMQBCO)^.^G?@:<Y;Y13'7S\$,F0%K?(FP9N7T+Y,+H;CR6B*GPC3_@A#GC@?
MW69?4]2TSNXR[/++UP5P)5%CW6=[0VL;7$@<B4A0UV$$;S;ZE#@>)9%#N"2!
MSYDO(CH[EN=-6#8*>@I<R-%PJ6ZJZ2UQL>=%C;M]97E6>3X$L5I[3)C-V7!P
M0U?>+6G6I&F?4>8RB(R(71'$T2P""64`HC,34!W.9OZ]^E0>;VT:;IT-\':4
MVM@48OQL=N1U%B+!&G]/1"73DP-=I[YH#KH*@A6JI2"$*UT*HI85MB&8)^)(
M@3Q.0)'!*H@\QX>HUC'":!+&7B!$5!/LTU.:B&-^DKFL9/LJCF7*K:"S@/.:
M22*M17>E8O5`GQE&;:!/P)+#W_"OYOM8L89SY9DH=D)D.N.P0!W?BXWC\X!)
M15W*)%^H'5_)>;8*A!IB;Y-A4IRWQ&E:=FX%5;'?ZH!5:;U4>4B]\^Y&&7'#
MV/4<>PV$QV'D`,P!K`.A8"EX1*/8EMZL=J5VG3![U'Q2+&%6"=M)\T./AIKB
MY<TXA%F%C1IOE4M'*JUY**6,5-A-\ZO_GS=`L$?1WO"ZHG`%.UW6VHXO1\$@
MR>X[;$Q,BMI"V&8RN194D4`XGA021/9=6.=".#J`V33*U[Y;'C(SLDC>UDFD
M.COM(!F/+V_*#U^.BE9*C2L]']+[),,>KC7.M(Z:T("F:>2XS]P0YC:6PH#U
MEMR!C54Y0LG`UXJ&S)A9Q=Q[_HF_!7->$=3N(L&*L^<OFT]:OSQQTOHT2?)3
MOT^WA7#CANCYD4\UWL;U7-@W!.#JR9`YGHH#&6B(]V,YA]3]U#AO/BX*/\HT
MD.4+*R3V805[X$+B]DUY!#.@A(-<DRK@X)8(-I\&\XF0MT2&9S09R!B?C._>
MC_*OV75Z[3_^.<9*G-G6Z?4GV=>BW:1-=4[AO?(_\RZDOR6N?'OC:4)*I0(C
M(CR#7)_@)&EID#(^)$$0A;#!^IBF%%B$+%QB9*V=UVYB-FZQE`VO84.M$C-9
M'YE+LL%TTN7PK@TFK<GA@UA'TE/,`8]:@R,)$;`VPG<\\$5TR'U"C(6'`SSN
M2UV_A;)>GH;P-S<I8I46/=ZNDN\?DHF-%89]VX((\+J<W*4C[_K?TW'1:W</
MB#3SV'PY.Q03S_<EJ(<P2$#B<0>\1>GX5(8T(-*/??79'JR#^/"#M7;(V\C4
M'14/?#$\J1M\G"23*;:66_CP`4!:E:5L"9.+A0^,+UQ6VEW&[J"]RX>P7*?P
M,?!@RX3RZH0I7H,Z)T6CA:(1S;M!V$WB[HA6)5,MFI^?$YS,PDDI-=W@["!N
M=RQ1R['>X4W>3P:SSW7I,79XX(@M8:*Z(VY/B;8(4L/GF''LH[[67)/][Y!M
MR!/:[HB@6M)PP^OMK;83K(T&'<B-VIN^V)(W0M7&_7&SH[24CMD#+\'Q_$CS
MX@]#C5Z376I)-/`.B>X0N#>=,FV[2]IV`5#K,2M`P5WPF.>C7IU[M3",[0GQ
M&+"(\]%]<CIA/0C#0HC$J$<,1&*1<OS`5TX<!DK[$AP^3E!8L(>.=(UF:D5F
M=:-$S;ZC]J3\'"<5YE1H4]\MJ\$VF$7F+BWH]?6UE1W/1S,(C^KT/$M!ZH>T
MP*JZO5Z<J]>R!AT;Q^T.3:O;JN#3JL]%?E2^^(,;LZ#UAX:CV:1TDL(V5NK7
M["K>4<UA2WT":XBG3**V+3PU^B?Z>IZU#=1H%1B7FM6LPHJA-Y+F,,\@\[@S
M)>GQ;/N2&6B,N:F013ZSRFLB06N]@>09[M,:%[%B=*%W^WHIEF0N)Q?[*J_R
M:OST)A^E-2<X^CX9)?D(/,`$(MQ)>F_;$.,Y6SX86'TI5L8Y*H1K-=U0IM4"
M8H?"H+WK<(I5U,YIL,U^F23,M',95JZM=5]HBW\1S8XOAF6_>SRY!+]S>2K2
MR>4-3-,98HD;B32$NHJT`_-0V*RR`O!V:2/\=)C>9&>Y@M&#U81)L[2`EX;?
MYN[%&=ITNNR8K1[[IMUK:\[PXX69MEDE65@-&^58(G/KI^EUM3R^0DB*9X>8
M)3]#@9$DALMF>>+3(CS5)=[>JOI05/:<P&T6@:N)4L9Q?8.743S7\5T_<$*?
MPB)&\B_AESO'8CN)M1*TZ<Q=!!9-'3G'F4:G&AOWB'I;M@XRM<I47EAVM.>8
MJ:3HBBT>,>TF8RN\8M@)A_UGB9>"8(8R^(J[$;&64C:/<U9UH3A!Z-/2$Q`O
M_F"&@5^Z<,JS1H;5#37.P/5IJ0%BA>>S08K&:==@D/>11W:U.W&"J7:%\F0<
M>HXB>&M4^9YC`A4Y/G&);XC2TF5%VKIYV:&=+(OR_Q-`&24#),R]OL^&V7B"
M"^%K>KXZCM>(&)="U*9\@Q2;G,(J,BWK(H_L.+3U"]W"35I[K+$L24/=:PPZ
MES=-?IUC2AUR0R,_\IQ`8<T:\93CL9!B!PEA)*$0*/+"76H0)ZT78:TC/!EE
M7S`K5Q[;GN$D4^2J:6QHZX78I-ME[#LN->(,9<;P%1ZHE;M.LQMR-#>N.0GX
M,26,72981`,'=)2`K3;&,2KV'!8K&E#EBD"[A1(W+I_7!_RT*$_QF9_A)$(,
M9]1"PKR-((U0#BNJWB1?\E'9A[TTWT>U2]SS*3>2.L*5R%W&0ZQ,)D[@&P/;
M,HNI",HI%8L5V4\.OU9]O;GM_!GNN$A?1X7`X^&60JQ@`%I]D'<&V:YVAY1Z
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M)X!.%BBT0XDW`H7=!&R)%%YZN+PYWU(1I)YS!5=:MD!E09B6`-2=!D#SXAXL
MT@C!/.T!7TMX9,5-TP*=#I)NQNX&G[CAX/@<`1-X_JTQS%B/6"OYUEW]K\)8
M+.VWES^NYR2V]GH(>A!OD^_9_73KC6L%1T!;VILV=]O:<FF4EQS`<Z+U`ZQM
MT=@=59BJ'P%57J!*R&ZH%FB<N:ZNHR)J@VI;]HL9JC^%KAX/578X77T._`:U
MZ=B=9H)5D87Y)-\2<4[T!EN3*\?@:]@;&^!@3.^KIL@/:1^&\+\YN*U%=`B*
ML`<[\T2G^%8:[X=!Y%(#>NY3A\=200CL!XY@OJ*,R#"@XC,I;H'6\S7'`^8(
M$Q)F6/PSO-[E'GV'>5@F7V@Y"](:G7UP?[=%HR/XXTY<X_MIG]YZ&K9AQ7"-
MYT9!H.%'T8B!+7.\@"NL._`C5\&\^3Y>";/V2[R4NL/<[`^L,Z+(;ST;[4CQ
MHTB9R(6PQH21='@4X)4\/X35$7/&0L5\:6;X$Z+<^@6S@S/C[SS%U2R>[Y)8
M47'6>DGP;GT*]@K6`7>-#]GXKWB4IG4/;P]N[>$W<5IL'YNO1>P?F&-/QW/P
MJ8H0@M9+](X%S(JN0D5?['`Z`I^X6%Y%OVS[GXT5N'6FYHC[0</X=!;Q^''`
M<S`AEM=)[F./[0Q,/6M6U37BE[#0<1^9CG;;Y!X8!,2<08#-ZS<W"U8#X,_A
MJ"`&^'M#^?8A/+?]UJ:3LA],!4%[T8Y9FK_B3)1Q9KBE+39<VW,G)82EZC54
M'*Z4OSQ\(NYBB\IMJOE/!AFGE,BC0<;*GEE,[XS8UN=1ZZP='CMUZ#&R&67#
M7*N83+K+;3;;&?JR>>%[^4F^W<-QW$;QGS',G"F^3.S:"N:JF^E[L0]^W:X@
MKW.)JFX6ES>[I8)7Y9(8%]@5BU$I5&<'L.T.2S[;EA28_N1@9Q8.9KH(W@HS
MB_H)(-N[7T(^VUHG;E';B-A*L<\*,$[X=KT"VP+&/ZL2,$*(J[DR/P)JU$AR
M2-389UFBYEC8%!6[P':\F.`$(&T1(CS_1.*61.FU1"+_E47<#?].IP<!'LMP
M+6%VC')XB#HMI>OXS`M"Y:K(5U[%):L/==[U`V81U\W#"@KW=K/P*XNXRS1L
MDT74TM.V_X[F&LE>PL`QL6`.A,.^BET.L\-G62S^LE,.Z^?+(I+.04,84Z&4
M-HX./`C&(L(=SYC`\;Q(Q\:-7,GG^#/FZE])Q+VNB&4GJ/V*^)5$/*\]O$PB
M*O$KB7@.TU$D$<E>RAZ>9Q+QD-O!3YY$/)#.VB3BPDG)*9*(1\^A;75:T"K#
M476D?U8Y-'*R')KM+X]=K@5]7CDT<K(<FNV8CBPFKOSQDVAD8Q*ME:&K;@K]
M2J)MAGEU$JW=?E)><CF_)-I^^9*/DSKCL]29ZN#[M"!7WDMCESH&$*?30W;Y
MD)\-PJ`[-K<YUX8H1\N*\5E6[.3]4=ZDM\G@;3*!T&6,I,&6P?4V'?:S='P%
M&/JP>?W5&5#Q!(N",3X)`AXY.@I=L%8<[)90`!9U`RZYB0/&BA*ZWP:3U]?9
MU]]N)Z]AO/C70V\\>1RD__WB/AG=9D-GDC^\(OIA\KI7OO$EGTSR^U<NOG4#
M`W;&X-R](O._;Y+[;/#XZBJ[!X?U7?JM]R&_3X8O:K_Q!5^_RR=IS_1^2^X?
M7O_'=^Q4^[KW!O"[M2#CQ_YA/V=?/6P8H=S?`+UQ+[_I_6LZ3,NA>>YKYO[>
M0[Q_[WF/DVGO6S+N#?-)[\%F]"9Y+QD^]@8XQ3`&.\?PG'S4Z]LFUK_#?U_#
MYX<I/CB;C'L/9;NM7C;NC:=?_@TV?>$I\.V'@CP1NYF^[%T,>Y.[M'<SG4#H
M4PSA/GGL?4EQX<]'T1P!_FPQA%XR`HT=WO:RXDE5&P'0N.EH;,?UI;R-_3M^
M`+X,QC0?V-P>_N^WNZQ_!V/O7>=I(7L"&MS/'C##\"V?#JY[=\G7M)?@S\-Z
ML#(DUU]3?'IV_Y"`A/`D%/ZF(#2&D3[DQ:WOW_''IH.)!3Z?$S?G(WA(/QG?
M]6X&^;?QRR5-^$>INK6>,&W6V4G[!L_6[(&88DC1-UB">TX)7]@H]M8W>,&3
M&5Y']P^#_#&M>*^PB=P!C!H-C3;,!U,&<8?#X]AUM#&QXVD>B2!64OCJ/(P:
M<1>M6H5/KR(\0X1.:.#0?B38*W1L%V1:#F^,-@2-2;6NP5AX]P]9/A?&O![W
MN$O^\Z__0A,%4KSL78$YP5?5$V</P';)\,#^C/D5C,,#\F`4%@6L3(;K>YP,
MP!#]7K>#Z2"[S0K2(K`,EN:IZ+Z,!BT9#J=@.RX^?.P-LGL8_\M*I)EI`A,$
MQJH2:SX"5.0V1J2+>C=8J?/\^ELV0-Z*)K%']5_O\T'6[UX&\M2J\'3(C1LI
M"$P@4N;"YXZ.=>3$#,)SU_49B;V-J^*M]^&?%^\<__+JZO+MJYY5I/CRW97S
M\>+_HE<],G\C]MY>O/GTJM=0K=>]\A%7E^_A\["REE8&OLCP106$Q3Z;+8`-
M2V'/0Y3S$:("@U4<3Y*/_6PXF6_Z#V6)#^S%F*Y*B@,&5%_<_ZU;V)L^P)_)
MT&ZVR>!QG(U+W>[=0/C6^VK]Y/*=I*B20B4>E*1<R%>7E$1F\(R;47[?^U?R
M]]^]]^!YWB?]%)2V#[M!L<QPYX1=<W%8A2,`>RVZL_8ITP=<1.AN/*;)J'@H
M_OXUKNEJ+'/.%7`OKF%U93>/Z"`4F__RX"MEML//AO,_5PJ%>)1B52OXVCYF
M6C@;V`,"'06`\1$D&"9%*%QX2M_2$8ZA!G"_(-T<//:2KTDVL'S0($T"G[<K
M'C[W)07KL[RX#Z;B=%&!T&2@^Y94IU!6VO1['SPJ%+@Q:3DX1B7460%^9H6J
M`XL^8SKI-9&&J;TM5]#+WL=I_PZ>4;V!_B0:P'G;;=@/X(>2[S@`<+?28J9&
M2'$\MB:U&$0QU6#&^S!R`#S%'`NJPQ#$AUWGKVJ.T^\/1?E1^2X:<`R23H\\
M*-.DV,]F:*#LV8QKJ=PY!K#7P/O?[L":PRS`4Y"T"GU/\->+QENX\?6S47]Z
MC\56??O&=8;3"L^H/_'_V;NRYL:1Y/P^$?T?8*TWHB<"T.`&N..9"(`$[;9[
MIQ7=O5[[:0,BBA)F2(`+D#K\ZYV952#`0Y3$$R"Q1[1(`G5D96;E4?4ERAZ:
MO6CM#XA)(QDY>H!CRH0X@06;921;G,JP@#A*:&84`[51U(H5`%%<;)S;Q23"
MP.OC%!I)$:T9VD7/0(87(X9+E7([K;#OP6XC&"4L?5Z5>!3#TM`7]CDTPA<3
M-R7N!Y<_5FD23F#(`V+44?@H[/.,W<U&PA:F_1FFDL4,MFXTYFFP"[2$.?(!
MB84KIC#&0<$/X72)R"`V%>J"]01,7NJ4E(8P`(<&>G[,P"M7HO2QL#"6:4\>
M$?#K':-?RUY08>'X"_<#WF`B8%Z2%+Q\KDC%>`7)<R!?A&N7$#/Q:NQB[7%H
MF,X7ULSZ4<&W!<_BBE:((XU!J4/S?Y#X%U%`I'F8D106BC0JG$-TEU"!DRV&
MT^5+,`0'+,U(>\RI_=(V5>Y'7.5<2]V2!PB(B]T]H[BL<`VZDR-\,8_O$M!I
M@Y"4MO#_IO>@@*3?9]$=M^;B!:^6ZR7J6FRH\P`-CKH@9A8A"X/-R'D)-<!<
MWG%;GC\3XB:$QNB:+0^_JFSYG.L*'@/]!V_^-7PN+0%=N/_4'XR/^_]5)JTL
M(5>Y]WSW18Y(<#CKXPEOL4;?;%,NQ8,'][`+C-B785%7YGOXQ%^#ECZ7>_5W
M%.C]NVN6[3A]OV<I6J=K(T:[H?@]W5:Z>M>P`LLR],[+ABG^C4L+&B=+GXC#
M:1=C5+^==M0*BX'N'X-G@?&,*(8GP%88D`W"HQ:HC;,X9T)V.3&HN9<L,F1!
M?'^8<I^F6%%0QQ->/UZH@_POV^][.GY1W=G4BM4\YY25]J>D?T4?[]Q'_2]?
M>\%7I?OE\V?OYAN\-(`)AI.<74D#-AKE(*:@5"CT@)\G8105GQ_C:'K_RY5C
M__D*C!R@_2]7`[(2KJ1;%+@,GRI,^']1%/!UP565B+FD_V!A)"E*=199]4,T
M;U[[\[R1GZ;1XC,/HE_N_LZ'Y+[\RKZ^/UG7/RW2*5NS[NYKRWZU<2K4[R*W
MO3+YI3<VORO&*QBOD(7L[O:C*L-_?Y2TR53*07U%5RM$!N8$CDSH&.LBRV$?
MJ'JV&&ZC)FCN8X*+/(2B&8"^6Q',=7+KI]'SLMQNI7I`2=S!;%/0$G_J=H.@
MWW^!*Z?II/K+9$M%)]3JYZ#_'5Y@XY^E[\'_?%<^_=8+?H-O%/BJZ*8H4S'?
M&&)*IY7[PZJ*WRL#K7OW5,_5>LQOT(5O8,3CL9VQD>T*HPQL"@X`G=^GV51!
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M-Z5<^EA)COW8AD/K,>;FFTR;W6`LIUT>QAC151T\-C%,,[P=U3A3R98-P[E$
M:\F07?,($V^:7M[,_=_PF$&:E!/6.D[E=&#CN-^T&A<ZW<NTW39ML/]4V:@P
M6AHG!IKE7J(8:!VU*6)0%Z:GJZ<*/P,_J-[9%LFSH[+^1621ZB<V;F.DIKZ;
MAU<<>X\3A>[4YGA&F)?PIH.?45G$NW';R4===IR=@I%-R[0==L)-VT)>B>T`
MK__E/-+)IJQK.RG#IO&Y)KMVFU1>)R^7$!9OJ=@FE=^:5!Z].X+?0/6_4YJY
M:;K?;!7_I:JLEHIM5OD,/`^^,]5R/UJG,M]V)>`2(UA;7I;XJ!_N^.\9;F$&
M*,(HG=V.V!&U[_:=UG83JP4=-W>UR+T_T65N\07_'WV]@@&PY67^EQ`!OLXQ
MN07T3\PBT9H(ERZV2@BTV.=!D`+Z=M_K&8&A=/VNJYBNZBD=QW85V^H[FM?K
M.T'O=;3*XZ#,E/H=D=`JB%`<3#>/(P&8)TVS,,G%_C<DH)0JX$0XAXF:`P,1
M.M-:U`E$&*G"$5P:YH#M'A1SP#7?CSE@MQ?_7WGW</?B@P+RIAP!0F5CO[>9
M]),8!H:]V3Y<]B-<GS^T+W+V@;!%B+2C^A,[6,F.7I-C<<W@O[IPVZ=E\,.C
M\]O.QW%DJRX'<IK!>O55?0M@JDWB06>G",'>&+!IH8*+B],V9U_@0<\"4D[X
MT4VQ1739Z!SA+N<92F2S@T[TQ89PTUXB18MA*%_@SWHE'N=-EO81KO930JBU
M^-4!BJ*81D]5.ZK24QU+P7(PBFOZFJ(;G<"R;=4.^KU3(Z43'#I00R)R2!5Z
MT$+%:Q?[2!CILR2<13%"S4ZR5*&!S>MV"#CI`H<;,SZC6<01-P5F)[0B0EX+
M@;`**&N82S'61R'$WUO&>$AM-N;XMA0R@T;^<S:JQ,@T"I$9LO083^\KD+$<
M)QN!.GGW5-H`Z$K#_C#'?.9PPQF3(F#E`0&,3WFM`'+@!>YL=9`$*0H-B!GF
M"WUF;,2QO\5[8RQW\']A`3E;0=9=05"_7J6QM$CC*"5L[XP-1S#4#S]0N9@*
M7/%P&`]BE@P(FG>23E%<$70`B"WEX0/B10M`U!)9^L,/)3P\$AMW^7`-0NXU
M8C=1T9@[Q,^&Q_/*8#_\L&:X2-62+0B*N^1F#F//`<G3!,F>$-XPO(-S3!B>
MTPVS&,&#.?0V+B75H0FG8DVF6`:B+!R#_%64*YGC+*?C6]`U_`0]DJM2J888
M+!X*`/3J$M^'40D&++J[Q;!.@G0NXK8<#GH^0V@C@3GB#.#GY6$+C./U96X(
M-9O/'%MY<>XLYE#.F]H2D-S\)^+N,>[QE2F'@_L8N#^B:2YS-SX!#:S(W7JI
M>P_H^].B*L+/2_'VI]H'H@\-?JN_/Q"](7:]K^]/UG7C8^`OQK7M=7'M_V5A
MEG.T<-KFEO#"]^&8-YZB+9SP)<`)G^79K/K&$'G@0ERN;4K`0I,-1Y,UU3YL
MP*)&\W4,6]:,3AN@N>20:4O%]H#P#IM07;:<X&0(T*=ZKM9C;KZ%L_D2>!=C
M8%@S*!Q!&\I"N<>C<^#.R7M7<V6[<W$@(KJL6J;LN`>V^)JF:#=S_M=S@3HP
M9-6V9%MOG+V_^\0[AB';VND-_T9O`2\)`NP&1=8&BP4^2Q]_PQ+>;O-NR6J6
M+7=<]]+D0],MV7*=)DA'763AWUG",CRK@HFG:!PG,57UC!^:APQBRJ;FR*[[
MIM#F.;&]+ALNF('VFX+6IV;\^FX+7C5%3Z7-%VJZKJ3I&R<@FJ'!KG!@XZ&&
MTU;K<<"Y#9:VP=*&4[%IMH_U"N!]GO,S3^6IF<8I]8^NK.NPZHZVK8)K&B:.
M+;NV+5O:UN[-SKA_9YD/J*]A]@D/+K!\*GT4@+<_"AB1Y@FKIIERI[.UA](T
M437!'[>,4\EI:W"U!E?#J7BQN]'Q]I[-V6DL/8,%9V3IE@W3C%4`K)JW^[BR
M85B8/+F4_<>6.YI^,-OXW.VNWAK0MEN6L&'<O)RA;@`K7%R>W-4,V>Z</B'2
M6F*M)=9P*IZG67-T/;XMBB28+IHF:U933)=MYVG+:@?FZAPF1-"JZGHKF4NF
MXN:>M@3+?"?`P!)(9HBP!]^F\,,-R_#^5'@'7WQY3%B6W\<3;SAEV7<$=PRI
M0N/V\`2S).9O3689NY(B-HC'X2C_Y<I8@2[PS:YKP9^*K@6Z8G9[?<7KNZK2
M=70SZ!J>T_=U#EV@7KN:50%R>.=L."TB%O_%&[,DPC1X?Q3>[0V#P7?\KMJQ
M?<7H6S`1R]05U^@&BF5K3M?M]7VMK\%$M*M?I]F,_=M/*R-9#R71I7O>/)ES
M`]PU>-[;B&W=Z#JJ[BD=2_44T_=@Q/V@K]A!T`L,5PT\O7MLU(@E=7U;B!+!
M0Q0TD:I$(4$IT2-NUPK?D7`D!)2J%`X&Z0Q1$P@;`/Z]+49>N9&>@YA$+%MS
M2W_,IO=IQ&$5J"&\G(\0$OS./'FP=+^]#T1(!G$X^O`#H1B(1[]-PR0*LRB7
M_!3K"7/U)Y!=/Y8?NS_WO6]^^;GW\X^59J#-LJ%N&L7#6"#"+C3A?>LNMN"J
MEBQ5GRB6[<,/BPM7>4L6\`T9(QB)O+R]GQ$`!`QHBI@!$@)<S(DY*%M#7(JL
M`'2AMX=AG*$VGQ'`0#@J\(L*6F<LDJ4*5CO^C/@N,C\[!JN8I(F"LI:EHQ&.
M(B[R-C$""90C9#_3*_`+:/$XOZ\.7ZPH(>"&^=+`H)4Q"W/0D70H9Y*NA:.8
M<]5\?OGJ5&@$:V:#-%M'KUS^4`!]X-1PFO`O(_Q>CO*TW!Y\7B((M3`G294@
M3)9X><<T65X+)B!.\SGJ"3Y`]"E@1#C-KJ5/"?%_%F%A+XZ"`LS&^:M"EP\_
M+%`&QBF(FDMW`D*N`DJ\O"JR6!9HA3U1"3WQX"+_%"@B)0KR)(QA?@]<@.EI
M:&+A^7@.*R0E;+H,G[6*,/'R=K^Z":R'OTZ'H!'B*?L</["H!'/DJ$9]`M>H
MG@H35Y4.A'UMJ8%C^TY7Z=JZHYAVOZ/X>M=4NF[']0._VSDQ]C6GQR*2S1PQ
MYIF%&0<L6(4K:)&KCX!<[;P?,,0Z+FK'0?`!ZAU?WQR$`;&PFQ*`<>J!"-B@
M$!NLKG/TU=TU8="<9:ZU6+OMPE^"?'?:9;Y(^=;5=N'/7KZ_WX.G'F)0M'&+
MK;>(ZDW-@M0M8?U>-5QC%\;6.ZU4;,&AYXQJOH\`X&)H\2O'SA-@Z91PI`#D
M_N.%AF/HMAE8BFJXFF)V/%_IN!U#<3S+U#W?5AU'.S6(^6(^2M!&JA"'EJ<&
MV:CY&#_'`UQBR;O+&.-0WA@B_YH^AR,,["\-^,C#O`F?"WCQ`4.>E6:3-)%R
MD#(!2#T2XP\KX\\8)=9XU)X4(J9_9CE/_,S?$-C3\UJ]]`7G?E:&[J&)$0/Y
MR(JP??$^%9Y'O/$0\<;AZR%;>B22HFQV=PTM_#6&-J9IPN#IYRI@.@XLO9V&
M,<TG8W<S^#;-GJ5P,LE2T">8AQG,QO@U8F%S&*=IF-V!P/)45$K0V/#T[VR`
MN;]QT=<<7KN:`9G#>D_C,:=']7F,=PN0[.N2!R3,D4`CMVRAG;P`SI0>[UDB
ML3!+UJ4MCB%[-W-^SM)H-I@N;1/X?^D;RQY@720\&'!BMO:>I[-J4JJ@(Z47
M)GP*M'BY&#-?=B(SKC:N:)PC$'L^"W."^G_`;-*`"5C_!)8R`^7.$X?L*<Z1
M6R(V@F>!N>XI,S$'>@<F+CJ:UQ_(,+E!.5""?,_P1^AR&#_1"_!ZQ%`"XH3B
MUSA8S!$`"_*<X#,^#0Y%GN(#SY1O?&-6Z]4M97$'VK"C'2^9Y?>LP`A47U$#
MQU5,$_[R;4U7^OV.HP5=UW6#DR:SYAR78<J*,I*4EZ*3`]4,E[AR6"1L,Y9/
M8$V!N-`(!_ZO42KK5<3N!D#?NVH+??].C^("@-I?A,G'E.*ZI/,^8BTMZ5N,
M_/WR4(N1W_SXO[?&/-@J%'*F:?SZ3/;HN$]OB#SM8ITO1YHP!(`/Y(<*,7F!
MUO6[EJGH3J\/5KS75SJZY2BZX7BFIII&WW'J%6+RBI/$)77J$F*:#RV;#XT"
M#',OA`<BXHQ./X*K.**P`AV1O":'Y0,6JX./=!QTR;LL#S\O=(!0=M(_9V$&
M^]H(CW[>@G_,`R&\7_A;XFT2[!WZ0'1\-"Q/U4+G\X)[:X_V86NX7\H@1Y4F
M,.:$,=SI<#8J!\=];>%3\YF_S0E^B=O7'^T45QWNTQ$X)GGPSQD0">%<_TZ!
M@&G^)?N*BB+?O]`XFF=U#=M3>@:\9G9]3?%4SU7<CJ4'IF%UG;Y[;*%9CK7$
M>3X#WGH4Q$#O%J;_^RSA%UGH[#">P\?2;ACL>`"60X=W%`XHA`(L(5%9N.RY
M."U>MD5'E2_TF*=K'M0YMHWW.\?NZ9SC<^ZZ=0Y?])U^FXUO659VGPYIH\ZD
MG\0("B5\UA[DW\EGXG6_*W/W'E@6WK&E;X,GE@WBO+*[WF"(^3((-!_`>MI\
M96.>#UKZOHM7:WCQU[*)S_%P+U2[/+^]=?,7W/POLVF.U_DP([#6[C6.[O3O
M>BY,4W79UK;&XVN8^V]>;P\]V%3`'_/:W!KKZA(/>;XJY&8KY*V0UVR%C>N.
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M3.`U"&IQ1X]A;2X4(644)TS`WD`+=#2W``K!YQEF7/!L8WZ].$2"Y.`%4/E1
MWOFIMS90OQRHWQR)=[3W1^(WO5(\LN$\V1;-[NO[DW7=@"C[.S;S2O`S*,3U
M0#UN/CEWJ<?EUKVQ/L#])Y7^LRFZO4K65S2GMJ0YWW!<=UFMKNGT;Z3NJQ%P
MT/OEQS@I_T:4GITQ7_=*PYJ<,CSNG`YPL/#\?/3/X:W$"BOX$#S[NC@;DB*=
MCO]>=0@[1SC?=DES/:_0]F<.GRGNRN'=N\*E**Y='E:>WFI*GH:?/MH[,=1N
M:.+'FJ-A'&R.;Y`5\T#WW$_.>\LR7+W"7IH'1X*2V+G#8_#FY5&M^=;9YMI`
MU:B2C`>6&[^C;)F),!IDA&TY1<NIA>UUT?O)\4!8=N^Q3CO*.='ME;M&I[XV
M7_4OVFOS6UR;GRN_13YL[\6O_;X!T>9#QQ?;2_&GH7OS;L2W4>N]^46;HVZ]
M-9O@KJ[1L>Q\_0AV_D5-]MV7P]]Z"JBLS=5+!S-\X/OSA!V[-)=Z]>O-EV^2
M]U=>G*LZE'*``94BZC*\JC/Z!-O2TW^Q_97DTGS=<^V.H?3\?J"8JFDKKA_H
MBF=U`D-53=_I63!2_>I7:%$S7,O57#[:M>-:/)/U*7F`G]/L^6#7ZWM]K=>S
M'27H>H9BNIZF=/J&I?0<7U,]5^WK;LT0'`N2K`(AGNP(5F5(ZZ[32^"=<*Q"
M/(Z%T&[C,/N#365^R1F__%!BM_$23*$TC+-\JL2)+/Y*9U-^<YY?Q!<N3#P(
M1R->3^DA9H^YJ'HTGJ2B8!+T&M/MZG*(X!"1T8]`AZ+@$;:0WL*VS+"\4@X#
M5L;I`^$Y9AS-\#$&5VJ6(.H=N3#QE(UA*)^&E2^A$?J:B`#-L>Q!8#@20AY]
M3=?S8:8)(BW.<I97<"&+03[+?(I4!XH3$PCRF$'C2I0^4N6P$J"`AO-`59SF
M5;XX<3CR'M5U&D_"."/D/4+,`X)6<!/?`Y#XM,@T^'G)4WUZ@QMXA%I\?T=D
MPB$OF`0,,<;+G40N8HLXG]?&@B6:9.GM'#.07&IZ#UH!&B7I.!X45=?Q1;0I
M"-82EH'P)T."B2@+B,%[,+*00QT**HA2=K_/HCO\5JSP()S$4WH]AT$P913.
MDL%]R0C0$HH'_ABG&:\8MX+'B4@`"=WW16X?A@/XE?/@-/R#)<18\.9"+3"Y
M4DF-1`9A%X$[\FDXG>5ES*#H#!HIND-J8=4Q69JD"#,*5$7^8E',442A*ZI:
MMOPX-)'/8')A+N7AD"%@1B:Q(9;H&SPC;N@T'L03RI-F+`<7"I]-,&GZP$8I
M[<$T%9!K`A[-.7L/TMDH(@8?"%[G)0=IE1-1I&^N%68)GM8DP;HE^8-E>X@K
M"!ZKK$+EV4AAT=E1E#!$HL1SG6DVA\8<X%V&B&!!:%CWX0,*^Y3#;'!BP,QN
MGX6L]WN>7*XSC80@($8P0=!IT`<,(2_8C9!;JRBIA`4B^BX&6:K=_$4*%JW1
MX,LFJH->-^`7AHOL^<8!\Y4IWD>DT'#P!X@(+H?0@$MM74LW)=,C\@CR*HRC
MQ*'ELD'*G^?7X=')#&8=HEZ=5\\CE-K)?9B-8?EF4^H!V@+!CZEZ(+$$P<Z&
MR0S%9Y8))%^.,[JTP$M;7$EKE)$7J+WJ?ZP8GB^9.DLG](=#'L3[E`"GLN_A
MTU<8$N*2)@/@8>+8+[C;>-'OLWS*)7+_17'-58.UKWF^;]N*977ZBAEXIM+Q
M'5OQ=;NG=S7;[_N(4\3/Z$.'1N64_A9S6K9N^_&(95UX[0[9Z\BVK7/UZS>@
M"XQ`^LHFB"`%["-*/59-W85!+B-)<1["RPDE_P@(JCT7T>T$FJL[L$J!Z7N*
MV5--Q;=]5;&ZOF?:JM4QS)K9O%^KVJQ"G[H8P%]?TK9\\T:%42I%W%T%RC':
MOVAD\-_R4JNLQ.R%1?<VF*976>DEO*8-R&@'`BFV`]`/@:J#8^L!+YJ&I_B:
MC0CZ01_TB>\%COXB+^+?-P1UOGRM8M.EBM->>C@P="\V_]X\P<&+4)ZPZS,-
ME>\#NK=-31R,WLW+3K1XO2U>[^%2,F*3;DH6QG7K<*+LK&9[Y@?[J_4JCL[E
M.Q]2UZV=,*EW.XE__.EJNS'\KH?RFU9\[JQ*,K94;(_6OWZT7M@K>SE5?ZQM
M_"BU-6LS6T>MA]'2-&5>BTJB9Z#.:T''S5UM79'U'7'@]R>GO&F?81)Z]`TS
MS9CO6GCX`+FJ3[_UM\U6J5>_JM>&J:K_S]Z5-;=M+.OW5/D_H'R=*KD*8`B`
M`,$X)U5<<Y3KV"I+R5U>7!`YE'`"`KQ8+/'\^MO=,X.%FV1*(@&*>8A%$IBE
MI[NGIZ>[O^^[K'I@CM]/M$\A!A/C52\07WCR94$K-L&;)OB&GNQCA$V%[OL,
M?M]G6?KWD?#[9KR$ONAZT5\8#T.,[`9XF7\>Q$E$L7'Q,]^FV1VSV;?Z(\UH
MFT.M-1@U-<<9M+7>R-"[3KNC#UI[QYIXH(H7T$<A`N%M248BI4`C4A`5N%B[
MPJ@`-XH6`A22X$LPR"4;M)</NAC3,G;C6W&S3W]B&0M0O/RQ#`AE[BZRL!^.
M62OC8&0=,&J!_^2+,!$9Y8;C\O(R8R+2A((3[JFN4*Q,D=(4F@6M3%(F8V/B
MVS!*%'@FC438"7Q+J3K99!YST_<H1B_+1@\KF;$X'K!X''ESTE;!!.OBQ9^G
M%QC)`/H>OWV!4$N]8YHCR];:HZZMM;HVAK1VNIK>&>A=V^ZW;6=P2#S23%"P
M8**BR_`U+#/^09%T4Y7N&%@I#R[L9HRB$!5Y9$Z1DELD"-W7]]>1KUZO^*WW
M!+A=U@QREC^MG615E`)%SO6\\'+L(;ZP"HIKW%#.\O7J?\!'\L^##TH68UE\
M2H1H%!]\K]SQ"_HPFH<1]^W%,)Z8W7FPQ'WQ-=$%PY^ZZ4T:%["=.UB[MFG(
M"WPT`$C+]O&@ZTY"$;QZY_*P):W4DW@IEB\-F._>42QIL)1(Y/`2N1DF%0+^
M*!@K`!H`%,HM@W]NQRX/?<0YHA2/*=*:@E.@01&F0(J5Z\E"Y!M52I2A8=-P
M3/%>\PC46N3Y"WP=!YI&,*L;C*="]>;%=(T=9]&]-)XIC]!58G:?@KJ>+.*I
M@#A2R^^/$;`J$M%V&&`;3%F44%S>80"\UXB'$/!5\:Z(5)1C3>5>=BVDFEA[
M&D8SRAN-PO0&MBL"^HYB'M;H@:F?^FZD`"/<P&*<X2H7)>8/^KXL,%F0Y<<4
M-C[DZX'GW@2P)7KC>)UP\N?*C>"R_[6(O'OEHA2H1V&CJTW0H^46:,@3'NJZ
M5EYAG"XT-DO]Q-/BA,WE+.&W+O!VH7Z;;DOYNJ)]^=:+,7:<,VIN>Y"@\A"[
M+#YW0TO"-&%""X&L75.H^]K&@,,X+0A\G8>OC]E<S`)>_Q1^8Q3OBYN3FK=&
M\?0)MYF^,0J97]?!FU+$).]*&CRH^*-<%_VQ@1'H)>0Z^;S8(DI+0L/_`V.1
M<H(8)A%$YR#N&$^IX@RAJ;D;\9`IKK"ZL[D7KG##.EV/#Y8Z1I,M\FY@YJAY
MLBEAAWRR2Z/.I`%)S9GBS0^<F(,_S@M;S=K^"S^O\K0H\;IAE;DDK%]FY7<W
M2!'<C=:XR#./7.7"&N.5%76U1TUJK%CQV\8ZYQHUW_\DC4K4*V9U"+8%&@LJ
MRMC]\A(CC^8FVDKS"F9[D7[@#]!A88JP>125#.=@Z),A>\*S8I!TO@`NQ601
MSJX1!:0K5-!><_TP8)OD#I40P3H2/".MY!<>9(_3NM3^&PQ,V/7&L`&"H/S&
M`G0CB),9[9K8"`AM?FJ[S)I7:0;P>3J52)<XU%[JPT@Q1`)V^[&B:ST=V:E/
MH8E@U?L\F0$>^&>FYM:VWR@\X"_437Q=CGP'FJ%@3XB<RVN&;;B4L[-0[EC$
M7[ME/HT&#!I&I&6*SVZ@#R0]GK[`Z@'KA@16JJ$"&Y2[C]E-!"\+.VY]DS05
M*2RX'08I2OH$V&><A7!"!S),4RV<#HNG0FB%.K\M4&EE%+C9E!46;M778?@W
M9A.A<L>806X?(;<*&Y4P/<<N+\(N#$8J.GV+`3%\C#+]A+8YG@^%7"O-,,5W
MK\.H<-;-7L_B3_$W_K(;AP$=C65-:XYN"FS.#\"K^T>V`@T4N6RT&SM-P@3,
MO(GRSK!;Z,K')9=0IM#".\,R"U^W:"LN4",.<]9R06S]L10BS/@BQQ)*BGN?
MU<'@L;E@5/+M#9^@W]<OIJ1C4=-GS!,Q.+D'I0,&!W4]BQE3Z/S8*I\?S^6(
MKMQ[%K^7AL5:`9J$Q+_28G"+NI.2-KAS@^>Z%?37!N8#>WO"$SF(\:AK9-5<
MV!_0S3-W(00JRZWY)C)0\EPIC%4&RRI>KYI)]'+M"&]FPGRP'>F!DR#/[!#L
M@IF"W"`"0C"9XQ1OW-O%VL6K&D^"!@,)_7T>;)8FOS)AU$*Y?*NR6GYVY"LF
M%.%I+X\L5W.5>T/[%8I][-T$=/8+$JE2D6AH[QUFTH2?O`%I1A7&IA>+-*!_
MA>27(W`*CJ7!V=W1&]:/Y!!9.6R%!3P;/$F#^H@1BN,PL_V\P6&@"ICA@!50
MAGFF0>Z)H'RRF+1?YH$H_*;"5HUY>]QLR`Z0?+JPV_B8)2G.A"CH[OBV1!%%
M4)0G==&.Q3BI9?Y=]B17=]0"=K*`.3;T=HL_38L5E`B_<DSY(L9&J"C0U"6.
MKF2EHS'AB^Y13$&=RD_"W4R"#ZS1#<`>QP,@S_$I)LM17A)7$Q$WJ(BHG$@R
M)>%+=M"FT?"Q'-BU(1U^J`_@<,$=&AEY6A\N(K`L7#C>B%R;`Z:8PT%R(:45
M76@4=RP/_&2Z^Z&T?P*^J6?)@&A5@05&RIGS_._NO_^]Z7"YZBB\9)C<M<0W
M%VD4IZC?9,*K[$$,4'8^(2.7;(R"U43>P:5F48_(=,._`TST)C?ATB+$Z;H(
M&,?Z\8/RU_#+U7F_^U'K?CS_[=//BHR<D7I@R-<.6L!OE;.Q"]W-W&L\?3.P
M$A)OPMZ7KE%8E+@>'D<31MM6RA-ZJ40&I[I`@.6VO#ABR4G(3,VXF#N*#]V%
MT=\H6/`S4"W&69XEX0U#$Y';O47R%PB0.>)+B\%//D#D=$;DEL,6DK>.S@53
MKYP+#4PDUXD?M58FDY\D77%WQ#V>(FFT,-JC3*Q'\T'R-AH(8R:3K[*<VW0^
MC8`O\'Z-1`Z^?J<WFLK,\WW0,`WIQ"<SGN2&Y^ZZ"Y)=<0`"5GMG\3B?[*8.
MA1<6=LK+V$W<!:P&H?L`$P8Q6&M9,G%A&30I=W(IB_GUN'[O#%Z+)NL&S^)L
MGK`RB+:T%Y0S[O",F/`(\,V2,C_Y`40R(*8K3QD9_/F$*?L<Y^K\B/LL2A"P
M#D]O+R7IXS#0+82U'I#7T!3'`P%-^/,X"<NCTVET;95\:7P>H"I0.\)[]]XL
MG0&MQ4&TN#1+)#<:%KI)Q5)QYTTVQ*4!HD>9[C?I&O2=+8YR!)>$M,5;`7)$
ML()KA;=)Y[_"#>E2RWE5C(S7L#,872L;6\6L9W[F%>M6GHWD3N$(*2MU9`*9
M;"[G2HGFL.,5'*>2^>@\]4;B1E6HAN-^$BAMYT43*)T=T)^VY%P^S_>GK+J-
M26<YB%,V`@R+(`LWQZFG*(D=9O7`2M0R-ZW^P=O;DW.N1+RB,+IW"L@\1$3S
M_LOAU9G_JL)M>7SLH?CMJ?E0NFI5!=JG'JQ77=7W6QA.\'11.QYLMRK!@'7+
MYC@EE55V7[BBX^U25$U=;!%#-3M/2@E^M1)9B;R@EY+)\G&G<)[ACQX`#..*
MJ@HN66!9>4>1E8^7`@C/[2H)"Q0$8-U836L?8Q[Q^_)BR0`>`88.(!H=6P\=
M<'+_[,']LZ4B546*6+V(TZ'.5B^(A5V7G56W]I"E?5R6%-YIU.Y`4Z-UKK1@
M.Z>5?Q42WCFM\^N4<*-Y6OGCE_`KQ+^@N(7:K7:[;55BM>OF"3GY)I^LAZM\
MCE&M=C4NC>HF%R</X<M[VY9"G2D[^R(*$?-DYBKG`29!KTO>/D!UDS1PTXDG
M@A,U&EB62B.B"S%YA_GA73&'6,26B\3$I7A'?M\@4B6QG`%B8"FW\!>%JV-H
M6CJ;R:0XRFSX/?4+L68\DM`4`%UN`4HD"94;S/X1H>T\/):2RC$"$A,]))8,
MAM#S%#K,P4V2R+M.N>M0QDL7!BF3!;*\F6*?2U'3)<<I9:5EF9XKKN#&*HV5
M,HU%LI4(VW^#\:`+F505W'!\(DSN);2B'/"(*K[$+F+2Q"+]'=.D>*OHG94.
M720V[DC9<(OAP92F&:&+TU^HH@9,-M@W/ZP9+E(U9PL,DO1R;L;8;)&PJH2!
MOQ"Y.JY(K`P8XC#Q=)Y2(A=,0$#UN#S".\_E0OZ:9^&H4PFDQ!.19:KV'4$P
MY?D0WE2$;A:7^-:=*.%8`%^([J[14QD4P78X;EDV0V@CP/3!B/$DT?*P5S//
MEK)YQ<RQE8US9Q[E)6YMBR(VY4_$W3/<"8LI(.-;CV$R"TYSF;OQB3<_K,K=
M>JG;?]#X<2-B&"?0[J.*)=T8'[H1BSOF-VJTS9TP+_89G7O"O'@]<<6G6+PU
M`4`B]WGO7J^=C_5F6U?UIOVRQ_H*S;=MVJIN=DYNC-?LWCM1<5].TJ/<A*JR
MY8@ZR0=(03C4<Y4><_TMG.TH&51K'`M,46JRMERGH%:W?+KJZ(YJ=VJ'G_'4
MB1MJTVJI;>>%+;ZZ*=KMG+\)[[=V;&^J3=M2;:-V]O[3)]XQ3=76#V_XUWH+
MV`A\K66W-G,72\6<45$\YWWM)$2W;+7C.*]-/G3#4BVG70?IJ(HLR&*M=/$T
MF7F!%R>\,&SMF+ZEMO2VZCB/<FT>$]L;JNF`&6@_RFE]:,:O[K;0+5[1HSQX
ML[GK1;+@T,HU?>T$1#=UV!5>V'BHX+1/J'LG-]^)BM6)*-V?PK>V`V*'L8`Q
MR*-F:J?4SQS5,&#5V_JN"JYN2-BVZMBV:ND['V^>BH5]G/<!U37,SJEH;IPH
M9Z(J_GM1";]^PJKK+;73V?F$4C=1;<%YW#(/):<G@^MD<-6<BJ]V-]K?WK/]
M=OH32Q0_C`E;8AI&K(#!4K_=QU%-T\++D]>R_]AJ1S=>S#8^=KMKL`9WZ)H%
M;.K5[\[0,($57MT]N:.;JMTY_(7(R1([66(UI^)QFC5[U^,[ACRCZ:+KJF[5
MQ739=9ZVVNS`7-LOXR(XJ>IJ*YG73,7M/94Y=R4I_Z>)]PT__O)3&FLWKCO_
M64(N#5@\CCS")^X&$P)#_SPM0J%?L?NDYX?COW^%MI1?Y/M#RA7WOC$.@GGE
MWG]Q$_:%(22]YWOT:O_6#6[@`6DHPT,<MO<OUT_I"804O2/47$2C@9Z^L.D_
MWK+0_WHQ;)NZT6IIFF[I3>T_F\VF\_7R:O#5M*VOF('6M,WFU^9;)0T\_M8\
MC=A;9<+&WLSU8SR`*][D'V^]R5>[9;4-W?S:&^G=7L^V-<OJC+36L-O2.KVV
MK?4,>V#T=;LWZK6_ZE_-M[]JS8;9[%@YN9YYNF5:$G0<!]"+A_^7>LE"P,K1
M#P0IMSM]EFB@=T:.T[<&6K/==K16;V1KW>9`UP;#MJWK5L]QF@.@0?/MKP)N
M4-D%93#'&-P59'`SQ.`C,0:_`V&00PR^+>$*<B2_M^\;.0\\8IF^7T8(B1DD
M[V,X=OWL.19722#TM[\V&TVCW?D^>=@TM3*1<JP%+BPC#\;//N("7X#V&R^>
MC?7;@U&[UX&)MD>M+K"^-=)ZW:8#DM!W6J..T6L:(\[ZJ#*%QEQ6UB\'P8;=
M7$M5SZN;N%B9@ANA>3V3Z[7;P1XJFW!P<:RN$./^XL6WA";+!ZE*O#A1^(%#
M<6.8T!3X`;Y#Q+0W"&+FB:(?7L3C2`FL#X58W%Y1'050*514@M?Z*`"*90C%
M_XMH;`'+^Y^PA$4SJF%Q39!S7C!AA(!($/2R.X*'F\\CUXM=7\7*RQ*/CO>U
MU"Z',)?E2*#--S^LU8+`=WJI/@30H.>%EU1GA.65*PB"%X=0+F/-%>G,]:AP
MQI^-RX88@.*#)!#5":KPGG"1?%!I.C2RH#QXH2_OYQYJ-P]!-3%ZUV@:AD1Z
MBS/`4@'>+&8';1``F^EP1+X[5(TY<GMAVILF;;[Y0<EJE6`G$AT:`\1B@3C\
MX&2),;9.UWIPL@ZV(D1&,J.<-:^K#;V]MLK:#]?AR`X[9;NU\/YC3S1[*YU]
MP*Z/M"S$?S3IOT>53%A;D>-4@^-EB%V_`AS/,;L7J+Y1Q^NG[3[*HG58`Q>E
MX^PAS/AUS?:X?.X?$;+>'8_36<J3S-RHD'&P=S9_\N6Z83T);:ENL03ZTSC^
MJ7[Y5AW\\OG>N"=W\I,[?&$3XM73K_Y&RO88F0OIG0G8_H-B=MR[;6,/4`"5
MF6V[(NE?M5+@^ZOW_?0>JZG"CXF"#UR^[@-_L+M(4KP80]?>I.SR+-?6%DYV
M])QR-VP\YQ<YZ(*E0LT50A]\T+M3!1>ITSS5(CYY[1YVD6+18BP`NPX%]#E.
M:2>ZG[RE)V_IHZI7B$VP+@>2]AY@NZLSV;T?1PYBL)T`HU\6,/H!FZU=P6OM
M8U?!=8)TWH?*/:[KFUHB.M=GF2LMUO4#=*[/PE=HF>N'YUR?9:ZR?-<0SKD^
M"U^59:XQFK/1;E5BM6MUA76Z0S]:'.>]7&`?FSR\H@O)U6S0!Y.PRCE;%Q%6
MA$P6%[X;)-U@@MEP5"(^2Q9]MJ0MR]2''<?J:I;9;&HM:VAH3J>G:T.G[0RZ
MW9;9L_K[3MHJY$2-O'M*6$*B47Y/=@?K)I1WTU"ZN*>*1)BY[XYY.DW,HF_>
MF*EO>#;3=+F="9M#4QX%0F*J[@T]AL7'4<PUWPN8,F/);8@(F)15P^+$FXGG
MV33U>2I-HSS$<EY,YD!\A9DQ3NM%$6KM+?>LFSR,6YR2>VBJ-EW7_J)SPP9>
MN-4;2EE^\;Y/:3W/=97[..3951K_2=HZ[Q)WW3C_Z`7YWY0"6:GIU/CJ_804
MO%,93./['J]4U<SJ.MD^NM<*DU;T3B>.9]Q]\,$IV.]RVO_US_.KH79YT>W#
MQ`L'13/O2<O_Y!*/[^_K>/=4_U&GEIEI=9CU<;E(5S+4LD/:01+4:L!C9_;+
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MA=G^(Y_F;L/F4Y\P[^=AD%!9^AL/(\6"Y),[>P*TPC)T0,_H.G;'U`:]T5!K
M-5NVYO2&AM:U.D.SV6SUV@.+5XOO_L_5GTKO_/-E_WSXJ3]4E?-/_<8O/VT:
M83[^+DQV@A,NP%(\V_A[[5Z_V;%[FCFR#*UEM0S-,?M#S;+U=M\9C'KZ"$;_
MU7C[*T=RB+%.^:<P88JNXT'F`LMH9X7OE6RL\(QB\-FM&_]RN7M@Y3$L\Q<6
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M\DZ@D3O/]Y5K_DA,F`)!D+J^OZ#'[R(O25B@3,([Z&&J>$!T/HS/B$7#(V.7
MJ1Y>)ZX7X%K?X/5O&"UXC?IO`N<``4A8!!:.CSX._A*2^!IMTUCE,Y3C`K+Z
M,#9OZC&"0Z"99A-+;MVD.(ER^7R<[)I@WRD#*DZ+7`1-(/K'1'1Q#:,,@S)X
M`A^F2E_R`8:I/X%.X5V)Q]!8-=/6!)`_0JTM:T*!"#+PXK$?QFG$GC]\W+#:
MPU;7ZFMV'UYN68ZC.<U.1W/:=JOKZ%:W-:R&`J1]IJ7D@F]^4#B%%`)-V:+J
M\`!T?QWYZO7*R6</6K`;`Q>Q;UZ8QB!=$UC+E`0.-!#-R2C/Z3*=S5P0'=`#
MEV!+@@",P0K`=L;C,`T(/H2XA6!!"LR,)2^\8.RG$]YX=S;WPI*>%+H#CZTD
M&8C'&K$DC0*,@@\C99Y&\S#F\!+0<HQA]X$;")&-$:YFQJM5;E3%"6'S8(`^
M+,T\I3+%(/L1FX.(DFY$_:<4M7[,0"]"TV(LQ0T`%:H'@Z.Y4$/D8)V$8%DG
MRJT+5@9J=9P(8A=1,;>;B-$H&T2Q"-V,_D)5QBC1Z&V%9]T$-H5K&!S,A#5N
M&IAD$("F#*412=B&RMB-HL4TC.[<:`)/1FSJ<V0F[K3=0IZ9"PL8T3\X4%11
MWUS/I^,W:!J<!.@BKFI`"1#^"FFTU4530`6S*+[UYJ@`0>O'A`%%=)B"PD8(
M$3^\4YSFCQF!H"%@A@DKK3853UG3?NFA'*D7VN#KP1?[(?+`=#U0X]3(//)@
M\MF674:_`M;Z:Q%Y]S18@87"=6H00KM@5D8E>F$CG&+T!G>6R^BB57QAON5)
M)8TH*K`E8`H(YT*9>X(07!/D$VC%^P8[0"!`=Q#7)J(MFTBUJMHW:XS[LL;`
MSTO7!/>/\,'O`4CI?`6.&>VSU*>E)3:!?=M?X"=DZI2V\HCL,(+W^5<:>?'$
MH]T[S@'):(T\K@(FRMF(@8TBMGY"NN+01'WTOKB3\#T0'HX*49Q7]2DL(YH-
M8((!OYR)(;X74B<N6<H\G,EA00H%,E)V_<(O-X00QZ*IJ`3(1;!HY>N8ZEW&
M5`47YVFW,48%ZPL=L.O3E<#6VYA"N@?=R^0?3Q<T1WI!<[J6.5W+5.%:IB<L
M)#=1IL*B*1M%>[^C>7H4=JOQA"#L'U]ZQ%6?XW'E;)!IKO+SW31C<6_EB%`_
M-C<:[<Z1<[G1<%YHBL>NU@F26N/^>O14L2"N)XR6U;#T75F@%DRN-YQ'F6;?
M/<'CTN/\2A:=)'C%(Y#FT??A!N/ZV2AFL]%YU#FCMFQM&`UC9]W]JE7WY_]G
M[]IZ&\>5]'L#^0_"(@OT`);7LN5;SV(!7V=[T3,==+IG,?NFR'3,:5GR$:4D
MGE^_547JYMA.XO@BV3K(F8X=B605B\5B5;&^8%;`&GRU:JUQU@)],`*+=(-F
M=15<PGW!?0G@)?+N-;KZ+!T^Q]M,ME\&3=+5*!I>2'].K=HX=W>.`8?YG7>7
M=Y]TB[:]G-FEOR-O,&?&O;Q?F1P^S^*@#"*.^364&L#FF#WB+U7&`&5B)MD`
M&,*_=^-LS2C/A\-K@@+ZZ>P0H#S)%9!)2=R]AU:BU">9-4!YBT^40$CO,=HE
M*"]*)$E9R<B@@?389#X$NI6("LPHB'-5XB050:-QN'7''1@]P_0LS)NR1`1:
M5*8C'"L=H6V\/1VA<[ITA(-W70;`3Q\`+T/A>SAFY->+-0A]S#/<G,3X7,4?
M_"!RJN=R/>;S.N_&UI:/><<A[.@SL(%T6/SSH\O;KB6*ZA=TV?08Q!8_8+!=
MYGNV[8<@\NJ^CCB^8GVG^Z/]KK*)IY#X%\:Q0PO/N9*<5]!D.=10SRB`O'V5
M_'D&8>./K7<!716MG*I1EE-=MT8N(7!4<O%8X;=\6SXO8!9Z@>5H]DM'S<+I
M>?,(Z)7YH]K(!VI=J?=+O5]P+I9I%R?>F+YX[CTYG39O2D+[F`J._5*Z0_,Q
MYN*;3-N/P7]L+W10.%.I56DT"EF=[]TIY)6.F8_Z[KG2R]NE_U86Q$H(-KKM
M5.&EPDF_V2R<ZW0O9'?*L,'^0V5.9+04;AD8S<XE+@.CA'![\P8PLWRVYE[D
M22H27T04*7_+IE.859/?S:.7%!I]L0AJX;:3C_5*N_TN9V31(FV');AH6\C+
M**"?SB.<;%;JQD4!=!J53JL,*J];+Y?@%B^Y6`:57QM4=M[LP2^@^G]7F+EH
MNM\L%?^EJJR2BV54^0Q.'G)GRN5^M$YEONY*P"5ZL':\+/&Q?KCTWS/<PL[L
MHGO)QT-L8_DK&$`X`S-+)'`.SZN54GT`_"?!`Y#P`RJU`X$+!$<L(_P/P9!5
MX%DVG\<8"/AV-A$$X4(L%\$DN*!X"(&!!!ZV$?K/'HZO[\._3#!&#)R&0>@S
MQ)$:AH17@@\L$7"6K0><14BJ9H+!D:XC`(U$^]F2X*?@^]"60_J'^9Z"HPH7
M"M3H.37!+!011YG`R>1BAO@8*)BK[CM@X!1V46H`\68D*3BJJP]KZAM4$?E&
MA/:L(MM?!?F0LY=%'%F=/0E+07474A-G3>'<N<(X>'D]ZZ!-VPH%TT"F+`D6
MB-.G<J*=I1:Z"I;EBN!Q"$"'X%A@!/CD'&8/^/R3P;/PM4N(+O1W*X;/4$!4
M5UB-`E;T/^LPH8ZQ-#Z["M`KDBPYG$A&@(UKZE!44JRY2N#%L(P%PU)[+_)!
MX`12*0TLP>%#&R`S$9#9NL(7Q"X%C!,SC`IO(`@)5MV(.1F#QJQKAT!N%,9:
M(N;W,"E25'"]3R,YA?=HHI7`3>3R4_4T$A238.9AR8X-E3U`F.AE1N!ET%Q5
M^SV1JX1U.`YAPU(*'9)-3"'P%>!;AI*405I!U)._I5+)CADU#HVZ(G/18&';
M/V%%(,]#EUZ6X#B(G.)8KBNA6[":U3V/4%OFUL](*J2,2)"D[RD$J3OF<!BH
MV##CT`A.6B3O:N:HQ7CAQLA1"8O2#(R1EJ1PK-,R!/TR>=L**@ST3IK;N(5%
M];9?AE?"S2M5E@:FY-IH5PUM#E-!#(3YOS9J53/YAF;CF5:$=D@OX@MK5:99
M216<D5,?P.88WJ%L2CWI\#D/++EK(LA5!N`*EE(BOJ2B"2A4[A[/1%H5W(G?
M?LX)7!E\2J(7!IR4A1Q%ML5H82?=J[5=B=0S%IB`@<#.S7TF%T6]UC"`0-\+
M[V?XP:R^E``JP<TRW&!/UARAKY#ILBR1W)C@ER4]'0_;9_?0A(/!8)B:2+_*
M.D81L]*J2+VO-!HT@#)SQYBK(2`@?+Y;*C0"%D%36G-$B4L-$"'GDM4%RYHF
MC\5X5W]\_1(/$!O)H*:E\>741*=:3A..Q@X!?T$3T*1(#=J2=H#\.LV/TVR2
MO?7K(ED5<@T$*TL5+9?8VIH2G?<^2D?HJA)4_RB=GBA#/\8JB[';I`$)FY;E
MH-X^$0LB$WIN@;&#0[W#L46@F2)32"OE12'9$G+MQD"#9.*N!>#J+18.M^,M
M7,KY6MA`*P$W7"AP0YJ*>$05;>8]XB9:H=X?/`?W*<+/>T)044'(J7^'DWO:
MB?'=4'X'FUTX7RC+42')*@41NHK(:`>M2&0X:7;"9DLFJ]R^8I@R0="?T;@(
MQ@_4`W\@LSC(@(_"J*>6'7C*($A01Q-#03$2J4,FA`2$2&0E<^%G:$#40S*5
M6:QM%I8(B$':/)1ZX\77;2H7+L$9\478S(6'EO`RVO%IR=H*Z!G7OH1;U+!5
M7T(>(BRLC89^)$XTJ!D70#)B[T(KJX+20U2]JXU`E%7M!UAS?LJ.B^!6:"Z3
M?8<LB?02C8X7P8J.BG988$,$/9<]<Z24F#RRR1TK`C%4D,!2+=2R6R.JR_]6
M8JG=PU?N!JQ$EE:'J^=.92\GF^7*`RL;3GK`KT.>W0PCFP6<O54&*P*G)YE_
M`T\$8\^GQ,`^'BAOK"6NL33Z>@_V%[G.OTZ3!U=;$7V"IR=/POZ1;(<-TZRU
M6Z;>JO7;NMEI#!#$=JBWQ\-1H]=H]YJ-^D8D6_Q]'5R@(#16T.SH25B/&!%E
M1J):\9)CJ=APH,]N,V4=O_W6\6N]O8Z?>;HZ?@?ONO!U_%89]PJH0&VTR1^T
MP^C.CZ-E9<2R,F*^\XN^;4B3/F']KE,]E^LQ%RUWX(6++VC>@=E.YX!2PG(Q
MYN)G4C:W9\J'WA,_OK#MF%UAU@MYCWQ':NNU5E%N0>5%G/]<^OSI^*KSG7FO
MW4*6DWTOU8TC7`@NOOK>;JC^IAR4:*=:DSEW.<5<$::A-%5S->:BZ=G25"W:
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M(]SAU.B![L=U^B.S46LV]&9MV-?-3K>F=T?]D=YH-EHMHU\;P,^;[\?Y;.H`
M04(5&TF3$=V&N_J0NC,9W<E_?N_MK.^E=>IOOY?6/-V]M(-W7=ZBVGZ'+>F=
M+K,E'\L[;0>;C=/>:3LZ646YR7:6L9+\>CWZJJ*9%<25$V3]!<]?:EB_X*B&
M^@Z&^3-#_&/#K+ZC)NB_'WK$>:>Q:(Z5[?)]B^5I*E$-LDC$GQ>0+)Z8UZOM
M[IE+>;W:.1")YZ[6;S<4+RF<F#>K36-7$2B$D!O5SJM,LS<3>%YZ?$"%J;"J
MU,,9`$TU:M7NJ\X9A17K>KU:WUEW7[3J_HHU(@LGT;5JK7'6`GTP`L\P5?:L
M$N;W)8"7R+LR.?;@F\GVJ\-Q_$G6W"RD/Z=6;9R[.\>`P_S.N\N[3[I%VU[.
M[`;!D3>87'!O>U=9F=TA\O_VL'LV@/]YOK"XCTD!7_TA%PM/6,[7Z1?/O?\"
MC4YZ!$=Q@X6KEP<H;%L;M\U!?:37ZKV>;G:;;;T_:K3U7F_<,,UA?SRLF1L#
M]X<J)M[)ZHB[:!8Y_I*P"YVLR":=^*1)1M%L\7C>[]9*P*%&WEJI@NY[8<!=
M+'B]8/[4\^=8"!Q^W-!R-)8X%Q1B!>8X8#ZHK`-_]2'ZGB`","\"WZ!:U5@(
MG$!2'2)=099@/7Z&L*G0I\81U`$KA,MBYS;W[7`N`HN@1K@[P=KI"HMF?1^R
M41P%P@;`B_<$N*'Z4@7[.<V&JO7-IX3=8TW^#D6@P'#@_4<+\UX"A&&A)!?-
MDP`\*09L@).(ZQE??5@#'E'!LOD\$0?VQ`7AF\"`$^;`JW+(KZIGO<-:S*[F
M@3>?\T"F^+B3@4=UYYF+1>?7U,C>VSINP_\:1KNFUT<=6,=-<ZSWFL.:WF]W
M!XW.N%<?=#87J#[F.O[#`ZEKIM+7&K]J*9Z1'&6XMF498]CWZ<YW*G?/XKU'
M6.&KH[;3HZ:ZZA,F;)_?(90&<[`&/SP5%_U&?(VK#PK#*YOXM&4U7%Q1;Z-6
M.VCVE+E#5>\M"5?[^K[LNNSZG+LNT\(VYD\1T/!1_`<GS!!KG3N![7,GL'/N
M!+XJHEA@`NNO<G06EL#O,^8S0G/=!YF7EXQZ08^?>Y0_A2([9<</RNQ<*ZMS
MC.I1N:&WT2JI+:DMJ2VI/3BUYUSNI&@Y%=NW[AO?$X%U:W/8NS^[#["%XUV9
M[[[EBFD!,_>.4@^R)/M`*N)]+>105Y0L*UE6LJQDV3FP[-R=&+<+1'7'5!,_
MQO"\]YET:SSR8`;?.X2!OK#\8%DXTZC1+)R-L`^RVR75)=4EU275)Z>ZM!(*
MYQT9.-SEMN6D3`)WH@4^AZ^\.QB5=2(8N_?:`O5NT5;/A9)]$4JC9%G)LI)E
M)<O.@67G[B;YW7)#O/43^MR]+YSA8S0N$W*R>&1?A+(H65:RK&19R;)S8-EY
M>7Z^3J?<9MH79HGB51DQC,(Y1_?BWFE>)-6MDNJ+H;IH1%_$SE>R[!#&0M$*
M.9U5K;N2BR472RZ67"RY6'*QY&(^N7B:2-,Q9G/7BW*5>KU>M!/2.^@U*F:]
M?4'TFJU"'OI+:E]#;?$BE.^BMG`.V@N_TELT;T0N"B.?@<58\O'4))5\+/E8
M\K'D8\G'`O%Q6SF[5+TZ^6@*$2$SZJ.6_4_5,!NK&F8YJ/+_V=7^)W265*>^
M(FO^4P5"-L&2^5YR0UG(*\J]^8)[VB.6)KQ;TO/0"#TTP>K]"VNI'KF6)Q#$
M#=#FG@NO8E5[,;.P:00)F&'1P<<9MV?0`G=M)YS`B&U/0%?116AH$<N+J[>F
MEDVX`A5XRE]XB,^#\,O3:455V/<0#$Z;<X&EN"V7>:%(NF)/B.O)1%7[/F."
M92ES',("<*$11F@86N@&W,'>EU0)78(2T*"XJSWZ'"NE:\`"6!0SNK#-V9H"
M_:<1M>TU=_(D?B1P7$1WW1(ANE859TAJ4`92-.E*/.#]A>]-0I@M'E,9+CR7
M7DB^"B+">4K8\S)7256`;]$5P%ZV*L`WM1ANXJH`>9FXK*;07B8%1#"<6_!Z
M_,"7+P/M8W(X'_SZ_1M\E7PQ_/476-W9R@@5.9$NPXEL5*&Y'^Z$23'!=2HB
MV)%M`ZIHU)/27=`&D/#H^3]E@?\[U"Z$T8%]69,'R[4)W@!:_<8FWM/M7[?:
M[5($;*Y-N'7O@G!R&P42QHDX*?"D[X7WL^S%S@F#)KV%!/N8PG.!5$?)2-.\
M29BGL$I22@C9Z86!9ELAZ#+00XR3\B,&H2ITM49-FUA+D?"R^ZOF>C!,EA?9
MCV^_?DLSZ3O=?OVZ<OLU!S(/>Z7MN2ZBMP![2:!1'OZ/^0%L-IH=44/7=R6D
M1B0K\'8L""(()[!95!1BSMR"UT"T[!B-`Q7BM;I*^I:I>LH2BI^SE#RM>,/6
M&6*'XF-MFR"0-LE<_%$P*O,Y\VT4AV&R<O(B#B\;2_,,18@L;KD(K0*/WH7<
MP<6.,$*Q0A&D4*1&L$/?1UG8("#PZK6Z=).7U?PLHSD'<_0YV2C6F[=:HZW,
M4P\L58NL.@<IP%D@-M,G;68AYA18?2"+"!2O^0J_Z[I>Z8*98LE6*DHM(`)"
M\ASJXX?4!A7M3[)I1*I:@"'SQ.>@VF''N38,BC)*01B0V"Q)@]C>O<O_88):
M100N:=-&[44&,FI_"YCK6^@"UQU$TX+!$#F;!U+5AAQL7V@:`;;N6/#(F#2E
M,BU!&RX+8G,:^R)>@-6FH(1\U(66$'S*"=I+<[A$!.-)N]!*).$3!IW*LDCP
M"=<]85_1^#)_J\)*<>.>T3*\^J"4:(2IA<<-[DT$JE#H6.(2B?Q`#KT(";(/
MQ*%VZZ"`0YW:VP&'S-,AP1R\Z\(CP:PR+BXWWUH'2_`76#$"O2UDK#[#^-IA
M=.?'T8/">C3WP>(\$VCN7X8N`>_BW`L#I#?_G9S6)\C#:!I%2\-X!['&$8C=
M`G9,7SP#1'T;G&D6"G6,%C\CX-3/,7ZLA%#]%AW+>G//#_@_Y*FX(>/3V!LF
MZLCLUD=FOZTWVV9/-P=C4^^V6P-].&Z/!YVZ.33["MOXQJC]E="\X[@E\1/&
M/PT].T26R3^`XARBKWU?9/7;_4&MV^KKC7&SCE"O=;W3&(ST9LMH#SK#<=\8
M&T!6X]_^"QO1:RV]4?O/_]@XKNR<W08PC3//`6M7C/X5PFD(`5L/B5P+0Q]V
MC.9`[X[;'2"GT==[W7%3;]6']5Z_:71&W=&+R+5SRX<-2`>M^LD@VT9](1?,
M)]*D4QBP+N#\]\E(/D^M.7>6G[98/W3X)M3:UG/46CB]$<=><TQ/C;%U@"$F
M;D%KP?%TFPSLU9Z$PPRQ%VQ!=E:XSN1;F(%=T0`5&#\(K3KH+*0(%OJE\=PK
MV2Z0.LT*@YDGT73)<V"A!Q?5I82POJY500R-I$$,IU%C&':#SIO;.M,6?G1^
MWM(;M+3:GQ9W\QK,Z5<ON>Q*_2$0>UX$Y/80>UN.]7&].VR,FGJ]-ASI9JMK
MZ)UV?ZQWS'J_WC,[K6XW9X#P/Z0')V9%7IQGZ'T""0(1B4'>I]S%2`@L3A'`
M4*7#!R,DMNWY$X1F)\&"EW]C+O,MQUEJ/=MF"XQ9P"]>2/NO=N-S:&;A$)([
M^7!^X)8U@35/PD`+I3<'-6];V?C0;[W>328\I/D,9`X%?IY$V`,//OUD&HMX
MJI:+)40X7U!402+'6S+:*[U("]@2T6,UQV&*!$)>A9=3;JR*-HG%FQZ,L;.#
MU#L9QY>EJ,*N)KB=1DZ[=2RE*J#KQT2.P`?FADP^%COB)M+-G+R&GY0_K*K=
M@OW%I\!.<D<"K^="$^'=WT2]![_:LX1;SWBEXO.D*$@8D)_H6\,I!VZ0>M'1
MX3DA/S>,B!ZK:(^6[T.?R9L5;1'Z]@P>I?@MNHRQ)5O],7YNA:OPJ^`3YJO'
MA.70I/HL"'U7#3@UH%"P:>C`!#S(^9GR)_)%IJ8S2Y_&5,_`-#Y?6-R?*P_O
MA$W)GJ(^N!M])(%XB!NM@G@'H:SD&CH!ZK/0F8"8H$M5F_H>A@0Q[R!F\FM4
M:U9'9O7G(,5G%2,>8/;$#1R[[>7^[9R6V6GWC,Y`'YGMMF[V.C6]-S!&^J!N
MM'NUH3'N&4=7K%NC2K0OZ7T2RC2S\J)?R62PI%(427J,)I=1[$^_6\:>_RB,
M%%&"Z2K*&RY?BK,?(BG#K!F>,BCP;Q:LR0DY[N$3-!%IHWM<J)F@`\B^C#EC
MT"K3*CU+;<?F0R@B]=-W+&#\K0TV`:X^6F.TU/&!N3=A#JVE))XAK:*8K"@+
MR,+CW3()64AEAD,5S']`S1'W"2W`D"8PLCD#&V?RFL7UR@6T<KZP9VP2.K`L
MT1\QDMPGO]'^5URO->P,6YV&WAXVX/PW'C9AQ;6&.KP_:(Z;([/6&6Q<<?C[
M:KQDQVA)&<THHQF%\;V7T8Q".?O+:$89S2BC&64T(W?$[BV:\988AOS9X&9[
MV?)<.2!:8H8Q#_@'W7(P:CQ/'.QX.!BV3:-1TQN]7@V.AZ.FWF_76WJG6V\-
MQ[W.L-LSCGT\;&W-/@6^R#1#_"7%H5R=#R._AT#WAC8#\803D<-AM.B,$($?
MRE-BY%2)/+MX-O1`FKEK.1J<V4*?$L/P!.@S)K/5X&SF:W!$DQF)3+.1$2QA
M!*96#U:^DP,2`9[GYI;/'6H4FF-+]+;_9'`J#,F_@@GX0D;>JD1+.A-9I/ZL
M+4@D\12"V?^8*.L_*.\0>@DM>5S$P%4`_U?4`SG9LZH\S&`&+HP)!L0#SQ=7
M,L5RX0DN/3W(G4KL7[-]!@UI_PHM)V9/RB5'5,"9-PB3E^6=%6A540#$W:1Z
MKD29WYB=+0^F2[`QXP"!B.F`J;JS'/)7D?_IR<:90%\5FRC7*70>RJ1PA\^!
MCE>=:E^SZK.*(G'5?YUN.A3?HFN"?"DWRC%Q`!72-;O#KC'0Z\UN1S?[H[K>
MZ;>'>F/4:[0[_5ZW9XYSX;JG:%H[&TV3D0_M<[(FMV@/--*>[GRG<O?,.CN)
M+ORZR%6F_0VL)S^Z_?4[\^^9GXJP!8^>S)A]B`-;D8\)EA,N^8]?0N\)U`G.
MC`PC:I)"[0:>H-7_Y]+G3QL>^*6"RB?T16C)6()<\O$`E(:::);*]"6OO%%I
M&YU*I][9%I%+!_\J\O(8?"O;?V04UDO=\H`G>Z`$G:1%HZ4BC[&G#U<N.L&D
M[H+W);^.F!5>SX:,%.^]=)@%28LB/7*O4`Y[#=2D".`#DD!S@OM6Y)47(D2G
M9GR[AZ8K-5%"-FS9-G,P-(!30GN/C6K5<>1MO767-A23HL94]!)=DDPZ]:D1
M,8O<L!0155(FO;0,-XU(1B=QYG0Z<9K<FJFP!39&9[(XO+HJ$AFI2T]GO&.Q
M)[P1(9@*G:@=2XZLHG'Y,=,KRK+%Z69=1.9JKX^8I$UVP,QRUW<#K5",2,U-
M!8Q>%92BMZ,>DL&HSK(3`*W$4Z#FB,:H[CRD&9X*9RF_+]ODI9$K`H=Q+>M5
MJ>:481#[F2>KSG.,>)NRI!<Q^-KHT*V;U0NH2J03O:&X0.$\$&]4"FDA1+N`
M+K'$5]'4+**K/8<KT_4".8-HM-`W*244B>35AX@=F4MVM"95RZFEF;7-`I^I
M&YLR"!8-`27'9WK$KZGG3QE86[X*05ZKJDTJE^&!>Z%P,E<ALE-*,H#141_L
ME-/P^2:[@+6M.U$%-@VC5J^T6T8F1823G9U>H#@G\;:#GGS4C;B`))^?!7E2
M6A1Y`J:I'4J1?EV8!MZG0$T5K]"0MQT)BIM1UTU6(TNQ<K#Q3AQ=ITY'65'A
MS:T)4G)O^9,HF@7[@0JWR^T!NJVHB+,<R4L!+=H@G&5T22K97WTN?OY_>^_:
MW+:1)0Q_3Y7^`\MO4N54$3+NER3C*EXSVK4MO98SJ=DO+H@$)20DP`%(V9I?
M_YQSNAMH@)1$2;P`%+9V-Y8$-+I/G_M5F8"]0XH\UOV`X8(DVF[=QLAY6#DY
MNF%&N#2HE,`V`?'NPF`ZSL+K(X:Z'$+3<`)0[P&GO&:U7!13DX[)(K^L,C,M
MA-W]\5]+;A+ABUFL^Y27)F7Q=\:"^:ZH$H;%]XAKT?<`Q_WK#`*"@.C1S+@!
MM3SQ651:JO;)48/A3@:D(HC0'!,?91D:IY?P`A`R&`I(@PQ&:+FP'`J?I5'`
M$;)M\2@AZG+\O58:C-`4#06JIV#83/TD,U'9GLI84\5:GDVX1.7#7[;]]/"7
M\?08U-:6:H(IZ#0W'@EE;1+(>M60W%HH:L];7!-,JE%H2-_.X\<>&AH(P9_K
M*'N-$*U!/7P0$Z7%X?_\Y]F7@7)YT>G!\:6PA^/]E']+D=P6JOL3?1H7V51(
M5.P,KO[8$8YK0MEGT`M;JWIA75!1.[7U]1>IGZI>;;!1/76L>VCJU#+V@Y$U
M8)5DW[S%2$OZ\Z$QU#JU6DK+.=TH>+SU;ZOP;?MTC2YS7-RI7S#5#WWEZD\5
M^>AN^B(^TED(+.N*M!:ZE*-!/B:Y8DRNHLU`]N-`\/2=.A`LZ^D.A`=\#MOZ
M??/IO7[Z53L3'DX!_;2<705)_OEX@I^\2EKO^`[DV/NQYL'^2>9],"X=O<.\
MV*7?#GCL,=_M!08A7P>`L@VLATU6OU_Z?4_R]7\()\<-K,[U-4:0%F7@G`$,
MPB@-1_G._H5QHFT`8P]NMCH;8N=2&L?:^+RQ5Q7]Z:B]9MJ79[<];Z/T_2-(
M=S9/+:-N1WWI#7NGGEVW,S][E)ON[&%TW28^AHH5FM2AC&5_7-YXD,O_CO'\
M8+_>EJVP<J.MNK5C;Z^)DQ_JN4KON?[>^X?9B3#T]NR^?6*YUN,K5'#BX.Y!
M=BRS&>O(&.JXY^/2A(8L4SD8O^N)4H.&B56;-!LF5BV&4,<]'^$@7VW^G7MA
MU_"0'<T%?/8WG\[FJH]3S9XK0[L5MZ9>Z((WCTY#H3'WCE,GV;I#+:26CI\7
MN_!5K6YG?K8+WW#,:KCPZV.G'<)CO0_.IWE66W.].J'^#CF?<ZIO5+Q3%5`T
M2MKQ*FF-R_LH?""-MZA:C*&.>SXN5>HUN+S?VKK5UNUG9P7]?!0,RCHU:]?E
ML^%`C;^Z\5<W='`\>ZZ_*?1"?[5U=.K%D6G^C8U4+8Y1QST?H89B@+8PCI=7
MTV"/*LKS/]KH*,V>7XN'X[%N(N2<I:(]_[Z9KXU24FU1VR@EU6(1==QSHY0<
M^J.-4M+LN7&<K%=3.K=^."4E!3LKLQ[+C;K2".$C(^,Z[KE1'`[]T49Q:/:\
M'>K=5O/$W<T6>6B&5;ME:W9;M1UI^%2XX)/6F\$BS6"1US=8Y`Q;@HX`YQ"]
M\SE4]U`1TAO1$0ZZ&H]I?"2.>A/(CX1SS;++Y5E5V()8>7A253/BI-BAU'9W
MVJ'4\?;0H?15-\`LWAVNB[-(\@_23)+\QV8X23/YXY6X:FH\RL,VUH\=<.QF
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M==SS<6EAA_9U;\/.>/M"4W*/4R)>FP79<)#&T=PXFALZ.)H]U]^4::9`'+?F
MWM@XU>(8==SS$6HH3=_$@V-5L^?*4&^E/!3-%(BC%[6-4E(M%E''/3=*R:$_
MVB@ES9X;QTDS!:(1PJ^6C.NXYT9Q./1'&\6AV?-VJ+=Z4R"H*:/".NCCE(,@
M2JG7/_7UCU(<@L`&,O`)`L6Q!C3`X*0XQ(&-1`BHYSZ^D2[@_9F8G1#/@\3G
M?>I3FA7A)Z,;6`+'`8R#VV`:S_%A\?V4_G`=1/#:E/[MCV=A%*8+7.8VD)[#
M<11I0(W\%S?BZZR_XQ4L^XV/+Q@'V)XUC()Q^4`^;_:/OQ[C;`'8+U.%-IM&
MP89"X"9AD6Q?I8_`MF%+=ZWX%H=52$,1`#!A/*9V_O`Z:XA)7V4=*I>SF9^$
M_X4%T\>NC"89T"K4@K9%`P16=#E2Y0BBJ/2\MLZ;CKW;,0$/='5<41OY.^;A
M>E#N_-.U[T%9!ES67\>^;V)!VAK<-[CC&;L[/HCNKO-@9J.^$,15/N!&I4E/
MPZ&F76*Y63_73N[539YEKE1;7ZWCGNL6,7PXIUEND]Y@6#7V7'_WK_4@SGU8
MQM_#_2/;<\M5]3V4JU;FM+IJ-\6Y3T-G&L*W?];Y-`MBY:(]O8Y8_=)3&VY=
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M_<KKQ6[BZ3@`7<&?SY/XEM>^X1LG(HWCG-6R80[1683%!I@^=#'UH]9;?#9?
MLT<%%O2G_)?]7W]NPU+?;L+130L_$8[A)+P2K>5_\Y-Q5C`H,D;:_$?<4S`*
MJ8@-UB#4A3\FH-,DX0@U'_X<;"V&Y9)6\)]EN+ACR[*O+.>H!OGXOG]]G037
MO'Y/(Y\R_E\KO?&3@(H01_%L!D>E5:G@+O\;O"__M;6,`&S3.U2V_"C[XN+&
M7[3@#?PT:T#=;HVH`S7\"X\0^"/88@);O[IC98?S)$1@Q*+>#PX/!TXG88!%
M8XN;>+F@+X1INL258!4!KS9ZCV"Q%BR`'R48?`O3H,4J&:D^\RV##.PL@F^>
M8`$B:^O_,SM#=N'L3K^%TVGK"FYFC+6!5SX<E5=XW@L*O]`C0NQSW>JGK0Y?
MX#*8+X+959#DF*J[`E6CF)57IJT;4&UA-T'4FOGC\I*P#"VZPIGO)[3O14+#
MGPN4Y,Z_EWCC.H_KK@BY%&"X$IPDQ'_\Z2<$$]I-F#&9[*&][-#.=TC(BY>-
M>,KWAL6UHSCZ:QF-B&<@_K9"^#U<EX&8?@LH">_.I_Z(2G\!(7@%ZQUBM0^X
MEZ]%E<"LWC5];66HKKG3,E3;>'H9JGNX,M1C_G13KWEO.>.G95%"Q!-BBTGK
MG?"`R#QQZUD]%8&"</.4SMYA3I_2;\7,GGRW%Z`J!:\#0-D&UL/FLW"/E7[?
MBZ-%XH\62W^:+_$AG&P%:GLHI:U8L/8@L=WJ>FD?;3UO[-6S\`Q/PIKD1KUM
M:Z]EQJEY6K]QKB^]8?/4U'9[YKIYPU_?(..&R"M^U)?>L''JZ74@\AK+]@-D
M;S5DWY#]@V?6]TSVU0N2?+D)TB!W-'X+D@`/CY[,S1KZP1K4TN^T=1:UR"N'
M3O*1/QTML2GBFH:(^!OQ00P$C()D`<9HRT_3Y4PT2<1]D)\;PQ0)<17LXQ='
MHDDBKD(?QB58/T6QW=$TIJWC#K,O2D$*V6-/D8@P_5N9)$$`ZX`A':0+[$`8
MM%NW,1PAG(:+.PHO!!1G&8<8MX%+O`N#Z;@MM3*D/T_!6#YM]6[\Z#I(1;Q`
M/MHH7D['`*`EP#T%)`LGX0A`@4&9\5_+=,':0&(0!`!&\1X6?NG!\3'X@:&1
M&84S?&F#`./1(DY@E27^XK\4C`$PEM)B6&!G[B>$@//EU31,;^#OV4)AD+*H
MRCR`FZ1G(_@=V\(]@$+W-&NU&+.&DG^<7IXB;B6!GRZ3.P8I=(@'DPE`"1-\
MJ>\D(*FX'M9#DF)A_*T3[%0Y6B:T)XKSA+-PZB>`%@O\[1W;4PQ+)NQ6TP7K
MA,GZ.J(C&:'G3UMS/QPKZ(_WY^$"?A8AMPSMX7YB#*[Q.!-?H1#9R;XCDP@<
MY$=#HZJ^G%S@S2+!9!?9F@6+FW@,`OSZ;C54\PXP"W_\[=TR5:Y]?_Y+/TP1
MEY=)<#[I25TL/[-^HST\\26&HKH(_0O_CG#G2_!]T9W"GM_#PJW?Q&+`##HC
M0+X((VL721S!/UGD(;V(I^'HCOW_[&V,7BS@A\_!Y!]O@GCZ]6+@&)INFHJB
M69JJ_"\<VOUZ^:7_U;"MKRC@5=M0OZIO6N'X'V_"\5?;M!Q=,[Z:`]7J]H=]
MQ1D.NHII=_N*Z_8LQ;0T>Z#W>MV!V?^JP8OO$0H<"+MF@>Y#\25X:7K7.F,!
MG1QHK2+4Z,XJ$'TZ8W%N'C!$O!YV+KLB'B5M_Q+U,XK-_C$?L^C36SEDW;G\
MHQ"LIA45#=0W^:DOP>@F`I8U!8Z4),&(-ZHE+G@VH\@Y`X^T%"-5'WX_9NPM
M">;8UQ9(?I1SRA%0=SA!PB<N'H^)->+Z;?B)O@5L'%D/-6OUY_,I_SMUH5V&
M8PRVMEO$!F?^WR`@P@C#L-*N!$>65\]#U5&\R#@Y;B-F45=?9M2"B<%[P)T2
M/(.?PWB.WE,2.[B)$?"R1?G]4O<1Y%LD/`7#:K?2.&.,R,ARL%%$FDZV<@9@
MFB&3O23I2!<7LBG[$X+L#L/MP32DH#AN&80GW"!L*(A&P&K;/#4!_Q0%`6O/
MR:Z&?RLEH<?!*H0NO\^5Z^!-AHF=YMM=00BZ@B2@A``0`3YLB%;*EH'KP:,0
M[!%LR,,Q1HI)&"0A\!<38)B`F)3RR3>)@BJ<\<[!*-N0P=.>8FP#7'CA"CW.
ME#3J3^"U5C\8E0+S2&%(%2C>!C[H$W!K7!\"(3C'5(,%93KD&DG^`":.B`W!
M^Z*9<0=.P1(3RC=]%4@'7L[I(RRC0+1`%DH!?#S@8H;?!]R.CU@Z:0%9"TI&
MI,48]`3N'B[;GZ*0S7I//R5[8'L:*&!^!S2UZ7K^)04R+O^`I^D@JM%>T;Z)
M-YUQM41.Y@*>M,S14CR!O.]R>05V<CAJN8:E&.K/O[0N`6J@P-T)(%Z4D+H?
M7"U(+O#L$Y+`IS*GR_>%"+XD/BOP.FV-\?TL*X1I++QY.&,W?DNJAZ*GIZ%_
MQ32\JXS(\L;A5_Z4E@(E+EBP]MX^:*C$*H%RERSW8)+$,\8Q0.%A>3HS9%A"
M^1+]R_&#L$+^R3`"KN!35M)5P-B;V("//!\5IP"X%\%EG&DKC,P`@7F?<VX$
M(!47OELZ8*Z[Y5A?4#09UR@#-0D629S.V0L(`$DNX)*9K($=<W%#M"@S;=AH
M.)]F9,4_@5158#@RNRAS"WCM`7[Q$+?@2Z\C2<8720BA;*+T'SC-;1@OT^D=
MIY&B?1`B]!]G!JI146;P/WZTQ!R8>]29;/]:42T9?`>I$:.EZ)/M@#?_1[0$
M4INVSN!,J43ONFXI>IG>ST`,@MB]%!"`-0KD#U)S($G-!8$<:&].<"U_GCY9
MX`QT2?-E,D>Y0P2`63V"XR-"`/T+N1QD,C/[0B!_`2X.U\<<,F09Z7*Z0'G'
MI.$=([XH1EJ.`=T3Y!V<7FA*01J@";@(`(5`LJ<I@*`M:)MU\F6T3+18^&YP
MRP@)216EM,_TOY(\+U#.R0],6$<1W@508YQ(S?Q7Z.@!*N+7FBZO4C@,?:<H
MWIGU%C!2D]A`1FJGS.7QN-PDJUT0:X%N-,'<B"K+-%0%"NHLKY?`,5'ZK2>@
M3_%I#EQ\#"PZ=(3(]%06?</LA!F%I,KO,8*-R"")<@(C.0T&'I)8;L/B*G]$
MW-M#*IM_Q3(Z6P-"VT)*+JS1X7(!$!;S$L*(S9_P6X7/%FBL;,\PC0'/5[!L
M3L5]XE\0"3*C`KXU#N`V`S(A(O^:3EI,%@;(S%%CSK?'<2AH?;L)>(HI>@F(
M%2.V@C*^0-!A%?LB/W:<7/L@Z@G&Q4_X^=HC?G1$?CS\=<R\'0SF1(BQR";.
M)/DDCA<@,`)9*`OA)FF9I$7`\1$::/\4I=T*J<++&Q.KW2X0(R<EIO9R6GPV
M)>:W6G%*_.C?/4"&=`;5DUR<G<M>ZPN)*%NURQ3Y&7DOD`!I<R)1A[.\'A`\
M2*]DC=6=<JL?02]RSC.%)^47S71.W$(BOL)]9,3E)W#3E*L,*\Q"]/1=Q\AN
MX9DT2&[!WF4&O-A%YD5KD6DYYO-LX)D3D?^.?^32BEG<M,(5_^64J;C!=ZZO
ML=V@Y*0/HXLR_S0[9V8IKII.Z\1/9H`]00`YC^)TZPHH&S6U+)4=SQDG(7P!
M'9'H<!T5Z+Z@[8J).O=3U0-$P_TFN5[;E@UI2:HC+^;:0#9SB*D;`E?HZ1&`
M#$["G1S3W//,U/E5.D-'?*9H"NALXN=\JFNRZ-B\S'TKTBKX!LB8[;LSN^:@
M9_9Z0Z6O]SW%U.V^TNGHCC+0S(&G=OM=5^U5PIWY"?F_+K$0X]?699Y@+H%-
M<A*BULM!]X!7$^-8WZ^2:?MJ)2]O#P[/58=MST_9!`KZQP!0&ZBB2CY:JA`0
MO#`EQ]5->'T#1#4-8;=CLK23)2-',!*`[:4B&$$%.QD+$=$/1K08BYD!8M\0
M+P9^+KCH"`$1Y(!`Q;=7^EV+^_V06>'@K"DM"LL%=_"9Y&^<$[8D#V(8844.
MDZ5KJJ?R/[?F1*G<FB&+(B$+@$L<WH`9DT\IYL=.GP5S!%]CG!F=S+`GV%"X
MB!-D^BC@P7X*>9`0H-,67@/TM<)"K?\`E\_`$Q2,6X1QN%CF+W-1%"[X">!P
M%]*746HG\?*:ZH[R86&L?@R4CC0[!Y4'D2<FY6(+;P*V,`E0]N$IX./`=\?D
M7@%9L4^=Y,%8A]`J/C,=@%31BA!-ML</(.6Q,5#G&O!]EAF@G^,[?[H0G"H\
MU#9%W`W5J"#$ND%RU9++'W0*P((IW[\O[3^19]!11@+Y[E,F7;,WT(F?H*<,
M5#`TWND7,U1AT$,H!N0A5@'&D996>!^+WY`SS$%$1PL*3I<>`:T@65XC>_@8
MPAH+H'YX.CL1B^''K?AJP?LI@+:*D?TXN>.%DCZ%X$?+&?X:M9C41\5RX2?7
MP8*[X9E_&Y[^BT7)9^);J3@B0B%W?<H18HKT2\\GJ./<A("W8$)D.$!J'QDH
MA7723*$%TPRC)`D0ZV%H[R+#YR1&SVS)A8W_U[ID*FWK$D%X6+0F)I>!,H<C
MF1]S=@3FCN%[9M=.8";S%SDN>3G3I9]2GWU*G!@%/-X&.BF&WYF%#3P3)!%@
MRSB8PK.`7#?DS8Y'I'^.)7V?."]Y0A.TV1,,M[`(%/XQ1!/P.[T`KXM!EI3N
M0$IM/)T""F8.;CR7G\81S9O$-(WD4.BQRIH'6:8'H0.P:!#]+-:*0:/X&PF<
MJG#K#%\PP)PGJ20B"D&24;8NYS'RI)",,CH83SQAJ)6BPS4S*$N>SMPSTYJA
MJPM#HFA(\:^2Z,V7GRP7:/((G$TD,/*X6P9,XD+9,%<1WV7JB+0`'8*"MO!E
M9(KID@:T9ALH;!'^-;U#$KH!%`=%;I0?N9U]`P`7@6V-OK,%XC7;GXB.8_(*
MAP7@](S'=M'6"^8+LGIQ;NPR828ZP0^V-Y%W07DK<"@*'X]#3&?!7_^U'%]S
M*S#AN4,(ROR!PIG0VXI^+/Y7KN^0V2E'=O+(9-ESAM8W807#`Y8,Q:ZU*F3'
MC2&D-Y3GE)17%1H36TNRK9$\9&27R<TP:44!XJD_)2E(V4I,<<]C0T%:9H9H
MM:_Y`#H/4*V&BTNF&-NX`G:>\M`:(W=?RG'*B(D6([_6]"ZO=E^?&YS-V*6*
M]WP)Y!/D-)TLI_GFF&C@(H"=_)54OI]%&'\!'E(=OB]M:1TNMN`JF5Z*X6YD
M,LRTY*XT_*4DIUD.H0\B/$D72ABU^;_0`B.TXP.J90.1>/9M&'Q+N<=Q)DQ$
M_&JX8/:IV&(H9:FB.K)@&4?Q51I/`TSZ3&'#RHPEML!N\T82RP@U'"()'GT#
M!IO_DLQ3C#-2^XDK,GS'PCI-`IY?!+@-)Z4(WS+-NW]P&QLW><?M2W)C,F!B
M)B?8_($RCK^A$U6B;MH.2ZT-(^X!Y.**M"SA2`\3$9<C@$HZ\F&<XW^BFL@%
M,^998JDNG4=$QX6S)""Y>Y4I<&34TWO(RKC0!%X0!9.0Q1U%)BYSA`@FV,Y2
M5!^([`AAR*^`YXN2^CM/`F7J+R/T%XB;H@`MYG!DWMXUQA'V=8BH>IL<`I2F
MRY!D`9(XHIMG89[<42[G#Q%.<R4!7:W+3.3F'V-9#_0YA!9Z']J2`@0($(S#
M0O[;RN,4J<(YKBDH\I,`Q4&"GFF@L=$=&G&+$/TW3'BOG_E*1P'"(RN0IRXP
M`2^%<L)H+**R<(P\%D!DR[Q-PH$/!`+7=AM*\FD559@["3D*==+(U*?3UC!.
M,I5MA)4I8Q)Z:S(JLH8_H'(R8ASV.^W\GFDGI(--0Y;ZN$`U*!7H1F9T,:DY
M5\3R-!3!%]-[(2A6H\U+NIRTZ74;OF>[B)X;;IC=C'@?S39_]#>0R)@'[UE:
MO;S6:>LB1WK4%1!781^Y4X#11E&C%J[-+(7?9X&/^8V?S.#Z0`'%+\!:Z,WC
MV0B<K0'1+I%\E@EWJS"CKW3!)1F4PYHG#ZR#=D44SR'9K1U,J:J,=&=[HC2O
M5?'.4E<[%#3C^6%(@T0JW%AO\\N;E-<9![RA5:'2!+-BT1>F`*X%/%T>I3/Z
MN7*;$O`;]4%T%""=RTL+EW9FA["F.;!^TS9GNVUSS*>WS7&>WD!FBTO5YM.U
M;X-S3]V=U*<D<VWM_-M9TPU[W3Y6K-%G[.?X[N\E_6E68?P'<6NYG0RP[?S'
M,,K_38FUE3K.P^UVLK+F8^TGE+5K>#VM?_2F]<\.V@-\\*\H]8`4[Q5-:<_2
M!Q^<Q&1/T['__.?9EX%R>='IP<&E$F\C_Y*2_Y-1/+Z_J>;PDNT_G76LF9J^
MAZ%AK_/4Q]6ZYP-FK?@C'LJG@J"\Z_!>B;8NE/76?A&2_5POBGIKO&B`[8.G
MK=/0P7U\HTSUKV&\:0/%;4"Q_JJD\:"4DOU];0R%':5D>F87)Z.6JMYSI^$Z
ME=#P&KET](-B&SCN0C95KQV:E,3(Y[]D\:.",93-JLU"\5(#`EY75IV`TZ/>
MYFW$FQQ[I_$F5WUZO.F!$-6V?G^P3[_J(,/#09U_!WZ"?`4HN(GO[`ST34!D
M>SA4Z8!($^'8R'G:7Z,>[-TR?:8AI>_!D'I5AZVDGOM@\ME9I%RP5-#69SD[
ML9_GR]%N*Y"3!EOE6:OW)U(6&L&<77SN%_J_\)3$E#6D6.25Q\5TX/_#7C51
M4*AV*V9!8L<&'Y;(1AFRJ6]1(`U]XS/Z-/90GIG>#>/+44A%-*(MT8].V^*3
M&#,CY)LO==>E!H)@B&#A&Z8I+V["9-R:^\E"Y`#[80K;$M7/*XV7108>W^]I
M"V'#&M5(&=?\,Q-,YPV4*16U8J5S=!U2'C8NPMHK8L>5[",G>>XN/I)2EBGU
MW9BR[FZ8Q;X(HA;EL8<3GIF.VSAG=8&X1!GJK/0T79=;S4OZ1$[P22'IEMIZ
MI&UV0K$O`"MK>!6RA%36D5$<#--LY4,4"VWQL&N2$+'?\]E$QJ(3+&@8A;R?
MD'\%N^2=D4MG8X6+;(.4*'W%.FZQ#-U74M-R0;7)E<EXI9Z.U'`M1<X<IC>4
MV,HVV18)IJ*R.[CF6#@)I_B[24!%A-AQFJ7:"_JDSJK48RG+O\9$?E;=RKH?
M%*B5\Z4,8<3WI4J9J[L2/[B/';0QH_M'SEG8MTKKLNI`B8LQ?O!4/I;5JU,V
M,&YAI50=*)"/'J,VX7EE^BU+"B?2_DXT!DQ#PVYKK-TB*Q5@4UZI!.(C,7Y=
MU75V)%9?Q`B1C607IT.2!FC_:+B,MXH:Y;N58]]W:..$\N!G63LT_@'B@2E/
M?G[TL(08#Q[7>O2P+J["2::4[?QZ<YUW['O"Y9_J`+(.YWO:^:<;!TB34%P=
M?TSC<&H<3J_1X23KS37P,;GN:TI-V,MICSS[E.O3!\H^?6FNI&YIKRDU5'L9
MPA]-;FB97EY#QF$#Q29O\_&\S0OAPCI$RN8SQ;BM>Z](:7'4:B@M=6/F1Y:D
MU\"Q27:4=>\FV;%)=CSLIQL':)/L6$G7;.-[;GS/K]'WW%FC'M3%IG->Y)>K
MG4GW2I,=)3UWR-J,%E3:;"0JYENT@O7RD[4FQC0/3"%ARG&%--W]Y%;8[FY5
MW0?:J54DP6$G`JO.W!\'D37<?MO2OD*WZ^S]=E\:?ZK/-5>:K-WFXE\#?7O-
M-;]*^M;5YN*/GKZ_X+@)FF1;N\O6';,2MUVW`&23!_%B-EQA$V8O20A'2!5-
M.'GW;K8':XJ[.-@!LSI[\>PJC,CS5IDZ/WG><#99#&>=8)GGE=BY5.N6MI;1
M.)NW*A?!L3D5TOPTBJ"G8M8-JRRC.2W2-.)\YG;KDH]=3^$>X3_%(N1")?.P
M<]DM5C(71G?G"_7B,0WWIOT5ENA<]HHKN*K5;LE/B&L[^:%X<=);;5ZAQL?(
MIWR6"_Z`!\*Y0SA=,VIA<70&S%&^&I\;PV90K:E5Q@G9K%;Y)*^N;K>F?!@0
M#1M+T^4,?\FF(=X![XL4G/*>Q%.JQ0S161FDBWPR%E_H5WHEJ^^4M\]OE$V2
M24L;@U5F@8\S0OFL:_C"*=T`'W/7EJN`Y>&I*T>A':PY#<)L';QH0%,^%`J/
M"?^E`3F\HKN\'OQ<`@BMD(%$!DB03\<JWT4^4]-/\[)4@@_A>P8S&H?)1O[1
MZ#XJGP1D8_A5K(Z6(8/SFQA0T]9U'(^I^-J7!@05;Z7-K^7D!VG,]OI:]\)(
M+5:2FQ5FXM.P1.%Y/@X.*\-QP%JY5/X)3*K&U=B_\RNH$IN^2&*@U<M1&$E#
MD\4H*3[W%V=&<G:7=TR@0=P^4C_-8,6QE8]V1BC3$;]^#`!AS.A__/_^MW51
M&%>5\O)M(-5IJ[2MF7]'G03&?RW3!:VRG-,\[8B'GK)`E""I$M(#6?$IA7Q&
M$FYD9?-Y:X9HM5/#RJ%D/L0Y.,O_PO'CK/*=T_S5G30KCW':;VRTLP1@/IT.
M>SS<^N&4%!+LBT&D&L4H_ZZ":?SM,),&"W*>(0D_;<X_2I<FC547/(&-?8P*
M<$8F488T7*U@8J>M2S85..-J(8&C-68CD?$MFJWF?\<-S.,T$%-5Y]C7A*;U
MT2;85?/96AAP1RZ.Z!#!\=GP._9F\'V.<]#@+^RW\&X*J+K/"6?W0!Z0"0=Q
M+B0>3[I6/II2-`IIX^!!K-`/X!:0R]^*Z<3R,.0P&2UG*8T^SO4L:H>0KXBT
MAS/S3O(QXFV:*HU[2K+9BGZ2$&TQ*.-84-SI;#Y%02#+"2#%XN)L;C&1<!O#
MR]@3@@9*+[!G!(EL:M<0QDDV\9`/Z*1F`GQNLR2(QYGPAP7'`("4E`ZZ3)1G
M8Z:)9G^48>+/8<LC0M2I_RUE`]!YTQ127TE/@J,D8<"F*;+-%F"YMI4)[SB1
M9H/;)2#C,/8<NFP$9\Y38B[LRS-,A80NPIY/O$ZN@]+<4F18N/]6/"=QCBIF
M,2<UFWD:Y#/?Q2C1F3^F8=TGV>QC<?>X-8"C-&!RS:[@MP)GQ30[@=79\'&F
MOLT9G`'F/BF$4K<8,>K43Y$C3#"10!I`+J:"`O)ET+Y/3.7RB+&<TU8OQP&<
MG[<(KN_R.;L2UK!AG,@3P+8EZX"8=C:<$QB0-`Z<`Y9OG/$E^C07J"31"`7X
M2-$LD_C*GW)<0@Z0T?LW&L:8#68\^8$:E:S3\^!7DLAG6"=PC`UP_>C?Y9J`
MSC,U3IGKDSX4Q3*22E>8C;-$Z8L8\4#J1U4&0_[!Q+(8FE8I$QI$%5QCUA=E
M(BQ<FE4;9*A4,@S@Y=^!PR?4&:I#4^QQ]&5N$E\`?QZ%\VD^8/X/[$4U1A-W
M$7!+I#,#JA_Y1?OV]T[GHFC@9D9JKLH@SA+=9JK."1L/*M,QXW:32<!'UV;3
MZ]FL>]:_)5.P8`%)Q6JWQF$ZFL;,KJ')M8]:;&OLJP77*U=`*D8AK]D3L5P0
MFLL@4PJ04Z:M\3+)&1^^1HV-6/X^*"LY4S@1HZS3Y=5?=/J8#0>6C,$2K)AI
MRD91$S(@/,48=X!&NHA'?RM,:43Y"SOBDXZ_`;>%;^9OMC-U#%E$2;EOY\^5
MH%H:H(QCN=GP6>!?0OA)&Y)GB#+$E0>41IR_2N>394>1M8A&:5SY%C\20MQF
MBZ*C8`$:#M<:.#<&-`$$R\V`5$+)JK"?LPAN+&A]\;]7A_50[4J8X5WF84,L
MP*`$4_)!LQ;W#_?4F<W#^)2_7'2R+?!LU+D*D7.YX`Z:C+IH*+W,95+&]8(,
MPV26PT;5"TF3KB?ATU8_@)M/V#X9`TJH,]PM=8YCW?[R5GO3;`XV=S=^0V$'
MZNQ86B;3"K)9O6S(.^U%LCM@#W`R/[GC^)=U[T)=.=.Q@'UQ3@.`'.%$Y@53
MCG"Y;^1G9'T7"QLH\+357<!#_KU;H$:(Z_>6,(U(_MU5L/@6!%&!$9[\L)X]
MKSC'X*60&5_(E4K7488C`(XW7)/X3\9.R%QI"Q2,YT#^Q)Y.?BA8STPYGL6P
MXC3\&_M]@82)R"0D49,BE1%?QK<3\H'F$D':G=@;Z3,133'/YMP7SR$Y'LL@
M2'*O1*83!23LF+S*E4I<!RT*ODK"!'!4$%1!!#HD'O-PIB:[=MQ,R!@6)VJB
MXREWPXL_`)R%5W\!>@"**]&!499Z_G),X0#`^`!E"^OU1T3,P+L$4DP81,.)
MX$N3<,I<#*G8!/$/P3,8>S@MV,=H1OGC>,XQ.%>$KI<A4YOPCI;PCP2[89:.
MP)SQG'6DHHUEB%A$$0O9UPX85USF"A2Q2<A[4<(OYOX=O(.F#;IY@O4("U!.
MX0G>W(XL,+Z;MJ"NDK><:S/\:T@)(W\Z$JT^F*M]BK8?F%3\*L4Y.-'0QRWU
MIVPSL8SXS!<%V+Z8L@^*_GU(0/YW"LGPV[HKPOXJ`%/_5IBW(;-I(U00T7:G
M8,T]@"^L4Y0H<Y!"HSO<.X<^FL`2=[S+B"[G:`6&Q@$EU%!LJAB3XBSQ4\EY
M/D:M*5WZ3+?%.!$YWQU3532UG3N:60PHQR_<Q1_B="QF4Y#WV5OFKV3W400!
ME/Y%IH/1MRZ%7&M]BD]S2TI3O8)@+$>B8$&VPZ+&+F2.`#2C4>2)J,R.%JRQ
MZE4@?B_B.[G`IYL!7.2V:?!]$0A+4CA[TU3@)>FVC.OG-,49(",+]@-I@5P[
M8WX.;LT6G!",\AA)/N"/D#&0"2]20Q3.J^1@#8(#-&9_*NP$G]24.`K*_$XH
M^R`%2-GG<.%*?B8DV[(I%!<</H3\H$5QM8J3(%"#Y#0HWDUF7G'$I%^R4*E\
MPZ\D?G))ADZ7#)V>9.A42G$NQ+O)0\S]^<#[F7UYE8<O6;PQ/\E)UJ%8#@(0
ME>7NKE6_%=,7V9/H5>2*PS4:?T5J*#@<Y57IV6+H#KVE3/YTISX`_G)T$Z/3
M()ZSH!^8C^0.C\?!E*L"(O1X\D/A6-0_-D7M!M33NSQ2R#V+R":"Y!:MT>R;
MZ-M/?"03II)7Q6"K>@/WS_=U;6=7<%^79.$YRAP:9?Z;-R;@MU:5"QDB.?Q+
MD$.6!0*2-ETDRUF5VE]_D1W@DB65F[!AONFVG)+@IS?<@J1_HE0`&F6/90P'
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M(RUUROT;031FVEF6(9"Y:8`R1F`]AY,[KO*/I`1`G%I`WP*U'(T*"GGQ<+$@
M3^%G:+.X,05'@,Q8C#[;E6"G\NJY@8J.`6&@X39B"K^CYT.R'9B/J97GC<C>
MCGD"]$PI&+B)$=CVB_+[_ABV%5*@$P4]"@*6>C8><_\#^=$89R%O8`8V\I?1
MR5;.`$9TR#PE9+D@&QGS6\G_A""[0]4XF(;,H*,L0]Z%'RQX"OPP-PQ+SPC&
M!`EV-?Q;*?.0,+!FWA-VGRO7P54;TE7S[:X@!%V!B,\":")NFV7+^)2TPV"/
M8)MP_R)E:J)\Q5],PA01DT80M$4J$2A2,V%`(J\+,;F!1XN++]#`%?('4?4)
M:)Y`ZE=!(KD#+!Y8A84&?H(90V.NJ>.T!F3L"S)/<[4B?X!/OZ$-G8C&4Z>M
M#GI)25THW_15(!V8C!0D:@0'P>_DA\SB"--R9@`/BF/4X/(/0<F"KT^D-%[)
MH7\0SR=@?@>LG.EZ_I6#'H[!9(REJ$9[)?N>S4D2#@<%6=$RQ\;L#V\OEU>+
M>!Z.8"W7L!1#_?F7UB4ERV0):L#GB[C<#ZX6)`X0]"=\PLJIS.#R[2!>+XF]
MYGZ%,;XOKDZ8:9F7!.E2]HG1T[F7[2JCK=Q.X`D*H!0&E.>)7*(U#HE#\B")
MW"*BI`[GR@SS7>('"XX]U"FQ20`\QP:#Y!M@62PDKD\97*0P\0F?/"1BJ2P!
M9!24OELZ8.YMS9$]\QRANYDQBS)0DV"1Q%(?-UD<E)+0?,G]5>#5/$0OJ(E_
M`HFIP&=D+E%F$B<_/,0F'F(2?.EUE,C8(<D>%AT)T!,0W(;Q,L6$%R*-HL^!
M]+C'>8!J5)0'_(\/*G=R=Y\6D^U?*VHC@^\@+"A['5[F\9T_HF6*ZOL9I0!D
M%-_2=4O1R_3.?<69^Q?6*)`_",N!)"R9HS'"?`_*:"E]GCY9X`PLQX1E1S("
MP'8L@M%S][H0QT$F*K,O!/(76%8#B(R46`:&X5',B7(%'DY#6@;E&@3*548O
MY&\6\1M`(3Y$[*XM:)NY,A@ML]QT^;L\AY%(%86S/Y+"!X739)1S\@.3T<R4
M6LG7>(*PY=>:+J]2.`Q]IRC56:0D8*0FL8&,U,1XND?%)3GZ!+$6Z$83S(VH
MLDQ#5:"@SO(:L_F8%;:.@`J!#7Q,`0B7`BMET9>[>C(*297?8P0;D4$2%42J
MKEJ*B236SZ0"KI+'9\@3<@5&-Z+M@-"V$'9"NYS+!4#8'F7'+`,6,BA\]J&H
M#%<4\'P%@^94W"?^A25?<%N"['*XS:`0\2X&Q-"P144YWQ['(0J?\[193-\C
M5HS8"CKX@F8LQ@"A_-AQ<NU'8BQ`X1-^OO:('_V$98ZVKF->-D,P)T*,1<`T
MD^23.%Y@OKHLE(5PDY1+TB+@^`@-\E46I-T*J5(4=4-BM=L%8N2DQ+1=3HO/
MIL3\5K=/B8\%;/2J!&S.<)3:W0-43B!2/2F)%\.H7T@"VJI=)OC/+-..*8M(
M;PDYI.@2>\!/0#@F:VSYE/L23G[(H_;S/.61X5$>?DG$5WC(F(0(IHU1>@BL
M,`O1[80YKI0ISR,5S"T@=I$/M"L61E&2=AZNY,*0V?$IC[/2+Z=,@PZ^<W60
M[08%,WV8.=+$IWGRK[`_5PVR==(M,^N>(-^<1TFF=06,`Q7!.6;B"Q=&G(37
MO&+G"D1>@:T4E&D1J;J?:!^@R1-1>"C4YK9LGDM*PS+)E`W&93('AL`5YN4$
MD,%)\I*;+!Y]3ZHHQI$S/59`9Y6TWXW#6_SQMW?+5+GV_?DO4CYH[@2[P*P&
M$$)?0+_I3N/1W^_A_=9OXR#\Y4OB([E<WLVNXBGQ7WCF<S#YQYL@GGZ]&#B&
MIINF`NQ'4Y7_5575_7KYI?_5L*VOJ"*HMJ%^5=^TPO$_WH3CK[9I.;IF?-6Z
M>L>U/4/I=X<#D(VFK;C=@:YT+&]@J*K9=?K65PU>?/_Y\L]/O[U;V0G;H#C4
MG]3#,QAWT`M]'7Q:XH6>3RXQ!'J^7!"HX=6NGX:C3C3NAU/*!7SV:991R-ZB
M(&OZAN;"SOQI2AWV2F?M#=V!W7$,134-5S%[NJZXGM55.JICN'VSJVE>%\ZJ
M&6_>>[KJ>)J3W];S#E8$SD"@/%/JO_C?/P,2<24"7CZ?<Y:1;@$@H-,',CC,
M%7!TAUJGV[5MQ;*\H6(..J;B=1U;Z>IV7^]I=G?8=0`<UIOWZJFJ&FH.C,T/
M4@1`]CBA^5V&Y%O#YH'>577+ZRD#IPO8/.P-E*[3&\(-#PW=Z9A#Q_,8-B--
M<I(\;#"JR?UM<G^;W-\F][?)_6UR?YO<WR;WM\G];7)_MY#[NVIOWJ=\%U7T
MSPQ"%WZRN/LBN=)SA^GVM7;5,JQ>WP6MO>MT%;,S,,$&M7M@IG74ONY99E<?
M5$)K_X2^2U>B=N/7%@=8BR#6DD'V@!*/S<6^7R73]M5*-_,]Z/>K5@AI[ZT/
M,<B`SG42!%5*9CV+@.W=DF<(G4%&N_6ONR3\SIIT$'^@"/44-^^+S?/N2,(H
MN9#8-\G"PL-M]B#[!7&_:0!<@7V&M9-A)?G7U^BU7,CJT(\&M@[$_X.%DWAY
M?<,3-<>W+%$.GJ$EX/T?+?YDX(]N3D$R4,LD[I9$]8?KUED;M-(^267P$^`6
ML_E4"D)SOEM@_WFOBB%7KM!$ER4!#X!1GALRT59\-0VON?\!HVZC)+Q"T4^[
MN6295)+TT1WS[?CG7(FF'`;T]PF7;2\>D_JJ>:Y-K6K(Q0\KOB7/Y!V*!FP0
M0ZE(I%^EU%T(;PZ.&(+"DO7<(*G^,V/L6/R+YA[;-`M94DRQ@`#<1A1]@-I%
MS7,!*+<(1TQVI9E%P7<4DN,^4*B!$'X&E!&&#:PK"6AQ=(`X=_R(G`=$DP7]
M$409J\7'L`J3,*`;,4R[$=TVI#KKVX!%-5A3$)%"(7_B/KQ@),`\8+@8;97"
MM+,9JFU8,2&0A/)W>><*WO8F$"4*XE7^(KE&X56ZNRPME"PU7(F=Y`H;ZE&1
M-J5WQ)38E`K!SV+%V$E%M!>CX/!]F9H\9,"IBY/0&/M-(/5H;9O3#Z%((0<C
M90$"XU33?E*,4T/_Z;1USC-W))RE\`(+X6.3FSB*&%I+KGL0<@AK+K@_!J`T
M)X)!@/H08/XI+,(`11]E>B2J2M)=Y<1$7,+,N(3<X[!TC4PYD"('/$^7W8XH
MVL]L`'J=V%+&]%#5Y_K0TQJJ;372^Y%J#]A]?EC&W]%AOVMFS;Z#:)(QY&=P
M6.*OB/=;X;#(@'BRP\LX+$>7(^>P'%5JP6(S='L&C^7GK":3S=69AYEL2VEE
M;!9=,RN,]CEL%A<J,%H!JPWY+![`7>6T3^*S2"EK.6W%^.Q:Z<:!+H`X"JBX
MPVP[MM9V7$="X"+VD0>?O&M`T&_#G_-%L[100']Z`AV_/"(.?.6.^@^>\-Z-
M[+O"8"]Q79*#FBJNI\V+A?`.10KV)$S((H]"Q&;T4I?$\-M0WML(-S:=2K>/
MS6&NX$HBWG>0HP_N7=Z:M*$,77[E'GKXQ`/?6/D"TP-*'\C\Y$79_UHJ=$5R
M1.5,R;)36!2<9I2=2JJ(J'Y+T,O$135S/Y$;H#+-RRXQZRM&Y2HK^ZP<X*4:
M(.,^G3#-SI%DY:N2Y4L7\^7SAP\].:54=%]F$I/NK>@J%A*34W?O)@PFK<M1
MR+J.CEKG$_C_R%KZB>1:[?J)<I[P]-%<\V08P22E4+7"8FXP\R>*8`&R4W[:
MMU'\C3CHSY09YZ,&\J--@@JU`V#&*!IC=D0N-B41-9&SCD3(A;=_O*?8E_/.
M\^\8L<4U/F>I]Q<QNFR9^WT.:V%EX>D]JKL_365MFQ0ST#MF7-[:('!(72#8
MA"E/R>?#(`.I)?2(9V\M)<W25D\Q?Y9.S\))(=X9B](*CWU6QX1AMER9+M0:
MH"3#:H-?108SL5\D<I:=CG8``'6RQ+ZQ7^@169'%0#!!,_@^QQ*?#`Z>G!6$
M3O%,[.?93MG#3I$GL/]=[XU]@I^UZ*"]S-*,!Y3TO'UWK-4'<Z+G=15=ZVB*
M:?3Z2M<U;,5VS`Z<L6OJAOTL=^R?_SS[,E`N+SH]X"81-FB=\C$[7SYW/ET.
MSS]_Q-]'`3QZ_KE/3YY]^IV+P][YA_//\B@(QHL87P(A.(_37TO\B/T25COK
MG_]Y"4^N\M5?6Q\&7[X,/N<?*VQ,S/^A'2C?@JN_PX6"4%92X#M_!PI-S*2_
MK_<6:UK179Q?7XON[[E\N6JPM'<!2A9G`=$Q964X>0HY*KFHC5(Y`.5S4%ZQ
MU-BP+-.Q:"A<+)'(>*3Y)KR^H1[3WX!5W5!%,_"=)3'%$.RIE%K&BDABUL*:
M@M3^-)!M2O0"E'1B4<M'B2:9XWBM4FR=ZBTPQJ=9X:%8GJF2M!K9''(4$I7P
M\);6Q+[5ST@/J!H*L?&]V\8AELQ$B?1D"&`+=KQ/O'BXLA&(M:QI?8S!8HJY
M4X([2DLTKJ<A*RA.%\NQ*.7$>''K_S"RFYO8`S;W`L1L_/WRWY>"[C5=9W]@
M[B#`MK]9/X=YN$!1&+-<7#+)@@0SF5A2\K#?4:CW`JM!7].D?_`K^0&^!6RB
MPS7K^(K%R)CDL\@*>YY:]/$Z,`,IC=$6Y>M@7#4-1A3NS[T*Z$2<HJV'Z<]8
MILQ)/AB+7M6</%GI,_5RUERAT(@2QS"1>Z>,\PZ[F7G-54N>Q1UG2J54$:.W
M6\/@*BG^%N0+TVQ7_Z2[A?SMW!F&I2'HE1OSX%:*@0W:,'.MQ<N$LJ:3@$VW
MR=+F6`X'[T6$THM15_`=T18;QG!WE.3SF[.T%4H@0-^-U$2]X%M"UP0KS4P"
MQL!!G]=_8GHOM<;-UF0!=ZR6P8^/XX!U_:=R"\I6PTQ=ILW-F2,QOZ9"AGK6
MK83YS+(B7#8A931*J+R%ZYGL?=&TFT:52QU<?BEZ3=R?RB[D$\J7IX3\6293
MF+\C!S]QB:*/0]/%4G+20K[4(AM&B,TS*'5=(*C<CSC[4J9LBT;T@*\L)8?7
M<6+AWC4O_R?'IL@](6_1$&@NW]REHO%\K,RQ=SGH9<<K+,19+/-`G?R0^Z"X
M!XJ\==.LQIF!FWM!22DO+$/G(4?]=X693GF#>L!87X(@%>T44$T4`1.F,431
MS)^D;<_\D'R'_&-\Z4+B"=L?>Q1/([DDZ1*OI!VPV4GX_$TP)4,U9E8G3_$4
M3MV3K%^+<%((?I`NKUBM(\_.R;=);1!P[5,1("AA<)N*>GE7H.R:<CV$,KL$
M);2+OF0TFT>C8!H4@<^9)N9'L1XNPKH"N39FG250G/GI#?E_5S."TW@:2!RF
MD4Z/2B=9T92#'U@Q3H_=Q--Q5CJ3U2I*7)R\+,3`(ZI=H.A!Y@YFRK1,CV"D
M4"\J%`F1T%;9+V$A35=_RM!AS7KR4HA3>38B)E6'O']')A5D\I%49&P10DA<
MR-B"%7XT3VT#!$"+'1N_*(EA%*!,@#-JX<#+>3D%G,2QBZ@9P:5D%4M"'13Q
M`7X:5MG,>I/D.B0--B'W^**%T8L%*/99+`(>O`;]+65Q./;"V^"[:,)1\"KG
M#!P'3J#LXRGNT?7/3("=_+!6A!7I\VTQJ?[_AYNCV5O(Q<5ZI?+3+T6W?0[^
M'/AR^%H">1;OHX$#_`3"L[<.082F\)\E[I[T+I;I6^*`P"K6P"%#1&3=$BIN
MM'E:BI>ADE[#E`V*\P#\V4X+XIR%@+Z1Y*5^^<3P,&,]RBQ%1BJE;5(T15Z)
M(^Z9K$,141(!IJ#(IVNA@LB5F:2%Z.=-.`UDKDP1+)F>B$7D6Y+JX[D^QX2_
MWUJ+(6U&H.(#C-Y2J<"59>4+O3*_>;1TL%4D>^`Q^I9"[5)EGA0E+`'V`<QB
MK(P95UE\BS6WV9"+X:<R/>4!UO54KK49AE'Z&$<S$39&ML%13O@ADE0Z]@J!
M\"Y3ZY"O$;:KPA:^?I6$X^L`LS`$S?6X&4T&S$>6@#@\^_2Y\^[R[*+7%OE^
M\/J'<!)@W[%6CZ$=]F/DF?>DZF0>FI9/HS2XIDGH(7NELOJ4HCN"6SK$"B67
M=]E#1#Q"^+#X:!+1?8H4/Z#'&5N*)T?D$SK')-;X(*N;<'Z*FCY?E[[+T;=T
M$NZ%(]QD6RD?U<T(C.1?P>6RLOR:]]E,+3'#!.,/P@]7I/BRYK-&EX&7']I-
MSD/YCKA]7]Y1%IVX$R)'IE1DSLQ*8$P<.5".4OB`D&CWZ!Z<]TN4S'0PWGU-
MN/ZR9CL$>QQ$F@03D&^DYF,%01CAU),@X&$:G:=$?5ES(@%=PHHL-#-!5P7O
M/(;L'E9AW>:BS.#GA\_YJ5H0Q26XG/Q0@,RSX$))`AED5F)MR#N9MX;OL.%V
M:[C=N6C&(KD9O+;L5B^%9@V'.0V(U42*R(E`5),*&LF:QEO`J8G,PFVE<^RO
M)3?=N<115*4R?VF\&+W,EKJAUL0L$PW+"%L)BVJR+!^K$#C-NQD`!IV#-<VS
MQ:UV;O,NX@5?B9@=KB5"DWFB6\`_CGI\WO<6Z.Q'0W/S0.>)&!9,3@"DI*N\
M]K18?9)-XL7GL&LK[^V=)4Y/_!$?CT>%;*"@H0-+F6(/5E;L>O\^T>KOWU.U
M65P)_=U98V>J+,$)R[P=^0FKC^5=ET(FNN2*QG(H-JN8%('9$SG/L?#7A@37
MDR#'TIP,+$&"LOU3I$0,16<1+TK^I9[%F#++A&*GF%,[O.RU/OA7J,7$"37/
M/(M&IZVW3-;*YN$E$+3L/R![L)R)*Z5"2'N4,N:R1L)YA@+S"I96IR*^),8`
M2^OO"`=64D[%11+.0`P@CJ3+#$OD%!1*A/K7X/.7LU[G@]+Y</;[IU_@(W."
M:QX6(92#)>3?JK^^7<#Z6-\]Q^9<\"'2NWXN3?[FM8BHN,.F6;H"[!5X#6\&
M*/(8J#LW6G!Q0HXS#.QPCP#`*<U&HO%44.$:I,%I<O&T*(5,A0X&<$.UD55A
M<IC`G<77U,6IO9**S!^!U\5D^<(]\@'N?/ZY.!_G(FMNYJ0T:"^'#6M&4[I;
M"E:R<XAC$FL3&_>3,,W;S$C)GZ7TFF*)+0^6^=)X@&RD\\I*TDGRNFWF5IU2
M%^R$-&/V,UG9;;Y;ZB8[BVGL^9@\;,B9*?P!R'*UI-Q&P/%OK',68ZQPT=,Q
MF>#H8,?,'\*'%K;34L(HEW7SPAAK7'>!'7?%:0G]$9M$I:^$G@W7O,<G*A@C
MZ;U9115VK.>X(-SX`O\$37`I5<IDROL:PP7]J)E:V_;,@K\<LX98U.XNS7IJ
M2@VBY(^)`M/L=C,&4=0*,*?JD;T48AC9.<7&HKB%'\*3^FQ>*S!@*=5;$]W.
M"H&(1Y=9FS!N,P;R=B2OI%L/K[1&S<N7H]947!\KCP8G]4YKNQ[=1$,&#RH/
M+7>=SH"WU0UC=!>*FA&&5$S\GY3ZJO-'BU7B)0O@HY\NJ$:EG-K;9M(_4Q.8
MA2>^SG*O11M`@-<2YPFPL*340^VD,/7Y8;D@'Q3#3T%T#58LRC[^319S1]\H
M"BC^7[&%[*-K1^;.E@L:D2X(DV)C\"I5M0!M!M%X.6-".T-;Z@*1=3',U+:\
MNYM(.,D/M+K#">\)OPX^L@`6M2[8CW7A9Z'U\KMMYMA(4_HW6N=2KBR-BJ<_
M\"H+YBI$US(`4L0Z.`-+RY=1\A%@J@#S$9QDG?9XGD`0HK9",ZC9366IDR5P
ML%HE]GX!TE(%A_1TU#)4QHQQWODBH-0OQCJH"810IUI7"=;9KENDU,^^A%*(
MC0]N=:.-GOS`T$=SU^]VPM?"(#2FF9Q1QN]?RRBOE,%(`'62%0[O^W5PC!#S
M9GP^4T1%=Q*),B0Z*`:9,3N$C_4I:"RD&%]C;R+AM93'AI-5ZA,.L#HNKJIA
M>((S=^PESJ+:>2RLC3_F@?2B/-?RZAWJ.(*G2E/6,9"+VOQTFV?;WILT6\RM
MO>#F\/FD+_0_](=^B3N3":C#E+;S\LYL81J;NN9\_>.R_W"_.J^OZ[9CVHK5
M\;J*Z6D]Q;6]CM(9]+5>;]!W;!O[U>GFF_>Z8SIV?MX-#E(\^:=@P?I#?(C3
MO9YQTYY\^IOWBN/HAJF:^3$+NRX>2&A]G7SL?0K(B_DK_N$.V[&L3M_J*'I'
M\Q13'SA*M]=UE&&_Y[A=6U4-4\/#:G!8U]`TS;+RPVY\HG)##SZJO'J7"G>J
MVYKCZG):/-MM\0R=;!X0HG"F(U\`RSB+>,R%.C'2O#QY*N#G@`$KX)K+!;&H
MSWDS%38T;(^PT>%6#4<UE0$@@V)V`4JN8?<!2E;''JKN`+#\JZNJSE<-OJKJ
MZIOWFJHYGN'F4-HU/,I=&UD(DV'8@/D0`>,JB%$>$(ZFF9YGRGUOUF^_>,AS
MX<>N-!MTD0O:AF[H4C?.-5M?:;M)J6[]@/WW+#KC9FE828'FO'EO>*:I%WH7
MW7^"XF$_`%:CCUO4R%?O$H&[NY:C22A:VO-ZI00H?43-H(0@"-+?DSVCZ887
MJ+G(M.A_5G62^\[Q&,[ROFH`)"QK)J=#]4YNP\$M1[7<AW!W]23K=1=@W%>\
MM1GKK8O1VIY<%MC!P"UK-9;VJ(T:K$Y)+N>3^UY!Q[-60=`9H,;:MEG`F3U`
MXC&TN\`4\G#,Y48%X88R`3YC&N9#.%<\QGUF#ZNSY[6)-$8J2P3KH('(@H'5
M@X%N@2JIJIJQS@3:Z%#K&E6C)!TF\6Q=8^MN`.9PWO\Z2`NC=FC.SJ<X$N7)
M))QY(E@%!9)*QI4)^S#+_0)W`H/-3;5#2/'-C#34RPU'TU1[,Q-MK6Q_Z(5-
MX<^X79J)%43K:+SF*@)@A5^PV73E8.F1O6O`AS:T=W<%FWO:U7.NV>7M=2M(
MP>@QT`U/4]?T^RSNOE1-CE9BMVPE5I'#KS&#UV^^)-MXAI_`D\P7AK^X\"E]
MI8*GA>-:*PKTXT=Y3)D1[<L/P%8W-1U,Y`5%\^C1<SQXY:)NAJ9!5N_`NO'F
MO6,^?-7R$4K6+L(#6-IGRBT[@)*J#UQ#[_7ZBF,9-C"HKJMT/>#P76O0<:U>
MKZN;/4Z^FEXXX]JMW^.4H6=3?/(P[B>KI[J:XWB*VO7ZBMGOJ$I7[?:4?E<'
M]NQVNCVKRW0"2RL<\L$3%`_;\],;``?^9P`2[]:?HOK*''1E"J@B'H,=8CH:
M"'0M/_Y3SK02D,"W+GA(L7OW![!YYO:AZ&6NN>]H?L[6X8-*-B"'Z;IV(8+Q
M@F-N!+(UQDY=0.8`U]`-2[=DG'K9,<O!$=8["2<VY9V3#L!&-]3SP,PU=,TS
M;$T.F3QPAN)QA=BL@&*[(0I8JWKM(X<H18ZFTWB$=O]Z7?$`-ZU:3L?&UAZ.
MI@X4T^EV%*_G#)0NJ+==3W-<6S7@X";INVY!F&QVF"(`?F<]00`Y.N-9&/%Z
M_-N@NC@.1`]_UVU3.ODCIR@)TJR`_7QRB?4_S`_8$V6U.W1^GGT:/MO]"7J@
M:9?TP$>/\GB@AWE<+EB:WI[5IDUU?A2->/9'(C[EHY1(G76<(U(XG\#38/JC
MTMQAF=9[/';?]/1!=]!1>H[34TRMXR@=HZ\K3L^V/%O3>UW'9-JB4]06'S["
MI@$2#J`J7K0&"O*JF_'A<Y1%V#R!C>S=33%4#<L8Z#W%454-V+;G*9XS["C&
MT-%[NJ-:/5=E=PH_J`5QE6_X_J/`OZ?4IP%9G(0%%;Q$`TTY5Y>)=9.3E"P[
MS`VDRA3NEQ^(TJ0]'MCL@'7JV;H":^APIV9?<?%V>UW/`Q%M#'6KQ^^T%)>Z
M=_ME290NSB?5C42#DN&ZFNK)`D?:<4F3B.,Q%E><S>9^F*".N=LDB76R%!#4
M[7BVIS@#MP.<U545=Z@-%<MQ=5.U^ZKI<<XJ*P]K-\X.EZ3?HGLT:+E#9P7O
MSL:(E^%Y0(8;'D(Z\5JFBQT+*NX%QC1`S;,MU>"GWN@@TL$?#BI4(,]ILX")
M*^4Y/?M<#^!#203+6-3C%:`51`Z03(IE:ZKEW8,=CQ]+@@E/RLDJ';;?:!<X
M;\?N@>C1:`"S-S05M^>`90CW[*K:0/<LX]%&NS,_N0XC91'/?Z$2&/[S5;Q8
MQ#/VJPGL5TG#_P:_:/G/$W\63N]^*=6SK&]B:Q1[V'+(Y$4@[X2(DQ()-VEL
M*^W=WM[>>==8V*LF1B&4Q\^P`[0+[;)9>9C<A)-/HBV6U/JPR[_BI/6_,:!4
MM)HP/Q)9]:)7.%9>AM<1J_-BXP)PI"TVB\*_8NMMUNH)@2OJ2/*/7F-K!C;!
MLU1..,IJ34;3)4U4H<Z'O*"&SQ_A+4IQ_<MX"?NG?6=%<GD]8CS!KA*L@R46
M'OSE4]L;:@!9*#8=K(Z39/5<HSQ)IS5.EM>LLRFLQ:&,HQ%AZ[R[J=@8U:9&
MK0"+,[&5T?@NG8@B"%SEM/7'G`VJP!F)^<B0E8%`V;@+/R\+7,XG24RU&+S2
MO;VV]RN_*RSQ_-'D9?ZLR!2O''L>L7&/\"B_]H7_G57&\"^(]?..XUD-/&]J
M3FW13XH31E.!B?!;1D"\I@+K1*22BM/61P!-NHBC(#]*RL?/Z?RLO!<?O!5E
M$[:S3XVR%"@JK$`,&]W@8%9Q]TEPC=>-W8M9SUG10F:TG!$>W#*P4?4R5LC@
M-%DL@6:PH_H>_V\LL+JE'K14%%2JLZ'6$E2S!7ND6ITDOL.9/=24@6K:=8L:
MB&1?XF-Q)C@3IXT=+JGS(7L+L?0[[[U&J,Q+,D4A(?U6H!FO9SIM?8KY^R&=
M@UJ:T(5QP`'24CO0C;@6J^_;#MLZXP-=>/?]M4,.Y6H.NAW.BK$10,8QWJ[4
MA_M3?QS*HQT+%$QL;1"-@3O!WY:L[=4'K#!#F+/[1>**L'C:9[F;..^2+0I6
M4+JVK)`_4"I%%X/5Q>M(+P\QL#:5:_,^F:(F6^9J/3_RQSZCZ\]!UKD/2U")
MWW4F@`[P=U'W3AH`)3XC2UQ>M2Y]8*LX^)(_V(NGR,A\+A`^8/@.6$R`?V4T
MOP)//C6`CZ)F7[AC'82R'ZB1!Q4U4?,.JI6E+CO`9SBUIU)ENVAPFLLCN2NX
M5%_,BNW$9]@4W[Q9:BX(!)#%=&0)A/(*I]GI,%T0:W%%I6\FO5AE%N?&B[7P
M8#P/.:;<AW&&#&(F.%G.QT1[=!K`11V)<0R53A5C)S]PYD!?94P+GZ-K#WU&
M!?)-1QEL<I:&[(XS-=Z>32R#/9EI#@CKRG`=`]M;R]B)53S$VC=B["C&\!=%
MYKY2C+@*T/+X\?R2[G)VEK-1=IK;>+J<K>%D>7W<PXKNAG;3H4LG-C.9',PK
MT4%8.MH&-M.]-17T)F8U^NG->8*F`_^!E]W(B3F53C$RY!2CYYU*@@B8VR`O
MB)PQWB^TC1%@I331!(VN[9M1`].RG:$^5'1/ZRCFT%.5KF<[RL#L>.[`'@R-
MKK/O\='2[",)-%G[F`PXQ?%2P$FF\3?6)68Y`\9-W"3K1)=W'5^0@]]_8,C?
M+\\?\T0ZS7W3ONZ?-<;VM*9GSP:@ZYY_[@\^*[WS#Q\Z%Y?PT@B.ZL_3X$T+
M.XUA%S$X-F$[_CQ'=LE_IO8(_WB#K>?>M,!JNX[^\69$:M.;UA65">-CP@[%
MP=M=FK9`R-CZ9^"/B_.W%XG\PUBL;]H_98N\6XR+S]SR[S(-,-N3?O\KV_I]
M\^GFT\?\Z7=%<DS6\!?W,?;RYL&C%%N$;7+XTAL/O\OWRQF<X+EYBYF6-E]@
MMZ]P_&8%R,`$@?/!+_0R9\-O?,$."\_8;WU.B,V"COV`SK$?T#WV`WI'?D!=
M/>H#?LD&Z&SCF$5YA=KF`)3Y%5USG2K:C<=W955TG3I=G`4+6[P)T&OVCS?N
M_0IJ_D@.#;-Y_(F/;Z",/&[L@%5R#5^*P2SY_\`<'PR']^@GHJMIV7Q[GE7Z
M83#$1G;!K-1V3H%?B<]\]"/_FK<H"P(Z<<%MM$V"7O/NCQMIGOQ'\A33:UK;
M91&0C5Z/XF^)/__'&_;?%^_Y`.<U[.:TS6F;TS:GW?EIU^UCL].77ER%1NY+
M1&_E5G>XV5K;$>95$=UR7T;1&NFN]86'Q/<NRI]XB2O88=53HK_"8S^RC^/@
M%0W(&I`U(&M`=@P@.W8GQN4\CM*8#1]B%1'E#-YL1@/F?==.-3*LVND(VSBV
MTYRZ.75SZN;4!S]UHR74SCO2FX81E<SD*D$TQG%;.)2+92AC\F?]=`'=JQOU
MO-)COPJFT8"L`5D#L@9DQP"R8W>3?)3GQ=5.\=$,HVX:P"L]]JM@%@W(&I`U
M(&M`=@P@.R[/S_ED@LT@J/MV_;0<K7;.T:VX=ZQ7>6J[.?6K.77=#OTJ)%\#
MLETH"^I*O=(Z(.^!:,M*!Z\EHPX'A4*R[[R0;,V-/55[V/4WGXY4#10;*#90
M;*#80+&!8@/%*D#Q,)&F?=SF<POEVKJNU\U">L%YM;:I.Z_HO*9=2Z._.>TF
MIZU?A/)%IZV=@_:5E_36S1MA@-8QCI=7TV"/JL[S/UI9C;&!XZ&/U,"Q@6,#
MQP:.#1QW#L>'/U74DMY1VV;^"_:_].MBB_AGM/>6FH-?L(;\^.IED-R&(QR$
M7M69>.J;]YICJ[;+CW[_YJ43TFS6R^45]O&>[WMVFJYIEN&HIC+H6)9B=N&(
MKF'WX8A6QQZJ[L!Q]*^NJCI?<=HHJ.;EQN\KN]]X8-K!QTAOV/R?)LSR.=+/
M/98$E.*<UHLDP%D9ZP?P]9?!EU@:-!;N=\3EAL,`<-JTKGFN&"?WL@,^.&CP
M"*#EX?0]2R*@EY]2`MD@7<`&<<HW#O'X'"R6283<!Z=_?_,CX#\7\30<W6U_
MD$*G,S1[F@&,!-[#>726TG$T5^EHACMP==UUU.&^!REH;M%BOQ(2+L1_9+!J
M$;!:'%I4WIG#BP1:F(G&J[5"<@^3(&C^%8Z)2<9I*\BVG@0H8)`#X3`>,3`&
M9_3,XP6@2TB%JW2PDQ_8G#8FDEI7=ZW1,@5M(<!96QTX-U:X+J>+=FN6]_*<
MP2,T>P?>%E^ER1'Y\I,ESGV2)N?D8(QQU&W+SX!Y\D/60&,1P^?9-$@VRD9:
M@`Y!HVW@RS1I9SFZD3=0V"+\:WKW7]C530C'27BM+FVBG7T#`!?%LW`$JRS@
M%V,^3N/&!U6$0"=@`30^8V/E<-3/*)@O<.=XXGB9P-L"?K"]B;P+&@`GYA2-
MP\DDH._^M1Q?\X%K"1]@1U/ML@<*9UH$5%8L_CIB6Z.)=32[G4]P.J'!(#B_
M+_>9>;^F<.IYG#"L$!K2<CKFU_KH*)\G\PYYA,O43]/SR9]^@A,'SY//-(OK
M3^J/&XP[.-;M.O@,D`UQ\!--A,'Z(7_Z)4AFV^-!9M=0^\""A[8%`MVT39S)
M["B68_>ZKJ/W#<_[:H(6@S+K0O^WIGW4^D)+?<D)9/$^_@LPB:[\2]SADYG\
MZ5G$I^$(Y:&7#SS\$/I7@!C(RB^`[U=9_;-P<+"JB0FZ+S_LAMKB>EG(=:P*
MZHS&F_>&:ENV;F^@,SYXN!<!Z&!CJ#>#$FJ.ENVY[K.!=,^(ZH<6.MQ<]<V`
M@E.J70U4QTW,C34CUQ]]1];/`9KY9//SR5D$TNXZ!%.\DZ;!HHJCV&P`CP'6
MAK<!=)YPTL=AA[-V_=_!G$O\*4K%\0PD0;I(:+PI)]8J`@Q8MFEJCNL^,NY[
MH_/)CAD^@1$@W0>]`Q9*L7ELBMZ=#JBDMV%%+3#-`8BXKN#,FYV#'7R9*M>^
M/_^E'UPM0`4`I2`%Z/6#%[MNOFJVH9F.^UWS;!UXXLK9NH8V'#H=37$'M@-G
M&PP53[-<Q>MXE@V\HJ>C`TI5=10]7VC(9QB-PGDVM)(&V^,H6!KG#M`=\V&A
M48P:_;=P.FVU_"7HP#Y-B)Z2P(`3+L3\V&@YNV)S1],;/V%6`"KFK0#P".1+
M&H"RS2Z=#QH56BKF/M&4:GI\`II`A"/9\$78'RRNZ>I/^732=1LO[YQ6PJV#
MLHS#+7'2'1N."IC-=ODV_)G])OZ&[[')OFA8XZ,X-CJD:P:]?'5G\,NW(;S_
MHWEJ&Z>_O7OTXF4-,)^%F<RXUO,I!J`&%\S0>0&.Z)KN?-=LT&$]8P5'#-70
MA_904S3=4`%'C*'2<1U7Z0)A.$/-<PS71APA*_P"-&6AQ3VRX2+N#X$M+((/
M."V[S$0S]5AFO&P-[46G-G0;*,.U0']?56&!*OJ#WD`Q[0%0?<=P%+>C>TJO
MW^F8CN;8W;[&3HU*OV;].[_-9QY%NNL'5AADHW0_PLEO_HU#6P\/`U+@=5=1
MA0K_M!-4!Q6`!)X'!K1?OFJ("EK=4>%E,-`)%?3MH`(H$#1-'0>\\IG`PP"]
M"*,`UWO)<0W+\8#GV0ZH-/"S"=JQ!C\;KFKISU$3NKWA8`!B5.FIUE`Q!RX(
M56]@*)[I=+O#04?3[0$C%L`2^!JY:C<\IZP?!0E.BO*O`U#0V=#YSV"KG$\^
M!0OF<-P]3.;+))"!H;\`&,`]U5/=$EK38Z>3(-'G(Z^YF?*9S;K.J6AW@'CV
M80WD#^J_^6$?.T"1%#[$T37H*K.+)9BK?AKD\<]M'=?Q=-?5\6?3LT%G=`S#
M<%9U1L\VX5"#GF+TP$HP3;6O=!T@^*X*AP8E4S<[/3RNB4&)"U/BAH\=01YG
M35KA^:3OWZ5?8J%!Y`/!NW?]8`JD@:V"_@3U<!%PW:*"8,!(WP40O%",GGVV
M(D)<HKK<Q?'JJ`\#RV`&*3H:K_DZ^2/<'.E\\Y/Q.:F6:)E,@A"=[&"9;`N'
M2).0S2RFU,O<XNS3<'5>]L#Q!BI8F5X?Z,@<]-!AV.V#C34T#:/O&%W;^^H@
M"0%.:9JC6D:.5CL`Q!,AG3[]"R47\.`[<+XP#2Z2K>#PRC5(8NSK/$B^KE[+
M*E]3O8XZZ/5<^*C34\PNZ'>=GNDH3L_N#E2GW^UWN]FE6*>8GG`HB)7N:W03
MC)=3$!OK]T')!?Q#W!:_V\X@^-4;*',-9^`96E=7+,,&1.\[IN(9`TOI@/+E
MJAW+[KG:ON.94@(R0:85,Z>#ST'3"E.<Z\Y&O:>O;8J[I^]TB+OE/'V(^P-S
MW[?U^^;3>_UT,U/\WF&X3%O*/Q]/*.<B:;WC.^",_!E'J@\0A.PK'9V+PM)O
MA63,=TLR\G4`*-O`>MAD7I?2[Z7(>[[$AW!RW%#K7(/-<0VV1PD:9P",,$K#
M4;ZS?_G3Y5:`L8=QU'5N@GN^7*0+/T(MI/4_RT@B8D-MMT#3-)Z5MKVCRK=G
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M:$K^7`L3HY869,-!&D=SXVANZ.!H]EQ_4^:%CF:KL7&J+7<;&Z=:'*..>SY"
M#:42<Q8:':79<R6HMU(>BH<U$NY<I1)#?]$H);44M8U24BT64<<]-TK)H3_:
M*"7-GAO'R7HUI7/KAU-24G`.RS4FMS3J2B.$CXV,Z[CG1G$X]$<;Q:'2>WZ$
M8AZ=^+F]SHY;[NPI$K.JV]=SM0?EYGT]W3?OU2TV]7P2L$H7A1=[EJ;+8-Q?
M8F-<M@!]+I5O/<N4JT$OVQ)XGWS$Q[N>RI<@+_$O?[IDMP??F['?[:D#:J^C
M.@-;ZR@#O6LIIMO5E(YNNXKGN9X[<$W'P);;]W1`Q7_C&!(_WW8+SOI@>]+#
MM@^UW9VV#W6\/;0/?=7=*8MWA^OBF(+\@X-H++<=7#''&G`^`LZLMNP!(.VD
M3>"V>DGIK]0A@=.[1C@7]#:>^CB#='&W7[?#*B[A@Q,07.+P?_[S[,M`N;SH
M].#XDLEO&S_EWU+R?SKV3_1E7&.7EUJ5*_P<IG^W)DD0Y(.P$MX.M`[7J)YZ
MZOJ+U$]5?3]760/ZQ)D;K;=W(+;2GP]]M=:IVE):]JEU[*35IP%R(+/NPF"Z
MY[J=5;"K/^W4!G^^G;'&'K]Z?)3'U3T6YK^`@X$Y&8T%[G^)\5=2SN&&HY=?
M-$WL0?M'M9R./>QW%$=3!XKI=#N*UW,&2E=3M:ZG.:ZM&FQ:$)B'%^J_2_9W
M)8`C#>KY(TK8W*+_!N/U#H*7#C'=S/OQB,MC8Z#;9),_\6A%),;)YB.:>/[0
M2]L"!PTJ,CP3QU-YGNGBN"K=L2S\V?!T:V?@TOE$*\TU"K/,-CM^14!FZKIF
M[PUD!A__YNDOAEAUIS]I3_:8]8>ZY3BNI[B]CJZ8`\U4.I[74SJ=@3OTU(%J
MFV8V:,C6+=VVF^E/3[F&YTQ_<NV..]`M4W%-MZ^8_7Y/\8:6H0#A=)VA:O;Z
MCBE-?S*WZ2A^V?2GYR+$T`\35%@"25D1HO)?F8F+\P@_^M_#V7*V@YLJCU9<
M1RX]=#";KJUT=,_!&5*&XMJVJG2-#ER*Z@RZ3N<K\1GM5'W*4*ZM`68/%R+4
M:_SJ'NYAE3XVO`74)T[5IQ#'2Z&Q9>Y%752.DW$Y;]X[-'OT`,"JZ,0Z;16<
MGJUI*LAE=6`C.+L]T&E,3?'LP<#MNOVAH0^:B755"CGM>F*=U4RL:S[]JH-8
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MK_/FO>99FNMMKPGO&D`<P:"VIW6R7.TIO7DGRPH-:MMF>U,<3S),@N",#R>A
M%K-A5/W>NSIU?=5L?4=]7Q\`S+ZOHPZMD`VZ#EW=!L=Z(F`J,L9PE_)@RV,,
M]]"EN@XL1$6<=7:%L0\"I@9S)5?[%-M6MVN:>A\05'<5T^II("R[NF(/]([5
M=6W7[)E'-%?2L7?:Y-=^H('LBF'-WS&>WG-V:TLU[6BQ)YEQW[C*M$5C*E<]
M1@TD"Y!<A5[F4:OT%H]S@.83'S]V+W"-YVTZWOHQC9KJ/C:EL?)G</<T:+(J
M:%CSF:':J:W?.S/4JPTV@FU@W4-3IY;1C#ZMY.A3JZ6TG-.-*FVV_NUF[.H!
MP+YN[.I!/MK,>MW]K-=5G\1&0R%-'E-I9KUN&D#9PB1.`KKU_%FO]%)G_-<R
M72#HO\2=\3C$Q_SIA1^.SZ*>/P\7_I1?!_[N8IFD2Q^?_1@DUT%R2!CIFF89
MCFHJ@XYE*687?9`&CO?J60`[U1TXCO[54U4'A^("J.PW[Q7=,1V;@^ME)W\:
M")GG>+^`W,Q%_@0H.CFJ;>/(!YR>JQULX+"%-*N_>6]H=KT&#FL'&SAL(\C4
M-^_A:]N9./P<D?10_&&K\A=_]@R5,-.P5>N9H1<N&BZ<;<CC1P]?8R";AF.N
M*CT;`9F&AYL`9.O?]L?]@;ER,@<Y@6%:*J*L;EO.SF20MB,95&F(&H:J[PRB
M]H$ANE]8FIKIV;M4-2F9X)5HF@_`=;LX:KY"JC=US]Z=+F^\1HB:^@[YJ+5C
MZ^@BB>=!LKB[F,(CZ!'YSS*<XP?^2(/)<HJS,U\",P`1Z/&>`<^YCRJ@:L=V
MU)[14[1.WU-,4]45;Z"["OQRV''UH>GU20'546D'W2C7C#8X116.O5XEW/38
M9*M<&"\Y=L52LCW0Z9"B;-M[NF[G&`/-<H=]11V8H$G#*HJK#KM*W]:TOJ=U
M3,UV,K`])?_WN=G81*&?@]L@24'L3G9O1$O@<Y^C?/3TH>%V#1/8C]553,TS
M%;?;UQ53U7JN"_:RV;,S")J@+JJ"#SWUE!*`/@3P3.<Z"5BN]4=_L4Q"0&&"
MY@N@8:J69Y#7Q=!-_%ES;/N[YE@V@(E<"A[]W7;`[%\!A6>:3L<;#)6^UW40
M'@.EVQEZ2M?L&;8##-ZP333+=,R6_>@GHQNL)O,X.!X\DW3VBR28`T<6SM+.
M+$X6X7\)4+4YOPX\R%8_:E:?'_[10^W9M_1BWY'5Z8`E/G`4&T`)L.C;``OX
MT7,[W9YJ6)VAJV=DL0W7T4,YP;TX0E*#=\\G[-^+\&H:7`8C1+'P1<&$/=C6
M+GDRT'0!NM$MSX%;V3`;^M&3E_`J4XW2>W4CE(^+.[R0.(('"^OV@ZO%#F"Y
M74N0P&DA.($,=5M&O"T<?T6,!4QC)-=1C6#COGFOV451)9_DOF,2VM6%G#PX
MH^79INVN.R<=I4@?GX+%632*9\&'EREM][F/MGZ9-IH_J@Z(KL!O#%,U<VPO
M'.;I?&"](_5S`/21A@M@,<EM.`H8,_K,(I_XP+;H8+?>(E=XBW003YJJ.9[A
M/HU/O`0\E63*>P(X,F5-\SS/,7?'F>]9+ENJNTS#*$A!?,ZNPHAN[D/H7V%"
M+,A,_&J-`&J!E$/=8<7]\=RS[UK$[0LP(.*4#64<*5F7RZMTE(1DP6[CF"6?
MU]:/:>'_4S7SS7N4Z+GAN7*8^ZJQAB'L+?@0W@9`90LP[9&4.FD:++97<F6"
M!:YRCZ"]<M2N8UJVTS.4H6:YBFE8MM+IFWW%'>A:3QMHIFEJ]Y9<B51`GMLG
MBB#R;,`GIP=22P%-SZL2ADNP4H.6+]EKK4D2SUJ+FZ"%.:&M8'U5#/51:85I
MRT]AF7LKP#8^@XZ_D'<IMX2XO[W"82O,;'>G%6:N]?0*LP=>V<[O]U`T4^>T
M:B`+>Z\IM?C'YPY/L[QF=-J3K]?9^_4^+]VYEO=<:<)VFYM_%13N-??\.BE<
M5YN;/WX*_W(3)($_`6V]=K?M.%8E;MNL6;^^HYJ/=!@^7&4[IFTY:D,7=>UC
MN>E''RC0I%\\4)JYL2.PZ$E<XTK&VK\PN@ZB!?PK#<=!LM(YL'>#_SR+0,Y\
MQG^=3\Z7"XQ3I?>\+-S3=Y\#/\6^2COS1EI.O^^X':7C=K%;XM!5NEK/4;2^
MJ^N..E35[A`3/`Q,<.G<+99`:VG<^A9.IZVY?]=R?\)V3[0]=@S\9WZ.%OQO
MN$A;4;!HI?X4V,W,'P<M$K6M\]$BOH+_&AKY#ITVKDANH=9RWEK$+1^>9HWR
M_.OK)+CV%P$^@B!MQ9.6'[7\S-G?^E$_M5HSV!?\>)K?^($NK(@U&*LYB])%
MLL35Y89W<G[#YI=LZ^R.74-C*5^:Z;APQ[:N65@G9>#=T9U;<,?PLZV9&@5G
M'=M^8N<U%SLRJDY/L0VWJYCP/XIK&!W%LSRCTQO:GJ[S-$2;&@9*0<7-CET=
M4)G[`)7.*Y?54TVO+ZBL)X!*?QZ@#-$F\50SMPDHD8;71W:R/>`4@?&<`YLB
M=PQXH:)JBGXO?LA'V!0GSJ)1@OF(_8#]=V='WS8>9%7GI^I&!%,^J!3SO!^*
M7[[%U<,%3>""KF@:CW0^>(1[CSKXO@BB]!GYI/LZ*E8U8DWCXWM_]#K98T\H
MW=S7&4&#NM#<]8<L;7XSG+W!?E*5.Z:>8ZWN/HZU>`CIN%*&RZ=X$:2#_V!/
MC1C@@N%4'U4Q4.5FO.U\%9A8U]"&0Z>C*>[`QH*#P5#Q,+3O=3S+MCVUIWM=
M)O4Q\>I4%SD+3SOI2IW**`C&Z3")9\_.BWH22%;+51[+\EBG(6T$*X-C49;B
ML<&I"]GTX2T@UL74'Y$R_Z>/BOT""YI?`)L'B6.HV:XVU#M*5W=[BHF]!;J#
MSE"Q/$O3>MU>SS*&3$<V>(728SN5SO,)<^PFRVB,IM'G8.&#/9,,7T3Y]^#Z
MQNDZFY^7F$&>IW/?6>3KD_"_,XN7T0(3M(`N!)0Z:'Q1"OUY1(1S&4]?(M&>
M3?B;0T$5EM$+3G@/B#C.I/#Z,AG=P$N\TD]F'IRU4%&2(*+S"2U=;<!I]P+N
MI>=^!)R%80U\&9:-F1<:[`?OUK'1S0%HHLC)R.\E)V4`X\>E#;W@N+08+`>;
M@0_QG^!G[$*W""=AD+32T0T0PS_>W"P6\U_>O?OV[=MI&HQ.K^/;=[VS_P6\
MP`10UW(UP([\M7RI-+A&6GK_V_>K9#H.?PF^SZ?A*%Q\#&;H=!J',Z95_N--
MYAQ<7J7!?Y:H<MYB*>W=/.A\#],W[^]Y@*WTV[NU'WC_VSNQ`W[6=X7#_C;/
MM5FVWX6?+,B@0[@I*IJ`L$;VV^S!(!I+C[F*H>'28^FAW]Y)B__VCM_92R_P
M2=I!)2^XJ(6RNRVK8L`F9F&:QLD=L8E'[GCC3Y,7L8A-?&[`MK[08._SU?T&
M6QM<VI5?M+*XE1=2=N_^B$*XS7Z0Y<]+Z':&"M/GX#I,T<<VEM2K;:%;@^DU
MQ/358,EQ8#K'N6#<8/<KQN[5J.D18'>#VL>*VH]D?502=T5F1F?$"HB+V`IH
M`^!,1V&T$`_N\`K-C:_05@QU7U<H%U56\@HO%P`$BM$5"Y73(BE^#D9!>(LN
M7W+=D^YX$T_'0?):KY3*@>M\I?<4K+_2^V1-+^I\GSP6,Q[X"<XS>*V\EO5H
MJ?-%;FZ>']T=%AI\5?(.J5_@JJHZF,VG\5T02(-A7MO=/:E+727O5H0AD0##
M!4M<&DV7V"#@0QQ=XTRM_$^2HCL,DY2,*'\ZG3UNJ&P><0BFV'#N`N[X[DOB
M1ZD_HCZ5W3OY+])&.K-Y&&_-/!/<ZG(41#X@3,DXX[_%#J6O#-6+[3FKB<IP
M*Y_\62`AQX=E##]\^19_N8F7J1^-O]R$R2(((HEGO?++K*C>L.8R_W67A-^;
MNWQ2=^9JWNU]C9Z[=[F6P>C7O\K^>/"8]FO!'-;.O,&<C3"'57J]-LQY<'A`
MI3!G'(2_?`BN_>F`=K.B&_1#_SJ*TT4XVIZ/OW$O;G&X1X--&V$3F$6[#1?5
M"G.JYZBN+N8T/O''YXHUJ-2XXU\Z[:_!H282\(+1FZ\=?1JS?:,QN`V:-#;Z
M,X92OW:TV5J(<^,OLHD?F5#\@(.6LERR7*%*`QS/U0&$"6Z#:3QG$3J:N]0@
M]`.#Z1N$KB1"_QY$0>)/`9\[XQF([W2!C:AN@P:ECU;#.^9+4X]%L%)L]>+&
M3V;^*%C"K?K3%`CZR+E1(UX?1^M:B]?7B=:-D+T7L8\;<8_TZAQ/=W%(+?`D
MSW;A9P-KV^IRE=TPO@U2UNN/=7+%&6];XT'(?LXG4A=8Z=,??2Q^YA,.TVRD
M\^O$(I:%2UFZKD8%DJYJU2:TLYLTU]^#^#KQYS?(7]C'1MC8*;G[Y7\_OQ[\
MT`W=)@%A5C5+^X&VW]V[C_Y?<=*;^FDJX<O_!0D\%UP`\'"&^RNC^.Q&07L]
MEAL]3^:O[AHUW4'+6E4]HYK7^$>4!",<E#C^`S3S*,NDX%45YU?3\)ID?O>N
M!^"ZCI.[\\D9,%_QQ'@3BU22[J\-!>1F!]5$@>UW$SBJ2]SYI=44/&937KT%
M=#<VNT_S$/=9P=2QZN9S5?HBJY>_5<FDJBK>89-45;FDJCJA29-4=;"DJEJ@
MR3'$?E];#LJAHKYU0NA:1WU?&T(?+MY;>90^5I0]YDLK^$3J5`.ZXVR3JE2"
MU@I_JN=3JSK^-$Z\AQ"J@KZ@JB-4XWS*<BKKZ'S:,1(U+JA'D*56+J@#(,NK
M=T0U10BUMMX;=]3C:%UK=]3K1.O&*74O8A\WXA[=U?$4-+PZ9UV7E^HV>3Z`
MB_S>;#A*8/\0^]&F90B;*X6[:!G]FK!8K2L6[UBR-KA<05RN5CYI=<!C-`&P
M32]-W^S2C$-=VI'SWZ.ZNFJQHRJ`1V/,VBB-JQ2*1X45C4;N%PHEC,T$F[&S
MZ9`:*R-Q!"95?[!I+<=[.CN[0+4DXS2;ROE5VS$>&)\$G,%VS7JPBN>.3[H,
ML%IP?_.39,XQ@5UUX,5QY1G8TR/1!YW;1&+UP-*7D9RFW6/VUX"D&NF+**)I
M&V$2/+933#)5LS%0GJ@WF9OI3>:N;HZK3:9FK^]*7ET6<(C2EJJ1OH68H=D;
MZ&WLL?TB4.,J;M#H:6BDX8^/-O.JMGEWL.9>6[8G:]I4S%(`KU3W<5SFC^T2
MEZU55P1E!WNV"BS2`WRK:,.A[C(-HR!-.Z/_+,,T+!F%%TDX2^.I>*BB^/MR
M)+(V0R+K$$AD.*J#2*2K\*\&J1[]:"^>786,Z5X&<S^!VYJ"N!W%UU'XWV`L
MBV%Y4W2/PWCYV)B]!LEWB.2NIQE&PSEWB^1?OFW/P=;@^)-QW+;!AC(:'-\I
MCI]'CZ62-CB^4QQ774MO<'RW?/P&;*P&RW?HZO)$QR\>D30UPS0EK$;75\5\
M$IMB=0S`34=AM-BZ;;=9S&T8)\'(3W<<ZO;(F?ZHK\O;L<_=T]WUW-*S+0?;
MF'J.6S&7:1;)GOK1)W\62,@#^N.7FWB9^M%X&$X601!)Q20=#%^/\,NWP09Q
MU7KR)T`8?0._$W]L=WCE:EZ3`O.<^W,5S=O@_MACN[L_&WW@U4H5I!:WFSA5
M^6.[`X[%\[M>H;!](79;E+GUZ`5:NTKP4HO-NIL+?.P"0TSX@J?E%M/B=[N\
M%]X,Q]1KWY!X%(2W_M4T2(=)/"-UY":>CH/'G+GUNJ?J-2VJ8@^APUY2T]V[
MTK=3O39-5>F:=)B+$1:P:]N>6\V+66,!L[0SR0[^<A,F)4-X^TG%A[^ABI+.
MFANBO*Y7<D'`VBRX(`.>JBH))3&<>W&'(%]THC&R.&IGT[W+'0&,LORK[(]'
M<3E-T6T%;Z)BOM8#)ZH?]#Z:\9N'&;]YH$MO9FK6ZYJ:09D5O1O;L%VWHMZ@
M)]U-WI_\B,B'!I0BE],K>D7;&E!:]H^?11B\@Z<I<V42),-'4U1J=Z45T^-W
M<J6=N\7RHQ\M)_YHL4S"Z!JL-G0]!<DH]*=20](CNUP-$S,-2W>XEJ)7=,#P
M^>(F2/(6`FO4D=X4N#`HD%\2N+`4KN]S,(Z_IW>I:"Q[N5B.PT>'SAX&_1Z=
M=RQ.)QZL/1H>/`M@GV=NAMR^'#'-_5]2$]NJ].TTL:UJ74SCF*_RY32.^0K>
M1,5\@M5QS._S/AH'4_6OJ'$P[</!=)@KU2KJ<SA2"_\`EVRZJENQ.34[N>2/
M?N2SVP0J/2;.Z[JNYE34V-KJ#9Y/)N$H^!#XVQ[-<]#KLSW3T<Q7<'T%%_XQ
M7:"IJMZ1B\F'!\%)DO(H[K69IM3TPJT?:C9]+QL$/2R"5BENN/,S&ZMQ0]VS
M*^:^?6+0`]!RES+<.,"=-+'<ZE]2$\NM].TTL=R*74PSDV9?,VF.?3;,81"X
MB7=7XB:JI*[O_,QZ]<ZL[SZ=4\S'*(@$DNV&;F'HP`&Q42T*%$Q/R`$TWTOY
M/Q=)/`O3-$[N/L6+K76=K)C1GHV]V#-V5!,;7N_E--[HQME70]2L.%]IO-''
MBZ#-8.=:XT<VKWEGYD\S>K3.^)%-%-V=@'-+_,/6-:OB\]\>Q8]>'-T&R0*S
MDXOVTY%,TBI*&'>G'*3I=OWL:\$FUCLL7U6U0J.XU]O,_H55QNI.J:=II_V\
M>[%VS-4LO>F2_;Q[T7>JC]"]5,EUO?,S-T/=GVHSF4_4B9=1R"XC3&-3UYRO
M?USV,_#.`C]=)L%[_K=?X&^_O1._9(OA^Z654CAPD*XLPGZ]P?O23K["QK^6
MUAN'MW!?^?GQO4^@YB;^(L[O;Y/=,]BL?Y^6[0<1J,C1?0NO.U&^YNK+O[V3
M]K[VZ"3HOZ)<7P$?"WQG?]\`CG/XZ\HR^,M[WF4("?_X?U!+`P04````"``<
MBDY'CF)*7S,4``"U+P$`%0`<`')S=VXM,C`Q-3`V,S!?8V%L+GAM;%54"0`#
M2,8>5DC&'E9U>`L``00E#@``!#D!``#M76UOXSB2_K[`_@=?%CC<`9?7GI[=
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M+UJ/QF$X>N"UV.@!,42?47"2-1IF<$?`T8A]/"HA?'VBX0FA\U/HYMWIIN#1
MG_\T2@M_>&6X4N'EW:;X^>G/GV\?_05:>L<X8K$7^96*O+&ZJN<__/##J?@U
M+<WP!R9:N26^X)("@2-I"?[7\:;8,?]T?'YQ_.[\Y)4%1W_G'?Y(28@>T&PD
M:/@0KU?HXQ'#RU6(CK)O"XIF'X\H>XDXY]^???_NC-?_RS7QDR6*`&KP*8IQ
MO)Y$,T*7@NJC$6_WZ\.D0KZWCI,G3,3LB;.I>,H+GC:V==J7T@>H^<MC#-.-
M]W$WN\$1C`_VPGO",._B*O08PS.,@JZ$*[9Z2`CW'D6=!Z!#T_$"Q=CW0OV@
M)B#1EJ@'Z5D#V@E[7`#P!0D#D'.??D]@?HZCX`X80;G`@9]0Q/`SZDU_MWZT
MP[SRV.(F)"]L$@68(C_N`66WK=[D7F/FAX0E%%TF#$>(L;$/3$HGZ=ULS!B*
M&3#LTF.8W<WN*4A^$"G\UW$0B%)>V$=(Z>[?)$>RG9+!3IGM-'?P#:97P%4%
M^'-*O8C-$*4HN"'TGA+8U!Y]''6>%&:(-,G;FR2&:N,EH3'^E_CRZ74%2[>S
M:!B$!I.<^1IY":P$V$DH$>O`S')L)$,C?QZ3Y=*C:Q#L>![!#NI[43SV?=")
M8U#<[TF(?8R89N'4I].#8^<J<Y"$B*L=KRA(!VUH[/6=&L1^C6!S!Y5+BZC0
MT;E!7MR#"A$=<@YL.C2(6>M6H:-SDW)`_^:ICP2-?+G%/F]R/*=(J,P/Z!E%
M"33K$R!R`*5UWPXU8DX-EZGWBACO%JS,,)4[&]--_+0_1,7VAT%4EJBI2@J?
M<RWD%GM/0$V,->%3[VT8M)HG9VO+&E&`5;'$,5\"G%5@3W`I@"(A`S:2HJ',
M_B#[=GP8'F@>V<X]'0;E`WSLO;$HMJ\9$8D>8^+_-L`X-;:L$47JVYI$+*9)
MRCV]6!3;'Q)16=5@+%FN>(\]9(=J!T-BNDW(*V9BBMR)[L9^C)^AC$98\CZ&
M1/9M3?'KL,"D70PZ"W/-EW=\R<_WN$\-I)(>S7K?#H?$_)-'*2P*-H%5@8()
M=QC^FD0^[_XG'"\F0"2*,*'P_1F!AO\4HFOT!#6A,9T+M!\=&CGT@$(O%H<W
M\5HX3#U!A&ZAVZT;K1;F$T._)WS#!8LFUNY.4VA=SU',%Q(C-B7Y`5Q^G,(V
M'LYKQ'R*4_E1Z]F<HM?X,H2EUQ6PUK[M8\?4@^75>74/0,'0K&ET<0S&CDZ]
MVL&"0X.W!/;FPZ'AY_T.S89M-]<``R[O8FAPN9NDV)\&P-?8BTF(NL660E]#
MPVUP(0PZQAW[M8L-NN?!7KT/+L^Y!54)!N)E!YT4ZET.#;[H4[A$<P,R,S*N
M"`-J>;24,#'OO;6H-0!+^A)B.:-TKR0]Y`S--)FI.NCBZM+IX$H2FGOA9R^.
M8:%O2[PA%":E[@ZPQ^3S$:CX!$V2-4*7*$(S'-^',"3#;+3JO0Z^IU2=&8-8
M0](N,G!^<?>`7SVH@(2R*`IX&';ZE?>E(X0\[?ETJ^M!Z5&,#!<T`!7`H4K/
M(N"1T.IX9QV+(/^9QYY$I'_"CN>>MSKE\^`4A3';?!$SX_CL/`OX_TOV^9?,
M2F,@?;FXA4D)7VB"RJ?&5PGEH=Z;[D/O"84?C_9IX=0\PI+D[0JMOJI)3`_(
M1_B9T_8%Q6I8:JMTP[`K:?B77[)A+\NX>I+:2AOA:.[*O?<P=]![*QQ[8>D@
M5,;7]HI&\&3!D_4TEX,<3=#5,E4K9<Q1^85$O@*AI6(F:-UXGV'&/<'>DH;*
M9SI57`F0WPCD=2NP?FV:X`*_8L*U2?@?-U:?O5`8\/&51^D:Z/[FA0F2H%6K
M:P15(44:`6P7TR+/KPCEN_DU>D8A6:%@BOQ%1$(R7\/.42?2FRN8X-\F'"X+
M;VP6.Y+"%M#=NE[EY4U2GP<AMBHG334,(RAIL<K#(*UF!LN*6QI,<4^3%C="
M>X*F9#R;B=#=MN5;6]8$U6#BX1C=XF<>Z0$VZ)R'<^3S6D)^2R43./Y)2/""
MPU!"<?ZS"=HF8(G/"I9Q[81Z?IQX87K57T)S:S4M.^=6+UOC.8GN*?%!N^+9
M"#SJ+XH]<RDQEOHU:,'X3*D7H"_>$BD.3*F\IA&)$44L[N`$4*]GAK_<H49H
MC2Y66\0$C95K#K4D[EY-,$8AK)G=$Z]VLNNK&<;2O%%:XI<37N/Z=95[1)N!
M=&G!!,)[FNF#K09<74E#%*\\'&21N<W<KR^K15IG3==O9^6CLSJ1K5[YL+1*
M->^]FS$S0\"R!S+X657,C[!`X`D:Y?M08Q43&`H7^`TERW*>E3N:&Q#LAE`>
MK<V3-_$,)L*KV^0([MNJ&4[$'HY0\,FC$8[F;.S[R3(1DPUL6>QCV9@J5#2!
M1WD';]JS2V>`8UHE'9;FID'XY\X!8#7A5E;BE/%K$+RU8]!NEYOZ,Y@D.Q[Y
M36=$Y@P?$0HDBZ1O?ST[.QJ](&ZVB+_AKQ7%A`*6CT<71Z.$`7%DE9Y-V(VN
M+!IS@.?.`=S:+\LX%=W3Q>B>OR'PS:>5!>:+-X2Y:I\5&-^](8P2;;$`^]T;
M`-M5(2W0OW\#Z)5<^@7D[UV#O*N45R=XD[);P/[;VX"M<NI7@/[A;8!6=R@7
MFLG9FX9>]M46F)U32)HQ%V<;!43G](^&9=SS"*)@BG,*2_.XMYW-%<"=4UX:
M9L->3JJ"%<YI,LUS0'XB7D!V2).I.68IHZT[%\AQ7C@TM"TX>\;!%2QY.T/?
M$$94P'7(S:((5QZU4Z!V2&57/:24+/HR:H=T]GU0UY7*P;]S4]0I^-64[FX4
M6YN;4[_).5$?)58@=G/:RYQ13?<LBJ7ND(VJ.,J26-X"LD,FZEX+7!*U5##`
M(0-6C0&=8D0*/CADLRJL=[78M0*]0X:KVK9>&T=3[.L.23HUO+NW/@JP#LDX
M-;`J%^\*^`Y).#7XO6-1"MY4I-[QVV!.>WA*@7\?N6?C-?#JPUIFR<Q>ES)R
M]8U!_YFR)XGBJ98Q<D4"18AZ(3>]@B6.,(NYB^D9Y<E4:^ENJV4FH)R/]"UA
MC`NBU'.6P**[6V5>,W:)9J22G/W3*]`-ZP^F,EU/8,H(7PL_.",AT#??*"X2
M+@S9HSD.`IW9,&99/1K1[Y8V0WG*MI2FC*"FBP62XF;"WD7^/=8L*;9+&0EX
M1W$QY25T5LN8H#);?7PMM=!:5U)32#4)$E^D7WM$]!F&3C*Z;:7-A-36G;$U
M[P?-=;3P=+]8>NU!]+IX+,97-C'SGXVJN`?84,NZ<NVZ=3)$Z<",DV]^3L8Z
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MX/M6`)8RT[?KV8%F*ZJFZ;1#H:HMF-)+Q_*$2\UU[$!1O5:L#&2KVD#K6H=.
MIJ%50^=77*$"T^H9@_Y\N?[*N"J213)$\^P14QZ45N-4E!]X]6G4(C[PA<1B
MS7Q0;=0B/N0>"9U\4&WT+9[KRDY)L_=R;@C=7&BKF2VU)Z9J-8VDE\I(NYM=
M<Q\5?DK$N);"^V4<5JEI%M%G1.>(EA\_JI%RK>C46C&)%%CN@]%-T>9&'F+_
MI/*ET5K-"BS25!"JJ.0-&$KCYB,4Y$>`8KW`?$I#2V68FBM9@X.O>_XA#:3L
M`F:KI@6(2J^!*R*IU#"2A"U_TJW!^FTI;-37OH\#LG)KI:=BY.3%^X&8IJQ5
M.WG;;R"F*9MD3N8!T&.';N5Y:M]%G+Q:.3BOJON3DW<Q!^"1BA4CN;9I^8G[
MD,Q2-)`D]SS_>(QKT>&=O!&JQ[E6Q($H.DDDB7_<G%-[,$O=AI?DY_TWIQH\
M!)+<&V[RK*-_=TM=K8].=U];Z,$5F;WL9&)D_>Q1"S!Q,D19'[.T1(\YF;AY
MB`G7$IOE9(IG_7Q2B\QQ,ZSZ$-RJ1&NX&7]]"#9MAX-([K3]83BE+3#%U>MM
M!UB8NZ%AKEYL.YC,SV-+G4P9/OCRK(T'=3+U^,"L4@G-=C([^2$6XTZ(;K]T
MYH>]77.-F1\2EA1.)^%92=,CW<W2;-VPKX&IC)FP;QC,AG00\R1BDVA&:#H6
M)FX(]<#`18,7K=DX%&?SO'Q425L]I5[$TO&](13F$8N]1Q]'':\>Z3GDO]S-
MM@U:/YE'^%\PJP,`A6?8RW/K9SZR`*"7$_LR6#CPL?(\V%:`P``=F0B*T`EC
M^^$"<45NNO"BE@>[#TN#EB!'G21/*P37!48.V)N1Y&1=WV\WL2T.)TAR%6/(
M2>2D#WM8GAL2>4ZZRP\S$G5,VD=S=D:7NDEBJ%;VAV_<1P;$<,.30S44CF<Q
MHO^+/'H#%222NT^+)C:B;O1^@3DS?4'A,_H,AM!"IACV;-1^/FB=!`Z-OR"5
M)%0?;MZ8&[BGT+V^`4];<P3Y"]&'&]JR#+7\?G%+):/JB1H@Q??UE$2]D_KT
MT&S*UX>3.NY!N)/*32>C0`[!GW0_=3+`XR#L$6J6DW$=0[-GRQ[I]]:W,P;D
MU\A+`LP/GB@1!PH[YPIFW,<E``Q(NTE)4TOH>K6`L48L/[+E9TY14)/;%<5W
MLZGWVN)%/B@I6IW)<LK;$G'MW<P!Z%=*X;]_.R8/3>H(5<FZH%Y_\/%I3ZN_
M5Q-6."]-"*4=Y[XRTYVT,*QGM4H6=8=LELZ2I^[@X["#Y:3MLQ>?]]_,>V;W
M-J6^/G).TO7=[!'/(SS#/K]AE,^+>Q)BGQ\#V1<$HT;XH[]`01(B_BK::WZ.
M94#?J+POUW[KI&M.&&W-&\I+4D]-8VZ?YDI6X9![:!NK&!6?*F"VK@PW#J*3
MNE%7)NA;Y1+5YFUL)X54+G.I<H[N"H![&.O(S);2Y&PKYJ%"LNP]&K+L"*QI
MHVBM9AF6?Q_G[>0#<&G+T.LTEZWC/\CV(`VS<@5`2[28*1C9LR[C.44H?:Y(
M7.K(X@/%>K'/XBN]&L<)C7R1[TB<MY1^,K$3?YK-$+]B4Y#X`$NV0VKB#@V8
MV*WJR:L.PCB^0?PZ2<A?LDF`D'6E<"?@W5JVE2.IGZVX.06%4JG^S0N3%%D8
MDA<O\OMPITLOMG+J"^'"(?%%NK=,0-:G+N&INWHPJV-'MO)+A*B/@U\3%HM$
M03TXLM.4K9C%`UD\.!W(",OR?G_LTB:-*I#=-Y.R,JE%5#NI>`_/-_D4=/(@
M:GB&=97K3IXS#<_&3HJ$DX%XP_-P=\OL%Y)G@1%4]J)N38SJ)2X3)M$.2=74
M5Y)=NZV6R?<4<YHV5]Z`R=O^&E5834W8@9%[X.K?*U2K8P4*GA>C&X92#2L0
MY&%&/%#ARJ-T/2/TQ:.!\E1K:,$*A/"/S;=,0RCK!3R$-HVP8)T-PD&ZLI1G
M/#<7?49<\(MT0%[(LK1`Y7U@;SZI-6\%;W9UHHXB0-Z`I?A`R_;[0BRU81AE
MI_EJT>PKD;(M9-*LZ?S:?7T*/9&/OA/8_7JPAT-=IFQ]-:/FBH*B49?U5:)=
M.>EMZ<N"O;<P)UTM?;G5L*E)?":6YRQM%OB-O"BSKF?0K4O@)=+3R928JIM"
MXSQH,HTDOATGYT5'MC1Z)]S,F*V%+]O^)S>S8FMAA1:3V\U<V3WYUU_)=S(S
MMI99UVRX]DN";8$WWL*`*5BT2YP>=_"7(,5IRAQ%(D)M$\?64,;$L8%X;,SS
M8]#^[YY"/&\*6ZXO:\+(K:7D.DD3'-S@6;S@60ZZP-BM;!,N_K;<?J#*-2U#
M1!*Z+Z2BJEV8%-/==6C`+GR/_(@WV&O,2E7MPC1=8+H?I**FV8>'FT1X64/H
M,F^=])%IX$1YACOI^=+`@]**<#)`2`,+RIN3DP$^.GA0J!Q.9M/JS8)M;=+-
M?%D-!H=;)M0#?+3B,@^GD0>G$O\W"SG([S3'ZTG$8IJD?'2`QO+M+IX!?97&
M'MI%Y&U"7C$3XWXG",R>^5E;1N>W-<6O]I-97.WCI.YX/:U8ZCM$_^11"I.4
M36"6<M\V2*A?D\CG%/R$X\4$8*$(=@+X_HRHB,.^1D]0$QHS/)_+SV^)]X<\
M0;:-\N$Q>6+H]X0+?/ZNIC44?B$Q8E-R@R,/MJ3T/H>XS\DV*8RN$?,I7FW\
M^KO9**?0_248NK^Y3O^4/V5A9$K+431>$GX#E+M(\^:#7;1O7\BVE,7Y>4<A
M&QVDU,8%UV!H6,_K;K3;R'VA\BU("`8U2W4L7M9ZQA<$BH.\7%?-5"MQY%R<
MX=][:U'K;8*Q<5K)5%SK)]8MFGOA9R^.83UL+VE+2=X*8?FT7(5DC3;Y.7F&
M-5LIW[(N5,C\\91W_P0+`?[X?U!+`P04````"``<BDY'T1NU\Y@L``"=-0,`
M%0`<`')S=VXM,C`Q-3`V,S!?9&5F+GAM;%54"0`#2,8>5DC&'E9U>`L``00E
M#@``!#D!``#M?5USVSB6Z/M6S7_P]59M[:U:QW&2GIE.379+CN->UW5BE^RD
M9^8E19.0C!Z*5!.D8_6OOP<D)9(2``(D*``R7[H="A_G'!P`YQM_^Y_G17CT
MA!*"X^C#\=FKU\='*/+C`$?S#\=?[TXF=Q^OKH[_Y[__]&]_^S\G)T?3Z=%%
M'$4H#-'JZ.\^"E'BI>CHWGN.HWBQ.KI`,QSA%`8[NL;1OQX\@O[KB/XW.()/
M?S^?7A^]>75V=/28ILOWIZ<_?OQXE23!>L17?KPX/3HY6<_VK8#K_=&?7[UY
M\^I=[9=IG$7!^Z.SVJ>/"?+RB0.`Z/W1F]=G/YV<O3XY>W=_]I?W/[U[_^:O
M_ZRWCI>K!,\?TZ/_]/\O-'[]TPGT>'LT?35]54/Q/X[NXHA`Z\72BU9'DS`\
MFM)>Y&B*"$J>4/"J'#0LT3T"@D;DPW$-P^>')'P5)_-3F.;MZ;KA\9_^[:AH
M_/Z9X$:''V_7S<].__[Y^LY_1`OO!$<D]2*_T9$.QNIZ]O///Y_FO]9;`QQ!
MNFE>!^NGT^+'HC7![TD^YW7LYS250.>(VX+^ZV3=[(1^.CE[<_+V[-4S"8[_
MFT[XMR0.T13-CG*(WZ>K)?IP3/!B&:+C\MMC@F8?CA/R(Z+K]-/K/[]]3?O_
M^T7L9PL4`6&"3U&*T]55-(N310[U\1$=]^OTJ@&^MTJS!QSGO):6?'M*&YX*
MQSKM"^D4>GZ_2X$YZ1PWLTL<P6IB+[R-2;YC/H8>(7B&4:`*N.2H^T3AUDN0
M\@(H#)T^HA3[7J@?J2LX_A:H!^CE`-H!NWL$Q!_C,(!3\=/O&?#G)`IN@!`)
M/9[@)Q01_(1ZPZ\VCW8T/WKD\3*,?Y"K*,`)\M,>J.R.U1O<"TS\,"99@LXS
M@B-$R,0'(A5,>C.;$()2`@0[]P@F-[/;!.X).%+HKY,@R%MY89]#2O?\)BE2
MWJL$[M7RIKF!;\!>`94KX)_WB1>1&4H2%%S&R6T2PQ5XY^-(F2G,`&F2MI=9
M"MTFBSA)\1_YET_/2]BZRD?#(#"8I,S7R,M@)\!-DL3Y/C"S'85@:*3/7;98
M>,D*#G8\C^`&];THG?@^2-`I2/FW<8A]C(CFPZG/I'O'G0K8018B*G8\HZ!8
MM*%Q9T]J$/<+!)<[B%Q:C@H=DQNDQ2V($-$^>6`]H4&<M5X5.B8W>0[HOSSU
M@:"1+M?8IT-.Y@G*1>8I>D)1!L/Z\;RPXVB^%[I.J!'G0G&Y]YX1H=."EAD6
MY\Y:=<M_ZHZBY/C#8%0_40N1%#YOI)!K[#T`-"G6A)_\;,-@JYDY6T?6B`5H
M%0N<TBU`207Z!#T%4)2?`>N30M"F.Y)])]X/#32OK/),^\%R"A][7RR2XVO&
M*([NTMC_UP#K)!Q9(Q:%;>LJ(FF2%=33BXOD^$-B5!<U",D62SICC[-#=H(A
M<;K.XF=,<A:YR:>;^"E^@C8:T>+/,21FWU8)?AX6,>X4@W+A1O*E$Y]3;R"U
MJ<&II$>R[CKAD#C_ZB4);`IR!;L"!5?48/A;%OET^E]Q^G@%0*((QPE\?T(@
MX3^$Z`(]0$\83.<&[0>'1@I-4>BEN?,F7>4&4R\'0O>AJS:-5@WS@:#?,WKA
M@D:3:C>G28RNQQ7S)4X1N8\W#KB-.X6L+9P7B/@)+LX/IF7S'CVGYR%L/56$
MM<YM'SGN/=A>RKM[``B&)HW0Q#$8.91FM8,$^T;>$K37'_:-_F;>H<FP;>8:
M8,'Y4PR-W,9,4MU/`^`GG,4DBKJ/+8FYAD978$(8=(T5Y[6+#+KYH-/L@Y_G
M5(-J!`/1MH,RA?R40R-?S9F;1#<*9*ED?(P)0$NCI7(5\]9;Y;T&($E?0"PG
ME.Z=I`><H8G&4U4'W5PJDPXN)*&Y%W[VTA0V^O:)-X3`)#7='NZ8#3\"%)]@
MR'B%T#F*T`RGMR$LR3`7K?RL@]\I36/&(-H0=XH2.2_Q9?'C!+:O0^9I1/M/
M.=I>&!X?E0/7D=CTPE%Z&N#%:=GFE'88$!Z8BH;JQM%)@&9>%J9JT.UVWP^L
M\<+#46=0B]Y#0IK/<+)`BP>4*(+9Z#H@C(\P1.)G#^AD0QDU2%D#E/`&FQ0?
MFN'3@!DV&8H"FK]0?*5#Z<B]*"8^;<X\)#22"166PM5,D#`)9)DC8!($M6R&
M'"@`"ZZ*!BQYY'><,+=COHEF'GG(=U)&3N:>MSRE%^(I"E.R_I)?D2>OS\K,
MIW\O/W^O;/FW'J8>&F^)4Q!4RO.EF##T'E#XX5BNSZD2%KO7-_T"4_R6D4(;
MO8_K_H9RKK7M&:CX`*Q8K.`FWH>"M06[KE'5L-.U1DRP&\0OF(LR51P5R2<-
MEUK*74H-0]M*DWSS/6S[7Z>HB)!'=RAYPCZZ10F.@UH(X#<OS%`/>O6:5O/N
MX0)9..!SGK[-$I)YM.UGE,QW=KV.$?>%54YZHA^W]G%-[(%:N)+PO-YMIV4]
MJ`J;X(<L)\IE$B_JVCV+T.(.W2E(D/]J'C_!#8\I\=[1/RB\[VHT@T_?"]'N
MHI3P&_#M_&P5--_?&.&OK8.?":JXK9-0]Z*V[.KGYJ!BC2?/F#`88+N%ECU;
MA)9=8&\>Q00D=,(\.(1-3:SI%Y06(O)U3+9IQ6YC`LI"\Q$>Q8TF)F`$@0/A
MI]S$3$_@FK=#"'=K-S.XI+!=4?#)2R(<S=F\W-)8RZZB:20)084HD,L*K`W%
M:*5_=I;PRFME8LT*2:J(!^2L5*.)$1C7^OO6]4`8)[5<'Z-87`/;7\&?K:!7
M#8W"FSO`VF`M&IF!<]M!S(5UIZ$Q>(O==)$E-"XIUSR+75:H\B1/#ZNI]7?(
MAZ9%HA8?M^Z#6D<'T.?\1U#9USGS7=#>&<,Z+"NO<]TRT057SD@689Q?<?V6
ME3V$ECL[GY&Z"=>1LZPK>[>1EKGS+(Q;6,"%YZ,L-]/3*#"^)B#NL(&I,J9/
MDB9T7N*OQRU=/*K>JK+W#&1/AK*^GBR6`O@H3N!(IN7FSGY^_?KX:`EK#>?2
MZL/QF^.CC`!L\;*P`=F(&U>#VV#UYK5U6$GIYA1%@6FKPN_,??R:JF*%VAOW
M46OQ*%6XOG4?UW9MND+WW2&@RU:X*R1_,H3D;JS)]J'*,;A1]';/W`U"KTV=
MI3L!*3WP^?[&+HQ82Z2D>]=YDL.\-N'+6$&]Z%JQP'G\F1#''4-$';%M]7^-
MS^O7)49%E-%[&B>*@@_':9+;N<J/<92BY_13F(_PX9B@.?W#TO-6EB"[=H9J
MD>V5@>2PTQ/34-'#7L%)<K4;=M$*+WN%)`4N[F%]JBAAK_PDIH2,K[S"TI0`
MI05+AE6CPNS/CF+6S<Y4X?T71_'6%H=7D>*OCI*BHPFY0MP^.U,G'N@635:9
MV^PU3.DA@T3X644,5R4XKL^Y0LU588SKS*]0<UT>&SYNMJ*5JQ);+U]:A;ZK
MHAPGZ*I"S)`DQTPK$J+7B"1@&AO89A?CMA0-J#)MA"5B;V01,Y0UL_MPQMZA
MT?[0A0'/.`/R_,\$(6%4;'L_$W[^P;`Q%%W-@HL?7\9K;0GD.Q=)._C71J/-
M&(HK[U65FD(+]V%&/[5@V7%0>^A0E"9(&\!/:"G'>9G0_TC_O(HF"UKK*C?>
M,;O04_),B5AZ9W:/HO>/:$K_NIG=9"D5O@BG\YJ!5E/DD;RL[@!4[@[-2Z!\
MKO#\+YX_6D+["AXM<6+RX(->Y%/I9\Z,/.\TCB7\4ZJW?Z#@*@#(\`Q3.;N4
M_@HI(FB^-9`7HJY>\9%EC+X3F:#7)96[T35^HJ5]4^!5O`%YBJAD!4M<?T&D
M4)]Y]T'7T4Q@GF?P7WL/<5+Z<<JBSKP%Y[<WDZ>T6AN`"LY:\R,BOR3\!*O6
M;EI.G>(!.T(?L%N/SX],Y3<V$HGLT;=(<JM1=9+!\?TC0@EYQ,O)+$5)K>P5
M+QI9=1@CN`)<'FS`RQCT<X^(L]XXC4W"_34B2^3G!4N$VB._O=/0&])YJQ=[
M&`HA.5_5_B7,`E(=QF@^TWH19++'&FWMR&ZB9<X*Q_X2!(\J9&-*;V'>9:X\
MC!VXEKZ?"DYI]'9[FC/O2UO*-CXOP:5KWO4E%SC:8DZK6_\EZ&/<`R`7/JH3
M:;N#2&5LC@T/C_)-<\`!IZK$$Z@W+D2@*O.*LMSN0MRI,A5D;D,7`E/[(]XF
M\K@0E*I*A7:C@`M!JJI8]W4#N1#>JH<F>W!@N!`S:SLQ:SX)%^)N9<G9PR'A
M0A3N?KE*TFOK0MRN!L+U=O&X$-*K2J?.KATG@H#;K*A-19)MZ#8>YBH?(]C1
MZ-IF/7`M5%(#&3@V7=6P2N/)U2R3-(OI&3O$^((K)E9W1K6+/<R1"%4:[^Q%
M*S()<^LZ;<]5>^#<*ZS#=]0Z/(:QCF&?!Q;V.8;X[(E>VX)D;F6^!YWDES@.
M?N#*\C\@*=MA&"ITKC/(]PV`)0/L=,UF@N=:V$'O2KD<;F0ZF,(&+5:#8]N8
M.7OO+EX+I/?1P6NC&57;Y72([N$]RT"'Z%MF87<X#N1!C<JF7,QNFA<=,<!<
M9BETJQO0RPB;T;[R<NTK`I\+@U/RH*1_("^YA`X<[/J,:#\%OL#>O?^!PB?T
M&82U1]X2]QS4?CIH90*'UC\'-<YX22<=!W,#[WN87M^"%Z,Y@OF/6!_>,)9E
M6+=9U*6Z6H;3%\3+HVCI-%KXUJ*U@%!RMKW6`:Q2MW18]4P%O8U6O87B<26T
M[K5S_@';];J2KZ\@[8(9;S^TV8@<+ICE]DB20OYTP9JW/Z(4RHAQRYU=-,D5
M4_.^-EMHLF6V<2%_9`#"Y!J!\72/#B9N63G\)1NWOT9>%F#ZN$$2Y_4O=\I@
MFD'D+ELLO&1U,[O#\PC/L.]%Z<3W:2X$K>T;A]BG?AA;JG?2X,P?7N2CRSBY
MB+.'=):%);BD>G>,H_A)=K;,4'"^^NS]%B<?0X^(WEI6&4&+"4$P(1SKN(B9
MS65G>K*S[`J*(UBV+J*J4*W=+,.EXH\OWD+LX%(=Y<5@:JAZT,NM-[>.G[A:
M+#V<Y)7;^3N2TUC+27@5E;<TDW!7$5SY/L@*4Y`&0,IZ!`'A`CVA,%X61I;=
M@['?@%IPNDF6?(-P]:.>=Y^E9!">$Z#3$'N$FV6*5NZN!=Y_H@08"=UZ*4U\
MY2\OLYW9)*T.\I&DUL6^$(P;C^4LYOLEBQ7%D/KIYJ+K?^-)8>\3XYKY'C"O
MG?K&?48[[I,^=T7U&I_*F7V`3I2^1%15Q&UVFFAAJ)["G\T>%%V\TJY$V^PR
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M=1$HW.6-$L\R1X!YJ[>4.V`X$EAA^N<&U,L+"^QP^K9M<8!VX'ZDD[IC;#;J
M#83^CCG3/HM=/\SUF05L-N(-Q!U;`;[V!C<KB,4;(R[+AF+>92IU;>[(E_75
M;(AWQJ]`B<5CR*-U?+8,,S;[YV0Q:AK$C'O4.D30R\GE4H=,7=0SSJY[(45M
M^ZK6G';#%5"_:1LE<=P`OXRC,>'%$*4A59),76)1CXOE#619,+#Q-((Q(-^*
M,'7;,-U3'0P]>(B#?1H[I,U/T6DH(_9D0;@PNXU9&V<+8>4LG5*#O*#07PMD
MR6'#7SG<;EP]XMH\^QQ%;"NHW,8Y8%NH+I*JQ#O:%_6Y1VIP97`73,=[H,^6
MP="=HK<J=_`8]]?0EKGU;]T`WZHBOKVJD"C;`<;BL6/QV+%X[%@\=BP>:Q76
MAV_X'(V%5AH+AS:<\:H2;&2Q3R3%"ZI<<84RGI&RQT![QX%?7T%YD-&@9YF.
M_1(,>OTW;97<KKYM#M"<IX>@NC0HFTU])BG%J"%LGZW/.(&V*PK;%T]JFD3;
M]87MBR8U3B'KB^J:I!"W]K!]57[V1J8MOX.A`D"2E0:ZJ@H'[G>XQG[.WG.X
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M:+U[(@B-BZ+FFDV(NU-)F`QYG8S$-A9FEE]0/$^\Y2/VO5!HY.>W=QIZ0_44
M[E(XF;8A$CB2^.VU\/6W58*?;Q\]D-=\E*5T<'(5^7P)1]QA_UH,[P[?6#$;
M$IO-^E@K)BUK5>'VLXWID0*A@F*XB[UQCP+;MBYQ,S$LZ-Q;XU`MYI)DXBHN
MQCTKFA%LE;6LM^RK,+Z<J&R]K5X%Y7;]UWJ[N](*MRMJUEO15?`5&*&,V\)5
M39LM*LSZ.MZYK8W?R`,@*B&7JZ:!FPAM:%6+**YURY)Q>[QD':Y6?:FQB'PJ
M&.==N;`=/>AVJ:]EQJ\`^DN\0/?><RX*Q9&/PZ(R`<WZV/QD,F6A!D:]AD)Q
MV</GS3.-U]A[`.A3;`V\`I>,&=@^QHL%3G,Y$`CV,<ZS/E"4YWRL,T,$;;1X
MDP3C"TV,4OVTV&0$,W%-C:U]3-BZ*!B)YZ>9%]X\A'@N*HG!;FL-U!=9X=J_
MQ#/F"Y2*G6W"ZRKJBE2]IV48Q5G2%:6JJUTX2:93*0Q@%WYW]/X/.JU9K:M=
M.-T_XJ0;2E5/+7?*9R\"59W>#]3JQ#?O,]OI@B";4503N)F$`.PTT_,$Y6R&
M?72-/,(NK\QII,=SG,0D]8@/.L%5!"HI]%O=)UY$0(H$.O/AD>NHR>/*>E)J
MDB2T'AK]\R.,056,=4,^U%V',E)ONPU6<2UNR=XF,/L:T4.Q5`!N,X`2N+HZ
M93Z"HCF/J<1-'P<B-\D=2IZ`^8M'Z$&W$;I5-0UNABX)7!>@'0<M2)RO*C2H
M>+]N$0C<M9H&WZM'2T4CVMA#VY640_5LJ9*K11NRV26M'U^.)&O>&KEW(M3%
M7?.N^[VC7Y.,-]B?V6=?'PC[NGY:H6^IIWL`]"N#0X6]I6YOW=AOFY$J`AAR
M@LLYU62-DG42Z)*TS/MNVAUP>J7MC9C%UMMM#HX9F""2JK3-T33#44A9J;4Y
M`F=@1NIL[[`YC&?XTVC7AF=SF,_`]&#8%(T'`\G%&>@U@C0O?3VD=B-^02`6
M[2$A\AXE"QSE`W^)4Z"B1%XDKX^>]$@@6>.0R(FR6("`B;VP=LX*4B@5AQC:
MY;XCY(]!`2\P*"`_XX&(4QKS&JZ+D+*A9K<U`S4A*+^?Z#ZJ1!MR`RJ?1[DA
MAY70,X%&WA34YJ+5:3#][LM;;T6Y%\ZMW'S8ZL;<;J_'G=A$.A\Y7)W#WW39
MK^B=XX4,SZ]B9Q-<<Y,^HJ1^=O#='<RF-L`L=%YQ&CL*MW(BX^BD'IW4MCBI
M[[('@G[/:%[%4QL>[+860'V_6HH>%.>UM@1R<?HTM[W3T!M*_AY#,IREBS&.
M<2A8I<_-_D^4I%Z$UI?N?0(2,,F5J"!^)BNROL3NTBS`H@C&;@.-`3>'$W`C
MH3':[$`;-LC(/G=8]S5NMX/:[-_JM<Y=+3LV.Z^Z,X*",<9F;U5/CF!:*(W[
MHX8++^%J8<;C18;#F6V;,YZA[DP,T5L;\K]%^>XBXZN($1S+<^^'9I?\=A-A
M!V+K[N;ZZJC[F(\:EBSA(+:6M1SICC&V#F1=8>]6<YP`6Q<J\MD6RFA?;H2-
MH8P69A%8'\IH8>K!P#13CE0RGZ@@=]L>7F3?&"+)\TBX'R1)K146O$M-(8RC
MNS3V_V5=T:1/L.CIZBHB:9(5-.P?6*K'.34)\\%1</?H)8B:V^@12A>S\50W
MV_DDV=F$TVWRPTN"%J=^LXV90,H-SW[TECCUPIR2N;:8/*'@,DZ*IVNN",F\
MR.<MA/HX)E\VJ?-(3<+Y%:>/5W"F/N$@6R,PR=)'.`[_R%%H(8*VX4W0YM-B
M&<8KA,I[@KVAOL2@8Q#8;SGGDOL8%KK^^T=01K[$Z3]06I;+_(/[`L1P\QFE
M'MT!-_E]*0Q#XK<_E-=JNM-RO0UN9L5=&@6_>G07I03VR%J,N:'/7^&=@/IN
M8QSL2SC760QC76!O'L%.P;X@Y('75",<]S_B^\<X(UX4T,S]%*&HQO^WH<?>
M,UU&T`+UEXR.5;)0-04SB8/;ULB;/#`S?8)8('HTFIB$41AVM=7($3AU!5/3
MRM,)\<*;62<AN=L81D(R-S5QV;#58Q/.5U6;\CV`0HQF)##I']\(==I@YH%\
MS<DZTSBP4_0HCF7R2RX'7)6E]W])8J*=0(*9K*08E^LK#34*I$["0:8:::8\
ME:F7R<94#-.0[R45@R.QU.1S6IVH*9X#CUY%]+T7_(3$PGZ78:Q^R:XW3'U4
M)[4!S#J>F%;31@3`(,>R(]XD(]2Q/9"D]<E#KA'$9L^UMH<<STS%:!_80XZ2
M!QC+]-)XPL_-DT<-+=N/#+%MI[G%Y&]>%X*'6C!6M=,:KSO9'^5.(FN%MZ$$
MD-98^<%,:PX_[#<H3=@GI?U)%7LARI;@:CR/P@ZJM.4>O;/GU6K]MN@&(?11
M^0#SEX>A?8N'T^;DYF&9L4-(E,V9T<,22]8Q:7,.];`4&C"NRN8\[`$/+76W
MN,WYV@/?K$/X2HVG@QLCI[X`4A=2UH:AH6)XGPN9:T/ZBIEWR6Z4J4UYO`-G
MMEI@:MAW7JMDNI@EN25W&"24&?9A3T]@LR^*JT1/U?)JO*^PE>[C"Y3F=7O0
MI8>3;UZ8H?+FVCF#&O7!.PRCI[:Y],3<@MRJ0QQ*0/D8:CU$`,EG[QDOLH4P
M4*?9Q@B4<("U0MEH8Z3"+KWN!8%#U>_&H!/7^*VUL!Y"4P%N767BS>%<.[^I
M@NJ#^GI!-0:XB*>@R^H.196>UQ@U']JQ>E#!BI:K.Q.1<9@)#X8;O\4A#!/"
M[4CYHCS\]\F6;``.E;[%M660OB4`SM-WBLF_+A.$KB*0AQ%)]\R]HND/D[;[
MXUS1]%8'_NZC$G0/G;BJ9*.JEQZ@GU4',4U<'#9[-URCZ?JZL-G%82U-A9>$
MS0X/MRBZRZ/V>4:T4W0@)=&\V\1!KF2;+8R'/\O5C^YH@6^4DZSL?,8]48,C
M+8KU-1?6.FP^D(5!2MKR@8S%"KW,?*`=G\#.0;*[0N8Q$GCP91%R)0>(X72H
M8[3E>7(A++8-HZ;'3S5VU9(8@^(0KZ?J^"F((^FJ>PW+T=U]^.[NL=+0(";C
M'=W#=*4A#M?V#8>=1$$1M+A<)LC'>>\IGC^FY%=$_X>"R1-*O#F:(KK]<32O
MO:5&5<[)`V$]CVX9<';0^LG#(=T*EW&2AR$/0K.=29S:=S=KA9Q6G"<4CR*C
M1_<VY,[C.+6V-D;Y"[I-,+?([[YF=Y&RL(EF"-/<J$W*P$!49,WD(L7&6G2J
M>-QD*4F]*(#KZPIN+PP:JY\;L`:B&W\^*VY)+GC3.`QAE]"F0UR<4O,ZSE^#
MWJ6[\SA.+3[##3R9XW0S((/(SG[`E*4,--L7M\H"XE0(;BN:/#7SC>[8W!Z0
M6,GA7,M04X6H1-\ACA"]0#A)9X:288+2JF`X2>NF>F*"S`H0&*$P->W1W&D4
M7.1O#19P%DGF-3_(9F-R[S7U@2QT=TLX\4UYZ`[,T3V6FAOK8UD=MSTP[0?2
MD%]NS2@3&I[-H5W#4-LREZ(%`6A.KH"<?=?Z%!"+&)%S(.W;!+)9LC?V19+M
MW3,QT/6P[2"J0M3MB_;?CT5^($*O/24VITVY1^"6XGOVY5$9('$'JXC->5/N
M,2DSYL/FM"KW2,P([[+YZ9K]$7BH.$/5NGN.4U?13VI`EW?CI1%'ED2G*\;\
M,U,O9ED4O;[&GZAY.2NC[">NUN9%J$D&[Q?I6.]J2>24`DO2X/*LWS$+;O`L
MN#'[S((8DC'[;,P^&[//[-EW8_;9F'UF$67'[+,Q^VS,/ANSSPXD+VC,/ANS
MS\;LL\.D[)A]-F:?C=EG>P/"23J/V6=C]ID]%+8A^^SP'WC82P'8,2]NS(L;
M\^*V*#OFQ:G2?B#=?<R+&_/BK,_*&O/B3*_`F!<W3$C`F!<WYL5917/WTC7&
MO+@Q+\XXB<>\N#$O[M!)/.;%C7EQ0U)WS(M[44LRYL4YN2QC7IRM*S/FQ5E[
MOQQZ7MQ=MEAXR>IFENLZ.X2B+]A&!'7/DNON29^$^>`H8"_A&C*V]URRLXD(
M@<*9!K,P\N_8;4Q`^6FQ#.,50C45F!D"T-Y^^)Q&EK=??X9E=UK^@B(X,<))
M%$R"!6QO:DA.\1,JN5!(5[F^)K"ZBN"@@?6&749/DFLZ$SU:^5PMZF$1!DQ&
MDNMS$%A\[Q-O:4L>\F&]QCE%!('H]0C'P`5Z0F&\I,LF<W[(]!PSO$7C6QFG
MZ4R&MQW1[]\0H8)[%%#&]^'/^YA^4O>[G@T4%*\10"OYE;O'*DDW"FY#+_KB
M+9#PZAID*BUWR]<H07X\C_`?+6K']N94[?V2XGR%L;!"E4J/A4;$G\:C2`_T
M79!]Q':;\LM4_(QF7A:F;(:6T*WJ[-VB`ICG4ZE=K!/I[V]L0+O=2"JEO-6Q
MEM($7`CQ4,9<THIB/CAC3-_0F+XA=3B,-&*)0255WKQ0JH@2?]Z.B3]CXL_0
MM)=U8+W0U!(5=?GEY7Y8:%BR.DED'Y:H^KH(_*.J,>R61`+\ZB5%W%8>#'T5
MP?K_ED4^A>!7G#Y>I>0.18`*?`=.23%<"A?H`7K2L)5C@YA,44A/V5LO25?W
M@`+Q_"(N,PAP0>BK:!8GBYP3U"(9.+:SR2Q%R02H%E#*\4UFS'9:K'>3Q1+'
MU[$73>8)0BU0\-KJ@Z1E<IWS??3(XR1X\B(?T;BIN\<X2>GY1!%D&E;%'4Q8
MR^%D6L11?G(4>0;%EN,8O'FM34`.&SZMC@R!JY_1T#R\%\A/$!S[P`5S_(0B
MQ*WBV-[//#:7GH\FBSC;J;C;VMP\[%>@'0`GIU,XN'.=/K@%31%^H`((_'-*
M;^O/WC->9`LI[)0&=`5_N#7UXE\.:![_5B\?M[G#L/>*J]$%/;WYI.#.&[H<
MN\>1'RYQ0G(TO3`4RTV<EGKBD.A]LI''R&</I&A`E%F,6:*#^_%:>GB=JM(W
MLX\)`LF?P^6-)J9AA$L9AT"PC=)]'B=)_(-JW]X2?DM7$EA(#&($SSB:PZ6T
MH,=*2[@SLZD-,`O/>4YC1^%6OIULB;#DP'&S1-0_&,WSD_-S'*6/(6P1D(C"
MTNK#`DFBEQ;H;A.T]'"PMG""8)ZD^(_<0L&_`]H[:8(M7F!"XF3U)4[9T:7\
M=B:X'P"!94M7=]G#;\A/[^.;I)Z3VUS3+XAW,R@/8P37+/$?87YJ%<!IX?OW
MPXP:<M?[NOI)<.2JCV,]ML)#K\M(+PYC0QI*W8`K1(G1T#%X+:!PS40N.!]$
M/2S"0)K\NWT.`@N[^&G'DRF'RK71W`*>^^A\5?]%?:NP!C"3:8,B#Z1#ZM,4
MI@HQ&IJ$]VM$ELC',XP"<4(`M[W9O"8YMI#+85(92\][1\B/HT#*3,9K:J;Z
M>AD?N&8*P;9EMWV9N16B6'2^SZ\>#\&WD1L/SI2+/N^'IBOQYFVNC$UT%C_`
MP.:*/=KR0RRLJZ(AH\=8I=@#"XF7/#E%%O#ZH<*SWMJ$I^#D[(>F*R>GV,2^
MV81LXVEUKIA*R)'CV,[6Q?HZ=S)AF6<!*5XW12!7=DD/\V55CY.G>[A0?5L'
M`7@A"M4];F]54;YMM"E:[JZIJ9ARN9-1PH+:3-,4&OK,;V6ITTXGTJZ<8%(F
MVHJ7F9'@U4:U+<M,UG#+SB%3,FD=<+Y8%RI>-T*3;"ZRT`=+5K"A^:(+>G&5
M24-P(:>O+Q?+!*^YD+C7G\_5PKE=2*/;%TW6(?XNO/O2GR;UE`T7:G1TP9B;
MW&2^,,<^EIB98^3":R9=4%</O*O4/><T`+XL(!-JZL)[*\J(2T2QNO`2BC+>
M+=D;YI\:Z673$$2^\+3]P[!K=$;<%=M&:VA-4^W?C1M2?>3`AI)"'>)P)(Q:
M3%XQS@/[(X^HNI)3%:=ZL@<K;,1XD:G]DX'M`RX)\>X%$8(3@592XJ<71(D.
MKM*22G]^0502NEA*>OS%<G%*&'7)$BD8\H?JU6FFU!`HN@3]GE%>?J)<V[_"
MD*8WA6KUK291\`5`JK[4N5(8`*XZBI'7DTQ@JBLW]AS'3X@4IM'(6W..("Y8
MW,$$_<\S@JE1:^+_GF%2'#3T3]"%A5'Z[?ULP88?,<YK;1)RN$(?<,$:'X%?
M<9";HN(H9^(92A(4\-ZL4!K"<AROL?=`G5&8OJ#H9_13?ZQ9@UI"ASNT]`!>
M1.V,ZR*:C=IW[5RL.IHCF$N=0NKCO6CL==U_M=*1-#J6?/J=%A>-*\?@S:SF
M/F)=B(HCZ(:Z&=TK*&W1VL=4):@","K2GZ^^1AADV0M$_`0O6^X^N;[FL:I!
M)(5)O;UYZ*5JBS&;.PR[%7717*ME63M@*IKF3Q'SQ#WY_EI.S>9TGZCV3;"H
MNHVX@WF*'TJ]S8LLP=&<N0Z*G>W""T3T//)B'8&AC-O.`.;Q6WN6+P`\*7P:
M'0;8Q_7Q[Z'?-E1278:&ZT>L"!5T&!"F8K=L'\L2'<SSGXDZK=96#KV:E9<F
M"OB"_VXC37.#\B`U/:.=/@BF:(X)/3&#FI;5`HVHCY%:B7GP3A04`5J;5UB8
M[,UN.U9;75.'$(0HC4`FJ)O4FP%QA,;%4[V\>$^$2^I.@YFJMDG!V/5P"N7#
MUFXF*X?N`B64$%N[:3ES/GOTX+A#R1/H)43BJ0MQ!Q/T+:/^A=ZH9ALME/L2
M1U,TRZ*`^IVG*(5+$"67;'&-VU8/)!G%ZF9VX:W(?4SYGYH>J^C)\]4%"C'<
M5_0I(I!^0.V#2P.6CPEJY\$&J"E+RDA?^I+0--<E<(J]\!_(8_*F?&<C=2>+
M0&6@:NF66QN+$?DEB;D/9;1V,XO+7;9<AA@E[>!7+?74T*T9I(O3_=;#P3T-
MIO1S3IW,*;O2-ZANHMPN?!>'[**_W4;2CL7Z>:A/S_`1$Y3;BDKS>_&6U!WR
MJ?J"Y7!1'F\PC("6Y2U6)*PT7`@E1#DSWR:QCU``#7(ZRV+8>7Q=&,-]?!EG
MB:"2\W8;C3/?1*(2TEM--,Z;FQK:9JXWTCGW#\&+6-M---7LQ@L2A^O35U2T
MF]50%PQ/<!EO#J:2_QDOCK0V-U1%/-]]ETF\:+YQ)R@8SNUAI)(IU9E$A4HW
MOQN#3B@'UUL8J1[9C.Z[;JEFRVUN`>SB0J_,MA9`+2R&RFIJ`\PKX=,FO-:6
M0"ZNK,MM;P)Z.CV(P)5E2$!U=EMSB5<=HU8W"8<MAI!-\/1;>RL*2`>.UK)+
MF3)-A:RIC%*IH/B6T-)Z6+P$:8QGEDFFE/8,5611I4/TFTW4DF`1D\1R)76U
M=RQD=:QLJZ75@6)OK1[=Z-<TU`I]>PN1:$>_;ARH"&!O=0[=!*C;@S;XOS-_
M6K85HI<.7]W.T67'*9H_^:1KTVO%W)53ORW"=,/5C-B,:EL?!'ZL^(\*17NK
M9JFA*`PPJ=`U54%J#R])N+,QI=Z1:$^>J(JEVE<7K/7-A9:,SHIC394_/-R7
M%T3U?;8-X8V,^[H=VCQ"$N6I=@WG=7RV(DPJEC-4:(Q;>[C-O-ZH%,`T#!]P
M26$5XL@4E;2WREQW3)O1\"Z4%9;!52::W85RPCIP+3(*7"@:W!/;34Z`"\6`
M.^*ZD_/E0I'?[J>3.!?)A7*_>G!OYI>Y4/57FK]5\]==J/O;?=&%*:@N%/I5
M05T8'>1"<5_5=>:DU+M0SU=Z/W>-TC5?X'<@(O0/B;7Y=5!ETO"S*,P_6Z63
M`T2!FS8_B:J%U^4#VLV_XJCWF.^:OV>\"K1.EE#(Z7'A_4&U]6=FPAI_O4RW
MZ-::VF3^@62]&/<MG.?"0Y,#T:.NNKQQ6[J33_&M,#X$H:U[PFE%![>E.OE$
M]0ICMZ4[8>IGA:0AN4V^K+@@'T+D'MNNN._""Q22J`H>6'#AG8D6+$7/:+CP
M?H3D(M8<\@Z]"2&)'"<QQ:$G'Q2VHD08HD.O.$@BSLWE,/Y`PV"H*N<DE*3X
MJ^6A02W9>RV7K#UQ4,IBTVZVGP#7W=@\4Q8/N=!P86Y@'4_E1#SS*RW%UD,1
MH$N@^#Z?9LF]#O?Q)1Q5D8^]</,4#5D?9/7K*0K./8+)S>PV080:O7+E'Z8_
M#ZF_UFGH\Q.=V(3#'8:[8H9]#[C1]ZF^2>,"XA#[F-J4&7";?_QC?,ID_Y!?
M4JY$U_@)!5?`U=&<.M8GA*"T\:)L:9_.^:7:LVST>@UIJ/A(_I(R?6PSA9U.
M'5#+_$ANP52BHZ;B+C%)/>+#];2=D-V`JZ6QD;('Y5MM\4S`%I=9FB6H*[]I
MG<(DC6Y$""B10F4D(QBO[ZD=>^(V0KL-C<(K+)+2;&0^7U6EV@/W@#$?(_L2
M*S[P\SBX.X?Y$.H+R-V0(TB7(]:)A`XI]&4D'"=2.J2P[2?3.I'NH<3T>F0O
MXXDA\N96YFVM8E-VS-PBI^R[9YY8?[`)\FOLT]VQB6BPDKQ7$;2&'?Q<O9[L
M')SVV=2J"`YJO:4AF<"T**(<:CF=U2"WC_)YZ/MC',+A3(KP8-K6<J)7X.41
M_/12S>_7\M7YCZ!RD3S"/\]QV`3/'"`J?<W,YE\ELO$=&8ZQ\#J+8:P+[,TC
M6!;L"TR%O*9FC6!U!J.<=1DG.[S5\*2%.5C0^F96-=P>A9SGVH^B&6V?L)BE
M.AO:_."]61:A!GZ*GX!5%4G8>6!;Z+%>YA]>$M3!_N:%68X+*%+9HOC6F38]
M)C%,)^;5O,[ON4FF>/Y8O]5:2:(XWFB^'MA\W><N^K9*\/,M,/G"\U$&-XP7
MDEJ%IMT;2=S!PAI4W-O6O-V\!U8MZV:^EL2!5=8:S?U#F?OU7..'XPG0(?`=
MCJ?`D-)Q>"Z&#G+@(?@31!DDCOD02E/.K9?`AJ]7LK;;R)93_[.7IL!VVZ9-
M*P&N'Q'4$[M8AO$*H7,4`2`I/2WLA'LK2%T"R+^=TMD?X%R$?_Q_4$L#!!0`
M```(`!R*3D<L.(P&A7P``'@.!P`5`!P`<G-W;BTR,#$U,#8S,%]L86(N>&UL
M550)``-(QAY62,8>5G5X"P`!!"4.```$.0$``.6]>W/D.)(G^/^:[7?`U:[=
M5)E%5@49[YZ975.F4GVZ4:9DDJI[9M/.VJ@(A,3I"#**9"BE_O0'@&\&``(D
M""!RUG:ZE!+I+_K/X0`<CG_YWV_['7B%4>R'P;_^Y/PZ_@G`8!UN_.#Y7W_Z
M_>'#Q<.GZ^N?_O?_^N__[5_^KP\?P/T]N`R#`.YV\!W\^QKN8.0E$#QZ;V$0
M[M_!C?<$=S&X\8._/WDQ'`'\OQL0!N#?/][?`/=7!X"7)#G\Z;??OG___FL4
M;7)JOZ[#_6_@PX><TU]2F?X$YK^Z[J_3RE_NPV.P^1-P*K_Z%$$O04^##9+F
M3\`=.[,/SOB#,WUT%G^:3?_D+O]/]>GP\![YSR\)^'G]"WIX//N`WIB`^U_O
M?ZVH]W^#AS"(T=/[@Q>\@XO=#MSCMV)P#V,8O<+-KQG17:8N0,8,XG_]J:+A
MVU.T^S6,GG]#;":_Y0_^]-__&T@?_M-;[-=>^#[)'W=^^_<O-P_K%[CW/OA!
MG'C!NO8B)D9[U5FM5K^1OZ9/Q_Z?8D+E)EP3*PD(")A/X']]R!_[@'_UP7$_
M3)Q?W^+-3_\+,_R7*-S!>[@%1(8_)>\'^*\_Q?[^L(,_9;][B>"6+L4NBG[#
M[_\6P&?T+3>8PPIS<.:8P__(?DW\[">`G_S]_IJIT*I&*WWI-VU"/H:)M^LD
M:>7-3-P=_@>&54U@^);`8`,WN<B8!N?K$A;$,0A13#9<UPCNL(N$$=4$A-;6
MBY\(P6/\X=GS#K]AK/T&=TF<_^8#0=_8R7SB?V2__MO%>HV`FZ#`<A?N_+4/
MXXNG.(F\=9)S(SK^ZT\"+_Q6R(]?J6D0P3@\1FLH99+T&TE*\;?=$WYIOT.O
MX&@)@P^_/_P$_,V__N1O_C:?SA:N,_F;,Y^ZB\GB;\[?G)_^5TD,Y-3`MYS>
M__<OJ2!J=4M0'(4W&A1TNREX$=4]T(O6N:#HQQ8-LR=^6X<H-AZ2#[4/N8W"
MO9`WY?Q#8:/\9@X_\9WW[CWMX$6P0;^)CBBL^=Z3O_,3).2G8Q3!H`500A3T
M(TQ$+&&/G"WGXQKD8I"1!UZP`1D#4.$P`AD/HRA4;P2W9H1#Q0A>9H1=R<$"
M@,KX-P6QP@:T`,+W<(<'^SLODL8N_55SH*7*(^ZH,V=%1^L(9)1!1MHNF"I0
MF^`SCTU)""[V!S^T"(=<)^4`D&T:D\B[AVOHOV+YOL)$#''45PP@C2:'L*NM
MW&D3826]$4`4+0%6?RWK`UY4T+,!4SSWHV&):0TY#$7Q]X`@8SR?C`DN\&_^
ME@V0>($#!C%9&J!#HNUIQ6C8A.OC'M$E/.1$$725Q6+LN.._33)7(6E0E=J@
M6*"!7:E:CA&UF!!7JIM;U6U=H68"WH(HPL@6,8*A@?&X/Y*A^A(>4+3TB5CH
MYQW$/^`\>A^B,?P?Y/=W47B`4?)^A[Y5@O[V^8^C?]AS!U$UY/4.N$ID%AZV
M%NYR68`V9PVJO$>@X)[.7RO\1R"7`/V$91B11PHQU(*=MJ)JE1FGV(XW,([Q
M_+8PYJ8B@>%$0"G<&DF#.H,;B46;C8\E\W9WGK^Y#CYY!S_Q=BA<[L/@(0G7
M?V>Y6ON+.N-'JS3"+CV=+?.5XX(HP%2!CP;SE.X(I)0!(6TH>U>LLMM0^8"H
M?D`JKU.Z1A$L[*0U;(H9R"+4?8'[)QC)?>_L'?-82P41]CEGNII38?:AA!GX
MEA(UM4NC3M$FN&04-8RRNE,*`*QB'S53YLU_'N,$CY+Q8UCR+/A]/,9^@)(/
M!.PG/R#C;&7]&8M&G1SUIZI]"MY;9$&G72UGR&VSJ7K)%"^5>J4/EV,#>,HX
MX]EASKJZQT$&DU\US^PU6\MI6NLQ!!7$7Y=@SSF#"NOJMAB)#KJG$&9LELX<
M&HX"#L<H/J(,&3M<\@+!'D;/,#*WVJ`L`)6K$FH,;29WH8I>&P+PO"9YQVLN
M88`>O-U^"H-7-/'QGW;P$CXQ5RY4D-::"?675V)G>38Y#3))+<B<3%-2[J!@
M#\(MJ`@`L`2FDBO=MB,YV'6,(\L:8D.LTSE<C*<"Q38@-A]\6[\@@A!LPPA<
MO"='L&'825]NI@YT]11.T5>P-1(]O'@1)`6QU17@>XATBOT$/L#HU5_#.QCY
MX>8>KL/G@%#YB[<[PAZ>VXNM91&LCR[B"!V["^GH1B3[D)8[5V7#%0R9="`3
M#Z3R@8J`]L8]?18G,9&LA61F-+V]HQO;LL&P]Z=1/"5F"GI[P+\DJ>)=EDX_
MAE]((LW/_#M1-#<5[B*N^"0%@:0Y#6[,@@]94,JGPF'*]G0BDTYBC$V"A[=3
M(WHWYK\D>%<FP1G;]/<Y8_S.%^9D;^CM<HVV(G'WYAB^^7'-8SZ$Q\3>Z6^?
M8$.9^G8VLZX82H)]K#Z2MM.U,)ZV"BV#@(ED5(T)\_,+KHJ-)A=B4^;G&6D5
M&ZY#O!UE3F=SW!4.4#+15\ST:F+P%CG*!9)F@R6B;G^RG],>(RE"B!;2C>>+
M25[[B,F`@LZP>YSLV-5;&4>[,BU!I;=&KJQ&>L(`!R,EK%G*JX'I<P0A)OSY
M[>!':243F>%2OP/S8>V`94DBZ!;+A3M;KC+4YK0`+(B!`Z&F.^M0HY53UZHD
MEJV4F4"P&LW<EN]E#LEM,"KAS+6$6DP_PFB?;3%^#9-B\8K[@5CO&$,X0R#1
MQ=#58K)8-H%>H0E2HD-"HQWO2G1T3.HH"'\EBJ8KVP>4PH81W)#V(0BG+Z#4
M/:GH'J2ZVQ(@6C!Y&B=X)C.R-;<CQ.&&3"8^-M?+45A#/S(WV,1>UKE-)B21
MJ(/.QF,GSY]SPLR]+)`1-[1;-8#BW#TG/%QCDF:/Q4MY;VT+2=Q>IF#Y'9<_
M7(7197A\2K;'W>FY1XXO"+RL&9;M$HF7P2\G;@E+0IA4@.2D`>4<KSE8JE;<
M/55\DRON9;1-@U+<=YN@%+16=U#&</WK<_CZVP;Z&(]3_`.&X;0"0_2KOQ63
M]$L8KR/_0$EMF8]I@!:+MZ@O35;363ZV%6LH%3IZ\:)&&U=*FZ'QT.9$V/.Y
M>FOT\:N=]\S[).3ONKT:,Q5V@,G4G33=&1,PZ,?R\KMB\FOUW*IKG+ALH:*1
M)*ER8/-V>QTDR,*XUO$BCF$2LT9D_DLZDR*N).*I^G*9GVFH$,1ELR5)D-(T
ME`,IU-,]T1.R9UW:$AXA/ZPE.NTF4;-V6.-S%T&\E9JOL%P$FTOX"G<A.=A\
M>82/8;TO$77MIQ]%[>N.O<05W[J>+.?9JF0#@X>4)8CR92W<?F!3<@6;(^EL
M%66=O`XI9]U;%1K-=!JJ;K<@8UE9_0MPDX?23(@MKH1H-#PSL?BIT52GT4[`
MHSY47>D=_/PU3"!8_F)NK51)#"I74OO;7U%H/?CA3>@%Q=(NIRJ"]:S^<$@7
M1,(M5XL\T.$S.)A69:7>4(F$$JT<,UJU11L5JKF=5-,4'?@PJN">8PEUB&X!
ML4G<RK4SF"_FXW$5J@:QV45R1Y/D`OCK(KXK)KX^C/%@U1E)BN;Q480/<9+S
M/&@$_QH&7OF;1_13[*U)C2._[8HD%9TS?3G1A->,7/3_,J!4.)"$$/'X4&$"
MJES`M\MP[_F!J6XM0UK#56L-;4L(W2!06U/H8%8C:.>NSNE?A9-:A9HNEXM\
MF7G`);7*W2C*A)YCH<G=*<!CBJ[-W]E+8UV7P%1Z9]OE*_6'M'NK[!TDD[D[
M=:M>:_Y>E1YZN'STZ75A[CTIITJ:<^F6?NZU9[0[M&0O<UR>-*WZ\\#]V<7"
M<2<E*E%YG;YO373FM6`_4=BX8PN%[.:SIAQ=^A*IR6I&=WA+(GDOO4A`_V2G
M][?'=YKJYM"`TOZU0*2O/*8=`R5OF;LKYG7W+XF8#/E=5:E$_2`,K(O\ITYT
MZO8-U=6LP,;Q<9\>9_T]QA<]7L*T]A]>>7Y$6K-DIUUOT.^N$[BG[U%W(*-]
M15=>1M'#5;/Y=)H?ABNY`,P&;Z$6C`#F!`BKXNCY-\P-$':Z%XJ'-HACIT%:
MUI^'MHH[B%7T+&MWCQ;E\G='^VH.=X^4:O].).P-<X\2A?!+9,KYO&N((YRL
MC6X=[-`QL@UH!U5!K8,Q.@8TMC$LBV6/S<,3G4UJ9)+RW8LVCXC+Q9O/W`.H
M/:-S>E)E+'&_\VR601"_#S`!-"M')$S-R+NKX0JKH6U"0G.8VFSD1%LU8_-[
M<OSB!<<MFM(?(S]XO@CP`<$]C-:^MZL4F7$*1B1):!^;Y>23:!CO.MG8C#LR
MUUB0NLZ22:W$TU"!RI!6<"RS0LNX/*0I7(8IO&ZFT#,J=PL"Y:C<P:!*HM='
M/WR%<7(=H`^>-AO`5Q:LV;&*_X+NR,251K15U,I=+K.>L!D]4".(_K4V%',4
MZN<8U(\?310JZ3*5'&$M?P4__Y3]]:=?S$<-(?`5,:+=3";R]/Q:DXMUVB\;
MB45^C"!,JZ48N6?[>QKS^59AQ*\&6\URJ.57`E6(CD!.UG!EG6*%W9X*ZYHC
M"#MK==X@9BM;L,>>+;.>-HPSF:GG9#4?L]%E="ZM1#4FCBR87[<X6QMBNLVY
M!\,):UM0Z!6SB)'=OYE/IO,E%S;&=J[4:\E!D.&=*!EG;`%3GQVFP1!U%X57
M8;3WKH,M_@_^U2-\2S[NV!=.RU(QBSN>:.)'#^;3*2\_1$P`X0(J;+)-!X#9
M`<+/'IRJLPJ![N^!=]SXY.!V%'[8-BUA&7!%?+X%RZWV4[/,<\HXSCE7STE?
M!)OK_<'S([SJTMHI12EI[4M':N067MN<3^?9_;L%\KT*:W!`R$_]W:N>X\>K
MGG[!'Q_K]\MF+6D9F.86$$8,QPR9<25DUAH@X)7SDC]N'6&XRXTYXYUVAQ#P
M*G.K8FIC5;E^IM#T@P?E3V&,>-_#5QB<W%HI^;)-@;4FF8P33\1"YQK1Q]X<
MI1PLBHP]-!>*?9@^#G(9!\M"6P_MTYK_[+O&W@[&'Q#5./$>UCZ]IMMXE**"
M5R@.G=IIR$A#,/-G&,#(VZ&H=['9^X&/#R<D_BO,&AO+Y'QB]"R)1T+"2KCJ
M:MD2HM((]9QR)".P5^-9],FV(VH-8!]^($OC6,:1I&]UGGG;=(O2M@%L1,+=
MGYE.8EN\DPHA;2%0W)R6K'G%Y>Q]'>[A31C'5\ADG\(@\8.C'SS?'F!ZUTO\
M$2+MX"=R"7U\'63-JM-*C\]O2,<PVOB!%[V3A;VO$`T#C]Z;^#K,\**877T;
M7#_AG9K%:K$27<+#HH*?L;"_``PF4,H+2H'!$Y$89"+C6S)+H4D0J(F=+F*/
M`)(<YT1(=C,GV^S_2N3T'#;3#@DRRLWLIY\EH=O-X'*BMG#2LB:IYRL./H=.
MI4?LLJ'C(QI9MG[SN&MG,I;DL3P915,/=^8LFXN3C'EF%M,0JSP?`QDS*[)6
M==80FG7KLL8JM48`GW&+TDY3<#5&F6*K7,(MC/`57&4D1;&5J;;Q^7A+(!":
MF?/,IR&2H>D)J?W#0F02H&`J[P,,.G;%,KJ0HI6@DP4:_46#6<HJQW&.8<3-
MIFBFPAZ"X4RO/;HO**HQ"IEL%TK_G"W`_)+%-4MC&3\4"`8SCO5LFULCN<H\
MM,-4I/Z^);/8FE#BMWHMQC.QJ2>>]-2FG_9-$7N8H#:OLW421_5;T9G7J7$&
M3S*R25WPG*^T,1IE]2!D4YK!E%)F>VHFMBT9YKR*-?ZANW%URC04F40HU2AX
M%<OZQAJ4Z;(+R39XFQC&DXO6$""47?#-I2^.,;.&3B2LC%W2`^AR@DPI.#LJ
M(9IE$C>,T=9PM.IJ!,DX-;01%,2GKI8@D0F_EFY2A,7RKMU1BIY>=3;7X)&)
M?OD0_>;TGL1LBE9<266&4(>3;8TJZ1;S"K4L^[*CP$*U;=CAK#HQ9-Z;9N12
M>IWV(4'NGN$:5@8ZH7@A%/+:S6@H^%4N77M7XQLUBO:'P:JX,O[L]HV%M<O_
MK(^(W<W4,RQ6[Y%\/XO@V-U4W`AIVVV1:F)-C^AY8F?;%L[IIP=DWK1DL5RN
M;GP^7<P<3M5\'?8&JN4'4]DMFX5';,5L6!NGU,;+6L4DVCZ%^R<_[<'S"8GG
M;[+Y,KD\*ZV-<%H^NA`)`_@3D4O8*V<S9]X`8H7^"-0X@`H+LX!4;X,*,@](
M[!<OABA'\]=6`%3&FVE(%3:7Y9"]\;TG?^?CVY^OTRL+-OT=A4;43EA3)!5V
M\OEBTJR)%@/Z"%38@IRO]?#O;:OT2.YF0\8W?*63%[^@S/J=]'GP`_!$F=<-
M8I57&#V%]MC%X;02VU4\Q>=XBH7QDQ-:.D94EJ7MB;%XA1U-DVH*5*\>38O&
MKX.+/2X9O]VR7L&GKN6R*;6<C4=KI>J(YRVKD[8+S9"><6E$]ZIHH^Q,"SG2
M0L3#)U98KX[2O@PV17^#ML\./A>F6M>LG*_&)"%(7B"H'(DN,DR[Q@N37DQ,
MF=[C@-QOS;"I?6/)("&T?<!1_ZG.;U1Z?('W^*?;[>TQP=O$,>/E?"!^OX=>
MC/XP""BZ2W,VHU=G%86[C"V6*[4C&I$71Y1<8C:-<I[S/@*9X.<XSFGZ2OE.
M1!(=\_;_:'*$)1G]@.&[=ZQ1%]+[?=__"F&>I!'_C__\8@F^2GE^X%!?*"F^
MFC!SFWM`9H(]$7T$L/#_-0)^QV_%6?C9'M$8`*N!/QL,K#C[82SPF(SZ]8]L
M=]POA&Z]\KH?32OC+T50\<GS<MJV?=<>_X:^?UM=^.MM*NZ*S7F$*@Y6NH4;
MEE&5UANVBW$'D5\%B??,K;.6HF.JME!&2-'ZK]5X.ATW*@K7)1_FG`L<"E:&
M2@B'LP8S\+%SQY*5P4K!X2S"7Y$^<)776A/8)1Z<5`)*V]&2+.@>KL/GP/\'
MW%QOD'3^UO>*YL4DK8[@YB*H;B"2.X'1+VD]W@=D9#9?ZBF]:&8P&R]/.E_6
MDJA2#E`5)&M1GM^?M2'EN-5:B4R:D9%>YK;8M5)7M<5W=;^2/9[6O*N_840;
M'Y@RS+PT3-K./2TDL:]B0E&T:DE.5=C^W,-[LY'];?("H\<7+_AS&&Z^^SL=
MKMPNPYD."JV*R<"W>6A%[7AQ<@W&"!!I08+$!;F\YS^>*/XD>:\H\[=D&`T.
M0P5:L:\UU*I!9[$?J7>.M$S+5'&S8`5"D2JB;=NFJ^FD>?*Q.C,7#8X7].`(
M'KWA+PB26=(P8E[VPL<YF%=ZD<2(C=.)B_FQ1%-`Y"VNJ+2_)3DZJW6:T"MF
M,V#9WE;SR7R^XBR6FFOKI5Y)MZN2!C-":@LO8=-8@J<'>/`B+X&[]S)8D+,0
M2$XB<_NMY[+4S*)01$3QBKKQ@@/0$2B950?X*CLK;E8?U#Q,:/<TCT'DRX"F
M)2@(V_M,XL5EN/?\YA2G/SV[8T8JI'!%PV1V<@F"-"Q2EN<3-[J8J&?DX)C(
MXMA1!U#/Z%&QNB7Q([X+=_ZZV9!*X`7#N7LJA?#(-YGR3FW'("4'OF7_M>;Z
M^;XJL_-XRV#8\,.VU+UB"Y-`NH3Q.O(/I-@TV'ST8C^^W=[A1F39VF)QP7W+
M=Y8@9`!XXM*)IZ*K<3-3KW`A6SJ$#RY#KW("WZS!YE!6J6%V5*T/Q\;(%B"9
M!K(!U_*PH.%=TKY*-DP^>?'+Q>;50ZK&5V'T\!)&R2.,]C>A=W+>4>`%W=L6
M7&E$O7#EC!>K=.<!TP,Y0=QF$1"2`-,$A*C>?0.%^CD&]>,OW"M4,NV]DG8C
M\'(U41S9(5+`>XX@--H15@AMQ8)ZNUU,I`)$JF"#__,9!>I7;X>/FUPDG[PH
M>O>#9W)\A#&2B+VK<<`7$DBXF,!QYN,*SO"017ZHD!X!+P$Y]?0`V2"(.\#(
M#S>?`^J%@@-J/ZUI3UH?P9(T5AZBWZ,A/!5P0-T?$B]*-&L_:]7^"3[[08"_
M_;`V:$WJ!M#>Y6IO,D^3BEG5U$S<2O:$XCOB5=?!.H)>#"]A^E\I-V"0,!Z8
MZ7()+^HMETNW-3ZG/$#.!/R<LS%TS]IPEBBN6EL7)Z'7YX->OINW@YAC08NP
M3)9]VA95Q-XUC]ZZ0,+.ZB[FJW;86K:@.8`)7*X)+$0HW7D%H$FQDBE,7NW"
M[_A\*_KQ.GB%,3XLAB2^\@,T+\,_KQ/_E90N7?KQ>A?&QPBVE`CU)JL9R7UD
ME=AP6U7G3IAG>L`<_ZM@2SR_8`Q*SJ!D;;PJ2:_-2%1`K#X02R65S;<_F0X)
M*K#3C!:]#:MFV73GQ?'M]J\>[KB1W$;W_O-+$O\5XO_`S<4KC+QG>`_QYB>2
M"9\QQ?R/W@ZOWU#7P'H1U+[LVD=:X8M+9M/Q/%N6Q?SPC/E[RA&$$8@(3_`]
M8PJ\E"N(<K;D9'O&%R#0[C4?8]=H)*<TTNT69!S!;012GB!G"C*NH&`+*GS)
M*K")]5]]AB+!4M`:-_X6CG)CQK@W5)R@X0<]9F[]6$78*=>7>]O=2%(6[O=^
M0GH<X<PQ/[Z_1A&?-1YSWM"92K'%$&^GM9KE*Q@EM70Z4*5G*.]1I:!+4W!=
MI9?=434S<D>5A"?6LI<6\U@&)O'IC!0-.P#7(^D>SU<+`0A:-2$9SA!4J'8T
MA`6X%9R'2-M3S:1#A.TC/F'%6C#L3$;[!$->1M%KL6?CL9N=,ZWZ[07/;PFG
MX2NQV%.)H<UQ$L]L,$?+K&%HFY#0]G#<[[WH/;W:0C+CTC,EZ!X4RHE`1U-:
MF[&T;IC($;$M9Y'?/W"<B2.;M)C?0AG0%NUYB_49"G]C1=YV0^<H-WX`KQ.X
MIY>5BKQG4192""6Z_C2>SN83D;3C&R8-"&U[LHR.Z@JD%8.KVSF+Z*CS2621
MU]ETXG""5)%,H6ZNH8,)R48D/VCZCD5!A`@DG)2Z17^<%N\B9.V)'1VT%(D;
M`VK9.61T4%4D7+!5-1TI:C`4B1*EA4Q-'L+@(4$ISR?OX"?>[N'%0QYR#V,8
MO<+-51A=D0LIKN/XB.ON.9FI'!W-4P@IX616_)8E-L,`$"8CD+$!*1^0,R+G
M2U)6(.=E;B8QH$G2E8)4>7()(3%.C-F!J&H,GV,%G7.+3AAH3B_D#6H8\E_@
M_@E&[2Z2/6<&LBESX0.4[GRV.(4D^):2,3AQ[Z&.*Z6.`=S4'8F!BXKFAOW^
MSHMNHX<$WRE+SBO<P8B@M?WK,=\T@PV6.!+]@%8N;0!#A'%)44HZ/96%SP&D
M`YIQ#*E1^P15(W#PLK;JEN"JS5$92./:QS#VTF'QXIB\A!%NCM+^M4_>,(.U
MIA@2;3AF,QK&LORHI&@<5_U4K.(I3E7T"E(@)K0MP17+"1EXHMK%"ASA;%(<
M0]G3)O&3BB"^-;%:4+*Y'#LCD)*S!#A==*.`QB=D.(#IK9K`O?9J/AQG'FA5
M)*C#B!L%*G:P(@)4JG!%/V7U%9.QH"*'\$@S<YP)+R"T%"4;B`J=M:2$AK"D
M9>.`2O%%+I::IC$,*&ZCCN9C9H`CU81@.B_N-*V#);NFV9+!LX-.O*D;^)^_
MCL=CYY_!9#P>C=/_R\!2R4?_.?]5-MKB:H<JNISIR)VM1O.E@T^!8]\ACRQ&
MJ[$SFKKS[+=32_#'[M=`L[,AG!U@$'M9,Z_/^\,N?(?P(PS@UD_NT%>/!8J4
MQ$GHQ:>P7,)#@+,LSGA7R!,GS!F`C`,@+.RH3QK($`3P5+T-`U#:IQO@E+.7
M:>#>PQU>5/H4QL*=&`3?-@17CDCBK0BF>2/+&E(STH#0MK`=PQ!62.=[>+#Y
M\-&+B?(E%UN0*N#$+)"V&<H4/L,`EQ;<;B_A%D81OBWF+;M3IGZ73.NY)6E*
MFG$K*9[P(+-<N.4:;<8%KUCD?`!B5&V\6KWPR8+#3,/:Q1W"+CJ1WQ$>S2C0
MQ<AF(D)Q,/GV:><_TRKQ^,]J135%`.%19S%9%F7\Y4'UDI`I1/;6R6WJ%`ZL
M4VO7M?XZE?<TFPT(''34(<_2V!I07Q[AQ1:YXY6_35[^`WKL6AZAETW#_D0B
M8?^:5=H`T.+`""#:P,/$`:$.,'F+HD-/U=,K%E]@!(F.UN&+Z:BM@*,;QB8$
M7@==X5=]TP+L5<01]SYW,F\'GA]8B[K.2A/(N6-W;"/8*#XI@K2F,2R#&?**
MKC@K7[4#:(4\PDXWG<ZG8D@CM.V$6D>U,ZPY*TNQ=N*8@F"KF\,NM'V%;\GC
M=[A[A5_0,R_L7E+"!*Q`7E,J<4=<NF,A_&$.:+B+U^C/-H*PGP5R*,[MA"++
M:\4`236-7;!\@,@^FTZ#8.55*Z!8RB/N@BMW*03"E+:5^.NJ=HZ\A9W(.W5,
M,<PUS&$7VAY?_*@;V,HWK<!:(8[X),=Q)T)0(Z2M1%I'I7.@+>T$VHE/BN&L
M;@Q%[0@0,__I2)IK7R'QL_W1.R]*FA?*"KR@OQ$!1QI1EYE/W''1A:!"#V""
M11$`(:F[`8$R[1QCVK4U'E"F(L%\VC\=^PS`8`07^X,?XA#WE_?(?S/8;D``
M9I5>`VU&,33$OJ)OB62ZW9("D?1.PO372#J''=Q;WM,[O/*%$;X>;#QSBNJ^
MG";>5\^*6;,+&PO"Q@96E>IF5U%B2!V#@^=OP`8^);B-<4H.)&%>YQ[!-?1Q
MCX!#Y(<1_@-V*\/#L9C_-@9C`0.J&HHQ3?]I!W$CZ/CS'[@M>7@'D5.@(?`9
MWFXKI<",8"I#P<!@+2&>1!/\R;P8O7,&(,`<\&U?^**$$%]+F#%IGF+2?8/"
M@$9PFD8@'`!A`1Y#4#+!5RI4B^_-C/R#&<+M[`TF,X0.Z*^F#++65!VT[I`R
M?AR'T3N1@-J91.P=@X&)*I"H\\U=9T8)127-#)"#=C(1B3P*M#R)-7JU%(XM
M"E0]B292JNJ.'EP8TN(%VT**(D0$+X+-)7R%N_``-X]P_1*$N_#Y_2MLEC$+
MO*`_-G"D$?2CA;MRIT6CU`B2?G@%15"2!(BF[J"@3#W'G'IMT4"9CB04E*HE
M!:41".BZ:8*_`,8JV&^SAYGEA3BYW=XCH0+.$=[J,UJ7#2J,Q6\07SE%:7.<
MX%0SHV!J,:"S$FY5B=C;F3ZU3G&5^JR]J:D)C[Z$3TFY?O#Q_??`_^,(+V&\
MCOP#.3#XYK-J,L3>U8@`(8'$>^*YBZP2`],%E16T"D7P#=,T="1G`'W=[OKJ
M0I:4RU81)VXN\TBL2"7T\:O/&T-<10CQNW17RRD59:.JV]F`K\[:E9A:EYC:
M\)4S`R:*U[$!U+2'>=!\]?;P,L3W9@I]T,KCQB!3RB#N4W-GQD`,I@:^I?2L
M&).ZJD<;A@34,X.:4[=C@Z9A$%.8N0[B)"*+"BWY7>-!S3BI<Q?OY3%=+"L(
M*:D8S];Z*.3**:03"W1W:J*`HKQY_Z\L,I8HO8O\-635"HB_;PPM'*'$F\,M
M5W,JB$:@0GY4G2<0#C:`2YG^-,R-\EJ"$_T/+/W-8%'`M=D0;3.A>>1>PG4$
MO1A>(5K^*PQ@+#:0T=XSAE2*,,*9TFKL3!D(S<F.0(6P#<CLK6^ZRH>OMMCM
MT@Y(X1;X`:[Q@1M,#GBD^L4>&'+\E`T_EIV4;'?567U^2V!`T`TC/VQV>19X
M0?=V%U<:T;V2Q6*R'*?;7<V<JJ`(4I)Z=[L4:D=-@;5HQ]_L4JAB.4#[I8I[
M+SE&?O(^`K!0]L!45LONEQ#DBMVO=@.9'WZOO#5,"PV%`G_E<6.#;2F#3!]8
M.H[0R(JH926T-HRL795+ZV6?GR/X["40Y[#!VC]X.\XXVELU@<[PBKX<-3Z(
MZ&@F5S@%%3M%:-C$?$2X#I#+PCBY1WYTB0)P\$S-*"1?-A8M6!*)7U<R7BT8
ML2.G#3!QD%(W,AX/J3H5>WZN>81HVP.\-M]EPY!K*[M`>1VDDXI\<B'M"R<$
MK`!G4RIA+UTM\[9^?(#B?Z:DP<\YDU]LPVD_*[1C=83^F1EAD\8K<REU=U<7
MPS'5EG9A.;UWK:R=Q[^[1Q\:?O'>_/UQ+^T_K02MP'J;E#++N_0]HA/L9[<3
M5@ZFD$&;<!V!C*]MT4"MG4ATN`F]`'AHG@!/@P.:<C/-8#X8B&)%+#@(F?9<
M@H4?*`X6&4'+@T4JI3`(YHM:R47W8)'R/9]@T<5.`L&";0:;@T4=*WV#1<6T
MYH/%EVS%]!*))^0^M1>,@;TJA<R(MF*`.:<'+AF34]TH[:X@=V$<;*R:?-.\
MCPVO$YL,L"=6Y?&(WFN"0N@5L_MB)_*('BB<3.?NLK(SQO(?D&"JFH^F*]61
MNC]6BP&`4#6^1=93S_98,$H_IB7;8TST,3;(Z.89.BQ\#R4_''K!HI#P/13=
M:756R\5,*"!\#^T)![+ZB02#[Z%=H4!61Z%`0%?2=!@HT282!#+##!@"TD7^
M9HVHP`MVA(!,&D'W68X7DWG6?JZ`1+K\B\NOD/_NP0[/^+;>&E]/]`Z.P09&
M(#X^)9$7K%_L2!,Z*4WBPD.A2$79'#C6Q(1.^O%C@E5E,PSLM02$JE7,S[2%
MSBA1'S<VRY8_Q#-QW3FK>-R2,TK]U:/7AEMU1HGG=NP)MG5GE!Y1R!7ZE.1!
M8SC!W,47:59YQ],3%\)T;`"&O#[I_5!X@$19P:ZV!&P/%*K>Q`9!H;P9]T^O
M?JS=W!Q%>-T8R_97/WFY#C;^J[\Y>KL'<L/\17'G_%487<?Q$9?(,S^S(O):
MH:9&9F&'GKKE!G%V"VGMXN4*<_`=<0<E^Q%(!0"E!&`;1B"7P12X35@PO]6U
MZ%XX`G%J'*]N')]C''V!0BWNZN%%H?E-!J7K8!WNX:/W]OD-*Y+?(]_B=:RW
M#(00ABCBYY!FDUDC,J0DR37%&5'P<T;66*&80F7=FK*)]V:VMY*@)]+0QS.'
M25#Q>XHUGS(`&LF67-/9;-P$B='&8KWT(/[_^P%Y(3X]X+V303_O'FX#$CA]
MQFB*6^#IGX[H'YRS0]2'S?E])H'XZ1-W.:>[_PADM*S`02>]ZL-!Q(:U(1@T
M?(N#AJKZ%H#BTH_7NS`^1O#B*287[(A]1<I[YJ!R*HS$(H(SIJ,&E%3!MYRN
ML>5#I?JZ_?0UA#&VJW+@QC"5!<C[B@P@,R)5GC>'M%((B5.1DP5K7"K)68&K
MKMIE]:?!\P>R5;>Q=YPZ=3H.=AKF4+2U76-Q#]?A<^`G+;T@6M[1O\'-%TAT
M.]29NHMI7N;2B,85HH::0JC4D3[":M*Q;6-;I:+41!5/W`I%C>]OBP&PLL4M
M8!^3X^FC]W81QS")ZRLN+2&?]9:!L94ABDR7HN8(BY<%4YJX,U-MR=#L2*M$
M5SK(=OD`;,-XV^*4M%&79QHK\/7G,-Q\]W>[BP")EJ#OA%NUI7\2_>H\$B:1
MQY%+YDH`'@QS%L`+,!1S)MG?+4&E,CL0B#[`-1GRG-4"G\?*R%D%3P&?YF*U
MS6!V`#<*XUAL^9/^CE%H5@01'R;FD^96>@V+F*8ERZ(*%*6/A_%+&"7V#8@T
M9^1#K&D7*S!UXWM/N/#8A_%7F`@NGK:];1)G=)&$'1%Q=3F(0R01WG9>'/M;
M?^UE%WO8L:JJU`2LM2`_W:]/D$T\P@S\O"O9_?(GJS#*=VXN6CDVM`*W2"C)
MD;#RADE\EF*(9V+S17-+L(%)7#7Y%V]WS`K,=KOP.Z[XL6UH[*K[215)BKUA
MM`H3;Z=%JSFI><7L0+8^RPXS5H654^QQ0TG#/I:%C_I@)IL`M-*Q(]30A1,?
M$9=.SP!D?<Z@UE9I[6H;J.U*%D0A(8AUCAFMB`"W!Q@AT8+G&SPM\:+H?1M&
MW[UH([P(QJ%@$O5LL81]>.G,)AR\%QP`9@%J/"R!LRHC$""3^%;HO,,ZKRLD
MK4)QNUMS\=MB-RN0BW[(?Y?5XM8JXX--5IH;DUKXCUY<+YW'UZ>*NI$*5B9C
M@0+YQ?&RF/.2!/QS\8=,F%']8`Q>4<\%RD["?'C",M4?PU)9$F:TVS==CZ]8
M9EVU#$QEL"H@*40K-W*I^A26AKA[&,/H%<9(D8OU.CIZNYC\%VXJ*S7=W5:,
MO%VA3$AF<7B-G>:Q@_;PE8M`0E<NQ`AD8H"*'-8&K`&LF%X,D=D@BTE6'/M1
MA2_)0"1N8BN"3S&/+Z;QDBNM;`(F`PA3*O$BT4G9_Y$2(O0MP*Y2]0-R\<I&
M*@"HLL(4FZ'4V,NI607S5D_F`IEO*DNA*ER.+D;#+L!V*>Q>N,V#(:V8':J<
M72EL.]N"(/<&QO&?P/GA5ZSP7=QLAE$LE;N;S\2[9(3H)]JR0(44V4`PGA]W
MUJU8(BS6^?$"?UX4H+C'6SV$/$KL57;_=JMRGU*T#,*2*"*>NEN6B%?$:2YJ
M>`<??0G<V@-/*Y!=7M"TXA*^PEUX2*]?CD7J>'MS,!Z!.HDM[/H+=TZK`JZ%
M+<IR9BD$R*4@:P,5.<CZI>+U@$Z9A69;3M-5@3^.?AI`/ARB<(VO78ZJAMJ4
M3.P+(KVPV!YYNG\%>\*5S/R#_IKQP-(ALUXL7=K*0#/)L>>DK!J-T]2G>/E\
M,J#.G[B2"^VDBT/M"VC"TRFV[<R$GD,8^TF<U9RTAQS&XUI##5T&\1,"BW(>
ME9(JZZ^,!Q45NKE5W<Q"A>]==8AP5#<$C0BN?=J9=^HC>B%0\!6OE)W-BVVY
M\G5C?MY1`;>I@!U;]:>NTO#MNKJF_;FU.)?RJ"'_EF[H,YV,5Z=^;D&=;%^=
M3EW?EJY$;,=BH<""*M:*,,'F8A]&B?\/:7`PWC2%%;HXPF[FS,;.*73P\LQA
M!XO"LBH+NV"E0OT3E/50WP@"^<[,!"3'=J;Q6=B_(:2`2S!?-810ECPR2=!<
M#J+F<:E&Z=/A#VOJM6AJ`H)M_LK"(-=.1D!8]`J\W59+/._A#B\9D5534@1*
M*FCOTJ:\<=OXV8^H3N#VDE1XSCYV5_D&2=EP,MS62[4SGNF61[VD.V=L?BS6
M:"]W<'MIBQQ*0%:+*?V_@]71YF-5[$?XEGQ$4OV]KU,RJ-H8;^BB2ARLG,S5
M!!S,&Q#FMH<<%28C,>?S'T=\*5]Y2Y'9%58UF.D4/3@F5=,9->LZBK*AST&"
MC'X=;,-HSYNCB[^GO4.J@%"BWCB?+U?93:`Y68#H@I0PJ%`>.B6@1;.!U'4L
M4+>E;ZIRG=W^.NMIH2J!U+*-JJBYNN<B,5S_^AR^_K:!/DY#IO@''&BFE>P#
M_:H0)>W?^CG8X`N,&Y^8_9R&#(')7*(5TV35P%!*"+G4AERMK1<QBC1R934:
M&@^M[H3]GZ^\/G]_1&0YWX7\6;-W8Y[BVR*+:7-@P.^;\V1YZ5TAZ75Z;=4I
MFLY:Z&=D?GB$C^'%=NOO?`25EI-TU&=USN5H`HB7B\^7>;?.(P1)"`I*IAN1
M]5>K=J:U4M3U(<IFG`<O0BG.SU_#!(*EV5(OGL?5YDQ,LY@`RF<O"OS@.49#
M2SY1\]>XX-7?'9&!&9^V[2V-X&D116+;/"\FS2GB%"%=RQ@!0C6M*4_IFH&4
M4F4)N$K%-BD-</&>'$$`D[3ES@'98)U=!XLYFH28H*]6P29B,".PVVYQ>^]7
M6%QP>8^#08@F-\$1"9QU!`H#UJ$2"0(ZP2@LE?@X,,[O&"N(5Z]OQ?3)52C!
MF@14LL&)OO9ZX'.DK270@YEB5;<%+GN.#$U@NGMS#:-REK(;KMF?ZA[9LLNI
MBKJ50.>*+#Q@E6VNI*.`\:U.([9RA["5??%$"&[=@DW[Q[`G$C6$3*[@!JFQ
M>TB\Y(@$>:\]+.6F<I2-1R`I<841A1)F1S;Z>`G(F(.">_,E+9F*?&@:THCD
M/&K6%`[;:)O9*"YL9&<RTPEA[8%'WM2V!IU/+^CSHP<$NH'T<$89+I8%(PG1
MA3&U6.7GY<4#4RH'\`-0.S6;RD)OS7,&46HXZY*(51KMU:[N/0-!4S9RR9K?
MUBCV-0PV<'-$CSWM8-810+JA\0",+(ME<M++I`BN;#BKB5+V!.'V,3Z+B#:H
MC4E0>TC"]=\I'8UMCV?=0"H;TCK8W]:H=IN\P.AB\Y_'."$%>#V\\H2499&I
M*9\P+F:SZ4HV]A!FH,+M+`)+3Q.1T$%HV!XG6&XO&PFH!K,5ZWCJ""^"S0T2
M8U<\Q^QTV(ND9=AGR2F^<CJ92Z_S$*9D`Y6PK3P/SR,<*+):EE&05:T@O9HJ
M7]NI-.AY2E=^;(\<;2"2C2!<&QN))/O#+GR'\`%&K_Z:D=>@#.@5QLC%+LA=
M-&3+LYGW?`V3_X`)UO8YP#W36(XX&#^=,6@H)<0;_<_GTRQ`9;*`3!CFA(?,
MD%*)0"K2Z'1"A)Y)P#M";2F3H;TR.TQ,=L]^#Z+B=>MN?!D<P+40-^A7,1K_
M\!3X]H#E^P+W3S!J\\N3YTW$GZ80PD/U9.7.FO$#$P,I-?`MI6=JHUR-?FZQ
MMI&I%7/UTHY8ELM1$4<UQ?!5_^DIFT\H=8UPPK*!;_\&WRG%[/3G-)T#H#*7
M**G/KUO,#DIEA`"A!!`I_6<#%&CDRFJDX[P`UYWR@P-LY77Y^V6X]_SFD<R3
M/VOU[I2G>+^#B>/4G/I;2D!S1.\GORLHOS[/K3M&W6$K&NKRTRM_!Z-/:$KY
M'$;LJ%Q_2JO7UEA+K"_.%C7G)61`3L>4"_=0QI521I\_4QVH[M:G6NOR[GOX
M[.,JNR#YZNUI9PZICVGU[SIO89]8.;-9S<%+.@`3,N7A?=1QY=31Y^-T-ZH[
M.45Q([-1TB>DK4J\_I#.>6>-L_A.\V*6[ZBE?5",%V+WT,,5UD/;?)+J-+5)
MY*F^YKP;+P6%`4KNJ4DV_UGMOMX00.*$CKNHN7Q!R%`BKE`M5UHMO4A@.-@I
M(&A64-*$Z'.<^'N\)??@[6!\#Y-C%)#K9_/2M_@NW/GK=U8;LHY$=+<GDI90
MT,]6RQERM+174<$#Q)@)B%(N:1O/@@\X$$:_ZNU7-+#^3EU_P@1D7$A?GY(/
M2!D9[*VFPR`NSR!>S2#&NAIUAG[1XJB;$4V,YU>>'^&R7GB[O?(#))J/E^N*
M%G>IF(QQ2.Q=C>.]D$`2Q96+;(*'Z9)B>M(ML2!=[04X*N";_==XA\0!C.$*
M&L-D_B#ET-5\0MQ>1G#J!WX";_Q7N+E&PWGPC`M9TZK\BS4:XX^DA8I`D_0.
MA'0B6%HZX;QW-EMF6T0IDP^$"RC9%)=!53@-V%!=O/!K<*,4]UD#KZ*Z+1W6
MN[M^#=[=C&@;UBOR967L%ULT%/P']*(K]$('#VJC:`GZ6\04ORAM-5X(AH'J
M?1_%610/<P68+<!\#8WMN@Q%1OS'%QA!HK>M84`0%:+Q0,2$]@>&KR@#??P.
M=Z_P2Q@D+ZRB\9Y$K0T/34G%'7\^F_>)$)@Q2#F#E/4Y!(E^YB)Q`GGM_'PB
M!`L>W8,$U83VQXE'#_VU[3:%7B2MC1%U.24J$^?C6H38T2,$-4"`;X2K!0L$
MVDR5%G&N7^#FN".K!C2[G$_DH`.F>]R@F-;^J*%TQF'_9*-+^KSLDT6<U0RC
MFW6RI,$=GP_TU<THSFPR0<1%;J;.73`QN^&.^(O?5(BDZ`]WQ/%LX"YMG7R.
ML#HSN%>\OB?<<Y.=!]P?$7MUPWM*S6K`$Q'%SQ:N'-']!#;B"<MS@7P'^^28
M7YX7YFNNWP_TI='.!/7?0W4.@VC9C?COH8P_3_OC_7MX-FB7M4V.]<698;UT
M^)Y(SPQF&<X_OG_Q_C.,/NV\.+YX\SML`YQ0L`/33;&$UZ3<B2NTP`^>W@%A
M`0@/\`USL6^QKI\=7)5VL`#E+'<7Q#;5F$H*BCE,41#QTT;E9.,`!Q-:::8D
M!=VEQ'+BB9:-+B:+Y2JM(TX9@'2QW2^]U$N]%!9,P!YS`>^(C>9RXB%M4(E8
M@(74DDFZ]4BR#@-5Q$/:@42LZ\;G'YU^?EQ-_,Y07TL=<3?$%T7$'6QH6>IQ
M=4R.$:254_!/Q_4B:4=RTBJG\"CMK*:"ZPQ?,0SHDX\K/\;][,@<Y(N'1+/A
M")\^\PDD.:K-9T$J)`P_P=Q([*-8%H/^'(5QASE/^IH=L83((KS6/IY.'+%X
M0>A:!_T.VA)XXY9D,2XN@''B/>W\^,4/GL'!2U@G$GIK^0JCIU"GG@Y1](ZM
MD@5!IX8WP<!2FL*RX''C!_`Z@?L.`:1\U8X@4L@C<?782JA2&GS#M`$A;E\F
MT5%OD661-KTM0..)`PLBLFXURU!9KM#@1A_<%@2R5.S`*DTTF817<)^BNJ:'
M&1EN:S"H081F`%(&L0#=/"`(`IUI6<LPCR9G\FZ#7[(#T4@2\51O)9K`(ZK6
M055:TVI.2[K-#Z-2VQ7/*E6:BZAD0?RH@$HP7.2FL"PZW$,<M]!\K[HX<0<C
M/]PX\M^;2\V.>,(347C7WG%%*Y@*=O7UL92A=2%(G7%(;-*E<K_E!(4>0;0N
M/WGU'#@X,/6W()Z)A`'!0-=J3D5[PE&<X"83WFZ']U:I;>MY3^K?XZ6)(>A?
MB]E\-9_E>[F($*A0&K9=/6?#MK]"C@&%VK9?^VOERFNE:5>5AYG*[BG3!":2
MES_#`%^?A'M`;?8HL.`-$WS/4+:#PHCW;6]I3$9:1!%/D-U55GR544R[?M5H
M\HX$#I]9*-74;6KJU6B:'$@%7;(Z8(J8QD)T<6^#$7O7'J1)WJ*R6DV7HG@S
M?&7,`(J?P*^#XI;@D7V_C+C=C&`S##??_1WSH^=_UHFPC*?,JDX^:&6O&D)(
M)\'=-L&U>7C#%6I.7%7-I)\B&#4G@Y=^O-Z%,2Y^X1>NR=$PX/%"@HDW=YA-
MQG58D!A[NE-:\C!>=#:@)5R5EM"-22FWIP%7W*"6H3O_$[?7K?C[=J"Z+I3$
M7NG,$4'T".1_MZ_Q[4!6L6X4%79E0;12C&,2J=?[@^='>.GFAEW!R7C8``;K
M$HAW1EA-%W7`C4!)"MP8J]!4H5=]0/0+2C:@A^Y>-*A0+*!D\?]Z^PG?LALE
M<,->]S]]2/>2_XD$X@W_9^B_9+7_>@L*(H86^GNJX>A5@[^\WU,7]T27[W[R
MX@<@7>U_\-^ROI7F%_N9&"G6^>FV4`30KV$BA%'*<_IA>BJ$C%M,"Z3BZ^/-
MH[6O-HY^;=I`VU<EEZJ2Q=AEPZ<"7X95U"$XO1<01N2&^WT8D&NX6]#,>\<(
MLCD"R3C1K(;RDBA(J687R!O$O#(]'=-Z"D0#9<JZ5&5'X.'%0Z+C0U$UO7\/
M-C#:O>/B'O0&)`T>*B?'R;4NM6B2E3U9$E,$`%V/+VUV-C'-+6<5M]&E'Q_"
MV-O=;F_"X)G4(Z53<OX5<[U(:9PB=Y%/_)+QY3AKC5"9-H<1R!EA;\:LLN+&
M?/G*MD6KX6WD-FU$L8O)B7D?0%2G[9TM:20*!.MP#_&ZPA4R!LJ#$C\XHKA\
M>X!I,(X_PFT8P?2Y1^\-QI_?DL@+HXT?>-$[.:/U%1D7O8D,C>1[O@YPI(M9
M6U1#<M094X930QA6B_$DGV<0+N!G+,\O`/LU*$4"I4S@B0@%LN>)6"-0$RP]
M3S@"==E`+IR9PQ'66)N<K/@*$[!#LHQR<_JI.1/OS6@`&Q[+M3@W\#<Q%PX?
MT%P(X@#>LMO.>EI[&#H107QG:39?U$)(0<KX1KD2U=P.JNG%*]/93K%&MX4%
M.+G!G!#B.>T=>6^8PTM5#&''FDY64P9F<GI&6S4JTY$.'@$=#2&(YH8<%)T8
MQB(D<9L*\-\QCR;)\_&SU6K9BB>CG0$4ZMF&*0L._`NYI`"N#!_F+_).X>I)
MWAO:44450[R'S'BRJF$*D;.I"E*9CFY7'?6BB>N&IUAB&\82)+4N"?->,8LE
M^3OD5JNYRP63^=5;96HV\`3-+LD*.%X+>&Q98D5"9<=A/L(`;OW6,:CQM`G,
MU$40OXQA/'5.X)(?=/HYH_:+J<OLU6A';JR_A%L81:07>+[^!YY2<E:@ANYP
M5,!0C&$4*X(;CZS'3:"EZ^;8=+Q<-N%BX?Z@$C7M'%U$-O5XZJLI%0K6$?1B
M>`G3_UZLU^$Q2.([[QU?SWH/=SBRW7E1\O[IB*).T!Q!NE+17DXD+:)$WXC)
M."LPRIB`G`O(V8",#\@8`<()9*PT5QP-;`K'.E.T%"4-;`\2?G[.J?^"Q^W4
M(GX`#IDMDA!<[`\^]9HL/25&G0-!6734S8Z&1OR:J-=!0UCV>-3RGMX<@"^,
M^+&5\6+6@&W-7T^P:RP;4*FP6U,8:>GE6A[86FI,$\0\M)$O"!C(+L#=PS7T
M7SMAKO*J%;`KY1'.3V<K9R6&O)*XP3FL:L6G3`A&7'7-H_#4;<6`V##5($D\
MX18=2=TOGF`+)\7T%TVGZE2I1%,P=X&"/2L[OR;XPJ1!E;;9=%R!NHP,7*>Z
M<BFW`IUIHSE1==VBJI'TF@M19D;--I,=8WJ^-'D/7V%P%!_0F^\9'<T;PH@O
MT<Z7#G<H+Q9N,\JV)-&]%.9-;C>YPA%;87,C.<-9^<,XS59V8"^O8LTR??;-
M`4*O&D7@J3SBG;^6KLL%84X[G\D:O$Y`O>(\,/JYXC8L.75Q8SXP&::S!9LH
M6B!N/N04JG+>,8S&0A#QV=UTULQ"FS`LB-HSG>VNZ<D\UL](O=N&KA-';(-5
MW21VX.DN@@?/W_"[2+>^9A15=5F$W6T^6?#'MXSN,+VD^X"KE\)9X4.N<3ZN
M$8T/F<8PI1R/0)B\0"/W7\MZ+!][%(L-M%R4<;J',41:OEP$FTN4W^["`UZG
MN3S"Q["R>7,ZB*FB:GZA259D\7X%D^6BL0JU@>5PD?MPE#$F[0<W)6NP.9*$
M+<JV3`\I^U]-KU0-:R_V,E8>Y7+&`'$&%=8`\0:/86V+67FJT7&E:UB;G2R#
MM;G6AZI/O8.?<6L,L*06RAE:*>L:G3C+:)V^@9G<9P.WY7T]^+PK+LH^>KM[
M__DE84\G6E[3FOOP91%?;YK-BKVRG&36QZ%"%*1434WI5>J:7O!]C)-P#R.P
MSHB9OUM/U"GKZ8V`912E-S5.C7ZO&/OA&L8Q'?OT$-Z'H/ZDIH>THELNJ^EL
MM<SSF9P?H%^DEX[7A"ESO-:=QV@SD6.WB=IR%VUVRM*6#X?,"JQLQ6!:HB"J
M5#*2OI:U(!EI=M+^^%Y>JWS3O(&=/U"*D3*7M`C))WSDR9W,YB>)S(Y^"RGX
MANFG[7&,%>$/;0M7D2T,)4!20.`D1>*6M0#]CY&W@?CV=$&(5YXWA^-2".%,
M?+5R6;,.0@T0<E8@LZMV!'ZI,@%^V[8)QJFK<4#4,((9I'#';^Z-*V+O:D60
M@$#BIWUGBP)-IRFO5T]Y;3R/IMP8>>;;9@RS>)1PZ#HV1>UE!J?U\;9R,78+
M1MO>TXK/%F'$.UM,R]J9DXN/KBH#GXVX5&H$@LD[+T$N:OBLJ*"#UC$G8@M#
M>",U.NFQUFQ?DU>HQGA<+[JH,HC7AXR71=NVK``K.XG\<T;M%Z,E:"K4<VOJ
M_9QMQ/^2-2@P#""NQS5PP[:%HI7I6HU:?8N)>[Q:X#W]Z\SM0HFZT6HV09G0
MI.9&>9EB8\L;K%/2VK>^56M;CPFT,]%86Y.GHE5K[%*_KP4GG\5165G`%;2.
MF7$V*S[DC:V51[2.IR5?\44*ISQ9D;UN=,SLJH);4\'LN'CJ(?6QL*&C43<6
M;<O#>-R$>W?L5S.9+AWWQ-7MFVVIT+*&!D9QEG8\"#7EX6BO)D^,XZ.'9+[=
M5B[NN0X^OZU?D%WA51A=K/\X^E%^K0=U^):EH3U_E!10I@PNSR4S%N"V<1/4
M=0!R/@`Q`CDGSGTP`Z:6@QK"L<X0+6GGH-9P:]8(M_AP,+9&3*SA!P#FUM@B
M:_SE/?+?@)?;Q#-V65"OJ%#FK%U,:V3@+P0E(EX$F[]Z4>0%28QD?(#1J[^&
M\2W>%_79!092-'2F"#*"B1__F\TF#:PC[TY!CC<2<A[$KW,N^,*PE(^A/&(X
M4Q"@%TJC.>8!2?^"2Z*KB!^!OW@[P^>2N_AZ+1V1-F)W2,=P_>MS^/H;:642
MO6-$3_)_8#!/*F#.?OVW?[MO?/W*'S3`KN0FT>%[EN7@_W9[__EB!.X_W_W^
M\>;Z$[B]T@N4KL*[A?`F7/OTRV-_;>BB)%%&-ON,1BRRE\B^VI;RE.YD]U0$
MT;QE,G/&6:4M(@(**H9NJ^VKB*-9$7ZRV5<;5TX;+6DB&Q-%(LA06PTD\0&;
MB^<(DDLYXB]><HS\Y#V]29?Z#;@O:`<J3QJ)N<8JNW*:T`,E09!3S.X6UHQ>
M==HYQK1K@;0Z%=U215A>$[WQ$B,)HSBZ2IRWVL+$["Z5*MC<8QSN^&?XZ<]J
MG*U1!1`_Q;4<9Z=8L^LI@V=`*,8HJ<2CQ2"G]$6G7PIT2RM'\3VJX`GC!&][
M@?`51B!Y@0!)L,?34/SS#C,S.='BNEUU0L4V2_^)TP;Z&"A3_`/&Q[2"#_0K
MQ/L9L0P2A%+*K8:T)S1@@<)6>#HR*>H]"060DC!R46%O-5P)-8;V:HZS8%]F
MZ6HFWB,YT-B#/PR"57IE[S,,UCZ,V_;TQ-[5.AX(""1Q6>QR7D5'1IBLV-5(
M6W#9TP":IX#R$__96'/.3DY:'RU$S6(&>W$,(1[1D%`7>%GP.<T%BWPD34<>
MT4B-MP4"WD6%'8EI16<7"<77UI:3:0Y7S`ADG$"5U0B<YGJ/62*4<S2%X.&M
MX]:379+U@0-S,J@/WGUP4,=[9R,:"0"^]^3O?$K3)MH3.J%:LA7O!3;/K\"N
MO#T,EO"4AHNEKN+/RQG3CJ^$-FR<NDC-X1N:&O9B-,:2?:Z7<+=!`0^O8R:L
M<SJMKYGQ=ZHL,EXT.P$!R1A30L;QH$`].DB(DI"II`&\<)V1`2*V>6Q$5LO=
MU<*O6X0TZ1N?YTMWSD.<\6NMA]'8I6E<)?Y/G(AC"QAYEUY+F<TP..FG@S@/
MF@&<Y+F0Z6(ZGYQ`:S3LJ1>)H:R3.I7!*SNK9&&F1SG7TJ*_'0`0'X^:+Q@%
MA'0$7KEYUQ$:,&P:<7IIF'4XM!PE@H,(S1)J:BK\-=Z#*G9R6:OF+0]KKZ5@
M22+:&FX^F\WG61U%2JNL-1A^19Q=1:%&+\>07BWU$VJ4<ZG*_99=FX,O,PR?
M`]_HE5RMJ"KK*+@V,3,P$HEB_D5;S:>T#H$UUN+]!&9SIX:,V.QM6;WTJ('`
M@CNP&%Y3'\Y.]37CX`$^IQ+!C<_.]2J/:'7MDJ_XS&`UR6K*;\+@^0.IC,&$
MR*X0(67*O[LJ4RG]\?:XMAMX.#YN0!B`7>@%Z3]-=ZZB^5'=WQOZFW;V*V^-
MT\GW>[CW_,`/GC^&411^1S]\\@[H;YS%;BDBA@#3+IFP%TX7BV*HJ`()Y#QP
MC5W&!11L0,['/-Y4V\*MVF)-6(S0L).;($-I>$SBQ`LVZ%>V`%/<YUG0%32E
M$7"C>(_#_25\2AX1,TI='_=1G4"E\!=VP<G$G35'.$QH!#`I(Q5_ZO1R.^BE
M#4D<!ZOAA64%&U!Q&6+@"GZ_[&&#R$@E$/:A\=3A8B,E9PDZNNC&P0='-U,(
MJ3L;#R,56YA""2XDNLL.+^-S^WZ"<^H+,IASOBCW-<W(X<DB7ABP'#M-#.5$
M04EU!%*ZYK"D3EN"JB]>C-B".#^S7TRK1B!)-YG"V.P42]!)FSAKM9/)<>E4
M,.H)1N'7#(Q5+%F$?="EK%E0$6?BL-\PVK8B#G$RC341]Z2-:5P+J=FG.H8H
MI[STO><`Q21_'7/.Y#,>U;Y'19=#YJ"HD^U0$4J@0LK4$7T5*CDF5&K9F5*A
ME]M!+SV[47SLE'M1'"LH!/'C]_#Q)3S&7K!Y?/&C!,*T7=3M`2/I#IFZ#=O"
M%,Q`7E0\8?>:S_,;\3+W0AQ`S@+D/+*63"D7@-D8C1+#6,&QS0HB@6484U3C
M#6Z09$N@D<5W(_Y(&4M)6/KB!5YZTN8*PJSK,LI?OH1!\D+[J-SG=8<<GC#"
M=17.+.]K69(#B%[1.QQ1!(2DWDBB3CG'F'+\`*%.0[>AX19IV&R$CH_+@3U+
M52TQ0@1L141HM8YZ_',F%M3GC.)=,D^=+L?+&0WGIN83_96AX-KH3**_1DT<
MXTAE?&3G082.5N63!T3]N,77>D=^\,P%Z<EC!C#:E$'X.HOIPID6$"VIF`-H
M/TT<S9JTHK.?.JZ<.KJPR0)&%9I4Q14A$R]JYOU@BU)6'D9Y+^A'*T<:T1QL
M,IDLYCENR1IOT0FY4G]M",/*]',,ZM>&;&5*NMV5U(1W`;A5D-]F&!-[85^\
M-W]_W%-#!/T9C;M<-<;B?;SFXR(=)>\;@H,"+5Q1+73M35'=I;H1=:JL$:_V
M@W:OKCVCTZNKC,5+U!;3;,<F>]^T5W?7PA750IM7T]REYM4GRIKPZJ\P^>3%
M+W=1^.IOX.;C^^\QW%P'5W[@!6O<J6B=^*_I*472H>R(?I=U+`H#5CUJ3Z(:
M<=-/4O%;W%#H38&&&`+,$>0LP=,[^!ES!7[P"R@8@Y+S")2\0<G<S"%WG0:;
MYP9;8X,=*@;;%F;R"GXFP:X&1=7HH,#.YQ=.6@[I*R)^-N%%^FC\9.Z.58<9
MXRT#3-@P;2^`[;?=A=]C@-'^@P4=7F\"A2:W*`CA^Q?C1'%.(TK4?-`1E%1\
MB![/7:%@4S`^LYQF$(/5<YIC:B/T_W,361U:)!$D$%)D;'Q^H:1;/B-+_&Q"
MB_18O)SF)W75A1A;\YE!;=C,9W[,N-,AI>EB=8OB4-$[6F5*(TK4?-P1E%3\
M<H&Y([9,4S8J/Z^49A"#T5.:L#"1U:%%$D$"(47&QN<72KJE-++$SR:TR'<O
MG+L+U2'&UI1F4!M2EVA^K*#3(9_I8G)#0>@Z6(=[>!/&G/2D\HS>D%`R%F^E
M,YM4%E]3`N!G3.(7<)$DD?]T3/)Z[3MON#;%`F#MJIV;:[=#KQI+;+I*/V^3
M7F-4.'7^!K@;2IK!Z/>+-;E]&\4.%&@"].,ZO;/F+MSYZ_?T?]NN8I,FHQ7I
M<K))'`J?%8NCWT')`]29C$#*`'S+_FO\MK9A+9(%D.^[=W`=QT>4ZC!-8Q:@
MW3R_CN$.AE12L?L5*8A2@]L(C3))]H]/WL%'D95<*X4'(I0$7"&5TW&(5G(I
M3T1W9:^TA(*NNIPZT^DBK?;-R(+;"`_9"<C_G?$!548`<QIR9&?6``]L"<<Z
M2_"KA0<V!XEAZ8&[F)Q&CH]/\3KR#T:;4G<&?5%+W,ULJB+6/=P>@PW.C^]A
MXOD!C*Y@LSTU_UD#\8<JB'A?B>ED5809$!6TT(\I,7S*\U?MH42!4GG$`"4M
MD!/#1][,!`4%BKDM7\LD_+D(JJ*<;0<CLXPP@7%V^O<>[KP$;G``P@L7.R^.
M_:T/-_Q+C&0HZ)Q;B(LE/H^=3_(-44P]/^2.&Q83!B#C,/!-2*V3B*%4=TO5
M\U/O1N<)\KY;FR)(FDG-6'O$]>:WVTOO/7X,<2\]/T"<B[-#']\OX<Y_A?@L
MX5\C/TE@@.3TU_3!N#,Q[:-U5TE%!XCQV%GDPSGA!6ZW`',#CR$H^%6.FGU\
M!R5+D/$$*5/-@[X>VS@6VZ8E>=!CH+8F@NEUV.!X0`G(]Q=__0+6X?[@!>]@
M[[V3%H.I'8M7P'<_>0'?,_,%1"2P#2.`WXF@%YN<L/2-0V5*T^OK*`VJC5Y&
MS9T-_K.F0F)3$%&GG3B3U:(6\<)M-B4.TP9=!TQ.]PQ&B5:-6'72=FR@W0^A
M*-1/,[?E>QD/""P,G>"=:@<E<+[=;E%XN$$!$K+[')P^I!O`)Q*(+F0ME\XB
M0VY*`Q`BAEH8]%3#T:L&'Z,]=7&E=-$"2R86"CS2=3:QEE!4/WQ^.Y#;R%JJ
ME=C/:UPG8`HA7`_CCO,[7\NBH9R8\=H@1>H19.0D3,[Y6WVL.L/G*V\4(JWE
M-[0G3<"B0[G';.I.FX"H%>28J5WIK=(\[:D?UZO=&$7&V@'!KVEA*:\F8<N)
MIZ,0[B"Y>[_'N=/NSGO?,_:X!=[2GM*UBB2<4+B+^3C+\0H0I#E%1A:D=$%&
M6'/2IUA1Q["B+6FA8FW3E:),._C'T3^0Y9X=T?J04C02%"316.:08@8:(%C$
M&;./Z&?,\!K?+NWM_@-Z]%F?\,MF0P=',HDM3_<D@A`7B],VP\CWGCQR0S'R
M/3]E`-X1!\U+/@-I3@LI<1%3,'D26$#&`&`.QF.+,NW3!O0DH.2?MOS8YCM-
M2X.8$6K:[&4T1T\EQ&)E\X>OL'4J2WW'1-Y.$T0XW5TN\RNDF@`<I:#+:(X`
MHFIX8MM?48(UHA9,*5B1S_.\CYK9,PUA%D1HIO')BZ+W;1A]]Z)-ZWSW]`4C
M\&E*(>I2L_%T/C_!#IXTULB9!DT_]8J3*.6)+WRJ`ZS;5-2/(I;[T2%$-8L1
M_$3/7N#_@Z2;G\(@#G?^AOSC(MC<(=_(4]';;=86R-L]H-^D%>YMZZY*:.M$
MI0J!A<<$9S')EZ\J?,GASY(SP/<B57GCW;R".RC9FU\!UF\\5Y/QM$43E6"L
M!1YEWT;-U#PZ<#9<BS]JGUKGG&7N#,R*P6[O[TSMJW:3.@L\!Z/;J-U$=T4,
MKF=ZVG3D<OI94\W(R)Z\P*B\S#6^>/.9.3'M49WC+H6_\+[AS,TO-2!D*C</
MX[".*)D:#WLKY<HJI6V<XKA6;=AAF<`&/%R&>\]OC@,M#QO$1"J!3'[D,%&1
MTK($%UT48R&#HY@I;-3=C(>.BB&,X0-]N##*#BGDQ0R\[TA]7C=*:$((KS,X
MR]FJ"A1"[$.4';3AE:)H@DI_[=(U?D3F&)$944@4#5]A]`*]#5B'L=ES^*V>
M=X(:IDU,`"<])LN],*3VB$9X5/E*M'"89T-'^KKAVT*ZZ^`*ZJ#+SVF.4G7M
M$TW->'."!Z,6=ZX^H]6?*XR%D^GY<CG/'3I)$P7#'MU9"U=4"WT^37&7NE,W
ME56RA)25B\17870)#V'L)S&ER2MMT4'P3=V+3V)B"2^4+-S%)%V9R@F3$V$Y
M:6HK9;WK5D,H[)A4>)4J',!GG)8P%[T&T7N*%<_)&5L.DP-EL58F81$S(V(J
MWNWVTH^+!BGQ8WBQW?H['WULUA1)Y$VMHV>K.!*M]ARW`;=P"VITR=G]@K)N
MK`VG-,':S3%\\^/B1)WW'AX3<#A&\=%#V2;2'$U3P!Y&SY!:+*9O>!;VW?J@
M+68TLW#\0LR;30,_X5DLY>J:5K<0HV($ID*B"7OO?%&FP25D4QY%9Q'"942]
M.<H\@H>P1XIFWWM"?HU?1UCV-\!V-$NY/AW9XL8TB7(4<M9_'/T(?CS&?@#C
M&,9_CMBGF5I?,X!CEBSBAX*6J^98BX?6E"@HJ8X`H6MJ4JM26S+/S2FDJJ*T
MD%1X>.4_R-+E(.J^PN@IU*FP4S8Z)P$(?6`O^\!/&5W3\5>1HB3@WB$Y7W"=
M.1J![A"1Q'M`@2<IG-F&*-L6>FAAE6LC*^(HLO8!1LD[[J607`2;S_FQ(M&O
MSR9@,K8RI1)/[B?+%3O*YO1'I"](,B(;*043:Z"IR@PG(-WZ;R@[])!#F]TK
MDO=G+DSY]C(+V(?CX;#ST;C;^O'+)XU`L&`O/A*,9\M3K!5T3&<P'15J:^RU
MSD=W.P!TXE]TI-2-H6;Q'J)O%R3>,[S=7NQQ\_0[9)7'$*$P[9U^\8S^!Y_5
MVMP&I'WB0[C;4!=3NU'2OKC?24SQJLB9D_7Y*1GAH.T15D5"><BY(:?$_XL/
M^J&I+FD9ASPU1BPU'^G481>G89?;+4A9`<P+MR8LN`'"CISYW(!;THD0V06S
M-%`<J\,VK@J?,;?=T"N,E-L/W0VM/!K>A^_>+GF_1XG?[?8K3!Z\'6,7L_4E
MDS&.*I&@:RYFL^EX?!+.$&PSJ@"3Q?_&!\,(97-!2X&BE/BD5U'Q,*1`V_0,
M;*;?H19Y`J1ES-)2>T#A(I$:.]C641XF_NI%$9JPQ)_?T"_]&$UC4*Z)YB[>
M[C'$4YCD_0&NCQ%9PA5)G:3IF0PNLL+*#(DK6AKU/6,(8,81'#!+W)'%V^%!
M$A*N*.?/V9K.I88U$25BY0Q!SA$0EH#PQ#E6RA64;&U(JX8U$PEU&8NFZU0B
M'\>+O`C:DV%UC3G46-G)\H.%493K94M=#R_(YO'M%I?EAP%I/9M)199Q[Z)P
M#>$&/4#R0%'_ZDS?AC#;57@9L"RY81=/0_*ER)C(@/^\)E)DG8T+$#UC21#(
M4E%(6H&%L2`6Z[$C+S;CJ6YNQU0&_.=4BJSW=1&OB20@%X4DH:'R*I[.`5N/
M+2FSX\PGI5SRQ!FM"N=]8Q\WO/?Z3JK"O1]NKI!/LD^<GSQC(.S6!!!U4W<\
M690S97QI!*9AZ!QZ/R4<K4JT1IP>FF0E^N2Z'X1W@.MK(I"\>"C&(G`2BF`R
M'@'DK'/S1]A9`*GB^M0:"K%Y&W"Z[S<?,8/,@K_H?A!N7S2I`1.1,(K+CBHX
M.E40065'/6J@Q-?E^`'8^J\0;/#U1-Z60!0-6?$VO2\#S4?V:.95G`-%8_CF
MN,;M+U^1NX31NRW`/4%/`[=U>RF$[2-ZIA6XU8?,0+<B@;#'C)<SMP9>0L0H
M?#NKX>A50P3"G77AC*S_[Q$%)]L&50I$&NALFD(E/K^'K>@L'C&$S9R_:%?L
ME3.9S.O(_!Z:Q64W%1R=*@AALIL>'$1^05AY`1/',D@V4=$$9,T.1NJ_D-V_
M>GO(:==4>T1GQ5>%K_"QY=5\EM=@H"<!?M]H6Z;N2KBB2F@KY:*X2JV&JZFJ
M27_FMEMJ/&3`I^6Z$$T6\^7DQ*N-ME7JHTC3LRUHHT1W&YIW&VZ;=!?&"=P?
M=B&IE_P(`[CU6SOCMKRDT_^YD@B[T:2,\C6"(*=HO#VM2D7=[HIJPX^06];P
MU&X@-=.3$#<$\;W=%W\'XR0,8%YK?`_7T'_%N20U415Y3_M$1D`HT91Z/)W.
M\W6'G"PHZ(*B4KZDK'G&HUQ7Q[2N+5,CY0JG)P0*-0_%X8<7+R&W>S]!`+TH
MP$=M@@V(X#I\#OQ_0(,5(!)H+>=2HH8S,F`C6C"*X(9L0MYYT6U$>EUO_N+M
MCA!-`\E6)6L4$7M9YP`N))%XX[39*FM*7Q!.2P-&")01"*.T:_H&$/(`T4]+
M"0P-Z@,H[]:5CU/E#TCY5TS4Z*`NY;JUP5W<4.8QF=8*7!R3ES#"P4_HXY^\
M9`R#34G$5QG<X@1J$WM9N4Y)U`:\]5.4CC.OH);5U=B#-Y9;LG%&-9`M^+J.
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M:M6D83T&5:H@)6MBMT"MJFD_P#`@NV\`L=Z;VP,0A5RY`2!D"Y7QX![&$%><
M702;2_@*=R'IXH7^=;%>1RB)R#N\OF<-3^^\")\M_3W`+W,^9S^ZAJ)*+Z%E
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MUL.M9%9V1B'N-&K(![N&N16%/7*V.>]0SSDE2'U0?^BB2"'J?*L)O@`W"TZ$
M3G'%@*ES@_W5<?2KTQ8]>NOD2NND">P<K%3@S-)?%6!?440H^M%FW74>42!E
M?`WFXP;`RY)%M&_H8C9VQ@6$,;5*P^:\O=XC8WUT4!RKT<PQI%DKI-6H5^N"
M2,9^/.;7NTJ;A'<;LJH@YUK$S%YOVC;K"JE$]@KP37UP\\D[^(G'WIWDOJ1U
M]Y<GB?"&Z7BU++:&LE9K^!N#"DF0T32U'ZQ.SW)?*+N5,=7U8G_P0[/[PR*N
M6-\H;K6*-9C"MU_B7Z17M,M\YL:;IM%5%T>XLF<Y*^Z.I$.,7/A*?I52M@AH
M?50F:"/8RKHZQL>G>!WYQ;6OK-N?C,*.[JVMV*,8R@(`OL(H\9]V\!(^"0*O
M]H8YP%7%$/>ZA<,:RW)Z`!.T`E_=-71/-5Q7--P,I:'(O8[*OF*+DK@7;&7P
MSO\&R;TK)-I8%%AH*.0$E!.KF0XD-_X:EZ)<09B=0>4<?>&_92B@4$01=L?5
MI#AL7?/&C";`1$%.U7QDZ:TJ`=[O!Z0CN<GH/=M[2$F-R$4C65-F6Q#&<4\6
MREA64K3D1/I=QA?!YB&[R>X>OL+@I!Z_[6G]"TXL441/ZL_=R3COW9H1(SLW
M.3F0T=.]W*1&+\>,7FV+36J4<RO*D6VD[!9&A'VF:IK6F=K@5%EFXMI"%;KW
M?AR'T3O>3.-M`%&>,X#H$R%$W0+E8?.B.#HG0VXR,+;[TU<91[LRK=CMJ9$K
MJY$NR#(Q4@4K77E#Z2[]+N.V9F2M[^E->?G""&>"D\FJ1$OU[N[ZU=WF&Y.I
MU=CMJ['&]%?,71L)L("QK$+?Q_='Q)O7SE7@31L06(HC?H9Z-IX)8'`$,&6S
M;6%5:]V.PU:MC2/QU'6%L-@PF55H)+<-R?I`^I(-&"22B)\DG2P=(?@1LI8!
MKX.J!'-7_AMNGQ?',(E'Z7UP5H*KYHE"N"HM8A6D;OP`7B=P+PVK\D4;H%5(
M(]XNSEF)C&[@&R8-"&W;1K>.2HLDF2U*&\??B=L*8;!N,*MP^!5*S_#P*S9@
M#\DAOL(_6RV%!C5$U#*T2:M)&=#PYD5:`^]2:^#[JQ<FWDZ/>G.J>E9&BPJX
MA.)$;@NK(L1=N//7[X_P+?F(V/]=]OLV7[<A<C1DDIFCS86B2,H`?,O^BSD!
MPLJVH;R7)2J!YH(@T4H0,OQ7")`T\U@%SLZPM`N0\@ZXG#DBLU3P[9%<,V4O
M`CNJ3K#WL'Z!F^..7#)M/0Z[(=!F["'._`N*!-ZT`GV%..(W`+F+E<0:K=E+
MCE3K+;Y*:\.=2.+N*P;(NM&L0N3O,=P>=S?^EMT`M/U-&Q!9BB.>D8T78KLF
M*6V`B5N&QZY:$SQ^CA-_3XY\'U,%=_ZKZ>:'PFXJA+R&>4PB[^'X])]PG3R&
MM]'%J^?O<(YU%4:WZ(]>X@?/-]"+8?O2DC`9`Y@4E4V\O'LUG]8!"C(>N'0[
MC$#!!FS1OPI&@'"R8&5J&(NDX"WR]1TF4MYQ9,G*CJR_T_`L93Y5%7MQXL5K
M/TA$^C:P'C90NT>71*;UV[PHX,MIF>_AH$0MQXQ:K?5\*G1S.^FFJ[*/CZ5J
M>1_'%JJ!?1V\(BR%T?MCY`7Q%D97S=OC&=^)\Z)!P+.EDFB$ZU+`7Q`&.65\
M@,5\*%"E\$E8,*&P<)!0I74E8#RPM+8I=+2CE19&6JQE9"*`7.,%Y2N?POW>
M3S"Z/[_AGJDXCPF#9]RRH_P3KXQ1FH[.J8"L<,*9K[.8YY#->("2T@@4;$#9
M_*S\N]F2QV%MXJJWB;:Y0E=(U"8+G<QK?03@+Y-WH&1K%)!<3EXZ[J)''#"[
MK#ZT7;K'`AN6W;O#HW,\,+PL?X^^*>_(0OEWC>@MF(K?,SH99^MTY%VCHVU'
MZ5T1Z74AX<0MJOY=5]"8UU)GS+0G='NNU*0(7S^X7-9\U^@(T5D#5TP#K1Y\
M.DUCJ6G$BTDS![*DC$0G=S.^A+L-^D*WT<5VZ^]\+X'Q51CA6P(]I/'M-FN9
M1BZ?8WW`GE1UHJ6?J.(EJ(O\<%K),>V+4N5)MG,*KF0_)^>+:W4RSNDUAVJQ
MN4I-%<!GO!?*1:=6BTUY/=&,@EL-<FH!08%ES081TBN&"),*SA\?VUXS$@;H
ML@A[[=0=NTV<9PV0*D0-+:<.HZW;2UO]>.4[*1V0'#L91IQ8F3WG!3,HZUQ`
M/EY.3O!E7^&\*DW3EJ#K=7C$50TE54N0)%`CWV())?N:]_#YN,-/OZ=US(P>
M)/QG=>]>L@01W<F:NI.%DVY8EJ2R0NZA^XPP=RC5*.4848J_"ZE&,[>+9EIV
M&]LP5&PP<@UA9C`LK[#A;AA0'M0Z^#6YBP\%JW$QZ%5O<3*\3--3(5=.(7W#
M&\N=ZL,:57G3_D]V^A$8T9C#6U'GO&$($0TQA#W)F><'2NJ>5*%G=B5>E8X4
MM(CI:`(W##=D`8AF&(N0)#RHG+YC'DURD7GJ3";4H:;F:]8,.SWU;,.49:,1
MTR4%<&7G&'73TLVG]37S^+J1;FKC+!;+5HC=F.[BHU;=-J2UJ&L8;2=N*@"X
M&^.]>QB"L59'A%\SCSG9R?=\.IXN9RV8,[>^,(RV?,B97G.0=5(!Q-FU$E$5
M[.-[]2_R$S,:`0M0>"J5>&.WU8J^HF'?5*VWFK1U#EMG:QQ7%4$@PU0V8?'2
MC]>[,#Y&L'W/3)R"!6BDB"6QCSL9MPZ/)0/PS8(-MH&LT#)LVHA9CDN+@)9E
M,D5;<[1;YR_P;;;/Y&;;3XB&O_9V^8/L0XA=2>G?V.LDI\0)-F>2[_NE!,C5
M.A5>H,(,Y-Q`\;29PXM:S.+8:I:VS44-MDDO\SU1&[=Y>8Q\]*O;IYW_[&6S
M`].G'WL&CLIV97?3FLE;6N1MJ:D3>UMKOB(DDOCD=KQJXMSCX-QTI=T`RJ<]
M_`X(IF&$DI0RW#U',%7ZNY^\@,:4PXH:/"G?KB<OXH:T![:?WP[XVD0IY\C?
M,0[13!")VS`7XQ9@9B1MPF(G+=T3+3<E1?L0UG##=EQ5C6(=FCH,@/4W;4&6
M9.QW76<NAB\K![T>2I_"359I*_`G.[J=6LPZ+*8EO5W\('O3%BRFX@B7Y,P6
MCBN&11MKTQ7;@0M/:]%8=UUA-%8,-.`"676M3GS!H/:6'<M>59%$O6HU<Z?S
MEA6NVN3&AH6L[HKRUZR&5[3+TE1W;;FI\X<HT_9`YJSIU3-+ZM4S!A>A:.!L
M66\ZL9>9D3SQ_`!N/GM1X`?/\<4:0?I(!+N$6W_MLTM"6E_4.HZW22.<7<[1
M?"['7TH4Y%3!SQ6Z(",\T"5([2.V6HWS4V6%>IN4BMFQ6M0YZT.UD&5L0%O+
MM)7ZL$%42?;?F$S*<\]-))F>C?97[`0PF7-9,N?D.1H/+:K[R]ZC`2\XPGNX
M#I\#GU?@V_JX_NR5*8OH+MMLLERN\K254`,5<L.7]'(25D6Z.<9T:\M1%2GH
M=E504S;:"J]*&LHWB9D1L2F3:/."MO>TCI,MPHB/+`MWQH24C<M&2A5G0<WL
M2"KHH/5!5<0N!O'&+C;._JP?/>(5M-/E=%$#R4`WQ[?=0]M-<'+G[".F#:*4
M@`7NS:CHK>BG+!F,8F]WN[W8D??@AK2T^NC%</,IW./55)*.T3?)N]$PD3;*
M""CH/BA`SE?C,I?$+,#M%A1,TJYQ@+`!53Z#;K%S,\SAS.!89H;V9'0X6[@U
M6X1;$!,+/!$+K*L6@&P+:,M6N^"_EL)*&U)AZ()?8/0,(\*3_:%K3YD)/U41
MA$M"Y].%6PTP$.P)E=2A?C41/[KKX53U2*FDH<$8_KOKXIY^DU'Z48P</F@!
M1`.M)VJKQ^-?O-VQ'8_I4T;Q2$20^?9C*AY?,1F3>.R@!PV/A(QI/';0A8)'
M.W!8`P(=AZ6Z)N:?#]X.WFY)U\P[B+XI`LXS^L7M]P!)^.(?+K;HRU5.(C&F
M7M)D-,YG9663V7;(UELQ"YSH$28C4++!ORP8`0]SJAY5,[-*-*Q!TJL]4KI8
M?93P[E&J&[/Z8>N:67?U].H,O)/EC,`:R>9%?G@51G#MQ?P#*8R'=4*4*H%$
MHZ!I=JU'3F@$<E*&=S95:.9VT$P;JKB.5L,.VQ(F$8*OXA9"1^5!`\@HN4M<
M%^.>H`*3L001735R)372C813AZ*AH*&]203\'L0'N/:W/MQPN^BQGS>`AQ,A
MQ.\?FTUF35A4J!GNG*=(/[>;?KJQPG0]&F3H)C&#G!>X.>)4\&-V"_3%^H^C
M'_M9@Y7*OQYQ5W7FMY8DHQ5G<K()N^=B,I[G\$M9X$E"S@14N8S`TWOU%^`;
M864,F4-:Q%5N$7U8[@:&.L0[V-8L\JN;&Y_".$%I;;GS<>>]-XX^Q]G^"'H:
M32"I6R28"M(59P9$R;:2&S.R&(E!&A64:."W6IP&LMH&)V9"+@@C,GQ(-P`S
M<:L-$!"N2XG).E+E^1.*,0X":=I+1#=?=G0&'RJ-K\?]WHO>BY6Z#W*;TOHC
MJH$@0P_+NK^KV=A^";<PBN#FT7O+[L\(-C>^]^3OT!`$8\GH+$?-2'R5$E$X
ML7''2TJJE_,"B%E^MPH^8E;A9V%@&]!")ZF?@(7L"$^=<$(/,/+V-1LB/F^W
M<)WXK_`Z6(=[B,2^]Q)28!JLR260>:HJ'B<ZD#02+.3E%!^J9V/G-&(4#$'*
MD>`"\P1UIA:&C:%ME=_K6+4"LEAI)UM"17>\T.-%1\,J*76I2!$G_AX7O5T=
MDV,$+_9AE/C_J!:\W?`.5W4CI+M@II.4@FZ\G"QFD^Q`5@'Y6P3YG!-(68$J
MK[*;S(VIXUH:;.)8:A-^)8\&P[C#&$9+<5"OT%'4#W4WLO;X1UO_[DC$YK@G
ML^*[&+O3^;QSS!MP#5Q)N.M@BJZASL1V@`Y[=(UPYC8#^L6%3H'-CHV`<'OE
M!WZ"PNPKW%RC:!(\^TBN=`[+EUUT9JB$A8&9H@JY9<ZKNJ<SQU2`#T0"4(J0
M+:J,!-!DSV12OSE/%J8XYK)AEJD2B[19I[(O8';IBJ.$6+5"*P$CRU)M4HDO
MRDZ7E(T]?BBQI31!K1%.`T!G(^A?<1)U<_KZDI`A[<:Q^,JS."4KD2T_O,T=
M=](1XO8D!(,9AL#>\K&^@_MW`[I-(_=U@)L`]AR]A8@8P;F(9,*>/%W1)@0E
M"]M'<O7&.!G-^QE#/^)EW)\.=F&CFL7Y710>8)20XICD(MA\_N/HDQ:U8@AO
M>=T(MODRB8]/L_P"L9Q@>@(D(042!5%;0*Q2:[>7UOK1*N;$=)P*V,TL0K-.
M8O]`,62#Q"*'$K*Z%5RJ'*%_U>I7T-^.>US=(I67J^%B!.]*1)>8K:XH@WTI
M`RB%R$>V7(R3VK-,$@O3?0,V3>\C#/<'+WC_I[A6I8R+D8/8W\`H_04Y]IP5
MKN&:9X3A./$>UK[9^R4&PBP];JG[0J;#F\C=T6+9B`PM0Z%*6$`9\%`6&-A7
M%I.#/8W+`.U(80:SSLET1)5U3$06:;BPXH><L4U'B>+&'>G$AO6FH0C`$$?\
M"K2YTZS8(AY=O?K,PGQ"B=I9#2K_ZD@3H&SQ3A8$>4917#]UVI=8H%Z*]9*Y
M^BB&1*)E?<YB-:'40U%[O)NM?E*BZ$FUDVY%16N;E&A[4LLDJ:WFRJ461%(J
ME7A6,CL^TP_>58_I?7P_/<7WW8LV8IE]7_I&QOJ>0@L/C1/T=4XS`N;!WJH`
M.-NEGAC&4M@R+]!JQY.YPK!VU)^L*((J/:51\:ELC&3D#/?M@<R0+O!A(#^;
M&XE/1#H3MBAVM4LK<:;,H:RCLL`V2D_1@XSW".3<+9SKZ#%=&J<J1BE,8G.8
M$<>13'P1M*TM@:4:]JJBX_:\:;S$:[7I[SH'F1Y,#`><[I*+C_3+">7P+W,`
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M(SD!?,92_!F&SY%W>/'7WH[?R9GYO,XQG26$Q.YCWN"\2L1T`V<U:KE2:FD;
M+-L<K388<BUA!"?4A0K6AZ0_K!,A5`F$_6CI.-DM3ZP%/$,(4:!6.:/]8->U
MBF*N5H,)VQSV8*2R6<#:*[CR_/0NJ\J<&1=2K!.XN?1?_0T,-KA'EY17J.1K
M'+D*E9&X#6`^XP>!ZI89=\=L!+!TZ1UQU26V$<@E!+F(I#N?3='%F.E)H"K,
M\N[#W<:^L#0`NMLCG.I/8BQ8/K5K]B2CV2.,]@[/NX=AJ#L\#J*%,#B=LE^,
MAKB(93,8#BTP-8F#A3V0V'OP\SOTHO@7X^%P4/R>Q,'AOL4/DRW^)=PA,CL_
M><?!_8OWYN^/>YW#/5V`<\\?J5J)9S/N9*$O8):RDE1R!#)Q?Z"<4L'GJ`?5
MUX+@".S9YCKK5),;&@;/.=F?[$>-O7Y@./9F`OQ@L3?52KR(8SIU3,;>5-P?
M-_9V^1R<V,LVUX\4>^NA07?LK7RRLX^]]W[\]ZL(PNL`H0'&B>:LE\?^7.,N
M1R?Q?3AW-AT\ZF)!`984Y*+^<`FOLF^1'C3%!MMB@_FYP2)BL!\MY16("H,%
MW;9/]F.&7'W)+H_]#Q5R)3,K9[&:&PRY/TR>J^Q;M(3<'RS3%8@*>D/NN6:Y
M-XQ;KQ02/H<P>2-YP1&^"WRB:KO>X$U0I@SGZC&<];'M!'Y*HM;-`#=)=94E
M/U<8I,=V+@Z'"*[36__2ROJ_0OP?N+EXA9'W#.\A+CST@^=/89!$WCHY>CN\
M<W;Q%)-_4FN=K1%.>T&^+9H+PG^UG$V=<78$``L&/O+A_S&#?_9<'?[Y$3FD
M17;$L*I'?M@GUP1DJH!"%U!1ANS\@V^Y/KI/(9SG=W3^BW['EJ,7Y_DQTU-B
M8D:^\;=&BG;MLN_I<1-;)+-HX'_U_!T^;7D51G_&1^H&0<P)D[,;B)L:B/;N
M&B_F8_4#:BX-0.(`(L^9C8?]S*EZ7--DSH&'I7XV)</+UR,^?H</;)>M:`KC
MX%[4SRSCG,?(P@IVZD8(ZD<XJR6GVWR[&$9K/\:ZI%ZA>FF"R><<%J18PLLL
MLZBK`BS`6I%G!%*)SFS!2HUA6<&L0O8LUZ/:L*ED>8K["<X\E#7R].PO\"[R
MU\K/TTER/\^PQU-)IBA!W=DZ>C`\F3CGD@(BZME'277?H;[.X&7F@KFY#ICB
MCQA)14+#0/&U]>.=8]1%&?`6^J0MT75P!R,_W`P$`QJG,XJF%/$EKA>?J*OS
M*")G12+<ARJ5Z3Q#9&_CLE+)C##<_/;)0V%JMX/G>1ZY':TJ@Q[K<YQC@"/S
M^T*-/T=AK+Q*@\/IC`(<17R);L!+=2<V"O"F$I6Q#?\&276>(:ZW>5DACA`^
M[[#&P:C*L,;Z!.<8UFZ/29QXP<8/GJ^#)/*#V%^3&KN!W)?-[XQ"'%,)423.
MG)D[P!RX(M<(%)*EQ;R#1+L#0<#G8#-DQ%-D[2FV]L7S<P2?O00VS8/FN(0#
M^.CM<(8WH+D>$B]*SL!@LQ:#?83/?A"TV.Q<AH[6.*AR`.%_("LJ!9@BWH>[
M'<KK\:-#[&L*\3VW>@(1I43W;Q?SR7*INL2@(F`3Y^`;%A)D4IY9)9YZPRLN
M1C!L^&%K%-1;W^4.26=;J2`3;)45+PA_G3.?U@Q:SW#*YSRG,9+;[NYL.1EX
M^C)@/8/N64L7XTY9-0T_XBREBX%F#`/]J+.2X4H_Z!_BS*,^>YHR,+/SC/_R
M&=E\ZDSF`RS65S-BDQFP34:F+]D/8H]7&#V%]EO$:9CDK]D-057W^4$"/V,.
MH.%KG/D08*#Z3Y3[>0X2*JK.)@B_ZCI(TZ<.)JK_=,\IU'V+*?6D8=UD/^B\
M0YT19T)&_%'G)KJ+*64^H;K=E*=V@9_Z"7P1;"XV&Q^_XNTN_7B]"V-</-7:
M;L$"T8SLR9C76W3]VIW/9]/*MHV2<4]JV!L!]"`HE0$5;<RV6CBWKZ@X>SF;
MKRBP6W1NGU)-ZR/MGU+?KI;Y#TK?^#(OUX\^1<:K`5M=*ZBB@OQX$^>*=N)'
M%2;NL"NOK;'+V%!S+E^G=LN[F24)O4NYP_@XO0U2N_%^L$DT)18;F$\W/^-9
M71W8JBJKBY/+PXYF2<[ALL'NZHDON:V&.`?)'__8_>W.[(9"7=]'MH/=R*J]
M.S,A1LFUAST_\#E&];_`&*L7;(KK'4/\*WD3*+]`5KV`9S0&J--:N#I@ZDY7
MZH>&5!&R7E->QAJ27_]7&S=,?5-ZHY*HL"ZY%1=_E%<DS3D/'^ICF<I11?'G
MMW+]+&9-E\C_/"+YD/YWR&F_>GMX&6+]NLZON["R:0VL@_PR6606RC__<<37
M*J9'9[ZE9&Q==QK<(JZ41:Q9".D!*JFECJ[V/Z](5.\J5;97&:+F3:T09Q&]
MNF@F4\`J<7@FEFR`!VN-3LZS$9[![R*RX%S:VNYN*8-$#S7!N/.'/,LP3>F#
M92)0RXIQ3J%:4C?AE&LV=24Z-PL':VK/O1\U7`_Z;<0"]KGU[QLHHB@-WET^
MZUF&[WJ_+Q.16T*"<PK:XFH)QX3E;"ZQ_BL<KT];"/Z8H7JH+R(6I<^A!:'Z
M8*$T*$M^P`%[39'?YA50E?5A9NVP.`4[^C^QQ!-$!OK?A;MJZ>24_D'T=.O`
M=?H#68#?4DFS!;CG^`8WQ;3]5+,-1_$&M\-,Q`Y6G*;K$0!;.CEQ+6D@;DOD
MO:JIVQWO561)L]5RYG8>"XPDHXK&"G76ZSJ.V'=>W*@9Q<Z#5^W7/B!9&(5%
M,_,AOH6Q59#X.HZ/D'N>)W]$]SI"QE?BYK=I]0P,FJ.G!`QW=^BD!H%<'44C
M$!-RQCLM=%*(Y&\G^1E/)ZWS^P8,3B;@59V-8-5_#ORMOT9QY6*]#H]!@JQX
M%^[\M0_C1_B6?$3,_\[Z:F(OZ\2WD$3"^[23L9OWX2T)@Y(RR$F#;Y@X(-1-
ME0L-H'IZ9OFXWWO1.YX=M5C!*-JD'+F&0W'#&4$HFCR0];BT$`MG!6&`E^<N
MWGSFO4#<=W3BD2>(N"].9^-:>5Y)!WS#E$Q!3IUVKJQVVG`EXGXU.+4:Q2B*
M_@S#Y\@[O""\[T00=/*\"?0TA1`O-%HZ6>I:)6$':/HIY4HHI1TK+">CXH1J
M!Z,8N?$#>(U^;`5'^:`)5!3<93PG7[S)B8!OF`P@=$PCHJ-"KIQ"VM%PXDY4
M&-25-^K_M]M/7OQRM0N_L_JA";UB`A,4.212_LFRB0Z4]&."@%`TWXI#F9IN
M=S6UXX?CCE0DL8QC&%-7?N`%:]_;W84QZ74DCBWVJV8PQI1'XG[,E4/!6D$8
MY)1MPIPBM4^Q)ZVV`0RVNB\#BWRC&<;D0Q*N__X2[C;("]+YFC@H.>^:025;
M()FY.`V65<K_!+)IND7`5*7Y*3([:&X`F^UNS`!GB^&,HO-A#0,O\D.158K:
MLR;05Q5`9C3(CZ=EK]NQ,M%=&5=0&>T8H3D3%1,GNAO%P*/WM&.6NM<?,N'U
MA+/X95*K?!F[,EDG)$P[?`<]FHL.;#VT^WK-::A.7NIKQKN;@P[S^YP\J-7+
MF]S%VZBLBHH)6OYPD221_W1,\%?`?53NO`A]%(/E%#TUI115&"VFZ*D.O:1B
MF!`5)MYN2%WF6)='S`5`\KK9",4"?CU*456V(U*U3@_MF!/VG0Y-ILYT(AW!
M+)@2JE'</57<1O3P)WD6SNR:(GT-$UCV>V\MMQ)^WRC6&$()QVW7G4\YT,/D
M*_<7V%!Y-8P)"`@_A?L]+BG'+.P"7XOO\K'(,Y`]T"2_?3CL_.13&+RB/_EA
M<(_KL9F].V7)&`<J6S899YVUX'64.C`@C$:@9`4(+YM@J\H@!+WW$%.`(";:
MQY@JB%@:FX5RNZ^W([K%=G8`._LFI:S"[G'ZIE'XGH@C?D[>G2[9B!V!W&TK
MH+4%HCV59J%R!#8P7D<^.=EN%SB9_LK'(]U0QB"8'G.X/$:XMCI=QB#''\I`
M<;M-?TY\-*=Z@&OT:.)#]LY'+Z*Z@=M94O%%6:<L;<-NG7($*<NBE4A^@*DR
M`N/2EY(S*%D;A+PF<Y%H@'GA]2ULB'6:;:>!`4WK+_8'/\2M6.#;^@7WQ0#;
M,`(7[\D1Q8NGQ(I31DK0=1)+^GT!Z\+,'?+3%R^&M]N+.(9)IZAR0L.6(-(4
M3&9(7(G'C)P-!DK*R,((T<\6_(#0C`-_>8_\-W"Q1N-MA,\O$X;6QP06%(1#
M`-7$UB&>?HZZBTLQ*-F"?KIXXF4+<\<1CP&L3F<C\!6FE7QEISX+HX,*6Y5K
MXYD=UC4[6(Y^/BR$8P#'D/9%`OS'1A=@9E\">4+6Q`&:=.)K5I/Y`/=\4AJ%
MVQ@5^EO.K7>1.C&`V4:#G=$A'@^8)K0H'/S%VQUAOYD`G83Y$$"52]B%Y[/:
M9C<C!R`\K)\&*+"$@EF`A7#G>K\`T-F&5=,ACBQ4'I^*5=C&9V<\I+U?6U,"
M0==:SF>3U3QKNY8NJU>(:.Z:UD\'1Z,.S"B@0A&"\W2)+]L*J)`"AS2G,==C
MC`6(LE4857TC`RX2`OYQQ$T?7D7.C[,>USF0,F007C!:+5;Y@GM!"A!:-API
M5Z*=VTD[;>-<B]/5QC2>/2Q`S!>(IPYB'S-[UAQ64@&$76FRF,]90$E)V0&2
M+FHQ$,)1RQ`ZZ@[&@4;%"A;@HK7_`NMQ<^B0;DB`/6E!!X@%'1>4*$>%B35]
M%EI<C@,6"_HK-`1JK2%F/F\0,?(%LE.W6*X\]2KS!<%J]*.BQB:D\(M^N4:P
M`"O<LZ6T1\TA1.Y\IK-8K5@)E]'CIKV58J1;%IP]Y;@6!Q2&SZ$VA$'\>+T&
M&$\;1$4F@K`/S9TI8]0`F);9Y@,J=*/CHT4W4QAIN!L/)E5C6(*4^KWA[1\S
M>]XL6B0O@4>Y^Y*+%\YM\$80TT4_'F9LN.V^S?5:<-/YWGG6/DW:#?QVRVV;
MS5H![D1"^QZ/G'R"[K::.XOY+-L!REJJW[:V5!]^+9F]332D&1S;S-"RTS2D
M+5S%MM"S/=4M#I2;5QTLJC&`T2:'TJ_;&;ADYEW+V=(I;HZ4\-`!IYD]XU4'
M[:5CE8E)]K`FD`Y1YJ;D74$N&9G,3MV+Q;26_9'3YS1.0$Z8B^\^3_(MPW(M
MU_A62$]U7"EU=$TOF(Y4G5;0->_N]S%<__H<OOZV@3YV^2G^`7OZM.+IZ%=_
M>XP\W%/KX7W_%#:_RNG?-7CV"5/Q]JJ.FR6]V?L@):#7E7O*[XK)/[3O,ET#
M^RQ=1269X^/W\/$E/,9>L+GRMPF$0:7L^2+87".)T1CQ"N^0,:D5'9W)Z,XD
M.\@H/.=9+9;C-*-$7$#.!F1\LJ8#*2>`6(&"%\#,AJT982:7@QO$L=,@_'QS
M<*N0B(.16+>")V<%+2EGC^A0I)Y=[6DD!44,;K>50T&<O2/ZLSI349H`XCWQ
M5ODZ.%D6Q@<?*F>AL#-^#8,/7N5W:`0*8I0HX?,P1K>5%"CN#J"XMO26YZ2U
M%)=I)R6IP^\!>A8^AY'_#[AAS-DX#^H>_JE2"-_M[4Z7V9)1C<[0$SCFV*U`
M&T>[-OR!5X%*KJQ*6D91+E"*<9*MOHF1$$D3!AMRMXNW*TY(/>W\9P*P3ZFH
M[[?;/X?A)KZ-'F#TZJ]AG)\9XVXE*R*N<:Q5(['X%7CCQ:S`9\FX/*=8LAZ!
MG#D>R@A[$$8@%Z`\Q&=V8]N$`5U]!M0U]JN%93594/B!%&47$5R'SP&.AO3.
M#)_?\(\GW=1DW]:?AXB*)KJ=L5BZBUF>G)3$TVX&X.-IUX.<@>Z491C%'4L4
M;\MNAM'>/=$>IG2`EX`O*+2\@(DS`AA@!A,@62Q7LB(ILYE)E4H1'[VWCS"`
M6S^)KU%`W4/TBSN((BIN(T<6.Y"7P!COO45'9L>6/A2U)D6=Q10>R&?.9$5!
M.*(.<GXCD'(DORQX9NMI*5>0L365^VBR$XD%-[[WY.]PEVK<R>$Y"N,8'*NV
M2Y"9GC(9S.8RO7%33V#Z6=E<Z(@V<-.2?GU\+Q,P7#N4/['A+%`J(JX]H/25
M6*)?JKNHQA;,&+3.%W"?J.J,`?,OGML871@U83]7F_WTQB55H#P-44J^CY%H
MA7OD?(X3?X^$8T:=^D,ZHT>-LT2OLUF>8:0-H`H2H[3VZQU\R_YK_!!F'Q5=
MFHI&<49UIQI>3M55LK9`VEO=H=G$WEO#8^*OO1W.$]CE#?P7=*\@<*41W8M>
MSB:KK&0A[?;5((B3:D-U"0KU<PSJQU\/4*BDRU;2>`6!$-2*V7Z[4=3AOU*7
M\/CB1XW"!'ZYDQP!(_%!5#IA5YO/5XMJO*C5]>0LZB4M!FN;!K2!8YD-!.+,
M,(:HQ!V$L8DEP486U_7@(V4I$TGX7Z'__)*@F<`KC+QGF/;GO=V2M=';8Q(G
M'KFS]Z,7^^N+8'/I[XX)<Z&Q(S&-27TW"<5+@&>S[/1\S@ADG$#9^3AM!PPJ
M[$:`,"1KC!E+,Q,"'>9Q:^;Q,O,$A7G(U3%Y.]G45&')VN0,HQ]6JC.1'G96
MDK'\'Q@A%O`3>A(G18^1CS(CQ.@>;L*W^#V^AS'$>ST/R7'CPYB=N70CI#N#
MZ22E>-*,)L1I)I/Q`3DCD'(B%<DY+Y`S`QDW0QF-!ILXEMJ$G^%H,(S+,XR7
M&^;A/Q[D#*,E*>H5.HKDJ+N15<:_.R_!;;=:PUO].4/1JR:$A+^-Q_7@E-$Q
M&W9Z*.-H5T8H7O30R)752"?0J1AIXOA4^10DF?`WZ!WT;_0O]`.^#@7]X_\'
M4$L#!!0````(`!R*3D<AHWS2ZT(``,Y*!0`5`!P`<G-W;BTR,#$U,#8S,%]P
M<F4N>&UL550)``-(QAY62,8>5G5X"P`!!"4.```$.0$``.U]ZW/C-I;O]ZW:
M_\&WM^KN;M5V=_J1F4EJLENRW<YUK;OELMW)['Y)T20D8X8B'3[45O[Z>T!2
M(BGA28(""/%+XK8!\)P?7N>-O_[7RRH\6Z,DQ7'TTZMW;[Y[=88B/PYPM/SI
MU=?[U[/[B^OK5__UG__\3W_]/Z]?G]W=G5W&483"$&W._N:C$"5>ALX>O)<X
MBE>;L]L$I2C*O`R&.[O!T3\>O13]QQGY;W`&O_K;^=W-V?LW[\[.GK+L^<>W
M;[]]^_8F28+MF&_\>/7V[/7K[?=^*2G[\>Q/;]Z_?_.Q\9>[.(^"'\_>-7YU
MD:#RPP'0]./9^^_>??_ZW7>OWWU\>/?G'[__^./[O_QOLW7\O$GP\BD[^S?_
MWZ'Q=]^_AAX?SN[>W+UI,/E_S^[C*(76JV<OVIS-PO#LCO1*S^Z`U62-@C?5
MH&'%[AE`&J4_O6IP^/*8A&_B9/D6/O/A[;;AJW_^I[.R\8\O*6YU^/9AV_S=
MV[]]OKGWG]#*>XVC-/,BO]61#$;K^NZ''WYX6_RU;)WB']-BE)O8+U"2(/",
MV8+\Z_6VV6ORJ]?OWK_^\.[-2QJ\^D_RP;\F<8CNT.*LH.'';/.,?GJ5XM5S
MB%Y5OWM*T.*G5TGZ+2+(?__=GSY\1_K_RV7LYRNRBJ+@4Y3A;',=+>)D55#]
MZHR,^_7NND6^M\GR1QP7JR>KUN);TO`M=ZRW?2F]@YZ_W<-R1^0;\\45CF!^
ML!?>QBDFG[@(O33%"XP"5<(E1STF"[=>@I0G0&'H[`EEV/="_4Q=PY&V0CU(
MKP;03MC]$S#^%(<!G'.??L]A?<ZB8`Y`).3`@3^A*,5KU)M^M>]H9_/"2Y^N
MPOA;>AT%.$%^UH.5P[%ZDWN)4S^,TSQ!YWF*(Y2F,Q]`*A?I?#%+4Y2E`-BY
ME^)TOFA><K,@*%IY89]#2O?W32)2W90IW)3533.'W\'R"HBL`/]\2+PH7:`D
M0<%5G-PF,5QJ]SZ.E!>%&2)-8GN59]!MMHJ3#/]1_.;3RS-L7>6C81`:3"+S
M-?)RV`EPDR1QL0_,;$<N&1KQN<]7*R_9P,&.EQ'<H+X793/?!YDX`\G]-@ZQ
MCU&J^7#J\]&C\TY$YB`/$1$[7E!03MK0O-,_:I#W2P27.XA<6HX*'1\WB,4M
MB!#1,=?`]H,&>=9Z5>CXN,ES0/_EJ8\$C;C<8)\,.5LFJ!"9[]`:13D,Z\=`
MY`!":]</:N2Y5%P>O!>4DL^"EAF6Y\Y6=2O^U)U%R?&'X:AYHI8B*?QZ)X7<
M8.\1J,FP)O[DOS8,MYH7IW!DC5R`5K'"&=D"!"K0)\@I@*+B#-B>%)PVW9GL
M^^'C8*!Y9I6_=!PN[^"7O2\6R?$U<Q1']UGL_V.`>>*.K)&+TK9U':59DI?H
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MX%#ZJAT0')MY2]C>_N+8[.^^.S0,^V:N`2:<_8FAF=N92>K[:0#^N%\QR:+N
M8TOB6T.SRS$A##K'BM^U"P;=ZZ#3UP<_SXD&U0H&(FT'713RGQR:^?J;A4ET
MIT!62L9%G`*U)%JJ4#%OO4W1:P!(^A)B.5"Z=Y(><H8&C:6J#KJY5#XZN)"$
MEE[XV<LRV.C[)]X0`I/4YXYPQ^S6(U#Q"8:,-PB=HP@M<'8;PI0,<]'*?W7P
M.Z5MS!A$&V)^HF+NN:$=D]R#%I?0&$4!B<,N?TL^IB.&O/@T?!P(:7VOB"N,
MDS:LU>>*6/H4^6^6\?IM@/!;0/HC^8%`_O'U=^^J2/I_@5_]-H-/!^3S#8O`
M=M30>T3A3Z^8S=X>C[JKT%ORR"K^KD;/X2(DO_EM.QTSRG3,'M,L\4A\<8L2
M^7[#([8EXQ8E.`9*@DM8X!3DZ.V.1]\##,LAJ_CS\-24,W4!'TR(831`+_^-
M-A2RZ.V.1=\5#E%R`?.SC!,V=>U6QZ+M#BTQ6=Q1]L5;T6:4VFQXZD!2(5EF
M]YO58QQ2R&K_?4=/\Y"?)6W:O,3?#@0_'ISP[12FJL7;YR+UY+7_A,/=Y;!(
MXI7*J;&E(J;LD;,X`:VGR*U[]]UWK\Z`@3*LYJ;DE4E@01T1;%#1DO3$<0(4
M_/3J_:NS/`7FXN?28S`N>/;NC!J?]Q,^[!N_ANG#!!/G(JUQ^CCA1#EH:WR^
MG_!A7Y,U3'^:8.)(8C5.?YYP8DJ$-4I_&1BEO[[=5X.'58YELY^KS^&,C/R.
MG,W?G;T^V_5N_1POSG9CG6T'^X^SQG"=I=.%ESX6\.;IZZ7G/1,1]?NW*,S2
M[6\*C;,AJU:__JUR0::WWH;8$F%)P&^2'#5#HB_RA*RG/6FVRPC=Y6]M'#;,
MBJJLT;N:Y.D.^0BO"6U?4";'"[6+%@M&->U-`QZ=)%%K(XCNXI1N/4RBS[QG
MG'EA(\J7A:NXHQ%^JLQ`.LW-##X3=#$,6HQ&YN@4;*E6&^-42H&ZW]8<U5_B
MR)>`M]',!*W;P#78SX]P>9=9]I4[)FOEUF^ONXV0L7YCFD"!5*<@CBCX'_%S
MK[VP\/UG%UZ2;(#N7[PPWS?"J?4UPA4O:8G.BS#;Z/@<5+<,=PKVFVFY[R_B
MA$A[EVB-PO@9!0_(?XKB,%YN0+*@7?G\#B;PV^8"5KF=_..>T=@"NH4G#KN]
M2>IW&9A"X977PS`'#2U'>AJ8W<SP\DQTT53R5F8V-T)[CA[BV6)1Y"V+MB^U
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MJ15U'L;,"HF?$9!!@J@+YR\<W`6-;!F!V\4$#[7[ZBJ)5\T"P/-DI]RE5W%"
MR@B0JN*DM&[AD>$Y<?J.:@:)S,,1"CYY282C93KS_7R5%XOM$D1E'[/F5**C
M"7YX+G?![2C5U0Q/DA*C)3*BLE0H(P<>,;RE[3JBQ;((/&>N1K7*`\._)%R-
M:A7C(^/R<#6857[UB,UNK@:R=L:H:?IR-8I5'IS:INQJJ*KD4=/31NQJ`*O\
M2A)Y68X7O&H;0MUUWQJS'TX,,[&W=(<-2(ZGB0T/DR[B=`SZM1N8-)'H(CB/
M!0F&,;L)B&0HV0ZO]R[?7Q)X\4.]:YA<OL0D8&K[.VM87+ZG)&!A.`5V^'QP
M^:[BX*/JJJ@!<]DN)+&@N+%[-4HN6X=D#NUV]D"-2Q>[D/V7OVIH01,JGBN\
M%IK<M*?UP:UG8D(-K9MFN#[0<J*K:]C<--#I@(T=%%VCYZ9)3],YV`2JB_;C
M]H7!S=JI@7-3'^H#'*]UC9N;"I.FG<D(`JW5S2[JU*BVJX+%0JJD0"T:.R^'
MR&A7]'R6&B3GI0Z1SLXK,E##Y+QXH:"I[^<VUBBY:5GM=5@Q$C]JS)P7*R0P
M4XK^KJ%S7K(0G5UR248[P#ZZ:9M56VM<F>&CFUY%E4C80ZLC1:C_Z*8YMBM.
M\LI`C:";!D@U18B:$U/K/FYZ1M2-$^V"'#4^KFY"%7QDRFS5B$V;3D/"2PVG
MBH;]0PEGA)9$1G$+4''>3(V9FPIW7\-A$Z$NNK:*#&9GZ<_;`N,GE&$?*#5;
M^@EHF2<%V4%QZ=RBI#@GMI]E5X-B]C1<S*H@(IWEV1.LC3_J:61S<M##"@[*
MMXQEJ:]:6T'Y/,]2\C0,G)"RY#>[F$_95MP4DIW-\R6Y-02=;.&#NT$X'6RA
M7[Q-1+V<3K4=D5%`]O1P/4-4#WZ'IY3KF:,Z<=N>BJ[GD^K$K'42NYYDVA4X
M*:7!]214#>#QCC<W?<_:0#L\V]QT0VL#C'&P.?SB2OG,_`Z<ZG&5]Z+'5<IN
M9_\&_P]S`M?9STF<IF>?O62)HW\W8Z1)@9\J`H.I1S?;F%`'MI;0[15P[J78
M)]DP.,PSIG8FZF6D(BV*4.*%).0L6.&H>/HJPVM4Y3\Q.!'U,E._DRSF&UB_
MQ.Q?1KGF`/?\N8KJ3\_1(DY0V>[!>T'IIQ>@&PX(.&V2S37LBR+VFE3@B$.@
M;[D-/V"@,.07S2&X.R$$>BVKM3G*`>%J`59O7W,I/VQMAO)RPDN:*H)X%6@9
MS<W4Y/3)YU/^:;W?RDCU3935FY5!9[N-"2JK<R-:5O,J>O2'W=XH]4*D:2TU
M5:>,@]POLASN4;*&A<=8FZ+69JH3TI)J^?<POX\63+N5)=5>CU07QL7\LA;F
M[L\F:/L5D7I?*)BM87<LT9=\]8B2^:*0%!L:C9RHV7$PD^J?0/IHY*"S-[GK
MIF8)C)B7L^OF9`5LZF.@G[W8_L!8!5`XTH?KQF$%E+J>TJZ;B!4@%!I/7+<,
M"^7\MG6S91!SW0BLA(U`9':]7J$45M)"O.N5"I56EM`LZGKM0B6TJ*J_ZY4,
ME1!BF_GZE3ET;"$-:L/O5QO)N07)L)AW*W,TIN0')9SV+,?]JAF-)(B_F3)3
MY3I$P3Q[0@DI(@!_`M3@+J0[G3_^Y4]\IW-S]'\]J[(C#-C;&(E5GQ'1Z!AF
M-7X?+?;66?#W/"V+]3S$]?=VWZ)4,6MD9Q*R:/98#:,:>?>>3G8+_'(%D949
M1\7RA6L#E/.,%"^_1(\LYXF6H6W%I-ACCU[:+OMQAX"?%&>HLIN"`H[CX`[Y
M\3(J1N$]VC;X9S7O'B:1\^*<+=;T;9Z0#$!H^QDERX-=KV/$8W%513YIYTT\
MKN'D&^YY?=A.RWP4C[3@Q[P`A4BJ(G<8OT-W!%/DOUG&Z[<!P@2\C^0'0N_'
M!F;PJ]\^@2"=;2[CE8>C/?H._FPDGJI]T%()Y;<='L,;D&W#$JG9"]YW(=):
M:%EK-WD,8UUB;QG%:8;]E+K@N4VGB`MF@E*A+'"/D%83L^\W%B='([682[>P
MFPTO,`HXH#;6%-6P)J:3\@JC93FR6NG_.DWH8K4RDOHF3CLTGFBH2.-O[\TF
M$>Y=82GE/I'K8Y2+&]B<A<%-1'K=T'#J9H?'.F7Z&N7J@1SQ(O++1G:\C\JD
MU=+W7*7I-7:J`"'EN7:9)W!1EOIU>=Z5!HL4U(Z6\>(>^="TK)S-YJ[[H-;A
M`%JK_^2E:+[8/B^ESO;!&-9QN0VG:-M?NO#*&,DBCLL4S%[32A]"BX179J/E
MCZF?X&?*)#`::?GV+YL$O]S"!*X\'^5%N9T4]"RVWLCO8,)5P[)9[`(:!#RZ
M6IQ=B`O36M"OX+J]B$A9D!C9HH?8N!DU+(U-VQSB>AU&:5@$GD+7JR]*XR2V
M5'6KK.@D5'1#F*ME%#D&=`++X;U61R.Z>5])V8):4=/TI74R.!U8FZ3K;7;)
M!7HN=:',2S(7\-$31^%Z!I'D6M-7<,JQ5=;7$N5ZFA$?19G(`M>SB"00HEA6
M7,\7ZK7[&'8RU_.()%:2CDC+;BE&8XJ6UG#T\U:?6_:Y3JNO6Z2BZPE(>B"4
M"(OLEZ?D!)"T>!37\Y)48=DO]>GH`^OZ],E^,>BNO[:NX5IE>7M=?W%=#CIF
MXM;)ZPC[02O]WDXO;1B?(C?$V':08+_'T<>&C$Q\7'LQM4/03L84W0JYHR)"
M-^IO`?KN]!"B^G^V>$PKIG4L[9;)$=:)P2SC"R]]N@KC;^EU%.`$-<Z8*I/X
M>Q)WP,LD)B.<%4.HY0^SLNQ6<9+A/PJ>YXO;!#V#.$NOG%*\.M]^C9@66-5S
M1!/1=A2C5UF&80E$PD\I#JI2#+,D\>"WA1)P\41^O(Z`X;QR'5&[$///.T:0
MWC&^;"17$58IS#7Y'[D6UEY8W`C9A9<D&R"5EW0KU]=)K@Q%4]-I*]4NT"<2
M!/K6)2K_K\0>8PA3/))CDQ1*@1^OHS5*R:8!HJN'%^!G/\/KPM!]B5,_C-,\
M08)DB=[#FLDDKMV2A?A;'B25AQ(%K--*W,\$-Y>5H*!6#UW4RPPG((+XN#B\
MX><0%:=X%#2O5"8[$EVU1%KO[^:9[Y-%D-YZ&R+P-7VW%WE"I$6:E-!A%$,U
M]EMDPIW;)I0Q'>)^=G%31S$J,]3H.LCZ*KZ4Y-ST#H6.=N"^/7WXKPB(^]G!
MS;;<6+6V>2\Y2'2UA2=`&+[&3A?C][&#BTK]XA?4%W8;:%_KT#8UC*J'NY1X
M6'U$E+%=KL5U].G%+W2UJSB9^2`7P]:E)FUU&\-0C0LB\]XF\1H4S>!\\S4E
M0A1%V*55,F2LP)Z#C@\'@5:A:7"+<*D5(XWK0W;0\>'0;7VH#FX1+KOZE#K7
MA^R@X\.AV_I0'=S%&DJ,^[NRW\P3(A54_ZAB.IKAR20ZN4P8I%W@ZH/H>0'*
MVQ1F81`00/4GCX>FE).`1K!D3S-5JDK2YHM+4HA\&Q[^$,\6"QQB$.!8JT.F
MIUF.RN"J2@PE;QVDE)M=R)W<*"8Y!<A+@77KYD!I\=:J@#5F-RMX@4,53LIL
M<QMZ40;:!3%W%[J%+%?L`32]!\?1?XA%L#2*;*.Z-VUMZ&OTS*BFJV5<(S.8
MQ#Y"P:ZZ>G$BP(XI#V;6K/$[6</'-F6&>BFI]+2`(XD"QKP>QFJP21>?L:F^
MS&%(@GQ9L,,N)@-.='GV=B'0'61!UU_=T8FQ@A?2]929(6`]2C"+ZXDXVL\4
M=?NPZRDZVB'6(_BZG@*DUV[=*J0D(Y^ZGDIT-'@952JZ9`[!4(_Q"0,K8VGJ
MEE\TIISG8P`L:?CJEK<T@2UC[>B5]W32!W!?SW>OO*H1/,6GU^-9BW62WHUN
MY4\=.#1Z`"QOL.]62G5"5]6%T*TLZX2SCM"3?K5?1WM`=PPYD,D[=[0X['!`
M"LL;.%I#=CA$Y7(J7"U!.QR^6K)':]C=+%`QY+(6)#W5T)Z4GJ<!6KDLF1I?
M5XO@'1/A5K9%#>V):7*#0+N?`K)#]\.):7)]+SL="2PU^&XZ]8Y[9AQFG=7X
MGI3W;M!;;Y?I6H,[J76]S@UJ0FN-[J3B]4!7)AV]AGK2]OJ>$@>9S#6XDTZG
MQ7XIG1I5(]]%Y;/??BD3M*H/SWKD7H^JC&!%:\)5V8)_,D^K],-5V77=ZWD6
M!W%5*V_5[T$6]TY1R:)GO5YI&=^;0#K!:Q7=[?*<R_B*[DJ#UR]"^'@/OAR[
MIFC-[394HX@M2''IBBF#R`&H<R_%:>&:J6>[\>K+(DY6I?YIL.QF@_(J0`*U
M'Y%D%,UD]S-91+1)5>-90PD>2&M+*+_9+Q@N)K_N8D\)USIQY2'QHK3:_/5[
M1G#[$YO`?KZKID'MP6$J96L*T8<G=$=^FB_F>49<M2FC<R,MQ4O9E4Y,47,*
MR!?"V/_#RR=+L*_IT5(80)Y\4(U\(BTL]RO&=1_'DO53O;GS!^C5`5"&%Y@8
MB2MI:9N`%S5/<_A;OF)4;1OP0R;P`J$:9^@&KXG5(8.UBG<DWR$B5Q%YNQ'Q
M4VK0K/N@ZV@F.)\G2R^JZ"`K.`YQX%6!8DW1>;ZH%`\OW"DSHKQY/6,;025[
M0@DH0/$V8Z>*(6!M`W9[*PJW&"E"PRS2$J>9EX(&FVW'_XQ6CRBA';CLQD9*
M1W@AJA+VZ_,=+K5O$>C+3_AYM@#%N9",8=UB=C$,U6&,\`IT>7`L7<4)\KTT
MH\Z1H+%)NK]&Z3/RX?)!`5>C9K<W0_T3"G*R/"AJ9GJ^:?SK@5.R6GD8HX58
MME/`L1G0VYJA>O_-K"]QALI7JI]!G*E+>]R1NXTE(B@/8P>OU1.9-9W2[!WV
M-&F/E;:_-4HL,*\MUQ/[!>8]6@46#JZN/QLG8U)L0L81-5WWOJM"I2Y_N>YG
M5T90YD1WW8G>'S31E=_/D>X>@@I)UEU\Z`XBUM>IT\NI/HJJ.'H0/8(SXWB>
M^&DB!+X-UVM5RDY%#Z>(ZW4IC[N:CU%S\E1.\]X.+M?+3JIBW-DIYGHA2:T^
MLY:FH6S^==V:(C3GM^&C^RQZE8@<!4C=O`8BRUUAY-L]3^_N$NN/'L.7L<7.
MX>TYR,IK7$N[Y>?N^N/YP6C'&^4L/-XU,*)H;Y)D[$6;=!86/C+2GFE$@2NC
M]/#<$P_/%!(^A80[%A(^A?\=":]]5:GP[SV`OO]S'`??<,AZ=NFX-`P55MN9
MY(<6P9+!M[J^9LF:$\53<KN8X$&PI/6NMC$'#IH.Z[+#VJ0AQ.9TW(-3B,U@
M;@YME]04H#.<55Y"CIJB>]KPTY"90G@&=Q<Y6BU#1D"=G!>377YDZ!FR+8_(
M;GJ59Z242,.SNZV@:X<Y;C*+3N8*W5F^E-5>1)/_#_*2*^C`8+'/B/8C\`7.
MGX=O*%RCSW&4/;&6:<]![<=!ZR(8T?P7I,8Y*^NSXV#CX/L!/J]OPLO11L+Y
MMU@?WS"695R+G'E272WCJ2@`K\H-Z309YK<Z!@<H.9.\<``;='G-QOB3B:*?
MC/$#F(G$6\YU[%2N*<G(;"DQWG6_Q7%PW0E+KOLAC@AG*76[[KXX'J"E^N9Z
M/O(1\2S,`*Z'(QP'SST#6Z^4Y=,$M?WP5Z?\8OO]D.HZVN0_ZX^;W&J=/&A4
M#]K7R,L#3![?2N*BSGSG<O."R-NF1Q2^=44^TCQI@;SKU;.'D_+M@?V9Y(79
M]AU::X0QC9B+.(7O[A[?4N.DW7E(6HN)_QE%*/%"\OAVL(*=1=3C#/86HZQH
M__$L<6[N\"X?:[Z)T_0*#BG:(S[G"#A#96)\NGN"L7SSXM,+\`=G#8Z\9%,<
M/7#SS1</WHN\YW1X4@9?\<P7K]76/FN8(]!?/EM:$K"S3G1@@#&.;:L>:*I7
M6X>EVNX_^/SLGH?;'B,,!W^/@8['`Q/X3D,,3C?])>7=T]5J'/`',\1+\SU2
M/0RU1K1M[],%$Y6>3H7Y'%$!ZG_.'20/2,B?KMHLCX2FX/QSU8)I%-WVB>RJ
M47-XB"55/%<-G$=:PTIV#5>++AX):ZH4[6K<QY$P96N_KM94U`.L6?-2K]*+
M%GM7CK;H&2:K;L46?RAQC="2""XN(]O!O-2O[**]2[5KI)F4=NYZ*)0L:'U6
M[?'BG\SY`._SU0INA_GB'B\CO,"^%V7U)7(;A]@G*<*V/#!-:IY]\R(?P=Q=
MQOECMLC#BMST#OD(KSE!S9*=+0N"/]]\]OX>)Q>A!PN8G52G,H(62RGG@["5
M<"F?%)&9)!:&9AE5',&R>>$].2CL9ADO]?KXXJWX":BJHUC&J>//GFY+9=16
M!(Z+CM%8R^EP#3?3@@G<=037KP\W,MV`1SLL^@VHA:=Y\LQ.`*K_J.5;=VB9
MAZ3UI@K(X;@LF6VU4"(G(32"IPX)5!WBB'33DJ"4NVNA]W]1`DL:W8(&"/((
M>Z%1VUD:`,J2720C\NC7T@EGS_#NZ9VV0U](KEJ.=:'6.-R=-@B++I8=($KG
MIZM[LL\-V#SD9/565\TV?7'4(5.ZFLZF:XV*=5VG8T&&15#R9:$N82!6/X2E
M9>.KFIJ<#OG0L$Y95@*G(SDZZ(.2>_M0RW$V":L/DMU6[VFD8LG!TDQ]>]E5
M;#7AAO']?)4747:7"-#Q<8$-_!RB*HZI=<\E\3,HI9O;D+`5!>2U:9JA3_OP
M6@PSL'IV([+-,I16)@S`G[T7O,I75#KI;8Q0"8>ID,I6&Q-4,M>5(')<W,\J
M;LXW#_!MCFM1IJ=5'/%<<X).5O'!,JHK=+2*'W8]-VX7JW@@*Y[K()7I:15'
M7U.TR,,;O&#%3<CT-,%1\6`ZY]RJ_VZ,.NX-UVQAMDH@>\U*U0@4=#?I%I"^
MP^FUW$3`N&KW[B`T-`&4.CU/%CNN;4;JF';5$#L0=`?F:[>2[?JAID^7[V9V
M'4/L^T#K<B]+IHO1U?[P=@5)>F<EI)E<7`]@.)!FFTNH)4RZ?G%2).<F%GO&
M(U==YK)HM`U^KCJYN^HL4N=P4YAUUG6C`\'&&;7%R=E3:)"5-CFV!(ZMI@AJ
M\'FN)AD,\T>KB0GS39,`@4>"VM3DYN+1WMQ([7DXWE4_G@U3A?F:V"2\LLBU
M4ME4'AG+L\-`EJ45&4_2F]+=IG0W<R\HZ4U>(U5P]DBJST?!3:<VA@DN^5',
MK7-`Y/_M-)01WR,GJ8G>QJP_3`"LG%=,:A!+4V:FQ*WCIB`Q-HKKMJU.)S[=
M4RNW95U?@GTNEZZY(!T,C5:G+!P12Z::U,W!.R97VA'0W7.O=7'ZVN]>ZR:T
M3)D-P^'9;65/YF":=8ORO):1?(<&&<+G9B0[&3<9M^,Z5"S(C)[6&)3YG+6"
M7P03.UF<*;E'>4:D<CMV9J^G^92-T:(1+;/^23V:JP&$@T'MQT'K(AC1_->/
MI^KBFPPV#KZK5W@U,5Z.-A+.R7/.NOB&L2SCVGWO&_/.%8AMO8:T#(/):V>E
MUVYHWPZKO-].'OV49GA%#%[,%<WRH_48Z.@\L`L5*@]BJ8]D\CGIQ5/ZSJB+
M<ZBOQQ/&=_+IM1#K?RK+.DUDM%I7X^!-HKS3)%Q-/S0.;JF@NIJG:!K>TN[A
M=G$X@^@6UC2W2\B907?/:NUJ(N31(-Z+"W"PR'-GQ7**"]"/9Y]U?1I1`3?8
M+\ZY)8@_Y0.^Q2MF=\B/EU'Q\)2&!Z@8-IC=1^M*LF597IJMA=U8BSUHMGK&
M,;O$8///9J('RJ7'?P)^OY4%E$IG#XC[:9GGO<\TUCE[Z0G[=,<Y1?Z;9;Q^
M&R!,(/Y(?B!4?VP@"[_Z[5.4P?E!-;P?_+D_-44`0K(A%'W8_H-0]:%!5?7K
MW_[[;H^>QA^&Q^4&+;VPY)[B?:*UT+**8-Y]<BXOX5*YBS=>F&WNX%Z9+T"^
MN?="1+5VBSOIH2TF-B_LA9\QC)G%Y#F2#3DXV:_TR?<S5#W/1R@HWN&MKJLK
MA"JJT/Z.E>VEZ:FH_1.!Z^_@-=?LU3C\E(07@]7)2$806A;UHU"\3+SG)^Q[
M(=?OR&YOA'J0V=`^/1S_.+N]EG7QRR;!+[=/'DAO/LHS,GAZ'?EL>8??P6RT
MH:1\09'_F9O"55<*2W388=,2>UVU;@A1$&R/&I<?G,.%(4`1:`YA<W6;R-[E
M[?(8>QJ9T\Y%17"$(IO3/D))L!2D=:>]?BIPB=5WISUX2BM+K*,Z[8]3P8IC
MB3P1KYI`7]S*`P?BPJDX'R3PD=#]G*W<IXZ6>(\>TP%C*.%59.,@0#4-K:YZ
M3J7-)JU]QD;O>(J*.<\=**CQ"CUX+X5<'4<^#O$NF7+W)Q.)@9\6"^1G(.CO
MZ"""QT5,DAIS'"WGSZB\8UG6,(4!3!CWY,FK_M2>'X$C3-?H]B"S1V!VA6!W
M>B'9[#EY#;O56`D5M9%M1>3BB=3VO8ZVR@TT*F,]?O'"O.1L^X9U#W14OF(K
M4E]B<FSFT`RDB2IDX_X)KI5S+T7!1;PBORFYC5.U#=;K0[;B-<^>4#(+_IZG
M66%3Z('(P5"V\ES($+,HN`$RPN9-V)UWYI`F927-MU!3LM)RC'>SAXZICI+A
M&6`O]&[6U0GZP>XA]VN*&9X0)1&JFXEXFHT>8H?[[U,='7*Z/MW-7-T&^D&E
M])X5!I#F(Q9[!P"Y(+'W"#AGV(PYA%P'<43V@9`\@6F@RT@F8X!WM&U_44Z9
M(`*8U<L*3CAE<V79X@UA!X^DS.Q%GI`C3YJI9A\KN&ALAB](]&Z\;&\K.`."
M%&>GT<,R#HH\IJ+RG81I5'T<*[BM[N=H>4/VB)<DFT6<?/.20/K(X(Q@!8?P
MP_9WE3;4U('@H#M'$5K@+%4VU@WR*4LQNP.)*5DC<I//?#_)O3`M_H]:$DQG
MG.2&MP*;0ZU-\<!C#V`I?U]`%^C+8F,,PUPJK5>+5E^#E/U#QGO&H!7A/TCL
M68I`+WR"?72)UBB,B^<%R<&BQFRW+]B#D,J2I7<SJ:_WT,IH8<`*HHVK@<)#
M(\L2Z%V-)1X.S];QK,,VK60Q,ILW)*D?<E<B3Z!W/41+)XY<8XJK63=#`+EO
M7]MA]\[-P$F=V&G176O`W;S3]0#>7[RN<7;5LZUS:?/5S!I+5YW2VE<M';[N
M7N0QRDVRMEO^S=]R,;B:LS4LAIT-B*ZF?0T+-\<FJ</I?HJ0-AU9_8H/C"YB
M04-5M=.VVNZPE*XPQNMA@@-EMZ!E7L"O45+F[?U1+(BMFK2#^1;!ZBZL4H5Z
MCV![9=5UQ&"PSXAF'U05KD4U2YR;2J0B3')6-C=MOHI0]=J*QRLN8>[FO8A7
M*UP&HP($9>CD$D7%ZXK;-Q@Y;0R%#;+(D;[RU,;04FJ,\\D;7FT\J7Y#4\BL
MD2?L8^(")F20B0,];_X8XF4I0[)6`JVM-51?YF6I]2N\R)Y(O745-@X[V\37
M==25J69/RSB*\Z0K2W57NWB2?)Y580"[^+LG^09!ISEK=+6+IX<GG'1CJ>ZI
MY4[Y[$7>LJA<0>J<L>MJ4MOIHB!?$%83N)FX!!PTT_+]^6*!?72#O!2QOW[8
M2$_)XR1.,R_U<91=1VL`-TXV#XD7I2#(`LYL>N0Z:BH53'-KS9*$)*X5'BX8
M@]0PV39D4]UU*!-[5T@K]_%*V=YFS!_D4*R,>+<Y4`FKNCYE+KP,+6.B5Y`H
MAW2>W*-D#8L_G?F_YQC4*VXU8TV#FS,+@4X9")@XW]1L$/%^VR+@U$G6-+CA
M<"YUO6Y7,4NLO#A=I%5%NVP:2!BJTO&<#F/'BB$BNQKM-A"`31G<U?BV@:!K
MB/JN1K<-A%Q367<U3FTHZ&K+3;?(LQ-%;M^6URW4;/S@,6O$ZA*2W2Z_JX*L
MPCIVO["L7MUT!R_=RN6ZVWH@,"6-5JY[NO6CJVQZ<O5UA8$7<&>+INOAOL.=
MOH<6?M=C>0?"DN*M</6AAV'LLFUA5L\<G4+5=HZ$>H2'EA]0LL)15<(R@SF0
M>&^9U4?/L\L`6>M<*T!9K5#B8R]L7"N<IYD5AS#CP9YBN:98+O=BN8H+%$"\
M(X=F6&4A,:BFMS5#=9JBXO(GIT4MKS;R^@FM*3GY2%AHQ-N6'0?3'W5RZVW(
MZH73N7#."*-/]MOKB0)I,UV,'&Y(TC29]FORQH\74@)V%#L;2=<@16V;9P?;
M2TUM:@/-W)@#1N,I0F>*T!EGA,Y]_IBBWW,@XM-:Q`>]K054/\#W>`^',UI;
M0CG_R79F^RF>:XKGZA3/U>?\_U^49%Z$MD?S0X))_CP16(/X)=VDVZ/N/LL#
MS`OR[3;0%),V/MM:)^>YA.CNJDMMV!@^MQQDW=>6V-SGJL>KU_KJ:A9PU9W5
M?0$J6`%<]5_U7(E4LYJK'JK.451,56D*B]J'BFZ]<OL]<AL"\]Z?/+)38-Y*
MM`W%V_7X+G([\&&$;W14U5U-N9`T'0JNSE-98T(S)0>GPY74)7',?HQLB7EU
M*ZO,QIA7QW*HK(]Y=2SQ:F"\E>/#7$W3FJ(X1Q+%26PV6XO-%&DX>.G4PL#8
MP/P+8G'%[S-*[YLD',?S)IG=D7%TG\7^/ZPIK=R@Z=9+X,3,2*%O4D><.&**
MYT0X.U#4TU0<<T57040ZR[,G6!)_,$OZ\GJ8X.`37%;91G``[C4R0>?M=I-V
M63Z2G<WS);F(!)U,GMWT]=1V6W/VC*N._D[PL%>YJSY^>9A$^\95CWY7A&36
MTM#N>G/24(G6=01HY:5<:8M,1!Y/\<FLT%]3XZ>02'8V<:_-2&%Z0:QNNXUA
M^:UZ<:T\2:J'@X*K.+G*,_)229KFY(D;L50G.8[)9XM;[_G5IKI?<?9T'05X
MC8-\RT!]I`(+`A"T#6\$F]U9412^WS%PAT*RP8KG]@J:'\DNN_4VY3'"EYM[
M#FI$'U@]A_$&H<J:13]8OL31&J7`0;&#T^+5MOTW(+_$V?^@[&[W#`-+M1CL
M>T;1(R?!O+C]N%D6[/;=J4^1_V89K]\&"!/"/Y(?"+T?&_3"KW[[%&5P)U*C
M]`_^;.1!H^HXF"]**T84_.J1TR1+X:S8&EOGR47HX8.LVVYC#(_Y#5IZ88DL
MY5ZDM=`2R7^3QS#6)?:6$>P4['-B]5E--=+Q\"U^>(KSU(L"4L0P0RAJK/_;
MT*/OF2XC:*'Z2T[&JI90_0EJIC>SK1';`GSYB[?BB6"M)B9IY&8+[372E-VX
M!MW%"^>+3B)XMS&,9*'Y3RC(0W(&4FEK1G:?;^HVE3A2"NF4V@'ZQS>"CHAF
M%LDWC((/&@<>%1[E89?^7-RNUU&965$\:ZL;(,Z7K$2,N>IK_3<*I,[!03YE
M06;LE(GL:"8RX^YMR&^D*&Y;?"N>Y//AJWB-^,)@EV&TT/_+)L$OM[#15IZ/
M\HS$-Y&W!=F4\COHHZF/:*TV@$G;-]6VV`I2'>1(=CT.6(\)K#4/^D1/5\%G
M66)V$7],W=W5"$HA(H+3M\;%K?13COV(0',(FZM;AF?>:#E`3^S\IJL0[6TC
M+R"X'A`O0$O55.GJBPZ2<'62Z&O,W,IU'\SRMCWG#ZX!9_.[!X62?I$XFP-^
M%"SW=#-GT[Z/`J:PGL.'"=8NL&JP^;N?FJ_/,[*3$MB>5-?C?O6"V2-\S?7(
MX6&`EG41NQYU/`RZ`\:<N5J+;,!#6CTPPM6:9<.N^D$\[:Z61!MV*O0%1KM>
M!V48_!5#/5TOAS)D1`GUWCV,5IXJ0TV5H317AAJ\`(E%Z67W&`30!?;A")O!
MV;8J;VP];Y?5XWV%W?\07Z*L*&N,KCR<%+E]E8!P<.0VHSVZ#*/GA3/I#S,?
MK%(=PI5<BBG+8(C8N,_>"U[E*VX,8KN-$2IQ)*:RU<;(VSE$0N'$1-9_-T8=
M__6>1@LK8XE9@M_NX&N<C40_]T%[OR2*"UQR=Z#*ZX[%EOZN,30?Q5P]JG!%
MJMV_X\$XS`>=68V_Q"$,$\+-0]9%=;`><UG2"7`5W_)*,(AO1<#H\;W#Z3^N
M$H2N(Y`U49H=>?7R/N\FML=;N;S/:Y&,OT9^62V2V`L9-0,X#:W.63AVJ?T>
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MC.HOZ#;!S,<'CO7U,2(+FVB!,,D#WJ6+#80B[4MC1&RJ8JO*QSS/TLR+`KB^
MKN'VPE&*_4(Y'`@W]O<F]'I\[[?W=D@93`+OXC"$4X8T'4+PD/KNR%?8H++(
MX7<FM!2^H[S_K,.+O4$'_MC(<3,@\\I^?4)VH*^/?[?SN".;<W&LDT"6D%'E
M(0G99)F,WNM.4.I!B94KG&GE;9L#:C5VB$-$+Q&CQ)EB,#"!M"H9H\2Z;6HP
M`;,"!480)F9Z4HL&!9<YZ'[+DLZRX$_#M[O;F,Q[37V@Z>$'AC_/U?`<';%]
M;H7H3#%L4_WP44&ITS_O;A"S_B@&G544698K5R/_1C,;TI:%7J'N,/AC?%IS
M95E0B[,A^1;/GIQWS>FT=8LV`.,8/;;!<#?=[]U2*X[NCQ[H0MP/#*A35#MD
M"C^7!HG,2[)IUHXW:[^U]ED'.;^<MT]18.>L'<>?/-!4;3W]O<J#6+^QQC=%
M@D+W;E4-,3`]':S>KE8)&=_FH,;VNEI$9'S30POPZE=<9)(`-$\1)4O#U:>U
MCS<Y0Z4:'>\U@='/C&)HE@$S;L]7DT]1U!YR4G7&C]03.QEU+9Y2Q3`WYQ_L
M=F-6E8/JZGEUJR#JR.956U!Y8T([6$=.3\,P.*G26<_UE`YM<K&HK$Y1S4UK
M59VIFLQ4Q<72^.VIBLM4Q66JXF+/OINJN$Q57"Q"=JKB,E5Q.9DZ)!-Z/<.,
MK)`RIBHNKM0EF=!2=/*/'*^IBLL0[LZA@71.YAT%LEIOVT&B_EODSJ)@%@2X
M-/G6ME=6_6^K2'-X#4_5<J9J.5.UG*,1,4J<IVHY4[4<>Q"VH5K.B;^(K>\Y
M-+<"G:=2,E,IF5%!.962<:IXR51*QJ;9F$K)V%R,9"HE,^;9FTK)V+0!&,?H
ML:UI4RD934[QJ93,-&M3*9D!G=I3*9F3FJ*IE,Q42L9=](<(,)Y*R=@R/5,I
M&>NG:"HE,Y62,3XS5@5LT3;9]#;(::6X3]6`QCBI4S6@DYO2J1J0B[,Z50,:
MY[Q.U8!.;U*G:D"\:D#W^6KE)1M0'(@I\0#F3R_D1]2]-E#W6-A96`R.`OH"
MV%)&CW^5[&PBQK=4MN`KE*I#]#8FJ-3S?N4>6ST'-8'#I]5S&&\0:EC:J<',
MXO;#5[3Z=)3Z6MVQ_!E%<.Z&A8%CA2-,IC7#:U3M1BZN<GU-<'4=P8$+\PTK
MF"S7&_(E<D&Q=S>OAT4<4!>27)_Q5V]CY#<P'Y!M?9[;U,0,WX%<`7+?$VR?
M2[1&8?Q,)DUFW\GTG.KB\<:W,E-K-'7Q[,A__06E1&V(`K+P??CQ(2:_4@_D
M>S=06JQ&`JU<K\P]5DO*47`;>M$7;X6X%]<@G])RMWR-$N3'RPC_(5!;]C>G
M:N\ITZ]MYZ!J9'KLA;SEZ;JG38\*.;DY]6:O,B58E_-6N8A(Y_.Z%=.@H+\V
M]Z!`671U7RGIRDV\I%0OU\-EE5&3-!6Y&N@ZY=H?,T&<>P).N?=]H-T3K;=@
M3NM46TV(]Q.44TT(VP(`#LR(K3-!TK';JW+`R:&K;$*:$OL[E]"PPU#K;`6`
M8UB%FW/*\?'W2C8=:TS0KUY2!B(768?7$:R\O^>13RCX%6=/UUEZCR)@!WX/
M:S3#<,=>HD?H2>(AU4*%&,;EB]!+T_FB(F2>*)5NH!F?^PTX!>#8],S2]*25
M=6[CJ=B]H4#9L96S5CH3BM]N+Z,&:?(;ESG"**D>]@D:UE<5RO3J'MTQ[^5`
MIVLOQ]TH*NQ9/1<=*B&ZZ4C4-TN6B6+.6J)LPWEO!?34`EUWJAHM$\&6<GK9
M%4\QXUP?^*W$Q"Y&P2DQ42(Q4;L,K:&BG<*4F3,T5H+`+6SNS0-`E'I^>8/L
MRIU<1X#WJB!!BQUQMH!S?`;3'Y`EP(Y-I;;3HFO-5L\XOHF]:+9,$!)0P6JK
MCQ+!QW5^[\)+GV;!VHM\1/+E[Y_B)",7,V&0&L',[V#"K@-;>P6;FD@WQ<ZN
M+.(,XPNKM1'K,7K,:HL^)Q>-TM`\O9?(3Q"<K;`*EGB-(L1\9%K<SSPW5YZ/
M9JLXCYA6>59S\[1?1W`PHC2[@X.[")`*;N'J(M<$2-[PSSMRXW[V7O`JW_>[
M:!AP+/R#_J&7_VI`\_P+TVF8S<W33O$%<AJ..3V;<0-?X20MV/3"D"]Y,%KJ
M29DE)_).HDD_>UE.Y--M,=1#8O@=QI]:K&>MDRB5^>("U`3,NE=:34S3"-<:
M#@&PG;WF/$Z2^!LQW'C/\+=L(\&%Q"!&^(RC)1SK*W*L""I[4)O:0#/WE&<T
M'F=*/8...6C2H'E&R^+\^1Q'V5,("PUNYK`R(=!(DNBEA;K;!#U[.-B&[X&`
MF&3XCT)39I^DXDZ::(M7.$WC9/,ESNCE!-CM3*Q](`2F+=O<YX]_1W[V$,^3
M9C';]IQ^0:SS57D8([SFB?\$WR?:*<[*W",_S(E5:KNKZS]Q#B[U<:SGEGOD
M=1G)3&F/VJC&98C2T#2]#2,@9^7Q>EC$@33XAWTLXN)&4`!$V,TB7D31D,)N
M-O%ROFG^17V[T`8P4[@'11[('B0LFUMYB-+0)+U?H_09^7B!4<"O+\)L;[9,
MDMRRD"N)I#*6GH@UY,=1(&7*8#4U\YQ[E5*Z712<;4MO.Y5JV8LQ8OHUFM%=
M;!NFZWG2(NOMSG_-]DNZ6EA>6QT0QTIX:Z@8X]B3I%/UA;U3A6??;)Z[+)OB
MJ>'#V$AT.UFO2O(C`*>S`:JYLCK9=5Q?=CV,774<&TNR[O5^\8F`QW*PUA>C
MFY'^;)MC6[X\7$MN)JI+V#3;)<&X!D37CRTI^VF]D*@AG+U>Z1XO1@?6V9;T
MU8H(<+6<8Q^$:/%!KF=EJ>`D$[?K:BZ4KITG$^?B>NF=_GM3+>[2]4(XQ\)S
M&\=[O*HW8\6S&=/=*\]P%/G77?!BYD[TJMGJ+%P2"1`U<&YJY%U@4X_DJG71
M27.0CGNL09N4"=EPS!JS2;&0203H]5+Y>/&2?/!"*7SC1"U(G!@IEOGM5&QN
MPBBF]JH[#-$ZWN.XIJM-=PB4DC#N4M?F"=66[X@JM_2YP[M5TV*DA4N=4.'X
MGNC1PQZV^'V8\!/@QPA_W`+X<0)0`&"'T(DMN-]/X':[J-LP_FF"L1N,-R?U
M3@8OSILF65/$\.-I(.8*0-WGCRGZ/2?GV)J<6/WK/NF)TV\^*3"+@B]`4OV;
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M:%'DEB4PR/?7<NZT/_>)Z#0IYE70X7<PC[@KM24O\P1'2^H\*':VBR\0\HI`
MGFU`CS)O!P.8YV_KN+\$\J3X:7488!\WQW^`?M1G:41=AJ;K6ZQ(%708D*9R
MM^P?RQ(=S*\_$S5)K:WQ>;VH+DT4L$7GPT::O@WBM]3G*>WT47"'EC@E)V;0
MT%,$U/#Z&*G&6,1&14$9=[=[`IFZO.EMI[JH6W32%"&"$<@$39-L.\XQ)2DM
M1+.->!6B.@YFJIXG(>/09\B5#X7=3-8F/22**R$*NVDY<SY[Y."X1\D:]))4
MXED'?@<3^%:),UQO1KN-%N2^D+?`%GD4$%_B'<K@$D3)%5U<8[;50TE.N)HO
M+KU-^A"3]4],=W5PZOGF$H48[BOR=@M(/Z#VP:7!>/"P^V`#U*U-JP!N\C3-
M7:%+X`Q[X?\@C[HVY3L;J>99O1'W$%>.G:VQ%:4_)S'S40AA-[.\W.?/SR%&
MB9C\NJ6>.KT-DVYYNM]Z.'@@<9Y^L5)G2[)<R:-&\ZBPK-['(=4LTG$D[5QL
MGUIJ/:A4&;#+9\WOD4_4%RS'B_)X@W$$6%:W6)D]U3+"5Q05B_DVB7V$`FA0
MX"S+8>?Q=7$,]_%5G"><:M'[;31^>1[QRE3O-='XW<+4(/IRLY'.;W_CO/ZT
MWT1377"\2N-P>_KR"H/3&NJB80V7\>Y@JM8_Y6T087-#E<J+W7>5Q*N&=9Q8
M.%BW!Z>'D7JV1&?BE:O=_=T8=5PYN-G"2`W1=LS4C:`^,[.Y!;3SR_U2VUI`
MM:B*-+.Y!;1SR_G2FMI`,_\!%59K2RCGUX9FMC=!/?D\B.^U58N#.KVMR9C;
MCC&;NVQ4@1EG%X[[P<V2(M)!EXV49ZHT5P/E9IJS()ZS&=TM@:GK>:8]XPII
M:'8(U)M09D*SOZGWU>%Z.[N9A:\;NH9674/G9B%?[=`UC2$U>&X6M]$-7M-V
MML/NHYO'G5*0[7[Z,ST2U/4;0A0#NUM-E/B1>BN>/#:T^)8:'C>+XZG!PPV^
MJ:%RLVC(]!J-IM=HQ/D@=<%GMY:2\/4508)GO<7<*B4[O<&R7_-JWX_22L)O
MNC%.`HE#JQXCN*G>(&Z6+A3YAU1KV$XH\;(=7*\6+X.33*:#ZU7B=>!49JJX
M7@N^)U*[/!77:[QWQ.D@A]'UVNW=3W)^7EZO*NXG@UL[3[-7*7=',.M4A<'U
M4N[=%QLWA=SUVNTJL'$C`UVOUZZZOAC%+%POT2Y]?G7-#'"]9GLG`/N'\+OZ
M!+<RK.R,,=>?E)1?>;P`=U??+->R/^63AEQ_HEGE.NV:7^W\`P*R2U$A7]/U
M-YC5UAVU0H+K#\$JJ03"=-D:K0YZP2C>7E/!JV\Q4->?^1X(RZ8B__YT]0;Y
M8A<U6J>N#G0OVU!C>+KZ@GRIF!JMT]4;N(4;:H!.0B/@/U)'S3ET/0J%EVG)
M0^?@'2%W7\601(CW2-7)+A_NPV?N/MTEN60:P7#N/\<EB0DCG=?]U[84CAF)
M+!+W']"2Q(N9^.K^VUB*""DGNVX1_/.I(\B6PT_@T3!^V0N!#'DJ8>_"$AL<
MG`YS1]PTHW,+>33Q4:Z9X>ZC=(6G_2&^@G,[\K$7[I[P2[>G>E,RB()S+\7I
M?'';(.<!/G\>DG@N$T_6^3XQU9!@O#C$/D:B,D6<#B:?85)`F<Y7AX&,EJT1
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MKL*![[H2*P>=C*SF?#$6*:3Z2?;.%VI1VJAZI%?G2[I0I225V!%W`]B$T-`6
MY#&#'<9F>IN,;AW4&#ED&>J-7.<1J3V2:)RBXU0.F^TOIKW8W63<"!),"\(V
M`JLQI8,)^B^\]`GD;_(_(H.OO9"LFY(@T5$BU]<(5_&*B&X%NG<HA.T07(#J
M+\N79&\M1N%/:897Y!/W`%]ZAT`(C4CTUBP,XV^PGY&`Z(Z#&'%2>#CYQ0OS
M4F$NSZHZ,X2_;>3ZFN#JYS@.ON$P!+CW58KMG[B<R?<WP=WUZAF0)QC/DTN<
M/L>I%\X7),6P4*)*.N6V5:>AC/`<P1T+:M^+)%^LYF9H+\H-I7`(I`A$+G)`
M7Z(U"N/"O,)=B7)]S7"UIZO7:KR`(U$_,]R0\.4XV<BN+T9S$[1_0=\:$E@"
M4F@>E96)JJTKQY/R,%8YE.5XE.YNY&5<Y".0V$C<BQPWG`YFZ*<=497%CGLF
MR/0TPQ%L\QQ5L7)%.)?DQ(CZF>#F:PJ2VE8L9;F%]QJ-Q^8@J36Y[NM1`TUB
M@;ON\I$#K*M>Z+JS1W6YL6\XUUTX:DBQY5'7HR+4<)*7!UVOTJ^ZOJ1T4M=+
M]*N")E1Y7:_/WRT?@F:)=[T@OQI2"A9+UTORJP&WK]2X7H=?]<1BF4U=+\2O
MJ#S*.J=<+[^O*L]+6'Q<+ZVO!IFDP\WU8ON*QU@GCY?KI?C5,%3W$ARO!K\]
MT3DWV"=GUZZ^;<>@.$9@`7MT2@`!N[$)X_'NZX)8H,-V1NOTL*C>V?0X4W**
MT6D[@1&.63^,TSQ!';>`9K]_38]@`?)Z&(U<H"$JS8(=4:`2LT'5/JBL3]NK
MC8BYB@?CWV1UVM=EM8J`MBHCIU7&1#'75VTTLYQ_6BR0GX$\O)L<\GPH<>W!
M(@QQ67I$C?T.0X[H>.H'G>N.Y,Y@*N[`4RR!4S__0,`A+W:!3H8BHL)9(G=)
M42BX)-3&,!23KC(//=BTXX#L-*M[=E(EP$Y1QE/#R)S49_L69]A0Y.#ER3F=
MAS%=$7%G6E>N<LCJ.<K#J/LR<%UFZWV^2ZVV4Y38BA>DG^(0.$_+%VM)6TN$
MM9(@P5&]U\A,K2=9$!DGFG1_DYN0/AOM@@32.)RB`%4#4;S?3G7,%^^[DQ=\
M@]UC<29WH#3)CTV2!3NVYZ`F=GC?J>L)!&-4DZ>!GI71>E6I+\;3F:(,FCDM
MS:V3)47^FV6\?AL@3"#X2'X@G']L<$[>X?M4/,%'+5=\\.?AJ3EX%?"`H/T6
M6C3=FSR&L2ZQMXQ@0K#/J4S+:FI68VTN+;*FKN+D8(^U'L@)"[*@]7Q1-]P?
M)3TOHOT5=>!CTF(6=3JUA<PY+X[G=$9\';!4%2'L/+`M>&RG^9N7!$VR23Q>
M*1.01P[*WW7&IL='#.-$U4I^+=ZKRM)Y<H>73V)9K?MX4[7D@:LE][F+?MDD
M^.46%OG*\U$.-XP7DF`&]HW$[^"61'XJ59Y9DED=3,>26%Q-6A0B(M@WKB8E
M<J3F[5/;;=A<W3+BBX9N?M<CM+CN[^B.JJIH['H5!%4DCZK:N5Y$07D9JTKJ
MKM=68->`IEY$)W/93"6QA8;A2NJ_]1(X]!OO,5OBVF61)S#P"KN9J:8E#[4:
M6[:Y@&5GK9U+JX#.*;IPBF/\LY<1\O>C6Z98V<&YE(.?SIU<WU%'3DG"<XH;
MMRGEDQ)-J^<PWB!TCB*TP!D1^(WO7WGZF-M7?@@C=5-!NT(%561**KI$4H2@
MD\G]*L</J\2'>)9/<9_>YX\I^CTG@9]KXQ%5^\0(EBJSN1$O#1-(.>+MN!)%
M,]#2)]D<&]Y)?WU+B"6N'/C'_P=02P,$%`````@`'(I.1SFG345[%```?^(`
M`!$`'`!R<W=N+3(P,34P-C,P+GAS9%54"0`#2,8>5DC&'E9U>`L``00E#@``
M!#D!``#M/=]SV[C1[YWI_\#ZX6LZ<[+B.,DUGO@Z_GGC&3O2R,[=M2\W$`E)
M:"E`!X"RU;^^"Y"40!*$2$I.J&_XDLC$[F(7NP`6"RSP^1\O\]!;8BX(H^='
M)\=OCSQ,?180.CT_^OK8NWB\NKL[^L=/?_[3Y[_T>MYHY%TS2G$8XI7WFX]#
MS)'$WA-Z893-5]ZC/\-S](,W1@(''J/>;Y>C>^_=\8GGS:1<G/7[S\_/QYP'
M*9%CG\W[7J^75O!+S,J9]_'XW;OC]T;)B$4T./-.C$]7'",)T%X`3)QY[]Z>
M?.B=O.V=O'\Z^?'LP_NS=W__EPG-%BM.IC/IO?'_!L!O/_0`X]0;'8^.#:G^
MSWMD5`#T?('HRKL(0V^DL(0WP@+S)0Z.$Z)""^M!"U)Q?F3(]WQZS/BT#U6<
M]'][N(\;Y>C/?_)BV+.7,0])!D-]27%.^X0*B:B/#920T/\X,%2Q:G.SD@)*
MPM;)IT^?^KK4@(Y$;XK08@T_06*LH9."OF[<MR>]TY,LEEPML+"BZ1(['A?/
M-,,:6LEH3)BV!H7Q]N/I6P.>@G:BN5W^0/*^JJH/0#V`PISX)NIVO`*.@@GD
M&LULZ@_]N-"`]L$P)5]EP07VCZ=LV4\*E5"GA6;P(\ZAMY6A)J4*]WT!-\#$
MC@8%=@S\XL_L**K$KBA"EUA(.U9<9I>,(N(+.YHN4E@G!2Q!?#L.%)1@R`4O
M08&2/(Y$?(KE%S3'8H%\7,T"88R;8RIO&9]?XPF*0FB./R(4D@G!P9&'I.1D
M'$F<`8CH!N0G1>4SHI1)/5KIO]67Q8+0"4O^A`^J2YYQ%N(G,$M/_?@ZNBME
M4B9C;E\!]J^9'RDV$0UNJ"1R=0>D^5Q7>.21X/S(";%F(F4CP!-"B6;WY"V,
MN5Z*;OX$4EY,RS.(?>[G*>2)1S`Y#.A/^K>/0C\*->(]_)T@)Q`NQ`6'X9C*
M!I@;SLKQDJ^I-O:CI$?@5AO38')+*(SP!(5#)C0K5R$2(K$II:X1(/Q>$<&M
MO5-0V9H0_+Y$H9I<O,<9QE)TVMI-6T,$@[2<84F@;6JK3F-OT=][I_Z\-QD.
M_M;ILX(^[\#%G6.[MI(RMTX^Y'2R_BT\-O$&"^46`V37NZIHXW$&%CQC80"^
M_\T?$4PG%S08@$5SY81#$::"++%+:?5(N'7[T:G;1\G\_R0U_=6+Z^JT7$'+
M5TC,;D/V+.YH0#CVI5V313"WMGYT:DM1\S2Y3D=E.OK")!9/;#U+;5KP,A*$
M8B&NL?`Y62C>H%M=(D'$8#(T)'W"+_(RA(YAZ'2O9-TV\'?EE!+AATQ$'*LI
M,JGA!^_"AQX:S[K*'BZ$4'.F<EQU?>J;66-G)?6MY)%,*3@S/J+RPM?K74*G
M0Q82GP!&+<NH2,IM#9_RUO`8S>>(K_3HO:G`V]3@I55TZJ^O_GOBP^2*+Z8<
MZP_U-%Z.[53RR=N\DA-"WII2?X27F$;8&V&?36/$3K_U]1O[3$_H9=/<]53L
M).#6\DE>RS$M%6_N.FL398(W/"=2_X0I]XKIX0]3-?8U56]-DFZ%O\LKW*"N
M9^T,_<X"&LS6QOHE7KTHV*;*KT[-K?=3F][!9=/T.S775_.F,6%)!4M@F!NU
M8",,38.AFPI0GEHT7ZJ=NB%:::QZRM^U#K=)O,^;1&Q?,`4(R77\N>O_#0PC
M4<X0<;EZX@A4YNM(5=,1H`X]M\(_Y!6>D/8T;<\DWBF^@9^.IRA\0%+"4)V?
MJ&OZ[)4HN97]L>B_2S+MUN#-_;KU\`LJN9DO0K;"^!)3X%4.0^@ZM;VZZ@3=
MJOZQ,)`GQ+R$FJ?(=5IOX,M%8X'_B.#GS;+^]%V.[=9G(=JV(>1I2ITJ7RN(
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MGRJY*L.I9[#J@>5Z!K.=_;ZF_=Y&$M`NYHQ+\E_]Y>9%37IX9_,LI^RVOD+(
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M9`DP6S5=CNE6=B$"9U5V3#T9Q6/Z7EI!I_%=-/[+BI.7)@HO173KNQ!ZL^I;
M$^_4_0KC^'H?1K6MSA,P,PE*?.ZF9-RF4,Q?MX[SQ@:.JJRG:_/,ZCK'?!^F
M\2OB'*D,-)A,<7"GCFO_.Z+Z7I!?B9S=@=8Q)8S#]R7FDHQ#?(W'@`G$MGL"
MNU%W&U(APF<UI)0#+V;!(_J<=\J$]PQ<>`2*8SX\@Q%OPTEG8C5,K.P*FTH+
MAGK(;@,IA/S*;\#IU@_[T'SN"HR*)V,KX#CU_,%RN#%[@T:G7?BL_E%OVHSP
MQ-//U9RIYUK.CP29+T*8^^-OB/L*W_W037_!V4*-DECT4[(I@0)V]F4=;3&Y
M]DNX2BG,.)Z<'ZDW;7KIRR&_`\;QRSQ,0221JI:K#1U/$1(_>"@,C_KME3RK
MQ@J"`X)%\.LUF0.1.T1C'%84&6`M(M\K"@<B;;Z;5Q`:4"Q"9Y([++)_[INO
MWL!?V5=Q/H/HC$N/6I_H*7DDRXO?X;I/$N,<*.JO7HK74Y]Z)^]ZIR?'+R)(
M6*S#P::EZW&0XM7EP/FX5AD/NG[K:UY]'$JQIM7;T*K?'-8WN"JUBHGY)494
MS?))-<O)QUTX:<9%,Q:L+X15M8H4057ZH;8AY!]GV\$.U)>Z9K#ML3,G.S:\
M](_>AD@#1BQ/IU7CQ$1<_]7;D*G/2^X]MDILI#CJQTZ5YU]VJU3[&DG_VLDB
MBF_$5>+`0$M^[V0.A2?G*C&QP8I_]C8$ZK.0>\&N$@,ICOJQ6^6YM_"JU9XB
MZ5\E]2>/XVD&SH\N?)]'V1#;E>Y"2:*^\B!^=P'%#I!^'O-LSB@L=?CJ3N*Y
M6AT<>6@L)(?U[_G1!(7:P=&`X/@0%CQIU'AREVG1.'XJZ_S(YQB64T<>)6&H
M+@4Y/Y+`!#0$++S`=8D4%S]S%BW2V@G46B)D\.](Q%OP3\Q<_5VA!9$H3)-A
M0<`QH8E+M3Z!-T0D,!MC#\1V;K0@XLE*-]=J`1[OO=%,,17_:U'C^+F6:1AQ
M$2$%^X#Y%'-K@S4C]'J-]2HF5BJDOC]'[*W-*I`S6TYH\(;MMH\&FDC,+^!#
MH#X^X/DX*["U.!8@?DKV+&!S1*A-@IBIUQ8@/;=_\[(@,=VAKLN4HAS&U$7*
MUW?4QN;Q%CY/1JDO3!(?E\M4"MHRT8RT&GU_P@+ZAGH'&I;ELPL:7.,E#ME"
M85Q'^(D9T>#U@=%8\!T)'<0@/U\0=L\076NYV#-+05K5.Q67=MY;R>[F6,E7
M@8,G=HVE[E[X%A'^"PHCG(SL]_!-L9FQS";8F<E`<D*G!R"]O@ZND>0)YC>6
M.I!G,\#D?C36[5XB_TI&#XA&$Z@\4CSIXZ;S.>`1%!KC2M&@ZV*VR>@O"5/K
MPCL**HOG$>4V^P4AM\"U2J3B'3YBR)EZ6!R9\P>HZ6X.\P=/'ZR%)<]4;0";
MEW3$PN^+XB%,/RYAU9V3@TF2(UFQ@7(X!]P$>OOP9TPQ1R&H^B*`,8XH?B59
MXN102@6SJ4CF@!OJ-KX(*\GC2D1*7JFH:#6EV(??+#""ZI%4"9A(]P57;Y<R
M](-8DKM$2Y[[IM.T#UPD/%=L&@=^B_RL2A+$VKUGHNHL9,4\>(NP+^PRIQ:W
MMLP6&H<^G-C%,T]3[=1.64*'U%A&J'>=W24S-[T.P4%7F^Q3FRG50T_<7_!]
M%_'7[Q=JL0B0W&7Q7QS<!0!()@2M?5)M"M";L^GT>DFGDNVW.,2O4<FK;5[L
MS\:ND)A=!$M%5D#G>9S!$D!%XE1$QFRF+7"'L$US%2(A!I/D-.V`C\AT)L6O
M6/T'"EU"9YCB$58+/N@CJJLHGB,4*CG-IMB-3KO"F=5><%"5Y)X2BYNB"79F
M@2W3[ZUL`EMTK!IXB]PT!\/Y^-=VT%8&O'0?(V.-+&XYFY<X#5O@#L+)-$[W
MZ_<V;OY0(PO;3.'Q#1-))G)6^%J(+7($#-;!QYL3(1C7STJ+0G!O.VB;XGM7
MC..-EPH.!/9GE(5LNLHNH[?`'8"?<8W'<I/5<O,B8<UBV^+<`M>NR3/+[`-2
M,7.YNH8AY6G&,2X5RP*9$0P^MU*H9U9-)`77=H%BBSK9*M`:KFVF%U_M5;Q-
MT-*EMH&V3#3F:PVH1X;!`5')>.ML%TL<K1IXB_RQ&T"8*[?C$87JZA>P,ZK<
M+?62R[->8.F+/5<VA[L!;MO<[5N5]H'OR5(E4V9WE3;'6A[`4YO]$R-S:J^+
M:*I\JC[ILN\I.!=Z@$%A:-U]+0-HD\=R-TD\+!P4^+>4M8MU\`-=W-N*6R?`
M"$^)4!LG@>&MVX5Q@K9*,`H+)"3P-8[_3^XX%D.T4I3-55KQ]'`3Y$.(_N;E
MNJ.6<]*.=BB!/TS1=SAGMP]BA]%H26:F=8I44C-P#X1=ZDQ[[43G`-:BZ<9S
M<80`9=L&F"K@AQ`!5_='***92,\=O7GQ9Z!C?,OX>GLCOTU2'_40^LP]&JL;
M-^R'X6R%;9HU[_5LEYZ:%=D%JRF'&Z[:RNC;N,CYN_)M2R`'3-N6.O'E7]<$
M32D#7+\8KBR%:)6A:2:?GMG3C$4"T>!I1L!'QM2X1&L(?;-$NNJ(;1+Z`5$T
MU1]N,4Z&?N@R>@UIB.@&.X0Q,"-!T4+MQ2W3U.;`LHW_8FF[V%=KM$?,ES"P
MB?)$B2UP;1+I"Z,^$K,!5TY2\D>25F9NP:D=.(#(>EL-<`^AEWU1QTHF$0UB
M%U*">C"_S>P1E(,<A("1LL/!Y!JMQ!-+D[DVT_3EZAJ'L*!0W?!7\#\D3M*\
MS!9H3J-=(>Q4D-P\)RRR%D%,419,G6U;8K4&F6+>;$&Q!X$&DPDTL_8D"P.3
MI:Q-@]'Z/&G,H9J8PY6Z%5TEO*YRB]\JP(?0&[-RB$202WV)#X5%/!@5"G/Q
M]1HXA[#8'?!%T50WW]IDHHEIJ8-UUUAW>7&G[[A0&5CQ[;'9F%95A(,XT6*>
M0+F8J]BM2C=_8C`<^AKN0AU8U9>G#J@^RO'(0G.!VY1`BTZXF"*,V`J%<C6"
MF6\P^8*EWNHK$;<$MJ62I1>9WKRHA$*!AQPFCN0<4GSSZ2/V57"".'5<GTS+
MVP-,->+^#`PTN77!#+(E@@%Y(73L%0<`H,UX2_LT)]NN]@+"MRSBA=&\6-2J
M05T3'M"BPU0H:1_;^E12">.9LA:R_EQ,U"^4M(IMIIZ+!M_J@<#@+6&:3J?W
M$?8Q6>;.Z%8#/X!MF&0;;IWB9F0?%V+8%6#;M0)T[C&J`SOQWFR:0[+*[BI]
MI8OLK5#[(7<(*Q>GI"7GNFO@'$Z_V"Z-BHX5=BL;81]$JY"Y8.OKSXI#O+V\
M50,]A]%9XO6R)/'3<NE%3JBV#7(LB'R=*Y+&I8L7*KB`#F-]FLDCL!B>K;A=
M=L>@=PJ?P"*XO/N4PK14%!7PH!*:73^",-&A<I=8+O@VB3C"4W4A/#":9)P6
MCSR7@U3;S/]&<EA]%368Q?N)5R&AQ$=A"EA07F,*[5)G#4?F_TOF>C'5P)9)
MZ81JE24O,1<H'$S4,7M?'[]7`17W(U1K$>NA'L24&(N%XXM`M4`%F;.%&6U^
MYZM",_SI.]W*F$\*#T(EC_X,!U&(!Y-UCLAMI%Y^,M?*B979.F-#_!9UTSH2
MY!.?&^!^8\FK94)OY"@.KN4RE\*V4T9@DP:N1)I2B#8Y!O9YP/!N+E<;D"3$
M=_&,>)#<0*G64_JQZ<6"8Y_$-Y?4N8K"XEBVB*<V#2R[MLH2$<W#+>,_<T3W
MVN)%VCO.M?L\-K*K=(-(*F8"?1N8,@)!?#TICU@8@L0*=(^-6:VZMEGF>+O`
MX^T"YSIH9F]57^V8WA*_N=C%MC1M#4=MTU+!+/77=*O6$'NK/9<CMK[GE['N
M4G7C]G`3S6QQ:Q+?KZW4E*D>?/0Y6<16MQ&Y6'88RY'U.\N;U^Z3S$Q0C4Y2
M+[E?J39FFWIZ)=X+CG@=K%:ZY$:*QRV9Y#(\U%725!TB(4ML31-IA-TF5_XK
M59&=*>/JSD#+I%A2WB+#_4KY^M)#9X!*9,2JCG0(4<M?5IR\#$&0.?(Q(/K`
MB^T"^2UP;;),S6J#S*V:>&T2^5^8P\R,T[V!)TY`/3"*C'#`7L1JG;C\**.`
M6!*>&N*WL`F&2)T4*I4P5_P=!?C<CY^?@Y__`U!+`0(>`Q0````(`!R*3D?X
M?`0[%^P``(-%"@`1`!@```````$```"D@0````!R<W=N+3(P,34P-C,P+GAM
M;%54!0`#2,8>5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!R*3D>.8DI?
M,Q0``+4O`0`5`!@```````$```"D@6+L``!R<W=N+3(P,34P-C,P7V-A;"YX
M;6Q55`4``TC&'E9U>`L``00E#@``!#D!``!02P$"'@,4````"``<BDY'T1NU
M\Y@L``"=-0,`%0`8```````!````I('D``$`<G-W;BTR,#$U,#8S,%]D968N
M>&UL550%``-(QAY6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`'(I.1RPX
MC`:%?```>`X'`!4`&````````0```*2!RRT!`')S=VXM,C`Q-3`V,S!?;&%B
M+GAM;%54!0`#2,8>5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!R*3D<A
MHWS2ZT(``,Y*!0`5`!@```````$```"D@9^J`0!R<W=N+3(P,34P-C,P7W!R
M92YX;6Q55`4``TC&'E9U>`L``00E#@``!#D!``!02P$"'@,4````"``<BDY'
M.:=-17L4``!_X@``$0`8```````!````I('9[0$`<G-W;BTR,#$U,#8S,"YX
M<V155`4``TC&'E9U>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``GP("
#````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869111236144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note 10 &#x2013; Employee Benefit Plan</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Aytu allows its employees to participate in Ampio&#x2019;s 401(k)
 plan. The plan allows participants to contribute a portion of their
 salary, subject to eligibility requirements and annual IRS limits.
 Aytu does not match employee contributions.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868927233408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement/Revenue Recognition - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_AmpioMember', window );">Ampio [Member] | KOREA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received, net proceed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PotentialMilestonePaymentsReceivable', window );">Milestone payments that may be earned and recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DeferredRevenueRecognitionPeriod', window );">Deferred revenue recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PercentageOfRoyaltyRateOfNetSales', window );">Royalty percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Upfront payment received</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PotentialMilestonePaymentsReceivable', window );">Milestone payments that may be earned and recognized</a></td>
<td class="nump">$ 3,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DeferredRevenueRecognitionPeriod', window );">Deferred revenue recognition period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AgreementExpirationPeriod', window );">Agreement expiration period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DeferredRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DeferredRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PercentageOfRoyaltyRateOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Royalty Rate Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PercentageOfRoyaltyRateOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_AmpioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_AmpioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869111236144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Taxes</a></td>
<td class="text"><div>
 <p>The following table reflects the reconciliation for the
 respective periods:</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Years&#xA0;Ended&#xA0;June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Benefit at federal statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.00</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.00</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State, net of federal income tax benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.79</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.89</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.51</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.84</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30.95</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22.29</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.03</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.03</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Effective tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.30</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12.73</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div>
 <p>The approximate tax effects of significant temporary differences
 which comprise the deferred tax assets and liabilities are as
 follows for the respective periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Current deferred income tax asset:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue short-term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total current deferred income tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Long-term deferred income tax assets (liabilities):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,337,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,847,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Section&#xA0;197 intangible</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">482,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue long-term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">158,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">190,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Share-based compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Acquired in-process research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,779,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,779,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,210,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,863,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total long-term deferred income tax assets (liabilities)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred income tax assets (liabilities)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(24,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868917997408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation - Future Amortization Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 628,776<span></span>
</td>
<td class="nump">$ 699,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 1,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868853388304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 08, 2015</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
<th class="th"><div>Aug. 19, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear', window );">Lease initial base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total base rent over the term of the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rswn_BiovestInternationalIncMember', window );">Biovest International, Inc. ("Biovest") [Member] | Master Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Master services agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice', window );">Master services agreement, period upon which company may terminate agreement with written notice for any reason</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rswn_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Debt conversion description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The principal and accrued interest under the notes will  automatically convert into a number of shares of such equity securities of the  Company sold in such financing equal to 120% of the principal and accrued  interest under such note divided by the lesser of (i) the lowest price paid by  an investor in such financing or (ii) $4.63.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold', window );">Percentage of amount paid to placement agent based on notes sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes', window );">Percentage of warrant to purchase shares of common stock equal to proceeds of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_NonRefundableRetainerFee', window );">Non refundable retainer fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PrivatePlacementWarrantTerm', window );">Warrant term of placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold', window );">Warrant exercise price percentage equal to equity securities are sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear', window );">Lease initial base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total base rent over the term of the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Primsol Business [Member] | Payable within five days after transfer of Primsol-related product inventory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additional cash payable in business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Primsol Business [Member] | Payable no later than March 31, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additional cash payable in business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Primsol Business [Member] | Payable no later than June 30, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additional cash payable in business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Primsol Business [Member] | Payable no later than September 30, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additional cash payable in business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Biovest International, Inc. ("Biovest") [Member] | Master Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Master services agreement, total cost</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Master services agreement, cash paid</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 22,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DebtInstrumentMaturityDateTwo', window );">Debt instrument maturity date, two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 11,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DebtInstrumentMaturityDateThree', window );">Debt instrument maturity date, three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DebtInstrumentMaturityPeriod1', window );">Debt instrument maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_DebtInstrumentExtensionPeriod', window );">Debt instrument maturity, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt instrument interest rate, increase during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ConvertibleNotesEqualToPercentageOfCommonStock', window );">Convertible notes equal to percentage of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, convertible, Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Notes [Member] | If Converted within First Six Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Notes [Member] | If Not Converted within First Six Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Notes [Member] | If Not Registered, Shares of Common Stock Underlying Notes by Expiration of First Six Month Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ConvertibleNotesEqualToPercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes equal to percentage of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ConvertibleNotesEqualToPercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DebtInstrumentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Extension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DebtInstrumentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DebtInstrumentMaturityDateThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity date three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DebtInstrumentMaturityDateThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DebtInstrumentMaturityDateTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maturity date two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DebtInstrumentMaturityDateTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_DebtInstrumentMaturityPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of term loan facility under subtranche.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_DebtInstrumentMaturityPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_NonRefundableRetainerFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable retainer fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_NonRefundableRetainerFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Days To Terminate Agreement By Delivering Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_NumberOfDaysToTerminateAgreementByDeliveringWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_OperatingLeasesMonthlyBaseRentInitialYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases monthly base rent initial year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_OperatingLeasesMonthlyBaseRentInitialYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount paid to placement agent based on notes sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PercentageOfAmountPaidToPlacementAgentBasedOnNotesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrants exercise price equal to equity securities sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PercentageOfWarrantsExercisePriceEqualToEquitySecuritiesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrants to purchase shares of common stock equal to gross proceeds of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PercentageOfWarrantsToPurchaseSharesOfCommonStockEqualToGrossProceedsOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_PrivatePlacementWarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Placement Warrant Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_PrivatePlacementWarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_BiovestInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_BiovestInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rswn_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rswn_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rswn_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rswn_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rswn_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rswn_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=rswn_PeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfNotConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfNotConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfNotRegisteredCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rswn_IfNotRegisteredCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868914383232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868853076064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Vyrix Pharmaceuticals [Member]</div></th>
<th class="th"><div>Luoxis Diagnostics [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Vyrix Pharmaceuticals [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Luoxis Diagnostics [Member]</div>
</th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th">
<div>Parent [Member] </div>
<div>Vyrix Pharmaceuticals [Member]</div>
</th>
<th class="th">
<div>Parent [Member] </div>
<div>Luoxis Diagnostics [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Vyrix Pharmaceuticals [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Luoxis Diagnostics [Member]</div>
</th>
<th class="th"><div>Receivables from Stockholder [Member]</div></th>
<th class="th">
<div>Receivables from Stockholder [Member] </div>
<div>Luoxis Diagnostics [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Luoxis Diagnostics [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2013</a></td>
<td class="nump">$ 9,811,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,471,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,418,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,079,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Jun. 30, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,437,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ContributionsFromRelatedParty', window );">Investment from Ampio in Vyrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock in exchange for Vyrix Acquired Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,108,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,108,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock in exchange for Vyrix Acquired Assets, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">499,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,578,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,578,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2014</a></td>
<td class="nump">5,369,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,026,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,657,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Jun. 30, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,901,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Issuance of common stock to Ampio in exchange for Aytu debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,999,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock to Ampio in exchange for Aytu debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,597,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_StockSubscription', window );">Ampio stock subscription payment</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid', window );">Liabilities paid pursuant to the merger</a></td>
<td class="num">(20,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger', window );">Luoxis options paid-out pursuant to the merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger', window );">Luoxis options paid-out pursuant to the merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ReverseMergerValue', window );">Reverse merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_ReverseMergerShare', window );">Reverse merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,596,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,017,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,723,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,723,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2015</a></td>
<td class="nump">$ 15,616,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,996,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,381,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Jun. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,259,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital options paid pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AdjustmentToAdditionalPaidInCapitalOptionsPaidPursuantToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital shares options paid pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AdjustmentToAdditionalPaidInCapitalSharesOptionsPaidPursuantToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional in capital business combination liabilities paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_AdjustmentsToAdditionalInCapitalBusinessCombinationLiabilitiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ContributionsFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions From Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ContributionsFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ReverseMergerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse merger share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ReverseMergerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_ReverseMergerValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse merger value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_ReverseMergerValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_StockSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_StockSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 22<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-30)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rswn_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139869111236144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 4 &#x2013; Income Taxes</b></p>
 <!-- xbrl,body -->
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 As previously discussed in Note 2 &#x2013; Summary of Significant
 Accounting Policies, the Company is included in Ampio&#x2019;s
 consolidated tax returns. For purposes of these financial
 statements, the Company&#x2019;s taxes are computed and reported on
 a &#x201C;separate return&#x201D; basis. Ampio and Aytu do not have a
 tax sharing agreement. Accordingly, certain tax attributes, e.g.,
 net operating loss carryforwards, reflected in these financial
 statements, may or may not be available to Aytu. In the event that
 Ampio&#x2019;s ownership interest in Aytu falls below 80% and Aytu
 is deconsolidated from Ampio&#x2019;s consolidated income tax
 return, the net operating loss carryforwards originated prior to
 the incorporation of Vyrix and Luoxis would no longer be available
 to Aytu and the related deferred income tax asset would be removed
 and recorded as a deemed dividend to the parent, Ampio.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Income tax benefit resulting from applying statutory rates in
 jurisdictions in which Aytu is taxed (Federal and State of
 Colorado) differs from the income tax provision (benefit) in the
 Aytu&#x2019;s financial statements. The following table reflects the
 reconciliation for the respective periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Years&#xA0;Ended&#xA0;June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Benefit at federal statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.00</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34.00</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State, net of federal income tax benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.79</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.89</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.51</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.84</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30.95</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22.29</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.03</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.03</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Effective tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.30</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12.73</td>
 <td valign="bottom" nowrap="nowrap">)%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Deferred income taxes arise from temporary differences in the
 recognition of certain items for income tax and financial reporting
 purposes. The approximate tax effects of significant temporary
 differences which comprise the deferred tax assets and liabilities
 are as follows for the respective periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Current deferred income tax asset:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue short-term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">32,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(64,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total current deferred income tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Long-term deferred income tax assets (liabilities):</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net operating loss carryforward</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,337,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,847,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Section&#xA0;197 intangible</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">453,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">482,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue long-term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">158,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">190,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Share-based compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Acquired in-process research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,779,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,779,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,210,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,863,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total long-term deferred income tax assets (liabilities)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(41,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred income tax assets (liabilities)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(24,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu has recorded income tax benefits in its statements of
 operations since inception, stemming from its operating losses, and
 is expected to incur operating losses for the foreseeable future.
 During the year ended June&#xA0;30, 2015, the net deferred tax
 liability was reduced to zero based upon the operating losses, thus
 Aytu established a valuation allowance offsetting any future net
 deferred tax asset. As such, Aytu would no longer record income tax
 benefits in its results of operations after the year ended
 June&#xA0;30, 2015 because management is currently unable to
 conclude that it is more likely than not that a benefit will be
 realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In assessing the realizability of deferred tax assets, management
 considers whether it is more likely than not that some portion or
 all of the deferred tax assets will not be realized. The ultimate
 realization of deferred tax assets is dependent upon the generation
 of future taxable income during periods in which those temporary
 differences become deductible. Management considers the scheduled
 reversal of deferred tax liabilities, projected future taxable
 income, carry back opportunities and tax planning strategies in
 making the assessment. The Company believes it is more likely than
 not it will realize the benefits of these deductible differences,
 net of the valuation allowance provided.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company has federal net operating loss carryforwards of
 approximately $17.1 million and $10.4 million as of June&#xA0;30,
 2015 and June&#xA0;30, 2014, respectively that, subject to
 limitation, may be available in future tax years to offset taxable
 income. The available net operating losses, if not utilized to
 offset taxable income in future periods, will begin to expire in
 2031 through 2034. Net operating loss carryforwards are subject to
 examination in the year they are utilized regardless of whether the
 tax year in which they are generated has been closed by statute.
 The amount subject to disallowance is limited to the NOL utilized.
 Accordingly, the Company may be subject to examination for prior
 NOLs generated as such NOLs are utilized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As of June&#xA0;30, 2015 and 2014, the Company has no liability for
 gross unrecognized tax benefits or related interest and
 penalties.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu has made its best estimates of certain income tax amounts
 included in the financial statements. Application of the
 Company&#x2019;s accounting policies and estimates, however,
 involves the exercise of judgment and use of assumptions as to
 future uncertainties and, as a result, could differ from these
 estimates. In arriving at its estimates, factors the Company
 considers include how accurate the estimates or assumptions have
 been in the past, how much the estimates or assumptions have
 changed and how reasonably likely such changes may have a material
 impact. Aytu has been historically included in the Ampio
 consolidated tax return. Under the general statute of limitations,
 the Company would not be subject to federal or Colorado income tax
 examinations for years prior to 2011 and 2010, respectively.
 However, given the net operating losses generated since inception,
 all tax years since inception are subject to examination.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868930865872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Acquisition of Assets and Basis of Presentation - Unaudited Pro-forma Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenue</a></td>
<td class="nump">$ 1,371,106<span></span>
</td>
<td class="nump">$ 1,736,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaCostOfRevenue', window );">Cost of sales-ProstaScint</a></td>
<td class="nump">1,818,690<span></span>
</td>
<td class="nump">2,054,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,065,626<span></span>
</td>
<td class="nump">3,933,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty', window );">Research and development-related party (Note 8)</a></td>
<td class="nump">156,988<span></span>
</td>
<td class="nump">125,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses', window );">General and administrative</a></td>
<td class="nump">4,417,884<span></span>
</td>
<td class="nump">2,388,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets', window );">Amortization and impairment of intangible assets</a></td>
<td class="nump">131,989<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,220,071)<span></span>
</td>
<td class="num">(6,866,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet', window );">Interest (expense) income</a></td>
<td class="num">(114,994)<span></span>
</td>
<td class="num">(45,553)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax', window );">Net loss, before income tax</a></td>
<td class="num">(8,335,065)<span></span>
</td>
<td class="num">(6,912,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">23,910<span></span>
</td>
<td class="nump">813,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,311,155)<span></span>
</td>
<td class="num">$ (6,098,374)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions pro forma amortization and impairment of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaAmortizationAndImpairmentOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaCostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions pro forma cost of revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaCostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisitions Pro Forma Income Tax Expense Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisitions Pro Forma Interest Income Expense Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaInterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions pro forma operating expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisitions Pro Forma Operating Income Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions, pro forma research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions, pro forma research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProFormaResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions proforma general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_BusinessAcquisitionsProformaGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma income from continuing operations before changes in accounting and extraordinary items, net of tax effect, for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(2)-(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>293</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Business, Acquisition of Assets and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - License Agreement/Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementTextBlock</Role>
      <ShortName>License Agreement/Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Equity Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Equity Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Business, Acquisition of Assets and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockTables</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Equity Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Equity Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Company's Allocation on Consideration Transferred for ProstaScint (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationCompanysAllocationOnConsiderationTransferredForProstaScint</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation - Company's Allocation on Consideration Transferred for ProstaScint (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Future Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationFutureAmortizationExpense</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation - Future Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Business, Acquisition of Assets and Basis of Presentation - Unaudited Pro-forma Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureBusinessAcquisitionOfAssetsAndBasisOfPresentationUnauditedProformaInformation</Role>
      <ShortName>Business, Acquisition of Assets and Basis of Presentation - Unaudited Pro-forma Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fixed Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFixedAssets</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fixed Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationExpense</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Summary of Significant Accounting Policies - Schedule of Patents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPatents</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Patents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Summary of Significant Accounting Policies - Schedule of Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAmortizationExpense</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFutureAmortizationExpense</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - License Agreement/Revenue Recognition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureLicenseAgreementRevenueRecognitionAdditionalInformation</Role>
      <ShortName>License Agreement/Revenue Recognition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxes</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Commitments and Contingencies - Rent Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureCommitmentsAndContingenciesRentExpense</Role>
      <ShortName>Commitments and Contingencies - Rent Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureCommonStockAdditionalInformation</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Equity Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsAdditionalInformation</Role>
      <ShortName>Equity Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Equity Instruments - Significant Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSignificantAssumptions</Role>
      <ShortName>Equity Instruments - Significant Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Equity Instruments - Luoxis Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsLuoxisStockOptionActivity</Role>
      <ShortName>Equity Instruments - Luoxis Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Equity Instruments - Vyrix Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsVyrixStockOptionActivity</Role>
      <ShortName>Equity Instruments - Vyrix Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Equity Instruments - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsSummaryOfStockBasedCompensationExpense</Role>
      <ShortName>Equity Instruments - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebentures</Role>
      <ShortName>Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rswn-20150630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Balance Sheets'', column(s) 3 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>rswn-20150630.xml</File>
    <File>rswn-20150630_cal.xml</File>
    <File>rswn-20150630_def.xml</File>
    <File>rswn-20150630_lab.xml</File>
    <File>rswn-20150630_pre.xml</File>
    <File>rswn-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920663088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Commitments and Contingencies (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManagementFeesMember', window );">Management Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember', window );">ProstaScint Inventory Transfer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Sponsored Research Agreement with Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember', window );">Clinical Research and Trial Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManufacturingMember', window );">Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rswn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rswn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rswn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rswn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManagementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManagementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ProstascintInventoryTransferFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ResearchAndDevelopmentArrangementClinicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_ManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=rswn_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139868920980608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Future Amortization Expense</a></td>
<td class="text"><div>
 <p>Patents consist of the following:</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Patents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">880,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(251,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(180,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Patents, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">700,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Fixed assets are recorded at cost. After being placed in service,
 the fixed assets are depreciated using the straight-line method
 over estimated useful lives. Fixed assets consist of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">Estimated</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">Useful&#xA0;Lives&#xA0;in&#xA0;years</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">3&#xA0;-&#xA0;5</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(60,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Fixed assets, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following depreciation expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Depreciation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">27,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aytu recorded the following amortization expense in the respective
 periods:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Year Ended June&#xA0;30,</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amortization expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">70,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future amortization from the year ended June&#xA0;30, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="87%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">274,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">629,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double"></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Future Amortization Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Future amortization from the year ended June&#xA0;30, 2015 is as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head -->
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">159,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">775,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,570,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rswn_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
